
<html lang="en"     class="pb-page"  data-request-id="7deb324f-a34d-4d64-b03d-8c91bd2986a0"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.1c00302;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Kinase Inhibitors as Underexplored Antiviral Agents" /></meta><meta name="dc.Creator" content="Javier  García-Cárceles" /></meta><meta name="dc.Creator" content="Elena  Caballero" /></meta><meta name="dc.Creator" content="Carmen  Gil" /></meta><meta name="dc.Creator" content="Ana  Martínez" /></meta><meta name="dc.Description" content="Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug..." /></meta><meta name="Description" content="Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 10, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00302" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00302" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00302" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00302" /></link>
        
    
    

<title>Kinase Inhibitors as Underexplored Antiviral Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00302" /></meta><meta property="og:title" content="Kinase Inhibitors as Underexplored Antiviral Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0013.jpeg" /></meta><meta property="og:description" content="Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potential solution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylation events that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost and effectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistry programs are needed in the field. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering the role of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viral infections in different development stages." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00302"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00302">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00302&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00302&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00302&amp;href=/doi/10.1021/acs.jmedchem.1c00302" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.0c01773" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00258" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Kinase Inhibitors as Underexplored Antiviral Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Javier García-Cárceles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Javier García-Cárceles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Javier++Garc%C3%ADa-C%C3%A1rceles">Javier García-Cárceles</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elena Caballero</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elena Caballero</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Caballero">Elena Caballero</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carmen Gil</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Gil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>(C.G.) E-mail: <a href="/cdn-cgi/l/email-protection#7f1c1e0d121a11511816133f1c0c161c511a0c"><span class="__cf_email__" data-cfemail="e68587948b8388c8818f8aa685958f85c88395">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Gil">Carmen Gil</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3882-6081" title="Orcid link">http://orcid.org/0000-0002-3882-6081</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Ana Martínez</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ana Martínez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centro de Investigaciones Biológicas Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</div></div><span class="conrtib-corresp"><strong>*</strong>(A.M.) E-mail: <a href="/cdn-cgi/l/email-protection#66070807480b0714120f08031c2605150f05480315"><span class="__cf_email__" data-cfemail="9ffef1feb1f2feedebf6f1fae5dffcecf6fcb1faec">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Mart%C3%ADnez">Ana Martínez</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2707-8110" title="Orcid link">http://orcid.org/0000-0002-2707-8110</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00302&amp;href=/doi/10.1021%2Facs.jmedchem.1c00302" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 10, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 February 2021</li><li><span class="item_label"><b>Published</b> online</span>10 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00302" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00302</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00302"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1332</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00302" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Kinase Inhibitors as Underexplored Antiviral Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Javier&quot;,&quot;last_name&quot;:&quot;García-Cárceles&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Caballero&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Gil&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Martínez&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00302&quot;},&quot;abstract&quot;:&quot;Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potential solution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylation events that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost and effectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistry programs are needed in the field. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering the role of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viral infections in different development stages.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00302&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00302" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00302&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00302" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00302&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00302" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00302&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00302&amp;href=/doi/10.1021/acs.jmedchem.1c00302" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00302" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00302" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00302%26sid%3Dliteratum%253Aachs%26pmid%3D33970631%26genre%3Darticle%26aulast%3DGarc%25C3%25ADa-C%25C3%25A1rceles%26date%3D2021%26atitle%3DKinase%2BInhibitors%2Bas%2BUnderexplored%2BAntiviral%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291430" title="Infectious diseases">Infectious diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=290659" title="DNA replication">DNA replication</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potential solution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylation events that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost and effectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistry programs are needed in the field. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering the role of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viral infections in different development stages.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>New Horizons in Drug Discovery - Understanding and Advancing Kinase Inhibitors</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinase enzymes are broadly present in nature, and they participate in a myriad of biological processes. These enzymes catalyze the phosphorylation reaction of a wide variety of substrates (e.g., lipids, carbohydrates, proteins, nucleic acids) through the addition of a phosphate group from the terminal phosphate of adenosine triphosphate (ATP). In particular, protein kinases (PKs) phosphorylate proteins mainly at serine, threonine, or tyrosine residues, as part of post-translational modification events. This produces conformational modifications that lead to functional changes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Since their discovery by Fischer and Krebs in the late 1950s,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> the field of research has expanded rapidly. PKs are one of the largest families in eukaryotes. There are 518 kinases encoded by approximately 2% of the human genome,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and they are regulated at many levels, from the phosphorylation state to proteolysis and recycling. PKs are traditionally classified into groups (10) and families (256) based on the primary structure of their catalytic domains.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The main groups of kinases are Ser/Thr kinases (STEs), tyrosine kinases (TKs), tyrosine kinase-like kinases (TKLs), casein kinases (CKs), AGC kinases (named after the protein kinase A, G, and C families), Ca<sup>2+</sup>/calmodulin-dependent protein kinases (CaMKs), CMGC kinases (named after the initials of some members, such as CDKs or MAPKs), and receptor guanylate cyclases (RGCs). These proteins play a key role in mediating signal transduction in cells. They regulate various cellular functions including metabolism, cell cycle regulation, survival, and differentiation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Mutations and deregulation of PKs are linked to abnormal phenotypes.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Since the first crystal structure of the protein kinase A catalytic domain was solved in 1991,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> incredible efforts have been made to understand the structural features that drive the phosphorylation reaction and to provide insights into the substrate binding and selectivity.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> According to the KLIFS database,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> in 2016 there were more than 2900 crystal structures of the catalytic domains of both human and mouse protein kinases deposited in the Protein Data Bank (PDB).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">Taking into consideration their important physiological role, an extensive number of research programs have been developed, both by academia and industry, toward the identification of ligands (agonists or antagonists) that modulate their activity (activating or blocking, respectively).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In most of the cases, PKs are upregulated in pathological phenotypes, so the search for inhibitors has prevailed. Efforts to develop protein kinase inhibitors (PKIs) as therapeutic agents began as early as the 1980s, when Hidaka disclosed ATP competitive isoquinoline sulfonamide derivatives as inhibitors of various PKs, such as cyclic-nucleotide-dependent protein kinases or protein kinase C (PKC).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, it was not until 2001 when imatinib<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> (<b>1</b>, Gleevec, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was the first PKI approved by the Food and Drug Administration (FDA), targeting Abelson tyrosine kinase (ABL). Since then, FDA approvals have been steadily rising,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> with special attention to the treatment of cancer<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and inflammatory processes (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Despite this fact, from all of the known human PKs, more than 100 have an unknown function, and 50% of them are largely uncharacterized.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Thus, there is still room for significant breakthrough therapies aimed at the design and development of inhibitors of untargeted PKs. Moreover, recent biological techniques implemented to assess kinase inhibition in living cells offer valuable tools for moving chemical probes to clinical drug candidates.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative chemical structures of FDA-approved PKIs for cancer or inflammatory processes and antitumoral LKIs with antiviral properties in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With respect to lipid kinases (LKs), they phosphorylate lipids in the cell, and they can be classified according to their substrates as diacylglycerol kinases, sphingosine kinases, and phosphatidylinositol kinases. These enzymes make a critical contribution not only to the lipid homeostasis but also to a variety of cellular functions.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> LKs have been shown to have an important role in cancer progression. As a consequence, inhibitors of these kinases are being studied as antitumoral agents.<a onclick="showRef(event, 'ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22">(20−22)</a> Additionally, other relevant functions in diseases related to the cardiovascular system, central nervous system, inflammation, or diabetes have been described.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> The implication of LKs in these diseases has motivated the development of specific inhibitors to be used as therapeutics.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> Furthermore, the addition of phosphate groups can change the reactivity and localization of the lipid regulating signal transmission. Identified lipid kinase inhibitors (LKIs) have reached clinical trials (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), but none of them have been approved for commercialization.</div><div class="NLM_p">Viral infections are a major health problem in our society; therefore, there is an urgent need for therapeutic strategies to tackle this issue. The most common treatment to avoid infection is vaccination, which is currently a successful approach for the eradication of some diseases (e.g., measles, rubella). Total eradication has been achieved for smallpox and rinderpest viruses.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> An alternative method consists of the treatment with antivirals upon infection. Most of these are the so-called direct-acting antivirals (DAAs), and they target proteins encoded by the viral genome.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The main drawbacks of this strategy are the following: (i) drug resistance generated by the virus;<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (ii) narrow therapeutic window, making it necessary to develop broad-spectrum antivirals.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> An attractive potential solution to overcome these problems may be to aim at host-based targets. Viruses are dependent on a wide variety of host cellular proteins, and phosphorylation events are crucial during their life cycle.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Particularly, a growing body of evidence has shown that viruses hijack several host PKs and LKs at distinct stages of an infection.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a></div><div class="NLM_p">The development of a new drug is a time-consuming (12–15 years) and expensive (over 1 billion dollars) process.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Thus, repurposing existing kinase inhibitors would help in the cost and the effectiveness of the process because data are already available for selected compounds (toxicity, pharmacokinetics, dosing, etc.), and this helps shorten the clinical pathway. In fact, some repurposing programs have been carried out, and they are rendered promising results.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> Novel phosphoproteomic programs are a very recent approach to discover kinase inhibitors with antiviral properties.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> They are based on the analysis and quantification of the phosphorylation pattern upon infection, leading to the identification of the main kinases involved in the process. Therefore, kinases activated during the infection of a virus can be identified as potential therapeutic targets for the development of antivirals.</div><div class="NLM_p last">In the present perspective, we aim to review the state-of-art of kinase inhibitors targeting viral infections, focusing on the most important advances carried out in different kinase families—namely, Numb-associated kinases (NAKs), receptor tyrosine kinases (RTKs), mitogen-activated protein kinases (MAPKs), Src kinases, cyclin-dependent kinases (CDKs), and phosphatidylinositol-3-phosphate-5 kinase (PIKfyve) among others. In order to unravel the mechanism of action of kinase inhibitors as antiviral agents, important attention will be paid to the relationship between infection and kinase regulation.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Numb-Associated Kinases (NAKs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00865" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00865" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The human Numb-associated kinase (NAK) family of Ser/Thr kinases is composed of four known members: adaptor-associated kinase 1 (AAK1), cyclin G-associated kinase (GAK), BMP-2 inducible kinase (BIKE/BMP2K), and serine/threonine kinase 16 (STK16). These kinases are involved in a broad range of cellular functions, and therefore they are related to different diseases such as cancer or Parkinson’s disease.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In fact, there are kinase inhibitors approved for the treatment of different cancers, such as sunitinib<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (<b>2</b>) or erlotinib (<b>3</b>),<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and baricitinib<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<b>4</b>) for the treatment of rheumatoid arthritis (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Also the physiological function of these enzymes has been also related to the regulation of intracellular membrane trafficking. In fact, AAK1 and GAK have key roles in endocytosis,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> which has motivated the study of their involvement in processes related to viral infection.</div><div class="NLM_p">Cells offer a variety of endocytosis, trafficking, and sorting mechanisms that viruses can use to their benefit. In fact, the majority of them need endocytic internalization for penetration and infection. Of the endocytic pathways used by viruses, one of the most commonly used is clathrin-mediated endocytosis.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This process is dependent on the action of the oligomeric clathrin and adaptor protein (AP), and it is widely used by many enveloped RNA viruses. After adhesion to the cell surface and binding to specific cellular receptors, viruses are internalized in clathrin-coated vesicles that are sorted into endosomal compartments. Within endosomes, a drop in pH can induce conformational changes in the viral envelope proteins. This initiates viral fusion with endosomal membranes and the release of the viral RNA into the host cell cytoplasm.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Thus, as clathrin-mediated endocytosis can be considered to be an attractive antiviral target, kinases that regulate clathrin-mediated trafficking can be druggable targets for the development of broad-spectrum antivirals. This is the case of AAK1 and GAK. In fact, by silencing their expression, it has been proved that both kinases are critical for hepatitis C virus (HCV) entry.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">The role of AAK1 in receptor-mediated endocytosis is mediated by specific phosphorylation of adaptor protein 2 (AP2), which stimulates the binding to cargo proteins. GAK shares some biological functions with AAK1, and it mediates the binding of clathrin to the plasma membrane and the trans-Golgi network.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Additionally, AAK1 and GAK regulate AP2M1 (μ subunit of the AP2 complex) activity, which is also essential for HCV assembly.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Taken together, these findings show that both enzymes regulate different steps in the virus cycle, entry, and assembly. Thus, they are very useful for the development of novel antiviral strategies. Moreover, the key role of AAK1 and GAK in virus infection has been expanded to other viruses beyond HCV, such as DENV and EBOV.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">GAK and AAK1 inhibitors, such as sunitinib (<b>2</b>) and erlotinib (<b>3</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> that were previously developed for other indications have been reported to have broad-spectrum antiviral activity against distant RNA viruses belonging to the <i>Flaviviridae</i>, <i>Filoviridae</i>, <i>Togaviridae</i>, <i>Arenaviridae</i>, or <i>Paramyxoviridae</i> families.<a onclick="showRef(event, 'ref49 ref52'); return false;" href="javascript:void(0);" class="ref ref49 ref52">(49,52)</a> Moreover, baricitinib (<b>4</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> a potent GAK and AAK1 inhibitor, has been proposed as an effective therapy for coronavirus disease 2019 (COVID-19).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In fact, treatment of COVID-19 pneumonia patients with <b>4</b> decreased ICU hospitalization and improved clinical parameters.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> However, its ability to also inhibit janus kinase (JNK1/2) could indicate other risks that need to be considered,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> despite being favorable for managing inflammation. Thus, only short treatments (7–14 days) with <b>4</b> are recommended to avoid opportunistic viral infections.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> To our knowledge, the first known inhibitors of AAK1 and GAK, rather than being selective, were multikinase inhibitors initially developed to inhibit other kinases. This is the case for sunitinib (<b>2</b>), erlotinib (<b>3</b>), baricitinib (<b>4</b>), dasatinib (<b>5</b>), or gefitinib (<b>6</b>), among others (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of GAK, AAK1, and BIKE inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Overview of Representative PKIs and LKIs and Their Effect on Virus Infection</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">virus</th><th class="colsep0 rowsep0" align="center">affected stage/effect</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">sunitinib (<b>2</b>)</td><td class="colsep0 rowsep0" align="left">GAK/AAK1</td><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">assembly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">GAK/AAK1</td><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">assembly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">baricitinib (<b>4</b>)</td><td class="colsep0 rowsep0" align="left">GAK/AAK1</td><td class="colsep0 rowsep0" align="left">SARS-CoV-2</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">assembly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dasatinib (<b>5</b>)</td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">assembly and secretion</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">HCV</td><td class="colsep0 rowsep0" align="left">drop of IC<sub>50</sub> 210-fold (in Huh7.5.1 cells in combination with sofosbuvir)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Fyn</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">reverse transcription</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">gefitinib (<b>6</b>)</td><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">TGEV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">infection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">rhinovirus</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">selumetinib (<b>9</b>)</td><td class="colsep0 rowsep0" align="left">MEK1/2</td><td class="colsep0 rowsep0" align="left">MERS-CoV</td><td class="colsep0 rowsep0" align="left">inhibitory effects</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">trametinib (<b>10</b>)</td><td class="colsep0 rowsep0" align="left">MEK1/2</td><td class="colsep0 rowsep0" align="left">MERS-CoV</td><td class="colsep0 rowsep0" align="left">inhibitory effects</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">palbociclib (<b>14</b>)</td><td class="colsep0 rowsep0" align="left">CDK4/6</td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HSV-1</td><td class="colsep0 rowsep0" align="left">reverse transcription</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">apilimod (<b>18</b>)</td><td class="colsep0 rowsep0" align="left">PIKfyve</td><td class="colsep0 rowsep0" align="left">EBOV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">SARS-CoV-2</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">genistein (<b>36</b>)</td><td class="colsep0 rowsep0" align="left">various RTKs</td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">arenavirus</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HSV-1</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R428 (<b>38</b>)</td><td class="colsep0 rowsep0" align="left">Axl</td><td class="colsep0 rowsep0" align="left">ZIKV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">activates IFN-1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AG879 (<b>39</b>)</td><td class="colsep0 rowsep0" align="left">TrKA</td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">tyrphostin A9 (<b>40</b>)</td><td class="colsep0 rowsep0" align="left">PDGFR</td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">TGEV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">U0126 (<b>41</b>)</td><td class="colsep0 rowsep0" align="left">MEK1/2</td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">vRNP export</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">astrovirus</td><td class="colsep0 rowsep0" align="left">all stages</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">MERS-CoV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SP600125 (<b>42</b>)</td><td class="colsep0 rowsep0" align="left">JNK-1</td><td class="colsep0 rowsep0" align="left">JEV</td><td class="colsep0 rowsep0" align="left">reduction of inflammatory cytokines</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SB203580 (<b>43</b>)</td><td class="colsep0 rowsep0" align="left">p38</td><td class="colsep0 rowsep0" align="left">MERS-CoV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">papaverine (<b>44</b>)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">vRNP export</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">paramyxovirus</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ATR-002 (<b>45</b>)</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">antiviral activity</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IBV</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">saracatinib (<b>46</b>)</td><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">assembly</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Fyn</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-roscovitine (<b>47</b>)</td><td class="colsep0 rowsep0" align="left">CDK2/5</td><td class="colsep0 rowsep0" align="left">HCMV</td><td class="colsep0 rowsep0" align="left">DNA synthesis</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">flavopiridol (<b>48</b>)</td><td class="colsep0 rowsep0" align="left">CDK1/2/4</td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IAV</td><td class="colsep0 rowsep0" align="left">antiviral activity (synergistic effect with dinaciclib, <b>51</b>)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">alsterpaullone (<b>49</b>)</td><td class="colsep0 rowsep0" align="left">CDK1/2</td><td class="colsep0 rowsep0" align="left">HIV-1</td><td class="colsep0 rowsep0" align="left">cell viability</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FIT-039 (<b>50</b>)</td><td class="colsep0 rowsep0" align="left">CDK9</td><td class="colsep0 rowsep0" align="left">HSV-1</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">transcription</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HSV-1</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HCMV</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HAdV-5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PHA-690509 (<b>52</b>)</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">ZIKV</td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">YM201636 (<b>53</b>)</td><td class="colsep0 rowsep0" align="left">PIKfyve</td><td class="colsep0 rowsep0" align="left">EBOV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vacuolin-1 (<b>54</b>)</td><td class="colsep0 rowsep0" align="left">PIKfyve</td><td class="colsep0 rowsep0" align="left">EBOV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GNF-2 (<b>57</b>)</td><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">replication</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BSA9 (<b>58</b>)</td><td class="colsep0 rowsep0" align="left">CaMKII</td><td class="colsep0 rowsep0" align="left">DENV</td><td class="colsep0 rowsep0" align="left">entry</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">ZIKV</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dorsomorphin (<b>60</b>)</td><td class="colsep0 rowsep0" align="left">AMPK</td><td class="colsep0 rowsep0" align="left">EBOV</td><td class="colsep0 rowsep0" align="left">replication</td></tr></tbody></table></div></div><div class="NLM_p">With respect to new chemical entities optimized and developed as antivirals, there have been remarkable efforts to improve the chemical space. These efforts have focused on the development of selective inhibitors. In this sense, the discovery of a hit bearing a isothiazolo[4,3-<i>b</i>]pyridine scaffold with <i>K</i><sub>d</sub> = 0.3 μM in GAK (<b>21</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) has been reported.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Structural variation at positions 3 and 6 led to optimized derivatives (<b>22</b>–<b>25</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) with stronger affinities for GAK in the nanomolar range.<a onclick="showRef(event, 'ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60">(58−60)</a> It was seen that an aromatic moiety at position 6, particularly 3,4,5-trimethoxyphenyl and 2-methoxy-3-aminophenyl, while maintaining a morpholino group at position 3 is the optimal substitution for a potent and selective inhibition of GAK. Moreover, further exploration around position 3 revealed that methyl-substituted morpholin analogues were optimal for GAK inhibition together with an antiviral effect.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The chemical diversity of this novel series of GAK inhibitors can be significantly improved with the newly reported possibilities that carbon-linked substituents at position 3<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> and even modifications in the pyridine moiety<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> offer. The most potent compound of this new series was derivative <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) that bears a 3-(3,4-dimethoxyphenyl) group at position 3 and presents a strong affinity for GAK (<i>K</i><sub>d</sub> = 42 nM) together with moderate activity against DENV (EC<sub>50</sub> = 3.4 μM).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Reported molecular docking studies showed that the 3,4-dimethoxyphenyl group at position 3 forms a hydrogen bond with Lys69 at the ATP binding site, while the 3,4-dimethoxyphenyl group at position 6 is oriented to establish a hydrogen bond with Arg44. These interactions offer new possibilities for optimization. In fact, different phenyl-substituted and <i>N</i>-piperidinyl moieties were introduced at position 3 of the main isothiazolo[4,3-<i>b</i>]pyridine scaffold in order to increase GAK affinity by hydrogen bond interaction with Lys69. Optimized compounds (<b>26</b> and <b>27</b>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) not only showed GAK inhibition in the nanomolar range (IC<sub>50</sub> = 7.7 nM and 13 nM, respectively) but also anti-DENV properties in the sub-micromolar range (EC<sub>50</sub> = 1.9 μM and 7.5 μM, respectively).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Besides 3,6-disubstituted isothiazolo[4,3-<i>b</i>]pyridines, other new scaffolds developed as selective GAK inhibitors, particularly, 4-anilinoquinolines and 4-anilinoquinazolines, showing potential antiviral properties have been reported, although the structure–activity relationship (SAR) has not being so extensively studied.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of 3,6-disubstituted isothiazolo[4,3-<i>b</i>]pyridines <b>21</b>–<b>27</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Regarding AAK1, as this enzyme was considered as a pharmacological target for neurological disorders, different chemotypes were developed as drugs for these diseases. Such is the case for a series of imidazo[1,2-<i>b</i>]pyridazines. Although these were originally described for neuropathic pain therapy,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> some derivatives showed antiviral activity against HCV and dengue virus (DENV) (<b>28</b> and <b>29</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> On the basis of this proof-of-concept, a potent AAK1 inhibitor (<b>30</b>, <i>K</i><sub>d</sub> = 53 nM, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) bearing a pyrrolo[2,3-<i>b</i>]pyridine scaffold was identified after a screening campaign using 577 chemically diverse kinase inhibitors and 200 protein kinases.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> It was chosen for optimization considering also antiviral properties. Chemical variations around this main core led to new derivatives in the low nanomolar range with AAK1 inhibition and improved activity against DENV (<b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). EC<sub>50</sub> for DENV was 8 μM (compound <b>30</b>) vs 0.72 μM (compound <b>31</b>).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> With respect to kinase selectivity, although not highly selective, optimized candidates presented a better profile than sunitinib (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), and they are useful pharmacological tools to be used instead of this drug.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of imidazo[1,2-<i>b</i>]pyridazines <b>28</b> and <b>29</b>, and pyrrolo[2,3-<i>b</i>]pyridines <b>30</b> and <b>31</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Besides the above-mentioned role of AAK1 and GAK in antiviral infection, another member of the NAK family, BIKE, has been validated as a druggable target for the development of broad-spectrum antivirals. The proof-of-concept of this assertion is based on the suppression of DENV infection by pharmacological inhibition of BIKE using a known nonselective inhibitor, the natural product 5<i>Z</i>-7-oxozeaenol (<b>20</b>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), that was developed as an antitumoral drug. BIKE is required for both early and late stages of the DENV life cycle. Importantly, this effect is partly mediated by the phosphorylation of the Thr156 residue of AP2M1.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">Further studies focused on the development of selective NAK inhibitors are needed to improve the knowledge around the NAK family members and to confirm their potential as broad-spectrum antivirals. In this regard, the use of chemical probes such SGC-GAK1<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>32</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) or SGC-AAK-1<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> (<b>33</b>, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) will be of utmost importance. It is also noteworthy that the structurally related negative controls, <b>34</b> and 35, are available (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref69 ref71'); return false;" href="javascript:void(0);" class="ref ref69 ref71">(69,71)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures for GAK and AAK1 probes <b>32</b> and <b>33</b>, and their structurally related negative controls <b>34</b> and <b>35</b>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">3.  Receptor Tyrosine Kinases (RTKs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Receptor tyrosine kinases (RTKs) are cell surface receptors that regulate key cellular processes, such as cell cycle control, metabolism, and cell differentiation, through downstream signaling pathways. There are 58 human RTKs that are classified into 20 subfamilies. All of them have a similar architecture: an extracellular region (usually glycosylated) for ligand binding, a transmembrane helix, and an intracellular part bearing the protein tyrosine kinase domain. Additionally, the mechanism of activation is highly conserved. It is based on a ligand-induced dimerization/oligomerization that produces the activation of downstream signaling pathways inside the cell. Because of the key biological role of this family of kinases, mutations and deregulations have been linked to diseases such as cancers, diabetes, inflammation, severe bone disorders, arteriosclerosis, and angiogenesis.<a onclick="showRef(event, 'ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref72 ref73 ref74 ref75">(72−75)</a></div><div class="NLM_p">RTKs have also been proven to be important factors implicated in the infection process of some viruses. In this sense, the epidermal growth factor receptor (EGFR) is a member of the ErbB subfamily of RTKs, and it has been the most studied.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> There are reports supporting that its activation is necessary for the entry of various viruses. For example, binding of cell culture HCV particles (HCVcc) to both primary human hepatocyte (PHH) cells or antibody-mediated cross-linking of CD81 induces EGFR activation, which is required for HCV clathrin-mediated endocytosis.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> While incubation of Huh-7.5 cells with EGFR ligands epidermal growth factor (EGF) and transforming growth factor-α (TGF-α) showed a higher infection rate by inducing EGFR internalization and colocalization with CD81, it did not have any effect on HCVcc infection if ligands were added after the viral genome had entered cells. Additionally, EGFR inhibitor erlotinib (<b>3</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) prevented HCVcc infection of Huh-7.5 cells. These results altogether suggest that endocytosis of EGFR is essential for HCV entry, although it does not have any effect on HCV RNA replication. It should be noted that the actual molecular mechanisms of EGFR-mediated endocytosis still remain unclear. Both genistein (<b>36</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), a general inhibitor of RTKs, and EGFR narrow spectrum inhibitor gefitinib (<b>6</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), impair influenza A virus (IAV) entry in A549 lung epithelial cells.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> The selective EGFR inhibitor AG1478 (<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) has been shown to block transmissible gastroenteritis virus (TGEV) uptake by porcine intestinal columnar epithelial cells (IPEC), and it has a negative impact in IAV and rhinovirus infection of epithelial BEAS-2b cells.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> Recently, EGFR inhibitors such as erlotinib (<b>3</b>) or gefitinib (<b>6</b>) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and platelet-derived growth factor receptor (PDGFR) inhibitor sorafenib (<b>7</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) have been proposed to prevent the excessive fibrotic response in different human coronavirus infections, including severe acute respiratory syndrome CoV-2 (SARS-CoV-2), but the beneficial effect of these kinase inhibitors is not associated directly with any antiviral activity.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In fact, nintedanib (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), a fibroblast growth factor receptor (FGFR) inhibitor, is in clinical trials to treat pulmonary fibrosis in mild COVID-19 patients (NCT04338802).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of representative RTK inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Axl belongs to the Tyro3 Axl Mer (TAM) RTK family, and it is implicated in the clearance of apoptotic cells and regulation of innate immunity.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> ZIKA virus (ZIKV) enters via clathrin-mediated endocytosis in human glial cells expressing the Axl receptor. Blocking its kinase activity by the small-molecule inhibitor R428 (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) avoids viral entry and increases type 1 interferon (IFN-1) signaling.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Similarly, the use of anti-Axl antibodies (Ab) completely inhibited the entry of the dengue virus (DENV) in different cell lines. A549, Vero, Cos-7, and Huh7 5.1 cells showed high levels of Axl receptor and infection by DENV occurred rapidly. In contrast, 293T, U937, or RAJI cells, all of which lack the receptor, were poorly susceptible to infection.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Axl mediates DENV infection not only by enhancing virus endocytosis but also by initiating downstream signaling pathways that facilitate infection. Additionally, Axl has recently been reported to mediate endocytosis of SARS-CoV-2, which causes the current COVID-19 pandemic.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Results show that blocking the Axl receptor decreases viral infection in H1299 pulmonary and human primary lung epithelial cells, and protein levels in COVID-19 patients correlate with the levels of spike protein of SARS-CoV-2 in bronchoalveolar fluid cells.</div><div class="NLM_p last">In addition to preventing the entry of the virus into the cells, RTK inhibitors are also capable of affecting other stages of the viral life cycle. For instance, genistein (<b>36</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) has been shown to block replication of human immunodeficiency virus-1 (HIV-1),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> arenavirus,<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> and herpes simplex virus type 1 (HSV-1).<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> The replication of IAV has also been disrupted by the inhibitors AG879 (tropomyosin receptor kinase A and human epidermal growth factor receptor 2-TrKA/HER2-inhibitor, <b>39</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and tyrphostin A9 (PDGFR, <b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), even though the mechanism of action and the specific targets are still unclear.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> A high-throughput screening (HTS) campaign of approximately 1300 compounds also found that tyrphostin A9 (<b>40</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) is able to block replication of TGEV in PK-15 or ST cells.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">4.  Mitogen-Activated Protein Kinases (MAPKs)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02180" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02180" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mitogen-activated protein kinase (MAPK) signaling pathway encompasses a complex network of phosphorylation cascades which transduce external stimuli into a wide range of cellular responses. Generally, the cascade is initiated by the interaction of a growth factor (GF) with its specific receptor (GFR), which drives the phosphorylation of MAPK kinase kinases (MAPKKKs) by a protein of the Ras/Rho family. The activation of MAPKKKs, which are Ser/Thr kinases, subsequently phosphorylates and activates MAPK kinases (MAPKKs, with seven MEK isoforms) and finally stimulates MAPK activity through dual phosphorylation on Thr and Tyr residues within a conserved Thr-X-Tyr motif located in the activation loop of the kinase domain (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). There are three important families within the MAPKs: ERKs (with ERK1 and ERK2 isoforms), JNKs (JNK1, JNK2, and JNK3 isoforms), and p38 MAPKs (with p38α, p38β, p38γ, and p38δ isoforms). Activated MAPKs lead to the activation of downstream proteins (MAPK-activated protein kinases, MAPKAPK) that produce the amplification of key molecules (mostly transcription factors) that are involved in important biological processes such as mitosis, metabolism, motility, survival, apoptosis, and differentiation (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. MAPK signaling cascade upon binding of a GF to its receptor, leading to the activation of MAPKAPK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the late 90s, some DNA and RNA viruses were proven to induce the MAPK cascade in infected cells.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> However, it was not until the turn of the millennium when Stephan Ludwig and co-workers disclosed an important breakthrough. They showed that proliferation of IAV was impaired by the inhibition of the RAF/MEK/ERK signaling pathway, which seems to be essential for virus production and ribonucleoprotein (RNP) export from the nucleus during the viral life cycle.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> They were able to show that treatment of infected Madin-Darby canine kidney (MDCK) cells with MEK1/2 inhibitor U0126 (<b>41</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) at 50 μM produced a decrease of virus titers up to 80%. This effect was observed at a multiplicity of infection (MOI) values of 0.0025 and 1.0 after 48 and 9 h, respectively. A reduction in the number of virus particles was also observed when a dominant negative mutant of ERK (ERK(2C3)) was transiently expressed. Importantly, whereas the synthesis of viral RNA or proteins was not affected by <b>41</b> treatments, viral RNP (vRNP) complexes were unable to exit the nucleus, inhibiting virus production. Later, they were also able to demonstrate that proliferation of both IAV and influenza B virus (IBV) was inhibited in MDCK cells by the treatment of <b>41</b> without the emergence of resistant variants,<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> including the H1N1 pandemic strain.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> This MEK1/2 inhibitor was additionally useful for the suppression of astrovirus replication in Caco-2 cells, and it was effective at all the stages of the viral life cycle.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of representative MAPK inhibitors with antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As discussed in the <a class="ref internalNav" href="#sec1" aria-label="Introduction">Introduction</a>, quantitative phosphoproteomic analysis is a recent methodology aimed at the study of phosphorylation profiles. In 2016, a study reported the use of this strategy to identify SP600125 (<b>42</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), a JNK-1 inhibitor, as a potential therapeutic solution for the infection of Japanese encephalitis virus (JEV).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> They examined the phosphorylation pattern in U251 cells upon JEV infection, and a number of the 604 proteins were differentially regulated compared to mock-infected cells. Then, the use of bioinformatic tools, such as the Ingenuity Pathway Analysis, allowed identification of JNKs as a protein kinase with a critical role in the infection. Experimental work to gain more insight into relationship between JEV infection and JNK-1 activation showed that JEV RNA genome extracted from infected cells participated in JNK-1 phosphorylation in a dose-dependent manner. Pharmacological inhibition of JNK-1 with derivative <b>42</b> produced a significant reduction of the inflammatory cytokines produced by JEV-infected U251 and BV-2 cells. Notably, they were able to reproduce the antiviral effect of <b>42</b><i>in vivo</i>. Quantification of the viral load in the brains of mice infected with JEV not only revealed a relevant decrease of infection but also an increased survival rate.</div><div class="NLM_p">Kinome (the complete set of protein kinases encoded in its genome) analysis has also proved to be useful in the identification of host signaling networks that are important for Middle East respiratory syndrome coronavirus (MERS-CoV) infection.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> In this study, they performed a temporal kinome analysis in Huh7 human hepatocytes infected with MERS-CoV. They found that the MAPK pathway (among others) has a pivotal role in the early stages of the infection. Briefly, incubation of a certain kinome (cell lysates) with immobilized peptide arrays as targets produces the phosphorylation of some of the substrates. Once the phosphorylated peptides are visualized using either radioactive ATP or specific phosphoprotein stains, the active kinases can be determined.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> They disclosed that both SB203580 (p38 inhibitor, <b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and U0126 (MEK1/2 inhibitor, <b>41</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) are capable of preventing infection by 45% and 51%, respectively, at 10 μM. In addition, U0126 (<b>41</b>) produced a much higher antiviral activity in preinfected cells when compared to its addition after 2 h of the infection. Importantly, the licensed drugs selumetinib (<b>9</b>) and trametinib (<b>10</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> and <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), which target the MAPK pathway, had outstanding inhibitory effects (>95%), making drug repurposing of existing medicines a useful strategy toward the treatment of MERS-CoV infection.</div><div class="NLM_p">Very recently, a drug repurposing strategy allowed the identification of the alkaloid papaverine (<b>44</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) as a therapeutic agent with antiviral properties against influenza viruses and paramyxoviruses.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> They selected various natural products (20) present in plants and known to have antiviral properties and evaluated them in infected HEK293T cells at 50 μM. Among them, <b>44</b> showed the best activity against different influenza virus and paramyxovirus strains, with IC<sub>50</sub> values ranging from 2.0 to 36.4 μM. Upon treatment of infected cells with <b>44</b>, the phosphorylation of MEK and ERK was reduced, while the total amount of protein remained unchanged. Additionally, inhibition of the MEK/ERK signaling pathway prevents vRNPs export from the nucleus, whereas it does not suppress viral RNA synthesis. These data suggest that the natural product papaverine exerts its effect at the end of the viral life cycle.</div><div class="NLM_p last">Atriva Therapeutics has discovered ATR-002 (<b>45</b>, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), an MEK inhibitor with antiviral properties. Compound <b>45</b> is the active metabolite of CI-1040, a compound that was previously used in clinical studies against cancer but was abandoned due to low plasma concentration presence. At that stage, the development of <b>45</b> was also discontinued, even though it had a lower IC<sub>50</sub> than CI-1040 for MEK inhibition (5.73 vs 17.00 nM).<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> However, <b>45</b> has been reported to have broad antiviral activity against different influenza virus strains of IAV and IBV, both in cell culture and in a mouse model.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> It has already successfully passed a Phase I clinical trial in 70 healthy subjects (Clinical trial identifier: NCT04385420).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Notably, Atriva Therapeutics is currently carrying out a double-blind, randomized Phase II trial designed to evaluate <b>45</b> as a treatment for COVID-19 (EU Clinical Trial Register Number: 2020-004206-59), the disease caused by SARS-CoV-2.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">5.  Src Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Src’s are nonreceptor Tyr kinases that are implicated in important cell physiological processes such as motility, differentiation, cell cycle progression, and survival, among others. There are 11 members in this family, classified in three different groups (I: Src, Fyn, Yes, and Fgr; II: Blk, Hck, Lck, and Lyn; III: Frk, Srm, and Brk).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Src inhibitors have been mainly studied in the oncology field. In fact, there are four FDA-approved compounds aimed at the treatment of different types of cancer: dasatinib (<b>5</b>), bosutinib (<b>11</b>), ponatinib (<b>12</b>), and vandetanib (<b>13</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Nevertheless, Src kinases are not the main players in the development of tumor malignancies, so a multidrug therapy is needed.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Targeting Src protein kinases has also been investigated for the treatment of other pathologies, such as for immunotherapy or viral infections.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> For instance, in 2019 saracatinib (<b>46</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was granted the Orphan Drug Designation by the FDA for the treatment of idiopathic pulmonary fibrosis and an early Phase I clinical trial for the treatment Parkinson’s disease psychosis is currently recruiting volunteers (Clinical trial identifier: NCT03661125).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Saracatinib (<b>46</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) inhibits MERS-CoV at early stages of the viral cycle with an estimated EC<sub>50</sub> of 2.9 μM and a CC<sub>50</sub> of >50 μM and other human coronaviruses such as hCoV-229E and OC43 with an EC<sub>50</sub> of 2.4 μM and 5.1 μM, respectively.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of FDA-approved Src kinase inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Regarding Src inhibitors targeting viral infections, dasatinib (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) has been the main player in this field so far. For instance, an immunofluorescence screening assay of 120 mammalian protein kinases showed a strong relationship between Src inhibition and anti-DENV activity.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Among the PKIs evaluated, <b>5</b> and <b>46</b> (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) displayed the best inhibition profile. They reduced DENV infection in Vero, Huh-7, and C6/36 cells in a dose-dependent manner from 0.05 to 5 μM. Notably, silencing the expression of Src protein using a small interfering RNA (siRNA) produced a significant drop in DENV titers 3 days after the infection, suggesting a key role of the Src kinase family in the DENV infection process. Specifically, Src kinase is necessary for the assembly and secretion of the virus, since immunofluorescence staining showed labeled DENV envelope protein accumulations within the perinuclear region but not throughout the cytoplasm and plasma membrane of the dasatinib-treated DENV-infected cells. Another recent study with <b>5</b> and <b>46</b> reported inhibition of DENV RNA replication via Fyn kinase.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a></div><div class="NLM_p">A lot of efforts have been made toward the identification of Src inhibitors for the treatment of HIV-1 infection. Lck kinase promotes T-cell lymphocyte activation through the activation of various transcription factors, such as NF-κB, NFAT and AP-1, which are essential for HIV-1 replication.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> In fact, an immunomodulation strategy using dasatinib (<b>5</b>, <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) has been proven to control HIV-1 viral replication through downregulation of T-cell proliferation by using antigens derived from trivalent influenza vaccine.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Regarding its mechanism of action, there are reports supporting that <b>5</b> blocks HIV-1 infection both during the entry at the hemifusion step and downstream by targeting the cellular restriction factor SAMHD1 for dephosphorylation. In the first case, treatment of U87.CD4.CCR5 cells with 300 nM of <b>5</b> decreased cell–cell fusion with HIV-1-envelope-expressing cells by 93%.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Nonetheless, <b>5</b> was ineffective in inhibiting HIV-1 fusion with peripheral blood lymphocytes (PBMC) at any concentration assayed, but it was able to completely impair HIV-1 reverse transcription in the same cell line.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Even though blocking Src kinases may have a great advantage in the treatment of HIV-1 over immunosuppression therapies, the risk for increased toxicity has to be carefully evaluated.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p last">Interestingly, a multidrug strategy has been carried out which found that the use of a combination of Src kinase inhibitor <b>5</b> with the viral entry inhibitor sofosbuvir showed synergistic effects in the treatment of HCV. This potent combination produced a drop in sofosbuvir’s IC<sub>50</sub> up to 210-fold in Huh7.5.1 cells, thus improving the antiviral activity against HCV.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">6.  Cyclin-Dependent Kinases</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80516" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80516" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cyclin-dependent kinases (CDKs) phosphorylate Ser/Thr residues in substrate proteins upon binding with a cyclin regulatory protein whose levels are controlled during the cell cycle. When a cyclin binds to a CDK, there is a conformational change that allows additional interactions of the kinase with the ATP in the catalytic domain so that phosphorylation can take place. The most important CDKs can be grouped according to their biological role. They are mainly involved in cell cycle regulation and gene transcription. There are three subfamilies related to the regulation of the cell cycle (CDK1, CDK4, and CDK5) that can bind multiple cyclins, and there are five more conserved transcriptional subfamilies (CDK7, CDK8, CDK9, CDK11, and CDK20) activated by a single cyclin.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Regarding their specificity, CDK inhibitors can be classified as nonspecific (not pharmacologically relevant), pan-specific (they preferentially inhibit CDKs, but they are not very selective), oligospecific (they only inhibit a subset of CDKs), and monospecific (specific against one CDK). Additionally, they can be grouped considering their chemical structure as purine-type and non-purine-type inhibitors.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Because CDKs are usually redundant regarding their biological functions, inhibition of a single CDK may be insufficient. Thus, searching for pan- or oligospecific inhibitors is usually a more fruitful approach than aiming for monospecific blockers.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Traditionally, blocking CDKs has been a popular strategy for the treatment of many types of cancer.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> In fact, palbociclib (<b>14</b>), ribociclib (<b>15</b>), and abemaciclib (<b>16</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) are the only FDA-approved CDK inhibitors that are prescribed as breast cancer medications.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Compound <b>14</b> inhibits HIV-1 and HSV-1 replication <i>in vitro</i> with EC<sub>50</sub> values of 0.016 μM and 0.020 μM, respectively. This is partially due to its CDK6 inhibitory properties (IC<sub>50</sub> = 0.016 μM).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Recently, compound <b>16</b> has shown <i>in vitro</i> activity against SARS-CoV-2 (IC<sub>50</sub> = 6.6 mM, CC<sub>50</sub> > 50 mM).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a></div><div class="NLM_p">The purine analogue CDK inhibitor (<i>R</i>)-roscovitine (<b>47</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was first reported to impair human cytomegalovirus (HCMV) DNA synthesis in 1997.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Since then, other CDK inhibitors (both purine- and non-purine-type) have been proven to have antiviral activities against a wide range of viruses.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> These agents exert their therapeutic action mainly by impairing viral transcription in infected cells. The selectivity against viral versus cellular transcription is not yet fully characterized and understood.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of the first molecules identified as CDK inhibitors with antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The inhibition of CDKs has been extensively studied for the treatment of HIV-1 infection. In the early 2000s, the CDK1/2/4 inhibitor flavopiridol (<b>48</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was one of the first CDK inhibitors disclosed to affect HIV-1 replication by impairing Tat-activated transcription.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> In 2010, Kashanchi and co-workers reported a small screening of CDK inhibitors for the identification of agents with antiviral activity against HIV-1.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> A set of 24 molecules was assayed in various cell lines by measuring cell viability after 74 h of the HIV-1 infection. The purine analogue alsterpaullone (<b>49</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was identified as the best compound. It showed a dose-dependent inhibition of viability in infected ACH2, OM10.1, J1-1, and U1 cells and good selectivity compared to the control uninfected group. By using [γ-<sup>32</sup>P]-labeled histone H1 as substrate for autoradiography visualization, immunoprecipitation experiments revealed that <b>49</b> completely inhibited CDK2 kinase activity in infected cells at 0.5 μM,. The expression and protein levels of functional CDK2 were also downregulated using the inhibitor in HIV-1 infected cells. Importantly, a synergistic effect was observed when both <b>47</b> and <b>49</b> were used in PBMC infected cells, reinforcing the idea indicated previously that inhibition of multiple CDKs may be needed to achieve the desired effect. A recent study also showed that palbociclib (<b>14</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), a potent CDK4/6 inhibitor, reduced phosphorylation of sterile α motif and HD domain-containing protein-1 (SAMHD1) in primary macrophages and CD4<sup>+</sup> T lymphocytes, blocking HIV-1 reverse transcription and replication.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> This effect of <b>14</b> on SAMHD1 has also been observed in the case of HSV-1.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p">Infections caused by DNA viruses have also been targeted using CDK inhibitors. For instance, an in-house kinase-directed library of 144 compounds was screened to identify selective CDK9 inhibitors as antiviral agents. As a result, compound FIT-039 (<b>50</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) showed the best results with an IC<sub>50</sub> of 5.8 μM, and it proved to be an ATP competitive inhibitor.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> In order to examine its antiviral properties, Vero cells were infected with HSV-1 at an MOI of 100, and viral replication was inhibited in a dose-dependent manner with no adverse effects on cell viability (EC<sub>50</sub> and EC<sub>80</sub> were 0.69 μM and 4.0 μM, respectively).</div><div class="NLM_p">Additionally, <b>50</b> decreased phosphorylation of the carboxyterminal domain of RNA polymerase II in HSV-1 infected HEK293 cells, suggesting that the antiviral activity may be attributed to hampered viral transcription. Notably, when treated with FIT-039, mice presenting an HSV-1 infected skin lesion showed regression of the injury and survival, demonstrating <i>in vivo</i> effects. Compound <b>50</b> inhibited the replication of other DNA viruses, such as HSV-2, HCMV, human adenovirus (HAdV) type 5, and hepatitis B virus (HBV).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Although the antiviral effect of <b>50</b> is acknowledged, the described biochemical IC<sub>50</sub> value for the inhibition of CDK9 is somewhat higher than cellular EC<sub>50</sub> and EC<sub>80</sub> values, compromising the idea that the kinase inhibition is the unique mechanism of action.</div><div class="NLM_p last">HTS campaigns have also proved to be rewarding in discovering CDK inhibitors as therapeutic agents for the treatment of other viruses such as IAV or ZIKV. In the first case, flavopiridol (<b>48</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was identified from a 273 kinase inhibitor library, showing antiviral activity against various IAV strains in A549 cells with no cytotoxic effects.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Even though they do not discuss the mechanism of action, they show an interesting synergistic effect using a combination of <b>48</b> (CDK1/2/4/6 inhibitor) and dinaciclib (CDK1/2/5/9 inhibitor, <b>51</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Interestingly, compound <b>51</b> has recently been identified as an antiviral agent in a quantitative mass spectrometry-based phosphoproteomics survey aimed at a study of the phosphorylation pattern produced by SARS-CoV-2 infection.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Regarding the ZIKV, they use both the Library of Pharmacologically Active Compounds and the NCATS pharmaceutical collection, with a total of 4096 compounds.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> ZIKV infection in SNB-19 cells was inhibited by compound PHA-690509 (<b>52</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) in a dose-dependent manner with an IC<sub>50</sub> of 1.72 μM. In this report, they investigated the underlying mechanism by carrying out time-of-addition experiments which revealed that the reduction of viral RNA was only apparent after the entry phase and regardless the moment of addition of <b>52</b> (1 h before or 4 h after inoculation of the virus). The results all together led them to suggest that the identified hit compound produced the antiviral effect in the RNA replication step.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">7.  Phosphatidylinositol-3-Phosphate-5 Kinase (PIKfyve)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11606" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11606" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Phosphatidylinositol-3-phosphate-5 kinase (PIKfyve) is a lipid kinase located in the endosome membrane on the cytosolic face. It is responsible for the synthesis of phosphatidylinositol-3,5-biphosphate (PtdIns(3,5)P<sub>2</sub>) by phosphorylation of phosphatidylinositol-3-phosphate (PtdIns3P).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">Phosphoinositides are eukaryotic membrane phospholipids.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> They are markers for defining the identity of the endolysosomal subcompartments since they are restricted to specific intracellular membranes. The phosphorylated derivatives of phosphatidylinositol (PtdIns) previously mentioned are necessary for the endosome membrane dynamics and protein sorting.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> PtdIns3P is found in early endosome membranes, and it is involved in endosome maturation and multivesicular body biogenesis. In addition, PtdIns(3,5)P<sub>2</sub> is a phosphoinositide implicated in various trafficking events associated with the endocytic pathway, it regulates the endosome maturation and it is involved in vacuole formation and size control. Although PtdIns(3,5)P<sub>2</sub> represents only 1% of the phosphoinositides, it is essential for regulating of endosomal membrane homeostasis and the endolysosomal trafficking system.<a onclick="showRef(event, 'ref131 ref134'); return false;" href="javascript:void(0);" class="ref ref131 ref134">(131,134)</a></div><div class="NLM_p">PIKfyve is crucial for lysosome fission and fusion between lysosomes and autophagosomes. These processes require a balance between PtdIns3P and PtdIns(3,5)P<sub>2</sub> on the lysosomal membrane that is established by PIKfyve. Therefore, PIKfyve plays an essential role in maintaining cell morphology by regulating late endocytic membrane homeostasis.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Because of this function, PIKfyve inhibition affects the early endocytic pathway.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> PIKfyve ablation causes endosomal swelling and vacuolation of late endosomes, and these changes could be caused by the decrease of the membrane fission and concomitant interference in endosomal traffic.<a onclick="showRef(event, 'ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref136 ref137">(136,137)</a> Thus, PIKfyve seems to play multiple roles in trafficking events. PIKfyve inhibitors have been developed as cancer therapeutics.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> Being a selective PIKfyve inhibitor, apilimod (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> is in clinical trials for treatment of B-cell non-Hodgkin lymphoma.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> In addition, PIKfyve has been identified as a therapeutic target in amyotrophic lateral sclerosis (ALS).<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Modulation of vesicle trafficking by PIKfyve inhibitors rescues neurodegeneration due to the C9ORF72 repeat expansion.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> The role of PIKfyve in endosomal maturation, and therefore in trafficking events, has also been exploited for the development of antimicrobials.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a></div><div class="NLM_p">As mentioned above, virus entry initiates when the virus attaches to the host cell. The viral entry ends when the viral content reaches the cytosol. The binding process can occur following the endocytic uptake and, in this case, can use different initial trafficking routes to reach the site on membrane fusion. Moreover, the precise endosomal compartment used for virus penetration differs among viruses, and the pH threshold for activation allows the distinction between early and late-penetrating viruses that penetrate through the membranes of early (pH 6.5 to 6.0) and late endosomes (pH 6.0 to 5.5), respectively.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><div class="NLM_p">Inhibition of PIKfyve has therefore been reported to have a negative effect in the infection by diverse viruses such as African swine fever virus (ASFV),<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Ebola virus (EBOV),<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> or even SARS-CoV-2.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">EBOV requires engagement of the receptor protein Niemann-Pick C1 (NPC1) to enter into the host cell.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> This receptor is a polytopic protein that resides in the limiting membrane of late endosomes/lysosomes, which indicates the need for endosomal trafficking to reach the intracellular compartments containing NPC1.<a onclick="showRef(event, 'ref146 ref147 ref149'); return false;" href="javascript:void(0);" class="ref ref146 ref147 ref149">(146,147,149)</a> PIKfyve inhibition impeded colocalization of EBOV with NPC1 receptor and therefore entry into the cytoplasm. The requirement of PIKfyve for EBOV entry was demonstrated by using enzymatically dead mutants and also inhibitors of the enzyme such as apilimod (<b>18</b>), YM-201636 (<b>53</b>), and vacuolin-1 (<b>54</b>) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Remarkably, all pathogenic filoviruses were susceptible to PIKfyve inhibition.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of representative PIKfyve inhibitors bearing a morpholino-azine core group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Coronaviruses can enter into the cells by direct fusion at the plasma membrane or following receptor-mediated endocytosis, depending both on the protease TMPRSS2 and angiotensin converting enzyme 2 (ACE2) receptor.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> After binding of the SARS-CoV-2 spike (S) protein to the ACE2 receptor, the virus enters into the cell and is delivered to the endo-/lysosomal pathway.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Thus, perturbation of the normal endosomal trafficking by PIKfyve inhibitors may block the entry of SARS-CoV-2.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> In fact, a phase 2 clinical trial is currently recruiting volunteers to study the effect of apilimod (<b>18</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) in COVID-19 patients (NCT04446377).</div><div class="NLM_p">The lack of PtdIns(3,5)P<sub>2</sub> caused by PIKfyve inhibition is behind the antiviral effect of PIKfyve inhibitors. On one hand, this depletion produces endosomal swelling into small and spherical vacuoles, and, as consequence, the virus particles are retained in these vacuoles located adjacent to the endosomal limiting membrane and cannot fuse with it.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> On the other hand, virions might fuse with smaller intraluminal vesicles in the endosomal lumen, but the lack of PtdIns(3,5)P<sub>2</sub> avoids the fusion with the endosomal limiting membrane and the subsequent release of virus genome into the cytosol.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><div class="NLM_p">However, in spite of the antiviral effects exerted by PIKfyve inhibition, the number and chemical diversity of the reported inhibitors are few,<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> most of them bear a morpholino-azine core group as the parent compound, apilimod<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> (<b>18</b>, <b>53</b>–<b>55</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><div class="NLM_p">The physiological effects described for these inhibitors include the inhibition of autophagy, reduced generation of IL-12/IL-23 and reduced dendritic cell infiltration in psoriasis.<a onclick="showRef(event, 'ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref154 ref155 ref156">(154−156)</a> As mentioned above, some PIKfyve inhibitors also prevent viral infection. However, despite their potential as broad-spectrum antivirals, no specific programs to optimize antiviral properties of PIKfyve inhibitors have been reported. Moreover, almost all of the known inhibitors shared the same fundamental structure, that is, an azine core together with a common morpholine ring (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><div class="NLM_p last">Therefore, since perturbing the common endosomal trafficking using PIKfyve inhibitors is thought to be the mechanism that may block entry of multiple viruses, the development of specific medicinal chemistry programs to optimize both enzyme inhibition and antiviral efficacy may be a promising strategy to obtain broad-spectrum antivirals targeting viruses that requires the endosomal pathway for infection.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">8.  Miscellaneous</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> G Protein-Coupled Receptor Kinases (GRKs)</h3><div class="NLM_p">GRKs modulate G protein-coupled receptor (GPCR) signaling through receptor phosphorylation, allowing the binding of arrestin proteins, which can lead to either receptor internalization or arrestin-mediated signaling cascades. GRKs are divided in three subfamilies based on their primary structure: visual family (GRK1 and GRK7), GRK2 family (GRK2 and GRK3), and GRK4 subfamily (GRK4, GRK5, and GRK6).<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> GPCR signaling is involved in a wide range of biological functions, and its deregulation is associated with several pathologies. Thus, GRKs are popular therapeutic targets for the development of drugs to control GPCR signaling cascades. Regarding their antiviral activity, GRK2 inhibitors have recently been proposed as an efficient strategy to treat IAV infections. A phosphoproteomic-based kinase screening in A549 cells allowed the investigation of the phosphorylation changes that occurred in the kinome upon IAV infection.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Quantification of the phosphorylation, which was carried out using stable isotope labeling with amino acids in cell culture (SILAC), revealed a unique phosphorylation signature induced by IAV entry (5–15 min postinfection). Among all the identified proteins, GRK2 was proposed to be a novel kinase activated in the early steps of the infection. Additional experiments validated that IAV infection induced activation of GRK2 and its translocation to the plasma membrane. Silencing the expression of GRK2 using siRNAs reduced viral titers by 10–100 fold, which supports the participation of GRK2 in the entry process of IAV infection. Moreover, the GRK2 inhibitor methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate (<b>56</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) also blocked viral replication. However, its high IC<sub>50</sub> value against GRK2 makes no definitive kinase intervention pointing to another mechanism of action that is probably associated with compound <b>56</b>.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of inhibitors <b>1</b>, <b>5</b>, <b>17</b>, <b>19</b>, and <b>56</b>–<b>61</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Abelson Tyrosine Kinases (ABL)</h3><div class="NLM_p">ABL genes encode for two different ABL proteins in humans, ABL1 and ABL2. The first one is involved in the repair of damaged DNA and cell differentiation, whereas ABL2 binds actin and microtubules to enhance cytoskeletal remodelling.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> A drug repurposing campaign of FDA-approved medicines and compounds in advanced clinical development (a total of 290 molecules) was carried out to search for antiviral agents for the treatment of MERS-CoV and SARS-CoV.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> An ELISA screening was carried out in the case of MERS-CoV, and a cytopathic effect inhibition assay was used instead for SARS-CoV. Data revealed a total of 66 active hits, from which three were reported to be ABL1 inhibitors. While imatinib (<b>1</b>) mesylate and dasatinib (<b>5</b>) are active against both infections, nilotinib (<b>17</b>) only inhibits SARS-CoV (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). These three compounds exert their antiviral activity with low toxicity and with EC<sub>50</sub> values ranging from 2.1 to 17.6 μM. The researchers did not perform any additional experiments in order to disclose mechanistic insights of the infection. Recently, <i>in vitro</i> inhibition of SARS-CoV-2 by imatinib (<b>1</b>) has been reported with an EC<sub>50</sub> value of 9.82 μM in Vero E6 cell cultures.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> However, based in the previous inhibition of imatinib (<b>1</b>) in human coronaviruses, clinical trials for COVID-19 with this ABL inhibitor have started (NCT04394416) despite the low possibility of reaching a high enough plasma or lung concentration in human with the standard imatinib dosage (400 or 800 mg/day).<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Moreover, recent preclinical studies using the golden Syrian hamster model show that imatinib (<b>1</b>) fails to prevent SARS-CoV-2 <i>in vivo</i> replication despite high drug concentrations in plasma and in the lung.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div><div class="NLM_p last">On the basis of a previous study aimed at the identification of molecules with anti-DENV activity,<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Yang and co-workers identified the allosteric inhibitor GNF-2 (<b>57</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) which inhibited ABL (IC<sub>50</sub> = 138 nM) and showed a reduction in DENV activity affecting both the viral entry and replication steps.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Compound <b>57</b> was proven to target the DENV E protein extracellularly and ABL inside the cell. A structure–activity relationship (SAR) was carried out around <b>57</b> in order to obtain selectivity between the ABL-dependent and -independent inhibition pathways. While 4,6-disubstituted pyrimidine analogues were more selective toward ABL, the 2,4-disubstituted counterparts showed more potency against DENV E protein. Although the latter is the most potent inhibitor of the DENV infection (IC<sub>50</sub> = 5–25 μM), ABL kinase was confirmed to be a valuable therapeutic target for the treatment of DENV infection.</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Calcium/Calmodulin-Dependent Protein Kinases II (CaMKII)</h3><div class="NLM_p last">The CaMKII family comprises four highly homologous isoforms (α, β, γ, and δ). These are extensively expressed in brain cells (>1% of the total protein), and they mediate cellular Ca<sup>2+</sup> to control neuronal plasticity and cognitive functions.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Inhibition of CaMKII has traditionally been a used as a therapeutic strategy for the treatment of heart diseases.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> However, CaMKII inhibitors have very recently been proposed to inhibit flavivirus infections such as DENV and ZIKV.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> On the basis of previous investigations, a series of benzenesulfonamides were designed and prepared to carry out a SAR study. The synthesized compounds were assessed for their anti-DENV activity using a reporter virus expressing the enhanced green fluorescent protein to infect human neuroblastoma BE(2)C cells. Data revealed that the <i>N</i>-phenyl substituent seemed to be crucial for the activity, cycloalkyl groups in the “terminal part” improved activity, and the benzenesulfonamide ring tolerates few modifications. The best CaMKII inhibitor (BSA9, <b>58</b>, IC<sub>50</sub> = 0.79 μM, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was able to inhibit infection with both DENV and ZIKV (EC<sub>50</sub> = 1.52 and 1.91 μM, respectively) in BE(2)C cells with no effects on cytotoxicity, cell proliferation, or cell viability. Regarding the mechanism of action, time-of-addition experiments showed that <b>58</b> blocks cellular entry in a concentration-dependent manner. Importantly, the optimized compound increased survival in DENV- and ZIKV-infected mice, suggesting inhibition of CaMKII as a novel therapeutic strategy for the treatment of these types of infections.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Ataxia Telangiectasia and Rad3-Related Kinase (ATR)</h3><div class="NLM_p last">ATR kinase is an important protein for ensuring faithful DNA replication during the S phase of the cell cycle.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Very recently, inhibition of ATR has been proposed as a novel strategy for treatment in the COVID-19 pandemic, caused by SARS-CoV-2.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> They used a library of 430 reported PKIs to identify the nucleoside analogue berzosertib (<b>59</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), a selective ATR kinase inhibitor, which showed remarkable antiviral activity in Vero-E6 cells and in HEK293T cells, overexpressing the angiotensin converting enzyme 2 (ACE2) receptor. Regarding the mechanism of action, <b>59</b> is known to inhibit the DNA damage response pathway,<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> and they observed an activation of this pathway upon SARS-CoV-2 infection in Vero-E6 cells. However, further experiments should be carried out in order to validate this hypothesis.</div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Adenosine 5′ Monophosphate-Activated Protein Kinase (AMPK)</h3><div class="NLM_p last">AMPK is known to be a critical sensor for the regulation of metabolism,<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> and some studies have linked its deregulation with viral replication.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> An interesting example published in 2013 stated that AMPK was required for EBOV entry, so its inhibition may provide a new avenue for the development of antivirals.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> They demonstrated that functional AMPK was necessary for EBOV infection, since it was drastically reduced in mouse embryonic fibroblasts lacking the catalytic subunits of the kinase. Besides, the selective inhibitor dorsomorphin (<b>60</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was able to block EBOV replication in Vero cells in a dose-dependent manner; it was most effective at early times of addition. Importantly, dorsomorphin was effective in decreasing the infection of human macrophages, which are critical targets of EBOV <i>in vivo</i>.</div></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Phosphatidylinositol 3-Kinases (PI3K)/Akt/Mammalian Target of the Rapamycin (mTOR) Pathway</h3><div class="NLM_p">Another central lipid kinase is phosphatidylinositol 3-kinase (PI3K), which phosphorylates inositol phospholipids to produce PtdIns3P, phosphatidylinositol-3,5-biphosphate (PtdIns(3,5)P<sub>2</sub>), and phosphatidylinositol-3,4,5-triphosphate (PtdIns(3,4,5)P<sub>3</sub>).<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> This kinase and its downstream effectors, Akt (also known as protein kinase B) and mTOR activates many intracellular signaling pathways that regulate diverse functions such as vesicle trafficking, cell metabolism or survival.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Regarding their structure and substrate specificity, PI3Ks can be divided into three classes (I, II, and III), where class I has been the most studied.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> Upregulation of PI3Ks has been traditionally linked to the development of human cancer. In fact, there are a great number of ongoing clinical trials with PI3K inhibitors for the treatment of different types of cancer, and three compounds have received FDA approval for commercialization (idelalisib, copanlisib, duvelisib).<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><div class="NLM_p last">There is also scientific evidence that PI3K is involved in different phases of the viral infection process, such as viral entry, viral genome replication, and its translation into proteins.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Particularly, there have been extensive studies regarding the activation of PI3K linked to viral uptake. For example, IAV attachment to the membrane of A549 lung epithelial cells induces the creation of lipid clusters which activate the PI3K/Akt signaling pathway, promoting viral internalization.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Infection of Vero-E6 cells with Zaire EBOV is impaired by preventing its entry using specific inhibitors of PI3K (LY294002 (<b>61</b>), <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) and its downstream effector Atk (no specified).<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Additionally, inhibitor <b>61</b> has also been used to block the entry of other viruses such as HSV-1<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> and African swine fever virus.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> In contrast to most studies, a recent article states that inhibition of PI3K with <b>61</b> increased viral titers in several cell lines when infected with West Nile virus (belonging to the <i>Flaviviridae</i> family), provoking also a downregulation of the IFN-1 signaling pathway.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> However, the molecular mechanisms that link PI3K activation with viral infection remain elusive in most cases, and more investigation needs to be carried out to shed light on this area.</div></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Sphingosine Kinase (SphK)</h3><div class="NLM_p last">Sphingolipids are molecules involved in signal transduction inside and outside the cell. The phosphorylation of sphingosine to its active monophosphate form (S1P) is catalyzed by the different SphK isozymes (SphK1 and SphK2). Inhibitors of SphK have been shown to have a place in reduction SARS-CoV-2 replication and viral load.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Opaganib (<b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), a specific SphK2 inhibitor with a <i>K</i><sub>i</sub> of 9.8 μM,<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> is able to reduce the inflammatory pathway, and it simultaneously reduces viral propagation in an <i>in vitro</i> model of human lung bronchial tissue.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> On the basis of these properties, compound <b>19</b>, a lipid kinase inhibitor, was evaluated in clinical trials phase 2/3 for severe COVID-19 patients requiring hospitalization and oxygen treatment (NCT04467840) with good results.</div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">9.  Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03207" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03207" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinases are involved in a myriad of physiological events, that are considered bona fide druggable targets. To date, kinase inhibitors are in clinical use for the treatment of cancer and inflammatory processes. However, because of the therapeutic potential of kinases, the scope of diseases is growing faster and is being expanded significantly beyond nononcologic diseases.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> In this perspective, we have revisited the state-of-art of kinase inhibitors, PKIs and LKIs, as alternative drugs for the treatment of viral infections based on host targets.</div><div class="NLM_p">Available kinase inhibitors approved by the FDA or in advance regulatory phases offer a unique opportunity to go deeper into their role in other diseases. However, since FDA-approved medicines and compounds in advanced clinical trials have already gone through an extensive optimization, repurposing strategies usually do not provide much improvement. Moreover, drug repurposing programs may help gain a better understanding on how kinases function during a viral infection and, together with all the structural knowledge already available, could assist the beginning of successful medicinal chemistry programs both in academia and industry, which are currently very scarce, and render new hits that could give more flexibility to improving pharmacokinetic and biological properties.</div><div class="NLM_p">A great body of evidence supports the relationship between PK inhibition and antiviral properties. Examples of such data encompass important PK families such as NAKs, RTKs, MAPKs, Src kinases, and CDKs, among others. As a result, there have been some successful results within drug repurposing campaigns with the identification of old compounds with antiviral properties as a novel strategy for the treatment of viral infections. Notably, important results have been obtained with the multikinase inhibitor dasatinib (<b>5</b>), which has shown remarkable potential as an antiviral agent both alone and in combination with other compounds. Nevertheless, there are still many aspects to be discerned in the use of dasatinib (<b>5</b>) regarding the mechanism of action or toxicity issues.</div><div class="NLM_p">In the case of LKs, regardless of their critical role in a variety of cellular functions, inhibitors have been identified that are able to reach different phases of clinical trials, but none of them have been yet commercialized by the FDA. Probably, further experimentation needs to be carried out in this field to fully discern and understand the mechanism of action of this type of inhibitors. PIKfyve and PI3K are promising LKs that have shown a great potential for the development of broad-spectrum antivirals.</div><div class="NLM_p last">In summary, extensive use of FDA-approved kinase inhibitors has been quite useful for deciphering the role of host kinases in viral infection. While specific kinase inhibitors are needed to completely unveil their mechanism of action, intensive medicinal chemistry programs focused on the optimization of kinase inhibitors with antiviral properties are also required. This is one of the challenges to be faced by scientists in this field in order to obtain high-quality kinase inhibitors as future antiviral drugs.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00302" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28162" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28162" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Gil</span> - <span class="hlFld-Affiliation affiliation">Centro de Investigaciones Biológicas
Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3882-6081" title="Orcid link">http://orcid.org/0000-0002-3882-6081</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c6a5a7b4aba3a8e8a1afaa86a5b5afa5e8a3b5"><span class="__cf_email__" data-cfemail="0467657669616a2a636d684467776d672a6177">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Martínez</span> - <span class="hlFld-Affiliation affiliation">Centro de Investigaciones Biológicas
Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2707-8110" title="Orcid link">http://orcid.org/0000-0002-2707-8110</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e0818e81ce8d819294898e859aa083938983ce8593"><span class="__cf_email__" data-cfemail="f8999699d695998a8c91969d82b89b8b919bd69d8b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Javier García-Cárceles</span> - <span class="hlFld-Affiliation affiliation">Centro de Investigaciones Biológicas
Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Caballero</span> - <span class="hlFld-Affiliation affiliation">Centro de Investigaciones Biológicas
Margarita Salas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain</span></div></li></ul></li><li></li><li><span class="author-information-subsection-header">Funding</span><p>Funding from “la Caixa” Banking Foundation (LCF/PR/HR19/52160012), CSIC (202020E103 and 202080E293), and AEI (Grant PID2019-105600RB-I00) is acknowledged. E.C. holds a JAE Intro fellowship (JAEINT_20_01339) from CSIC.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Javier García-Cárceles</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=BIO-d7e3202-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Javier García-Cárceles</b> received his Ph.D. in organic chemistry from Complutense University of Madrid (Spain) in 2017, where he worked on the development of novel GPCR allosteric modulators for neurodegenerative diseases. He has carried out a secondment with Brian Kobilka (Nobel Prize of Chemistry 2012) at the University of Stanford (USA), working on biochemistry and biophysics of cell membrane proteins. After his Ph.D., he moved to the School of Chemistry at the University of Bristol (UK) to hold a Research Associate position, where he worked on the development of novel catalysts for the activation of C–C and C–N bonds. In 2020, he started as a postdoctoral researcher at CIB-CSIC, where he is currently working on the design and development of new molecules for unmet diseases.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Elena Caballero</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=BIO-d7e3207-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Elena Caballero</b> received her degree in chemistry in 2020 with honors from the Complutense University of Madrid (Spain). She is currently enrolled in the Drug Discovery Master Program of the same University. She has obtained a starting grant (JAE Intro CSIC fellowship) for design and synthesis of new drugs for COVID-19 and neurodegenerative diseases at CIB-CSIC.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Carmen Gil</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=BIO-d7e3212-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carmen Gil</b> received her Ph.D. from Complutense University of Madrid (Spain) in 2001. After a postdoctoral appointment at Bonn University (Germany), she joined the Medicinal Chemistry Institute (IQM-CSIC) in 2004 (first as Associate Researcher and since 2007 as Tenured Scientist). In 2014, she cofounded the spin-off Ankar Pharma. Currently, she is Research Scientist at CIB-CSIC. Her main expertise is in the drug discovery field. With a strong background in medicinal chemistry, her research is applied with a high content of translational research and focuses on those areas that will have an impact on the treatment of human diseases.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Ana Martínez</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=BIO-d7e3217-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ana Martínez</b> received her organic chemistry degree and Ph.D. in medicinal chemistry from Complutense University (Spain). Since 1990, she has been a tenured research staff member of CSIC. She has great experience in technological transfer, being R&D Director of NeuroPharma from 2002 to 2008 and founder of Ankar Pharma in 2014. Currently, she is a research professor at CSIC and head of the Medicinal and Biological Chemistry group at CIB-CSIC. Her interests are focused on drug discovery and development for severe unmet diseases, having some compounds in clinical trials.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AAK1</td><td class="NLM_def"><p class="first last">adaptor-associated kinase 1</p></td></tr><tr><td class="NLM_term">Ab</td><td class="NLM_def"><p class="first last">antibody</p></td></tr><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">Abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">ACE2</td><td class="NLM_def"><p class="first last">angiotensin converting enzyme 2</p></td></tr><tr><td class="NLM_term">AGC</td><td class="NLM_def"><p class="first last">protein kinase A, G, and C families</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">adenosine-5′-monophosphate-activated protein kinase</p></td></tr><tr><td class="NLM_term">AP</td><td class="NLM_def"><p class="first last">adaptor protein</p></td></tr><tr><td class="NLM_term">AP-1</td><td class="NLM_def"><p class="first last">activator protein 1</p></td></tr><tr><td class="NLM_term">AP2</td><td class="NLM_def"><p class="first last">adaptor protein 2</p></td></tr><tr><td class="NLM_term">AP2M1</td><td class="NLM_def"><p class="first last">μ subunit of the AP2 complex</p></td></tr><tr><td class="NLM_term">ASFV</td><td class="NLM_def"><p class="first last">African swine fever virus</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and Rad3-related kinase</p></td></tr><tr><td class="NLM_term">BIKE/BMP2K</td><td class="NLM_def"><p class="first last">BMP-2 inducible kinase</p></td></tr><tr><td class="NLM_term">CaMKII</td><td class="NLM_def"><p class="first last">calcium/calmodulin-dependent protein kinases II</p></td></tr><tr><td class="NLM_term">CaMKs</td><td class="NLM_def"><p class="first last">Ca<sup>2+</sup>/calmodulin-dependent protein kinases</p></td></tr><tr><td class="NLM_term">CDKs</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">CK</td><td class="NLM_def"><p class="first last">casein kinase</p></td></tr><tr><td class="NLM_term">CLK</td><td class="NLM_def"><p class="first last">CDC-like kinase</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease 2019</p></td></tr><tr><td class="NLM_term">DAAs</td><td class="NLM_def"><p class="first last">direct-acting antivirals</p></td></tr><tr><td class="NLM_term">DENV</td><td class="NLM_def"><p class="first last">dengue virus</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">EBOV</td><td class="NLM_def"><p class="first last">Ebola virus</p></td></tr><tr><td class="NLM_term">EGF</td><td class="NLM_def"><p class="first last">epidermal growth factor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">ERKs</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">GAK</td><td class="NLM_def"><p class="first last">cycling G-associated kinase</p></td></tr><tr><td class="NLM_term">GF</td><td class="NLM_def"><p class="first last">growth factor</p></td></tr><tr><td class="NLM_term">GFR</td><td class="NLM_def"><p class="first last">growth factor receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">GRKs</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinases</p></td></tr><tr><td class="NLM_term">GSK</td><td class="NLM_def"><p class="first last">glycogen synthase kinase</p></td></tr><tr><td class="NLM_term">HAdV</td><td class="NLM_def"><p class="first last">human adenovirus</p></td></tr><tr><td class="NLM_term">HCMV</td><td class="NLM_def"><p class="first last">human cytomegalovirus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HCVcc</td><td class="NLM_def"><p class="first last">cell culture HCV particles</p></td></tr><tr><td class="NLM_term">HIV-1</td><td class="NLM_def"><p class="first last">human immunodeficiency virus-1</p></td></tr><tr><td class="NLM_term">HSV-1</td><td class="NLM_def"><p class="first last">herpes simplex virus type 1</p></td></tr><tr><td class="NLM_term">HSV-2</td><td class="NLM_def"><p class="first last">herpes simplex virus type 2</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">IAV</td><td class="NLM_def"><p class="first last">influenza A virus</p></td></tr><tr><td class="NLM_term">IBV</td><td class="NLM_def"><p class="first last">influenza B virus</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">IFN-1</td><td class="NLM_def"><p class="first last">type 1 interferon</p></td></tr><tr><td class="NLM_term">IPEC</td><td class="NLM_def"><p class="first last">porcine intestinal columnar epithelial cells</p></td></tr><tr><td class="NLM_term">JEV</td><td class="NLM_def"><p class="first last">Japanese encephalitis virus</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">janus kinase</p></td></tr><tr><td class="NLM_term">LKI</td><td class="NLM_def"><p class="first last">lipid kinase inhibitor</p></td></tr><tr><td class="NLM_term">LK</td><td class="NLM_def"><p class="first last">lipid kinase</p></td></tr><tr><td class="NLM_term">MAPKs</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinases</p></td></tr><tr><td class="NLM_term">MAPKAPK</td><td class="NLM_def"><p class="first last">MAPK-activated protein kinases</p></td></tr><tr><td class="NLM_term">MAPKKs</td><td class="NLM_def"><p class="first last">MAPK kinases</p></td></tr><tr><td class="NLM_term">MAPKKKs</td><td class="NLM_def"><p class="first last">MAPK kinase kinases</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin-Darby canine kidney</p></td></tr><tr><td class="NLM_term">MERS-CoV</td><td class="NLM_def"><p class="first last">middle east respiratory syndrome coronavirus</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">MAPK/ERK kinase</p></td></tr><tr><td class="NLM_term">MOI</td><td class="NLM_def"><p class="first last">multiplicity of infection</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mammalian target of rapamycin</p></td></tr><tr><td class="NLM_term">NAK</td><td class="NLM_def"><p class="first last">Numb-associated kinase</p></td></tr><tr><td class="NLM_term">NFAT</td><td class="NLM_def"><p class="first last">nuclear factor of activated T-cells</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor κ-light-chain-enhancer of activated B cells</p></td></tr><tr><td class="NLM_term">NPC1</td><td class="NLM_def"><p class="first last">Niemann-Pick C1 receptor</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood lymphocytes</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PHH</td><td class="NLM_def"><p class="first last">primary human hepatocyte</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">PIKfyve</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-phosphate-5 kinase</p></td></tr><tr><td class="NLM_term">PKC</td><td class="NLM_def"><p class="first last">protein kinase C</p></td></tr><tr><td class="NLM_term">PKI</td><td class="NLM_def"><p class="first last">protein kinase inhibitor</p></td></tr><tr><td class="NLM_term">PKs</td><td class="NLM_def"><p class="first last">protein kinase</p></td></tr><tr><td class="NLM_term">PtdIns</td><td class="NLM_def"><p class="first last">phosphatidylinositol</p></td></tr><tr><td class="NLM_term">PtdIns(3,5)P<sub>2</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol-3,5-biphosphate</p></td></tr><tr><td class="NLM_term">PtdIns3P</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-phosphate</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">RGCs</td><td class="NLM_def"><p class="first last">receptor guanylate cyclases</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">RNP</td><td class="NLM_def"><p class="first last">ribonucleoprotein</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAMHD1</td><td class="NLM_def"><p class="first last">SAM domain and HD domain 1</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SARS-CoV</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus</p></td></tr><tr><td class="NLM_term">SARS-CoV-2</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus 2</p></td></tr><tr><td class="NLM_term">SILAC</td><td class="NLM_def"><p class="first last">stable isotope labeling with amino acids in cell culture</p></td></tr><tr><td class="NLM_term">siRNA</td><td class="NLM_def"><p class="first last">small interfering RNA</p></td></tr><tr><td class="NLM_term">STE</td><td class="NLM_def"><p class="first last">Ser/Thr kinase</p></td></tr><tr><td class="NLM_term">STK16</td><td class="NLM_def"><p class="first last">Ser/Thr kinase 16</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">Tyro3 Axl Mer</p></td></tr><tr><td class="NLM_term">TGEV</td><td class="NLM_def"><p class="first last">transmissible gastroenteritis virus</p></td></tr><tr><td class="NLM_term">TGF-α</td><td class="NLM_def"><p class="first last">transforming growth factor-α</p></td></tr><tr><td class="NLM_term">TK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKL</td><td class="NLM_def"><p class="first last">tyrosine kinase-like kinase</p></td></tr><tr><td class="NLM_term">TrKA/HER2</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase A/human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">vRNP</td><td class="NLM_def"><p class="first last">viral RNP</p></td></tr><tr><td class="NLM_term">ZIKV</td><td class="NLM_def"><p class="first last">ZIKA virus</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14007" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14007" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 184 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Muzio, L.</span></span> <span> </span><span class="NLM_article-title">The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2017.3036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3892%2Fijmm.2017.3036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28656226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2htb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=271-280&author=F.+Arditoauthor=M.+Giulianiauthor=D.+Perroneauthor=G.+Troianoauthor=L.+Lo+Muzio&title=The+crucial+role+of+protein+phosphorylation+in+cell+signaling+and+its+use+as+targeted+therapy&doi=10.3892%2Fijmm.2017.3036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (review)</span></div><div class="casAuthors">Ardito, Fatima; Giuliani, Michele; Perrone, Donatella; Troiano, Giuseppe; Muzio, Lorenzo Lo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1791-244X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Protein phosphorylation is an important cellular regulatory mechanism as many enzymes and receptors are activated/deactivated by phosphorylation and dephosphorylation events, by means of kinases and phosphatases.  In particular, the protein kinases are responsible for cellular transduction signaling and their hyperactivity, malfunction or overexpression can be found in several diseases, mostly tumors.  Therefore, it is evident that the use of kinase inhibitors can be valuable for the treatment of cancer.  In this review, we discuss the mechanism of action of phosphorylation, with particular attention to the importance of phosphorylation under physiol. and pathol. conditions.  We also discuss the possibility of using kinase inhibitors in the treatment of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJNhgNZEVXbVg90H21EOLACvtfcHk0ljNj5c-EftAqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2htb7N&md5=f88bf52fc0ecb24364b6c28049a7d91e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2017.3036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2017.3036%26sid%3Dliteratum%253Aachs%26aulast%3DArdito%26aufirst%3DF.%26aulast%3DGiuliani%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DD.%26aulast%3DTroiano%26aufirst%3DG.%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26atitle%3DThe%2520crucial%2520role%2520of%2520protein%2520phosphorylation%2520in%2520cell%2520signaling%2520and%2520its%2520use%2520as%2520targeted%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2017%26volume%3D40%26spage%3D271%26epage%3D280%26doi%3D10.3892%2Fijmm.2017.3036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. H.</span></span> <span> </span><span class="NLM_article-title">The phosphorylase <i>b</i> to a converting enzyme of rabbit skeletal muscle</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1956</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/0006-3002(56)90273-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2F0006-3002%2856%2990273-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=13315361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaG28XmtVCkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1956&pages=150-157&author=E.+G.+Krebsauthor=E.+H.+Fischer&title=The+phosphorylase+b+to+a+converting+enzyme+of+rabbit+skeletal+muscle&doi=10.1016%2F0006-3002%2856%2990273-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylase b-to-a converting enzyme of rabbit skeletal muscle</span></div><div class="casAuthors">Krebs, Edwin G.; Fischer, Edmond H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-7</span>CODEN:
                <span class="NLM_cas:coden">BBACAQ</span>;
        ISSN:<span class="NLM_cas:issn">0006-3002</span>.
    </div><div class="casAbstract">cf. C.A. 49, 16017g.  Studies of the conversion of phosphorylase b to phosphorylase a in rabbit muscle exts. in the presence of metal ions and adenosinetriphosphate (ATP) are extended to studies in isolated systems with purified components.  A method for assaying the converting enzyme is described, and the course of the reaction at several concns. of the enzyme shown.  Converting enzyme units are defined.  The pH optimum of the enzyme is approx. 9.0.  The reaction requires Mn++ or Mg++ and ATP.  A mono-Mn-ATP complex is probably involved in the reaction.  Phosphorylase a produced from phosphorylase b in the presence of ATP-P32 is shown to contain firmly bound isotopic phosphate, at least 2 atoms P32/mole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytWjjKYNOB7Vg90H21EOLACvtfcHk0lgTdKT91g0igg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG28XmtVCkug%253D%253D&md5=7cb87a32dc3079477274c32b0dbc94c1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0006-3002%2856%2990273-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3002%252856%252990273-6%26sid%3Dliteratum%253Aachs%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26atitle%3DThe%2520phosphorylase%2520b%2520to%2520a%2520converting%2520enzyme%2520of%2520rabbit%2520skeletal%2520muscle%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1956%26volume%3D20%26spage%3D150%26epage%3D157%26doi%3D10.1016%2F0006-3002%2856%2990273-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. H.</span></span> <span> </span><span class="NLM_article-title">The muscle phosphorylase <i>b</i> kinase reaction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)77286-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0021-9258%2819%2977286-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=13538949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaG1cXnt1Oitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1958&pages=73-83&author=E.+G.+Krebsauthor=A.+B.+Kentauthor=E.+H.+Fischer&title=The+muscle+phosphorylase+b+kinase+reaction&doi=10.1016%2FS0021-9258%2819%2977286-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Muscle phosphorylase b kinase reaction</span></div><div class="casAuthors">Krebs, Edwin G.; Kent, Alan B.; Fischer, Edmond H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-83</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. preceding abstr.  The conversion of cryst. phosphorylase b to phosphorylase a with adenosinetriphosphate-P32 and phosphorylase b kinase was studied.  In the reaction 4 moles of phosphate are incorporated/mole phosphorylase a, and 4 moles of adenosinediphosphate are formed.  The reaction is essentially irreversible.  In the process the mol. wt. of the enzyme is doubled.  The changes that occur in the activity of phosphorylase during the conversion were studied.  With complete conversion the phosphorylase a formed has the same activity with or without adenosinemonophosphate.  No exchange of the firmly bound phosphate in the enzyme with inorg. phosphate occurs during phosphorolysis of glycogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXmJc_6ueVo7Vg90H21EOLACvtfcHk0lgTdKT91g0igg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXnt1Oitw%253D%253D&md5=11b5ac525c1f625a276057212863652c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2977286-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252977286-X%26sid%3Dliteratum%253Aachs%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26aulast%3DKent%26aufirst%3DA.%2BB.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26atitle%3DThe%2520muscle%2520phosphorylase%2520b%2520kinase%2520reaction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1958%26volume%3D231%26spage%3D73%26epage%3D83%26doi%3D10.1016%2FS0021-9258%2819%2977286-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lirf5O5_ztk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anamika, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, N.</span></span> <span> </span><span class="NLM_article-title">Classification of protein kinases on the basis of both kinase and non-kinase regions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e12460</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0012460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0012460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20856812" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&author=J.+Martinauthor=K.+Anamikaauthor=N.+Srinivasan&title=Classification+of+protein+kinases+on+the+basis+of+both+kinase+and+non-kinase+regions&doi=10.1371%2Fjournal.pone.0012460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0012460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0012460%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DAnamika%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DClassification%2520of%2520protein%2520kinases%2520on%2520the%2520basis%2520of%2520both%2520kinase%2520and%2520non-kinase%2520regions%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26doi%3D10.1371%2Fjournal.pone.0012460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Protein kinase biochemistry and drug discovery</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bioorg.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21872901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GqsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=192-210&author=P.+A.+Schwartzauthor=B.+W.+Murray&title=Protein+kinase+biochemistry+and+drug+discovery&doi=10.1016%2Fj.bioorg.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase biochemistry and drug discovery</span></div><div class="casAuthors">Schwartz, Phillip A.; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">192-210</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are fascinating biol. catalysts with a rapidly expanding knowledge base, a growing appreciation in cell regulatory control, and an ascendant role in successful therapeutic intervention.  To better understand protein kinases, the mol. underpinnings of phosphoryl group transfer, protein phosphorylation, and inhibitor interactions are examd.  This anal. begins with a survey of phosphate group and phosphoprotein properties which provide context to the evolutionary selection of phosphorylation as a central mechanism for biol. regulation of most cellular processes.  Next, the kinetic and catalytic mechanisms of protein kinases are examd. with respect to model aq. systems to define the elements of catalysis.  A brief structural biol. overview further delves into the mol. basis of catalysis and regulation of catalytic activity.  Concomitant with a prominent role in normal physiol., protein kinases have important roles in the disease state.  To facilitate effective kinase drug discovery, classic and emerging approaches for characterizing kinase inhibitors are evaluated including biochem. assay design, inhibitor mechanism of action anal., and proper kinetic treatment of irreversible inhibitors.  As the resulting protein kinase inhibitors can modulate intended and unintended targets, profiling methods are discussed which can illuminate a more complete range of an inhibitor's biol. activities to enable more meaningful cellular studies and more effective clin. studies.  Taken as a whole, a wealth of protein kinase biochem. knowledge is available, yet it is clear that a substantial extent of our understanding in this field remains to be discovered which should yield many new opportunities for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9JNgQhbDT7Vg90H21EOLACvtfcHk0lirf5O5_ztk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GqsrfE&md5=3c85386861ef6effbd7ef95d638df0a2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DProtein%2520kinase%2520biochemistry%2520and%2520drug%2520discovery%26jtitle%3DBioorg.%2520Chem.%26date%3D2011%26volume%3D39%26spage%3D192%26epage%3D210%26doi%3D10.1016%2Fj.bioorg.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele, R. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations in human disease: interpreting genotype-phenotype relationships</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1038/nrg2707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrg2707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20019687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFOht7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=60-74&author=P.+Lahiryauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=R.+A.+Hegele&title=Kinase+mutations+in+human+disease%3A+interpreting+genotype-phenotype+relationships&doi=10.1038%2Fnrg2707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations in human disease: interpreting genotype-phenotype relationships</span></div><div class="casAuthors">Lahiry, Piya; Torkamani, Ali; Schork, Nicholas J.; Hegele, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-74</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are one of the largest gene families in humans.  Through a comprehensive survey of kinase mutations the authors highlight the structure-function relationships that control the activities of these proteins and their contribution to a varied set of human diseases.  Protein kinases are one of the largest families of evolutionarily related proteins and comprise one of the most abundant gene families in humans.  Here we survey kinase gene mutations from the perspective of human disease phenotypes and further analyze the structural features of mutant kinases, including mutational hotspots.  Our evaluation of the genotype-phenotype relationship across 915 human kinase mutations - that underlie 67 single-gene diseases, mainly inherited developmental and metabolic disorders and also certain cancers - enhances our understanding of the role of kinases in development, kinase dysfunction in pathogenesis and kinases as potential targets for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89P0vZvjopLVg90H21EOLACvtfcHk0lirf5O5_ztk1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFOht7bF&md5=d5fde109645b8b8a4e88ee1ae44de255</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrg2707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2707%26sid%3Dliteratum%253Aachs%26aulast%3DLahiry%26aufirst%3DP.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DHegele%26aufirst%3DR.%2BA.%26atitle%3DKinase%2520mutations%2520in%2520human%2520disease%253A%2520interpreting%2520genotype-phenotype%2520relationships%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2010%26volume%3D11%26spage%3D60%26epage%3D74%26doi%3D10.1038%2Fnrg2707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Eyck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowadski, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1126/science.1862342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscience.1862342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1862342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK3MXmsFSqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1991&pages=407-414&author=D.+Knightonauthor=J.+Zhengauthor=L.+Ten+Eyckauthor=V.+Ashfordauthor=N.+Xuongauthor=S.+Taylorauthor=J.+Sowadski&title=Crystal+structure+of+the+catalytic+subunit+of+cyclic+adenosine+monophosphate-dependent+protein+kinase&doi=10.1126%2Fscience.1862342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</span></div><div class="casAuthors">Knighton, Daniel R.; Zheng, Jianhua; Ten Eyck, Lynn F.; Ashford, Victor A.; Nguyen Huu Xuong; Taylor, Susan S.; Sowadski, Janusz M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">5018</span>),
    <span class="NLM_cas:pages">407-14</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 Å resoln. to an R factor of 0.212.  The magnesium ATP (MgATP) binding site was located by difference Fourier synthesis.  The enzyme structure is bilobal with a deep cleft between the lobes.  The cleft is filled by MgATP and a portion of the inhibitor peptide.  The smaller lobe, consisting mostly of amino-terminal sequence, is assocd. with nucleotide binding, and its largely antiparallel β sheet architecture constitutes an unusual nucleotide binding motif.  The large lobe is dominated by helical structure with a single β sheet at the domain interface.  This lobe is primarily involved in peptide binding and catalysis.  Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases.  Most of the invariant amino acids in this conserved catalytic core are clustered at the site of nucleotide binding and catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-BPvdNuboTbVg90H21EOLACvtfcHk0liMc77rndAp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsFSqsLw%253D&md5=1b1dc6aaa1a63fc665b81f8967e143b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1862342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1862342%26sid%3Dliteratum%253Aachs%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DTen%2BEyck%26aufirst%3DL.%26aulast%3DAshford%26aufirst%3DV.%26aulast%3DXuong%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DSowadski%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520catalytic%2520subunit%2520of%2520cyclic%2520adenosine%2520monophosphate-dependent%2520protein%2520kinase%26jtitle%3DScience%26date%3D1991%26volume%3D253%26spage%3D407%26epage%3D414%26doi%3D10.1126%2Fscience.1862342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The structural basis for control of eukaryotic protein kinases</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-052410-090317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1146%2Fannurev-biochem-052410-090317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22482904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=587-613&author=J.+A.+Endicottauthor=M.+E.+M.+Nobleauthor=L.+N.+Johnson&title=The+structural+basis+for+control+of+eukaryotic+protein+kinases&doi=10.1146%2Fannurev-biochem-052410-090317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for control of eukaryotic protein kinases</span></div><div class="casAuthors">Endicott, Jane A.; Noble, Martin E. M.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">587-613</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases are key regulators of cell processes.  Comparison of the structures of protein kinase domains, both alone and in complexes, allows generalizations to be made about the mechanisms that regulate protein kinase activation.  Protein kinases in the active state adopt a catalytically competent conformation upon binding of both the ATP and peptide substrates that has led to an understanding of the catalytic mechanism.  Docking sites remote from the catalytic site are a key feature of several substrate recognition complexes.  Mechanisms for kinase activation through phosphorylation, addnl. domains or subunits, by scaffolding proteins and by kinase dimerization are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow52PIce_NWLVg90H21EOLACvtfcHk0liMc77rndAp_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fF&md5=a7ce0f2ac75956288c2ea436d34cad8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-052410-090317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-052410-090317%26sid%3Dliteratum%253Aachs%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structural%2520basis%2520for%2520control%2520of%2520eukaryotic%2520protein%2520kinases%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2012%26volume%3D81%26spage%3D587%26epage%3D613%26doi%3D10.1146%2Fannurev-biochem-052410-090317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanev, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Linden, O. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span> <span> </span><span class="NLM_article-title">KLIFS: a structural kinase-ligand interaction database</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">D365</span>– <span class="NLM_lpage">D371</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv1082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fnar%2Fgkv1082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26496949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=D365-D371&author=A.+J.+Kooistraauthor=G.+K.+Kanevauthor=O.+P.+J.+Van+Lindenauthor=R.+Leursauthor=I.+J.+P.+De+Eschauthor=C.+De+Graaf&title=KLIFS%3A+a+structural+kinase-ligand+interaction+database&doi=10.1093%2Fnar%2Fgkv1082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">KLIFS: a structural kinase-ligand interaction database</span></div><div class="casAuthors">Kooistra, Albert J.; Kanev, Georgi K.; van Linden, Oscar P. J.; Leurs, Rob; de Esch, Iwan J. P.; de Graaf, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D365-D371</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Protein kinases play a crucial role in cell signaling and are important drug targets in several therapeutic areas.  The KLIFS database contains detailed structural kinase-ligand interaction information derived from all (>2900) structures of catalytic domains of human and mouse protein kinases deposited in the Protein Data Bank in order to provide insights into the structural determinants of kinase-ligand binding and selectivity.  The kinase structures have been processed in a consistent manner by systematically analyzing the structural features and mol. interaction fingerprints (IFPs) of a predefined set of 85 binding site residues with bound ligands.  KLIFS has been completely rebuilt and extended (>65% more structures) since its first release as a data set, including: novel automated annotation methods for (i) the assessment of ligand-targeted subpockets and the anal. of (ii) DFG and (iii) αC-helix conformations; improved and automated protocols for (iv) the generation of sequence/structure alignments, (v) the curation of ligand atom and bond typing for accurate IFP anal. and (vi) weekly database updates.  KLIFS is now accessible via a website (http://klifs.vucompmedchem. nl) that provides a comprehensive visual presentation of different types of chem., biol. and structural chemogenomics data, and allows the user to easily access, compare, search and download the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfCaKwwgOlbVg90H21EOLACvtfcHk0lgZ_oJy2uy1KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrfP&md5=bc093b02225987fe791a2d41738e4d99</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1082%26sid%3Dliteratum%253Aachs%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DKanev%26aufirst%3DG.%2BK.%26aulast%3DVan%2BLinden%26aufirst%3DO.%2BP.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DDe%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26atitle%3DKLIFS%253A%2520a%2520structural%2520kinase-ligand%2520interaction%2520database%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3DD365%26epage%3DD371%26doi%3D10.1093%2Fnar%2Fgkv1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardecki, C.</span></span> <span> </span><span class="NLM_article-title">RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1002/pro.3331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fpro.3331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29067736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2nsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=316-330&author=S.+K.+Burleyauthor=H.+M.+Bermanauthor=C.+Christieauthor=J.+M.+Duarteauthor=Z.+Fengauthor=J.+Westbrookauthor=J.+Youngauthor=C.+Zardecki&title=RCSB+Protein+Data+Bank%3A+Sustaining+a+living+digital+data+resource+that+enables+breakthroughs+in+scientific+research+and+biomedical+education&doi=10.1002%2Fpro.3331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education</span></div><div class="casAuthors">Burley, Stephen K.; Berman, Helen M.; Christie, Cole; Duarte, Jose M.; Feng, Zukang; Westbrook, John; Young, Jasmine; Zardecki, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-330</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB) is one of two archival resources for exptl. data central to biomedical research and education worldwide (the other key Primary Data Archive in biol. being the International Nucleotide Sequence Database Collaboration).  The PDB currently houses >134,000 at. level biomol. structures detd. by crystallog., NMR spectroscopy, and 3D electron microscopy.  It was established in 1971 as the first open-access, digital-data resource in biol., and is managed by the Worldwide Protein Data Bank partnership (wwPDB; wwpdb.org).  US PDB operations are conducted by the RCSB Protein Data Bank (RCSB PDB; RCSB.org; Rutgers University and UC San Diego) and funded by NSF, NIH, and DoE.  The RCSB PDB serves as the global Archive Keeper for the wwPDB.  During calendar 2016, >591 million structure data files were downloaded from the PDB by Data Consumers working in every sovereign nation recognized by the United Nations.  During this same period, the RCSB PDB processed >5300 new at. level biomol. structures plus exptl. data and metadata coming into the archive from Data Depositors working in the Americas and Oceania.  In addn., RCSB PDB served >1 million RCSB.org users worldwide with PDB data integrated with ∼40 external data resources providing rich structural views of fundamental biol., biomedicine, and energy sciences, and >600,000 PDB101.rcsb.org educational website users around the globe.  RCSB PDB resources are described in detail together with metrics documenting the impact of access to PDB data on basic and applied research, clin. medicine, education, and the economy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIN3U6NfSPrVg90H21EOLACvtfcHk0lgZ_oJy2uy1KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2nsbbF&md5=476af887e708fd78d51f276aabccb023</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpro.3331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.3331%26sid%3Dliteratum%253Aachs%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DChristie%26aufirst%3DC.%26aulast%3DDuarte%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZardecki%26aufirst%3DC.%26atitle%3DRCSB%2520Protein%2520Data%2520Bank%253A%2520Sustaining%2520a%2520living%2520digital%2520data%2520resource%2520that%2520enables%2520breakthroughs%2520in%2520scientific%2520research%2520and%2520biomedical%2520education%26jtitle%3DProtein%2520Sci.%26date%3D2018%26volume%3D27%26spage%3D316%26epage%3D330%26doi%3D10.1002%2Fpro.3331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases-the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases-the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lgZ_oJy2uy1KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases-the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5036</span>– <span class="NLM_lpage">5041</span>, <span class="refDoi"> DOI: 10.1021/bi00316a032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00316a032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=5036-5041&author=H.+Hidakaauthor=M.+Inagakiauthor=S.+Kawamotoauthor=Y.+Sasaki&title=Isoquinolinesulfonamides%2C+novel+and+potent+inhibitors+of+cyclic+nucleotide+dependent+protein+kinase+and+protein+kinase+C&doi=10.1021%2Fbi00316a032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C</span></div><div class="casAuthors">Hidaka, Hiroyoshi; Inagaki, Masaki; Kawamoto, Sachiyo; Sasaki, Yasuharu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5036-41</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Naphthalenesulfonamides, such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) are potent calmodulin (CaM) antagonists and act upon several protein kinases at higher concn.  When the naphthalene ring was replaced by isoquinoline, the derivs. were no longer CaM antagonists but retained the ability to inhibit protein kinases, and some of the derivs. exhibited selective inhibition toward a certain protein kinase.  The cAMP-dependent, cGMP-dependent, and Ca2+-phospholipid-dependent (protein kinase C) protein kinases were inhibited significantly by addn. of 10-6M N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7).  H-8 was the most active of the inhibitors in this series and inhibited more markedly cyclic nucleotide-dependent protein kinases, than other kinases, whereas the deriv. with the sulfonylpiperazine residue (H-7) was the most potent in inhibiting protein kinase C.  The apparent Ki values of H-8 were 0.48 and 1.2 μM for cGMP-dependent and cAMP-dependent protein kinases, resp., and the Ki of H-7 for protein kinase C was 11 μM.  Both the holoenzyme and the catalytic subunit (or fragment), which was active without an enzyme activator, were susceptible to these compds. with a similar concn. dependency, thereby indicating that the inhibitory effect is attributed to the direct interaction of the compd. with the active center of the enzyme but not with the enzyme activator.  The inhibitions were freely reversible and of the competitive type with respect to ATP and of the noncompetitive type with respect to the phosphate acceptor.  Kinetic studies with the catalytic subunit of cAMP-dependent protein kinase indicated that isoquinolinesulfonamides, structurally unrelated to ATP, compete with ATP for free enzyme but do not interact with the same enzyme form as does the phosphate acceptor (i.e., enzyme-ATP complex).  The inhibitory potency of these derivs. appeared to be dependent on the position and the strength of the plus charge contributed by the terminal N atom in the isoquinolinesulfonamide mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrknTWDxnFUhrVg90H21EOLACvtfcHk0lh4lMD2zlf40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVKltLo%253D&md5=d40aea66a748ad3b97ed5397331f9512</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbi00316a032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00316a032%26sid%3Dliteratum%253Aachs%26aulast%3DHidaka%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DKawamoto%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DY.%26atitle%3DIsoquinolinesulfonamides%252C%2520novel%2520and%2520potent%2520inhibitors%2520of%2520cyclic%2520nucleotide%2520dependent%2520protein%2520kinase%2520and%2520protein%2520kinase%2520C%26jtitle%3DBiochemistry%26date%3D1984%26volume%3D23%26spage%3D5036%26epage%3D5041%26doi%3D10.1021%2Fbi00316a032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vigneri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1038/84683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2F84683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11175855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVyksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=228-234&author=P.+Vigneriauthor=J.+Y.+Wang&title=Induction+of+apoptosis+in+chronic+myelogenous+leukemia+cells+through+nuclear+entrapment+of+BCR-ABL+tyrosine+kinase&doi=10.1038%2F84683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase</span></div><div class="casAuthors">Vigneri, Paolo; Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-234</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The chimeric BCR-ABL oncoprotein is the mol. hallmark of chronic myelogenous leukemia (CML).  BCR-ABL contains nuclear import and export signals but it is localized only in the cytoplasm where it activates mitogenic and anti-apoptotic pathways.  We have found that inhibition of the BCR-ABL tyrosine kinase, either by mutation or by the drug STI571, can stimulate its nuclear entry.  By combining STI571 with leptomycin B (LMB) to block nuclear export, we trapped BCR-ABL in the nucleus and the nuclear BCR-ABL tyrosine kinase activates apoptosis.  As a result, the combined treatment with STI571 and LMB causes the irreversible and complete killing of BCR-ABL transformed cells, whereas the effect of either drug alone is fully reversible.  The combined treatment with STI571 and LMB also preferentially eliminates mouse bone marrow cells that express BCR-ABL.  These results indicate that nuclear entrapment of BCR-ABL can be used as a therapeutic strategy to selectively kill chronic myelogenous leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjHFOglUtfZLVg90H21EOLACvtfcHk0lh4lMD2zlf40g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVyksL4%253D&md5=dab17bd86b7097b653acde502ee7f84d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F84683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F84683%26sid%3Dliteratum%253Aachs%26aulast%3DVigneri%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DInduction%2520of%2520apoptosis%2520in%2520chronic%2520myelogenous%2520leukemia%2520cells%2520through%2520nuclear%2520entrapment%2520of%2520BCR-ABL%2520tyrosine%2520kinase%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D228%26epage%3D234%26doi%3D10.1038%2F84683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanev, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würdinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span> <span> </span><span class="NLM_article-title">The landscape of atypical and eukaryotic protein kinases</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.tips.2019.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31677919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=818-832&author=G.+K.+Kanevauthor=C.+De+Graafauthor=I.+J.+P.+De+Eschauthor=R.+Leursauthor=T.+W%C3%BCrdingerauthor=B.+A.+Westermanauthor=A.+J.+Kooistra&title=The+landscape+of+atypical+and+eukaryotic+protein+kinases&doi=10.1016%2Fj.tips.2019.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Landscape of Atypical and Eukaryotic Protein Kinases</span></div><div class="casAuthors">Kanev, Georgi K.; de Graaf, Chris; de Esch, Iwan J. P.; Leurs, Rob; Wuerdinger, Thomas; Westerman, Bart A.; Kooistra, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-832</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases are attractive anticancer targets due to their central role in the growth, survival, and therapy resistance of tumor cells.  This review explores the two primary kinase classes, the eukaryotic protein kinases (ePKs) and the atypical protein kinases (aPKs), and provides a structure-centered comparison of their sequences, structures, hydrophobic spines, mutation and SNP hotspots, and inhibitor interaction patterns.  Despite the limited sequence similarity between these two classes, atypical kinases commonly share the archetypical kinase fold but lack conserved eukaryotic kinase motifs and possess altered hydrophobic spines.  Furthermore, atypical kinase inhibitors explore only a limited no. of binding modes both inside and outside the orthosteric binding site.  The distribution of genetic variations in both classes shows multiple ways they can interfere with kinase inhibitor binding.  This multilayered review provides a research framework bridging the eukaryotic and atypical kinase classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM49MHogshXLVg90H21EOLACvtfcHk0li4XIw6MjXmmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajurrO&md5=fc6b47539dc35e0da20eede4fdc72207</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DKanev%26aufirst%3DG.%2BK.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26aulast%3DDe%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DW%25C3%25BCrdinger%26aufirst%3DT.%26aulast%3DWesterman%26aufirst%3DB.%2BA.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520landscape%2520of%2520atypical%2520and%2520eukaryotic%2520protein%2520kinases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D818%26epage%3D832%26doi%3D10.1016%2Fj.tips.2019.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannaiyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of protein kinase inhibitors for cancer therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1527688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14737140.2018.1527688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30259761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1249-1270&author=R.+Kannaiyanauthor=D.+Mahadevan&title=A+comprehensive+review+of+protein+kinase+inhibitors+for+cancer+therapy&doi=10.1080%2F14737140.2018.1527688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of protein kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Kannaiyan, Radhamani; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1249-1270</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in various cellular functions.  About 2% of the human genome encodes for protein kinases.  Dysregulation of protein kinases is implicated in various processes of carcinogenesis.  The advent of protein kinase inhibitors in cancer therapy has led to a paradigm shift in cancer therapy.  Several protein kinase inhibitors have been approved by FDA in the last few decades.  This article provides a review of the FDA approved protein kinase inhibitors as of Dec. 2017 for the well-known oncogenic protein kinases.  A list of FDA approved protein kinase inhibitors and their FDA approved clin. indications were cataloged.  The role of the resp. oncogenic protein kinases in carcinogenesis and cancer progression and the relevant landmark clin. trials of resp. protein kinase inhibitors leading up to the FDA approval were PubMed searched and discussed.  Further understanding of the mol. origin of various cancers would help identify new targets.  Use of biomarker profiling might select the patient population that would benefit better from kinase inhibitors.  Clin. trials should be designed to identify the appropriate sequence of the available kinase inhibitors.  It would prove to be useful to test these drugs in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeLoNJcZUGLVg90H21EOLACvtfcHk0li4XIw6MjXmmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK&md5=853138e6be969ecb6d137356bf5d2fd3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1527688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1527688%26sid%3Dliteratum%253Aachs%26aulast%3DKannaiyan%26aufirst%3DR.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520review%2520of%2520protein%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D1249%26epage%3D1270%26doi%3D10.1080%2F14737140.2018.1527688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/cei.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fcei.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24313320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2014&pages=1-10&author=H.+Pattersonauthor=R.+Nibbsauthor=I.+McInnesauthor=S.+Siebert&title=Protein+kinase+inhibitors+in+the+treatment+of+inflammatory+and+autoimmune+diseases&doi=10.1111%2Fcei.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span></div><div class="casAuthors">Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Protein kinases mediate protein phosphorylation, which is a fundamental component of cell signalling, with crucial roles in most signal transduction cascades: from controlling cell growth and proliferation to the initiation and regulation of immunol. responses.  Aberrant kinase activity is implicated in an increasing no. of diseases, with more than 400 human diseases now linked either directly or indirectly to protein kinases.  Protein kinases are therefore regarded as highly important drug targets, and are the subject of intensive research activity.  The success of small mol. kinase inhibitors in the treatment of cancer, coupled with a greater understanding of inflammatory signalling cascades, has led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of immune-mediated diseases.  Herein we discuss the main classes of kinase inhibitors; namely Janus kinase (JAK), mitogen-activated protein kinase (MAPK) and spleen tyrosine kinase (Syk) inhibitors.  We provide a mechanistic insight into how these inhibitors interfere with kinase signalling pathways and discuss the clin. successes and failures in the implementation of kinase-directed therapeutics in the context of inflammatory and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6xmLNBP2V7Vg90H21EOLACvtfcHk0livjiiE_NB9Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D&md5=fb65f5c7ee7086383ddbc95c787da2b4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fcei.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12248%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DH.%26aulast%3DNibbs%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%26aulast%3DSiebert%26aufirst%3DS.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2014%26volume%3D176%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fcei.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span> <span> </span><span class="NLM_article-title">Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2017.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29174542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=206-214&author=J.+D.+Vastaauthor=C.+R.+Coronaauthor=J.+Wilkinsonauthor=C.+A.+Zimprichauthor=J.+R.+Hartnettauthor=M.+R.+Ingoldauthor=K.+Zimmermanauthor=T.+Machleidtauthor=T.+A.+Kirklandauthor=K.+G.+Huwilerauthor=R.+F.+Ohanaauthor=M.+Slaterauthor=P.+Ottoauthor=M.+Congauthor=C.+I.+Wellsauthor=B.+T.+Bergerauthor=T.+Hankeauthor=C.+Glasauthor=K.+Dingauthor=D.+H.+Drewryauthor=K.+V.+M.+Huberauthor=T.+M.+Willsonauthor=S.+Knappauthor=S.+Mullerauthor=P.+L.+Meisenheimerauthor=F.+Fanauthor=K.+V.+Woodauthor=M.+B.+Robers&title=Quantitative%2C+wide-spectrum+kinase+profiling+in+live+cells+for+assessing+the+effect+of+cellular+ATP+on+target+engagement&doi=10.1016%2Fj.chembiol.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement</span></div><div class="casAuthors">Vasta, James D.; Corona, Cesear R.; Wilkinson, Jennifer; Zimprich, Chad A.; Hartnett, James R.; Ingold, Morgan R.; Zimmerman, Kristopher; Machleidt, Thomas; Kirkland, Thomas A.; Huwiler, Kristin G.; Ohana, Rachel Friedman; Slater, Michael; Otto, Paul; Cong, Mei; Wells, Carrow I.; Berger, Benedict-Tilman; Hanke, Thomas; Glas, Carina; Ding, Ke; Drewry, David H.; Huber, Kilian V. M.; Willson, Timothy M.; Knapp, Stefan; Muller, Susanne; Meisenheimer, Poncho L.; Fan, Frank; Wood, Keith V.; Robers, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-214.e11</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">For kinase inhibitors, intracellular target selectivity is fundamental to pharmacol. mechanism.  Although a no. of acellular techniques have been developed to measure kinase binding or enzymic inhibition, such approaches can fail to accurately predict engagement in cells.  Here we report the application of an energy transfer technique that enabled the first broad-spectrum, equil.-based approach to quant. profile target occupancy and compd. affinity in live cells.  Using this method, we performed a selectivity profiling for clin. relevant kinase inhibitors against 178 full-length kinases, and a mechanistic interrogation of the potency offsets obsd. between cellular and biochem. anal.  For the multikinase inhibitor crizotinib, our approach accurately predicted cellular potency and revealed improved target selectivity compared with biochem. measurements.  Due to cellular ATP, a no. of putative crizotinib targets are unexpectedly disengaged in live cells at a clin. relevant drug dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPVDw5pU6zrVg90H21EOLACvtfcHk0livjiiE_NB9Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfN&md5=bc3a1f618ab0d2ad6355f31af66d7ef4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DIngold%26aufirst%3DM.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DHuwiler%26aufirst%3DK.%2BG.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DGlas%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26atitle%3DQuantitative%252C%2520wide-spectrum%2520kinase%2520profiling%2520in%2520live%2520cells%2520for%2520assessing%2520the%2520effect%2520of%2520cellular%2520ATP%2520on%2520target%2520engagement%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D206%26epage%3D214%26doi%3D10.1016%2Fj.chembiol.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelli, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D. M.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinases: relationship to other lipid kinases</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2018.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30348515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKitrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=104-110&author=Q.+Maauthor=S.+B.+Gabelliauthor=D.+M.+Raben&title=Diacylglycerol+kinases%3A+relationship+to+other+lipid+kinases&doi=10.1016%2Fj.jbior.2018.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol kinases: Relationship to other lipid kinases</span></div><div class="casAuthors">Ma, Qianqian; Gabelli, Sandra B.; Raben, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Lipid kinases regulate a wide variety of cellular functions and have emerged as one the most promising targets for drug design.  Diacylglycerol kinases (DGKs) are a family of enzymes that catalyze the ATP-dependent phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PtdOH).  Despite the crit. role in lipid biosynthesis, both DAG and PtdOH have been shown as bioactive lipids mediating a no. of signaling pathways.  Although there is increasing recognition of their role in signaling systems, our understanding of the key enzyme which regulate the balance of these two lipid messages remain limited.  Solved structures provide a wealth of information for understanding the function and regulation of these enzymes.  Solving the structures of mammalian DGKs by traditional NMR and X-ray crystallog. approaches have been challenging and so far, there are still no three-dimensional structures of these DGKs.  Despite this, some insights may be gained by examg. the similarities and differences between prokaryotic DGKs and other mammalian lipid kinases.  This review focuses on summarizing and comparing the structure of prokaryotic and mammalian DGKs as well as two other lipid kinases: sphingosine kinase and phosphatidylinositol-3-kinase.  How these known lipid kinases structures relate to mammalian DGKs will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ur-DEswYVLVg90H21EOLACvtfcHk0lgQaKnRFGiBfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKitrnF&md5=8f57d349539108ddad84075b51e639f2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DRaben%26aufirst%3DD.%2BM.%26atitle%3DDiacylglycerol%2520kinases%253A%2520relationship%2520to%2520other%2520lipid%2520kinases%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2019%26volume%3D71%26spage%3D104%26epage%3D110%26doi%3D10.1016%2Fj.jbior.2018.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Ayuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila-Flores, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz-Nicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tello-Lafoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcos, R.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinases in cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27697466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SitbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=22-31&author=I.+Meridaauthor=P.+Torres-Ayusoauthor=A.+Avila-Floresauthor=J.+Arranz-Nicolasauthor=E.+Andradaauthor=M.+Tello-Lafozauthor=R.+Liebanaauthor=R.+Arcos&title=Diacylglycerol+kinases+in+cancer&doi=10.1016%2Fj.jbior.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol kinases in cancer</span></div><div class="casAuthors">Merida, Isabel; Torres-Ayuso, Pedro; Avila-Flores, Antonia; Arranz-Nicolas, Javier; Andrada, Elena; Tello-Lafoz, Maria; Liebana, Rosa; Arcos, Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-31</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diacylglycerol kinases (DGK) are a family of enzymes that catalyze the transformation of diacylglycerol into phosphatidic acid.  In T lymphocytes, DGKα and ζ limit the activation of the PLCγ/Ras/ERK axis, providing a crit. checkpoint to inhibit T cell responses.  Upregulation of these isoforms limits Ras activation, leading to hypo-responsive, anergic states similar to those caused by tumors.  Recent studies have identified DGKα upregulation in tumor lymphocyte infiltrates, and cells from DGKα and ζ deficient mice show enhanced antitumor activity, suggesting that limitation of DAG based signals by DGK is used by tumors to evade immune attack.  DGKα expression is low or even absent in other healthy cells like melanocytes, hepatocytes or neurons.  Expression of this isoform, nevertheless is upregulated in melanoma, hepatocarcinoma and glioblastoma where DGKα contributes to the acquisition of tumor metastatic traits.  A model thus emerges where tumor milieu fosters DGKα expression in tumors as well as in tumor infiltrating lymphocytes with opposite consequences.  Here we review the mechanisms and targets that facilitate tumor "addiction" to DGKα, and discuss its relevance in the more advanced forms of cancer for tumor immune evasion.  A better knowledge of this function offers a new perspective in the search of novel approaches to prevent inhibition of immune attack in cancer.  Part of the failure in clin. progress may be attributed to the complexity of the tumor/T lymphocyte interaction.  As they develop, tumors use a no. of mechanisms to drive endogenous, tumor reactive T cells to a general state of hyporesponsiveness or anergy.  A better knowledge of the mol. mechanisms that tumors use to trigger T cell anergic states will greatly help in the advance of immunotherapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Cpu3SrUtFLVg90H21EOLACvtfcHk0ljqBNaH2l-Umg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SitbbI&md5=4b78f0fdd9c0605379790531dad82a42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMerida%26aufirst%3DI.%26aulast%3DTorres-Ayuso%26aufirst%3DP.%26aulast%3DAvila-Flores%26aufirst%3DA.%26aulast%3DArranz-Nicolas%26aufirst%3DJ.%26aulast%3DAndrada%26aufirst%3DE.%26aulast%3DTello-Lafoz%26aufirst%3DM.%26aulast%3DLiebana%26aufirst%3DR.%26aulast%3DArcos%26aufirst%3DR.%26atitle%3DDiacylglycerol%2520kinases%2520in%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D22%26epage%3D31%26doi%3D10.1016%2Fj.jbior.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase, growth disorders, and cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1704560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1056%2FNEJMra1704560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30462943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2ltbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2052-2062&author=M.+D.+Goncalvesauthor=B.+D.+Hopkinsauthor=L.+C.+Cantley&title=Phosphatidylinositol+3-kinase%2C+growth+disorders%2C+and+cancer&doi=10.1056%2FNEJMra1704560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase, growth disorders, and cancer</span></div><div class="casAuthors">Goncalves, Marcus D.; Hopkins, Benjamin D.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2052-2062</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the discovery of discussion on phosphatidylinositol 3-kinase growth disorders in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH19P_K_L-ZbVg90H21EOLACvtfcHk0ljqBNaH2l-Umg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2ltbvE&md5=30fe8bd267667fbbf0c31ea99d92a065</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1704560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1704560%26sid%3Dliteratum%253Aachs%26aulast%3DGoncalves%26aufirst%3DM.%2BD.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DPhosphatidylinositol%25203-kinase%252C%2520growth%2520disorders%252C%2520and%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2052%26epage%3D2062%26doi%3D10.1056%2FNEJMra1704560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Buri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2017.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2017.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28942351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFemsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=97-106&author=N.+J.+Pyneauthor=A.+El+Buriauthor=D.+R.+Adamsauthor=S.+Pyne&title=Sphingosine+1-phosphate+and+cancer&doi=10.1016%2Fj.jbior.2017.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and cancer</span></div><div class="casAuthors">Pyne, Nigel J.; El Buri, Ashref; Adams, David R.; Pyne, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The bioactive lipid, sphingosine 1-phosphate (S1P) is produced by phosphorylation of sphingosine and this is catalyzed by two sphingosine kinase isoforms (SK1 and SK2).  Here we discuss structural functional aspects of SK1 (which is a dimeric quaternary enzyme) that relate to coordinated coupling of membrane assocn. with phosphorylation of Ser225 in the 'so-called' R-loop, catalytic activity and protein-protein interactions (e.g. TRAF2, PP2A and Gq).  S1P formed by SK1 at the plasma-membrane is released from cells via S1P transporters to act on S1P receptors to promote tumorigenesis.  We discuss here an addnl. novel mechanism that can operate between cancer cells and fibroblasts and which involves the release of the S1P receptor, S1P2 in exosomes from breast cancer cells that regulates ERK-1/2 signalling in fibroblasts.  This novel mechanism of signalling might provide an explanation for the role of S1P2 in promoting metastasis of cancer cells and which is dependent on the micro-environmental niche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOIeSH1AVNrVg90H21EOLACvtfcHk0ljqBNaH2l-Umg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFemsLzO&md5=bcef61d0d930c89116e5dd97a874290a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2017.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2017.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DEl%2BBuri%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DPyne%26aufirst%3DS.%26atitle%3DSphingosine%25201-phosphate%2520and%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2018%26volume%3D68%26spage%3D97%26epage%3D106%26doi%3D10.1016%2Fj.jbior.2017.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.plipres.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.plipres.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26970273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=93-106&author=S.+Pyneauthor=D.+R.+Adamsauthor=N.+J.+Pyne&title=Sphingosine+1-phosphate+and+sphingosine+kinases+in+health+and+disease%3A+Recent+advances&doi=10.1016%2Fj.plipres.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances</span></div><div class="casAuthors">Pyne, Susan; Adams, David R.; Pyne, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-106</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Sphingosine kinases (isoforms SK1 and SK2) catalyze the formation of a bioactive lipid, sphingosine 1-phosphate (S1P).  S1P is a well-established ligand of a family of five S1P-specific G protein coupled receptors but also has intracellular signalling roles.  There is substantial evidence to support a role for sphingosine kinases and S1P in health and disease.  This review summarizes recent advances in the area in relation to receptor-mediated signalling by S1P and novel intracellular targets of this lipid.  New evidence for a role of each sphingosine kinase isoform in cancer, the cardiovascular system, central nervous system, inflammation and diabetes is discussed.  There is continued research to develop isoform selective SK inhibitors, summarized here.  Anal. of the crystal structure of SK1 with the SK1-selective inhibitor, PF-543, is used to identify residues that could be exploited to improve selectivity in SK inhibitor development for future therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVKxUdCGqsrVg90H21EOLACvtfcHk0lgyUxk3PVhg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cmsb8%253D&md5=fdda88832419c066eecb87a07ae3e6ec</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.plipres.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.plipres.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520sphingosine%2520kinases%2520in%2520health%2520and%2520disease%253A%2520Recent%2520advances%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2016%26volume%3D62%26spage%3D93%26epage%3D106%26doi%3D10.1016%2Fj.plipres.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for regulation of phosphoinositide kinases and their involvement in human disease</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.molcel.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30193094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Omu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=653-673&author=J.+E.+Burke&title=Structural+basis+for+regulation+of+phosphoinositide+kinases+and+their+involvement+in+human+disease&doi=10.1016%2Fj.molcel.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease</span></div><div class="casAuthors">Burke, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-673</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Lipid phosphoinositides play fundamental roles in virtually all pathways that control a cell's decision to grow, move, divide, and die.  Because of this, kinases that phosphorylate phosphoinositide lipids are critically involved in myriad essential functions including growth, development, and membrane trafficking.  The misregulation of phosphoinositide kinases is crit. in human diseases, including cancer, primary immunodeficiencies, and developmental disorders.  Phosphoinositide kinases also play a role in mediating bacterial and viral infections for many potent human pathogens.  Furthermore, inhibitors of parasite phosphoinositide kinases are in development as therapies for both malaria and cryptosporidiosis.  Therefore, understanding how phosphoinositide kinases are regulated has implications for the treatment of many devastating human diseases.  Recent structures of phosphoinositide kinases have revealed unique mol. insight into their regulation.  This review will summarize our current mol. knowledge on phosphoinositide kinase regulation, and how this information is being used to generate novel small mol. inhibitors as potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDXWNHxkyBbVg90H21EOLACvtfcHk0lgyUxk3PVhg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Omu7fI&md5=17f9dd8a903b2026a9dff0e2afe2a473</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26atitle%3DStructural%2520basis%2520for%2520regulation%2520of%2520phosphoinositide%2520kinases%2520and%2520their%2520involvement%2520in%2520human%2520disease%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D71%26spage%3D653%26epage%3D673%26doi%3D10.1016%2Fj.molcel.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz-Nicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Ayuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila-Flores, A.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinase malfunction in human disease and the search for specific inhibitors</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/164_2019_221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2F164_2019_221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2019&pages=133-162&author=I.+Meridaauthor=J.+Arranz-Nicolasauthor=P.+Torres-Ayusoauthor=A.+Avila-Flores&title=Diacylglycerol+kinase+malfunction+in+human+disease+and+the+search+for+specific+inhibitors&doi=10.1007%2F164_2019_221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F164_2019_221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2019_221%26sid%3Dliteratum%253Aachs%26aulast%3DMerida%26aufirst%3DI.%26aulast%3DArranz-Nicolas%26aufirst%3DJ.%26aulast%3DTorres-Ayuso%26aufirst%3DP.%26aulast%3DAvila-Flores%26aufirst%3DA.%26atitle%3DDiacylglycerol%2520kinase%2520malfunction%2520in%2520human%2520disease%2520and%2520the%2520search%2520for%2520specific%2520inhibitors%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2019%26volume%3D259%26spage%3D133%26epage%3D162%26doi%3D10.1007%2F164_2019_221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span> <span> </span><span class="NLM_article-title">Drugging sphingosine kinases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/cb5008426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=225-233&author=W.+L.+Santosauthor=K.+R.+Lynch&title=Drugging+sphingosine+kinases&doi=10.1021%2Fcb5008426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging Sphingosine Kinases</span></div><div class="casAuthors">Santos, Webster L.; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The transfer of the gamma phosphate from ATP to sphingosine (Sph) to generate a small signaling mol., sphingosine 1-phosphate (S1P), is catalyzed by sphingosine kinases (SphK), which exist as two isoforms, SphK1 and SphK2.  SphK is a key regulator of S1P and the S1P:Sph/ceramide ratio.  Increases in S1P levels have been linked to diseases including sickle cell disease, cancer, and fibrosis.  Therefore, SphKs are potential targets for drug discovery.  However, the current chem. biol. toolkit needed to validate these enzymes as drug targets is inadequate.  With this review, we survey in vivo active SphK inhibitors and highlight the need for developing more potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAcry5FA9Mv7Vg90H21EOLACvtfcHk0lgyUxk3PVhg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrtbnP&md5=acafec4ecc0cf83d22d0813b8e8e9464</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb5008426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008426%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DDrugging%2520sphingosine%2520kinases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D225%26epage%3D233%26doi%3D10.1021%2Fcb5008426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span> <span> </span><span class="NLM_article-title">Drugging the Phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1274</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-50621-6_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2F978-3-030-50621-6_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32894512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXosFOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1274&publication_year=2020&pages=203-222&author=J.+A.+McPhailauthor=J.+E.+Burke&title=Drugging+the+Phosphoinositide+3-kinase+%28PI3K%29+and+phosphatidylinositol+4-kinase+%28PI4K%29+family+of+enzymes+for+treatment+of+cancer%2C+immune+disorders%2C+and+viral%2Fparasitic+infections&doi=10.1007%2F978-3-030-50621-6_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections</span></div><div class="casAuthors">McPhail, Jacob A.; Burke, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1274</span>
        (<span class="NLM_cas:issue">Druggable Lipid Signaling Pathways</span>),
    <span class="NLM_cas:pages">203-222</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The lipid kinases that generate the lipid signalling phosphoinositides have been established as fundamental signalling enzymes that control numerous aspects of how cells respond to their extracellular environment.  In addn., they play crit. roles in regulating membrane trafficking and lipid transport within the cell.  The class I phosphoinositide kinases which generate the crit. lipid signal PIP3 are hyperactivated in numerous human pathologies including cancer, overgrowth syndromes, and primary immunodeficiencies.  The type III phosphatidylinositol 4-kinase beta isoform (PI4KB), which are evolutionarily similar to the class I PI3Ks, have been found to be essential host factors mediating the replication of numerous devastating pathogenic viruses.  Finally, targeting the parasite variant of PI4KB has been established as one of the most promising strategies for the development of anti-malarial and anti-cryptosporidium strategies.  Therefore, the development of targeted isoform selective inhibitors for these enzymes are of paramount importance.  The first generation of PI3K inhibitors have recently been clin. approved for a no. of different cancers, highlighting their therapeutic value.  This review will examine the history of the class I PI3Ks, and the type III PI4Ks, their relevance to human disease, and the structural basis for their regulation and inhibition by potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQdQoT9Pavn7Vg90H21EOLACvtfcHk0lgyUxk3PVhg6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXosFOrs7o%253D&md5=d535b647d165a0478bae1ddc4eebae81</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26atitle%3DDrugging%2520the%2520Phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25204-kinase%2520%2528PI4K%2529%2520family%2520of%2520enzymes%2520for%2520treatment%2520of%2520cancer%252C%2520immune%2520disorders%252C%2520and%2520viral%252Fparasitic%2520infections%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2020%26volume%3D1274%26spage%3D203%26epage%3D222%26doi%3D10.1007%2F978-3-030-50621-6_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, C. D.</span></span> <span> </span><span class="NLM_article-title">Eradicating infectious disease: can we and should we?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2011.00053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffimmu.2011.00053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22566843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC38nhtlSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=53&author=C.+D.+Russell&title=Eradicating+infectious+disease%3A+can+we+and+should+we%3F&doi=10.3389%2Ffimmu.2011.00053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Eradicating infectious disease: can we and should we?</span></div><div class="casAuthors">Russell Clark Donald</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR938jJiAEZVzAyhZbj3lKdfW6udTcc2eYcz4g0QjGHqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nhtlSktA%253D%253D&md5=32721fd27f2e2ea20776b3b2c8b8355d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2011.00053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2011.00053%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DC.%2BD.%26atitle%3DEradicating%2520infectious%2520disease%253A%2520can%2520we%2520and%2520should%2520we%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2011%26volume%3D2%26spage%3D53%26doi%3D10.3389%2Ffimmu.2011.00053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Littler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, B.</span></span> <span> </span><span class="NLM_article-title">Achievements and challenges in antiviral drug discovery</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1177/095632020501600302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1177%2F095632020501600302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16004079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=155-168&author=E.+Littlerauthor=B.+Oberg&title=Achievements+and+challenges+in+antiviral+drug+discovery&doi=10.1177%2F095632020501600302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Achievements and challenges in antiviral drug discovery</span></div><div class="casAuthors">Littler, Eddy; Oberg, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-168</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review with refs.  The last 40 years have seen the development of several antiviral drugs with therapeutic value in treating life-threatening or debilitating diseases such as those caused by HIV, hepatitis B virus, herpesviruses (such as herpes simplex virus and varicella zoster virus) and influenza virus.  These relatively recent advances have been due to tech. breakthroughs in the cultivation of viruses in the lab., identification of viral enzymes and, more recently, their mol. biol.  We describe here the antecedence of several of the existing antivirals and their strengths and weaknesses.  We indicate where the major challenges lie for future improvements of current therapies and possible new indications, such as hepatitis C virus and papillomavirus.  We also describe how current antiviral therapies are restricted to a rather limited no. of viral diseases of sufficient interest to the pharmaceutical industry.  Finally we describe the potential threat of emerging viruses and bioweapons and the challenges that they present to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhaU27yTcDHLVg90H21EOLACvtfcHk0ljwz21jAqZnBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsro%253D&md5=d4e10261e4708bc7a4fcc3a21ac5f52c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F095632020501600302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600302%26sid%3Dliteratum%253Aachs%26aulast%3DLittler%26aufirst%3DE.%26aulast%3DOberg%26aufirst%3DB.%26atitle%3DAchievements%2520and%2520challenges%2520in%2520antiviral%2520drug%2520discovery%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D155%26epage%3D168%26doi%3D10.1177%2F095632020501600302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K.</span></span> <span> </span><span class="NLM_article-title">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.806482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1517%2F13543784.2013.806482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23735127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1107-1121&author=N.+Shahauthor=T.+Pierceauthor=K.+Kowdley&title=Review+of+direct-acting+antiviral+agents+for+the+treatment+of+chronic+hepatitis+C&doi=10.1517%2F13543784.2013.806482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Shah, Nihar; Pierce, Tracey; Kowdley, Kris V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic disease.  In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV.  Several DAAs currently in late-stage clin. trials, including NS3/NS4A serine PIs, NS5A inhibitors, NS5B polymerase inhibitors (both nucleoside and non-nucleoside) and cyclophilin inhibitors, both with and without peg-IFN and RBV, are promising for the treatment of HCV.  DAA regimens offer several advantages including that they specifically target HCV viral replication and thus appear to be less dependent on host characteristics, very high SVR rates accompanied by fewer side effects (SE) and lower pill burdens.  A review on the treatment of HCV is important and timely as the development on DAAs is progressing rapidly and the health-care providers need to be aware about this as these regimens are anticipated to become clin. available soon.  Areas covered: The literature was searched and reviewed using PubMed as well as data gathered from those presented at the international liver meetings, AASLD and EASL as well as CROI.  Expert opinion: With the potential of eliminating IFN and RBV, several DAAs under clin. development appear to be promising using novel approaches with good antiviral effects, shorter duration and lower SE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZExgJKmkr7Vg90H21EOLACvtfcHk0ljwz21jAqZnBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO&md5=f761cff6a6710f4de9473db6509d20a9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.806482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.806482%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DPierce%26aufirst%3DT.%26aulast%3DKowdley%26aufirst%3DK.%26atitle%3DReview%2520of%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1107%26epage%3D1121%26doi%3D10.1517%2F13543784.2013.806482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adalja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, T.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum antiviral agents: a crucial pandemic tool</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1080/14787210.2019.1635009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14787210.2019.1635009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31216912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ersLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=467-470&author=A.+Adaljaauthor=T.+Inglesby&title=Broad-spectrum+antiviral+agents%3A+a+crucial+pandemic+tool&doi=10.1080%2F14787210.2019.1635009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool</span></div><div class="casAuthors">Adalja, Amesh; Inglesby, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">467-470</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1XfpombjYCbVg90H21EOLACvtfcHk0ljD_pZJYNXRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ersLbK&md5=28134086c84d06611beed2c76bdf1153</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F14787210.2019.1635009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2019.1635009%26sid%3Dliteratum%253Aachs%26aulast%3DAdalja%26aufirst%3DA.%26aulast%3DInglesby%26aufirst%3DT.%26atitle%3DBroad-spectrum%2520antiviral%2520agents%253A%2520a%2520crucial%2520pandemic%2520tool%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2019%26volume%3D17%26spage%3D467%26epage%3D470%26doi%3D10.1080%2F14787210.2019.1635009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation events during viral infections provide potential therapeutic targets</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1002/rmv.722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Frmv.722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22113983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=166-181&author=J.+A.+Keatingauthor=R.+Striker&title=Phosphorylation+events+during+viral+infections+provide+potential+therapeutic+targets&doi=10.1002%2Frmv.722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation events during viral infections provide potential therapeutic targets</span></div><div class="casAuthors">Keating, Julie A.; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-181</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : For many medically relevant viruses, there is now considerable evidence that both viral and cellular kinases play important roles in viral infection.  Ultimately, these kinases, and the cellular signaling pathways that they exploit, may serve as therapeutic targets for treating patients.  Currently, small mol. inhibitors of kinases are under investigation as therapy for herpes viral infections.  Addnl., a no. of cellular or host-directed tyrosine kinase inhibitors that have been previously FDA approved for cancer treatment are under study in animal models and clin. trials, as they have shown promise for the treatment of various viral infections as well.  This review will highlight the wide range of viral proteins phosphorylated by viral and cellular kinases, and the potential for variability of kinase recognition sites within viral substrates to impact phosphorylation and kinase prediction.  Research studying kinase-targeting prophylactic and therapeutic treatments for a no. of viral infections will also be discussed.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAakENW1lBobVg90H21EOLACvtfcHk0ljD_pZJYNXRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D&md5=101ce4dec72322383e78230028d79569</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Frmv.722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.722%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DJ.%2BA.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DPhosphorylation%2520events%2520during%2520viral%2520infections%2520provide%2520potential%2520therapeutic%2520targets%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2012%26volume%3D22%26spage%3D166%26epage%3D181%26doi%3D10.1002%2Frmv.722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brass, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S.</span></span> <span> </span><span class="NLM_article-title">A genome-wide genetic screen for host factors required for hepatitis C virus propagation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">16410</span>– <span class="NLM_lpage">16415</span>, <span class="refDoi"> DOI: 10.1073/pnas.0907439106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.0907439106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19717417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OjsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=16410-16415&author=Q.+Liauthor=A.+Brassauthor=A.+Ngauthor=Z.+Huauthor=R.+Xavierauthor=T.+J.+Liangauthor=S.+Elledge&title=A+genome-wide+genetic+screen+for+host+factors+required+for+hepatitis+C+virus+propagation&doi=10.1073%2Fpnas.0907439106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide genetic-screen for host factors required for hepatitis C virus propagation</span></div><div class="casAuthors">Li, Qisheng; Brass, Abraham L.; Ng, Aylwin; Hu, Zongyi; Xavier, Ramnik J.; Liang, T. Jake; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">16410-16415, S16410/1-S16410/65</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and a leading indication for liver transplantation.  Current therapy fails in many instances and is assocd. with significant side effects.  HCV encodes only a few proteins and depends heavily on host factors for propagation.  Each of these host dependencies is a potential therapeutic target.  To find host factors required by HCV, we completed a genome-wide small interfering RNA (siRNA) screen using an infectious HCV cell culture system.  We applied a two-part screening protocol to allow identification of host factors involved in the complete viral life cycle.  The candidate genes found included known or previously identified factors, and also implicate many addnl. host cell proteins in HCV infection.  To create a more comprehensive view of HCV and host cell interactions, we performed a bioinformatic meta-anal. that integrates our data with those of previous functional and proteomic studies.  The identification of host factors participating in the complete HCV life cycle will both advance our understanding of HCV pathogenesis and illuminate therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRs-NQOwhbJrVg90H21EOLACvtfcHk0ljD_pZJYNXRSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OjsbbK&md5=f984eed64ef7e89dbbf7439bbbf17baf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0907439106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0907439106%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBrass%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXavier%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DElledge%26aufirst%3DS.%26atitle%3DA%2520genome-wide%2520genetic%2520screen%2520for%2520host%2520factors%2520required%2520for%2520hepatitis%2520C%2520virus%2520propagation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D16410%26epage%3D16415%26doi%3D10.1073%2Fpnas.0907439106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-Z.</span></span> <span> </span><span class="NLM_article-title">A high throughput RNAi screen reveals determinants of HIV-1 activity in host kinases</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24966931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ejsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=2229-2237&author=W.-M.+Jiangauthor=X.-Y.+Zhangauthor=Y.-Z.+Zhangauthor=L.+Liuauthor=H.-Z.+Lu&title=A+high+throughput+RNAi+screen+reveals+determinants+of+HIV-1+activity+in+host+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A high throughput RNAi screen reveals determinants of HIV-1 activity in host kinases</span></div><div class="casAuthors">Jiang, Wei-Min; Zhang, Xin-Yun; Zhang, Yun-Zhi; Liu, Li; Lu, Hong-Zhou</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2229-2237, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Drug resistance remains a great challenge in HIV/AIDS treatment despite the recent advances in novel therapeutics.  It may be a good strategy to develop drugs targeting the essential host factors to decrease the risk of drug resistance.  Previous studies suggested that so many host kinases play roles in HIV life cycles.  More importantly, many kinase genes are drugable targets, therefore, it is vital to figure out host kinases responsible for HIV-1 infection and replication to provide novel therapeutic regimens and to deepen the authors' understanding to HIV-host interaction.  In present work, a high throughput RNAi screen with a shRNA library aginst 474 kinases was applied to HEK293T cells stably expressed a HIV-1 LTR (long terminal repeat)-driven reporter plasmid.  Four genes, AK1, EphB2, PRKACB and CDK5R2, were found to specifically suppress the HIV-1 LTR activity following effective knockdown.  Furthermore, overexpression of AK1 and PRKACB upregulated the HIV-1 LTR activity.  Therefore, AK1 and PRKACB are in pos. control of HIV-1 activity.  DNA microarray anal. demonstrated that overlapped genes between AK1-silenced and PRKACB-silenced cells were mainly enriched in several amino acid biosynthesis pathways, TGF-β signaling and p53 signaling pathways.  These alterations may repress the viral infection by the downregulation of ERK1/2, p38MAPK and NFκB signaling pathways.  Collectively, the authors' work uncovers several host kinases involving the HIV-1 infection and may provide potential therapeutic targets for AIDS treatment in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPu7jevQHCqrVg90H21EOLACvtfcHk0lgzuXw2tnE9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ejsbbF&md5=bfcaf63a5a12bb3a686ae9f55c0999c6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DW.-M.%26aulast%3DZhang%26aufirst%3DX.-Y.%26aulast%3DZhang%26aufirst%3DY.-Z.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DH.-Z.%26atitle%3DA%2520high%2520throughput%2520RNAi%2520screen%2520reveals%2520determinants%2520of%2520HIV-1%2520activity%2520in%2520host%2520kinases%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2014%26volume%3D7%26spage%3D2229%26epage%3D2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehle, A.</span></span> <span> </span><span class="NLM_article-title">Influenza virus recruits host protein kinase C to control assembly and activity of its replication machinery</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e26910</span> <span class="refDoi"> DOI: 10.7554/eLife.26910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.7554%2FeLife.26910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28758638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlelsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&author=A.+Mondalauthor=A.+R.+Dawsonauthor=G.+K.+Pottsauthor=E.+C.+Freibergerauthor=S.+F.+Bakerauthor=L.+A.+Moserauthor=K.+A.+Bernardauthor=J.+J.+Coonauthor=A.+Mehle&title=Influenza+virus+recruits+host+protein+kinase+C+to+control+assembly+and+activity+of+its+replication+machinery&doi=10.7554%2FeLife.26910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus recruits host protein kinase C to control assembly and activity of its replication machinery</span></div><div class="casAuthors">Mondal, Arindam; Dawson, Anthony R.; Potts, Gregory K.; Freiberger, Elyse C.; Baker, Steven F.; Moser, Lindsey A.; Bernard, Kristen A.; Coon, Joshua J.; Mehle, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e26910/1-e26910/23</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Influenza virus expresses transcripts early in infection and transitions towards genome replication at later time points.  This process requires de novo assembly of the viral replication machinery, large ribonucleoprotein complexes (RNPs) composed of the viral polymerase, genomic RNA and oligomeric nucleoprotein (NP).  Despite the central role of RNPs during infection, the factors dictating where and when they assemble are poorly understood.  Here we demonstrate that human protein kinase C (PKC) family members regulate RNP assembly.  Activated PKCδ interacts with the polymerase subunit PB2 and phospho-regulates NP oligomerization and RNP assembly during infection.  Consistent with its role in regulating RNP assembly, knockout of PKCδ impairs virus infection by selectively disrupting genome replication.  However, primary transcription from pre-formed RNPs deposited by infecting particles is unaffected.  Thus, influenza virus exploits host PKCs to regulate RNP assembly, a step required for the transition from primary transcription to genome replication during the infectious cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQs9uzGI3iMLVg90H21EOLACvtfcHk0lgzuXw2tnE9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlelsb7I&md5=319ca579e33707e57b1756f49e6f1e42</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.7554%2FeLife.26910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.26910%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DA.%2BR.%26aulast%3DPotts%26aufirst%3DG.%2BK.%26aulast%3DFreiberger%26aufirst%3DE.%2BC.%26aulast%3DBaker%26aufirst%3DS.%2BF.%26aulast%3DMoser%26aufirst%3DL.%2BA.%26aulast%3DBernard%26aufirst%3DK.%2BA.%26aulast%3DCoon%26aufirst%3DJ.%2BJ.%26aulast%3DMehle%26aufirst%3DA.%26atitle%3DInfluenza%2520virus%2520recruits%2520host%2520protein%2520kinase%2520C%2520to%2520control%2520assembly%2520and%2520activity%2520of%2520its%2520replication%2520machinery%26jtitle%3DeLife%26date%3D2017%26volume%3D6%26doi%3D10.7554%2FeLife.26910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalindjian, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, K. L.</span></span> <span> </span><span class="NLM_article-title">Principles of early drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01127.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+P.+Hughesauthor=S.+Reesauthor=S.+B.+Kalindjianauthor=K.+L.+Philpott&title=Principles+of+early+drug+discovery&doi=10.1111%2Fj.1476-5381.2010.01127.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0lgzuXw2tnE9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BP.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%2BB.%26aulast%3DPhilpott%26aufirst%3DK.%2BL.%26atitle%3DPrinciples%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249%26doi%3D10.1111%2Fj.1476-5381.2010.01127.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control Influenza A virus replication</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+Influenza+A+virus+replication&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0lh9MiLc7HsF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520Influenza%2520A%2520virus%2520replication%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broad-spectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broad-spectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0lh9MiLc7HsF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugaswami, V.</span></span> <span> </span><span class="NLM_article-title">Antiviral drug screen of kinase inhibitors identifies cellular signaling pathways critical for SARS-CoV-2 replication</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">108940</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2021.108940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2021.108940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33784499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsVSmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2021&pages=108940&author=G.+Garciaauthor=A.+Sharmaauthor=A.+Ramaiahauthor=C.+Senauthor=D.+Kohnauthor=B.+Gompertsauthor=C.+N.+Svendsenauthor=R.+D.+Damoiseauxauthor=V.+Arumugaswami&title=Antiviral+drug+screen+of+kinase+inhibitors+identifies+cellular+signaling+pathways+critical+for+SARS-CoV-2+replication&doi=10.1016%2Fj.celrep.2021.108940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication</span></div><div class="casAuthors">Garcia, Gustavo; Sharma, Arun; Ramaiah, Arunachalam; Sen, Chandani; Purkayastha, Arunima; Kohn, Donald B.; Parcells, Mark S.; Beck, Sebastian; Kim, Heeyoung; Bakowski, Malina A.; Kirkpatrick, Melanie G.; Riva, Laura; Wolff, Karen C.; Han, Brandon; Yuen, Constance; Ulmert, David; Purbey, Prabhat K.; Scumpia, Phillip; Beutler, Nathan; Rogers, Thomas F.; Chatterjee, Arnab K.; Gabriel, Gulsah; Bartenschlager, Ralf; Gomperts, Brigitte; Svendsen, Clive N.; Betz, Ulrich A. K.; Damoiseaux, Robert D.; Arumugaswami, Vaithilingaraja</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108940</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SARS-CoV-2 has currently pptd. the COVID-19 global health crisis.  We developed a medium-throughput drug-screening system and identified a small-mol. library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells.  These drug inhibitors are in various stages of clin. trials.  We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are crit. for SARS-CoV-2 infection.  A drug-protein interaction-based secondary screen confirmed compds., such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity.  Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step.  Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well.  Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKjvqUTDcBubVg90H21EOLACvtfcHk0lh9MiLc7HsF-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsVSmu78%253D&md5=94d62725aa7d42373572305576df4793</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2021.108940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2021.108940%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DRamaiah%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DC.%26aulast%3DKohn%26aufirst%3DD.%26aulast%3DGomperts%26aufirst%3DB.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DDamoiseaux%26aufirst%3DR.%2BD.%26aulast%3DArumugaswami%26aufirst%3DV.%26atitle%3DAntiviral%2520drug%2520screen%2520of%2520kinase%2520inhibitors%2520identifies%2520cellular%2520signaling%2520pathways%2520critical%2520for%2520SARS-CoV-2%2520replication%26jtitle%3DCell%2520Rep.%26date%3D2021%26volume%3D35%26spage%3D108940%26doi%3D10.1016%2Fj.celrep.2021.108940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span> <span> </span><span class="NLM_article-title">Quantitative phosphoproteomic analysis identifies the critical role of JNK1 in neuroinflammation induced by Japanese encephalitis virus</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">ra98</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaf5132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscisignal.aaf5132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27703031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=J.+Yeauthor=H.+Zhangauthor=W.+Heauthor=B.+Zhuauthor=D.+Zhouauthor=Z.+Chenauthor=U.+Ashrafauthor=Y.+Weiauthor=Z.+Liuauthor=Z.+F.+Fuauthor=H.+Chenauthor=S.+Cao&title=Quantitative+phosphoproteomic+analysis+identifies+the+critical+role+of+JNK1+in+neuroinflammation+induced+by+Japanese+encephalitis+virus&doi=10.1126%2Fscisignal.aaf5132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaf5132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaf5132%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAshraf%26aufirst%3DU.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DS.%26atitle%3DQuantitative%2520phosphoproteomic%2520analysis%2520identifies%2520the%2520critical%2520role%2520of%2520JNK1%2520in%2520neuroinflammation%2520induced%2520by%2520Japanese%2520encephalitis%2520virus%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26doi%3D10.1126%2Fscisignal.aaf5132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yángüez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schading, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3679</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06119-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41467-018-06119-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30206219" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3679&author=E.+Y%C3%A1ng%C3%BCezauthor=A.+Hunzikerauthor=M.+P.+Dobayauthor=S.+Yildizauthor=S.+Schadingauthor=E.+Elshinaauthor=U.+Karakusauthor=P.+Gehrigauthor=J.+Grossmannauthor=R.+Dijkmanauthor=M.+Schmolkeauthor=S.+Stertz&title=Phosphoproteomic-based+kinase+profiling+early+in+influenza+virus+infection+identifies+GRK2+as+antiviral+drug+target&doi=10.1038%2Fs41467-018-06119-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06119-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06119-y%26sid%3Dliteratum%253Aachs%26aulast%3DY%25C3%25A1ng%25C3%25BCez%26aufirst%3DE.%26aulast%3DHunziker%26aufirst%3DA.%26aulast%3DDobay%26aufirst%3DM.%2BP.%26aulast%3DYildiz%26aufirst%3DS.%26aulast%3DSchading%26aufirst%3DS.%26aulast%3DElshina%26aufirst%3DE.%26aulast%3DKarakus%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DP.%26aulast%3DGrossmann%26aufirst%3DJ.%26aulast%3DDijkman%26aufirst%3DR.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DPhosphoproteomic-based%2520kinase%2520profiling%2520early%2520in%2520influenza%2520virus%2520infection%2520identifies%2520GRK2%2520as%2520antiviral%2520drug%2520target%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3679%26doi%3D10.1038%2Fs41467-018-06119-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0ljwuQpTmhGuLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Sunitinib</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2255</span>– <span class="NLM_lpage">2266</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666170-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.2165%2F00003495-200666170-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17137406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=2255-2266&author=E.+D.+Deeksauthor=G.+M.+Keating&title=Sunitinib&doi=10.2165%2F00003495-200666170-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib</span></div><div class="casAuthors">Deeks, Emma D.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2255-2266</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases assocd. with tumor growth and angiogenesis.  The clin. efficacy of oral sunitinib has been demonstrated in patients with advanced gastrointestinal stromal tumors (GIST).  In a phase III, randomised, double-blind, placebo-controlled, multicenter trial in patients with metastatic and/or unresectable GIST following unsuccessful imatinib therapy, the median time to tumor progression and median progression-free survival time were ≥4-fold longer in patients receiving sunitinib 50 mg/day than in those receiving placebo, in 6-wk cycles consisting of 4 wk of treatment followed by a 2-wk rest period.  Sunitinib also exhibited antitumor activity in patients with advanced renal cell carcinoma (RCC) following unsuccessful cytokine therapy.  In two multicentre, single-arm, phase II clin. trials in patients with cytokine-refractory metastatic RCC, partial responses were reported in 40% and 43% of patients receiving sunitinib 50 mg/day for 4 wk followed by 2 wk without treatment in 6-wk cycles; 27% and 22% of patients achieved stable disease for ≥3 mo.  Sunitinib was more effective than interferon-α as a first-line therapy in patients with metastatic RCC.  In a large, well designed, phase III trial in previously untreated patients, progression-free survival was significantly longer in patients receiving sunitinib 50 mg/day in 6-wk cycles (4 wk of treatment followed by a 2-wk rest period) compared with those receiving interferon-α 9MU three times weekly (47.3 vs 24.9 wk).  In general, sunitinib was well tolerated in patients with GIST and RCC, with adverse events usually being of mild or moderate severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj2acnnCHjT7Vg90H21EOLACvtfcHk0ljwuQpTmhGuLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCmu78%253D&md5=2ef4be4892ac6aab32355e0892501ddb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666170-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666170-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DSunitinib%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D2255%26epage%3D2266%26doi%3D10.2165%2F00003495-200666170-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelgalil, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kahtani, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jenoobi, F. I.</span></span> <span> </span><span class="NLM_article-title">Erlotinib</span>. <i>Profiles Drug Subst., Excipients, Relat. Methodol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/bs.podrm.2019.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fbs.podrm.2019.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32164971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB383islaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=93-117&author=A.+A.+Abdelgalilauthor=H.+M.+Al-Kahtaniauthor=F.+I.+Al-Jenoobi&title=Erlotinib&doi=10.1016%2Fbs.podrm.2019.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib</span></div><div class="casAuthors">Abdelgalil Ahmed A; Al-Kahtani Hamad M; Al-Jenoobi Fahad I</div><div class="citationInfo"><span class="NLM_cas:title">Profiles of drug substances, excipients, and related methodology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-117</span>
        ISSN:<span class="NLM_cas:issn">1871-5125</span>.
    </div><div class="casAbstract">Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer.  Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells.  This study presents a comprehensive profile of erlotinib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis).  Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry.  Chromatographic methods of analyses include thin layer chromatography, and high-performance liquid chromatography.  Pharmacology of erlotinib including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented.  An appropriate table and figures were attached to each of the above mentioned sections along with total of 48 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScjIwfRcn866cY7HFp97qMfW6udTcc2ebwp5vrH4eM1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383islaqtQ%253D%253D&md5=612f3c7b1ece857634ade4904b2f062c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fbs.podrm.2019.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.podrm.2019.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelgalil%26aufirst%3DA.%2BA.%26aulast%3DAl-Kahtani%26aufirst%3DH.%2BM.%26aulast%3DAl-Jenoobi%26aufirst%3DF.%2BI.%26atitle%3DErlotinib%26jtitle%3DProfiles%2520Drug%2520Subst.%252C%2520Excipients%252C%2520Relat.%2520Methodol.%26date%3D2020%26volume%3D45%26spage%3D93%26epage%3D117%26doi%3D10.1016%2Fbs.podrm.2019.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0723-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs40265-017-0723-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28290136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=697-704&author=A.+Markham&title=Baricitinib%3A+first+global+approval&doi=10.1007%2Fs40265-017-0723-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an orally-administered, small-mol., janus-assocd. kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.  JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions.  In Feb. 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).  Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan.  This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-U2lbkEPpbVg90H21EOLACvtfcHk0ljrmArNDl7aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D&md5=54dbb2c53eb3cfd5831284df95beb184</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0723-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0723-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBaricitinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D697%26epage%3D704%26doi%3D10.1007%2Fs40265-017-0723-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smythe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscough, K. R.</span></span> <span> </span><span class="NLM_article-title">The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin skeleton</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.embor776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fsj.embor.embor776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12634840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=246-251&author=E.+Smytheauthor=K.+R.+Ayscough&title=The+Ark1%2FPrk1+family+of+protein+kinases.+Regulators+of+endocytosis+and+the+actin+skeleton&doi=10.1038%2Fsj.embor.embor776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin cytoskeleton</span></div><div class="casAuthors">Smythe, Elizabeth; Ayscough, Kathryn R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-251</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Ark/Prk serine/threonine kinases initiate phosphorylation cycles that control the endocytic machinery in mammalian cells and yeast, and the actin cytoskeleton in yeast.  The members of this protein family are unified by homologies in their kinase domain, but are generally diverse in their other domains.  The evolution of Ark/Prk family members in different organisms may have allowed the conserved role of the kinase domain, which is required for the phosphorylation of both endocytic and cytoskeletal components, to be coupled to other functional domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XGXyl51NTrVg90H21EOLACvtfcHk0ljrmArNDl7aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFyntr8%253D&md5=1faa1e2d9498cd426a5570b446b19fe8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.embor776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.embor776%26sid%3Dliteratum%253Aachs%26aulast%3DSmythe%26aufirst%3DE.%26aulast%3DAyscough%26aufirst%3DK.%2BR.%26atitle%3DThe%2520Ark1%252FPrk1%2520family%2520of%2520protein%2520kinases.%2520Regulators%2520of%2520endocytosis%2520and%2520the%2520actin%2520skeleton%26jtitle%3DEMBO%2520Rep.%26date%3D2003%26volume%3D4%26spage%3D246%26epage%3D251%26doi%3D10.1038%2Fsj.embor.embor776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Fusion of enveloped viruses in endosomes</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1111/tra.12389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Ftra.12389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26935856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslWls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=593-614&author=J.+M.+Whiteauthor=G.+R.+Whittaker&title=Fusion+of+enveloped+viruses+in+endosomes&doi=10.1111%2Ftra.12389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of enveloped viruses in endosomes</span></div><div class="casAuthors">White, Judith M.; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-614</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Ari Helenius launched the field of enveloped virus fusion in endosomes with a seminal paper in the Journal of Cell Biol. in 1980.  In the intervening years, a great deal has been learned about the structures and mechanisms of viral membrane fusion proteins as well as about the endosomes in which different enveloped viruses fuse and the endosomal cues that trigger fusion.  We now recognize three classes of viral membrane fusion proteins based on structural criteria and four mechanisms of fusion triggering.  After reviewing general features of viral membrane fusion proteins and viral fusion in endosomes, we delve into three characterized mechanisms for viral fusion triggering in endosomes: by low pH, by receptor binding plus low pH and by receptor binding plus the action of a protease.  The authors end with a discussion of viruses that may employ novel endosomal fusion-triggering mechanisms.  A key take-home message is that enveloped viruses that enter cells by fusing in endosomes traverse the endocytic pathway until they reach an endosome that has all of the environmental conditions (pH, proteases, ions, intracellular receptors and lipid compn.) to (if needed) prime and (in all cases) trigger the fusion protein and to support membrane fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIH6MfR6awv7Vg90H21EOLACvtfcHk0ljrmArNDl7aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslWls70%253D&md5=915c967ab0f18e75e824f6cfc3de5cdf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Ftra.12389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftra.12389%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DFusion%2520of%2520enveloped%2520viruses%2520in%2520endosomes%26jtitle%3DTraffic%26date%3D2016%26volume%3D17%26spage%3D593%26epage%3D614%26doi%3D10.1111%2Ftra.12389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Viral journeys on the intracellular highways</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3714</span>, <span class="refDoi"> DOI: 10.1007/s00018-018-2882-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs00018-018-2882-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30043139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2018&pages=3693-3714&author=M.+Robinsonauthor=S.+Schorauthor=R.+Barouch-Bentovauthor=S.+Einav&title=Viral+journeys+on+the+intracellular+highways&doi=10.1007%2Fs00018-018-2882-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Viral journeys on the intracellular highways</span></div><div class="casAuthors">Robinson, Makeda; Schor, Stanford; Barouch-Bentov, Rina; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3693-3714</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Viruses are obligate intracellular pathogens that are dependent on cellular machineries for their replication.  Recent technol. breakthroughs have facilitated reliable identification of host factors required for viral infections and better characterization of the virus-host interplay.  While these studies have revealed cellular machineries that are uniquely required by individual viruses, accumulating data also indicate the presence of broadly required mechanisms.  Among these overlapping cellular functions are components of intracellular membrane trafficking pathways.  Here, we review recent discoveries focused on how viruses exploit intracellular membrane trafficking pathways to promote various stages of their life cycle, with an emphasis on cellular factors that are usurped by a broad range of viruses.  We describe broadly required components of the endocytic and secretory pathways, the Endosomal Sorting Complexes Required for Transport pathway, and the autophagy pathway.  Identification of such overlapping host functions offers new opportunities to develop broad-spectrum host-targeted antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7AbAAm0W8PLVg90H21EOLACvtfcHk0ljrmArNDl7aGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrt7fI&md5=5a964c5d61495441e6476013dded83d6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs00018-018-2882-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-018-2882-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DViral%2520journeys%2520on%2520the%2520intracellular%2520highways%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2018%26volume%3D75%26spage%3D3693%26epage%3D3714%26doi%3D10.1007%2Fs00018-018-2882-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AP-2-associated+protein+kinase+1+and+cyclin+G-associated+kinase+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the μ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0liXF0PbZroW9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAP-2-associated%2520protein%2520kinase%25201%2520and%2520cyclin%2520G-associated%2520kinase%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. E.</span></span> <span> </span><span class="NLM_article-title">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4311</span>– <span class="NLM_lpage">4321</span>, <span class="refDoi"> DOI: 10.1242/jcs.02548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.02548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16155256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4311-4321&author=D.+W.+Leeauthor=X.+Zhaoauthor=F.+Zhangauthor=E.+Eisenbergauthor=L.+E.+Greene&title=Depletion+of+GAK%2Fauxilin+2+inhibits+receptor-mediated+endocytosis+and+recruitment+of+both+clathrin+and+clathrin+adaptors&doi=10.1242%2Fjcs.02548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span></div><div class="casAuthors">Lee, Dong-won; Zhao, Xiaohong; Zhang, Fang; Eisenberg, Evan; Greene, Lois E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4311-4321</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK/auxilin 2), the ubiquitous form of the neuronal-specific protein auxilin 1, is an essential cofactor for the Hsc70-dependent uncoating of clathrin-coated vesicles.  We have now investigated the effect of knocking down GAK in HeLa cells by vector-based small hairpin RNA.  Functionally, depletion of GAK caused a marked decrease in internalization of both transferrin and epidermal growth factor and altered mannose 6-phosphate receptor trafficking, but had little effect on the recycling of transferrin receptor back to the plasma membrane.  Structurally, depletion of GAK caused a marked redn. in perinuclear clathrin assocd. with the trans-Golgi network and in the no. of clathrin-coated pits on the plasma membrane, and reduced clathrin exchange on the few clathrin-coated pits that remained.  Surprisingly, while clathrin depletion does not prevent adaptors from assembling on the membrane, depletion of GAK caused a dramatic redn. in AP2 and epsin on the plasma membrane and AP1 and GGA at the trans-Golgi network.  A similar effect was caused by expression of a dominant neg. Hsp70 mutant.  These results suggest that GAK, in conjunction with Hsc70, not only uncoats clathrin-coated vesicles and induces clathrin exchange on clathrin-coated pits, but also mediates binding of clathrin and adaptors to the plasma membrane and the trans-Golgi network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IvRfVSaZT7Vg90H21EOLACvtfcHk0liXF0PbZroW9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK&md5=0172190491cf9b908e705e434b763d60</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02548%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DGreene%26aufirst%3DL.%2BE.%26atitle%3DDepletion%2520of%2520GAK%252Fauxilin%25202%2520inhibits%2520receptor-mediated%2520endocytosis%2520and%2520recruitment%2520of%2520both%2520clathrin%2520and%2520clathrin%2520adaptors%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4311%26epage%3D4321%26doi%3D10.1242%2Fjcs.02548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0liXF0PbZroW9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eYERlG6w-BvMrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhSpaaqh5eHaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">e30</span>– <span class="NLM_lpage">e31</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=e30-e31&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0lhg6gub7imLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3De30%26epage%3De31%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicastri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobbione, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span> <span> </span><span class="NLM_article-title">Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.jinf.2020.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jinf.2020.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32333918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=318-356&author=F.+Cantiniauthor=L.+Niccoliauthor=D.+Matarreseauthor=E.+Nicastriauthor=P.+Stobbioneauthor=D.+Goletti&title=Baricitinib+therapy+in+COVID-19%3A+a+pilot+study+on+safety+and+clinical+impact&doi=10.1016%2Fj.jinf.2020.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span></div><div class="casAuthors">Cantini, Fabrizio; Niccoli, Laura; Matarrese, Daniela; Nicastri, Emanuele; Stobbione, Paolo; Goletti, Delia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-356</span>CODEN:
                <span class="NLM_cas:coden">JINFD2</span>;
        ISSN:<span class="NLM_cas:issn">1532-2742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preliminary results on 12 patients with moderate COVID-19 pneumonia confirmed the safety of baricitinib therapy in a clin. context.  In the baricitinib-treated group, all clin. characteristics and respiratory function parameters improved both at wk 1 and 2 compared to baseline.  C-reactive protein values significantly decreased in the same timeframes.  No infections, cardiovascular, and hematol. adverse events occurred after a 2 wk treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0f8W8UmI8rVg90H21EOLACvtfcHk0lhg6gub7imLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO&md5=d47bb194919c10f50d24312f137ec88d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jinf.2020.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinf.2020.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DNicastri%26aufirst%3DE.%26aulast%3DStobbione%26aufirst%3DP.%26aulast%3DGoletti%26aufirst%3DD.%26atitle%3DBaricitinib%2520therapy%2520in%2520COVID-19%253A%2520a%2520pilot%2520study%2520on%2520safety%2520and%2520clinical%2520impact%26jtitle%3DJ.%2520Infect.%26date%3D2020%26volume%3D81%26spage%3D318%26epage%3D356%26doi%3D10.1016%2Fj.jinf.2020.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puvvada, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">M, V. A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105967</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2020.105967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ijantimicag.2020.105967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32259575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsV2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105967&author=D.+Praveenauthor=R.+C.+Puvvadaauthor=V.+A.+M&title=Janus+kinase+inhibitor+baricitinib+is+not+an+ideal+option+for+management+of+COVID-19&doi=10.1016%2Fj.ijantimicag.2020.105967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19</span></div><div class="casAuthors">Praveen, D.; Puvvada, Ranadheer Chowdary; M, Vijey Aanandhi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">105967</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Wuhan outbreak of novel Corona virus infection has been the global focus since Dec. 2019.  This infection has become a global pandemic.  It is highly important to understand the virol. of the pathogen and to explore the therapeutic options for management of this pandemic.  Drug repurposing strategies are being considered for management of COVID 19.  Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin assocd. endocytosis.  We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl3tkQaMBwdbVg90H21EOLACvtfcHk0lhg6gub7imLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsV2rtb0%253D&md5=53ee40e8ae424cf392fbf9c7987707c3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105967%26sid%3Dliteratum%253Aachs%26aulast%3DPraveen%26aufirst%3DD.%26aulast%3DPuvvada%26aufirst%3DR.%2BC.%26aulast%3DM%26aufirst%3DV.%2BA.%26atitle%3DJanus%2520kinase%2520inhibitor%2520baricitinib%2520is%2520not%2520an%2520ideal%2520option%2520for%2520management%2520of%2520COVID-19%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105967%26doi%3D10.1016%2Fj.ijantimicag.2020.105967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggioggero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maioli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, R.</span></span> <span> </span><span class="NLM_article-title">Baricitinib for COVID-19: a suitable treatment?</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(20)30262-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS1473-3099%2820%2930262-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32251638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVCitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1012-1013&author=E.+G.+Favalliauthor=M.+Biggioggeroauthor=G.+Maioliauthor=R.+Caporali&title=Baricitinib+for+COVID-19%3A+a+suitable+treatment%3F&doi=10.1016%2FS1473-3099%2820%2930262-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib for COVID-19: a suitable treatment?</span></div><div class="casAuthors">Favalli, Ennio G.; Biggioggero, Martina; Maioli, Gabriella; Caporali, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1012-1013</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A correspondence to the use of baricitinib for COVID-19 and its complication is given.  In conclusion, we believe that, beyond the intriguing opportunity to directly block the penetration of SARS-CoV-2 into the cell, the use of baricitinib in susceptible patients with ongoing pneumonia assocd. with COVID-19 should be considered with extreme caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqQU1fZWMa6LVg90H21EOLACvtfcHk0lhg6gub7imLxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVCitLY%253D&md5=5fed9d0b4df4f489cf6d7d7768dff536</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930262-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930262-0%26sid%3Dliteratum%253Aachs%26aulast%3DFavalli%26aufirst%3DE.%2BG.%26aulast%3DBiggioggero%26aufirst%3DM.%26aulast%3DMaioli%26aufirst%3DG.%26aulast%3DCaporali%26aufirst%3DR.%26atitle%3DBaricitinib%2520for%2520COVID-19%253A%2520a%2520suitable%2520treatment%253F%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D1012%26epage%3D1013%26doi%3D10.1016%2FS1473-3099%2820%2930262-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis C agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3410</span>, <span class="refDoi"> DOI: 10.1021/jm501759m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501759m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3393-3410&author=S.+Kovackovaauthor=L.+Changauthor=E.+Bekermanauthor=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Chaikuadauthor=C.+Herovenauthor=M.+Salaauthor=S.+De+Jongheauthor=S.+Knappauthor=S.+Einavauthor=P.+Herdewijn&title=Selective+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+as+anti-hepatitis+C+agents&doi=10.1021%2Fjm501759m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents</span></div><div class="casAuthors">Kovackova, Sona; Chang, Lei; Bekerman, Elena; Neveu, Gregory; Barouch-Bentov, Rina; Chaikuad, Apirat; Heroven, Christina; Sala, Michal; De Jonghe, Steven; Knapp, Stefan; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3393-3410</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin G assocd. kinase (GAK) emerged as a promising drug target for the treatment of viral infections.  However, no potent and selective GAK inhibitors have been reported in the literature to date.  This paper describes the discovery of isothiazolo[5,4-b]pyridines as selective GAK inhibitors, with the most potent congeners displaying low nanomolar binding affinity for GAK.  Cocrystn. expts. revealed that these compds. behaved as classic type I ATP-competitive kinase inhibitors.  In addn., the authors have demonstrated that these compds. exhibit a potent activity against hepatitis C virus (HCV) by inhibiting two temporally distinct steps in the HCV life cycle (i.e., viral entry and assembly).  Hence, these GAK inhibitors represent chem. probes to study GAK function in different disease areas where GAK has been implicated (including viral infection, cancer, and Parkinson's disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjwEtUi0av7Vg90H21EOLACvtfcHk0liWP56nSdn6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D&md5=ed7f93eb3d49f6c7265dd2c0da880b43</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm501759m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501759m%26sid%3Dliteratum%253Aachs%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DM.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DSelective%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520as%2520anti-hepatitis%2520C%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3393%26epage%3D3410%26doi%3D10.1021%2Fjm501759m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of isothiazolo[4,3- b]pyridine-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6178</span>– <span class="NLM_lpage">6192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6178-6192&author=S.+Y.+Puauthor=R.+Woutersauthor=S.+Schorauthor=J.+Rozenskiauthor=R.+Barouch-Bentovauthor=L.+I.+Prugarauthor=C.+M.+O%E2%80%99Brienauthor=J.+M.+Brannanauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+De+Jongheauthor=S.+Einav&title=Optimization+of+isothiazolo%5B4%2C3-+b%5Dpyridine-based+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+with+broad-spectrum+antiviral+activity&doi=10.1021%2Facs.jmedchem.8b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Isothiazolo[4,3-b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">Pu, Szu-Yuan; Wouters, Randy; Schor, Stanford; Rozenski, Jef; Barouch-Bentov, Rina; Prugar, Laura I.; O'Brien, Cecilia M.; Brannan, Jennifer M.; Dye, John M.; Herdewijn, Piet; De Jonghe, Steven; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6178-6192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue and other emerging viral infections.  We reported that cyclin G-assocd. kinase (GAK), a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle.  We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity.  Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity.  These compds. demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses.  Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compds.  These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDe8aVxkBtKLVg90H21EOLACvtfcHk0liWP56nSdn6lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP&md5=fe33e256835ea01c5e1932c3ccea7eac</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00613%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BM.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520isothiazolo%255B4%252C3-%2520b%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6178%26epage%3D6192%26doi%3D10.1021%2Facs.jmedchem.8b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescrinier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ejmech.2018.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30529544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVemsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=256-265&author=R.+Woutersauthor=S.+Y.+Puauthor=M.+Froeyenauthor=E.+Lescrinierauthor=S.+Einavauthor=P.+Herdewijnauthor=S.+De+Jonghe&title=Cyclin+G-associated+kinase+%28GAK%29+affinity+and+antiviral+activity+studies+of+a+series+of+3-C-substituted+isothiazolo%5B4%2C3-b%5Dpyridines&doi=10.1016%2Fj.ejmech.2018.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines</span></div><div class="casAuthors">Wouters, Randy; Pu, Szu-Yuan; Froeyen, Mathy; Lescrinier, Eveline; Einav, Shirit; Herdewijn, Piet; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256-265</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK) is a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, which regulates intracellular trafficking of dengue virus during early and late stages of the viral lifecycle.  Previously, the discovery of isothiazolo[4,3-b]pyridines as potent and selective GAK inhibitors with promising antiviral activity was reported.  In this manuscript, the synthesis of isothiazolo[4,3-b]pyridines with a carbon-linked substituent at position 3 is described by the application of regioselective Suzuki and Sonogashira coupling reactions.  A deriv. I with a 3,4-dimethoxyphenyl residue at position 3 demonstrates low nanomolar binding affinity for GAK and antiviral activity against dengue virus.  These findings reveal that appropriate substitution of a Ph moiety at position 3 of the scaffold can improve GAK binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUueVjB8L_7Vg90H21EOLACvtfcHk0lgWBwXaAYq9UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVemsb%252FE&md5=b12e5c6fddd96549f70cd6a06980f20d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DLescrinier%26aufirst%3DE.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DCyclin%2520G-associated%2520kinase%2520%2528GAK%2529%2520affinity%2520and%2520antiviral%2520activity%2520studies%2520of%2520a%2520series%2520of%25203-C-substituted%2520isothiazolo%255B4%252C3-b%255Dpyridines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D256%26epage%3D265%26doi%3D10.1016%2Fj.ejmech.2018.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115188</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bmc.2019.115188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31757682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115188&author=B.+Martinez-Gualdaauthor=S.+Y.+Puauthor=M.+Froeyenauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Structure-activity+relationship+study+of+the+pyridine+moiety+of+isothiazolo%5B4%2C3-b%5Dpyridines+as+antiviral+agents+targeting+cyclin+G-associated+kinase&doi=10.1016%2Fj.bmc.2019.115188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Pu, Szu-Yuan; Froeyen, Mathy; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115188</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 3,6-disubstituted isothiazolo[4,3-b]pyridines as potent and selective cyclin G-assocd. kinase (GAK) inhibitors with promising antiviral activity was reported.  In this manuscript, the structure-activity relationship study was expanded to synthesis of isothiazolo[4,3-b]pyridines with modifications of the pyridine moiety.  This effort led to the discovery of an isothiazolo[4,3-b]pyridine deriv. with a 3,4-dimethoxyphenyl residue at position 5 that displayed low nanomolar GAK binding affinity and antiviral activity against dengue virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqu1a3iqS1i7Vg90H21EOLACvtfcHk0lgWBwXaAYq9UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM&md5=cf709736ad37cfcda6e2310a243c55d4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115188%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520the%2520pyridine%2520moiety%2520of%2520isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520antiviral%2520agents%2520targeting%2520cyclin%2520G-associated%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115188%26doi%3D10.1016%2Fj.bmc.2019.115188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">113158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ejmech.2021.113158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33497888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXit1artr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2021&pages=113158&author=B.+Martinez-Gualdaauthor=S.+Saulauthor=M.+Froeyenauthor=D.+Scholsauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Discovery+of+3-phenyl-+and+3-N-piperidinyl-isothiazolo%5B4%2C3-b%5Dpyridines+as+highly+potent+inhibitors+of+cyclin+G-associated+kinase&doi=10.1016%2Fj.ejmech.2021.113158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Saul, Sirle; Froeyen, Mathy; Schols, Dominique; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural modifications at position 3 of the isothiazolo[4,3-b]pyridine scaffold afforded a new series of cyclin G-assocd. kinase (GAK) inhibitors.  It was shown that the insertion of a carboxamide residue at position 3 of a Ph or piperidinyl moiety generated potent GAK inhibitors with IC50 values in a low nanomolar range.  This potent GAK binding affinity was rationalized by mol. modeling demonstrating that the carboxamide moiety engages in an extra hydrogen bond with GAK.  Moreover, this new series of compds. was also endowed with antiviral activity against dengue virus, highlighting the potential utility of GAK as a target for the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVK3lpIDifX7Vg90H21EOLACvtfcHk0lgWBwXaAYq9UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXit1artr8%253D&md5=8befd946b1eb30e7eb04a329dcce3933</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113158%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25203-phenyl-%2520and%25203-N-piperidinyl-isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520highly%2520potent%2520inhibitors%2520of%2520cyclin%2520G-associated%2520kinase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D213%26spage%3D113158%26doi%3D10.1016%2Fj.ejmech.2021.113158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornsife, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of 4-anilinoquinolines as inhibitors of cyclin G associated Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fcmdc.201700663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29072804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKhurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=48-66&author=C.+R.+M.+Asquithauthor=T.+Laitinenauthor=J.+M.+Bennettauthor=P.+H.+Godoiauthor=M.+P.+Eastauthor=G.+J.+Tizzardauthor=L.+M.+Gravesauthor=G.+L.+Johnsonauthor=R.+E.+Dornsifeauthor=C.+I.+Wellsauthor=J.+M.+Elkinsauthor=T.+M.+Willsonauthor=W.+J.+Zuercher&title=Identification+and+optimization+of+4-anilinoquinolines+as+inhibitors+of+cyclin+G+associated+Kinase&doi=10.1002%2Fcmdc.201700663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase</span></div><div class="casAuthors">Asquith, Christopher R. M.; Laitinen, Tuomo; Bennett, James M.; Godoi, Paulo H.; East, Michael P.; Tizzard, Graham J.; Graves, Lee M.; Johnson, Gary L.; Dornsife, Ronna E.; Wells, Carrow I.; Elkins, Jonathan M.; Willson, Timothy M.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-66</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-Anilinoquinolines were identified as potent and narrow-spectrum inhibitors of the cyclin G assocd. kinase (GAK), an important regulator of viral and bacterial entry into host cells.  Optimization of the 4-anilino group and the 6,7-quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000-fold selectivity relative to other members of the numb-assocd. kinase (NAK) subfamily, and a compd. (6,7-dimethoxy-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine; I) with a narrow-spectrum kinome profile.  These compds. may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCmCJJ-T_rrVg90H21EOLACvtfcHk0lgwEwA7g64X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKhurfJ&md5=4ea89909e674ef29c37e78fbe7622a68</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700663%26sid%3Dliteratum%253Aachs%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DTizzard%26aufirst%3DG.%2BJ.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DDornsife%26aufirst%3DR.%2BE.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DIdentification%2520and%2520optimization%2520of%25204-anilinoquinolines%2520as%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520Kinase%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D48%26epage%3D66%26doi%3D10.1002%2Fcmdc.201700663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span> <span> </span><span class="NLM_article-title">Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127284</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bmcl.2020.127284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32631507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeksLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127284&author=S.+Saulauthor=S.+Y.+Puauthor=W.+J.+Zuercherauthor=S.+Einavauthor=C.+R.+M.+Asquith&title=Potent+antiviral+activity+of+novel+multi-substituted+4-anilinoquin%28az%29olines&doi=10.1016%2Fj.bmcl.2020.127284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines</span></div><div class="casAuthors">Saul, Sirle; Pu, Szu-Yuan; Zuercher, William J.; Einav, Shirit; Asquith, Christopher R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127284</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Screening a series of 4-anilinoquinolines and 4-anilinoquinazolines enabled identification of potent novel inhibitors of dengue virus (DENV).  Prepn. of focused 4-anilinoquinoline/quinazoline scaffold arrays led to the identification of a series of high potency 6-substituted bromine and iodine derivs.  The most potent compd. 6-iodo-4-((3,4,5-trimethoxyphenyl)amino)quinoline-3-carbonitrile inhibited DENV infection with an EC50 = 79 nM.  Crucially, these compds. showed very limited toxicity with CC50 values >10μM in almost all cases.  This new promising series provides an anchor point for further development to optimize compd. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsDse-6-n89LVg90H21EOLACvtfcHk0lgwEwA7g64X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeksLfL&md5=af8311c1236ae5eca2d305d7f261c47d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127284%26sid%3Dliteratum%253Aachs%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26atitle%3DPotent%2520antiviral%2520activity%2520of%2520novel%2520multi-substituted%25204-anilinoquin%2528az%2529olines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127284%26doi%3D10.1016%2Fj.bmcl.2020.127284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokania, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vattikundala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenarsipur, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouraldeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaffield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikramadithyan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.235333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1124%2Fjpet.116.235333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27411717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=371-386&author=W.+Kostichauthor=B.+D.+Hammanauthor=Y.+W.+Liauthor=S.+Naiduauthor=K.+Dandapaniauthor=J.+Fengauthor=A.+Eastonauthor=C.+Bourinauthor=K.+Bakerauthor=J.+Allenauthor=K.+Savelievaauthor=J.+V.+Louisauthor=M.+Dokaniaauthor=S.+Elavazhaganauthor=P.+Vattikundalaauthor=V.+Sharmaauthor=M.+L.+Dasauthor=G.+Shankarauthor=A.+Kumarauthor=V.+K.+Holenarsipurauthor=M.+Gulianelloauthor=T.+Molskiauthor=J.+M.+Brownauthor=M.+Lewisauthor=Y.+Huangauthor=Y.+Luauthor=R.+Pieschlauthor=K.+O%E2%80%99Malleyauthor=J.+Lippyauthor=A.+Nouraldeenauthor=T.+H.+Lanthornauthor=G.+Yeauthor=A.+Wilsonauthor=A.+Balakrishnanauthor=R.+Dentonauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=K.+S.+Santoneauthor=Y.+Biauthor=A.+Mainauthor=J.+Swaffieldauthor=K.+Carsonauthor=S.+Mandlekarauthor=R.+K.+Vikramadithyanauthor=S.+J.+Naraauthor=C.+Dzierbaauthor=J.+Bronsonauthor=J.+E.+Macorauthor=R.+Zaczekauthor=R.+Westphalauthor=L.+Kissauthor=L.+Bristowauthor=C.+M.+Conwayauthor=B.+Zambrowiczauthor=C.+F.+Albright&title=Inhibition+of+AAK1+kinase+as+a+novel+therapeutic+approach+to+treat+neuropathic+pain&doi=10.1124%2Fjpet.116.235333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span></div><div class="casAuthors">Kostich, Walter; Hamman, Brian D.; Li, Yu-Wen; Naidu, Sreenivasulu; Dandapani, Kumaran; Feng, Jianlin; Easton, Amy; Bourin, Clotilde; Baker, Kevin; Allen, Jason; Savelieva, Katerina; Louis, Justin V.; Dokania, Manoj; Elavazhagan, Saravanan; Vattikundala, Pradeep; Sharma, Vivek; Das, Manish Lal; Shankar, Ganesh; Kumar, Anoop; Holenarsipur, Vinay K.; Gulianello, Michael; Molski, Ted; Brown, Jeffrey M.; Lewis, Martin; Huang, Yanling; Lu, Yifeng; Pieschl, Rick; O'Malley, Kevin; Lippy, Jonathan; Nouraldeen, Amr; Lanthorn, Thomas H.; Ye, Guilan; Wilson, Alan; Balakrishnan, Anand; Denton, Rex; Grace, James E.; Lentz, Kimberley A.; Santone, Kenneth S.; Bi, Yingzhi; Main, Alan; Swaffield, Jon; Carson, Ken; Mandlekar, Sandhya; Vikramadithyan, Reeba K.; Nara, Susheel J.; Dzierba, Carolyn; Bronson, Joanne; Macor, John E.; Zaczek, Robert; Westphal, Ryan; Kiss, Laszlo; Bristow, Linda; Conway, Charles M.; Zambrowicz, Brian; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays.  One of the lines from this screen, which contained a null allele of the adapter protein-2 assocd. kinase 1 (AAK1) gene, had a normal response in acute pain assays (hot plate, phase I formalin), but a markedly reduced response to persistent pain in phase II formalin.  AAK1 knockout mice also failed to develop tactile allodynia following the Chung procedure of spinal nerve ligation (SNL).  Based on these findings, potent, small-mol. inhibitors of AAK1 were identified.  Studies in mice showed that one such inhibitor, LP-935509, caused a reduced pain response in phase II formalin and reversed fully established pain behavior following the SNL procedure.  Further studies showed that the inhibitor also reduced evoked pain responses in the rat chronic constriction injury (CCI) model and the rat streptozotocin model of diabetic peripheral neuropathy.  Using a nonbrain-penetrant AAK1 inhibitor and local administration of an AAK1 inhibitor, the relevant pool of AAK1 for antineuropathic action was found to be in the spinal cord.  Consistent with these results, AAK1 inhibitors dose-dependently reduced the increased spontaneous neural activity in the spinal cord caused by CCI and blocked the development of windup induced by repeated elec. stimulation of the paw.  The mechanism of AAK1 antinociception was further investigated with inhibitors of α2 adrenergic and opioid receptors.  These studies showed that α2 adrenergic receptor inhibitors, but not opioid receptor inhibitors, not only prevented AAK1 inhibitor antineuropathic action in behavioral assays, but also blocked the AAK1 inhibitor-induced redn. in spinal neural activity in the rat CCI model.  Hence, AAK1 inhibitors are a novel therapeutic approach to neuropathic pain with activity in animal models that is mechanistically linked (behaviorally and electrophysiol.) to α2 adrenergic signaling, a pathway known to be antinociceptive in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cJpGeOPjm7Vg90H21EOLACvtfcHk0lgwEwA7g64X9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI&md5=d4cec6b3681b63ba7d9119424e53ab61</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.235333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.235333%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DW.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DNaidu%26aufirst%3DS.%26aulast%3DDandapani%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DBourin%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DSavelieva%26aufirst%3DK.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDokania%26aufirst%3DM.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DVattikundala%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DM.%2BL.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHolenarsipur%26aufirst%3DV.%2BK.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DNouraldeen%26aufirst%3DA.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMain%26aufirst%3DA.%26aulast%3DSwaffield%26aufirst%3DJ.%26aulast%3DCarson%26aufirst%3DK.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DVikramadithyan%26aufirst%3DR.%2BK.%26aulast%3DNara%26aufirst%3DS.%2BJ.%26aulast%3DDzierba%26aufirst%3DC.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DInhibition%2520of%2520AAK1%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520approach%2520to%2520treat%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D371%26epage%3D386%26doi%3D10.1124%2Fjpet.116.235333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K.</span></span> <span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7898</span>– <span class="NLM_lpage">7914</span>, <span class="refDoi"> DOI: 10.1021/jm8011036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery&doi=10.1021%2Fjm8011036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0ljqGVppRHbVYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914%26doi%3D10.1021%2Fjm8011036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 3,5-disubstituted-pyrrolo[2,3- b]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.+Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.+J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure-activity+relationships+of+3%2C5-disubstituted-pyrrolo%5B2%2C3-+b%5Dpyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0ljqGVppRHbVYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.%2BJ.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25203%252C5-disubstituted-pyrrolo%255B2%252C3-%2520b%255Dpyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">104966</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2020.104966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33137362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2020&pages=104966&author=S.+Puauthor=S.+Schorauthor=M.+Karimauthor=S.+Saulauthor=M.+Robinsonauthor=S.+Kumarauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+Brannanauthor=J.+M.+Dyeauthor=S.+Einav&title=BIKE+regulates+dengue+virus+infection+and+is+a+cellular+target+for+broad-spectrum+antivirals&doi=10.1016%2Fj.antiviral.2020.104966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals</span></div><div class="casAuthors">Pu, Szuyuan; Schor, Stanford; Karim, Marwah; Saul, Sirle; Robinson, Makeda; Kumar, Sathish; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer; Dye, John M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104966</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Global health is threatened by emerging viruses, many of which lack approved therapies and effective vaccines, including dengue, Ebola, and Venezuelan equine encephalitis.  We previously reported that AAK1 and GAK, two of the four members of the understudied Numb-assocd. kinases (NAK) family, control intracellular trafficking of RNA viruses.  Nevertheless, the role of BIKE and STK16 in viral infection remained unknown.  Here, we reveal a requirement for BIKE, but not STK-16, in dengue virus (DENV) infection.  BIKE mediates both early (postinternalization) and late (assembly/egress) stages in the DENV life cycle, and this effect is mediated in part by phosphorylation of a threonine 156 (T156) residue in theμ subunit of the adaptor protein (AP) 2 complex.  Pharmacol. compds. with potent anti-BIKE activity, including the investigational anticancer drug 5Z-7-oxozeaenol and more selective inhibitors, suppress DENV infection both in vitro and ex vivo.  BIKE overexpression reverses the antiviral activity, validating that the mechanism of antiviral action is, at least in part, mediated by BIKE.  Lastly, 5Z-7-oxozeaenol exhibits antiviral activity against viruses from three unrelated RNA viral families with a high genetic barrier to resistance.  These findings reveal regulation of poorly understood stages of the DENV life cycle via BIKE signaling and establish a proof-of-principle that pharmacol. inhibition of BIKE can be potentially used as a broad-spectrum strategy against acute emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OM0FhHoGxbVg90H21EOLACvtfcHk0liQHRq3pdMU3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOqs7vK&md5=4c32d80ba91b13ebecaa8387ad619867</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104966%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DKarim%26aufirst%3DM.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DBIKE%2520regulates%2520dengue%2520virus%2520infection%2520and%2520is%2520a%2520cellular%2520target%2520for%2520broad-spectrum%2520antivirals%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D184%26spage%3D104966%26doi%3D10.1016%2Fj.antiviral.2020.104966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crona, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrice, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">SGC-GAK-1: a chemical probe for cyclin G associated kinase (GAK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2830</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2830-2836&author=C.+R.+M.+Asquithauthor=B.+T.+Bergerauthor=J.+Wanauthor=J.+M.+Bennettauthor=S.+J.+Capuzziauthor=D.+J.+Cronaauthor=D.+H.+Drewryauthor=M.+P.+Eastauthor=J.+M.+Elkinsauthor=O.+Fedorovauthor=P.+H.+Godoiauthor=D.+M.+Hunterauthor=S.+Knappauthor=S.+Mullerauthor=C.+D.+Torriceauthor=C.+I.+Wellsauthor=H.+S.+Earpauthor=T.+M.+Willsonauthor=W.+J.+Zuercher&title=SGC-GAK-1%3A+a+chemical+probe+for+cyclin+G+associated+kinase+%28GAK%29&doi=10.1021%2Facs.jmedchem.8b01213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)</span></div><div class="casAuthors">Asquith, Christopher R. M.; Berger, Benedict-Tilman; Wan, Jing; Bennett, James M.; Capuzzi, Stephen J.; Crona, Daniel J.; Drewry, David H.; East, Michael P.; Elkins, Jonathan M.; Fedorov, Oleg; Godoi, Paulo H.; Hunter, Debra M.; Knapp, Stefan; Muller, Susanne; Torrice, Chad D.; Wells, Carrow I.; Earp, H. Shelton; Willson, Timothy M.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2830-2836</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe SGC-GAK-1 (11), a potent, selective, and cell-active inhibitor of cyclin G-assocd. kinase (GAK), together with a structurally related neg. control SGC-GAK-1N (14).  11 Was highly selective in an in vitro kinome-wide screen, but cellular engagement assays defined RIPK2 as a collateral target.  We identified 18 as a potent RIPK2 inhibitor lacking GAK activity.  Together, this chem. probe set can be used to interrogate GAK cellular biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo59Ri_VO0xCLVg90H21EOLACvtfcHk0liQHRq3pdMU3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCrtr4%253D&md5=95b6a31e3df7d87fb129d0814dc81bad</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01213%26sid%3Dliteratum%253Aachs%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DCapuzzi%26aufirst%3DS.%2BJ.%26aulast%3DCrona%26aufirst%3DD.%2BJ.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DHunter%26aufirst%3DD.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DTorrice%26aufirst%3DC.%2BD.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DSGC-GAK-1%253A%2520a%2520chemical%2520probe%2520for%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2830%26epage%3D2836%26doi%3D10.1021%2Facs.jmedchem.8b01213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agajanian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-De-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamir, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammons, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, M. B.</span></span> <span> </span><span class="NLM_article-title">WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2018.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30605688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=79-93&author=M.+J.+Agajanianauthor=M.+P.+Walkerauthor=A.+D.+Axtmanauthor=R.+R.+Ruela-De-Sousaauthor=D.+S.+Serafinauthor=A.+D.+Rabinowitzauthor=D.+M.+Grahamauthor=M.+B.+Ryanauthor=T.+Tamirauthor=Y.+Nakamichiauthor=M.+V.+Gammonsauthor=J.+M.+Bennettauthor=R.+M.+Counagoauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=C.+Gileadiauthor=O.+Gileadiauthor=P.+H.+Godoiauthor=N.+Kapadiaauthor=S.+Mullerauthor=A.+S.+Santiagoauthor=F.+J.+Sorrellauthor=C.+I.+Wellsauthor=O.+Fedorovauthor=T.+M.+Willsonauthor=W.+J.+Zuercherauthor=M.+B.+Major&title=WNT+activates+the+AAK1+kinase+to+promote+clathrin-mediated+endocytosis+of+LRP6+and+establish+a+negative+feedback+loop&doi=10.1016%2Fj.celrep.2018.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop</span></div><div class="casAuthors">Agajanian, Megan J.; Walker, Matthew P.; Axtman, Alison D.; Ruela-de-Sousa, Roberta R.; Serafin, D. Stephen; Rabinowitz, Alex D.; Graham, David M.; Ryan, Meagan B.; Tamir, Tigist; Nakamichi, Yuko; Gammons, Melissa V.; Bennett, James M.; Counago, Rafael M.; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Carina; Gileadi, Opher; Godoi, Paulo H.; Kapadia, Nirav; Muller, Susanne; Santiago, Andre S.; Sorrell, Fiona J.; Wells, Carrow I.; Fedorov, Oleg; Willson, Timothy M.; Zuercher, William J.; Major, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-93.e8</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">β-Catenin-dependent WNT signal transduction governs development, tissue homeostasis, and a vast array of human diseases.  Signal propagation through a WNT-Frizzled/LRP receptor complex requires proteins necessary for clathrin-mediated endocytosis (CME).  Paradoxically, CME also neg. regulates WNT signaling through internalization and degrdn. of the receptor complex.  Here, using a gain-of-function screen of the human kinome, we report that the AP2 assocd. kinase 1 (AAK1), a known CME enhancer, inhibits WNT signaling.  Reciprocally, AAK1 genetic silencing or its pharmacol. inhibition using a potent and selective inhibitor activates WNT signaling.  Mechanistically, we show that AAK1 promotes clearance of LRP6 from the plasma membrane to suppress the WNT pathway.  Time-course expts. support a transcription-uncoupled, WNT-driven neg. feedback loop; prolonged WNT treatment drives AAK1-dependent phosphorylation of AP2M1, clathrin-coated pit maturation, and endocytosis of LRP6.  We propose that, following WNT receptor activation, increased AAK1 function and CME limits WNT signaling longevity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SJx0zBLnLLVg90H21EOLACvtfcHk0lgNMnMIDpkr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVegug%253D%253D&md5=c1b67d54b0bb92caa1b290b67803da92</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DAgajanian%26aufirst%3DM.%2BJ.%26aulast%3DWalker%26aufirst%3DM.%2BP.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26aulast%3DRuela-De-Sousa%26aufirst%3DR.%2BR.%26aulast%3DSerafin%26aufirst%3DD.%2BS.%26aulast%3DRabinowitz%26aufirst%3DA.%2BD.%26aulast%3DGraham%26aufirst%3DD.%2BM.%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DTamir%26aufirst%3DT.%26aulast%3DNakamichi%26aufirst%3DY.%26aulast%3DGammons%26aufirst%3DM.%2BV.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DCounago%26aufirst%3DR.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DC.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DKapadia%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DSantiago%26aufirst%3DA.%2BS.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DMajor%26aufirst%3DM.%2BB.%26atitle%3DWNT%2520activates%2520the%2520AAK1%2520kinase%2520to%2520promote%2520clathrin-mediated%2520endocytosis%2520of%2520LRP6%2520and%2520establish%2520a%2520negative%2520feedback%2520loop%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D79%26epage%3D93%26doi%3D10.1016%2Fj.celrep.2018.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couñago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente-Macias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-De-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zutshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span> <span> </span><span class="NLM_article-title">SGC-AAK1–1: a chemical probe targeting AAK1 and BMP2K</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00399</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00399" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=340-345&author=C.+Wellsauthor=R.+M.+Cou%C3%B1agoauthor=J.+C.+Limasauthor=T.+L.+Almeidaauthor=J.+G.+Cookauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=O.+Gileadiauthor=N.+R.+Kapadiaauthor=A.+Lorente-Maciasauthor=J.+E.+Pickettauthor=A.+Riemenauthor=R.+R.+Ruela-De-Sousaauthor=T.+M.+Willsonauthor=C.+Zhangauthor=W.+J.+Zuercherauthor=R.+Zutshiauthor=A.+D.+Axtman&title=SGC-AAK1%E2%80%931%3A+a+chemical+probe+targeting+AAK1+and+BMP2K&doi=10.1021%2Facsmedchemlett.9b00399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span></div><div class="casAuthors">Wells, Carrow; Counago, Rafael M.; Limas, Juanita C.; Almeida, Tuanny L.; Cook, Jeanette Gowen; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Opher; Kapadia, Nirav R.; Lorente-Macias, Alvaro; Pickett, Julie E.; Riemen, Alexander; Ruela-de-Sousa, Roberta R.; Willson, Timothy M.; Zhang, Cunyu; Zuercher, William J.; Zutshi, Reena; Axtman, Alison D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors based on a 3-acylaminoindazole scaffold were synthesized to yield potent dual AAK1/BMP2K inhibitors.  Optimization furnished a small mol. chem. probe (SGC-AAK1-1, 25 (I)) that is potent and selective for AAK1/BMP2K over other NAK family members, demonstrates narrow activity in a kinome-wide screen, and is functionally active in cells.  This inhibitor represents one of the best available small mol. tools to study the functions of AAK1 and BMP2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSOYD5xWr1LVg90H21EOLACvtfcHk0lhs7ECH-7lfEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K&md5=d525d20f1ba1282697684e6ac1d09693</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00399%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%26aulast%3DCou%25C3%25B1ago%26aufirst%3DR.%2BM.%26aulast%3DLimas%26aufirst%3DJ.%2BC.%26aulast%3DAlmeida%26aufirst%3DT.%2BL.%26aulast%3DCook%26aufirst%3DJ.%2BG.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DKapadia%26aufirst%3DN.%2BR.%26aulast%3DLorente-Macias%26aufirst%3DA.%26aulast%3DPickett%26aufirst%3DJ.%2BE.%26aulast%3DRiemen%26aufirst%3DA.%26aulast%3DRuela-De-Sousa%26aufirst%3DR.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DZutshi%26aufirst%3DR.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26atitle%3DSGC-AAK1%25E2%2580%25931%253A%2520a%2520chemical%2520probe%2520targeting%2520AAK1%2520and%2520BMP2K%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Facsmedchemlett.9b00399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00114-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2FS0092-8674%2800%2900114-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0lhs7ECH-7lfEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225%26doi%3D10.1016%2FS0092-8674%2800%2900114-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor-tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor-tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0lhs7ECH-7lfEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor-tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ségaliny, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellez-Gabriel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymann, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymann, D.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span>. <i>J. Bone Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.jbo.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbo.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26579483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-12&author=A.+I.+S%C3%A9galinyauthor=M.+Tellez-Gabrielauthor=M.-F.+Heymannauthor=D.+Heymann&title=Receptor+tyrosine+kinases%3A+Characterisation%2C+mechanism+of+action+and+therapeutic+interests+for+bone+cancers&doi=10.1016%2Fj.jbo.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span></div><div class="casAuthors">Segaliny Aude I; Tellez-Gabriel Marta; Heymann Marie-Francoise; Heymann Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn">2212-1366</span>.
    </div><div class="casAbstract">Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment.  In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche.  As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed.  These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours.  The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl42y4bB4mnvYfW6udTcc2eZypt2q6ndfe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D&md5=57563bfe33ca5752242d56cc24546c1c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jbo.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbo.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A9galiny%26aufirst%3DA.%2BI.%26aulast%3DTellez-Gabriel%26aufirst%3DM.%26aulast%3DHeymann%26aufirst%3DM.-F.%26aulast%3DHeymann%26aufirst%3DD.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520Characterisation%252C%2520mechanism%2520of%2520action%2520and%2520therapeutic%2520interests%2520for%2520bone%2520cancers%26jtitle%3DJ.%2520Bone%2520Oncol.%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.jbo.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span> <span> </span><span class="NLM_article-title">Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0796-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fs12943-018-0796-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29455668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=45&author=Y.+Zhangauthor=M.+Xiaauthor=K.+Jinauthor=S.+Wangauthor=H.+Weiauthor=C.+Fanauthor=Y.+Wuauthor=X.+Liauthor=X.+Liauthor=G.+Liauthor=Z.+Zengauthor=W.+Xiong&title=Function+of+the+c-Met+receptor+tyrosine+kinase+in+carcinogenesis+and+associated+therapeutic+opportunities&doi=10.1186%2Fs12943-018-0796-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities</span></div><div class="casAuthors">Zhang, Yazhuo; Xia, Mengfang; Jin, Ke; Wang, Shufei; Wei, Hang; Fan, Chunmei; Wu, Yingfen; Li, Xiaoling; Li, Xiayu; Li, Guiyuan; Zeng, Zhaoyang; Xiong, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45/1-45/14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">C-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming gene) family, and is expressed on the surfaces of various cells.  Hepatocyte growth factor (HGF) is the ligand for this receptor.  The binding of HGF to c-Met initiates a series of intracellular signals that mediate embryogenesis and wound healing in normal cells.  However, in cancer cells, aberrant HGF/c-Met axis activation, which is closely related to c-Met gene mutations, overexpression, and amplification, promotes tumor development and progression by stimulating the PI3K/AKT, Ras/MAPK, JAK/STAT, SRC, Wnt/β-catenin, and other signaling pathways.  Thus, c-Met and its assocd. signaling pathways are clin. important therapeutic targets.  In this review, we elaborate on the mol. structure of c-Met and HGF and the mechanism through which their interaction activates the PI3K/AKT, Ras/MAPK, and Wnt signaling pathways.  We also summarize the connection between c-Met and RON and EGFR, which are also receptor tyrosine kinases.  Finally, we introduce the current therapeutic drugs that target c-Met in primary tumors, and their use in clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxr1VpZ-qwwbVg90H21EOLACvtfcHk0lgdP3BpnAMvcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7nE&md5=23db43661c4a23160dbed1ee1c26f8db</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0796-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0796-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DXiong%26aufirst%3DW.%26atitle%3DFunction%2520of%2520the%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520in%2520carcinogenesis%2520and%2520associated%2520therapeutic%2520opportunities%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D45%26doi%3D10.1186%2Fs12943-018-0796-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor cell proliferation signaling pathways</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">52</span>, <span class="refDoi"> DOI: 10.3390/cancers9050052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fcancers9050052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=52&author=P.+Weeauthor=Z.+Wang&title=Epidermal+growth+factor+receptor+cell+proliferation+signaling+pathways&doi=10.3390%2Fcancers9050052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor cell proliferation signaling pathways</span></div><div class="casAuthors">Wee, Ping; Wang, Zhixiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">52/1-52/45</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.  Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, or the exon 19 truncation.  These EGFR aberrations over-activate downstream pro-oncogenic signaling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR pathways.  These pathways then activate many biol. outputs that are beneficial to cancer cell proliferation, including their chronic initiation and progression through the cell cycle.  Here, we review the mol. mechanisms that regulate EGFR signal transduction, including the EGFR structure and its mutations, ligand binding and EGFR dimerization, as well as the signaling pathways that lead to G1 cell cycle progression.  We focus on the induction of CYCLIN D expression, CDK4/6 activation, and the repression of cyclin-dependent kinase inhibitor proteins (CDKi) by EGFR signaling pathways.  We also discuss the successes and challenges of EGFR-targeted therapies, and the potential for their use in combination with CDK4/6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpti1TbuQ7GPrVg90H21EOLACvtfcHk0lgdP3BpnAMvcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK&md5=5d5a81e10b147d1a74957dfa293e75c3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3390%2Fcancers9050052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9050052%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520cell%2520proliferation%2520signaling%2520pathways%26jtitle%3DCancers%26date%3D2017%26volume%3D9%26spage%3D52%26doi%3D10.3390%2Fcancers9050052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, S. B.</span></span> <span> </span><span class="NLM_article-title">Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">10935</span>– <span class="NLM_lpage">10949</span>, <span class="refDoi"> DOI: 10.1128/JVI.00750-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.00750-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22855500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=10935-10949&author=J.+Diaoauthor=H.+Pantuaauthor=H.+Nguauthor=L.+Komuvesauthor=L.+Diehlauthor=G.+Schaeferauthor=S.+B.+Kapadia&title=Hepatitis+C+virus+induces+epidermal+growth+factor+receptor+activation+via+CD81+binding+for+viral+internalization+and+entry&doi=10.1128%2FJVI.00750-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry</span></div><div class="casAuthors">Diao, Jingyu; Pantua, Homer; Ngu, Hai; Komuves, Laszlo; Diehl, Lauri; Schaefer, Gabriele; Kapadia, Sharookh B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10935-10949</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">While epidermal growth factor receptor (EGFR) has been shown to be important in the entry process for multiple viruses, including hepatitis C virus (HCV), the mol. mechanisms by which EGFR facilitates HCV entry are not well understood.  Using the infectious cell culture HCV model (HCVcc), we demonstrate that the binding of HCVcc particles to human hepatocyte cells induces EGFR activation that is dependent on interactions between HCV and CD81 but not claudin 1.  EGFR activation can also be induced by antibody mediated crosslinking of CD81.  In addn., EGFR ligands that enhance the kinetics of HCV entry induce EGFR internalization and colocalization with CD81.  While EGFR kinase inhibitors inhibit HCV infection primarily by preventing EGFR endocytosis, antibodies that block EGFR ligand binding or inhibitors of EGFR downstream signaling have no effect on HCV entry.  These data demonstrate that EGFR internalization is crit. for HCV entry and identify a hitherto-unknown assocn. between CD81 and EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO8haZF28serVg90H21EOLACvtfcHk0lgQ8detYO4ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyru7bK&md5=514c49e7f64fca75b2fe4d3643615bd5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1128%2FJVI.00750-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00750-12%26sid%3Dliteratum%253Aachs%26aulast%3DDiao%26aufirst%3DJ.%26aulast%3DPantua%26aufirst%3DH.%26aulast%3DNgu%26aufirst%3DH.%26aulast%3DKomuves%26aufirst%3DL.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DKapadia%26aufirst%3DS.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520activation%2520via%2520CD81%2520binding%2520for%2520viral%2520internalization%2520and%2520entry%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D10935%26epage%3D10949%26doi%3D10.1128%2FJVI.00750-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baktash, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span> <span> </span><span class="NLM_article-title">Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chom.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29544098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslSmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=382-394&author=Y.+Baktashauthor=A.+Madhavauthor=K.+E.+Collerauthor=G.+Randall&title=Single+particle+imaging+of+polarized+hepatoma+organoids+upon+hepatitis+C+virus+infection+reveals+an+ordered+and+sequential+entry+process&doi=10.1016%2Fj.chom.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process</span></div><div class="casAuthors">Baktash, Yasmine; Madhav, Anisha; Coller, Kelly E.; Randall, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-394.e5</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters hepatocytes via various entry factors, including scavenger receptor BI (SR-B1), cluster of differentiation 81 (CD81), epidermal growth factor receptor (EGFR), claudin-1 (CLDN1), and occludin (OCLN).  As CLDN1 and OCLN are not readily accessible due to their tight junctional localization, HCV likely accesses them by either disrupting cellular polarity or migrating to the tight junction.  In this study, we image HCV entry into a three-dimensional polarized hepatoma system and reveal that the virus sequentially engages these entry factors through actin-dependent mechanisms.  HCV initially localizes with the early entry factors SR-B1, CD81, and EGFR at the basolateral membrane and then accumulates at the tight junction in an actin-dependent manner.  HCV assocs. with CLDN1 and then OCLN at the tight junction and is internalized via clathrin-mediated endocytosis by an active process requiring EGFR.  Thus, HCV uses a dynamic and multi-step process to engage and enter host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3WXKlaIjjTLVg90H21EOLACvtfcHk0lgQ8detYO4ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslSmsLk%253D&md5=0678419260c3f14266ab3e8fd40610ce</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DBaktash%26aufirst%3DY.%26aulast%3DMadhav%26aufirst%3DA.%26aulast%3DColler%26aufirst%3DK.%2BE.%26aulast%3DRandall%26aufirst%3DG.%26atitle%3DSingle%2520particle%2520imaging%2520of%2520polarized%2520hepatoma%2520organoids%2520upon%2520hepatitis%2520C%2520virus%2520infection%2520reveals%2520an%2520ordered%2520and%2520sequential%2520entry%2520process%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2018%26volume%3D23%26spage%3D382%26epage%3D394%26doi%3D10.1016%2Fj.chom.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eierhoff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrincius, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001099</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1001099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20844577" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=T.+Eierhoffauthor=E.+R.+Hrinciusauthor=U.+Rescherauthor=S.+Ludwigauthor=C.+Ehrhardt&title=The+epidermal+growth+factor+receptor+%28EGFR%29+promotes+uptake+of+influenza+A+viruses+%28IAV%29+into+host+cells&doi=10.1371%2Fjournal.ppat.1001099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001099%26sid%3Dliteratum%253Aachs%26aulast%3DEierhoff%26aufirst%3DT.%26aulast%3DHrincius%26aufirst%3DE.%2BR.%26aulast%3DRescher%26aufirst%3DU.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DEhrhardt%26aufirst%3DC.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520promotes%2520uptake%2520of%2520influenza%2520A%2520viruses%2520%2528IAV%2529%2520into%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueki, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min-Oo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballon-Landa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koff, J. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1084/jem.20121401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1084%2Fjem.20121401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23999497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1929-1936&author=I.+F.+Uekiauthor=G.+Min-Ooauthor=A.+Kalinowskiauthor=E.+Ballon-Landaauthor=L.+L.+Lanierauthor=J.+A.+Nadelauthor=J.+L.+Koff&title=Respiratory+virus-induced+EGFR+activation+suppresses+IRF1-dependent+interferon+%CE%BB+and+antiviral+defense+in+airway+epithelium&doi=10.1084%2Fjem.20121401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium</span></div><div class="casAuthors">Ueki, Iris F.; Min-Oo, Gundula; Kalinowski, April; Ballon-Landa, Eric; Lanier, Lewis L.; Nadel, Jay A.; Koff, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1936</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Viruses suppress host responses to increase infection, and understanding these mechanisms has provided insights into cellular signaling and led to novel therapies.  Many viruses (e.g., influenza virus, Rhinovirus [RV], Cytomegalovirus, Epstein-Barr virus, and Hepatitis C virus) activate epithelial epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, but the role of EGFR in viral pathogenesis is not clear.  Interferon (IFN) signaling is a crit. innate antiviral host response and recent expts. have implicated IFN-λ, a type III IFN, as the most significant IFN for mucosal antiviral immune responses.  Despite the importance of IFN-λ in epithelial antiviral responses, the role and mechanisms of epithelial IFN-λ signaling have not been fully elucidated.  We report that respiratory virus-induced EGFR activation suppresses endogenous airway epithelial antiviral signaling.  We found that Influenza virus- and RV-induced EGFR activation suppressed IFN regulatory factor (IRF) 1-induced IFN-λ prodn. and increased viral infection.  In addn., inhibition of EGFR during viral infection augmented IRF1 and IFN-λ, which resulted in decreased viral titers in vitro and in vivo.  These findings describe a novel mechanism that viruses use to suppress endogenous antiviral defenses, and provide potential targets for future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2xVzMrOcUv7Vg90H21EOLACvtfcHk0lgQ8detYO4ziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM&md5=121a4a1514a53f104045e6516447e860</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121401%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DI.%2BF.%26aulast%3DMin-Oo%26aufirst%3DG.%26aulast%3DKalinowski%26aufirst%3DA.%26aulast%3DBallon-Landa%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26aulast%3DNadel%26aufirst%3DJ.%2BA.%26aulast%3DKoff%26aufirst%3DJ.%2BL.%26atitle%3DRespiratory%2520virus-induced%2520EGFR%2520activation%2520suppresses%2520IRF1-dependent%2520interferon%2520%25CE%25BB%2520and%2520antiviral%2520defense%2520in%2520airway%2520epithelium%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1929%26epage%3D1936%26doi%3D10.1084%2Fjem.20121401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0ljmqTdRb2ABvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlin, C. V.</span></span> <span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0ljmqTdRb2ABvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324-333&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.-M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0ljmqTdRb2ABvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.-M.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26epage%3D333%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnec, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guivel-Benhassine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chom.2012.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=544-557&author=L.+Meertensauthor=X.+Carnecauthor=M.+P.+Lecoinauthor=R.+Ramdasiauthor=F.+Guivel-Benhassineauthor=E.+Lewauthor=G.+Lemkeauthor=O.+Schwartzauthor=A.+Amara&title=The+TIM+and+TAM+families+of+phosphatidylserine+receptors+mediate+dengue+virus+entry&doi=10.1016%2Fj.chom.2012.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry</span></div><div class="casAuthors">Meertens, Laurent; Carnec, Xavier; Lecoin, Manuel Perera; Ramdasi, Rasika; Guivel-Benhassine, Florence; Lew, Erin; Lemke, Greg; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases.  However, the mol. interactions mediating DV entry are poorly understood.  We detd. that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors.  Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors.  Conversely, DV infection of susceptible cells is inhibited by anti-TIM or anti-TAM antibodies or knockdown of TIM and TAM expression.  TIM receptors facilitate DV entry by directly interacting with virion-assocd. PtdSer.  TAM-mediated infection relies on indirect DV recognition, in which the TAM ligand Gas6 acts as a bridging mol. by binding to PtdSer within the virion.  This dual mode of virus recognition by TIM and TAM receptors reveals how DVs usurp the apoptotic cell clearance pathway for infectious entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYGMhUV8WdLVg90H21EOLACvtfcHk0lhs5T7hIPMBVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK&md5=7a00c7dc61dc042960aa302124140818</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DCarnec%26aufirst%3DX.%26aulast%3DLecoin%26aufirst%3DM.%2BP.%26aulast%3DRamdasi%26aufirst%3DR.%26aulast%3DGuivel-Benhassine%26aufirst%3DF.%26aulast%3DLew%26aufirst%3DE.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DThe%2520TIM%2520and%2520TAM%2520families%2520of%2520phosphatidylserine%2520receptors%2520mediate%2520dengue%2520virus%2520entry%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D12%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.chom.2012.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-00460-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41422-020-00460-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33420426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=126-140&author=S.+Wangauthor=Z.+Qiuauthor=Y.+Houauthor=X.+Dengauthor=W.+Xuauthor=T.+Zhengauthor=P.+Wuauthor=S.+Xieauthor=W.+Bianauthor=C.+Zhangauthor=Z.+Sunauthor=K.+Liuauthor=C.+Shanauthor=A.+Linauthor=S.+Jiangauthor=Y.+Xieauthor=Q.+Zhouauthor=L.+Luauthor=J.+Huangauthor=X.+Li&title=AXL+is+a+candidate+receptor+for+SARS-CoV-2+that+promotes+infection+of+pulmonary+and+bronchial+epithelial+cells&doi=10.1038%2Fs41422-020-00460-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span></div><div class="casAuthors">Wang, Shuai; Qiu, Zongyang; Hou, Yingnan; Deng, Xiya; Xu, Wei; Zheng, Tingting; Wu, Peihan; Xie, Shaofang; Bian, Weixiang; Zhang, Chong; Sun, Zewei; Liu, Kunpeng; Shan, Chao; Lin, Aifu; Jiang, Shibo; Xie, Youhua; Zhou, Qiang; Lu, Lu; Huang, Jing; Li, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-140</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge.  The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry.  Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, esp. in the respiratory tract.  Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist.  In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.  Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells.  Sol. human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL.  The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients.  Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clin. intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1wmry9H6UrVg90H21EOLACvtfcHk0lhs5T7hIPMBVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D&md5=d708204bc6dd130cdb30f0bf5fc2742b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-00460-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-00460-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DShan%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAXL%2520is%2520a%2520candidate%2520receptor%2520for%2520SARS-CoV-2%2520that%2520promotes%2520infection%2520of%2520pulmonary%2520and%2520bronchial%2520epithelial%2520cells%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D126%26epage%3D140%26doi%3D10.1038%2Fs41422-020-00460-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stantchev, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, C. C.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2006.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.virusres.2006.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17030448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2007&pages=178-189&author=T.+S.+Stantchevauthor=I.+Markovicauthor=W.+G.+Telfordauthor=K.+A.+Clouseauthor=C.+C.+Broder&title=The+tyrosine+kinase+inhibitor+genistein+blocks+HIV-1+infection+in+primary+human+macrophages&doi=10.1016%2Fj.virusres.2006.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span></div><div class="casAuthors">Stantchev, Tzanko S.; Markovic, Ingrid; Telford, William G.; Clouse, Kathleen A.; Broder, Christopher C.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Binding of HIV-1 envelope glycoprotein (Env) to its cellular receptors elicits a variety of signaling events, including the activation of select tyrosine kinases.  To evaluate the potential role of such signaling, we examd. the effects of the tyrosine kinase inhibitor, genistein, on HIV-1 entry and infection of human macrophages using a variety of assays.  Without altering cell viability, cell surface expression of CD4 and CCR5 or their abilities to interact with Env, genistein inhibited infection of macrophages by reporter gene-encoding, β-lactamase contg., or wild type virions, as well as Env-mediated cell-fusion.  The observation that genistein blocked virus infection if applied before, during or immediately after the infection period, but not 24 h later; coupled with a more pronounced inhibition of infection in the reporter gene assays as compared to both β-lactamase and p24 particle entry assays, imply that genistein exerts its inhibitory effects on both entry and early post-entry steps.  These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as addnl. opportunities for the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOAvO4kSxB7Vg90H21EOLACvtfcHk0lhs5T7hIPMBVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D&md5=310c85933553074029e094e7d3a1bdb8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2006.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2006.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DStantchev%26aufirst%3DT.%2BS.%26aulast%3DMarkovic%26aufirst%3DI.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26aulast%3DClouse%26aufirst%3DK.%2BA.%26aulast%3DBroder%26aufirst%3DC.%2BC.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520genistein%2520blocks%2520HIV-1%2520infection%2520in%2520primary%2520human%2520macrophages%26jtitle%3DVirus%2520Res.%26date%3D2007%26volume%3D123%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.virusres.2006.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowick, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. F.</span></span> <span> </span><span class="NLM_article-title">Genistein treatment of cells inhibits arenavirus infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2007.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17961732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=153-156&author=E.+M.+Velaauthor=G.+C.+Bowickauthor=N.+K.+Herzogauthor=J.+F.+Aronson&title=Genistein+treatment+of+cells+inhibits+arenavirus+infection&doi=10.1016%2Fj.antiviral.2007.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein treatment of cells inhibits arenavirus infection</span></div><div class="casAuthors">Vela, Eric M.; Bowick, Gavin C.; Herzog, Norbert K.; Aronson, Judith F.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arenaviridae is a family of enveloped viruses some of which are capable of causing hemorrhagic fever syndromes in humans.  In this report, we demonstrate that treatment of host cells with the tyrosine kinase inhibitor genistein inhibits infection of cells with the New World arenavirus Pichinde (PICV).  The greatest degree of inhibition was obsd. in pre-treated target cells, but modest inhibition of infection was also seen when drug was added to cultures up to 48 h after infection.  We show that PICV-induced phosphorylation of the activating transcription factor-2 protein (ATF-2) and cAMP response element binding protein (CREB) is inhibited following genistein treatment.  Lastly, genistein treatment also inhibited transduction of cells with pseudotyped retrovirus particles expressing envelope proteins of the Old World arenavirus Lassa virus.  These results demonstrate that kinase activity is required for arenavirus infection and that therapeutics designed to inhibit kinase activity should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxt-7U7F05bVg90H21EOLACvtfcHk0liDl5cBcCTNyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D&md5=ed23a98d1235f071148053c4620f5594</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DE.%2BM.%26aulast%3DBowick%26aufirst%3DG.%2BC.%26aulast%3DHerzog%26aufirst%3DN.%2BK.%26aulast%3DAronson%26aufirst%3DJ.%2BF.%26atitle%3DGenistein%2520treatment%2520of%2520cells%2520inhibits%2520arenavirus%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.antiviral.2007.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1007/BF01309554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2FBF01309554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8397505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1993&pages=451-461&author=Y.+Yuraauthor=H.+Yoshidaauthor=M.+Sato&title=Inhibition+of+herpes+simplex+virus+replication+by+genistein%2C+an+inhibitor+of+protein-tyrosine+kinase&doi=10.1007%2FBF01309554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span></div><div class="casAuthors">Yura, Y.; Yoshida, H.; Sato, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">451-61</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    </div><div class="casAbstract">Genistein, an inhibitor of protein-tyrosine kinase, inhibited the replication of herpes simplex virus type 1 (HSV-1) at genistein concns. of more than 25 μM, whereas the related compds., which do not inhibit protein-tyrosine kinases, did not affect the replication of HSV-1.  In the presence of genistein, the phosphorylation of tyrosine residues in specific viral polypeptides was markedly reduced.  These results indicate that the phosphorylation of tyrosine residues in viral polypeptides may be essential for the replication of HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPTvlkqS9JUbVg90H21EOLACvtfcHk0liDl5cBcCTNyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D&md5=ddabba9625d89206daf303e7f4739274</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2FBF01309554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01309554%26sid%3Dliteratum%253Aachs%26aulast%3DYura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520replication%2520by%2520genistein%252C%2520an%2520inhibitor%2520of%2520protein-tyrosine%2520kinase%26jtitle%3DArch.%2520Virol.%26date%3D1993%26volume%3D132%26spage%3D451%26epage%3D461%26doi%3D10.1007%2FBF01309554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2827</span>, <span class="refDoi"> DOI: 10.1128/JVI.01969-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01969-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21209112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=2818-2827&author=N.+Kumarauthor=Y.+Liangauthor=T.+G.+Parslowauthor=Y.+Liang&title=Receptor+tyrosine+kinase+inhibitors+block+multiple+steps+of+influenza+A+virus+replication&doi=10.1128%2FJVI.01969-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span></div><div class="casAuthors">Kumar, Naveen; Liang, Yuhong; Parslow, Tristram G.; Liang, Yuying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2818-2827</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host signaling pathways play important roles in the replication of influenza virus, but their functional effects remain to be characterized at the mol. level.  Here we identify two receptor tyrosine kinase inhibitors (RTKIs) of the tyrphostin class that exhibit robust antiviral activity against influenza A virus replication in cultured cells.  One of these (AG879) is a selective inhibitor of the nerve growth factor receptor and human epidermal growth factor receptor 2 (TrkA/HER2) signaling; the other, tyrphostin A9 (A9), inhibits the platelet-derived growth factor receptor (PDGFR) pathway.  We find that each inhibits at least three postentry steps of the influenza virus life cycle: AG879 and A9 both strongly inhibit the synthesis of all three influenza virus RNA species, block Crm1-dependent nuclear export, and also prevent the release of viral particles through a pathway that is modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).  Tests of short hairpin RNA (shRNA) knockdown and addnl. small-mol. inhibitors confirmed that interventions targeting TrkA can suppress influenza virus replication.  Our study suggests that host cell receptor tyrosine kinase signaling is required for maximal influenza virus RNA synthesis, viral ribonucleoprotein (vRNP) nuclear export, and virus release and that specific RTKIs hold promise as novel anti-influenza virus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDOKlH_iMWLVg90H21EOLACvtfcHk0liDl5cBcCTNyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM&md5=5b0e29955db6cd71e6d371db771138d0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1128%2FJVI.01969-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01969-10%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DParslow%26aufirst%3DT.%2BG.%26aulast%3DLiang%26aufirst%3DY.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520multiple%2520steps%2520of%2520influenza%2520A%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D2818%26epage%3D2827%26doi%3D10.1128%2FJVI.01969-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">104651</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2019.104651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31751591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2020&pages=104651&author=W.+Dongauthor=W.+Xieauthor=Y.+Liuauthor=B.+Suiauthor=H.+Zhangauthor=L.+Liuauthor=Y.+Tanauthor=X.+Tongauthor=Z.+F.+Fuauthor=P.+Yinauthor=L.+Fangauthor=G.+Peng&title=Receptor+tyrosine+kinase+inhibitors+block+proliferation+of+TGEV+mainly+through+p38+mitogen-activated+protein+kinase+pathways&doi=10.1016%2Fj.antiviral.2019.104651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Dong, Wanyu; Xie, Wenting; Liu, Yunbo; Sui, Baokun; Zhang, Hao; Liu, Liran; Tan, Yubei; Tong, Xiaohan; Fu, Zhen F.; Yin, Ping; Fang, Liurong; Peng, Guiqing</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104651</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available.  Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays.  Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV) and feline infectious peritonitis virus (FIPV).  We further performed a comparative phosphoproteomic anal. to investigate the mechanism of action of A9 against TGEV infection in vitro.  We specifically identified p38 and JNK1, which are the downstream mols. of receptor tyrosine kinases (RTKs) required for efficient TGEV replication, as A9 targets through plaque assays, qRT-PCR and Western blotting assays. p38 and JNK1 inhibitors and RNA interference further showed that the inhibitory activity of A9 against TGEV infection was mainly mediated by the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  All these findings indicated that the RTKI A9 directly inhibits TGEV replication and that its inhibitory activity against TGEV replication mainly occurs by targeting p38, which provides vital clues to the design of novel drugs against CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnYnZ9MxD37Vg90H21EOLACvtfcHk0lgTCs9H_B-5dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO&md5=d0b78e75caf0d2932528e2ff6706d961</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104651%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DG.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520proliferation%2520of%2520TGEV%2520mainly%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D173%26spage%3D104651%26doi%3D10.1016%2Fj.antiviral.2019.104651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cargnello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span> <span> </span><span class="NLM_article-title">Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1128/MMBR.00031-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FMMBR.00031-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21372320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2011&pages=50-83&author=M.+Cargnelloauthor=P.+P.+Roux&title=Activation+and+function+of+the+MAPKs+and+their+substrates%2C+the+MAPK-activated+protein+kinases&doi=10.1128%2FMMBR.00031-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</span></div><div class="casAuthors">Cargnello, Marie; Roux, Philippe P.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-83</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review. The mitogen-activated protein (MAP) kinases (MAPKs) regulate diverse cellular programs by relaying extracellular signals to intracellular responses.  In mammals, there are more than a dozen MAPKs that coordinately regulate cell proliferation, differentiation, motility, and survival.  The best known are the conventional MAPKs, which include the extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinases 1-3 (JNK1 to JNK3), p38 (α, β, γ, and δ), and ERK5 families.  There are addnl., atypical MAPKs, including ERK3/4, ERK7/8, and Nemo-like kinase (NLK), which have distinct regulation and functions.  Together, the MAPKs regulate a large no. of substrates, including members of a family of protein Ser/Thr kinases termed MAPK-activated protein kinases (MAPKAPKs).  The MAPKAPKs are related enzymes that respond to extracellular stimulation through direct MAPK-dependent activation loop phosphorylation and kinase activation.  There are five MAPKAPK subfamilies: p90 ribosomal S6 kinase (RSK), mitogen- and stress-activated kinase (MSK), MAPK-interacting kinase (MNK), MAPK-activated protein kinase 2/3 (MK2/3), and MK5 (also known as p38-regulated/activated protein kinase).  These enzymes have diverse biol. functions, including regulation of nucleosome and gene expression, mRNA stability and translation, and cell proliferation and survival.  Here,the authors review the mechanisms of MAPKAPK activation by the different MAPKs and discuss their physiol. roles based on established substrates and recent discoveries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWcx7oIOM6lLVg90H21EOLACvtfcHk0lgTCs9H_B-5dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVequ78%253D&md5=e074f5af1f56957f0f10b2ecd837e69c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00031-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00031-10%26sid%3Dliteratum%253Aachs%26aulast%3DCargnello%26aufirst%3DM.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26atitle%3DActivation%2520and%2520function%2520of%2520the%2520MAPKs%2520and%2520their%2520substrates%252C%2520the%2520MAPK-activated%2520protein%2520kinases%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2011%26volume%3D75%26spage%3D50%26epage%3D83%26doi%3D10.1128%2FMMBR.00031-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braicu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busuioc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raduly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irimie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanasov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaby, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berindan-Neagoe, I.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review on MAPK: a promising therapeutic target in cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1618</span>, <span class="refDoi"> DOI: 10.3390/cancers11101618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fcancers11101618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1GltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1618&author=C.+Braicuauthor=M.+Buseauthor=C.+Busuiocauthor=R.+Drulaauthor=D.+Guleiauthor=L.+Radulyauthor=A.+Rusuauthor=A.+Irimieauthor=A.+G.+Atanasovauthor=O.+Slabyauthor=C.+Ionescuauthor=I.+Berindan-Neagoe&title=A+comprehensive+review+on+MAPK%3A+a+promising+therapeutic+target+in+cancer&doi=10.3390%2Fcancers11101618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review on MAPK: a promising therapeutic target in cancer</span></div><div class="casAuthors">Braicu, Cornelia; Buse, Mihail; Busuioc, Constantin; Drula, Rares; Gulei, Diana; Raduly, Lajos; Rusu, Alexandru; Irimie, Alexandru; Atanasov, Atanas G.; Slaby, Ondrej; Ionescu, Calin; Berindan-Neagoe, Ioana</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1618</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses.  Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes.  Numerous studies focused on both the homeostatic and the pathol. conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclin. and clin. research.  MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to exptl. MAPK inhibition.  The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways.  Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components.  Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhFMNc9OogLVg90H21EOLACvtfcHk0lgTCs9H_B-5dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1GltLw%253D&md5=55e2b6da7e8736cb486015b04a1c8938</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101618%26sid%3Dliteratum%253Aachs%26aulast%3DBraicu%26aufirst%3DC.%26aulast%3DBuse%26aufirst%3DM.%26aulast%3DBusuioc%26aufirst%3DC.%26aulast%3DDrula%26aufirst%3DR.%26aulast%3DGulei%26aufirst%3DD.%26aulast%3DRaduly%26aufirst%3DL.%26aulast%3DRusu%26aufirst%3DA.%26aulast%3DIrimie%26aufirst%3DA.%26aulast%3DAtanasov%26aufirst%3DA.%2BG.%26aulast%3DSlaby%26aufirst%3DO.%26aulast%3DIonescu%26aufirst%3DC.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26atitle%3DA%2520comprehensive%2520review%2520on%2520MAPK%253A%2520a%2520promising%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1618%26doi%3D10.3390%2Fcancers11101618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. J.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1128/JVI.70.8.4978-4985.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.70.8.4978-4985.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8764004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK28Xktlejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1996&pages=4978-4985&author=J.+Bennauthor=F.+Suauthor=M.+Doriaauthor=R.+J.+Schneider&title=Hepatitis+B+virus+HBx+protein+induces+transcription+factor+AP-1+by+activation+of+extracellular+signal-regulated+and+c-Jun+N-terminal+mitogen-activated+protein+kinases&doi=10.1128%2FJVI.70.8.4978-4985.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases</span></div><div class="casAuthors">Benn, Jacqueline; Su, Fei; Doria, Margherita; Schneider, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4978-4985</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The HBx protein of hepatitis B virus is a dual-specificity activator of transcription, stimulating signal transduction pathways in the cytoplasm and transcription factors in the nucleus, when expressed in cell lines in culture.  In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.  Here the authors show that HBx protein stimulates two independently regulated members of the MAP kinase family when expressed transiently in cells.  HBx protein stimulates the extracellular signal-regulated kinases (ERKs) and the c-Jun N-terminal kinases (JNKs).  HBx activation of ERKs and JNKs leads to induction and activation of AP-1 DNA binding activation involving transient de novo synthesis of c-Fos protein and prolonged synthesis of c-Jun, mediated by N-terminal phosphorylation of c-Jun carried out by HBx-activated JNK.  New c-Jun synthesis was blocked by coexpression with a dominant-neg. MAP kinase kinase (MEK kinase, MEKK-1), confirming that HBx stimulates the prolonged synthesis of c-Jun by activating JNK signaling pathways.  Activation of the c-fos gene was blocked by coexpression with a Raf-C4 catalytic mutant, confirming that HBx induces c-Fos by acting on Ras-Raf linked pathways.  HBx activation of ERK and JNK pathways resulted in prolonged accumulation of AP-1-cJun dimer complexes.  HBx activation of JNK and sustained activation of c-Jun, should they occur in the context of hepatitis B virus infection, might play a role in viral transformation and pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDzR7FTc2UQ7Vg90H21EOLACvtfcHk0lhDW4vxRXtXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktlejsbw%253D&md5=15866e858bcc3c4042a5a0dd85fb2c50</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FJVI.70.8.4978-4985.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.70.8.4978-4985.1996%26sid%3Dliteratum%253Aachs%26aulast%3DBenn%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DDoria%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DR.%2BJ.%26atitle%3DHepatitis%2520B%2520virus%2520HBx%2520protein%2520induces%2520transcription%2520factor%2520AP-1%2520by%2520activation%2520of%2520extracellular%2520signal-regulated%2520and%2520c-Jun%2520N-terminal%2520mitogen-activated%2520protein%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D1996%26volume%3D70%26spage%3D4978%26epage%3D4985%26doi%3D10.1128%2FJVI.70.8.4978-4985.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovesdi, I.</span></span> <span> </span><span class="NLM_article-title">Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1128/JVI.71.1.398-404.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.71.1.398-404.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8985363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK28XnsF2gs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=398-404&author=J.+T.+Bruderauthor=I.+Kovesdi&title=Adenovirus+infection+stimulates+the+Raf%2FMAPK+signaling+pathway+and+induces+interleukin-8+expression&doi=10.1128%2FJVI.71.1.398-404.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression</span></div><div class="casAuthors">Bruder, Joseph T.; Kovesdi, Imre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">398-404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Previous studies have shown that airway administration of adenovirus or adenovirus vectors results in a dose-dependent inflammatory response which limits the duration of transgene expression.  The authors explored the possibility that adenovirus infection triggers signal transduction pathways that induce the synthesis of cytokines and thus contribute to the early inflammatory response.  Since stimulation of the Raf/mitogen-activated protein kinase (MAPK) pathway activates transcription factors that control the expression of inflammatory cytokines, the authors examd. the activation of this pathway following adenovirus infection.  Adenovirus infection induced the rapid activation of Raf-1 and a transient increase in the tyrosine phosphorylation and activation of p42mapk at early times post-infection.  Activation of the Raf/MAPK pathway by adenovirus is likely triggered by the infection process, since it occurred rapidly and with various mutant adenoviruses and adenovirus vectors.  Moreover, interleukin-8 (IL-8) mRNA accumulation was evident at 20 min post-infection and was induced even in the presence of cycloheximide.  Both MAPK activation and IL-8 prodn. were inhibited by forskolin, a potent inhibitor of Raf-1.  These results suggest that adenovirus-induced Raf/MAPK activation contributes to IL-8 prodn.  Adenovirus-induced activation of the Raf/MAPK signaling pathway and IL-8 prodn. may play crit. roles in the inflammation obsd. following in vivo administration of adenovirus vectors for gene therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2gUVkFOYlZLVg90H21EOLACvtfcHk0lhDW4vxRXtXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsF2gs7o%253D&md5=0ad5443be939c580ecab85d492a262bd</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.1.398-404.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.1.398-404.1997%26sid%3Dliteratum%253Aachs%26aulast%3DBruder%26aufirst%3DJ.%2BT.%26aulast%3DKovesdi%26aufirst%3DI.%26atitle%3DAdenovirus%2520infection%2520stimulates%2520the%2520Raf%252FMAPK%2520signaling%2520pathway%2520and%2520induces%2520interleukin-8%2520expression%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D398%26epage%3D404%26doi%3D10.1128%2FJVI.71.1.398-404.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0lhDW4vxRXtXQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span> <span> </span><span class="NLM_article-title">MEK inhibition impairs in£uenza B virus propagation without emergence of resistant variants</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(04)00108-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0014-5793%2804%2900108-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15013748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2004&pages=37-43&author=S.+Ludwigauthor=T.+Wolffauthor=C.+Ehrhardtauthor=W.+J.+Wurzerauthor=J.+Reinhardtauthor=O.+Planzauthor=S.+Pleschka&title=MEK+inhibition+impairs+in%C2%A3uenza+B+virus+propagation+without+emergence+of+resistant+variants&doi=10.1016%2FS0014-5793%2804%2900108-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span></div><div class="casAuthors">Ludwig, Stephan; Wolff, Thorsten; Ehrhardt, Christina; Wurzer, Walter Jurgen; Reinhardt, Jens; Planz, Oliver; Pleschka, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Influenza A and B viruses are still a major worldwide threat.  We demonstrate that influenza B virus infection induces signaling via the Raf/MEK/ERK cascade, a process required for efficient virus prodn.  Expression of dominant-neg. Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers.  MEK inhibition appears to interfere with a distinct viral nuclear export process.  Most importantly, no resistant virus variants emerged in the presence of U0126 demonstrating that influenza viruses cannot easily adapt to the missing cellular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH2SOtrmGyrbVg90H21EOLACvtfcHk0lijPmGTf1yUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D&md5=30a70331cb39e18f1db14f415063ba91</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2804%2900108-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252804%252900108-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DWurzer%26aufirst%3DW.%2BJ.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26atitle%3DMEK%2520inhibition%2520impairs%2520in%25C2%25A3uenza%2520B%2520virus%2520propagation%2520without%2520emergence%2520of%2520resistant%2520variants%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D561%26spage%3D37%26epage%3D43%26doi%3D10.1016%2FS0014-5793%2804%2900108-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Droebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21854809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2011&pages=195-203&author=K.+Droebnerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+activity+of+the+MEK-inhibitor+U0126+against+pandemic+H1N1v+and+highly+pathogenic+avian+influenza+virus+in+vitro+and+in+vivo&doi=10.1016%2Fj.antiviral.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span></div><div class="casAuthors">Droebner, Karoline; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of the 2009 H1N1 pandemic swine influenza A virus is a good example of how this viral infection can impact health systems around the world in a very short time.  The continuous zoonotic circulation and reassortment potential of influenza A viruses (IAV) in nature represents an enormous public health threat to humans.  Beside vaccination antivirals are needed to efficiently control spreading of the disease.  In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v = variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.  U0126 showed antiviral activity in cell culture against all tested IAV strains including oseltamivir resistant variants.  Furthermore, we were able to demonstrate that treatment of mice with U0126 via the aerosol route led to (i) inhibition of MEK activation in the lung (ii) redn. of progeny IAV titers compared to untreated controls (iii) protection of IAV infected mice against a 100× lethal viral challenge.  Moreover, no adverse effects of U0126 were found in cell culture or in the mouse.  Thus, we conclude that U0126, by inhibiting the cellular target MEK, has an antiviral potential not only in vitro in cell culture, but also in vivo in the mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6szZdpUCJ_bVg90H21EOLACvtfcHk0lijPmGTf1yUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI&md5=2818e18e307a3cda653b302d30857638</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDroebner%26aufirst%3DK.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520activity%2520of%2520the%2520MEK-inhibitor%2520U0126%2520against%2520pandemic%2520H1N1v%2520and%2520highly%2520pathogenic%2520avian%2520influenza%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D92%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.antiviral.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Cherry, S.</span></span> <span> </span><span class="NLM_article-title">Suppression of astrovirus replication by an ERK1/2 inhibitor</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7475</span>– <span class="NLM_lpage">7482</span>, <span class="refDoi"> DOI: 10.1128/JVI.02193-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.02193-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18508903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVSltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=7475-7482&author=L.+A.+Moserauthor=S.+Schultz-Cherry&title=Suppression+of+astrovirus+replication+by+an+ERK1%2F2+inhibitor&doi=10.1128%2FJVI.02193-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of astrovirus replication by an ERK1/2 inhibitor</span></div><div class="casAuthors">Moser, Lindsey A.; Schultz-Cherry, Stacey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7475-7482</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human astroviruses are nonenveloped, pos.-sense single-strand RNA viruses assocd. with self-limiting diarrhea.  Although they are recognized as a leading cause of disease in young children, the cellular factors involved in astrovirus replication are not well defined.  The extracellular signal-regulated kinase (ERK) pathway has been shown to regulate many viral infections, but its role during astrovirus infection is unknown.  In this report, we show that astrovirus activates ERK1/2 early in infection independently of replication.  Inhibition of ERK activation with U0126, a specific ERK inhibitor, significantly reduced viral prodn.  Investigations into the mechanism of ERK1/2 regulation revealed that all steps of the viral life cycle, including early and late protein expression as well as subgenomic and genomic RNA transcription, were diminished during U0126 treatment of monolayers.  These data support a role for ERK1/2 in a postattachment step, although the precise mechanism remains under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj4Baf6rmSALVg90H21EOLACvtfcHk0ljs43TW_D_hYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVSltL4%253D&md5=916f786530b570845cc846eebe7fb328</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1128%2FJVI.02193-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02193-07%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DL.%2BA.%26aulast%3DSchultz-Cherry%26aufirst%3DS.%26atitle%3DSuppression%2520of%2520astrovirus%2520replication%2520by%2520an%2520ERK1%252F2%2520inhibitor%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D7475%26epage%3D7482%26doi%3D10.1128%2FJVI.02193-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2FmTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0ljs43TW_D_hYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252FmTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peppelenbosch, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinome profiling</span>. <i>Scientifica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">306798</span>, <span class="refDoi"> DOI: 10.6064/2012/306798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.6064%2F2012%2F306798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24278683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ntFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=306798&author=M.+P.+Peppelenbosch&title=Kinome+profiling&doi=10.6064%2F2012%2F306798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome profiling</span></div><div class="casAuthors">Peppelenbosch Maikel P</div><div class="citationInfo"><span class="NLM_cas:title">Scientifica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306798</span>
        ISSN:<span class="NLM_cas:issn">2090-908X</span>.
    </div><div class="casAbstract">The use of arrays in genomics has led to a fast and reliable way to screen the transcriptome of an organism.  It can be automated and analysis tools have become available and hence the technique has become widely used within the past few years.  Signal-transduction routes rely mainly on the phosphorylation status of already available proteins; therefore kinases are central players in signal-transduction routes.  The array technology can now also be used for the analysis of the kinome.  To enable array analysis, consensus peptides for kinases are spot on a solid support.  After incubation with cell lysates and in the presence of radioactive ATP, radioactive peptides can be visualized and the kinases that are active in the cells can be determined.  The present paper reviews comprehensively the different kinome array platforms available and results obtained hitherto using such platforms.  It will appear that this technology does not disappoint its high expectations and is especially powerful because of its species independence.  Nevertheless, improvements are still possible and I shall also sketch future possible directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhIuTuUFCHQHRxY89Cm6SyfW6udTcc2eZICb1wKuylhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ntFWqtg%253D%253D&md5=83202cc92e99e3e1364e7c286a8e27cf</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.6064%2F2012%2F306798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6064%252F2012%252F306798%26sid%3Dliteratum%253Aachs%26aulast%3DPeppelenbosch%26aufirst%3DM.%2BP.%26atitle%3DKinome%2520profiling%26jtitle%3DScientifica%26date%3D2012%26volume%3D2012%26spage%3D306798%26doi%3D10.6064%2F2012%2F306798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leser, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing papaverine as an antiviral agent against influenza viruses and paramyxoviruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>, <span class="NLM_elocation-id">e01888-19</span> <span class="refDoi"> DOI: 10.1128/JVI.01888-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01888-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31896588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&author=M.+Aggarwalauthor=G.+P.+Leserauthor=R.+A.+Lamb&title=Repurposing+papaverine+as+an+antiviral+agent+against+influenza+viruses+and+paramyxoviruses&doi=10.1128%2FJVI.01888-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1128%2FJVI.01888-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01888-19%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DM.%26aulast%3DLeser%26aufirst%3DG.%2BP.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520papaverine%2520as%2520an%2520antiviral%2520agent%2520against%2520influenza%2520viruses%2520and%2520paramyxoviruses%26jtitle%3DJ.%2520Virol.%26date%3D2020%26volume%3D94%26doi%3D10.1128%2FJVI.01888-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varterasian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. B.</span></span> <span> </span><span class="NLM_article-title">Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5281</span>– <span class="NLM_lpage">5293</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.14.415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1200%2FJCO.2005.14.415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16009947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5281-5293&author=P.+M.+Lorussoauthor=A.+A.+Adjeiauthor=M.+Varterasianauthor=S.+Gadgeelauthor=J.+Reidauthor=D.+Y.+Mitchellauthor=L.+Hansonauthor=P.+DeLucaauthor=L.+Bruzekauthor=J.+Piensauthor=P.+Asburyauthor=K.+Van+Becelaereauthor=R.+Herreraauthor=J.+Sebolt-Leopoldauthor=M.+B.+Meyer&title=Phase+I+and+pharmacodynamic+study+of+the+oral+MEK+inhibitor+CI-1040+in+patients+with+advanced+malignancies&doi=10.1200%2FJCO.2005.14.415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies</span></div><div class="casAuthors">LoRusso, Patricia M.; Adjei, Alex A.; Varterasian, Mary; Gadgeel, Shirish; Reid, Joel; Mitchell, David Y.; Hanson, Lorelei; DeLuca, Pamela; Bruzek, Laura; Piens, Jill; Asbury, Peggy; Van Becelaere, Keri; Herrera, Roman; Sebolt-Leopold, Judith; Meyer, Mark B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5281-5293</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, max. tolerated dose (MTD), and clin. activity of CI-1040, a small-mol. inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2, in patients with advanced malignancy.  Patients and Methods: CI-1040 was tested in multiple daily dosing frequencies administered for 21 days repeated every 28 days leading ultimately to continuous administration, and effect of food on absorption was tested.  Single dose and steady-state pharmacokinetics were assessed during cycle 1 and phosphorylated extracellular receptor kinase (pERK) levels were assessed in WBCs and also in tumor tissue from selected patients.  Results: Seventy-seven patients received CI-1040 at dose levels ranging from 100 mg QD to 800 mg tid.  Grade 3 asthenia was dose limiting at the highest dose level tested, 800 mg tid administered with food.  Ninety-eight percent of all drug-related adverse events were grade 1 or 2 in severity; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting.  Plasma concns. of CI-1040 and its active metabolite, PD 0184264, increased in a less than dose proportional manner from 100 to 800 mg QD.  Administration with a high-fat meal resulted in an increase in drug exposure.  The MTD and recommended phase II dose was 800 mg BID administered with food.  Sixty-six patients were assessable for response.  One partial response was achieved in a patient with pancreatic cancer and 19 patients (28%) achieved stable disease lasting a median of 5.5 mo (range, 4 to 17 mo).  Inhibition of tumor pERK (median, 73%; range, 46% to 100%) was demonstrated in 10 patients.  Conclusion: CI-1040 was well tolerated at 800 mg BID administered with food.  Both target suppression and antitumor activity were demonstrated in this phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn9_7twRmM4LVg90H21EOLACvtfcHk0ljcRotWDTWJfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtL8%253D&md5=6af34b8a2037ede667d91e6a3e884d87</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.14.415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.14.415%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DVarterasian%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DD.%2BY.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DDeLuca%26aufirst%3DP.%26aulast%3DBruzek%26aufirst%3DL.%26aulast%3DPiens%26aufirst%3DJ.%26aulast%3DAsbury%26aufirst%3DP.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DM.%2BB.%26atitle%3DPhase%2520I%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520MEK%2520inhibitor%2520CI-1040%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5281%26epage%3D5293%26doi%3D10.1200%2FJCO.2005.14.415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Heier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quernheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104806</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2020.104806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32304723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104806&author=M.+Laureauthor=H.+Hamzaauthor=J.+Koch-Heierauthor=M.+Quernheimauthor=C.+M%C3%BCllerauthor=A.+Schreiberauthor=G.+M%C3%BCllerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+efficacy+against+influenza+virus+and+pharmacokinetic+analysis+of+a+novel+MEK-inhibitor%2C+ATR-002%2C+in+cell+culture+and+in+the+mouse+model&doi=10.1016%2Fj.antiviral.2020.104806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span></div><div class="casAuthors">Laure, Martin; Hamza, Hazem; Koch-Heier, Julia; Quernheim, Martin; Mueller, Christin; Schreiber, Andre; Mueller, Gerhard; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104806</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiviral therapies against influenza are required, esp. for high-risk patients, severe influenza and in case of highly pathogenic influenza virus (IV) strains.  This may be overcome by targeting host cell factors that are required for IV propagation.  IV induces a variety of host cell signaling cascades, such as the Raf/MEK/ERK kinase pathway.  MEK-inhibitors block the activation of the pathway on the bottleneck of the signaling cascade leading to impaired virus propagation.  In the present study, we aimed to compare the antiviral potency and bioavailability of the MEK-inhibitor CI-1040 vs. its major active metabolite ATR-002, in vitro as well as in the mouse model.  In cell culture assays, an approx. 10-fold higher concn. of ATR-002 is required to generate the same antiviral activity as for CI-1040.  Interestingly, we obsd. that considerably lower concns. of ATR-002 were required to achieve a redn. of the viral load in vivo.  Pharmacokinetic studies with ATR-002 and CI-1040 in mice have found the Cmax and AUC to be far higher for ATR-002 than for CI-1040.  Our results thereby demonstrate the in vivo superiority of the active metabolite ATR-002 over CI-1040 as an antiviral agent despite its weaker cell membrane permeability.  Therefore, ATR-002 is an attractive candidate for development as an efficient antiviral agent, esp. given the fact that a treatment based on cellular pathway inhibition would be far less likely to lead to viral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCdKB75g1RNbVg90H21EOLACvtfcHk0lik6tL4gJ5m0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D&md5=9d7774956ebbe323b85b719653716ef4</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104806%26sid%3Dliteratum%253Aachs%26aulast%3DLaure%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DH.%26aulast%3DKoch-Heier%26aufirst%3DJ.%26aulast%3DQuernheim%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520efficacy%2520against%2520influenza%2520virus%2520and%2520pharmacokinetic%2520analysis%2520of%2520a%2520novel%2520MEK-inhibitor%252C%2520ATR-002%252C%2520in%2520cell%2520culture%2520and%2520in%2520the%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104806%26doi%3D10.1016%2Fj.antiviral.2020.104806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a> (accessed February <span class="NLM_year">2021</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.clinicaltrials.gov%2F+%28accessed+February+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.phrs.2015.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25662515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=9-25&author=R.+Roskoski&title=Src+protein-tyrosine+kinase+structure%2C+mechanism%2C+and+small+molecule+inhibitors&doi=10.1016%2Fj.phrs.2015.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The physiol. Src proto-oncogene is a protein tyrosine kinase that plays key roles in cell growth, division, migration, and survival signaling pathways.  From the N- to C-terminus, Src contains a unique domain, an SH3 domain, an SH2 domain, a protein tyrosine kinase domain, and a regulatory tail.  The chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphorylation in the kinase domain by an adjacent Src mol. and an inhibitory pTyr530 in the regulatory tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase).  The oncogenic Rous sarcoma viral protein lacks the equiv. of Tyr530 and is constitutively activated.  Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp.  Protein kinases including Src contain hydrophobic regulatory and catalytic spines and collateral shell residues that are required to assemble the active enzyme.  In the inactive enzyme, the regulatory spine contains a kink or a discontinuity with a structure that is incompatible with catalysis.  The conversion of inactive to active Src is accompanied by electrostatic exchanges involving the breaking and making of distinct sets of kinase domain salt bridges and hydrogen bonds.  Src-catalyzed protein phosphorylation requires the participation of two Mg2+ ions.  Although nearly all protein kinases possess a common K/E/D/D signature, each enzyme exhibits its unique variations of the protein-kinase reaction template.  Bosutinib, dasatinib, and ponatinib are Src/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia and vandetanib is approved for the treatment of medullary thyroid cancer.  The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clin. trials for a variety of solid tumors including breast and lung cancers.  Both ATP and targeted therapeutic Src protein kinase inhibitors such as dasatinib and ponatinib make hydrophobic contacts with catalytic spine residues and form hydrogen bonds with hinge residues connecting the small and large kinase lobes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWw-wmm7q2cbVg90H21EOLACvtfcHk0lik6tL4gJ5m0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D&md5=a40c394ab772b445fe0944c58e1f3deb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSrc%2520protein-tyrosine%2520kinase%2520structure%252C%2520mechanism%252C%2520and%2520small%2520molecule%2520inhibitors%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D94%26spage%3D9%26epage%3D25%26doi%3D10.1016%2Fj.phrs.2015.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Torres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San José, E.</span></span> <span> </span><span class="NLM_article-title">Src tyrosine kinase inhibitors: new perspectives on their immune, antiviral, and senotherapeutic potential</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1011</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2019.01011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31619990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1011&author=J.+Rivera-Torresauthor=E.+San+Jos%C3%A9&title=Src+tyrosine+kinase+inhibitors%3A+new+perspectives+on+their+immune%2C+antiviral%2C+and+senotherapeutic+potential&doi=10.3389%2Ffphar.2019.01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential</span></div><div class="casAuthors">Rivera-Torres Jose; San Jose Esther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1011</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Deregulated activity of the Src tyrosine kinases leads to malignant transformation.  Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has increased notably due to their beneficial effects.  Dasatinib, a second-generation STKI inhibitor widely studied, proved high efficiency in CML patients resistant to imatinib.  In the last decade STKIs have also been implicated and showed therapeutic potential for the treatment of diverse pathologies other than cancer.  In this regard, we review the properties of STKIs, dasatinib in particular, including its immunomodulatory role.  Similarly, the potential benefits, adverse effects, and safety concerns of these inhibitors regarding viral infections are considered.  Moreover, since life expectancy has increased in the last decades accompanied by age-related morbidity, the reduction of undesirable effects associated to aging has become a powerful therapeutic target.  Here, we comment on the ability of STKIs to alleviate age-associated physical dysfunction and their potential impact in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuB58-0Ghq7mQt-ICR3qNfW6udTcc2earoErSF0HGULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D&md5=abb7070b94a2328a1c01559aecbeb7d5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01011%26sid%3Dliteratum%253Aachs%26aulast%3DRivera-Torres%26aufirst%3DJ.%26aulast%3DSan%2BJos%25C3%25A9%26aufirst%3DE.%26atitle%3DSrc%2520tyrosine%2520kinase%2520inhibitors%253A%2520new%2520perspectives%2520on%2520their%2520immune%252C%2520antiviral%252C%2520and%2520senotherapeutic%2520potential%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1011%26doi%3D10.3389%2Ffphar.2019.01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi"> DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+middle+east+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0lg5rpaQGDrG5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520middle%2520east%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">c-Src protein kinase inhibitors block assembly and maturation of dengue virus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611681104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.0611681104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17360676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3520-3525&author=J.+J.+H.+Chuauthor=P.+L.+Yang&title=c-Src+protein+kinase+inhibitors+block+assembly+and+maturation+of+dengue+virus&doi=10.1073%2Fpnas.0611681104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src protein kinase inhibitor block assembly and maturation of dengue virus</span></div><div class="casAuthors">Chu, J. J. H.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3520-3525</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that represents an important emerging infectious disease and is an international health concern.  Currently, there is no vaccine or effective antiviral therapy to prevent or to treat dengue virus infection.  The slow progress in developing antiviral agents might be alleviated by the availability of efficient high-throughput anti-dengue virus screening assays.  In this study, we report an immunofluorescence image-based assay suitable for identification of small mol. inhibitors of dengue virus infection and replication.  Using this assay, we have discovered that inhibitors of the c-Src protein kinase exhibit a potent inhibitory effect on dengue virus (serotypes 1-4) and murine flavivirus Modoc.  Mechanism of action studies demonstrated that the c-Src protein kinase inhibitor dasatinib prevents the assembly of dengue virions within the virus-induced membranous replication complex.  These results demonstrate that this cell-based screen may provide a powerful means to identify new potential targets for anti-dengue drug development while simultaneously providing pharmacol. probes to investigate dengue virus-host cell interactions at the biochem. level.  Given the simplicity and excellent reproducibility of the assay, it should be useful in high-throughput screens of both small mol. and RNAi libraries when implemented on a robotic image-based high- throughput screen (HTS) platform.  Given the reasonable clin. safety of inhibitors such as dasatinib and AZD0530, inhibitors of c-Src protein kinase may have the potential to become a new class of anti-dengue viral therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5wnglMCrULVg90H21EOLACvtfcHk0lg5rpaQGDrG5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D&md5=7b8dd352cb73b762b349ee386a39f649</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611681104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611681104%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3Dc-Src%2520protein%2520kinase%2520inhibitors%2520block%2520assembly%2520and%2520maturation%2520of%2520dengue%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3520%26epage%3D3525%26doi%3D10.1073%2Fpnas.0611681104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>– <span class="NLM_lpage">7381</span>, <span class="refDoi"> DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+De+Wispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0li-uvQFbZLhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1080/14740338.2017.1313224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14740338.2017.1313224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28387147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=547-559&author=M.+Coirasauthor=J.+Ambrosioniauthor=F.+Cervantesauthor=J.+M.+Mir%C3%B3author=J.+Alcam%C3%AD&title=Tyrosine+kinase+inhibitors%3A+potential+use+and+safety+considerations+in+HIV-1+infection&doi=10.1080%2F14740338.2017.1313224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span></div><div class="casAuthors">Coiras, Mayte; Ambrosioni, Juan; Cervantes, Francisco; Miro, Jose M.; Alcami, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-559</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism.  New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection.: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection.  These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia.  The most relevant papers have been selected and commented.: The family of TKIs are directed against the activation of tyrosine kinases from the Src family.  Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1.  During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not.  Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBdl_4AHijwrVg90H21EOLACvtfcHk0li-uvQFbZLhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D&md5=5976725b6d26c627218be0207febd954</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1080%2F14740338.2017.1313224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2017.1313224%26sid%3Dliteratum%253Aachs%26aulast%3DCoiras%26aufirst%3DM.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520potential%2520use%2520and%2520safety%2520considerations%2520in%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2017%26volume%3D16%26spage%3D547%26epage%3D559%26doi%3D10.1080%2F14740338.2017.1313224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayrhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span> <span> </span><span class="NLM_article-title">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.clim.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18395492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2008&pages=330-339&author=S.+Blakeauthor=T.+P.+Hughesauthor=G.+Mayrhoferauthor=A.+B.+Lyons&title=The+Src%2FABL+kinase+inhibitor+dasatinib+%28BMS-354825%29+inhibits+function+of+normal+human+T-lymphocytes+in+vitro&doi=10.1016%2Fj.clim.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span></div><div class="casAuthors">Blake, Stephen; Hughes, Timothy P.; Mayrhofer, Graham; Lyons, A. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia.  Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib.  Dasatinib also inhibits many Src-family tyrosine kinases.  We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clin. relevant concns.  T-cell functions including proliferation, activation and cytokine prodn. were all uniformly inhibited in the presence of dasatinib.  We also demonstrated inhibition of TCR signaling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signaling by dasatinib is responsible for the suppression of T-cell function.  These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon59yxL66SFLVg90H21EOLACvtfcHk0li-uvQFbZLhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D&md5=59574b5a4a2bf4e774a152e74d57850e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26atitle%3DThe%2520Src%252FABL%2520kinase%2520inhibitor%2520dasatinib%2520%2528BMS-354825%2529%2520inhibits%2520function%2520of%2520normal%2520human%2520T-lymphocytes%2520in%2520vitro%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D127%26spage%3D330%26epage%3D339%26doi%3D10.1016%2Fj.clim.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, L.</span></span> <span> </span><span class="NLM_article-title">Role of Abl kinase and the wave2 signaling complex in HIV-1 entry at a post-hemifusion</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1000956</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1000956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20585556" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=B.+Harmonauthor=N.+Campbellauthor=L.+Ratner&title=Role+of+Abl+kinase+and+the+wave2+signaling+complex+in+HIV-1+entry+at+a+post-hemifusion&doi=10.1371%2Fjournal.ppat.1000956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000956%26sid%3Dliteratum%253Aachs%26aulast%3DHarmon%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DN.%26aulast%3DRatner%26aufirst%3DL.%26atitle%3DRole%2520of%2520Abl%2520kinase%2520and%2520the%2520wave2%2520signaling%2520complex%2520in%2520HIV-1%2520entry%2520at%2520a%2520post-hemifusion%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1000956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Huertas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Pérez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Climent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descours, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Mora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rus-Bercial, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkirane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bcp.2016.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26851491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=30-45&author=M.+Bermejoauthor=M.+R.+L%C3%B3pez-Huertasauthor=J.+Garc%C3%ADa-P%C3%A9rezauthor=N.+Climentauthor=B.+Descoursauthor=J.+Ambrosioniauthor=E.+Mateosauthor=S.+Rodr%C3%ADguez-Moraauthor=L.+Rus-Bercialauthor=M.+Benkiraneauthor=J.+M.+Mir%C3%B3author=M.+Planaauthor=J.+Alcam%C3%ADauthor=M.+Coiras&title=Dasatinib+inhibits+HIV-1+replication+through+the+interference+of+SAMHD1+phosphorylation+in+CD4%2B+T+cells&doi=10.1016%2Fj.bcp.2016.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells</span></div><div class="casAuthors">Bermejo, Mercedes; Lopez-Huertas, Maria Rosa; Garcia-Perez, Javier; Climent, Nuria; Descours, Benjamin; Ambrosioni, Juan; Mateos, Elena; Rodriguez-Mora, Sara; Rus-Bercial, Lucia; Benkirane, Monsef; Miro, Jose M.; Plana, Montserrat; Alcami, Jose; Coiras, Mayte</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-45</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Massive activation of infected CD4+ T cells during acute HIV-1 infection leads to reservoir seeding and T-cell destruction.  During T-cell activation, the antiviral effect of the innate factor SAMHD1 is neutralized through phosphorylation at T592, allowing HIV-1 infection.  Dasatinib, a tyrosine kinase inhibitor currently used for treating chronic myeloid leukemia, has been described to control HIV-1 replication through its neg. effect on T-cell proliferation and viral entry.  The authors demonstrate that Dasatinib can actually interfere with SAMHD1 phosphorylation in human peripheral blood lymphocytes, preserving its antiviral activity against HIV-1.  Dasatinib prevented SAMHD1 phosphorylation in vitro and ex vivo, impairing HIV-1 reverse transcription and proviral integration.  This was the major mechanism of action because the presence of Vpx, which degrades SAMHD1, in HIV-1 virions impeded the inhibitory effect of Dasatinib on HIV-1 replication.  In fact, infection with VSV-pseudotyped HIV-1 virions and fusion of BlaM-Vpr-contg. HIV-1 viruses with activated PBMCs in the presence of Dasatinib suggested that Dasatinib was not acting at fusion level.  Finally, PBMCs from patients on chronic treatment with Dasatinib showed a lower level of SAMHD1 phosphorylation in response to activating stimuli and low susceptibility to HIV-1 infection ex vivo.  Consequently, Dasatinib is a compd. currently used in clinic that preserves the antiviral function of SAMHD1.  Using Dasatinib as adjuvant of antiretroviral therapy during early primary HIV-1 infection would contribute to reduce viral replication and spread, prevent reservoir seeding, and preserve CD4 counts and CTL responses.  These events would create a more favorable virol. and immunol. environment for future interventional studies aiming at HIV-1 eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRkqB8GdNRbVg90H21EOLACvtfcHk0lgRjDdoqd4dUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2lt7s%253D&md5=af4ec2aea6fa9ece9bda63f9980b3240</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DL%25C3%25B3pez-Huertas%26aufirst%3DM.%2BR.%26aulast%3DGarc%25C3%25ADa-P%25C3%25A9rez%26aufirst%3DJ.%26aulast%3DCliment%26aufirst%3DN.%26aulast%3DDescours%26aufirst%3DB.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DMateos%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Mora%26aufirst%3DS.%26aulast%3DRus-Bercial%26aufirst%3DL.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DPlana%26aufirst%3DM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26aulast%3DCoiras%26aufirst%3DM.%26atitle%3DDasatinib%2520inhibits%2520HIV-1%2520replication%2520through%2520the%2520interference%2520of%2520SAMHD1%2520phosphorylation%2520in%2520CD4%252B%2520T%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D106%26spage%3D30%26epage%3D45%26doi%3D10.1016%2Fj.bcp.2016.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2013-306155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1136%2Fgutjnl-2013-306155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24848265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=483-494&author=F.+Xiaoauthor=I.+Fofanaauthor=C.+Thumannauthor=L.+Maillyauthor=R.+Allesauthor=E.+Robinetauthor=N.+Meyerauthor=M.+Schaefferauthor=F.+Habersetzerauthor=M.+Doffo%C3%ABlauthor=P.+Leyssenauthor=J.+Neytsauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Synergy+of+entry+inhibitors+with+direct-acting+antivirals+uncovers+novel+combinations+for+prevention+and+treatment+of+hepatitis+C&doi=10.1136%2Fgutjnl-2013-306155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span></div><div class="casAuthors">Xiao, Fei; Fofana, Isabel; Thumann, Christine; Mailly, Laurent; Alies, Roxane; Robinet, Eric; Meyer, Nicolas; Schaeffer, Mickael; Habersetzer, Francois; Doffoel, Michel; Leyssen, Pieter; Neyts, Johan; Zeisel, Mirjam B.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection.  Viral entry is a promising target for antiviral therapy.  Design Aiming to explore the role of entry inhibitors for future clin. development, we investigated the antiviral efficacy and toxicity of entry inhibitors in combination with DAAs or other host-targeting agents (HTAs).  Screening a large series of combinations of entry inhibitors with DAAs or other HTAs, we uncovered novel combinations of antivirals for prevention and treatment of HCV infection.  Results Combinations of DAAs or HTAs and entry inhibitors including CD81-, scavenger receptor class B type I (SR-BI)- or claudin-1 (CLDN1)-specific antibodies or small-mol. inhibitors erlotinib and dasatinib were characterised by a marked and synergistic inhibition of HCV infection over a broad range of concns. with undetectable toxicity in exptl. designs for prevention and treatment both in cell culture models and in human liver-chimeric uPA/SCID mice.  Conclusions Our results provide a rationale for the development of antiviral strategies combining entry inhibitors with DAAs or HTAs by taking advantage of synergy.  The uncovered combinations provide perspectives for efficient strategies to prevent liver graft infection and novel interferon-free regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEKArTUoU-LVg90H21EOLACvtfcHk0lgRjDdoqd4dUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D&md5=553f99c08b810f3a9058ed71124ee7c9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2013-306155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2013-306155%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DAlles%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DSynergy%2520of%2520entry%2520inhibitors%2520with%2520direct-acting%2520antivirals%2520uncovers%2520novel%2520combinations%2520for%2520prevention%2520and%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D483%26epage%3D494%26doi%3D10.1136%2Fgutjnl-2013-306155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2ebfj-wXrcndwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+cyclin-dependent+kinases+%28CDKs%29+as+novel+targets+for+antiviral+drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0li8c-Ul0NIWPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%2520as%2520novel%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galán, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerezo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2004.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2004.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15315761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2004&pages=493-504&author=M.+Malumbresauthor=R.+Sotilloauthor=D.+Santamar%C3%ADaauthor=J.+Gal%C3%A1nauthor=A.+Cerezoauthor=S.+Ortegaauthor=P.+Dubusauthor=M.+Barbacid&title=Mammalian+cells+cycle+without+the+D-type+cyclin-dependent+kinases+Cdk4+and+Cdk6&doi=10.1016%2Fj.cell.2004.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6</span></div><div class="casAuthors">Malumbres, Marcos; Sotillo, Rocio; Santamaria, David; Galan, Javier; Cerezo, Ana; Ortega, Sagrario; Dubus, Pierre; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">493-504</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cdk4 and Cdk6 are thought to be essential for initiation of the cell cycle in response to mitogenic stimuli.  Previous studies have shown that Cdk4 is dispensable for proliferation in most cell types, an observation attributed to a putative compensatory role by Cdk6.  Cdk6-null mice are viable and develop normally although hematopoiesis is slightly impaired.  Embryos defective for Cdk4 and Cdk6 die during the late stages of embryonic development due to severe anemia.  However, these embryos display normal organogenesis and most cell types proliferate normally.  In vitro, embryonic fibroblasts lacking Cdk4 and Cdk6 proliferate and become immortal upon serial passage.  Moreover, quiescent Cdk4/Cdk6-null cells respond to serum stimulation and enter S phase with normal kinetics although with lower efficiency.  These results indicate that D-type cyclin-dependent kinases are not essential for cell cycle entry and suggest the existence of alternative mechanisms to initiate cell proliferation upon mitogenic stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoonn2gu_HOALVg90H21EOLACvtfcHk0li8c-Ul0NIWPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlCmu7c%253D&md5=b6b54b2b4d7c69bd66e79e2bbcc5e3e1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DSotillo%26aufirst%3DR.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DGal%25C3%25A1n%26aufirst%3DJ.%26aulast%3DCerezo%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMammalian%2520cells%2520cycle%2520without%2520the%2520D-type%2520cyclin-dependent%2520kinases%2520Cdk4%2520and%2520Cdk6%26jtitle%3DCell%26date%3D2004%26volume%3D118%26spage%3D493%26epage%3D504%26doi%3D10.1016%2Fj.cell.2004.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0li8c-Ul0NIWPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span>, <span> </span><span class="NLM_article-title">CDK inhibitors as sensitizing agents for cancer chemotherapy</span>. In  <i>Protein Kinase Inhibitors as Sensitizing Agents for Cancer Chemotherapy</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">United States</span>, <span class="NLM_year">2019</span>, Vol.  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">149</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FB978-0-12-816435-8.00009-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=125-149&author=P.+Gupta&author=S.+Narayanan&author=D.-H.+Yangauthor=Z.-S.+Chen&author=D.-H.+Yang&title=Protein+Kinase+Inhibitors+as+Sensitizing+Agents+for+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-816435-8.00009-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-816435-8.00009-2%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26atitle%3DCDK%2520inhibitors%2520as%2520sensitizing%2520agents%2520for%2520cancer%2520chemotherapy%26btitle%3DProtein%2520Kinase%2520Inhibitors%2520as%2520Sensitizing%2520Agents%2520for%2520Cancer%2520Chemotherapy%26aulast%3DChen%26aufirst%3DZ.-S.%26pub%3DAcademic%2520Press%26date%3D2019%26volume%3D4%26spage%3D125%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile α motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0ljXFMYM0y4eWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span> <span> </span><span class="NLM_article-title">Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>, <span class="NLM_elocation-id">e00819-20</span> <span class="refDoi"> DOI: 10.1128/AAC.00819-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.00819-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32366720" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&author=S.+Jeonauthor=M.+Koauthor=J.+Leeauthor=I.+Choiauthor=S.+Y.+Byunauthor=S.+Parkauthor=D.+Shumauthor=S.+Kim&title=Identification+of+antiviral+drug+candidates+against+SARS-CoV-2+from+FDA-approved+drugs&doi=10.1128%2FAAC.00819-20"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1128%2FAAC.00819-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00819-20%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DByun%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DShum%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520antiviral%2520drug%2520candidates%2520against%2520SARS-CoV-2%2520from%2520FDA-approved%2520drugs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26doi%3D10.1128%2FAAC.00819-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresnahan, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldogh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1006/viro.1997.8489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1006%2Fviro.1997.8489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=9168886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1997&pages=239-247&author=W.+A.+Bresnahanauthor=I.+Boldoghauthor=P.+Chiauthor=E.+A.+Thompsonauthor=T.+Albrecht&title=Inhibition+of+cellular+Cdk2+activity+blocks+human+cytomegalovirus+replication&doi=10.1006%2Fviro.1997.8489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span></div><div class="casAuthors">Bresnahan, Wade A.; Boldough, Istvan; Chi, Ping; Thompson, E. Aubrey; Albrecht, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Human cytomegalovirus is a herpesvirus that induces numerous cellular processes upon infection.  Among these are activation of cyclin-dependent kinase 2, which regulates cell cycle progression in G1 and S phase.  We report here that inhibition of cellular Cdk2 activity blocks HCMV replication.  Inhibition of Cdk2 activity by roscovitine inhibits HCMV DNA synthesis, prodn. of infectious progeny, and late antigen expression in infected cells in a dose-dependent manner.  HCMV replication is also inhibited by the expression of a Cdk2 dominant neg. mutant, whereas expression of wild-type Cdk2 has no effect on viral replication.  These data indicate that activation of cellular Cdk2 is necessary for HCMV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3AKL3CzS17Vg90H21EOLACvtfcHk0ljXFMYM0y4eWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D&md5=ae27d67b0473636f85e5a292eb5db347</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Fviro.1997.8489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1997.8489%26sid%3Dliteratum%253Aachs%26aulast%3DBresnahan%26aufirst%3DW.%2BA.%26aulast%3DBoldogh%26aufirst%3DI.%26aulast%3DChi%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26aulast%3DAlbrecht%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cellular%2520Cdk2%2520activity%2520blocks%2520human%2520cytomegalovirus%2520replication%26jtitle%3DVirology%26date%3D1997%26volume%3D231%26spage%3D239%26epage%3D247%26doi%3D10.1006%2Fviro.1997.8489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M+Schangauthor=M.+R+St.+Vincentauthor=J.+J+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0ljV5Te8bfd2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR%26aulast%3DLacasse%26aufirst%3DJ.%2BJ%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>– <span class="NLM_lpage">28348</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.-H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0ljV5Te8bfd2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.-H.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2eblJdNwiezuzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile a motif and HD domain-containing protein-1 (SAMHD1) activity</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1097/QAD.0000000000000399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1097%2FQAD.0000000000000399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25036183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2213-2222&author=E.+Paulsauthor=R.+Badiaauthor=J.+Torres-Torronterasauthor=A.+Ruizauthor=M.+Permanyerauthor=E.+Riveira-Mu%C3%B1ozauthor=B.+Clotetauthor=R.+Martiauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Palbociclib%2C+a+selective+inhibitor+of+cyclin-dependent+kinase4%2F6%2C+blocks+HIV-1+reverse+transcription+through+the+control+of+sterile+a+motif+and+HD+domain-containing+protein-1+%28SAMHD1%29+activity&doi=10.1097%2FQAD.0000000000000399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span></div><div class="casAuthors">Pauls, Eduardo; Badia, Roger; Torres-Torronteras, Javier; Ruiz, Alba; Permanyer, Marc; Riveira-Munoz, Eva; Clotet, Bonaventura; Marti, Ramon; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2213-2222</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Sterile α motif and HD domain-contg. protein-1 (SAMHD1) inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides.  SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation.  However, the exact mechanism of SAMHD1 regulation in primary cells is unclear.  We explore the effect of palbociclib, a CDK6 inhibitor, in HIV-1 replication.  Methods: Human primary monocytes were differentiated into macrophages with monocyte-colony stimulating factor and CD4 T lymphocytes stimulated with phytohaemagglutinin (PHA)/interleukin-2.  Cells were treated with palbociclib and then infected with a Green fluorescent protein-expressing HIV-1 or R5 HIV-1 BaL.  Viral DNA was measured by quant. PCR and infection assessed by flow cytometry.  Deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation.  HIV-1 replication was blocked by AT7519 (66.4±3.8%; n=4), roscovitine (47.3±3.9%; n=4) and purvalanol A (55.7±15.7%; n=4) at subtoxic concns.  Palbociclib, a potent and selective CDK6 inhibitor, blocked SAMHD1 phosphorylation, intracellular dNTP levels, HIV-1 reverse transcription and HIV-1 replication in primary macrophages and CD4 T lymphocytes.  Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160.  The antiviral effect was lost when SAMHD1 was degraded by Vpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect.  Conclusions: Our results indicate that SAMHD1-mediated HIV-1 restriction is controlled by CDK as previously suggested but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation.  Our study provides a new signaling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnbJDONasm7Vg90H21EOLACvtfcHk0ljV5Te8bfd2Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM&md5=68935096ca65c2f15a2b24423c006302</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1097%2FQAD.0000000000000399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0000000000000399%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DMarti%26aufirst%3DR.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DPalbociclib%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase4%252F6%252C%2520blocks%2520HIV-1%2520reverse%2520transcription%2520through%2520the%2520control%2520of%2520sterile%2520a%2520motif%2520and%2520HD%2520domain-containing%2520protein-1%2520%2528SAMHD1%2529%2520activity%26jtitle%3DAIDS%26date%3D2014%26volume%3D28%26spage%3D2213%26epage%3D2222%26doi%3D10.1097%2FQAD.0000000000000399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1172/JCI73805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1172%2FJCI73805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25003190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3479-3488&author=M.+Yamamotoauthor=H.+Onogiauthor=I.+Kiiauthor=S.+Yoshidaauthor=K.+Iidaauthor=H.+Sakaiauthor=M.+Abeauthor=T.+Tsubotaauthor=N.+Itoauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+prevents+replication+of+multiple+DNA+viruses&doi=10.1172%2FJCI73805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span></div><div class="casAuthors">Yamamoto, Makoto; Onogi, Hiroshi; Kii, Isao; Yoshida, Suguru; Iida, Kei; Sakai, Hiroyuki; Abe, Minako; Tsubota, Toshiaki; Ito, Nobutoshi; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3479-3488</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk.  Here, we explored the use of compds. that inhibit or interfere with the action of essential host factors to prevent virus replication.  In particular, we focused on the cyclin-dependent kinase 9 (CDK9) inhibitor, FIT-039, which suppressed replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.  Specifically, FIT-039 inhibited replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells, and topical application of FIT-039 ointment suppressed skin legion formation in a murine HSV-1 infection model.  FIT-039 did not affect cell cycle progression or cellular proliferation in host cells.  Compared with the general CDK inhibitor flavopiridol, transcriptome analyses of FIT-039-treated cells revealed that FIT-039 specifically inhibited CDK9.  Given at concns. above the inhibitory concn., FIT-039 did not have a cytotoxic effect on mammalian cells.  Importantly, administration of FIT-039 ameliorated the severity of skin lesion formation in mice infected with an acydovir-resistant HSV-1, without noticeable adverse effects.  Together, these data indicate that FIT-039 has potential as an antiviral agent for clin. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_l0ZnQV7lWLVg90H21EOLACvtfcHk0lhkb1acbds4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I&md5=f5e7516ba1e29c56f33530b2cd2f6811</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1172%2FJCI73805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI73805%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DTsubota%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520prevents%2520replication%2520of%2520multiple%2520DNA%2520viruses%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D3479%26epage%3D3488%26doi%3D10.1172%2FJCI73805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama-Dobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriishi, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27515132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=156-164&author=T.+Tanakaauthor=K.+Okuyama-Dobashiauthor=S.+Murakamiauthor=W.+Chenauthor=T.+Okamotoauthor=K.+Uedaauthor=T.+Hosoyaauthor=Y.+Matsuuraauthor=A.+Ryoauthor=Y.+Tanakaauthor=M.+Hagiwaraauthor=K.+Moriishi&title=Inhibitory+effect+of+CDK9+inhibitor+FIT-039+on+hepatitis+B+virus+propagation&doi=10.1016%2Fj.antiviral.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span></div><div class="casAuthors">Tanaka, Tomohisa; Okuyama-Dobashi, Kaori; Murakami, Shuko; Chen, Wenjia; Okamoto, Toru; Ueda, Keiji; Hosoya, Takamitsu; Matsuura, Yoshiharu; Ryo, Akihide; Tanaka, Yasuhito; Hagiwara, Masatoshi; Moriishi, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current therapies for hepatitis B virus (HBV) cannot completely eliminate the HBV genome because of the stable population of covalently closed circular DNA (cccDNA) and so on.  FIT-039, which is a cyclin-dependent kinase (CDK) 9 inhibitor, is known to suppress the replication of several DNA viruses including HSV, HPV and human adenovirus.  In this study, we investigated the antiviral effect of FIT-039 on HBV infection.  HepG2 cells expressing human sodium taurocholate cotransporting polypeptide (HepG2/NTCP cells) were infected with HBV in the presence of FIT-039.  FIT-039 dose-dependently reduced intracellular viral RNA, nucleocapsid-assocd. viral DNA, and supernatant viral antigens without cytotoxicity in the infected cells (IC50 = 0.33 μM, CC50 > 50 μM).  The antiviral activity of FIT-039 was prominent at an early phase of viral infection, although the compd. did not inhibit preS1-binding to HepG2/NTCP cells.  FIT-039 reduced cccDNA in HBV-replicating or HBV-infected cells.  Furthermore, the antiviral activity of entecavir was significantly enhanced by the combination with FIT-039 in the chimeric mice having human hepatocytes infected with HBV.  None of the mice had significant drug-related body wt. or serum human-albumin concn. changes.  These data suggest that CDK9 inhibitor FIT-039 is a promising antiviral candidate for HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWi-qx6kiD2rVg90H21EOLACvtfcHk0lhkb1acbds4jg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL&md5=1ab41f68b2a0645ce4d1031798e281d0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOkuyama-Dobashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DMoriishi%26aufirst%3DK.%26atitle%3DInhibitory%2520effect%2520of%2520CDK9%2520inhibitor%2520FIT-039%2520on%2520hepatitis%2520B%2520virus%2520propagation%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D133%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.antiviral.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa Marrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulferts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugourd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdeolivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manners, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez-Rodriguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tenOever, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">The global phosphorylation landscape of SARS-CoV-2 infection</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2020.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32645325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=685-712&author=M.+Bouhaddouauthor=D.+Memonauthor=B.+Meyerauthor=K.+M.+Whiteauthor=V.+V.+Rezeljauthor=M.+Correa+Marreroauthor=B.+J.+Polaccoauthor=J.+E.+Melnykauthor=S.+Ulfertsauthor=R.+M.+Kaakeauthor=J.+Batraauthor=A.+L.+Richardsauthor=E.+Stevensonauthor=D.+E.+Gordonauthor=A.+Rojcauthor=K.+Obernierauthor=J.+M.+Fabiusauthor=M.+Soucherayauthor=L.+Miorinauthor=E.+Morenoauthor=C.+Kohauthor=Q.+D.+Tranauthor=A.+Hardyauthor=R.+Robinotauthor=T.+Valletauthor=B.+E.+Nilsson-Payantauthor=C.+Hernandez-Armentaauthor=A.+Dunhamauthor=S.+Weigangauthor=J.+Knerrauthor=M.+Modakauthor=D.+Quinteroauthor=Y.+Zhouauthor=A.+Dugourdauthor=A.+Valdeolivasauthor=T.+Patilauthor=Q.+Liauthor=R.+Huttenhainauthor=M.+Cakirauthor=M.+Muralidharanauthor=M.+Kimauthor=G.+Jangauthor=B.+Tutuncuogluauthor=J.+Hiattauthor=J.+Z.+Guoauthor=J.+Xuauthor=S.+Bouhaddouauthor=C.+J.+P.+Mathyauthor=A.+Gaultonauthor=E.+J.+Mannersauthor=E.+Felixauthor=Y.+Shiauthor=M.+Goffauthor=J.+K.+Limauthor=T.+McBrideauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=E.+De+Witauthor=A.+R.+Leachauthor=T.+Kortemmeauthor=B.+Shoichetauthor=M.+Ottauthor=J.+Saez-Rodriguezauthor=B.+R.+tenOeverauthor=R.+D.+Mullinsauthor=E.+R.+Fischerauthor=G.+Kochsauthor=R.+Grosseauthor=A.+Garcia-Sastreauthor=M.+Vignuzziauthor=J.+R.+Johnsonauthor=K.+M.+Shokatauthor=D.+L.+Swaneyauthor=P.+Beltraoauthor=N.+J.+Krogan&title=The+global+phosphorylation+landscape+of+SARS-CoV-2+infection&doi=10.1016%2Fj.cell.2020.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The Global Phosphorylation Landscape of SARS-CoV-2 Infection</span></div><div class="casAuthors">Bouhaddou, Mehdi; Memon, Danish; Meyer, Bjoern; White, Kris M.; Rezelj, Veronica V.; Correa Marrero, Miguel; Polacco, Benjamin J.; Melnyk, James E.; Ulferts, Svenja; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Miorin, Lisa; Moreno, Elena; Koh, Cassandra; Tran, Quang Dinh; Hardy, Alexandra; Robinot, Remy; Vallet, Thomas; Nilsson-Payant, Benjamin E.; Hernandez-Armenta, Claudia; Dunham, Alistair; Weigang, Sebastian; Knerr, Julian; Modak, Maya; Quintero, Diego; Zhou, Yuan; Dugourd, Aurelien; Valdeolivas, Alberto; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Bouhaddou, Sophia; Mathy, Christopher J. P.; Gaulton, Anna; Manners, Emma J.; Felix, Eloy; Shi, Ying; Goff, Marisa; Lim, Jean K.; McBride, Timothy; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; De wit, Emmie; Leach, Andrew R.; Kortemme, Tanja; Shoichet, Brian; Ott, Melanie; Saez-Rodriguez, Julio; tenOever, Benjamin R.; Mullins, R. Dyche; Fischer, Elizabeth R.; Kochs, Georg; Grosse, Robert; Garcia-Sastre, Adolfo; Vignuzzi, Marco; Johnson, Jeffery R.; Shokat, Kevan M.; Swaney, Danielle L.; Beltrao, Pedro; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-712.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies.  Here, we present a quant. mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins.  SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, prodn. of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest.  Infection also stimulated a marked induction of CK2-contg. filopodial protrusions possessing budding viral particles.  Eighty-seven drugs and compds. were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways.  We found pharmacol. inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeZZGqGpEn7Vg90H21EOLACvtfcHk0lgOHixQAGPHOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF&md5=cb6e1da08aaaf061b76004416ce27355</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DCorrea%2BMarrero%26aufirst%3DM.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DUlferts%26aufirst%3DS.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DStevenson%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DRojc%26aufirst%3DA.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DHardy%26aufirst%3DA.%26aulast%3DRobinot%26aufirst%3DR.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DDunham%26aufirst%3DA.%26aulast%3DWeigang%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DJ.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DQuintero%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDugourd%26aufirst%3DA.%26aulast%3DValdeolivas%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHuttenhain%26aufirst%3DR.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DG.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DBouhaddou%26aufirst%3DS.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DManners%26aufirst%3DE.%2BJ.%26aulast%3DFelix%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGoff%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DMcBride%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DSaez-Rodriguez%26aufirst%3DJ.%26aulast%3DtenOever%26aufirst%3DB.%2BR.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26aulast%3DFischer%26aufirst%3DE.%2BR.%26aulast%3DKochs%26aufirst%3DG.%26aulast%3DGrosse%26aufirst%3DR.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520global%2520phosphorylation%2520landscape%2520of%2520SARS-CoV-2%2520infection%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D685%26epage%3D712%26doi%3D10.1016%2Fj.cell.2020.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.-K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.-I.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of ∼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0ljl4bAnje6bVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.-K.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.-I.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lartigue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tooze, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clague, M. J.</span></span> <span> </span><span class="NLM_article-title">PIKfyve regulation of endosome-linked pathways</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0854.2009.00915.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fj.1600-0854.2009.00915.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19582903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFGrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=883-893&author=J.+de+Lartigueauthor=H.+Polsonauthor=M.+Feldmanauthor=K.+Shokatauthor=S.+A.+Toozeauthor=S.+Urbeauthor=M.+J.+Clague&title=PIKfyve+regulation+of+endosome-linked+pathways&doi=10.1111%2Fj.1600-0854.2009.00915.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve regulation of endosome-linked pathways</span></div><div class="casAuthors">de Lartigue, Jane; Polson, Hannah; Feldman, Morri; Shokat, Kevan; Tooze, Sharon A.; Urbe, Sylvie; Clague, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-893</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The phosphoinositide 5-kinase (PIKfyve) is a crit. enzyme for the synthesis of PtdIns(3,5)P2, that was implicated in various trafficking events assocd. with the endocytic pathway.  We have now directly compared the effects of siRNA-mediated knockdown of PIKfyve in HeLa cells with a specific pharmacol. inhibitor of enzyme activity.  Both approaches induce changes in the distribution of cation-independent mannose 6-phosphate receptor (CI-M6PR) and trans-Golgi network (TGN)-46 proteins, which cycles between endosomes and TGN, leading to their accumulation in dispersed punctae, while the TGN marker golgin-245 retains a perinuclear disposition.  Trafficking of CD8-CI-M6PR (retromer-dependent) and CD8-Furin (retromer-independent) chimeras from the cell surface to the TGN is delayed following drug administration, as is the transport of the Shiga toxin B-subunit.  SiRNA knockdown of PIKfyve produced no defect in epidermal growth factor receptor (EGFR) degrdn., unless combined with knockdown of its activator mol. Vac14, suggesting that a low threshold of PtdIns(3,5)P2 is necessary and sufficient for this pathway.  Accordingly pharmacol. inhibition of PIKfyve results in a profound block to the lysosomal degrdn. of activated epidermal growth factor (EGF) and Met receptors.  Immunofluorescence revealed EGF receptors to be trapped in the interior of a swollen endosomal compartment.  In cells starved of amino acids, PIKfyve inhibition leads to the accumulation of the lipidated form of GFP-LC3, a marker of autophagosomal structures, which can be visualized as fluorescent punctae.  We suggest that PIKfyve inhibition may render the late endosome/lysosome compartment refractory to fusion with both autophagosomes and with EGFR-contg. multivesicular bodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjAHcsNBejkbVg90H21EOLACvtfcHk0ljl4bAnje6bVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFGrsb8%253D&md5=5522c9dfb2e576da77e2a6b166f08b51</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0854.2009.00915.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0854.2009.00915.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLartigue%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DH.%26aulast%3DFeldman%26aufirst%3DM.%26aulast%3DShokat%26aufirst%3DK.%26aulast%3DTooze%26aufirst%3DS.%2BA.%26aulast%3DUrbe%26aufirst%3DS.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26atitle%3DPIKfyve%2520regulation%2520of%2520endosome-linked%2520pathways%26jtitle%3DTraffic%26date%3D2009%26volume%3D10%26spage%3D883%26epage%3D893%26doi%3D10.1111%2Fj.1600-0854.2009.00915.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijuin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate synthesis and turnover that regulates the progression of endosomal transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">23878</span>– <span class="NLM_lpage">23891</span>, <span class="refDoi"> DOI: 10.1074/jbc.M611678200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.M611678200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17556371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslOntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=23878-23891&author=D.+Sbrissaauthor=O.+C.+Ikonomovauthor=Z.+Fuauthor=T.+Ijuinauthor=J.+Gruenbergauthor=T.+Takenawaauthor=A.+Shisheva&title=Core+protein+machinery+for+mammalian+phosphatidylinositol+3%2C5-bisphosphate+synthesis+and+turnover+that+regulates+the+progression+of+endosomal+transport.+Novel+Sac+phosphatase+joins+the+ArPIKfyve-PIKfyve+complex&doi=10.1074%2Fjbc.M611678200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Core Protein Machinery for Mammalian Phosphatidylinositol 3,5-Bisphosphate Synthesis and Turnover That Regulates the Progression of Endosomal Transport: Novel Sac Phosphatase Joins the ArPIKfyve-PIKfyve Complex</span></div><div class="casAuthors">Sbrissa, Diego; Ikonomov, Ognian C.; Fu, Zhiyao; Ijuin, Takeshi; Gruenberg, Jean; Takenawa, Tadaomi; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">23878-23891</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Perturbations in phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2)-synthesizing enzymes result in enlarged endocytic organelles from yeast to humans, indicating evolutionarily conserved function of PtdIns(3,5)P2 in endosome-related events.  This is reinforced by the structural and functional homol. of yeast Vac14 and human Vac14 (ArPIKfyve), which activate yeast and mammalian PtdIns(3,5)P2-producing enzymes, Fab1 and PIKfyve, resp.  In yeast, PtdIns(3,5)P2-specific phosphatase, Fig4, in assocn. with Vac14, turns over PtdIns(3,5)P2, but whether such a mechanism operates in mammalian cells and what the identity of mammalian Fig4 may be are unknown.  Here we have identified and characterized Sac3, a Sac domain phosphatase, as the Fig4 mammalian counterpart.  Endogenous Sac3, a widespread 97-kDa protein, formed a stable ternary complex with ArPIKfyve and PIKfyve.  Concordantly, Sac3 cofractionated and colocalized with ArPIKfyve and PIKfyve.  The intrinsic Sac3WT phosphatase activity preferably hydrolyzed PtdIns(3,5)P2 in vitro, although the other D5-phosphorylated polyphosphoinositides were also substrates.  Ablation of endogenous Sac3 by short interfering RNAs elevated PtdIns(3,5)P2 in 32P-labeled HEK293 cells.  Ectopically expressed Sac3WT in COS cells colocalized with and dilated EEA1-pos. endosomes, consistent with the PtdIns(3,5)P2 requirement in early endosome dynamics.  In vitro reconstitution of carrier vesicle formation from donor early endosomes revealed a gain of function upon Sac3 loss, whereas PIKfyve or ArPIKfyve protein depletion produced a loss of function.  These data demonstrate a coupling between the machinery for PtdIns(3,5)P2 synthesis and turnover achieved through a phys. assembly of PIKfyve, ArPIKfyve, and Sac3.  We suggest that the tight regulation in PtdIns(3,5)P2 homeostasis is mechanistically linked to early endosome dynamics in the course of cargo transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsZiUzSilWWbVg90H21EOLACvtfcHk0ljl4bAnje6bVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslOntrc%253D&md5=f45f6265aae85924bbff3a1edb3925a4</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M611678200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M611678200%26sid%3Dliteratum%253Aachs%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DIjuin%26aufirst%3DT.%26aulast%3DGruenberg%26aufirst%3DJ.%26aulast%3DTakenawa%26aufirst%3DT.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DCore%2520protein%2520machinery%2520for%2520mammalian%2520phosphatidylinositol%25203%252C5-bisphosphate%2520synthesis%2520and%2520turnover%2520that%2520regulates%2520the%2520progression%2520of%2520endosomal%2520transport.%2520Novel%2520Sac%2520phosphatase%2520joins%2520the%2520ArPIKfyve-PIKfyve%2520complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D23878%26epage%3D23891%26doi%3D10.1074%2Fjbc.M611678200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Localized PtdIns 3,5-P2 synthesis to regulate early endosome dynamics and fusion</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">C393</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.00019.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1152%2Fajpcell.00019.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16510848" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2006&pages=C393-404&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Localized+PtdIns+3%2C5-P2+synthesis+to+regulate+early+endosome+dynamics+and+fusion&doi=10.1152%2Fajpcell.00019.2006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00019.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00019.2006%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DLocalized%2520PtdIns%25203%252C5-P2%2520synthesis%2520to%2520regulate%2520early%2520endosome%2520dynamics%2520and%2520fusion%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2006%26volume%3D291%26spage%3DC393%26epage%3D404%26doi%3D10.1152%2Fajpcell.00019.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schink, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raiborg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, H.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-phosphate, a lipid that regulates membrane dynamics, protein sorting and cell signalling</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1002/bies.201300064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fbies.201300064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23881848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGgu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=900-912&author=K.+O.+Schinkauthor=C.+Raiborgauthor=H.+Stenmark&title=Phosphatidylinositol+3-phosphate%2C+a+lipid+that+regulates+membrane+dynamics%2C+protein+sorting+and+cell+signalling&doi=10.1002%2Fbies.201300064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-phosphate, a lipid that regulates membrane dynamics, protein sorting and cell signalling</span></div><div class="casAuthors">Schink, Kay O.; Raiborg, Camilla; Stenmark, Harald</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">900-912</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-phosphate (PtdIns3P) is generated on the cytosolic leaflet of cellular membranes, primarily by phosphorylation of phosphatidylinositol by class II and class III phosphatidylinositol 3-kinases.  The bulk of this lipid is found on the limiting and intraluminal membranes of endosomes, but it can also be detected in domains of phagosomes, autophagosome precursors, cytokinetic bridges, the plasma membrane and the nucleus.  PtdIns3P controls cellular functions through recruitment of specific protein effectors, many of which contain FYVE or PX domains.  Cellular processes known to be controlled by PtdIns3P and its effectors include endosomal fusion, sorting and motility, autophagy, cytokinesis, regulated exocytosis and signal transduction.  Here we discuss how Ptdins3P is generated on specific cellular membranes, how its localizations and functions can be studied, and how its effectors serve to control cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXUrll_PcBbVg90H21EOLACvtfcHk0lgJLYf-fRyRhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGgu7fJ&md5=93fa2b0d09c538b9528eecdddac4a89b</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fbies.201300064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.201300064%26sid%3Dliteratum%253Aachs%26aulast%3DSchink%26aufirst%3DK.%2BO.%26aulast%3DRaiborg%26aufirst%3DC.%26aulast%3DStenmark%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-phosphate%252C%2520a%2520lipid%2520that%2520regulates%2520membrane%2520dynamics%252C%2520protein%2520sorting%2520and%2520cell%2520signalling%26jtitle%3DBioEssays%26date%3D2013%26volume%3D35%26spage%3D900%26epage%3D912%26doi%3D10.1002%2Fbies.201300064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saric, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griner, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePamphilis, M. L.</span></span> <span> </span><span class="NLM_article-title">A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1080/15548627.2019.1586257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F15548627.2019.1586257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30806145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFKmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1694-1718&author=G.+Sharmaauthor=C.+M.+Guardiaauthor=A.+Royauthor=A.+Vassilevauthor=A.+Saricauthor=L.+N.+Grinerauthor=J.+Maruganauthor=M.+Ferrerauthor=J.+S.+Bonifacinoauthor=M.+L.+DePamphilis&title=A+family+of+PIKFYVE+inhibitors+with+therapeutic+potential+against+autophagy-dependent+cancer+cells+disrupt+multiple+events+in+lysosome+homeostasis&doi=10.1080%2F15548627.2019.1586257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis</span></div><div class="casAuthors">Sharma, Gaurav; Guardia, Carlos M.; Roy, Ajit; Vassilev, Alex; Saric, Amra; Griner, Lori N.; Marugan, Juan; Ferrer, Marc; Bonifacino, Juan S.; DePamphilis, Melvin L.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1694-1718</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">High-throughput screening identified 5 chem. analogs (termed the WX8-family) that disrupted 3 events in lysosome homeostasis: (1) lysosome fission via tubulation without preventing homotypic lysosome fusion; (2) trafficking of mols. into lysosomes without altering lysosomal acidity, and (3) heterotypic fusion between lysosomes and autophagosomes.  Remarkably, these compds. did not prevent homotypic fusion between lysosomes, despite the fact that homotypic fusion required some of the same machinery essential for heterotypic fusion.  These effects varied 400-fold among WX8-family members, were time and concn. dependent, reversible, and resulted primarily from their ability to bind specifically to the PIKFYVE phosphoinositide kinase.  The ability of the WX8-family to prevent lysosomes from participating in macroautophagy/autophagy suggested they have therapeutic potential in treating autophagy-dependent diseases.  In fact, the most potent family member (WX8) was 100-times more lethal to 'autophagy-addicted' melanoma A375 cells than the lysosomal inhibitors hydroxychloroquine and chloroquine.  In contrast, cells that were insensitive to hydroxychloroquine and chloroquine were also insensitive to WX8.  Therefore, the WX8-family of PIKFYVE inhibitors provides a basis for developing drugs that could selectively kill autophagy-dependent cancer cells, as well as increasing the effectiveness of established anti-cancer therapies through combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlajGQ8jh2DLVg90H21EOLACvtfcHk0lgJLYf-fRyRhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFKmtLw%253D&md5=77481df9d3e911f58e6b9645f89714b4</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1080%2F15548627.2019.1586257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2019.1586257%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DGuardia%26aufirst%3DC.%2BM.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DA.%26aulast%3DSaric%26aufirst%3DA.%26aulast%3DGriner%26aufirst%3DL.%2BN.%26aulast%3DMarugan%26aufirst%3DJ.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26aulast%3DDePamphilis%26aufirst%3DM.%2BL.%26atitle%3DA%2520family%2520of%2520PIKFYVE%2520inhibitors%2520with%2520therapeutic%2520potential%2520against%2520autophagy-dependent%2520cancer%2520cells%2520disrupt%2520multiple%2520events%2520in%2520lysosome%2520homeostasis%26jtitle%3DAutophagy%26date%3D2019%26volume%3D15%26spage%3D1694%26epage%3D1718%26doi%3D10.1080%2F15548627.2019.1586257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fligger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, R. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Active PIKfyve associates with and promotes the membrane attachment of the late endosome-to-trans-Golgi network transport factor Rab9 effector p40</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">50863</span>– <span class="NLM_lpage">50871</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307260200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.M307260200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=14530284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=50863-50871&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=K.+Mlakauthor=R.+Deebauthor=J.+Fliggerauthor=A.+Soansauthor=R.+L.+Finleyauthor=A.+Shisheva&title=Active+PIKfyve+associates+with+and+promotes+the+membrane+attachment+of+the+late+endosome-to-trans-Golgi+network+transport+factor+Rab9+effector+p40&doi=10.1074%2Fjbc.M307260200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Active PIKfyve Associates with and Promotes the Membrane Attachment of the Late Endosome-to-trans-Golgi Network Transport Factor Rab9 Effector p40</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Mlak, Krzysztof; Deeb, Robert; Fligger, Jason; Soans, Aleric; Finley, Russell L., Jr.; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">50863-50871</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">PIKfyve, a kinase that displays specificity for phosphatidylinositol (PtdIns), PtdIns 3-phosphate (3-P), and proteins, is important in multivesicular body/late endocytic function.  Enzymically inactive PIKfyve mutants elicit enormous dilation of late endocytic structures, suggesting a role for PIKfyve in endosome-to-trans-Golgi network (TGN) membrane retrieval.  Here we report that p40, a Rab9 effector reported previously to bind Rab9-GTP and stimulate endosome-to-TGN transport, interacts with PIKfyve as detd. by yeast two-hybrid assays, glutathione S-transferase (GST) pull-down assays, and co-immunopptn. in doubly transfected HEK293 cells.  The interaction engages the PIKfyve chaperonin domain and four out of the six C-terminally positioned kelch repeats in p40.  Differential centrifugation in a HEK293 cell line, stably expressing PIKfyveWT, showed the membrane-assocd. immunoreactive p40 co-sedimenting with PIKfyve in the high speed pellet (HSP) fraction.  Remarkably, similar anal. in a HEK293 cell line stably expressing dominant-neg. kinase-deficient PIKfyveK1831E demonstrated a marked depletion of p40 from the HSP fraction.  GST-p40 failed to specifically assoc. with the PIKfyve lipid products PtdIns 5-P and PtdIns 3,5-P2 in a liposome binding assay but was found to be an in vitro substrate of the PIKfyve serine kinase activity.  A band with the p40 electrophoretic mobility was found to react with a phosphoserine-specific antibody mainly in the PIKfyveWT-contg. fractions obtained by d. gradient sedimentation of total membranes from PIKfyveWT-expressing HEK293 cells.  Together these results identify the Rab9 effector p40 as a PIKfyve partner and suggest that p40-PIKfyve interaction and the subsequent PIKfyve-catalyzed p40 phosphorylation anchor p40 to discrete membranes facilitating late endosome-to-TGN transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjGs3YUluHk7Vg90H21EOLACvtfcHk0lgJLYf-fRyRhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslOiu7s%253D&md5=e5bc482a93c1ae22aeb619715d4bfac1</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307260200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307260200%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DMlak%26aufirst%3DK.%26aulast%3DDeeb%26aufirst%3DR.%26aulast%3DFligger%26aufirst%3DJ.%26aulast%3DSoans%26aufirst%3DA.%26aulast%3DFinley%26aufirst%3DR.%2BL.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DActive%2520PIKfyve%2520associates%2520with%2520and%2520promotes%2520the%2520membrane%2520attachment%2520of%2520the%2520late%2520endosome-to-trans-Golgi%2520network%2520transport%2520factor%2520Rab9%2520effector%2520p40%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D50863%26epage%3D50871%26doi%3D10.1074%2Fjbc.M307260200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujny, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. J.</span></span> <span> </span><span class="NLM_article-title">The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">3944</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1242/jcs.03153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.03153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16954148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=3944-3957&author=A.+C.+Rutherfordauthor=C.+Traerauthor=T.+Wassmerauthor=K.+Pattniauthor=M.+V.+Bujnyauthor=J.+G.+Carltonauthor=H.+Stenmarkauthor=P.+J.+Cullen&title=The+mammalian+phosphatidylinositol+3-phosphate+5-kinase+%28PIKfyve%29+regulates+endosome-to-TGN+retrograde+transport&doi=10.1242%2Fjcs.03153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport</span></div><div class="casAuthors">Rutherford, Anna C.; Traer, Colin; Wassmer, Thomas; Pattni, Krupa; Bujny, Miriam V.; Carlton, Jeremy G.; Stenmark, Harald; Cullen, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3944-3957</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The yeast gene fab1 and its mammalian orthologue Pip5k3 encode the phosphatidylinositol 3-phosphate [PtdIns(3)P] 5-kinases Fab1p and PIKfyve, resp., enzymes that generates phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P2].  A shared feature of fab1Δ yeast cells and mammalian cells overexpressing a kinase-dead PIKfyve mutant is the formation of a swollen vacuolar phenotype: a phenotype that is suggestive of a conserved function for these enzymes and their product, PtdIns(3,5)P2, in the regulation of endomembrane homeostasis.  In the current study, fixed and live cell imaging has established that, when overexpressed at low levels in HeLa cells, PIKfyve is predominantly assocd. with dynamic tubular and vesicular elements of the early endosomal compartment.  Moreover, through the use of small interfering RNA, it has been shown that suppression of PIKfyve induces the formation of swollen endosomal structures that maintain their early and late endosomal identity.  Although internalization, recycling and degradative sorting of receptors for epidermal growth factor and transferrin was unperturbed in PIKfyve suppressed cells, a clear defect in endosome to trans-Golgi-network (TGN) retrograde traffic was obsd.  These data argue that PIKfyve is predominantly assocd. with the early endosome, from where it regulates retrograde membrane trafficking to the TGN.  It follows that the swollen endosomal phenotype obsd. in PIKfyve-suppressed cells results primarily from a redn. in retrograde membrane fission rather than a defect in multivesicular body biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqgs0VHr1Z7Vg90H21EOLACvtfcHk0liOgizJO1DrCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1CgtA%253D%253D&md5=1e4111d4d82c8636424d7b60a79d06d8</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1242%2Fjcs.03153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.03153%26sid%3Dliteratum%253Aachs%26aulast%3DRutherford%26aufirst%3DA.%2BC.%26aulast%3DTraer%26aufirst%3DC.%26aulast%3DWassmer%26aufirst%3DT.%26aulast%3DPattni%26aufirst%3DK.%26aulast%3DBujny%26aufirst%3DM.%2BV.%26aulast%3DCarlton%26aufirst%3DJ.%2BG.%26aulast%3DStenmark%26aufirst%3DH.%26aulast%3DCullen%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520mammalian%2520phosphatidylinositol%25203-phosphate%25205-kinase%2520%2528PIKfyve%2529%2520regulates%2520endosome-to-TGN%2520retrograde%2520transport%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2006%26volume%3D119%26spage%3D3944%26epage%3D3957%26doi%3D10.1242%2Fjcs.03153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">114771</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2019.114771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.taap.2019.114771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31628917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2019&pages=114771&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Small+molecule+PIKfyve+inhibitors+as+cancer+therapeutics%3A+Translational+promises+and+limitations&doi=10.1016%2Fj.taap.2019.114771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114771</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Through synthesis of two rare phosphoinositides, PtdIns(3,5)P2 and PtdIns5P, the ubiquitously expressed phosphoinositide kinase PIKfyve is implicated in pleiotropic cellular functions.  Small mols. specifically inhibiting PIKfyve activity cause cytoplasmic vacuolation in all dividing cells in culture yet trigger non-apoptotic death through excessive vacuolation only in cancer cells.  Intriguingly, cancer cell toxicity appears to be inhibitor-specific suggesting that addnl. targets beyond PIKfyve are affected.  One PIKfyve inhibitor - apilimod - is already in clin. trials for treatment of B-cell malignancies.  However, apilimod is inactivated in cultured cells and exhibits unexpectedly low plasma levels in patients treated with max. oral dosage.  Thus, the potential widespread use of PIKfyve inhibitors as cancer therapeutics requires progress on multiple fronts: (i) advances in methods for isolating relevant cancer cells from individual patients; (ii) delineation of the mol. mechanisms potentiating the vacuolation induced by PIKfyve inhibitors in sensitive cancer cells; (iii) design of PIKfyve inhibitors with favorable pharmacokinetics; and (iv) development of effective drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCqd6_1ZLsrVg90H21EOLACvtfcHk0liOgizJO1DrCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ&md5=992d773408d82e75fe81132678d6c0df</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.114771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.114771%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520PIKfyve%2520inhibitors%2520as%2520cancer%2520therapeutics%253A%2520Translational%2520promises%2520and%2520limitations%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D383%26spage%3D114771%26doi%3D10.1016%2Fj.taap.2019.114771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar-Roman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Camilli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span> <span> </span><span class="NLM_article-title">PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23890009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=912-921&author=X.+Caiauthor=Y.+Xuauthor=A.+K.+Cheungauthor=R.+C.+Tomlinsonauthor=A.+Alcazar-Romanauthor=L.+Murphyauthor=A.+Billichauthor=B.+Zhangauthor=Y.+Fengauthor=M.+Klumppauthor=J.+M.+Rondeauauthor=A.+N.+Fazalauthor=C.+J.+Wilsonauthor=V.+Myerauthor=G.+Jobertyauthor=T.+Bouwmeesterauthor=M.+A.+Labowauthor=P.+M.+Finanauthor=J.+A.+Porterauthor=H.+L.+Ploeghauthor=D.+Bairdauthor=P.+De+Camilliauthor=J.+A.+Tallaricoauthor=Q.+Huang&title=PIKfyve%2C+a+class+III+PI+kinase%2C+is+the+target+of+the+small+molecular+IL-12%2FIL-23+inhibitor+apilimod+and+a+player+in+Toll-like+receptor+signaling&doi=10.1016%2Fj.chembiol.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling</span></div><div class="casAuthors">Cai, Xinming; Xu, Yongyao; Cheung, Atwood K.; Tomlinson, Ronald C.; Alcazar-Roman, Abel; Murphy, Leon; Billich, Andreas; Zhang, Bailin; Feng, Yan; Klumpp, Martin; Rondeau, Jean-Michel; Fazal, Aleem N.; Wilson, Christopher J.; Myer, Vic; Joberty, Gerard; Bouwmeester, Tewis; Labow, Mark A.; Finan, Peter M.; Porter, Jeffrey A.; Ploegh, Hidde L.; Baird, Daniel; De Camilli, Pietro; Tallarico, John A.; Huang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">912-921</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) signaling is a key component of innate immunity.  Aberrant TLR activation leads to immune disorders via dysregulation of cytokine prodn., such as IL-12/IL-23.  Herein, we identify and characterize PIKfyve, a lipid kinase, as a crit. player in TLR signaling using apilimod as an affinity tool.  Apilimod is a potent small mol. inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clin. trials for patients with Crohn's disease or rheumatoid arthritis.  Using a chem. genetic approach, we show that it binds to PIKfyve and blocks its phosphotransferase activity, leading to selective inhibition of IL-12/IL-23p40.  Pharmacol. or genetic inactivation of PIKfyve is necessary and sufficient for suppression of IL-12/IL-23p40 expression.  Thus, we have uncovered a phosphoinositide-mediated regulatory mechanism that controls TLR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpALdejwmIR_rVg90H21EOLACvtfcHk0liOgizJO1DrCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE&md5=9b296c00beb17b95ec9a17c1750a1862</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCheung%26aufirst%3DA.%2BK.%26aulast%3DTomlinson%26aufirst%3DR.%2BC.%26aulast%3DAlcazar-Roman%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DKlumpp%26aufirst%3DM.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DFazal%26aufirst%3DA.%2BN.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%2BA.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DBaird%26aufirst%3DD.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DPIKfyve%252C%2520a%2520class%2520III%2520PI%2520kinase%252C%2520is%2520the%2520target%2520of%2520the%2520small%2520molecular%2520IL-12%252FIL-23%2520inhibitor%2520apilimod%2520and%2520a%2520player%2520in%2520Toll-like%2520receptor%2520signaling%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D912%26epage%3D921%26doi%3D10.1016%2Fj.chembiol.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gayle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landrette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeharry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H.</span></span> <span> </span><span class="NLM_article-title">Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1768</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-736892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1182%2Fblood-2016-09-736892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28104689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1768-1778&author=S.+Gayleauthor=S.+Landretteauthor=N.+Beeharryauthor=C.+Conradauthor=M.+Hernandezauthor=P.+Beckettauthor=S.+M.+Fergusonauthor=T.+Mandelkernauthor=M.+Zhengauthor=T.+Xuauthor=J.+Rothbergauthor=H.+Lichenstein&title=Identification+of+apilimod+as+a+first-in-class+PIKfyve+kinase+inhibitor+for+treatment+of+B-cell+non-Hodgkin+lymphoma&doi=10.1182%2Fblood-2016-09-736892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma</span></div><div class="casAuthors">Gayle, Sophia; Landrette, Sean; Beeharry, Neil; Conrad, Chris; Hernandez, Marylens; Beckett, Paul; Ferguson, Shawn M.; Mandelkern, Talya; Zheng, Meiling; Xu, Tian; Rothberg, Jonathan; Lichenstein, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1768-1778</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We identified apilimod as an antiproliferative compd. by high-throughput screening of clin.-stage drugs.  Apilimod exhibits exquisite specificity for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) lipid kinase and has selective cytotoxic activity in B-cell non-Hodgkin lymphoma (B-NHL) compared with normal cells.  Apilimod displays nanomolar activity in vitro, and in vivo studies demonstrate single-agent efficacy as well as synergy with approved B-NHL drugs.  Using biochem. and knockdown approaches, and discovery of a kinase domain mutation conferring resistance, we demonstrate that apilimod-mediated cytotoxicity is driven by PIKfyve inhibition.  Furthermore, a crit. role for lysosome dysfunction as a major factor contributing to apilimod's cytotoxicity is supported by a genome-wide CRISPR screen.  In the screen, TFEB (master transcriptional regulator of lysosomal biogenesis) and endosomal/lysosomal genes CLCN7, OSTM1, and SNX10 were identified as important determinants of apilimod sensitivity.  These findings thus suggest that disruption of lysosomal homeostasis with apilimod represents a novel approach to treat B-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTjIKokPhHrVg90H21EOLACvtfcHk0ljc7DVEFz2gCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7fM&md5=224b5d68b7c4e202010f4d192398491e</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-736892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-736892%26sid%3Dliteratum%253Aachs%26aulast%3DGayle%26aufirst%3DS.%26aulast%3DLandrette%26aufirst%3DS.%26aulast%3DBeeharry%26aufirst%3DN.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DBeckett%26aufirst%3DP.%26aulast%3DFerguson%26aufirst%3DS.%2BM.%26aulast%3DMandelkern%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DRothberg%26aufirst%3DJ.%26aulast%3DLichenstein%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520apilimod%2520as%2520a%2520first-in-class%2520PIKfyve%2520kinase%2520inhibitor%2520for%2520treatment%2520of%2520B-cell%2520non-Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1768%26epage%3D1778%26doi%3D10.1182%2Fblood-2016-09-736892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandoorne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staats, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span> <span> </span><span class="NLM_article-title">The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1651</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1093/brain/awaa022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fbrain%2Fawaa022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32206784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB383mvV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2020&pages=1651-1673&author=W.+Guoauthor=T.+Vandoorneauthor=J.+Steyaertauthor=K.+A.+Staatsauthor=L.+Van+Den%0ABosch&title=The+multifaceted+role+of+kinases+in+amyotrophic+lateral+sclerosis%3A+genetic%2C+pathological+and+therapeutic+implications&doi=10.1093%2Fbrain%2Fawaa022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications</span></div><div class="casAuthors">Guo Wenting; Vandoorne Tijs; Steyaert Jolien; Van Den Bosch Ludo; Guo Wenting; Vandoorne Tijs; Steyaert Jolien; Van Den Bosch Ludo; Guo Wenting; Staats Kim A</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1651-1673</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amyotrophic lateral sclerosis is the most common degenerative disorder of motor neurons in adults.  As there is no cure, thousands of individuals who are alive at present will succumb to the disease.  In recent years, numerous causative genes and risk factors for amyotrophic lateral sclerosis have been identified.  Several of the recently identified genes encode kinases.  In addition, the hypothesis that (de)phosphorylation processes drive the disease process resulting in selective motor neuron degeneration in different disease variants has been postulated.  We re-evaluate the evidence for this hypothesis based on recent findings and discuss the multiple roles of kinases in amyotrophic lateral sclerosis pathogenesis.  We propose that kinases could represent promising therapeutic targets.  Mainly due to the comprehensive regulation of kinases, however, a better understanding of the disturbances in the kinome network in amyotrophic lateral sclerosis is needed to properly target specific kinases in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuvu_j6jnHPQqdek-gHSrIfW6udTcc2eaCd4xf098Dn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383mvV2lug%253D%253D&md5=578afee922c410314ba84a284f56b8ab</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawaa022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawaa022%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DVandoorne%26aufirst%3DT.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DStaats%26aufirst%3DK.%2BA.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DThe%2520multifaceted%2520role%2520of%2520kinases%2520in%2520amyotrophic%2520lateral%2520sclerosis%253A%2520genetic%252C%2520pathological%2520and%2520therapeutic%2520implications%26jtitle%3DBrain%26date%3D2020%26volume%3D143%26spage%3D1651%26epage%3D1673%26doi%3D10.1093%2Fbrain%2Fawaa022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staats, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolwine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsodendris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangoor, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennes, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belgard, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunseich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasterkamp, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlokovic, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichida, J. K.</span></span> <span> </span><span class="NLM_article-title">Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nm.4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnm.4490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29400714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=313-325&author=Y.+Shiauthor=S.+Linauthor=K.+A.+Staatsauthor=Y.+Liauthor=W.+H.+Changauthor=S.+T.+Hungauthor=E.+Hendricksauthor=G.+R.+Linaresauthor=Y.+Wangauthor=E.+Y.+Sonauthor=X.+Wenauthor=K.+Kislerauthor=B.+Wilkinsonauthor=L.+Menendezauthor=T.+Sugawaraauthor=P.+Woolwineauthor=M.+Huangauthor=M.+J.+Cowanauthor=B.+Geauthor=N.+Koutsodendrisauthor=K.+P.+Sandorauthor=J.+Kombergauthor=V.+R.+Vangoorauthor=K.+Senthilkumarauthor=V.+Hennesauthor=C.+Seahauthor=A.+R.+Nelsonauthor=T.+Y.+Chengauthor=S.+J.+Leeauthor=P.+R.+Augustauthor=J.+A.+Chenauthor=N.+Wisniewskiauthor=V.+Hanson-Smithauthor=T.+G.+Belgardauthor=A.+Zhangauthor=M.+Cobaauthor=C.+Grunseichauthor=M.+E.+Wardauthor=L.+H.+van+den+Bergauthor=R.+J.+Pasterkampauthor=D.+Trottiauthor=B.+V.+Zlokovicauthor=J.+K.+Ichida&title=Haploinsufficiency+leads+to+neurodegeneration+in+C9ORF72+ALS%2FFTD+human+induced+motor+neurons&doi=10.1038%2Fnm.4490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons</span></div><div class="casAuthors">Shi, Yingxiao; Lin, Shaoyu; Staats, Kim A.; Li, Yichen; Chang, Wen-Hsuan; Hung, Shu-Ting; Hendricks, Eric; Linares, Gabriel R.; Wang, Yaoming; Son, Esther Y.; Wen, Xinmei; Kisler, Kassandra; Wilkinson, Brent; Menendez, Louise; Sugawara, Tohru; Woolwine, Phillip; Huang, Mickey; Cowan, Michael J.; Ge, Brandon; Koutsodendris, Nicole; Sandor, Kaitlin P.; Komberg, Jacob; Vangoor, Vamshidhar R.; Senthilkumar, Ketharini; Hennes, Valerie; Seah, Carina; Nelson, Amy R.; Cheng, Tze-Yuan; Lee, Shih-Jong J.; August, Paul R.; Chen, Jason A.; Wisniewski, Nicholas; Hanson-Smith, Victor; Belgard, T. Grant; Zhang, Alice; Coba, Marcelo; Grunseich, Chris; Ward, Michael E.; van den Berg, Leonard H.; Pasterkamp, R. Jeroen; Trotti, Davide; Zlokovic, Berislav V.; Ichida, Justin K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear.  Using human induced motor neurons (iMNs), we found that repeat-expanded C9ORF72 was haploinsufficient in ALS.  We found that C9ORF72 interacted with endosomes and was required for normal vesicle trafficking and lysosomal biogenesis in motor neurons.  Repeat expansion reduced C9ORF72 expression, triggering neurodegeneration through two mechanisms: accumulation of glutamate receptors, leading to excitotoxicity, and impaired clearance of neurotoxic dipeptide repeat proteins derived from the repeat expansion.  Thus, cooperativity between gain- and loss-of-function mechanisms led to neurodegeneration.  Restoring C9ORF72 levels or augmenting its function with constitutively active RAB5 or chem. modulators of RAB5 effectors rescued patient neuron survival and ameliorated neurodegenerative processes in both gain- and loss-of-function C9ORF72 mouse models.  Thus, modulating vesicle trafficking was able to rescue neurodegeneration caused by the C9ORF72 repeat expansion.  Coupled with rare mutations in ALS2, FIG4, CHMP2B, OPTN and SQSTM1, our results reveal mechanistic convergence on vesicle trafficking in ALS and FTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZRo0XUC17WrVg90H21EOLACvtfcHk0lh5LdNcXnZ6Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7Y%253D&md5=0d79b78361920b00ef1c4e8d397fd4ce</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnm.4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4490%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DStaats%26aufirst%3DK.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DW.%2BH.%26aulast%3DHung%26aufirst%3DS.%2BT.%26aulast%3DHendricks%26aufirst%3DE.%26aulast%3DLinares%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSon%26aufirst%3DE.%2BY.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DKisler%26aufirst%3DK.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DMenendez%26aufirst%3DL.%26aulast%3DSugawara%26aufirst%3DT.%26aulast%3DWoolwine%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DM.%2BJ.%26aulast%3DGe%26aufirst%3DB.%26aulast%3DKoutsodendris%26aufirst%3DN.%26aulast%3DSandor%26aufirst%3DK.%2BP.%26aulast%3DKomberg%26aufirst%3DJ.%26aulast%3DVangoor%26aufirst%3DV.%2BR.%26aulast%3DSenthilkumar%26aufirst%3DK.%26aulast%3DHennes%26aufirst%3DV.%26aulast%3DSeah%26aufirst%3DC.%26aulast%3DNelson%26aufirst%3DA.%2BR.%26aulast%3DCheng%26aufirst%3DT.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DAugust%26aufirst%3DP.%2BR.%26aulast%3DChen%26aufirst%3DJ.%2BA.%26aulast%3DWisniewski%26aufirst%3DN.%26aulast%3DHanson-Smith%26aufirst%3DV.%26aulast%3DBelgard%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DCoba%26aufirst%3DM.%26aulast%3DGrunseich%26aufirst%3DC.%26aulast%3DWard%26aufirst%3DM.%2BE.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DL.%2BH.%26aulast%3DPasterkamp%26aufirst%3DR.%2BJ.%26aulast%3DTrotti%26aufirst%3DD.%26aulast%3DZlokovic%26aufirst%3DB.%2BV.%26aulast%3DIchida%26aufirst%3DJ.%2BK.%26atitle%3DHaploinsufficiency%2520leads%2520to%2520neurodegeneration%2520in%2520C9ORF72%2520ALS%252FFTD%2520human%2520induced%2520motor%2520neurons%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D313%26epage%3D325%26doi%3D10.1038%2Fnm.4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span> <span> </span><span class="NLM_article-title">From hitchhiker to hijacker: pathogen exploitation of endosomal phosphoinositides (1)</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1139/bcb-2017-0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1139%2Fbcb-2017-0317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29746785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=1-9&author=S.+Qiuauthor=M.+Cote&title=From+hitchhiker+to+hijacker%3A+pathogen+exploitation+of+endosomal+phosphoinositides+%281%29&doi=10.1139%2Fbcb-2017-0317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">From hitchhiker to hijacker: pathogen exploitation of endosomal phosphoinositides1</span></div><div class="casAuthors">Qiu, Shirley; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Signalling through phosphoinositide lipids is essential for regulating many cellular processes, including endosomal trafficking.  A no. of intracellular pathogens have found ways to subvert host trafficking pathways via exploitation of endosomal phosphoinositides.  This review will discuss how pathogens such as bacteria, viruses, and eukaryotic parasites depend on endosomal phosphoinositides for infection as well as the mechanisms through which some are able to actively manipulate these signalling lipids to facilitate invasion, survival, replication, and immune evasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHame4AaAjTrVg90H21EOLACvtfcHk0lhwR-SjZumSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsL7F&md5=54653a8857f5729eeb38051eeebf8d7f</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1139%2Fbcb-2017-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fbcb-2017-0317%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DM.%26atitle%3DFrom%2520hitchhiker%2520to%2520hijacker%253A%2520pathogen%2520exploitation%2520of%2520endosomal%2520phosphoinositides%2520%25281%2529%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2019%26volume%3D97%26spage%3D1%26epage%3D9%26doi%3D10.1139%2Fbcb-2017-0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huotari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helenius, A.</span></span> <span> </span><span class="NLM_article-title">Late-penetrating viruses</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2011.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.coviro.2011.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22440565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=35-43&author=P.+Y.+Lozachauthor=J.+Huotariauthor=A.+Helenius&title=Late-penetrating+viruses&doi=10.1016%2Fj.coviro.2011.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Late-penetrating viruses</span></div><div class="casAuthors">Lozach, Pierre-Yves; Huotari, Jatta; Helenius, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-43</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Many enveloped and non-enveloped animal viruses delay the penetration into the cytosol of host cells until they have arrived to endocytic vacuoles deep in the cytoplasm.  The late timing is generally detd. by a low pH-threshold for the acid-activated penetration process (pH 6.2-4.9), but there can be a combination of other reasons for a delay.  Since late-penetrating viruses (L-PVs) must be sorted into the degradative pathway, they are particularly sensitive to perturbations that interfere with mol. sorting and proper maturation of endosomes, including switching of Rabs, formation of intraluminal vesicles, and microtubule-mediated transport.  In this short review, we focus on L-PVs from several virus families, and their interactions with the endocytic machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3_5Yz_K9K7Vg90H21EOLACvtfcHk0lhwR-SjZumSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtL3I&md5=7bbfd1cf3008b8a75ea1b4670b6dc44c</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2011.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2011.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLozach%26aufirst%3DP.%2BY.%26aulast%3DHuotari%26aufirst%3DJ.%26aulast%3DHelenius%26aufirst%3DA.%26atitle%3DLate-penetrating%2520viruses%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2011%26volume%3D1%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.coviro.2011.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta-Geijo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galindo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernaez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quetglas, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau-Mena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, C.</span></span> <span> </span><span class="NLM_article-title">Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine fever virus entry</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e48853</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0048853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0048853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23133661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWjsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=M.+A.+Cuesta-Geijoauthor=I.+Galindoauthor=B.+Hernaezauthor=J.+I.+Quetglasauthor=I.+Dalmau-Menaauthor=C.+Alonso&title=Endosomal+maturation%2C+Rab7+GTPase+and+phosphoinositides+in+African+swine+fever+virus+entry&doi=10.1371%2Fjournal.pone.0048853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine fever virus entry</span></div><div class="casAuthors">Cuesta-Geijo, Miguel A.; Galindo, Inmaculada; Hernaez, Bruno; Quetglas, Jose Ignacio; Dalmau-Mena, Inmaculada; Alonso, Covadonga</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e48853</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The authors analyzed the dependence of African swine fever virus (ASFV) infection on the integrity of the endosomal pathway.  Using confocal immunofluorescence with antibodies against viral capsid proteins, we found colocalization of incoming viral particles with early endosomes (EE) during the first minutes of infection.  Conversely, viral capsid protein was not detected in acidic late endosomal compartments, multivesicular bodies (MVBs), late endosomes (LEs) or lysosomes (LY).  Using an antibody against a viral inner core protein, we found colocalization of viral cores with late compartments from 30 to 60 min postinfection.  The absence of capsid protein staining in LEs and LYs suggested that virus desencapsidation would take place at the acid pH of these organelles.  In fact, inhibitors of intraluminal acidification of endosomes caused retention of viral capsid staining virions in Rab7 expressing endosomes and more importantly, severely impaired subsequent viral protein prodn.  Endosomal acidification in the first hour after virus entry was essential for successful infection but not thereafter.  In addn., altering the balance of phosphoinositides (PIs) which are responsible of the maintenance of the endocytic pathway impaired ASFV infection.  Early infection steps were dependent on the prodn. of phosphatidylinositol 3-phosphate (PtdIns3P) which is involved in EE maturation and multivesicular body (MVB) biogenesis and on the interconversion of PtdIns3P to phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2).  Likewise, GTPase Rab7 activity should remain intact, as well as processes related to LE compartment physiol., which are crucial during early infection.  The data demonstrate that the EE and LE compartments and the integrity of the endosomal maturation pathway orchestrated by Rab proteins and PIs play a central role during early stages of ASFV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQBz20LmA_rVg90H21EOLACvtfcHk0lhwR-SjZumSZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWjsbzN&md5=256c351c18985dab5f4002e90b263d75</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048853%26sid%3Dliteratum%253Aachs%26aulast%3DCuesta-Geijo%26aufirst%3DM.%2BA.%26aulast%3DGalindo%26aufirst%3DI.%26aulast%3DHernaez%26aufirst%3DB.%26aulast%3DQuetglas%26aufirst%3DJ.%2BI.%26aulast%3DDalmau-Mena%26aufirst%3DI.%26aulast%3DAlonso%26aufirst%3DC.%26atitle%3DEndosomal%2520maturation%252C%2520Rab7%2520GTPase%2520and%2520phosphoinositides%2520in%2520African%2520swine%2520fever%2520virus%2520entry%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0048853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005540</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0lhdVSaZ3b-3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlauf, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cureton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">20803</span>– <span class="NLM_lpage">20813</span>, <span class="refDoi"> DOI: 10.1073/pnas.2007837117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.2007837117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32764148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=20803-20813&author=Y.+L.+Kangauthor=Y.+Y.+Chouauthor=P.+W.+Rothlaufauthor=Z.+Liuauthor=T.+K.+Sohauthor=D.+Curetonauthor=J.+B.+Caseauthor=R.+E.+Chenauthor=M.+S.+Diamondauthor=S.+P.+J.+Whelanauthor=T.+Kirchhausen&title=Inhibition+of+PIKfyve+kinase+prevents+infection+by+Zaire+ebolavirus+and+SARS-CoV-2&doi=10.1073%2Fpnas.2007837117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span></div><div class="casAuthors">Kang, Yuan-Lin; Chou, Yi-ying; Rothlauf, Paul W.; Liu, Zhuoming; Soh, Timothy K.; Cureton, David; Case, James Brett; Chen, Rita E.; Diamond, Michael S.; Whelan, Sean P. J.; Kirchhausen, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20803-20813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Virus entry is a multistep process.  It initiates when the virus attaches to the host cell and ends when the viral contents reach the cytosol.  Genetically unrelated viruses can subvert analogous subcellular mechanisms and use similar trafficking pathways for successful entry.  Antiviral strategies targeting early steps of infection are therefore appealing, particularly when the probability for successful interference through a common step is highest.  We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) contg. the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small-mol. inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.  We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.  These results define tools for studying the intracellular trafficking of pathogens elicited by inhibition of PIKfyve kinase and suggest the potential for targeting this kinase in developing small-mol. antivirals against SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYcbVh--KCN7Vg90H21EOLACvtfcHk0lhdVSaZ3b-3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP&md5=a7e1b43b16edffb6dabc91258b88ab7c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2007837117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2007837117%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BL.%26aulast%3DChou%26aufirst%3DY.%2BY.%26aulast%3DRothlauf%26aufirst%3DP.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSoh%26aufirst%3DT.%2BK.%26aulast%3DCureton%26aufirst%3DD.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DR.%2BE.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DWhelan%26aufirst%3DS.%2BP.%2BJ.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520PIKfyve%2520kinase%2520prevents%2520infection%2520by%2520Zaire%2520ebolavirus%2520and%2520SARS-CoV-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D20803%26epage%3D20813%26doi%3D10.1073%2Fpnas.2007837117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filone, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>477</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1038/nature10380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnature10380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21866101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=344-348&author=M.+Coteauthor=J.+Misasiauthor=T.+Renauthor=A.+Bruchezauthor=K.+Leeauthor=C.+M.+Filoneauthor=L.+Hensleyauthor=Q.+Liauthor=D.+Oryauthor=K.+Chandranauthor=J.+Cunningham&title=Small+molecule+inhibitors+reveal+Niemann-Pick+C1+is+essential+for+Ebola+virus+infection&doi=10.1038%2Fnature10380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span></div><div class="casAuthors">Cote, Marceline; Misasi, John; Ren, Tao; Bruchez, Anna; Lee, Kyung-Ae; Filone, Claire Marie; Hensley, Lisa; Li, Qi; Ory, Daniel; Chandran, Kartik; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7364</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa.  The clin. symptoms are manifestations of the massive prodn. of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%.  The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV.  Here, the authors report the identification of a novel benzylpiperazine adamantane diamide-derived compd. that inhibits EboV infection.  Using mutant cell lines and informative derivs. of the lead compd., they show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1).  They find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compds. interfere with GP binding to NPC1.  Combined with the results of previous studies on GP structure and function, these findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit.  Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH09MFk31Ol7Vg90H21EOLACvtfcHk0lhdVSaZ3b-3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI&md5=99e7763b2b95af9d046992a9d36fd3a2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnature10380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10380%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DM.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DFilone%26aufirst%3DC.%2BM.%26aulast%3DHensley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DOry%26aufirst%3DD.%26aulast%3DChandran%26aufirst%3DK.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520reveal%2520Niemann-Pick%2520C1%2520is%2520essential%2520for%2520Ebola%2520virus%2520infection%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D344%26epage%3D348%26doi%3D10.1038%2Fnature10380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warkentin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salambanga, F. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobasa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span> <span> </span><span class="NLM_article-title">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2017.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.virol.2017.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29031163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=17&author=S.+Qiuauthor=A.+Leungauthor=Y.+Boauthor=R.+A.+Kozakauthor=S.+P.+Anandauthor=C.+Warkentinauthor=F.+D.+R.+Salambangaauthor=J.+Cuiauthor=G.+Kobingerauthor=D.+Kobasaauthor=M.+Cote&title=Ebola+virus+requires+phosphatidylinositol+%283%2C5%29+bisphosphate+production+for+efficient+viral+entry&doi=10.1016%2Fj.virol.2017.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span></div><div class="casAuthors">Qiu, Shirley; Leung, Anders; Bo, Yuxia; Kozak, Robert A.; Anand, Sai Priya; Warkentin, Corina; Salambanga, Fabiola D. R.; Cui, Jennifer; Kobinger, Gary; Kobasa, Darwyn; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For entry, Ebola virus (EBOV) requires the interaction of its viral glycoprotein with the cellular protein Niemann-Pick C1 (NPC1) which resides in late endosomes and lysosomes.  How EBOV is trafficked and delivered to NPC1 and whether this is pos. regulated during entry remain unclear.  Here, we show that the PIKfyve-ArPIKfyve-Sac3 cellular complex, which is involved in the metab. of phosphatidylinositol (3,5) bisphosphate (PtdIns(3,5)P2), is crit. for EBOV infection.  Although the expression of all subunits of the complex was required for efficient entry, PIKfyve kinase activity was specifically crit. for entry by all pathogenic filoviruses.  Inhibition of PIKfyve prevented colocalization of EBOV with NPC1 and led to virus accumulation in intracellular vesicles with characteristics of early endosomes.  Importantly, genetically-encoded phosphoinositide probes revealed an increase in PtdIns(3,5)P2-pos. vesicles in cells during EBOV entry.  Taken together, our studies suggest that EBOV requires PtdIns(3,5)P2 prodn. in cells to promote efficient delivery to NPC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBj4bGDkDZELVg90H21EOLACvtfcHk0lhB6H4bglni1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI&md5=1a0bed541a6186ca937abcc2cabc4bb6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2017.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2017.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAnand%26aufirst%3DS.%2BP.%26aulast%3DWarkentin%26aufirst%3DC.%26aulast%3DSalambanga%26aufirst%3DF.%2BD.%2BR.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DKobinger%26aufirst%3DG.%26aulast%3DKobasa%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DM.%26atitle%3DEbola%2520virus%2520requires%2520phosphatidylinositol%2520%25283%252C5%2529%2520bisphosphate%2520production%2520for%2520efficient%2520viral%2520entry%26jtitle%3DVirology%26date%3D2018%26volume%3D513%26spage%3D17%26doi%3D10.1016%2Fj.virol.2017.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine-Weber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiergens, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, S.</span></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2020.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32142651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=271-280&author=M.+Hoffmannauthor=H.+Kleine-Weberauthor=S.+Schroederauthor=N.+Krugerauthor=T.+Herrlerauthor=S.+Erichsenauthor=T.+S.+Schiergensauthor=G.+Herrlerauthor=N.+H.+Wuauthor=A.+Nitscheauthor=M.+A.+Mullerauthor=C.+Drostenauthor=S.+Pohlmann&title=SARS-CoV-2+cell+entry+depends+on+ACE2+and+TMPRSS2+and+is+blocked+by+a+clinically+proven+protease+inhibitor&doi=10.1016%2Fj.cell.2020.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span></div><div class="casAuthors">Hoffmann, Markus; Kleine-Weber, Hannah; Schroeder, Simon; Krueger, Nadine; Herrler, Tanja; Erichsen, Sandra; Schiergens, Tobias S.; Herrler, Georg; Wu, Nai-Huei; Nitsche, Andreas; Mueller, Marcel A.; Drosten, Christian; Poehlmann, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280.e8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency.  Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases.  Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets.  Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.  A TMPRSS2 inhibitor approved for clin. use blocked entry and might constitute a treatment option.  Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry.  Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq92X1lVQaLirVg90H21EOLACvtfcHk0lhB6H4bglni1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D&md5=60aea5c939a2d4df034a91d6198fb3ef</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DKleine-Weber%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DKruger%26aufirst%3DN.%26aulast%3DHerrler%26aufirst%3DT.%26aulast%3DErichsen%26aufirst%3DS.%26aulast%3DSchiergens%26aufirst%3DT.%2BS.%26aulast%3DHerrler%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DN.%2BH.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%2BA.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DPohlmann%26aufirst%3DS.%26atitle%3DSARS-CoV-2%2520cell%2520entry%2520depends%2520on%2520ACE2%2520and%2520TMPRSS2%2520and%2520is%2520blocked%2520by%2520a%2520clinically%2520proven%2520protease%2520inhibitor%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D271%26epage%3D280%26doi%3D10.1016%2Fj.cell.2020.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilieva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somasundaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzuriaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenough, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzan, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1038/nature02145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnature02145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=14647384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1GlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=450-454&author=W.+Liauthor=M.+J.+Mooreauthor=N.+Vasilievaauthor=J.+Suiauthor=S.+K.+Wongauthor=M.+A.+Berneauthor=M.+Somasundaranauthor=J.+L.+Sullivanauthor=K.+Luzuriagaauthor=T.+C.+Greenoughauthor=H.+Choeauthor=M.+Farzan&title=Angiotensin-converting+enzyme+2+is+a+functional+receptor+for+the+SARS+coronavirus&doi=10.1038%2Fnature02145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</span></div><div class="casAuthors">Li, Wenhui; Moore, Michael J.; Vasilieva, Natalya; Sui, Jianhua; Wong, Swee Kee; Berne, Michael A.; Somasundaran, Mohan; Sullivan, John L.; Luzuriaga, Katherine; Greenough, Thomas C.; Choe, Hyeryun; Farzan, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6965</span>),
    <span class="NLM_cas:pages">450-454</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), assoc. with cellular receptors to mediate infection of their target cells.  Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SARS coronavirus (SARS-CoV)-permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein.  We found that a sol. form of ACE2, but not of the related enzyme ACE1, blocked assocn. of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein.  Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells.  Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells.  Together our data indicate that ACE2 is a functional receptor for SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqK17Cf3rQS7Vg90H21EOLACvtfcHk0lhB6H4bglni1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1GlsLs%253D&md5=884851c53d0f77cbdd6520aaa79efbed</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature02145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02145%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26aulast%3DVasilieva%26aufirst%3DN.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%2BK.%26aulast%3DBerne%26aufirst%3DM.%2BA.%26aulast%3DSomasundaran%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DJ.%2BL.%26aulast%3DLuzuriaga%26aufirst%3DK.%26aulast%3DGreenough%26aufirst%3DT.%2BC.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DFarzan%26aufirst%3DM.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520is%2520a%2520functional%2520receptor%2520for%2520the%2520SARS%2520coronavirus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D450%26epage%3D454%26doi%3D10.1038%2Fnature02145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgonovo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meldolesi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">The small chemical vacuolin-1 inhibits Ca(2+)-dependent lysosomal exocytosis but not cell resealing</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7400243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fsj.embor.7400243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15332114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=883-888&author=J.+Cernyauthor=Y.+Fengauthor=A.+Yuauthor=K.+Miyakeauthor=B.+Borgonovoauthor=J.+Klumpermanauthor=J.+Meldolesiauthor=P.+L.+McNeilauthor=T.+Kirchhausen&title=The+small+chemical+vacuolin-1+inhibits+Ca%282%2B%29-dependent+lysosomal+exocytosis+but+not+cell+resealing&doi=10.1038%2Fsj.embor.7400243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The small chemical vacuolin-1 inhibits Ca2+-dependent lysosomal exocytosis but not cell resealing</span></div><div class="casAuthors">Cerny, Jan; Feng, Yan; Yu, Anan; Miyake, Katsuya; Borgonovo, Barbara; Klumperman, Judith; Meldolesi, Jacopo; McNeil, Paul L.; Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">883-888</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Resealing after wounding, the process of repair following plasma membrane damage, requires exocytosis.  Vacuolins are mols. that induce rapid formation of large, swollen structures derived from endosomes and lysosomes by homotypic fusion combined with uncontrolled fusion of the inner and limiting membranes of these organelles.  Vacuolin-1, the most potent compd., blocks the Ca2+-dependent exocytosis of lysosomes induced by ionomycin or plasma membrane wounding, without affecting the process of resealing.  In contrast, other cell structures and membrane trafficking functions including exocytosis of enlargeosomes are unaffected.  Because cells heal normally in the presence of vacuolin-1, we suggest that lysosomes are dispensable for resealing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx4hEOqmL3SbVg90H21EOLACvtfcHk0liBRM0HlCQTfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Kgtro%253D&md5=bf07123ddc68d80d585e8066914f6a0c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7400243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7400243%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DA.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DBorgonovo%26aufirst%3DB.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DMeldolesi%26aufirst%3DJ.%26aulast%3DMcNeil%26aufirst%3DP.%2BL.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DThe%2520small%2520chemical%2520vacuolin-1%2520inhibits%2520Ca%25282%252B%2529-dependent%2520lysosomal%2520exocytosis%2520but%2520not%2520cell%2520resealing%26jtitle%3DEMBO%2520Rep.%26date%3D2004%26volume%3D5%26spage%3D883%26epage%3D888%26doi%3D10.1038%2Fsj.embor.7400243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Blanc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luyet, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petiot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaurex, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberg, J.</span></span> <span> </span><span class="NLM_article-title">Endosome-to-cytosol transport of viral nucleocapsids</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1038/ncb1269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fncb1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15951806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslWhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=653-664&author=I.+Le+Blancauthor=P.+P.+Luyetauthor=V.+Ponsauthor=C.+Fergusonauthor=N.+Emansauthor=A.+Petiotauthor=N.+Mayranauthor=N.+Demaurexauthor=J.+Faureauthor=R.+Sadoulauthor=R.+G.+Partonauthor=J.+Gruenberg&title=Endosome-to-cytosol+transport+of+viral+nucleocapsids&doi=10.1038%2Fncb1269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Endosome-to-cytosol transport of viral nucleocapsids</span></div><div class="casAuthors">Le Blanc, Isabelle; Luyet, Pierre-Philippe; Pons, Veronique; Ferguson, Charles; Emans, Neil; Petiot, Anne; Mayran, Nathalie; Demaurex, Nicolas; Faure, Julien; Sadoul, Remy; Parton, Robert G.; Gruenberg, J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">During viral infection, fusion of the viral envelope with endosomal membranes and nucleocapsid release were thought to be concomitant events.  We show here that for the vesicular stomatitis virus they occur sequentially, at two successive steps of the endocytic pathway.  Fusion already occurs in transport intermediates between early and late endosomes, presumably releasing the nucleocapsid within the lumen of intra-endosomal vesicles, where it remains hidden.  Transport to late endosomes is then required for the nucleocapsid to be delivered to the cytoplasm.  This last step, which initiates infection, depends on the late endosomal lipid lysobisphosphatidic acid (LBPA) and its putative effector Alix/AIP1, and is regulated by phosphatidylinositol-3-phosphate (PtdIns(3)P) signaling via the PtdIns(3)P-binding protein Snx16.  We conclude that the nucleocapsid is exported into the cytoplasm after the back-fusion of internal vesicles with the limiting membrane of late endosomes, and that this process is controlled by the phospholipids LBPA and PtdIns(3)P and their effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy7VMWqmq1Y7Vg90H21EOLACvtfcHk0liBRM0HlCQTfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslWhtLw%253D&md5=f6e1e7a16b55f62007b6767844fba82e</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fncb1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1269%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBlanc%26aufirst%3DI.%26aulast%3DLuyet%26aufirst%3DP.%2BP.%26aulast%3DPons%26aufirst%3DV.%26aulast%3DFerguson%26aufirst%3DC.%26aulast%3DEmans%26aufirst%3DN.%26aulast%3DPetiot%26aufirst%3DA.%26aulast%3DMayran%26aufirst%3DN.%26aulast%3DDemaurex%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DJ.%26aulast%3DSadoul%26aufirst%3DR.%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DGruenberg%26aufirst%3DJ.%26atitle%3DEndosome-to-cytosol%2520transport%2520of%2520viral%2520nucleocapsids%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D653%26epage%3D664%26doi%3D10.1038%2Fncb1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbloom, S.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/ibd.21159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fibd.21159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19918967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1209-1218&author=B.+E.+Sandsauthor=E.+W.+Jacobsonauthor=T.+Sylwestrowiczauthor=Z.+Younesauthor=G.+Drydenauthor=R.+Fedorakauthor=S.+Greenbloom&title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+oral+interleukin-12%2F23+inhibitor+apilimod+mesylate+for+treatment+of+active+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease</span></div><div class="casAuthors">Sands Bruce E; Jacobson Eric W; Sylwestrowicz Thomas; Younes Ziad; Dryden Gerald; Fedorak Richard; Greenbloom Susan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1209-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD).  We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD.  METHODS:  We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450).  Patients were stratified according to C-reactive protein (CRP) levels and corticosteroid use and were randomly assigned to receive placebo or apilimod mesylate 50 mg daily or 100 mg daily.  The study was divided into an induction phase (43 days) and a maintenance phase (125 days).  The primary analysis involved a comparison of the proportion of patients experiencing clinical response, defined as at least a 100-point decrease in CDAI score from baseline at day 29.  Data on adverse events were also collected.  RESULTS:  In all, 220 of the planned 282 patients were enrolled when the Data Monitoring Committee determined that the drug was not efficacious as a treatment and closed enrollment.  A clinical response was experienced by 18 patients (24.7%) in the 50-mg daily (QD) group (n = 73) and 19 patients (25.7%) in the 100 mg QD group (n = 74), as compared with 21 patients (28.8%) in the placebo group (n = 73) on day 29 (P = 0.71 for each comparison).  No significant adverse safety signal was observed.  CONCLUSIONS:  Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKP1Ngip31hrrIbt-tGZmxfW6udTcc2ebIGaLaO6-y1rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D&md5=4e87fe88e4b06cb7a47d7554a6597a4a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fibd.21159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21159%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DDryden%26aufirst%3DG.%26aulast%3DFedorak%26aufirst%3DR.%26aulast%3DGreenbloom%26aufirst%3DS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520oral%2520interleukin-12%252F23%2520inhibitor%2520apilimod%2520mesylate%2520for%2520treatment%2520of%2520active%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2010%26volume%3D16%26spage%3D1209%26epage%3D1218%26doi%3D10.1002%2Fibd.21159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatcherian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e35069</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0035069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0035069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22493730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVyqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=Y.+Wadaauthor=I.+Cardinaleauthor=A.+Khatcherianauthor=J.+Chuauthor=A.+B.+Kantorauthor=A.+B.+Gottliebauthor=N.+Tatsutaauthor=E.+Jacobsonauthor=J.+Barsoumauthor=J.+G.+Krueger&title=Apilimod+inhibits+the+production+of+IL-12+and+IL-23+and+reduces+dendritic+cell+infiltration+in+psoriasis&doi=10.1371%2Fjournal.pone.0035069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis</span></div><div class="casAuthors">Wada, Yumiko; Cardinale, Irma; Khatcherian, Artemis; Chu, John; Kantor, Aaron B.; Gottlieb, Alice B.; Tatsuta, Noriaki; Jacobson, Eric; Barsoum, James; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e35069</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Psoriasis is characterized by hyperplasia of the epidermis and infiltration of leukocytes into both the dermis and epidermis.  IL-23, a key cytokine that induces TH17 cells, has been found to play a crit. role in the pathogenesis of psoriasis.  Apilimod is a small-mol. compd. that selectively suppresses synthesis of IL-12 and IL-23.  An open-label clin. study of oral administration of apilimod was conducted in patients with psoriasis.  Substantial improvements in histol. and clin. measurements were obsd. in patients receiving 70mg QD.  The expression of IL-23p19 and IL-12/IL-23p40 in skin lesions was significantly reduced in this dose group, with a simultaneous increase in IL-10 obsd.  A decrease in the levels of TH1 and TH17 cytokines/chemokines in skin lesions followed these p19 and p40 changes.  In parallel, a redn. in skin-infiltrating CD11c+ dendritic cells and CD3+ T cells was seen, with a greater decrease in the CD11c+ population.  This was accompanied by increases in T and B cells, and decreases in neutrophils and eosinophils in the periphery.  This study demonstrates the immunomodulatory activity of apilimod and provides clin. evidence supporting the inhibition of IL-12/IL-23 synthesis for the treatment of TH1- and TH17-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxAQtGmEdUGbVg90H21EOLACvtfcHk0lh2w5BhDdZc2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVyqu7c%253D&md5=18f569c46e0e86ee9167ceb96cce2b49</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035069%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DCardinale%26aufirst%3DI.%26aulast%3DKhatcherian%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DKantor%26aufirst%3DA.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DJacobson%26aufirst%3DE.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DApilimod%2520inhibits%2520the%2520production%2520of%2520IL-12%2520and%2520IL-23%2520and%2520reduces%2520dendritic%2520cell%2520infiltration%2520in%2520psoriasis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0035069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazetani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span> <span> </span><span class="NLM_article-title">Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2F1873-3468.12195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27135648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KrurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=1576-1585&author=O.+Sanoauthor=K.+Kazetaniauthor=M.+Funataauthor=Y.+Fukudaauthor=J.+Matsuiauthor=H.+Iwata&title=Vacuolin-1+inhibits+autophagy+by+impairing+lysosomal+maturation+via+PIKfyve+inhibition&doi=10.1002%2F1873-3468.12195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition</span></div><div class="casAuthors">Sano, Osamu; Kazetani, Kenichi; Funata, Masaaki; Fukuda, Yasunori; Matsui, Junji; Iwata, Hidehisa</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1576-1585</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Lysosomal protein degrdn. via autophagy strictly regulates cellular protein homoeostasis.  Here, the authors performed high-content screening to identify compds. that inhibit autophagy pathways.  The authors obtained 11 hit compds. and performed cluster anal. using cellular morphol. information.  Vacuolin-1, which induces the formation of giant vacuoles and is a target unknown compd., clustered with known phosphatidylinositol inositol kinase PIKfyve inhibitor YM 201636.  The authors further confirmed that vacuolin-1 is a potent PIKfyve inhibitor, and finally concluded that PIKfyve inhibitors are novel chem. tools for regulating autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK_2ltJVHVo7Vg90H21EOLACvtfcHk0lh2w5BhDdZc2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KrurfO&md5=6be36200b98fce892f0be438731ddf9d</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12195%26sid%3Dliteratum%253Aachs%26aulast%3DSano%26aufirst%3DO.%26aulast%3DKazetani%26aufirst%3DK.%26aulast%3DFunata%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DIwata%26aufirst%3DH.%26atitle%3DVacuolin-1%2520inhibits%2520autophagy%2520by%2520impairing%2520lysosomal%2520maturation%2520via%2520PIKfyve%2520inhibition%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D1576%26epage%3D1585%26doi%3D10.1002%2F1873-3468.12195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span> <span> </span><span class="NLM_article-title">GPCR signaling regulation: the role of GRKs and arrestins</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2019.00125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30837883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaktLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=125&author=V.+V.+Gurevichauthor=E.+V.+Gurevich&title=GPCR+signaling+regulation%3A+the+role+of+GRKs+and+arrestins&doi=10.3389%2Ffphar.2019.00125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR signaling regulation: the role of GRKs and arrestins</span></div><div class="casAuthors">Gurevich, Vsevolod V.; Gurevich, Eugenia V.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Every animal species expresses hundreds of different G protein-coupled receptors (GPCRs) that respond to a wide variety of external stimuli.  GPCRs-driven signaling pathways are involved in pretty much every physiol. function and in many pathologies.  Therefore, GPCRs are targeted by about a third of clin. used drugs.  The signaling of most GPCRs via G proteins is terminated by the phosphorylation of active receptor by specific kinases (GPCR kinases, or GRKs) and subsequent binding of arrestin proteins, that selectively recognize active phosphorylated receptors.  In addn., GRKs and arrestins play a role in multiple signaling pathways in the cell, both GPCR-initiated and receptor-independent.  Here we focus on the mechanisms of GRK- and arrestin-mediated regulation of GPCR signaling, which includes homologous desensitization and redirection of signaling to addnl. pathways by bound arrestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq199I_nwuu6LVg90H21EOLACvtfcHk0lgRCs1UC0UY9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaktLzJ&md5=bd1f9e684e6cad5d0c4fdd59bd955e72</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00125%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26atitle%3DGPCR%2520signaling%2520regulation%253A%2520the%2520role%2520of%2520GRKs%2520and%2520arrestins%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D125%26doi%3D10.3389%2Ffphar.2019.00125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span> <span> </span><span class="NLM_article-title">ABL tyrosine kinases: evolution of function, regulation, and specificity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">re6</span> <span class="refDoi"> DOI: 10.1126/scisignal.3139re6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscisignal.3139re6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20841568" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&author=J.+Colicelli&title=ABL+tyrosine+kinases%3A+evolution+of+function%2C+regulation%2C+and+specificity&doi=10.1126%2Fscisignal.3139re6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.3139re6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.3139re6%26sid%3Dliteratum%253Aachs%26aulast%3DColicelli%26aufirst%3DJ.%26atitle%3DABL%2520tyrosine%2520kinases%253A%2520evolution%2520of%2520function%252C%2520regulation%252C%2520and%2520specificity%26jtitle%3DSci.%2520Signaling%26date%3D2010%26volume%3D3%26doi%3D10.1126%2Fscisignal.3139re6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+middle+east+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0lgRCs1UC0UY9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assaad, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaad-Khalil, S.</span></span> <span> </span><span class="NLM_article-title">Imatinib a tyrosine kinase inhibitor: a potential treatment for SARS- COV-2 induced pneumonia</span>. <i>Alex. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1080/20905068.2020.1778417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F20905068.2020.1778417" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=68-72&author=H.+S.+Assaadauthor=S.+Assaad-Khalil&title=Imatinib+a+tyrosine+kinase+inhibitor%3A+a+potential+treatment+for+SARS-+COV-2+induced+pneumonia&doi=10.1080%2F20905068.2020.1778417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1080%2F20905068.2020.1778417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F20905068.2020.1778417%26sid%3Dliteratum%253Aachs%26aulast%3DAssaad%26aufirst%3DH.%2BS.%26aulast%3DAssaad-Khalil%26aufirst%3DS.%26atitle%3DImatinib%2520a%2520tyrosine%2520kinase%2520inhibitor%253A%2520a%2520potential%2520treatment%2520for%2520SARS-%2520COV-2%2520induced%2520pneumonia%26jtitle%3DAlex.%2520J.%2520Med.%26date%3D2020%26volume%3D56%26spage%3D68%26epage%3D72%26doi%3D10.1080%2F20905068.2020.1778417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Imatinib is not a potent anti-SARS-CoV-2 drug</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3087</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-01045-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41375-020-01045-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32999432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=3085-3087&author=H.+Zhaoauthor=M.+Mendenhallauthor=M.+W.+Deininger&title=Imatinib+is+not+a+potent+anti-SARS-CoV-2+drug&doi=10.1038%2Fs41375-020-01045-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib is not a potent anti-SARS-CoV-2 drug</span></div><div class="casAuthors">Zhao, Helong; Mendenhall, Michelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3085-3087</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Imatinib is not a potent anti-SARS-CoV-2 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC_1Nzxr3RxrVg90H21EOLACvtfcHk0lj9xa1UAPqOfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ&md5=44846fa32deeaf672ba1b8bf2d066b7b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-01045-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-01045-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMendenhall%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DImatinib%2520is%2520not%2520a%2520potent%2520anti-SARS-CoV-2%2520drug%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D3085%26epage%3D3087%26doi%3D10.1038%2Fs41375-020-01045-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touret, F.</span>; <span class="NLM_string-name">Driouich, J.-S.</span>; <span class="NLM_string-name">Cochin, M.</span>; <span class="NLM_string-name">Petit, P. R.</span>; <span class="NLM_string-name">Gilles, M.</span>; <span class="NLM_string-name">Barthélémy, K.</span>; <span class="NLM_string-name">Moureau, G.</span>; <span class="NLM_string-name">Malvy, D.</span>; <span class="NLM_string-name">Solas, C.</span>; <span class="NLM_string-name">De Lamballerie, X.</span>; <span class="NLM_string-name">Nougairède, A.</span></span>, <span> </span><span class="NLM_article-title">Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2</span>.  <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.11.17.386904</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1101%2F2020.11.17.386904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32511380" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Touret&author=J.-S.+Driouich&author=M.+Cochin&author=P.+R.+Petit&author=M.+Gilles&author=K.+Barth%C3%A9l%C3%A9my&author=G.+Moureau&author=D.+Malvy&author=C.+Solas&author=X.+De+Lamballerie&author=A.+Nougair%C3%A8de&title=Preclinical+evaluation+of+Imatinib+does+not+support+its+use+as+an+antiviral+drug+against+SARS-CoV-2&doi=10.1101%2F2020.11.17.386904"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1101%2F2020.11.17.386904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.11.17.386904%26sid%3Dliteratum%253Aachs%26aulast%3DTouret%26aufirst%3DF.%26atitle%3DPreclinical%2520evaluation%2520of%2520Imatinib%2520does%2520not%2520support%2520its%2520use%2520as%2520an%2520antiviral%2520drug%2520against%2520SARS-CoV-2%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.11.17.386904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potisopon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27105280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=443-452&author=M.+J.+Clarkauthor=C.+Miduturuauthor=A.+G.+Schmidtauthor=X.+Zhuauthor=J.+D.+Pittsauthor=J.+Wangauthor=S.+Potisoponauthor=J.+Zhangauthor=A.+Wojciechowskiauthor=J.+J.+H.+Chuauthor=N.+S.+Grayauthor=P.+L.+Yang&title=GNF-2+inhibits+dengue+virus+by+targeting+Abl+kinases+and+the+viral+E+protein&doi=10.1016%2Fj.chembiol.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein</span></div><div class="casAuthors">Clark, Margaret J.; Miduturu, Chandra; Schmidt, Aaron G.; Zhu, Xuling; Pitts, Jared D.; Wang, Jinhua; Potisopon, Supanee; Zhang, Jianming; Wojciechowski, Amy; Chu, Justin Jang Hann; Gray, Nathanael S.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-452</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus.  Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yielded drugs that have advanced to the clinic.  Here, we show that the allosteric Abl kinase inhibitor GNF-2 interferes with dengue virus replication via activity mediated by cellular Abl kinases but addnl. blocks viral entry via an Abl-independent mechanism.  To characterize this newly discovered antiviral activity, we developed disubstituted pyrimidines that block dengue virus entry with structure-activity relationships distinct from those driving kinase inhibition.  We demonstrate that biotin- and fluorophore-conjugated derivs. of GNF-2 interact with the dengue glycoprotein, E, in the pre-fusion conformation that exists on the virion surface, and that this interaction inhibits viral entry.  This study establishes GNF-2 as an antiviral compd. with polypharmacol. activity and provides "lead" compds. for further optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-_Dumc6V_A7Vg90H21EOLACvtfcHk0lj9xa1UAPqOfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D&md5=d5bd0ad159a7df03b992ecb96a7d231f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPitts%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPotisopon%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DGNF-2%2520inhibits%2520dengue%2520virus%2520by%2520targeting%2520Abl%2520kinases%2520and%2520the%2520viral%2520E%2520protein%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D443%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayer, K. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, H.</span></span> <span> </span><span class="NLM_article-title">CaM kinase: still inspiring at 40</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.neuron.2019.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31394063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2019&pages=380-394&author=K.+U.+Bayerauthor=H.+Schulman&title=CaM+kinase%3A+still+inspiring+at+40&doi=10.1016%2Fj.neuron.2019.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">CaM Kinase: Still Inspiring at 40</span></div><div class="casAuthors">Bayer, K. Ulrich; Schulman, Howard</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-394</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) was touted as a memory mol., even before its involvement in long-term potentiation (LTP) was shown.  The enzyme has not disappointed, with subsequent demonstrations of remarkable structural and regulatory properties.  Its neuronal functions now extend to long-term depression (LTD), and last year saw the first direct evidence for memory storage by CaMKII.  Although CaMKII may have taken the spotlight, it is a member of a large family of diverse and interesting CaM kinases.  Our aim is to place CaMKII in context of the other CaM kinases and then review certain aspects of this kinase that are of current interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4GLt04enxbVg90H21EOLACvtfcHk0liN20T6yfbS9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjtLzK&md5=c576935107864506b1d940e9fcae32a6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DBayer%26aufirst%3DK.%2BU.%26aulast%3DSchulman%26aufirst%3DH.%26atitle%3DCaM%2520kinase%253A%2520still%2520inspiring%2520at%252040%26jtitle%3DNeuron%26date%3D2019%26volume%3D103%26spage%3D380%26epage%3D394%26doi%3D10.1016%2Fj.neuron.2019.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, H.</span></span> <span> </span><span class="NLM_article-title">CaMKII inhibitors: from research tools to therapeutic agents</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2014.00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24600394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1ynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=21&author=P.+Pellicenaauthor=H.+Schulman&title=CaMKII+inhibitors%3A+from+research+tools+to+therapeutic+agents&doi=10.3389%2Ffphar.2014.00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII inhibitors: from research tools to therapeutic agents</span></div><div class="casAuthors">Pellicena Patricia; Schulman Howard</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The cardiac field has benefited from the availability of several CaMKII inhibitors serving as research tools to test putative CaMKII pathways associated with cardiovascular physiology and pathophysiology.  Successful demonstrations of its critical pathophysiological roles have elevated CaMKII as a key target in heart failure, arrhythmia, and other forms of heart disease.  This has caught the attention of the pharmaceutical industry, which is now racing to develop CaMKII inhibitors as safe and effective therapeutic agents.  While the first generation of CaMKII inhibitor development is focused on blocking its activity based on ATP binding to its catalytic site, future inhibitors can also target sites affecting its regulation by Ca(2+)/CaM or translocation to some of its protein substrates.  The recent availability of crystal structures of the kinase in the autoinhibited and activated state, and of the dodecameric holoenzyme, provides insights into the mechanism of action of existing inhibitors.  It is also accelerating the design and development of better pharmacological inhibitors.  This review examines the structure of the kinase and suggests possible sites for its inhibition.  It also analyzes the uses and limitations of current research tools.  Development of new inhibitors will enable preclinical proof of concept tests and clinical development of successful lead compounds, as well as improved research tools to more accurately examine and extend knowledge of the role of CaMKII in cardiac health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHND5-dNwnhC-bLEOO4dYpfW6udTcc2eYrxh9llIM48Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1ynsA%253D%253D&md5=90410be031e0b96ca2810e239a60bffd</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00021%26sid%3Dliteratum%253Aachs%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchulman%26aufirst%3DH.%26atitle%3DCaMKII%2520inhibitors%253A%2520from%2520research%2520tools%2520to%2520therapeutic%2520agents%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D21%26doi%3D10.3389%2Ffphar.2014.00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simanjuntak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-S.</span></span> <span> </span><span class="NLM_article-title">Benzenesulfonamide derivatives as calcium/calmodulin-dependent protein kinase inhibitors and antiviral agents against dengue and zika virus infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1313-1327&author=W.-C.+Chenauthor=Y.+Simanjuntakauthor=L.-W.+Chuauthor=Y.-H.+Pingauthor=Y.-L.+Leeauthor=Y.-L.+Linauthor=W.-S.+Li&title=Benzenesulfonamide+derivatives+as+calcium%2Fcalmodulin-dependent+protein+kinase+inhibitors+and+antiviral+agents+against+dengue+and+zika+virus+infections&doi=10.1021%2Facs.jmedchem.9b01779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections</span></div><div class="casAuthors">Chen, Wei-Chia; Simanjuntak, Yogy; Chu, Li-Wei; Ping, Yueh-Hsin; Lee, Yi-Ling; Lin, Yi-Ling; Li, Wen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1313-1327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging and resurging mosquito-borne flaviviruses are an important public health challenge.  The increased prevalence of dengue virus (DENV) infection has had a significant socioeconomic impact on epidemic countries.  The recent outbreak of Zika virus (ZIKV) has created an international public health emergency because ZIKV infection has been linked to congenital defects and Guillain-Barr´e syndrome.  To develop potentially prophylactic antiviral drugs for combating these acute infectious diseases, we have targeted the host calcium/calmodulin-dependent kinase II (CaMKII) for inhibition.  By using CaMKII structure-guided inhibitor design, we generated four families of benzenesulfonamide (BSA) derivs. for SAR anal.  Among these substances, N-(4-cycloheptyl-4-oxobutyl)-4-methoxy-N-phenylbenzenesulfonamide (9) showed superior properties as a lead CaMKII inhibitor and antiviral agent.  BSA 9 inhibited CaMKII activity with an IC50 value of 0.79 μM and displayed EC50 values of 1.52 μM and 1.91 μM against DENV and ZIKV infections of human neuronal BE(2)C cells, resp.  Notably, 9 significantly reduced the viremia level and increased animal survival time in mouse-challenge models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPIVcnOOQM9LVg90H21EOLACvtfcHk0lgVOFBga_PArA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D&md5=4222b9a25616a59243c22bfd57b223e7</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01779%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.-C.%26aulast%3DSimanjuntak%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DL.-W.%26aulast%3DPing%26aufirst%3DY.-H.%26aulast%3DLee%26aufirst%3DY.-L.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DLi%26aufirst%3DW.-S.%26atitle%3DBenzenesulfonamide%2520derivatives%2520as%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520antiviral%2520agents%2520against%2520dengue%2520and%2520zika%2520virus%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1313%26epage%3D1327%26doi%3D10.1021%2Facs.jmedchem.9b01779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saldivar, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span> <span> </span><span class="NLM_article-title">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrm.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28811666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=622-636&author=J.+C.+Saldivarauthor=D.+Cortezauthor=K.+A.+Cimprich&title=The+essential+kinase+ATR%3A+ensuring+faithful+duplication+of+a+challenging+genome&doi=10.1038%2Fnrm.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span></div><div class="casAuthors">Saldivar, Joshua C.; Cortez, David; Cimprich, Karlene A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">622-636</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  One way to preserve a rare book is to lock it away from all potential sources of damage.  Of course, an inaccessible book is also of little use, and the paper and ink will continue to degrade with age in any case.  Like a book, the information stored in our DNA needs to be read, but it is also subject to continuous assault and therefore needs to be protected.  In this Review, we examine how the replication stress response that is controlled by the kinase ataxia telangiectasia and Rad3-related (ATR) senses and resolves threats to DNA integrity so that the DNA remains available to read in all of our cells.  We discuss the multiple data that have revealed an elegant yet increasingly complex mechanism of ATR activation.  This involves a core set of components that recruit ATR to stressed replication forks, stimulate kinase activity and amplify ATR signalling.  We focus on the activities of ATR in the control of cell cycle checkpoints, origin firing and replication fork stability, and on how proper regulation of these processes is crucial to ensure faithful duplication of a challenging genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-97TQtMh0bVg90H21EOLACvtfcHk0lgpLMDyPxeOvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF&md5=b65c70da63f009deae253c8f3f215234</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DSaldivar%26aufirst%3DJ.%2BC.%26aulast%3DCortez%26aufirst%3DD.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DThe%2520essential%2520kinase%2520ATR%253A%2520ensuring%2520faithful%2520duplication%2520of%2520a%2520challenging%2520genome%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D622%26epage%3D636%26doi%3D10.1038%2Fnrm.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5674</span>– <span class="NLM_lpage">5685</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.18632%2Foncotarget.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25010037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5674-5685&author=A.+B.+Hallauthor=D.+Newsomeauthor=Y.+Wangauthor=D.+M.+Boucherauthor=B.+Eustaceauthor=Y.+Guauthor=B.+Hareauthor=M.+A.+Johnsonauthor=H.+Liauthor=S.+Miltonauthor=C.+E.+Murphyauthor=D.+Takemotoauthor=C.+Tolmanauthor=M.+Woodauthor=P.+Charltonauthor=J.-D.+Charrierauthor=B.+Fureyauthor=J.+Golecauthor=P.+M.+Reaperauthor=J.+R.+Pollard&title=Potentiation+of+tumor+responses+to+DNA+damaging+therapy+by+the+selective+ATR+inhibitor+VX-970&doi=10.18632%2Foncotarget.2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span></div><div class="casAuthors">Hall Amy B; Newsome Dave; Wang Yuxin; Boucher Diane M; Eustace Brenda; Gu Yong; Hare Brian; Johnson Mac A; Milton Sean; Murphy Cheryl E; Takemoto Darin; Tolman Crystal; Wood Mark; Furey Brinley; Charlton Peter; Charrier Jean-Damien; Golec Julian; Reaper Philip M; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5674-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor.  This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR).  ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents.  However, there are limited in vivo proof-of-concept data for ATR inhibition.  To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1.  VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed.  In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts.  The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model.  These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8Vj8UJVglDeLt9HypzAgQfW6udTcc2eYV6buIJt6SOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D&md5=8901708b1d60ad622d534a14da665414</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2158%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%2BB.%26aulast%3DNewsome%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DD.%2BM.%26aulast%3DEustace%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMilton%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DC.%2BE.%26aulast%3DTakemoto%26aufirst%3DD.%26aulast%3DTolman%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DCharrier%26aufirst%3DJ.-D.%26aulast%3DFurey%26aufirst%3DB.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DPotentiation%2520of%2520tumor%2520responses%2520to%2520DNA%2520damaging%2520therapy%2520by%2520the%2520selective%2520ATR%2520inhibitor%2520VX-970%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5674%26epage%3D5685%26doi%3D10.18632%2Foncotarget.2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, R. J.</span></span> <span> </span><span class="NLM_article-title">AMPK: guardian of metabolism and mitochondrial homeostasis</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrm.2017.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28974774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2rtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=121-135&author=S.+Herzigauthor=R.+J.+Shaw&title=AMPK%3A+guardian+of+metabolism+and+mitochondrial+homeostasis&doi=10.1038%2Fnrm.2017.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">AMPK: guardian of metabolism and mitochondrial homeostasis</span></div><div class="casAuthors">Herzig, Sebastien; Shaw, Reuben J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-135</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cells constantly adapt their metab. to meet their energy needs and respond to nutrient availability.  Eukaryotes have evolved a very sophisticated system to sense low cellular ATP levels via the serine/threonine kinase AMP-activated protein kinase (AMPK) complex.  Under conditions of low energy, AMPK phosphorylates specific enzymes and growth control nodes to increase ATP generation and decrease ATP consumption.  In the past decade, the discovery of numerous new AMPK substrates has led to a more complete understanding of the minimal no. of steps required to reprogramme cellular metab. from anabolism to catabolism.  This energy switch controls cell growth and several other cellular processes, including lipid and glucose metab. and autophagy.  Recent studies have revealed that one ancestral function of AMPK is to promote mitochondrial health, and multiple newly discovered targets of AMPK are involved in various aspects of mitochondrial homeostasis, including mitophagy.  This Review discusses how AMPK functions as a central mediator of the cellular response to energetic stress and mitochondrial insults and coordinates multiple features of autophagy and mitochondrial biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWI3PnQxZd7Vg90H21EOLACvtfcHk0lgpLMDyPxeOvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2rtb7L&md5=d3bf6ff181c0d620e9179faecbc0b4fc</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.95%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26atitle%3DAMPK%253A%2520guardian%2520of%2520metabolism%2520and%2520mitochondrial%2520homeostasis%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D121%26epage%3D135%26doi%3D10.1038%2Fnrm.2017.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankouri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span> <span> </span><span class="NLM_article-title">Viruses and the fuel sensor: the emerging link between AMPK and virus replication</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1002/rmv.687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Frmv.687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21538667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVensbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=205-212&author=J.+Mankouriauthor=M.+Harris&title=Viruses+and+the+fuel+sensor%3A+the+emerging+link+between+AMPK+and+virus+replication&doi=10.1002%2Frmv.687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Viruses and the fuel sensor: the emerging link between AMPK and virus replication</span></div><div class="casAuthors">Mankouri, Jamel; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-212</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Adenosine 5' monophosphate-activated protein kinase (AMPK) is conserved in all eukaryotic cells and functions as the key regulator of cellular metab. by responding to the energy status of the cell.  It is activated by an increase in the AMP : ATP ratio and then attempts to redress the balance by upregulating catabolic processes, while concomitantly inhibiting anabolic processes.  Despite its crit. importance in the functioning of eukaryotic cells, there has been a paucity of studies investigating the potential for dysregulation of AMPK by viruses.  Recently, however, there have been a no. of reports that have begun to address this gap in our knowledge.  In this article, we will review this emerging field, outlining how a variety of viruses have been shown to either stimulate or inhibit AMPK activity.  We will also document the effects of these perturbations on the biol. of virus infection, in particular with regard to the ability of viruses to persist or cause cytopathogenesis.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRtuWl3zqqtrVg90H21EOLACvtfcHk0lhXlXWInC5XUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVensbY%253D&md5=d8460c465146485e41732ca01ce13565</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Frmv.687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.687%26sid%3Dliteratum%253Aachs%26aulast%3DMankouri%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DViruses%2520and%2520the%2520fuel%2520sensor%253A%2520the%2520emerging%2520link%2520between%2520AMPK%2520and%2520virus%2520replication%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2011%26volume%3D21%26spage%3D205%26epage%3D212%26doi%3D10.1002%2Frmv.687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondratowicz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maury, W. J.</span></span> <span> </span><span class="NLM_article-title">AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1128/JVI.01634-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01634-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23115293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2jtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=746-755&author=A.+S.+Kondratowiczauthor=C.+L.+Huntauthor=R.+A.+Daveyauthor=S.+Cherryauthor=W.+J.+Maury&title=AMP-activated+protein+kinase+is+required+for+the+macropinocytic+internalization+of+ebolavirus&doi=10.1128%2FJVI.01634-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase is required for the macropinocytic internalization of Ebolavirus</span></div><div class="casAuthors">Kondratowicz, Andrew S.; Hunt, Catherine L.; Davey, Robert A.; Cherry, Sara; Maury, Wendy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">746-755</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Identification of host factors that are needed for Zaire Ebolavirus (EBOV) entry provides insights into the mechanism(s) of filovirus uptake, and these factors may serve as potential antiviral targets.  In order to identify novel host genes and pathways involved in EBOV entry, gene array findings in the National Cancer Institute's NCI-60 panel of human tumor cell lines were correlated with permissivity for EBOV glycoprotein (GP)-mediated entry.  The gene encoding the γ2 subunit of AMP-activated protein kinase (AMPK) strongly correlated with EBOV transduction in the tumor panel.  The AMPK inhibitor compd. C inhibited infectious EBOV replication in Vero cells and diminished EBOV GP-dependent, but not Lassa fever virus GPC-dependent, entry into a variety of cell lines in a dose-dependent manner.  Compd. C also prevented EBOV GP-mediated infection of primary human macrophages, a major target of filoviral replication in vivo.  Consistent with a role for AMPK in filovirus entry, time-of-addn. studies demonstrated that compd. C abrogated infection when it was added at early time points but became progressively less effective when added later.  Compd. C prevented EBOV pseudovirion internalization at 37° as cell-bound particles remained susceptible to trypsin digestion in the presence of the inhibitor but not in its absence.  Mouse embryonic fibroblasts lacking the AMPKa1 and AMPKα2 catalytic subunits were significantly less permissive to EBOV GP-mediated infection than their wild-type counterparts, likely due to decreased macropinocytic uptake.  In total, these findings implicate AMPK in macropinocytic events needed for EBOV GP-dependent entry and identify a novel cellular target for new filoviral antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0gJca2kyg7Vg90H21EOLACvtfcHk0lhXlXWInC5XUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2jtL0%253D&md5=33cdce39496e6ae3070af5ea112cb2a3</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1128%2FJVI.01634-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01634-12%26sid%3Dliteratum%253Aachs%26aulast%3DKondratowicz%26aufirst%3DA.%2BS.%26aulast%3DHunt%26aufirst%3DC.%2BL.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26aulast%3DCherry%26aufirst%3DS.%26aulast%3DMaury%26aufirst%3DW.%2BJ.%26atitle%3DAMP-activated%2520protein%2520kinase%2520is%2520required%2520for%2520the%2520macropinocytic%2520internalization%2520of%2520ebolavirus%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D746%26epage%3D755%26doi%3D10.1128%2FJVI.01634-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantrell, D. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase signalling pathways</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1242/jcs.114.8.1439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.114.8.1439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11282020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVyiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=1439-1445&author=D.+A.+Cantrell&title=Phosphoinositide+3-kinase+signalling+pathways&doi=10.1242%2Fjcs.114.8.1439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase signalling pathways</span></div><div class="casAuthors">Cantrell, Doreen Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review, with 83 refs.  Phosphoinositide 3-kinases (PI3Ks) phosphorylate the 3'-OH position of the inositol ring of inositol phospholipids, producing three lipid products: PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3.  These lipids bind to the pleckstrin homol. (PH) domains of proteins and control the activity and subcellular localization of a diverse array of signal transduction mols.  Three major classes of signaling mol. are regulated by binding of D-3 phosphoinositides to PH domains: guanine-nucleotide-exchange proteins for Rho family GTPases, the TEC family tyrosine kinases such as BTK and ITK in B and T lymphocytes, resp., and the AGC superfamily of serine/threonine protein kinases.  These mols. are activated by a variety of extracellular stimuli and have been implicated in a wide range of cellular processes, including cell cycle progression, cell growth, cell motility, cell adhesion and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR4dxjthM76bVg90H21EOLACvtfcHk0lhXlXWInC5XUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVyiu74%253D&md5=cb1910b42b49b62561279a315450c76b</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1242%2Fjcs.114.8.1439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.114.8.1439%26sid%3Dliteratum%253Aachs%26aulast%3DCantrell%26aufirst%3DD.%2BA.%26atitle%3DPhosphoinositide%25203-kinase%2520signalling%2520pathways%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D1439%26epage%3D1445%26doi%3D10.1242%2Fjcs.114.8.1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+evolution+of+phosphatidylinositol+3-kinases+as+regulators+of+growth+and+metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0lixwQ544LO9cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520evolution%2520of%2520phosphatidylinositol%25203-kinases%2520as%2520regulators%2520of%2520growth%2520and%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0lixwQ544LO9cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+cancer%3A+mechanisms+and+advances+in+clinical+trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eY3A9QO0CYwd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520cancer%253A%2520mechanisms%2520and%2520advances%2520in%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaal, H.</span></span> <span> </span><span class="NLM_article-title">Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3192</span>– <span class="NLM_lpage">3212</span>, <span class="refDoi"> DOI: 10.3390/v5123192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fv5123192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24351799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVyitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=3192-3212&author=N.+Diehlauthor=H.+Schaal&title=Make+yourself+at+home%3A+viral+hijacking+of+the+PI3K%2FAkt+signaling+pathway&doi=10.3390%2Fv5123192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway</span></div><div class="casAuthors">Diehl, Nora; Schaal, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3192-3212, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  As viruses do not possess genes encoding for proteins required for translation, energy metab. or membrane biosynthesis, they are classified as obligatory intracellular parasites that depend on a host cell to replicate.  This genome limitation forces them to gain control over cellular processes to ensure their successful propagation.  A diverse spectrum of virally encoded proteins tackling a broad spectrum of cellular pathways during most steps of the viral life cycle ranging from the host cell entry to viral protein translation has evolved.  Since the host cell PI3K/Akt signaling pathway plays a crit. regulatory role in many cellular processes including RNA processing, translation, autophagy and apoptosis, many viruses, in widely varying ways, target it.  This review focuses on a no. of remarkable examples of viral strategies, which exploit the PI3K/Akt signaling pathway for effective viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQHZafpgAH7Vg90H21EOLACvtfcHk0lhpH3yejzG8sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVyitLc%253D&md5=a113117ad659018ed1f18e52fba605a9</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fv5123192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv5123192%26sid%3Dliteratum%253Aachs%26aulast%3DDiehl%26aufirst%3DN.%26aulast%3DSchaal%26aufirst%3DH.%26atitle%3DMake%2520yourself%2520at%2520home%253A%2520viral%2520hijacking%2520of%2520the%2520PI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DViruses%26date%3D2013%26volume%3D5%26spage%3D3192%26epage%3D3212%26doi%3D10.3390%2Fv5123192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e1000141</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1000141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18769720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&author=M.+F.+Saeedauthor=A.+A.+Kolokoltsovauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Phosphoinositide-3+kinase-Akt+pathway+controls+cellular+entry+of+Ebola+virus&doi=10.1371%2Fjournal.ppat.1000141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span></div><div class="casAuthors">Saeed Mohammad F; Kolokoltsov Andrey A; Freiberg Alexander N; Holbrook Michael R; Davey Robert A</div><div class="citationInfo"><span class="NLM_cas:title">PLoS pathogens</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1000141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide-3 kinase (PI3K) pathway regulates diverse cellular activities related to cell growth, migration, survival, and vesicular trafficking.  It is known that Ebola virus requires endocytosis to establish an infection.  However, the cellular signals that mediate this uptake were unknown for Ebola virus as well as many other viruses.  Here, the involvement of PI3K in Ebola virus entry was studied.  A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of Zaire Ebola virus (ZEBOV).  Inhibitors of PI3K and Akt significantly reduced infection by ZEBOV at an early step during the replication cycle.  Furthermore, phosphorylation of Akt-1 was induced shortly after exposure of cells to radiation-inactivated ZEBOV, indicating that the virus actively induces the PI3K pathway and that replication was not required for this induction.  Subsequent use of pseudotyped Ebola virus and/or Ebola virus-like particles, in a novel virus entry assay, provided evidence that activity of PI3K/Akt is required at the virus entry step.  Class 1A PI3Ks appear to play a predominant role in regulating ZEBOV entry, and Rac1 is a key downstream effector in this regulatory cascade.  Confocal imaging of fluorescently labeled ZEBOV indicated that inhibition of PI3K, Akt, or Rac1 disrupted normal uptake of virus particles into cells and resulted in aberrant accumulation of virus into a cytosolic compartment that was non-permissive for membrane fusion.  We conclude that PI3K-mediated signaling plays an important role in regulating vesicular trafficking of ZEBOV necessary for cell entry.  Disruption of this signaling leads to inappropriate trafficking within the cell and a block in steps leading to membrane fusion.  These findings extend our current understanding of Ebola virus entry mechanism and may help in devising useful new strategies for treatment of Ebola virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVYOnEFnn8xZVVjGoY74BafW6udTcc2eaCKE7yrXd1LLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D&md5=337fa485785e2a091d392f6ff1dcc1a4</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000141%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide-3%2520kinase-Akt%2520pathway%2520controls%2520cellular%2520entry%2520of%2520Ebola%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26doi%3D10.1371%2Fjournal.ppat.1000141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">3002</span>– <span class="NLM_lpage">3009</span>, <span class="refDoi"> DOI: 10.1099/vir.0.024166-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1099%2Fvir.0.024166-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20810749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=3002-3009&author=V.+Tiwariauthor=D.+Shukla&title=Phosphoinositide+3+kinase+signalling+may+affect+multiple+steps+during+herpes+simplex+virus+type-1+entry&doi=10.1099%2Fvir.0.024166-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry</span></div><div class="casAuthors">Tiwari, Vaibhav; Shukla, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3002-3009</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Early interactions of herpes simplex virus type-1 (HSV-1) with cells lead to cytoskeletal changes facilitating filopodia formation and membrane fusion.  Here, we demonstrate that phosphoinositide 3 kinase (PI3K) signaling may affect multiple steps during HSV-1 entry.  An inhibitor of PI3K (LY294002) blocked HSV-1 entry and the blockage was cell-type- and gD receptor-independent.  Entry inhibition was also obsd. with primary cultures of the human corneal fibroblasts and unrelated β- and γ-herpesviruses.  Immunofluorescence anal. demonstrated that LY294002 neg. affected HSV-1-induced filopodia formation.  Similar effects of the inhibitor were seen on HSV-1 glycoprotein-induced cell-to-cell fusion.  Cells expressing HSV-1 glycoproteins (gB, gD, gH and gL) showed significantly less fusion with target cells in the presence of the inhibitor.  Expression of a dominant-neg. PI3K mutant neg. affected both entry and fusion.  We also show that inhibition of PI3K signaling also affected RhoA activation required for HSV-1 entry into certain cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZM1xcsTUErVg90H21EOLACvtfcHk0lhpH3yejzG8sQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsLfI&md5=32c707fe3d6630cbc7dd9252911f2194</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.024166-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.024166-0%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DV.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DPhosphoinositide%25203%2520kinase%2520signalling%2520may%2520affect%2520multiple%2520steps%2520during%2520herpes%2520simplex%2520virus%2520type-1%2520entry%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2010%26volume%3D91%26spage%3D3002%26epage%3D3009%26doi%3D10.1099%2Fvir.0.024166-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Nunez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrascosa, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla, Y.</span></span> <span> </span><span class="NLM_article-title">African swine fever virus uses macropinocytosis to enter host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002754</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1002754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22719252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1WrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=E.+G.+Sanchezauthor=A.+Quintasauthor=D.+Perez-Nunezauthor=M.+Nogalauthor=S.+Barrosoauthor=A.+L.+Carrascosaauthor=Y.+Revilla&title=African+swine+fever+virus+uses+macropinocytosis+to+enter+host+cells&doi=10.1371%2Fjournal.ppat.1002754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">African swine fever virus uses macropinocytosis to enter host cells</span></div><div class="casAuthors">Sanchez, Elena G.; Quintas, Ana; Perez-Nunez, Daniel; Nogal, Marisa; Barroso, Susana; Carrascosa, Angel L.; Revilla, Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1002754</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">African swine fever (ASF) is caused by a large and highly pathogenic DNA virus, African swine fever virus (ASFV), which provokes severe economic losses and expansion threats.  Presently, no specific protection or vaccine against ASF is available, despite the high hazard that the continued occurrence of the disease in sub-Saharan Africa, the recent outbreak in the Caucasus in 2007, and the potential dissemination to neighboring countries, represents.  Although virus entry is a remarkable target for the development of protection tools, knowledge of the ASFV entry mechanism is still very limited.  Whereas early studies have proposed that the virus enters cells through receptor-mediated endocytosis, the specific mechanism used by ASFV remains uncertain.  Here we used the ASFV virulent isolate Ba71, adapted to grow in Vero cells (Ba71V), and the virulent strain E70 to demonstrate that entry and internalization of ASFV includes most of the features of macropinocytosis.  By a combination of optical and electron microscopy, we show that the virus causes cytoplasm membrane perturbation, blebbing and ruffles.  We have also found that internalization of the virions depends on actin reorganization, activity of Na+/H+ exchangers, and signaling events typical of the macropinocytic mechanism of endocytosis.  The entry of virus into cells appears to directly stimulate dextran uptake, actin polarization and EGFR, PI3K-Akt, Pak1 and Rac1 activation.  Inhibition of these key regulators of macropinocytosis, as well as treatment with the drug EIPA, results in a considerable decrease in ASFV entry and infection.  In conclusion, this study identifies for the first time the whole pathway for ASFV entry, including the key cellular factors required for the uptake of the virus and the cell signaling involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWmiT3epDeT7Vg90H21EOLACvtfcHk0ljOQQJvCmjH_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1WrtbY%253D&md5=1cc17081dd757815ca20add6cb30a8b1</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002754%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DE.%2BG.%26aulast%3DQuintas%26aufirst%3DA.%26aulast%3DPerez-Nunez%26aufirst%3DD.%26aulast%3DNogal%26aufirst%3DM.%26aulast%3DBarroso%26aufirst%3DS.%26aulast%3DCarrascosa%26aufirst%3DA.%2BL.%26aulast%3DRevilla%26aufirst%3DY.%26atitle%3DAfrican%2520swine%2520fever%2520virus%2520uses%2520macropinocytosis%2520to%2520enter%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fikrig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An essential role of PI3K in the control of West Nile virus infection</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3724</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03912-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41598-017-03912-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28623344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptFGjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3724&author=L.+Wangauthor=L.+Yangauthor=E.+Fikrigauthor=P.+Wang&title=An+essential+role+of+PI3K+in+the+control+of+West+Nile+virus+infection&doi=10.1038%2Fs41598-017-03912-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role of PI3K in the control of West Nile virus infection</span></div><div class="casAuthors">Wang Leilei; Yang Long; Wang Penghua; Wang Leilei; Fikrig Erol; Fikrig Erol</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphatidyl-inositol-3 kinases (PI3K) pathway regulates a variety of cellular processes, including cell proliferation, RNA processing, protein translation, autophagy, apoptosis and antiviral immunity.  Many viruses depend on PI3K signaling for replication.  However, its role in flaviviral infection has not been clearly defined.  Here we report that PI3K signaling is critical for the control of West Nile virus (WNV) infection by regulating type I IFN (IFN-I) response.  Inhibition of PI3K activity by 3-methyl adenine (3-MA), Wortmannin (WM) and LY294002 (LY) increased viral titers by 3-16 folds in primary mouse macrophages, embryonic fibroblasts and human cell lines.  Both 3-MA and LY repressed IFN-I mRNA and protein expression significantly.  Surprisingly, WM enhanced the mRNA expression of IFN-I and TNF-α, and TNF-α protein production modestly, while dramatically decreased the secreted IFN-I.  Further studies showed that the catalytic subunit p110δ of class I PI3K played a role in induction of antiviral immune responses.  Lastly translocation of interferon regulatory factor 7(IRF7) from the cytosol to the nuclei was effectively blocked in the presence of PI3K inhibitors.  Our results clearly define an antiviral role of PI3K by modulating immune responses and demonstrate differential mode of action of three PI3K inhibitors on IFN-I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJFccvOyb6-f9pSBfyDvp7fW6udTcc2eZRy2b6YYd5kbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptFGjsA%253D%253D&md5=2358dee5af4d0bd714017a84632eaaba</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03912-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03912-5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DFikrig%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520essential%2520role%2520of%2520PI3K%2520in%2520the%2520control%2520of%2520West%2520Nile%2520virus%2520infection%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3724%26doi%3D10.1038%2Fs41598-017-03912-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7189</span>, <span class="refDoi"> DOI: 10.3390/ijms21197189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fijms21197189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWit7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=7189&author=E.+M.+McGowanauthor=N.+Haddadiauthor=N.+T.+Nassifauthor=Y.+Lin&title=Targeting+the+SphK-S1P-SIPR+pathway+as+a+potential+therapeutic+approach+for+COVID-19&doi=10.3390%2Fijms21197189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19</span></div><div class="casAuthors">McGowan, Eileen M.; Haddadi, Nahal; Nassif, Najah T.; Lin, Yiguang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7189</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The world is currently experiencing the worst health pandemic since the Spanish flu in 1918-the COVID-19 pandemic-caused by the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  This pandemic is the world's third wake-up call this century.  In 2003 and 2012, the world experienced two major coronavirus outbreaks, SARS-CoV-1 and Middle East Respiratory syndrome coronavirus (MERS-CoV), causing major respiratory tract infections.  At present, there is neither a vaccine nor a cure for COVID-19.  The severe COVID-19 symptoms of hyperinflammation, catastrophic damage to the vascular endothelium, thrombotic complications, septic shock, brain damage, acute disseminated encephalomyelitis (ADEM), and acute neurol. and psychiatric complications are unprecedented.  Many COVID-19 deaths result from the aftermath of hyperinflammatory complications, also referred to as the "cytokine storm syndrome", endotheliitus and blood clotting, all with the potential to cause multiorgan dysfunction.  The sphingolipid rheostat plays integral roles in viral replication, activation/modulation of the immune response, and importantly in maintaining vasculature integrity, with sphingosine 1 phosphate (S1P) and its cognate receptors (SIPRs: G-protein-coupled receptors) being key factors in vascular protection against endotheliitus.  Hence, modulation of sphingosine kinase (SphK), S1P, and the S1P receptor pathway may provide significant beneficial effects towards counteracting the life-threatening, acute, and chronic complications assocd. with SARS-CoV-2 infection.  This review provides a comprehensive overview of SARS-CoV-2 infection and disease, prospective vaccines, and current treatments.  We then discuss the evidence supporting the targeting of SphK/S1P and S1P receptors in the repertoire of COVID-19 therapies to control viral replication and alleviate the known and emerging acute and chronic symptoms of COVID-19.  Three clin. trials using FDA-approved sphingolipid-based drugs being repurposed and evaluated to help in alleviating COVID-19 symptoms are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8DR8YuR9t7Vg90H21EOLACvtfcHk0ljOQQJvCmjH_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWit7zM&md5=cbbdcef7e1509a760411e882728628bd</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms21197189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21197189%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DE.%2BM.%26aulast%3DHaddadi%26aufirst%3DN.%26aulast%3DNassif%26aufirst%3DN.%2BT.%26aulast%3DLin%26aufirst%3DY.%26atitle%3DTargeting%2520the%2520SphK-S1P-SIPR%2520pathway%2520as%2520a%2520potential%2520therapeutic%2520approach%2520for%2520COVID-19%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D7189%26doi%3D10.3390%2Fijms21197189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maines, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beljanski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.163444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1124%2Fjpet.109.163444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20061445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFGktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2010&pages=129-139&author=K.+J.+Frenchauthor=Y.+Zhuangauthor=L.+W.+Mainesauthor=P.+Gaoauthor=W.+Wangauthor=V.+Beljanskiauthor=J.+J.+Upsonauthor=C.+L.+Greenauthor=S.+N.+Kellerauthor=C.+D.+Smith&title=Pharmacology+and+antitumor+activity+of+ABC294640%2C+a+selective+inhibitor+of+sphingosine+kinase-2&doi=10.1124%2Fjpet.109.163444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2</span></div><div class="casAuthors">French, Kevin J.; Zhuang, Yan; Maines, Lynn W.; Gao, Peng; Wang, Wenxue; Beljanski, Vladimir; Upson, John J.; Green, Cecelia L.; Keller, Staci N.; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingolipid-metabolizing enzymes control the dynamic balance of the cellular levels of important bioactive lipids, including the apoptotic compd. ceramide and the proliferative compd. sphingosine 1-phosphate (S1P).  Many growth factors and inflammatory cytokines promote the cleavage of sphingomyelin and ceramide leading to rapid elevation of S1P levels through the action of sphingosine kinases (SK1 and SK2).  SK1 and SK2 are overexpressed in a variety of human cancers, making these enzymes potential mol. targets for cancer therapy.  We have identified an aryladamantane compd., termed ABC294640 [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], that selectively inhibits SK2 activity in vitro, acting as a competitive inhibitor with respect to sphingosine with a Ki of 9.8 μM, and attenuates S1P formation in intact cells.  In tissue culture, ABC294640 suppresses the proliferation of a broad panel of tumor cell lines, and inhibits tumor cell migration concomitant with loss of microfilaments.  In vivo, ABC294640 has excellent oral bioavailability, and demonstrates a plasma clearance half-time of 4.5 h in mice.  Acute and chronic toxicol. studies indicate that ABC294640 induces a transient minor decrease in the hematocrit of rats and mice; however, this normalizes by 28 days of treatment.  No other changes in hematol. parameters, or gross or microscopic tissue pathol., result from treatment with ABC294640.  Oral administration of ABC294640 to mice bearing mammary adenocarcinoma xenografts results in dose-dependent antitumor activity assocd. with depletion of S1P levels in the tumors and progressive tumor cell apoptosis.  Therefore, this newly developed SK2 inhibitor provides an orally available drug candidate for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJFYxYhWjhbVg90H21EOLACvtfcHk0lhcH6r5RBuk2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFGktro%253D&md5=63e0792b887d9ad70c76f209e577a693</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.163444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.163444%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DK.%2BJ.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DMaines%26aufirst%3DL.%2BW.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBeljanski%26aufirst%3DV.%26aulast%3DUpson%26aufirst%3DJ.%2BJ.%26aulast%3DGreen%26aufirst%3DC.%2BL.%26aulast%3DKeller%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DPharmacology%2520and%2520antitumor%2520activity%2520of%2520ABC294640%252C%2520a%2520selective%2520inhibitor%2520of%2520sphingosine%2520kinase-2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D333%26spage%3D129%26epage%3D139%26doi%3D10.1124%2Fjpet.109.163444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corman, A.</span>; <span class="NLM_string-name">Kanellis, D. C.</span>; <span class="NLM_string-name">Häggblad, M.</span>; <span class="NLM_string-name">Lafarga, V.</span>; <span class="NLM_string-name">Bartek, J.</span>; <span class="NLM_string-name">Carreras-Puigvert, J.</span>; <span class="NLM_string-name">Fernandez-Capetillo, O.</span></span>, <span> </span><span class="NLM_article-title">A chemical screen identifies a link between lipid metabolism and mRNA translation</span>.  <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.11.088005</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1101%2F2020.05.11.088005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Corman&author=D.+C.+Kanellis&author=M.+H%C3%A4ggblad&author=V.+Lafarga&author=J.+Bartek&author=J.+Carreras-Puigvert&author=O.+Fernandez-Capetillo&title=A+chemical+screen+identifies+a+link+between+lipid+metabolism+and+mRNA+translation&doi=10.1101%2F2020.05.11.088005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1101%2F2020.05.11.088005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.11.088005%26sid%3Dliteratum%253Aachs%26aulast%3DCorman%26aufirst%3DA.%26atitle%3DA%2520chemical%2520screen%2520identifies%2520a%2520link%2520between%2520lipid%2520metabolism%2520and%2520mRNA%2520translation%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.11.088005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors for the treatment of nononcologic diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1345</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01511</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01511" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhslOjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=1283-1345&author=Z.+Xieauthor=X.+Yangauthor=Y.+Duanauthor=J.+Hanauthor=C.+Liao&title=Small-molecule+kinase+inhibitors+for+the+treatment+of+nononcologic+diseases&doi=10.1021%2Facs.jmedchem.0c01511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases</span></div><div class="casAuthors">Xie, Zhouling; Yang, Xiaoxiao; Duan, Yajun; Han, Jihong; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1283-1345</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Great successes have been achieved in developing small-mol. kinase inhibitors as anticancer therapeutic agents.  However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.  Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria.  Indeed, the first small-mol. kinase inhibitor for treatment of a nononcol. disease was approved in 2011 by the U.S.  To date, 10 such inhibitors have been approved, and more are in clin. trials for applications other than cancer.  This Perspective discusses a no. of kinases and their small-mol. inhibitors for the treatment of diseases in nononcol. therapeutic fields.  The opportunities and challenges in developing such inhibitors are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9Nmho6XaDbVg90H21EOLACvtfcHk0lhcH6r5RBuk2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhslOjsLc%253D&md5=ad9d3e32276fef906c1832e9bb91d7a1</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520nononcologic%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D1283%26epage%3D1345%26doi%3D10.1021%2Facs.jmedchem.0c01511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative chemical structures of FDA-approved PKIs for cancer or inflammatory processes and antitumoral LKIs with antiviral properties in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of GAK, AAK1, and BIKE inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Chemical structures of 3,6-disubstituted isothiazolo[4,3-<i>b</i>]pyridines <b>21</b>–<b>27</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of imidazo[1,2-<i>b</i>]pyridazines <b>28</b> and <b>29</b>, and pyrrolo[2,3-<i>b</i>]pyridines <b>30</b> and <b>31</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures for GAK and AAK1 probes <b>32</b> and <b>33</b>, and their structurally related negative controls <b>34</b> and <b>35</b>, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Chemical structures of representative RTK inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. MAPK signaling cascade upon binding of a GF to its receptor, leading to the activation of MAPKAPK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Chemical structures of representative MAPK inhibitors with antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical structures of FDA-approved Src kinase inhibitors with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Chemical structures of the first molecules identified as CDK inhibitors with antiviral activities.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Chemical structures of representative PIKfyve inhibitors bearing a morpholino-azine core group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/medium/jm1c00302_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures of inhibitors <b>1</b>, <b>5</b>, <b>17</b>, <b>19</b>, and <b>56</b>–<b>61</b> with antiviral activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00302/20210608/images/large/jm1c00302_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00302&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i24">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36784" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36784" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 184 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ardito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troiano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Muzio, L.</span></span> <span> </span><span class="NLM_article-title">The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2017.3036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3892%2Fijmm.2017.3036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28656226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2htb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2017&pages=271-280&author=F.+Arditoauthor=M.+Giulianiauthor=D.+Perroneauthor=G.+Troianoauthor=L.+Lo+Muzio&title=The+crucial+role+of+protein+phosphorylation+in+cell+signaling+and+its+use+as+targeted+therapy&doi=10.3892%2Fijmm.2017.3036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (review)</span></div><div class="casAuthors">Ardito, Fatima; Giuliani, Michele; Perrone, Donatella; Troiano, Giuseppe; Muzio, Lorenzo Lo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1791-244X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Protein phosphorylation is an important cellular regulatory mechanism as many enzymes and receptors are activated/deactivated by phosphorylation and dephosphorylation events, by means of kinases and phosphatases.  In particular, the protein kinases are responsible for cellular transduction signaling and their hyperactivity, malfunction or overexpression can be found in several diseases, mostly tumors.  Therefore, it is evident that the use of kinase inhibitors can be valuable for the treatment of cancer.  In this review, we discuss the mechanism of action of phosphorylation, with particular attention to the importance of phosphorylation under physiol. and pathol. conditions.  We also discuss the possibility of using kinase inhibitors in the treatment of tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoJNhgNZEVXbVg90H21EOLACvtfcHk0lh9MZ5ABy57LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2htb7N&md5=f88bf52fc0ecb24364b6c28049a7d91e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2017.3036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2017.3036%26sid%3Dliteratum%253Aachs%26aulast%3DArdito%26aufirst%3DF.%26aulast%3DGiuliani%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DD.%26aulast%3DTroiano%26aufirst%3DG.%26aulast%3DLo%2BMuzio%26aufirst%3DL.%26atitle%3DThe%2520crucial%2520role%2520of%2520protein%2520phosphorylation%2520in%2520cell%2520signaling%2520and%2520its%2520use%2520as%2520targeted%2520therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2017%26volume%3D40%26spage%3D271%26epage%3D280%26doi%3D10.3892%2Fijmm.2017.3036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. H.</span></span> <span> </span><span class="NLM_article-title">The phosphorylase <i>b</i> to a converting enzyme of rabbit skeletal muscle</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1956</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">150</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1016/0006-3002(56)90273-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2F0006-3002%2856%2990273-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=13315361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaG28XmtVCkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1956&pages=150-157&author=E.+G.+Krebsauthor=E.+H.+Fischer&title=The+phosphorylase+b+to+a+converting+enzyme+of+rabbit+skeletal+muscle&doi=10.1016%2F0006-3002%2856%2990273-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylase b-to-a converting enzyme of rabbit skeletal muscle</span></div><div class="casAuthors">Krebs, Edwin G.; Fischer, Edmond H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta</span>
        (<span class="NLM_cas:date">1956</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">150-7</span>CODEN:
                <span class="NLM_cas:coden">BBACAQ</span>;
        ISSN:<span class="NLM_cas:issn">0006-3002</span>.
    </div><div class="casAbstract">cf. C.A. 49, 16017g.  Studies of the conversion of phosphorylase b to phosphorylase a in rabbit muscle exts. in the presence of metal ions and adenosinetriphosphate (ATP) are extended to studies in isolated systems with purified components.  A method for assaying the converting enzyme is described, and the course of the reaction at several concns. of the enzyme shown.  Converting enzyme units are defined.  The pH optimum of the enzyme is approx. 9.0.  The reaction requires Mn++ or Mg++ and ATP.  A mono-Mn-ATP complex is probably involved in the reaction.  Phosphorylase a produced from phosphorylase b in the presence of ATP-P32 is shown to contain firmly bound isotopic phosphate, at least 2 atoms P32/mole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoytWjjKYNOB7Vg90H21EOLACvtfcHk0lh9MZ5ABy57LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG28XmtVCkug%253D%253D&md5=7cb87a32dc3079477274c32b0dbc94c1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0006-3002%2856%2990273-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-3002%252856%252990273-6%26sid%3Dliteratum%253Aachs%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26atitle%3DThe%2520phosphorylase%2520b%2520to%2520a%2520converting%2520enzyme%2520of%2520rabbit%2520skeletal%2520muscle%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1956%26volume%3D20%26spage%3D150%26epage%3D157%26doi%3D10.1016%2F0006-3002%2856%2990273-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krebs, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. H.</span></span> <span> </span><span class="NLM_article-title">The muscle phosphorylase <i>b</i> kinase reaction</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1958</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(19)77286-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0021-9258%2819%2977286-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=13538949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaG1cXnt1Oitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1958&pages=73-83&author=E.+G.+Krebsauthor=A.+B.+Kentauthor=E.+H.+Fischer&title=The+muscle+phosphorylase+b+kinase+reaction&doi=10.1016%2FS0021-9258%2819%2977286-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Muscle phosphorylase b kinase reaction</span></div><div class="casAuthors">Krebs, Edwin G.; Kent, Alan B.; Fischer, Edmond H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1958</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-83</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. preceding abstr.  The conversion of cryst. phosphorylase b to phosphorylase a with adenosinetriphosphate-P32 and phosphorylase b kinase was studied.  In the reaction 4 moles of phosphate are incorporated/mole phosphorylase a, and 4 moles of adenosinediphosphate are formed.  The reaction is essentially irreversible.  In the process the mol. wt. of the enzyme is doubled.  The changes that occur in the activity of phosphorylase during the conversion were studied.  With complete conversion the phosphorylase a formed has the same activity with or without adenosinemonophosphate.  No exchange of the firmly bound phosphate in the enzyme with inorg. phosphate occurs during phosphorolysis of glycogen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXmJc_6ueVo7Vg90H21EOLACvtfcHk0lh9MZ5ABy57LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXnt1Oitw%253D%253D&md5=11b5ac525c1f625a276057212863652c</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2977286-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252977286-X%26sid%3Dliteratum%253Aachs%26aulast%3DKrebs%26aufirst%3DE.%2BG.%26aulast%3DKent%26aufirst%3DA.%2BB.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26atitle%3DThe%2520muscle%2520phosphorylase%2520b%2520kinase%2520reaction%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1958%26volume%3D231%26spage%3D73%26epage%3D83%26doi%3D10.1016%2FS0021-9258%2819%2977286-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whyte, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudarsanam, S.</span></span> <span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>298</i></span>,  <span class="NLM_fpage">1912</span>– <span class="NLM_lpage">1934</span>, <span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lgTiVg1Ir8ReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anamika, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, N.</span></span> <span> </span><span class="NLM_article-title">Classification of protein kinases on the basis of both kinase and non-kinase regions</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">e12460</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0012460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0012460" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20856812" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&author=J.+Martinauthor=K.+Anamikaauthor=N.+Srinivasan&title=Classification+of+protein+kinases+on+the+basis+of+both+kinase+and+non-kinase+regions&doi=10.1371%2Fjournal.pone.0012460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0012460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0012460%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DAnamika%26aufirst%3DK.%26aulast%3DSrinivasan%26aufirst%3DN.%26atitle%3DClassification%2520of%2520protein%2520kinases%2520on%2520the%2520basis%2520of%2520both%2520kinase%2520and%2520non-kinase%2520regions%26jtitle%3DPLoS%2520One%26date%3D2010%26volume%3D5%26doi%3D10.1371%2Fjournal.pone.0012460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span> <span> </span><span class="NLM_article-title">Protein kinase biochemistry and drug discovery</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2011.07.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bioorg.2011.07.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21872901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1GqsrfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=192-210&author=P.+A.+Schwartzauthor=B.+W.+Murray&title=Protein+kinase+biochemistry+and+drug+discovery&doi=10.1016%2Fj.bioorg.2011.07.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase biochemistry and drug discovery</span></div><div class="casAuthors">Schwartz, Phillip A.; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">192-210</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are fascinating biol. catalysts with a rapidly expanding knowledge base, a growing appreciation in cell regulatory control, and an ascendant role in successful therapeutic intervention.  To better understand protein kinases, the mol. underpinnings of phosphoryl group transfer, protein phosphorylation, and inhibitor interactions are examd.  This anal. begins with a survey of phosphate group and phosphoprotein properties which provide context to the evolutionary selection of phosphorylation as a central mechanism for biol. regulation of most cellular processes.  Next, the kinetic and catalytic mechanisms of protein kinases are examd. with respect to model aq. systems to define the elements of catalysis.  A brief structural biol. overview further delves into the mol. basis of catalysis and regulation of catalytic activity.  Concomitant with a prominent role in normal physiol., protein kinases have important roles in the disease state.  To facilitate effective kinase drug discovery, classic and emerging approaches for characterizing kinase inhibitors are evaluated including biochem. assay design, inhibitor mechanism of action anal., and proper kinetic treatment of irreversible inhibitors.  As the resulting protein kinase inhibitors can modulate intended and unintended targets, profiling methods are discussed which can illuminate a more complete range of an inhibitor's biol. activities to enable more meaningful cellular studies and more effective clin. studies.  Taken as a whole, a wealth of protein kinase biochem. knowledge is available, yet it is clear that a substantial extent of our understanding in this field remains to be discovered which should yield many new opportunities for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9JNgQhbDT7Vg90H21EOLACvtfcHk0lgTiVg1Ir8ReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1GqsrfE&md5=3c85386861ef6effbd7ef95d638df0a2</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2011.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2011.07.004%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DProtein%2520kinase%2520biochemistry%2520and%2520drug%2520discovery%26jtitle%3DBioorg.%2520Chem.%26date%3D2011%26volume%3D39%26spage%3D192%26epage%3D210%26doi%3D10.1016%2Fj.bioorg.2011.07.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahiry, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torkamani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schork, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegele, R. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations in human disease: interpreting genotype-phenotype relationships</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1038/nrg2707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrg2707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20019687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFOht7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=60-74&author=P.+Lahiryauthor=A.+Torkamaniauthor=N.+J.+Schorkauthor=R.+A.+Hegele&title=Kinase+mutations+in+human+disease%3A+interpreting+genotype-phenotype+relationships&doi=10.1038%2Fnrg2707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations in human disease: interpreting genotype-phenotype relationships</span></div><div class="casAuthors">Lahiry, Piya; Torkamani, Ali; Schork, Nicholas J.; Hegele, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">60-74</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases are one of the largest gene families in humans.  Through a comprehensive survey of kinase mutations the authors highlight the structure-function relationships that control the activities of these proteins and their contribution to a varied set of human diseases.  Protein kinases are one of the largest families of evolutionarily related proteins and comprise one of the most abundant gene families in humans.  Here we survey kinase gene mutations from the perspective of human disease phenotypes and further analyze the structural features of mutant kinases, including mutational hotspots.  Our evaluation of the genotype-phenotype relationship across 915 human kinase mutations - that underlie 67 single-gene diseases, mainly inherited developmental and metabolic disorders and also certain cancers - enhances our understanding of the role of kinases in development, kinase dysfunction in pathogenesis and kinases as potential targets for therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq89P0vZvjopLVg90H21EOLACvtfcHk0lgTiVg1Ir8ReQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFOht7bF&md5=d5fde109645b8b8a4e88ee1ae44de255</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrg2707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg2707%26sid%3Dliteratum%253Aachs%26aulast%3DLahiry%26aufirst%3DP.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DN.%2BJ.%26aulast%3DHegele%26aufirst%3DR.%2BA.%26atitle%3DKinase%2520mutations%2520in%2520human%2520disease%253A%2520interpreting%2520genotype-phenotype%2520relationships%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2010%26volume%3D11%26spage%3D60%26epage%3D74%26doi%3D10.1038%2Fnrg2707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ten Eyck, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashford, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xuong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowadski, J.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">414</span>, <span class="refDoi"> DOI: 10.1126/science.1862342</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscience.1862342" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1862342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK3MXmsFSqsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1991&pages=407-414&author=D.+Knightonauthor=J.+Zhengauthor=L.+Ten+Eyckauthor=V.+Ashfordauthor=N.+Xuongauthor=S.+Taylorauthor=J.+Sowadski&title=Crystal+structure+of+the+catalytic+subunit+of+cyclic+adenosine+monophosphate-dependent+protein+kinase&doi=10.1126%2Fscience.1862342"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase</span></div><div class="casAuthors">Knighton, Daniel R.; Zheng, Jianhua; Ten Eyck, Lynn F.; Ashford, Victor A.; Nguyen Huu Xuong; Taylor, Susan S.; Sowadski, Janusz M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">5018</span>),
    <span class="NLM_cas:pages">407-14</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate analog inhibitor has been solved and partially refined at 2.7 Å resoln. to an R factor of 0.212.  The magnesium ATP (MgATP) binding site was located by difference Fourier synthesis.  The enzyme structure is bilobal with a deep cleft between the lobes.  The cleft is filled by MgATP and a portion of the inhibitor peptide.  The smaller lobe, consisting mostly of amino-terminal sequence, is assocd. with nucleotide binding, and its largely antiparallel β sheet architecture constitutes an unusual nucleotide binding motif.  The large lobe is dominated by helical structure with a single β sheet at the domain interface.  This lobe is primarily involved in peptide binding and catalysis.  Residues 40 through 280 constitute a conserved catalytic core that is shared by more than 100 protein kinases.  Most of the invariant amino acids in this conserved catalytic core are clustered at the site of nucleotide binding and catalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-BPvdNuboTbVg90H21EOLACvtfcHk0ljAOt4AfHAu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmsFSqsLw%253D&md5=1b1dc6aaa1a63fc665b81f8967e143b1</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1862342&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1862342%26sid%3Dliteratum%253Aachs%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DTen%2BEyck%26aufirst%3DL.%26aulast%3DAshford%26aufirst%3DV.%26aulast%3DXuong%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DSowadski%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520catalytic%2520subunit%2520of%2520cyclic%2520adenosine%2520monophosphate-dependent%2520protein%2520kinase%26jtitle%3DScience%26date%3D1991%26volume%3D253%26spage%3D407%26epage%3D414%26doi%3D10.1126%2Fscience.1862342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M. E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The structural basis for control of eukaryotic protein kinases</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1146/annurev-biochem-052410-090317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1146%2Fannurev-biochem-052410-090317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22482904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2012&pages=587-613&author=J.+A.+Endicottauthor=M.+E.+M.+Nobleauthor=L.+N.+Johnson&title=The+structural+basis+for+control+of+eukaryotic+protein+kinases&doi=10.1146%2Fannurev-biochem-052410-090317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis for control of eukaryotic protein kinases</span></div><div class="casAuthors">Endicott, Jane A.; Noble, Martin E. M.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">587-613</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases are key regulators of cell processes.  Comparison of the structures of protein kinase domains, both alone and in complexes, allows generalizations to be made about the mechanisms that regulate protein kinase activation.  Protein kinases in the active state adopt a catalytically competent conformation upon binding of both the ATP and peptide substrates that has led to an understanding of the catalytic mechanism.  Docking sites remote from the catalytic site are a key feature of several substrate recognition complexes.  Mechanisms for kinase activation through phosphorylation, addnl. domains or subunits, by scaffolding proteins and by kinase dimerization are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow52PIce_NWLVg90H21EOLACvtfcHk0ljAOt4AfHAu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGls7fF&md5=a7ce0f2ac75956288c2ea436d34cad8c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1146%2Fannurev-biochem-052410-090317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-biochem-052410-090317%26sid%3Dliteratum%253Aachs%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DNoble%26aufirst%3DM.%2BE.%2BM.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520structural%2520basis%2520for%2520control%2520of%2520eukaryotic%2520protein%2520kinases%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2012%26volume%3D81%26spage%3D587%26epage%3D613%26doi%3D10.1146%2Fannurev-biochem-052410-090317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanev, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Linden, O. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span> <span> </span><span class="NLM_article-title">KLIFS: a structural kinase-ligand interaction database</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">D365</span>– <span class="NLM_lpage">D371</span>, <span class="refDoi"> DOI: 10.1093/nar/gkv1082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fnar%2Fgkv1082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26496949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=D365-D371&author=A.+J.+Kooistraauthor=G.+K.+Kanevauthor=O.+P.+J.+Van+Lindenauthor=R.+Leursauthor=I.+J.+P.+De+Eschauthor=C.+De+Graaf&title=KLIFS%3A+a+structural+kinase-ligand+interaction+database&doi=10.1093%2Fnar%2Fgkv1082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">KLIFS: a structural kinase-ligand interaction database</span></div><div class="casAuthors">Kooistra, Albert J.; Kanev, Georgi K.; van Linden, Oscar P. J.; Leurs, Rob; de Esch, Iwan J. P.; de Graaf, Chris</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D365-D371</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Protein kinases play a crucial role in cell signaling and are important drug targets in several therapeutic areas.  The KLIFS database contains detailed structural kinase-ligand interaction information derived from all (>2900) structures of catalytic domains of human and mouse protein kinases deposited in the Protein Data Bank in order to provide insights into the structural determinants of kinase-ligand binding and selectivity.  The kinase structures have been processed in a consistent manner by systematically analyzing the structural features and mol. interaction fingerprints (IFPs) of a predefined set of 85 binding site residues with bound ligands.  KLIFS has been completely rebuilt and extended (>65% more structures) since its first release as a data set, including: novel automated annotation methods for (i) the assessment of ligand-targeted subpockets and the anal. of (ii) DFG and (iii) αC-helix conformations; improved and automated protocols for (iv) the generation of sequence/structure alignments, (v) the curation of ligand atom and bond typing for accurate IFP anal. and (vi) weekly database updates.  KLIFS is now accessible via a website (http://klifs.vucompmedchem. nl) that provides a comprehensive visual presentation of different types of chem., biol. and structural chemogenomics data, and allows the user to easily access, compare, search and download the data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocfCaKwwgOlbVg90H21EOLACvtfcHk0ljAOt4AfHAu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2nsrfP&md5=bc093b02225987fe791a2d41738e4d99</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv1082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv1082%26sid%3Dliteratum%253Aachs%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26aulast%3DKanev%26aufirst%3DG.%2BK.%26aulast%3DVan%2BLinden%26aufirst%3DO.%2BP.%2BJ.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DDe%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26atitle%3DKLIFS%253A%2520a%2520structural%2520kinase-ligand%2520interaction%2520database%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2016%26volume%3D44%26spage%3DD365%26epage%3DD371%26doi%3D10.1093%2Fnar%2Fgkv1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burley, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duarte, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westbrook, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zardecki, C.</span></span> <span> </span><span class="NLM_article-title">RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1002/pro.3331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fpro.3331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29067736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2nsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=316-330&author=S.+K.+Burleyauthor=H.+M.+Bermanauthor=C.+Christieauthor=J.+M.+Duarteauthor=Z.+Fengauthor=J.+Westbrookauthor=J.+Youngauthor=C.+Zardecki&title=RCSB+Protein+Data+Bank%3A+Sustaining+a+living+digital+data+resource+that+enables+breakthroughs+in+scientific+research+and+biomedical+education&doi=10.1002%2Fpro.3331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">RCSB Protein Data Bank: Sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education</span></div><div class="casAuthors">Burley, Stephen K.; Berman, Helen M.; Christie, Cole; Duarte, Jose M.; Feng, Zukang; Westbrook, John; Young, Jasmine; Zardecki, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-330</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The Protein Data Bank (PDB) is one of two archival resources for exptl. data central to biomedical research and education worldwide (the other key Primary Data Archive in biol. being the International Nucleotide Sequence Database Collaboration).  The PDB currently houses >134,000 at. level biomol. structures detd. by crystallog., NMR spectroscopy, and 3D electron microscopy.  It was established in 1971 as the first open-access, digital-data resource in biol., and is managed by the Worldwide Protein Data Bank partnership (wwPDB; wwpdb.org).  US PDB operations are conducted by the RCSB Protein Data Bank (RCSB PDB; RCSB.org; Rutgers University and UC San Diego) and funded by NSF, NIH, and DoE.  The RCSB PDB serves as the global Archive Keeper for the wwPDB.  During calendar 2016, >591 million structure data files were downloaded from the PDB by Data Consumers working in every sovereign nation recognized by the United Nations.  During this same period, the RCSB PDB processed >5300 new at. level biomol. structures plus exptl. data and metadata coming into the archive from Data Depositors working in the Americas and Oceania.  In addn., RCSB PDB served >1 million RCSB.org users worldwide with PDB data integrated with ∼40 external data resources providing rich structural views of fundamental biol., biomedicine, and energy sciences, and >600,000 PDB101.rcsb.org educational website users around the globe.  RCSB PDB resources are described in detail together with metrics documenting the impact of access to PDB data on basic and applied research, clin. medicine, education, and the economy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIN3U6NfSPrVg90H21EOLACvtfcHk0lhbMfLMj8JSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2nsbbF&md5=476af887e708fd78d51f276aabccb023</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fpro.3331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.3331%26sid%3Dliteratum%253Aachs%26aulast%3DBurley%26aufirst%3DS.%2BK.%26aulast%3DBerman%26aufirst%3DH.%2BM.%26aulast%3DChristie%26aufirst%3DC.%26aulast%3DDuarte%26aufirst%3DJ.%2BM.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DWestbrook%26aufirst%3DJ.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZardecki%26aufirst%3DC.%26atitle%3DRCSB%2520Protein%2520Data%2520Bank%253A%2520Sustaining%2520a%2520living%2520digital%2520data%2520resource%2520that%2520enables%2520breakthroughs%2520in%2520scientific%2520research%2520and%2520biomedical%2520education%26jtitle%3DProtein%2520Sci.%26date%3D2018%26volume%3D27%26spage%3D316%26epage%3D330%26doi%3D10.1002%2Fpro.3331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinases-the major drug targets of the twenty-first century?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1038/nrd773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrd773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12120282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=309-315&author=P.+Cohen&title=Protein+kinases-the+major+drug+targets+of+the+twenty-first+century%3F&doi=10.1038%2Fnrd773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Timeline: Protein kinases - the major drug targets of the twenty-first century?</span></div><div class="casAuthors">Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-315</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease.  A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clin. use.  Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors.  Here, I give a personal view of some of the most important advances that have shaped this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRd_GqiGAWaLVg90H21EOLACvtfcHk0lhbMfLMj8JSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivVGmtr8%253D&md5=67d2fbc11a55b5980ee0692f7bc13cc9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd773%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DProtein%2520kinases-the%2520major%2520drug%2520targets%2520of%2520the%2520twenty-first%2520century%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D309%26epage%3D315%26doi%3D10.1038%2Fnrd773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hidaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, Y.</span></span> <span> </span><span class="NLM_article-title">Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5036</span>– <span class="NLM_lpage">5041</span>, <span class="refDoi"> DOI: 10.1021/bi00316a032</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00316a032" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaL2cXlsVKltLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1984&pages=5036-5041&author=H.+Hidakaauthor=M.+Inagakiauthor=S.+Kawamotoauthor=Y.+Sasaki&title=Isoquinolinesulfonamides%2C+novel+and+potent+inhibitors+of+cyclic+nucleotide+dependent+protein+kinase+and+protein+kinase+C&doi=10.1021%2Fbi00316a032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C</span></div><div class="casAuthors">Hidaka, Hiroyoshi; Inagaki, Masaki; Kawamoto, Sachiyo; Sasaki, Yasuharu</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5036-41</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Naphthalenesulfonamides, such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) are potent calmodulin (CaM) antagonists and act upon several protein kinases at higher concn.  When the naphthalene ring was replaced by isoquinoline, the derivs. were no longer CaM antagonists but retained the ability to inhibit protein kinases, and some of the derivs. exhibited selective inhibition toward a certain protein kinase.  The cAMP-dependent, cGMP-dependent, and Ca2+-phospholipid-dependent (protein kinase C) protein kinases were inhibited significantly by addn. of 10-6M N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) and 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7).  H-8 was the most active of the inhibitors in this series and inhibited more markedly cyclic nucleotide-dependent protein kinases, than other kinases, whereas the deriv. with the sulfonylpiperazine residue (H-7) was the most potent in inhibiting protein kinase C.  The apparent Ki values of H-8 were 0.48 and 1.2 μM for cGMP-dependent and cAMP-dependent protein kinases, resp., and the Ki of H-7 for protein kinase C was 11 μM.  Both the holoenzyme and the catalytic subunit (or fragment), which was active without an enzyme activator, were susceptible to these compds. with a similar concn. dependency, thereby indicating that the inhibitory effect is attributed to the direct interaction of the compd. with the active center of the enzyme but not with the enzyme activator.  The inhibitions were freely reversible and of the competitive type with respect to ATP and of the noncompetitive type with respect to the phosphate acceptor.  Kinetic studies with the catalytic subunit of cAMP-dependent protein kinase indicated that isoquinolinesulfonamides, structurally unrelated to ATP, compete with ATP for free enzyme but do not interact with the same enzyme form as does the phosphate acceptor (i.e., enzyme-ATP complex).  The inhibitory potency of these derivs. appeared to be dependent on the position and the strength of the plus charge contributed by the terminal N atom in the isoquinolinesulfonamide mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrknTWDxnFUhrVg90H21EOLACvtfcHk0lhbMfLMj8JSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXlsVKltLo%253D&md5=d40aea66a748ad3b97ed5397331f9512</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fbi00316a032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00316a032%26sid%3Dliteratum%253Aachs%26aulast%3DHidaka%26aufirst%3DH.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DKawamoto%26aufirst%3DS.%26aulast%3DSasaki%26aufirst%3DY.%26atitle%3DIsoquinolinesulfonamides%252C%2520novel%2520and%2520potent%2520inhibitors%2520of%2520cyclic%2520nucleotide%2520dependent%2520protein%2520kinase%2520and%2520protein%2520kinase%2520C%26jtitle%3DBiochemistry%26date%3D1984%26volume%3D23%26spage%3D5036%26epage%3D5041%26doi%3D10.1021%2Fbi00316a032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vigneri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1038/84683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2F84683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11175855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVyksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=228-234&author=P.+Vigneriauthor=J.+Y.+Wang&title=Induction+of+apoptosis+in+chronic+myelogenous+leukemia+cells+through+nuclear+entrapment+of+BCR-ABL+tyrosine+kinase&doi=10.1038%2F84683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase</span></div><div class="casAuthors">Vigneri, Paolo; Wang, Jean Y. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-234</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The chimeric BCR-ABL oncoprotein is the mol. hallmark of chronic myelogenous leukemia (CML).  BCR-ABL contains nuclear import and export signals but it is localized only in the cytoplasm where it activates mitogenic and anti-apoptotic pathways.  We have found that inhibition of the BCR-ABL tyrosine kinase, either by mutation or by the drug STI571, can stimulate its nuclear entry.  By combining STI571 with leptomycin B (LMB) to block nuclear export, we trapped BCR-ABL in the nucleus and the nuclear BCR-ABL tyrosine kinase activates apoptosis.  As a result, the combined treatment with STI571 and LMB causes the irreversible and complete killing of BCR-ABL transformed cells, whereas the effect of either drug alone is fully reversible.  The combined treatment with STI571 and LMB also preferentially eliminates mouse bone marrow cells that express BCR-ABL.  These results indicate that nuclear entrapment of BCR-ABL can be used as a therapeutic strategy to selectively kill chronic myelogenous leukemia cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjHFOglUtfZLVg90H21EOLACvtfcHk0liV3MRdbZe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVyksL4%253D&md5=dab17bd86b7097b653acde502ee7f84d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F84683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F84683%26sid%3Dliteratum%253Aachs%26aulast%3DVigneri%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DJ.%2BY.%26atitle%3DInduction%2520of%2520apoptosis%2520in%2520chronic%2520myelogenous%2520leukemia%2520cells%2520through%2520nuclear%2520entrapment%2520of%2520BCR-ABL%2520tyrosine%2520kinase%26jtitle%3DNat.%2520Med.%26date%3D2001%26volume%3D7%26spage%3D228%26epage%3D234%26doi%3D10.1038%2F84683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanev, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Graaf, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Esch, I. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leurs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würdinger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westerman, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kooistra, A. J.</span></span> <span> </span><span class="NLM_article-title">The landscape of atypical and eukaryotic protein kinases</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.tips.2019.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31677919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVajurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=818-832&author=G.+K.+Kanevauthor=C.+De+Graafauthor=I.+J.+P.+De+Eschauthor=R.+Leursauthor=T.+W%C3%BCrdingerauthor=B.+A.+Westermanauthor=A.+J.+Kooistra&title=The+landscape+of+atypical+and+eukaryotic+protein+kinases&doi=10.1016%2Fj.tips.2019.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The Landscape of Atypical and Eukaryotic Protein Kinases</span></div><div class="casAuthors">Kanev, Georgi K.; de Graaf, Chris; de Esch, Iwan J. P.; Leurs, Rob; Wuerdinger, Thomas; Westerman, Bart A.; Kooistra, Albert J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-832</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases are attractive anticancer targets due to their central role in the growth, survival, and therapy resistance of tumor cells.  This review explores the two primary kinase classes, the eukaryotic protein kinases (ePKs) and the atypical protein kinases (aPKs), and provides a structure-centered comparison of their sequences, structures, hydrophobic spines, mutation and SNP hotspots, and inhibitor interaction patterns.  Despite the limited sequence similarity between these two classes, atypical kinases commonly share the archetypical kinase fold but lack conserved eukaryotic kinase motifs and possess altered hydrophobic spines.  Furthermore, atypical kinase inhibitors explore only a limited no. of binding modes both inside and outside the orthosteric binding site.  The distribution of genetic variations in both classes shows multiple ways they can interfere with kinase inhibitor binding.  This multilayered review provides a research framework bridging the eukaryotic and atypical kinase classes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpM49MHogshXLVg90H21EOLACvtfcHk0liV3MRdbZe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVajurrO&md5=fc6b47539dc35e0da20eede4fdc72207</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DKanev%26aufirst%3DG.%2BK.%26aulast%3DDe%2BGraaf%26aufirst%3DC.%26aulast%3DDe%2BEsch%26aufirst%3DI.%2BJ.%2BP.%26aulast%3DLeurs%26aufirst%3DR.%26aulast%3DW%25C3%25BCrdinger%26aufirst%3DT.%26aulast%3DWesterman%26aufirst%3DB.%2BA.%26aulast%3DKooistra%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520landscape%2520of%2520atypical%2520and%2520eukaryotic%2520protein%2520kinases%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D818%26epage%3D832%26doi%3D10.1016%2Fj.tips.2019.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kannaiyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahadevan, D.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review of protein kinase inhibitors for cancer therapy</span>. <i>Expert Rev. Anticancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1249</span>– <span class="NLM_lpage">1270</span>, <span class="refDoi"> DOI: 10.1080/14737140.2018.1527688</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14737140.2018.1527688" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30259761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=1249-1270&author=R.+Kannaiyanauthor=D.+Mahadevan&title=A+comprehensive+review+of+protein+kinase+inhibitors+for+cancer+therapy&doi=10.1080%2F14737140.2018.1527688"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review of protein kinase inhibitors for cancer therapy</span></div><div class="casAuthors">Kannaiyan, Radhamani; Mahadevan, Daruka</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1249-1270</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are involved in various cellular functions.  About 2% of the human genome encodes for protein kinases.  Dysregulation of protein kinases is implicated in various processes of carcinogenesis.  The advent of protein kinase inhibitors in cancer therapy has led to a paradigm shift in cancer therapy.  Several protein kinase inhibitors have been approved by FDA in the last few decades.  This article provides a review of the FDA approved protein kinase inhibitors as of Dec. 2017 for the well-known oncogenic protein kinases.  A list of FDA approved protein kinase inhibitors and their FDA approved clin. indications were cataloged.  The role of the resp. oncogenic protein kinases in carcinogenesis and cancer progression and the relevant landmark clin. trials of resp. protein kinase inhibitors leading up to the FDA approval were PubMed searched and discussed.  Further understanding of the mol. origin of various cancers would help identify new targets.  Use of biomarker profiling might select the patient population that would benefit better from kinase inhibitors.  Clin. trials should be designed to identify the appropriate sequence of the available kinase inhibitors.  It would prove to be useful to test these drugs in the adjuvant setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeLoNJcZUGLVg90H21EOLACvtfcHk0liV3MRdbZe0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOqs7nK&md5=853138e6be969ecb6d137356bf5d2fd3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F14737140.2018.1527688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737140.2018.1527688%26sid%3Dliteratum%253Aachs%26aulast%3DKannaiyan%26aufirst%3DR.%26aulast%3DMahadevan%26aufirst%3DD.%26atitle%3DA%2520comprehensive%2520review%2520of%2520protein%2520kinase%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2018%26volume%3D18%26spage%3D1249%26epage%3D1270%26doi%3D10.1080%2F14737140.2018.1527688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nibbs, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInnes, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siebert, S.</span></span> <span> </span><span class="NLM_article-title">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1111/cei.12248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fcei.12248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24313320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2014&pages=1-10&author=H.+Pattersonauthor=R.+Nibbsauthor=I.+McInnesauthor=S.+Siebert&title=Protein+kinase+inhibitors+in+the+treatment+of+inflammatory+and+autoimmune+diseases&doi=10.1111%2Fcei.12248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases</span></div><div class="casAuthors">Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Summary : Protein kinases mediate protein phosphorylation, which is a fundamental component of cell signalling, with crucial roles in most signal transduction cascades: from controlling cell growth and proliferation to the initiation and regulation of immunol. responses.  Aberrant kinase activity is implicated in an increasing no. of diseases, with more than 400 human diseases now linked either directly or indirectly to protein kinases.  Protein kinases are therefore regarded as highly important drug targets, and are the subject of intensive research activity.  The success of small mol. kinase inhibitors in the treatment of cancer, coupled with a greater understanding of inflammatory signalling cascades, has led to kinase inhibitors taking center stage in the pursuit for new anti-inflammatory agents for the treatment of immune-mediated diseases.  Herein we discuss the main classes of kinase inhibitors; namely Janus kinase (JAK), mitogen-activated protein kinase (MAPK) and spleen tyrosine kinase (Syk) inhibitors.  We provide a mechanistic insight into how these inhibitors interfere with kinase signalling pathways and discuss the clin. successes and failures in the implementation of kinase-directed therapeutics in the context of inflammatory and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro6xmLNBP2V7Vg90H21EOLACvtfcHk0lgaX7jTfuvmXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXktVylurw%253D&md5=fb65f5c7ee7086383ddbc95c787da2b4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1111%2Fcei.12248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcei.12248%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DH.%26aulast%3DNibbs%26aufirst%3DR.%26aulast%3DMcInnes%26aufirst%3DI.%26aulast%3DSiebert%26aufirst%3DS.%26atitle%3DProtein%2520kinase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520autoimmune%2520diseases%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2014%26volume%3D176%26spage%3D1%26epage%3D10%26doi%3D10.1111%2Fcei.12248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vasta, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corona, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingold, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machleidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkland, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huwiler, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohana, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisenheimer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span> <span> </span><span class="NLM_article-title">Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2017.10.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29174542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=206-214&author=J.+D.+Vastaauthor=C.+R.+Coronaauthor=J.+Wilkinsonauthor=C.+A.+Zimprichauthor=J.+R.+Hartnettauthor=M.+R.+Ingoldauthor=K.+Zimmermanauthor=T.+Machleidtauthor=T.+A.+Kirklandauthor=K.+G.+Huwilerauthor=R.+F.+Ohanaauthor=M.+Slaterauthor=P.+Ottoauthor=M.+Congauthor=C.+I.+Wellsauthor=B.+T.+Bergerauthor=T.+Hankeauthor=C.+Glasauthor=K.+Dingauthor=D.+H.+Drewryauthor=K.+V.+M.+Huberauthor=T.+M.+Willsonauthor=S.+Knappauthor=S.+Mullerauthor=P.+L.+Meisenheimerauthor=F.+Fanauthor=K.+V.+Woodauthor=M.+B.+Robers&title=Quantitative%2C+wide-spectrum+kinase+profiling+in+live+cells+for+assessing+the+effect+of+cellular+ATP+on+target+engagement&doi=10.1016%2Fj.chembiol.2017.10.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement</span></div><div class="casAuthors">Vasta, James D.; Corona, Cesear R.; Wilkinson, Jennifer; Zimprich, Chad A.; Hartnett, James R.; Ingold, Morgan R.; Zimmerman, Kristopher; Machleidt, Thomas; Kirkland, Thomas A.; Huwiler, Kristin G.; Ohana, Rachel Friedman; Slater, Michael; Otto, Paul; Cong, Mei; Wells, Carrow I.; Berger, Benedict-Tilman; Hanke, Thomas; Glas, Carina; Ding, Ke; Drewry, David H.; Huber, Kilian V. M.; Willson, Timothy M.; Knapp, Stefan; Muller, Susanne; Meisenheimer, Poncho L.; Fan, Frank; Wood, Keith V.; Robers, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-214.e11</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">For kinase inhibitors, intracellular target selectivity is fundamental to pharmacol. mechanism.  Although a no. of acellular techniques have been developed to measure kinase binding or enzymic inhibition, such approaches can fail to accurately predict engagement in cells.  Here we report the application of an energy transfer technique that enabled the first broad-spectrum, equil.-based approach to quant. profile target occupancy and compd. affinity in live cells.  Using this method, we performed a selectivity profiling for clin. relevant kinase inhibitors against 178 full-length kinases, and a mechanistic interrogation of the potency offsets obsd. between cellular and biochem. anal.  For the multikinase inhibitor crizotinib, our approach accurately predicted cellular potency and revealed improved target selectivity compared with biochem. measurements.  Due to cellular ATP, a no. of putative crizotinib targets are unexpectedly disengaged in live cells at a clin. relevant drug dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaPVDw5pU6zrVg90H21EOLACvtfcHk0lgaX7jTfuvmXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVOitbfN&md5=bc3a1f618ab0d2ad6355f31af66d7ef4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DVasta%26aufirst%3DJ.%2BD.%26aulast%3DCorona%26aufirst%3DC.%2BR.%26aulast%3DWilkinson%26aufirst%3DJ.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DIngold%26aufirst%3DM.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DHuwiler%26aufirst%3DK.%2BG.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DOtto%26aufirst%3DP.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DHanke%26aufirst%3DT.%26aulast%3DGlas%26aufirst%3DC.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DMeisenheimer%26aufirst%3DP.%2BL.%26aulast%3DFan%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DK.%2BV.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26atitle%3DQuantitative%252C%2520wide-spectrum%2520kinase%2520profiling%2520in%2520live%2520cells%2520for%2520assessing%2520the%2520effect%2520of%2520cellular%2520ATP%2520on%2520target%2520engagement%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D206%26epage%3D214%26doi%3D10.1016%2Fj.chembiol.2017.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabelli, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D. M.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinases: relationship to other lipid kinases</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2018.09.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2018.09.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30348515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFKitrnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2019&pages=104-110&author=Q.+Maauthor=S.+B.+Gabelliauthor=D.+M.+Raben&title=Diacylglycerol+kinases%3A+relationship+to+other+lipid+kinases&doi=10.1016%2Fj.jbior.2018.09.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol kinases: Relationship to other lipid kinases</span></div><div class="casAuthors">Ma, Qianqian; Gabelli, Sandra B.; Raben, Daniel M.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Lipid kinases regulate a wide variety of cellular functions and have emerged as one the most promising targets for drug design.  Diacylglycerol kinases (DGKs) are a family of enzymes that catalyze the ATP-dependent phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PtdOH).  Despite the crit. role in lipid biosynthesis, both DAG and PtdOH have been shown as bioactive lipids mediating a no. of signaling pathways.  Although there is increasing recognition of their role in signaling systems, our understanding of the key enzyme which regulate the balance of these two lipid messages remain limited.  Solved structures provide a wealth of information for understanding the function and regulation of these enzymes.  Solving the structures of mammalian DGKs by traditional NMR and X-ray crystallog. approaches have been challenging and so far, there are still no three-dimensional structures of these DGKs.  Despite this, some insights may be gained by examg. the similarities and differences between prokaryotic DGKs and other mammalian lipid kinases.  This review focuses on summarizing and comparing the structure of prokaryotic and mammalian DGKs as well as two other lipid kinases: sphingosine kinase and phosphatidylinositol-3-kinase.  How these known lipid kinases structures relate to mammalian DGKs will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ur-DEswYVLVg90H21EOLACvtfcHk0lgaX7jTfuvmXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFKitrnF&md5=8f57d349539108ddad84075b51e639f2</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2018.09.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2018.09.014%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DGabelli%26aufirst%3DS.%2BB.%26aulast%3DRaben%26aufirst%3DD.%2BM.%26atitle%3DDiacylglycerol%2520kinases%253A%2520relationship%2520to%2520other%2520lipid%2520kinases%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2019%26volume%3D71%26spage%3D104%26epage%3D110%26doi%3D10.1016%2Fj.jbior.2018.09.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Ayuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila-Flores, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz-Nicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrada, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tello-Lafoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liebana, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcos, R.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinases in cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2016.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2016.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27697466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1SitbbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2017&pages=22-31&author=I.+Meridaauthor=P.+Torres-Ayusoauthor=A.+Avila-Floresauthor=J.+Arranz-Nicolasauthor=E.+Andradaauthor=M.+Tello-Lafozauthor=R.+Liebanaauthor=R.+Arcos&title=Diacylglycerol+kinases+in+cancer&doi=10.1016%2Fj.jbior.2016.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Diacylglycerol kinases in cancer</span></div><div class="casAuthors">Merida, Isabel; Torres-Ayuso, Pedro; Avila-Flores, Antonia; Arranz-Nicolas, Javier; Andrada, Elena; Tello-Lafoz, Maria; Liebana, Rosa; Arcos, Raquel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22-31</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Diacylglycerol kinases (DGK) are a family of enzymes that catalyze the transformation of diacylglycerol into phosphatidic acid.  In T lymphocytes, DGKα and ζ limit the activation of the PLCγ/Ras/ERK axis, providing a crit. checkpoint to inhibit T cell responses.  Upregulation of these isoforms limits Ras activation, leading to hypo-responsive, anergic states similar to those caused by tumors.  Recent studies have identified DGKα upregulation in tumor lymphocyte infiltrates, and cells from DGKα and ζ deficient mice show enhanced antitumor activity, suggesting that limitation of DAG based signals by DGK is used by tumors to evade immune attack.  DGKα expression is low or even absent in other healthy cells like melanocytes, hepatocytes or neurons.  Expression of this isoform, nevertheless is upregulated in melanoma, hepatocarcinoma and glioblastoma where DGKα contributes to the acquisition of tumor metastatic traits.  A model thus emerges where tumor milieu fosters DGKα expression in tumors as well as in tumor infiltrating lymphocytes with opposite consequences.  Here we review the mechanisms and targets that facilitate tumor "addiction" to DGKα, and discuss its relevance in the more advanced forms of cancer for tumor immune evasion.  A better knowledge of this function offers a new perspective in the search of novel approaches to prevent inhibition of immune attack in cancer.  Part of the failure in clin. progress may be attributed to the complexity of the tumor/T lymphocyte interaction.  As they develop, tumors use a no. of mechanisms to drive endogenous, tumor reactive T cells to a general state of hyporesponsiveness or anergy.  A better knowledge of the mol. mechanisms that tumors use to trigger T cell anergic states will greatly help in the advance of immunotherapy research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Cpu3SrUtFLVg90H21EOLACvtfcHk0liZJM9RDclsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1SitbbI&md5=4b78f0fdd9c0605379790531dad82a42</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2016.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2016.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMerida%26aufirst%3DI.%26aulast%3DTorres-Ayuso%26aufirst%3DP.%26aulast%3DAvila-Flores%26aufirst%3DA.%26aulast%3DArranz-Nicolas%26aufirst%3DJ.%26aulast%3DAndrada%26aufirst%3DE.%26aulast%3DTello-Lafoz%26aufirst%3DM.%26aulast%3DLiebana%26aufirst%3DR.%26aulast%3DArcos%26aufirst%3DR.%26atitle%3DDiacylglycerol%2520kinases%2520in%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2017%26volume%3D63%26spage%3D22%26epage%3D31%26doi%3D10.1016%2Fj.jbior.2016.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-kinase, growth disorders, and cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">2052</span>– <span class="NLM_lpage">2062</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1704560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1056%2FNEJMra1704560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30462943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2ltbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2018&pages=2052-2062&author=M.+D.+Goncalvesauthor=B.+D.+Hopkinsauthor=L.+C.+Cantley&title=Phosphatidylinositol+3-kinase%2C+growth+disorders%2C+and+cancer&doi=10.1056%2FNEJMra1704560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-kinase, growth disorders, and cancer</span></div><div class="casAuthors">Goncalves, Marcus D.; Hopkins, Benjamin D.; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2052-2062</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article discusses the discovery of discussion on phosphatidylinositol 3-kinase growth disorders in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH19P_K_L-ZbVg90H21EOLACvtfcHk0liZJM9RDclsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2ltbvE&md5=30fe8bd267667fbbf0c31ea99d92a065</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1704560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1704560%26sid%3Dliteratum%253Aachs%26aulast%3DGoncalves%26aufirst%3DM.%2BD.%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DPhosphatidylinositol%25203-kinase%252C%2520growth%2520disorders%252C%2520and%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D379%26spage%3D2052%26epage%3D2062%26doi%3D10.1056%2FNEJMra1704560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Buri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and cancer</span>. <i>Adv. Biol. Regul.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.jbior.2017.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbior.2017.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28942351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFemsLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=97-106&author=N.+J.+Pyneauthor=A.+El+Buriauthor=D.+R.+Adamsauthor=S.+Pyne&title=Sphingosine+1-phosphate+and+cancer&doi=10.1016%2Fj.jbior.2017.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and cancer</span></div><div class="casAuthors">Pyne, Nigel J.; El Buri, Ashref; Adams, David R.; Pyne, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Biological Regulation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97-106</span>CODEN:
                <span class="NLM_cas:coden">ABRDE5</span>;
        ISSN:<span class="NLM_cas:issn">2212-4934</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The bioactive lipid, sphingosine 1-phosphate (S1P) is produced by phosphorylation of sphingosine and this is catalyzed by two sphingosine kinase isoforms (SK1 and SK2).  Here we discuss structural functional aspects of SK1 (which is a dimeric quaternary enzyme) that relate to coordinated coupling of membrane assocn. with phosphorylation of Ser225 in the 'so-called' R-loop, catalytic activity and protein-protein interactions (e.g. TRAF2, PP2A and Gq).  S1P formed by SK1 at the plasma-membrane is released from cells via S1P transporters to act on S1P receptors to promote tumorigenesis.  We discuss here an addnl. novel mechanism that can operate between cancer cells and fibroblasts and which involves the release of the S1P receptor, S1P2 in exosomes from breast cancer cells that regulates ERK-1/2 signalling in fibroblasts.  This novel mechanism of signalling might provide an explanation for the role of S1P2 in promoting metastasis of cancer cells and which is dependent on the micro-environmental niche.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOIeSH1AVNrVg90H21EOLACvtfcHk0liZJM9RDclsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFemsLzO&md5=bcef61d0d930c89116e5dd97a874290a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jbior.2017.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbior.2017.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26aulast%3DEl%2BBuri%26aufirst%3DA.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DPyne%26aufirst%3DS.%26atitle%3DSphingosine%25201-phosphate%2520and%2520cancer%26jtitle%3DAdv.%2520Biol.%2520Regul.%26date%3D2018%26volume%3D68%26spage%3D97%26epage%3D106%26doi%3D10.1016%2Fj.jbior.2017.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyne, N. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances</span>. <i>Prog. Lipid Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">106</span>, <span class="refDoi"> DOI: 10.1016/j.plipres.2016.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.plipres.2016.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26970273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2016&pages=93-106&author=S.+Pyneauthor=D.+R.+Adamsauthor=N.+J.+Pyne&title=Sphingosine+1-phosphate+and+sphingosine+kinases+in+health+and+disease%3A+Recent+advances&doi=10.1016%2Fj.plipres.2016.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and sphingosine kinases in health and disease: Recent advances</span></div><div class="casAuthors">Pyne, Susan; Adams, David R.; Pyne, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Lipid Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-106</span>CODEN:
                <span class="NLM_cas:coden">PLIRDW</span>;
        ISSN:<span class="NLM_cas:issn">0163-7827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Sphingosine kinases (isoforms SK1 and SK2) catalyze the formation of a bioactive lipid, sphingosine 1-phosphate (S1P).  S1P is a well-established ligand of a family of five S1P-specific G protein coupled receptors but also has intracellular signalling roles.  There is substantial evidence to support a role for sphingosine kinases and S1P in health and disease.  This review summarizes recent advances in the area in relation to receptor-mediated signalling by S1P and novel intracellular targets of this lipid.  New evidence for a role of each sphingosine kinase isoform in cancer, the cardiovascular system, central nervous system, inflammation and diabetes is discussed.  There is continued research to develop isoform selective SK inhibitors, summarized here.  Anal. of the crystal structure of SK1 with the SK1-selective inhibitor, PF-543, is used to identify residues that could be exploited to improve selectivity in SK inhibitor development for future therapeutic application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCVKxUdCGqsrVg90H21EOLACvtfcHk0liZJM9RDclsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cmsb8%253D&md5=fdda88832419c066eecb87a07ae3e6ec</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.plipres.2016.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.plipres.2016.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPyne%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DD.%2BR.%26aulast%3DPyne%26aufirst%3DN.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520sphingosine%2520kinases%2520in%2520health%2520and%2520disease%253A%2520Recent%2520advances%26jtitle%3DProg.%2520Lipid%2520Res.%26date%3D2016%26volume%3D62%26spage%3D93%26epage%3D106%26doi%3D10.1016%2Fj.plipres.2016.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span> <span> </span><span class="NLM_article-title">Structural basis for regulation of phosphoinositide kinases and their involvement in human disease</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.molcel.2018.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30193094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Omu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2018&pages=653-673&author=J.+E.+Burke&title=Structural+basis+for+regulation+of+phosphoinositide+kinases+and+their+involvement+in+human+disease&doi=10.1016%2Fj.molcel.2018.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease</span></div><div class="casAuthors">Burke, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">653-673</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Lipid phosphoinositides play fundamental roles in virtually all pathways that control a cell's decision to grow, move, divide, and die.  Because of this, kinases that phosphorylate phosphoinositide lipids are critically involved in myriad essential functions including growth, development, and membrane trafficking.  The misregulation of phosphoinositide kinases is crit. in human diseases, including cancer, primary immunodeficiencies, and developmental disorders.  Phosphoinositide kinases also play a role in mediating bacterial and viral infections for many potent human pathogens.  Furthermore, inhibitors of parasite phosphoinositide kinases are in development as therapies for both malaria and cryptosporidiosis.  Therefore, understanding how phosphoinositide kinases are regulated has implications for the treatment of many devastating human diseases.  Recent structures of phosphoinositide kinases have revealed unique mol. insight into their regulation.  This review will summarize our current mol. knowledge on phosphoinositide kinase regulation, and how this information is being used to generate novel small mol. inhibitors as potential therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDXWNHxkyBbVg90H21EOLACvtfcHk0liLiQwVxJmF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Omu7fI&md5=17f9dd8a903b2026a9dff0e2afe2a473</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26atitle%3DStructural%2520basis%2520for%2520regulation%2520of%2520phosphoinositide%2520kinases%2520and%2520their%2520involvement%2520in%2520human%2520disease%26jtitle%3DMol.%2520Cell%26date%3D2018%26volume%3D71%26spage%3D653%26epage%3D673%26doi%3D10.1016%2Fj.molcel.2018.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merida, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arranz-Nicolas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Ayuso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila-Flores, A.</span></span> <span> </span><span class="NLM_article-title">Diacylglycerol kinase malfunction in human disease and the search for specific inhibitors</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>259</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1007/164_2019_221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2F164_2019_221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=259&publication_year=2019&pages=133-162&author=I.+Meridaauthor=J.+Arranz-Nicolasauthor=P.+Torres-Ayusoauthor=A.+Avila-Flores&title=Diacylglycerol+kinase+malfunction+in+human+disease+and+the+search+for+specific+inhibitors&doi=10.1007%2F164_2019_221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2F164_2019_221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2019_221%26sid%3Dliteratum%253Aachs%26aulast%3DMerida%26aufirst%3DI.%26aulast%3DArranz-Nicolas%26aufirst%3DJ.%26aulast%3DTorres-Ayuso%26aufirst%3DP.%26aulast%3DAvila-Flores%26aufirst%3DA.%26atitle%3DDiacylglycerol%2520kinase%2520malfunction%2520in%2520human%2520disease%2520and%2520the%2520search%2520for%2520specific%2520inhibitors%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2019%26volume%3D259%26spage%3D133%26epage%3D162%26doi%3D10.1007%2F164_2019_221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span> <span> </span><span class="NLM_article-title">Drugging sphingosine kinases</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1021/cb5008426</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb5008426" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyrtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=225-233&author=W.+L.+Santosauthor=K.+R.+Lynch&title=Drugging+sphingosine+kinases&doi=10.1021%2Fcb5008426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging Sphingosine Kinases</span></div><div class="casAuthors">Santos, Webster L.; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">225-233</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The transfer of the gamma phosphate from ATP to sphingosine (Sph) to generate a small signaling mol., sphingosine 1-phosphate (S1P), is catalyzed by sphingosine kinases (SphK), which exist as two isoforms, SphK1 and SphK2.  SphK is a key regulator of S1P and the S1P:Sph/ceramide ratio.  Increases in S1P levels have been linked to diseases including sickle cell disease, cancer, and fibrosis.  Therefore, SphKs are potential targets for drug discovery.  However, the current chem. biol. toolkit needed to validate these enzymes as drug targets is inadequate.  With this review, we survey in vivo active SphK inhibitors and highlight the need for developing more potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAcry5FA9Mv7Vg90H21EOLACvtfcHk0liLiQwVxJmF4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyrtbnP&md5=acafec4ecc0cf83d22d0813b8e8e9464</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fcb5008426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb5008426%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DW.%2BL.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DDrugging%2520sphingosine%2520kinases%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D225%26epage%3D233%26doi%3D10.1021%2Fcb5008426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span> <span> </span><span class="NLM_article-title">Drugging the Phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1274</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">222</span>, <span class="refDoi"> DOI: 10.1007/978-3-030-50621-6_9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2F978-3-030-50621-6_9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32894512" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXosFOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1274&publication_year=2020&pages=203-222&author=J.+A.+McPhailauthor=J.+E.+Burke&title=Drugging+the+Phosphoinositide+3-kinase+%28PI3K%29+and+phosphatidylinositol+4-kinase+%28PI4K%29+family+of+enzymes+for+treatment+of+cancer%2C+immune+disorders%2C+and+viral%2Fparasitic+infections&doi=10.1007%2F978-3-030-50621-6_9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Drugging the Phosphoinositide 3-Kinase (PI3K) and Phosphatidylinositol 4-Kinase (PI4K) Family of Enzymes for Treatment of Cancer, Immune Disorders, and Viral/Parasitic Infections</span></div><div class="casAuthors">McPhail, Jacob A.; Burke, John E.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1274</span>
        (<span class="NLM_cas:issue">Druggable Lipid Signaling Pathways</span>),
    <span class="NLM_cas:pages">203-222</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The lipid kinases that generate the lipid signalling phosphoinositides have been established as fundamental signalling enzymes that control numerous aspects of how cells respond to their extracellular environment.  In addn., they play crit. roles in regulating membrane trafficking and lipid transport within the cell.  The class I phosphoinositide kinases which generate the crit. lipid signal PIP3 are hyperactivated in numerous human pathologies including cancer, overgrowth syndromes, and primary immunodeficiencies.  The type III phosphatidylinositol 4-kinase beta isoform (PI4KB), which are evolutionarily similar to the class I PI3Ks, have been found to be essential host factors mediating the replication of numerous devastating pathogenic viruses.  Finally, targeting the parasite variant of PI4KB has been established as one of the most promising strategies for the development of anti-malarial and anti-cryptosporidium strategies.  Therefore, the development of targeted isoform selective inhibitors for these enzymes are of paramount importance.  The first generation of PI3K inhibitors have recently been clin. approved for a no. of different cancers, highlighting their therapeutic value.  This review will examine the history of the class I PI3Ks, and the type III PI4Ks, their relevance to human disease, and the structural basis for their regulation and inhibition by potent and selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQdQoT9Pavn7Vg90H21EOLACvtfcHk0lj23SPbCMThBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXosFOrs7o%253D&md5=d535b647d165a0478bae1ddc4eebae81</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-3-030-50621-6_9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-030-50621-6_9%26sid%3Dliteratum%253Aachs%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26atitle%3DDrugging%2520the%2520Phosphoinositide%25203-kinase%2520%2528PI3K%2529%2520and%2520phosphatidylinositol%25204-kinase%2520%2528PI4K%2529%2520family%2520of%2520enzymes%2520for%2520treatment%2520of%2520cancer%252C%2520immune%2520disorders%252C%2520and%2520viral%252Fparasitic%2520infections%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2020%26volume%3D1274%26spage%3D203%26epage%3D222%26doi%3D10.1007%2F978-3-030-50621-6_9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Russell, C. D.</span></span> <span> </span><span class="NLM_article-title">Eradicating infectious disease: can we and should we?</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">53</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2011.00053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffimmu.2011.00053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22566843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC38nhtlSktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=53&author=C.+D.+Russell&title=Eradicating+infectious+disease%3A+can+we+and+should+we%3F&doi=10.3389%2Ffimmu.2011.00053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Eradicating infectious disease: can we and should we?</span></div><div class="casAuthors">Russell Clark Donald</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">53</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR938jJiAEZVzAyhZbj3lKdfW6udTcc2eZHyCO4oGTxUrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38nhtlSktA%253D%253D&md5=32721fd27f2e2ea20776b3b2c8b8355d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2011.00053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2011.00053%26sid%3Dliteratum%253Aachs%26aulast%3DRussell%26aufirst%3DC.%2BD.%26atitle%3DEradicating%2520infectious%2520disease%253A%2520can%2520we%2520and%2520should%2520we%253F%26jtitle%3DFront.%2520Immunol.%26date%3D2011%26volume%3D2%26spage%3D53%26doi%3D10.3389%2Ffimmu.2011.00053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Littler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberg, B.</span></span> <span> </span><span class="NLM_article-title">Achievements and challenges in antiviral drug discovery</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1177/095632020501600302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1177%2F095632020501600302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16004079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2005&pages=155-168&author=E.+Littlerauthor=B.+Oberg&title=Achievements+and+challenges+in+antiviral+drug+discovery&doi=10.1177%2F095632020501600302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Achievements and challenges in antiviral drug discovery</span></div><div class="casAuthors">Littler, Eddy; Oberg, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-168</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press</span>)
        </div><div class="casAbstract">A review with refs.  The last 40 years have seen the development of several antiviral drugs with therapeutic value in treating life-threatening or debilitating diseases such as those caused by HIV, hepatitis B virus, herpesviruses (such as herpes simplex virus and varicella zoster virus) and influenza virus.  These relatively recent advances have been due to tech. breakthroughs in the cultivation of viruses in the lab., identification of viral enzymes and, more recently, their mol. biol.  We describe here the antecedence of several of the existing antivirals and their strengths and weaknesses.  We indicate where the major challenges lie for future improvements of current therapies and possible new indications, such as hepatitis C virus and papillomavirus.  We also describe how current antiviral therapies are restricted to a rather limited no. of viral diseases of sufficient interest to the pharmaceutical industry.  Finally we describe the potential threat of emerging viruses and bioweapons and the challenges that they present to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhaU27yTcDHLVg90H21EOLACvtfcHk0lj23SPbCMThBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtF2lsro%253D&md5=d4e10261e4708bc7a4fcc3a21ac5f52c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1177%2F095632020501600302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020501600302%26sid%3Dliteratum%253Aachs%26aulast%3DLittler%26aufirst%3DE.%26aulast%3DOberg%26aufirst%3DB.%26atitle%3DAchievements%2520and%2520challenges%2520in%2520antiviral%2520drug%2520discovery%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2005%26volume%3D16%26spage%3D155%26epage%3D168%26doi%3D10.1177%2F095632020501600302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K.</span></span> <span> </span><span class="NLM_article-title">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span>, <span class="refDoi"> DOI: 10.1517/13543784.2013.806482</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1517%2F13543784.2013.806482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23735127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1107-1121&author=N.+Shahauthor=T.+Pierceauthor=K.+Kowdley&title=Review+of+direct-acting+antiviral+agents+for+the+treatment+of+chronic+hepatitis+C&doi=10.1517%2F13543784.2013.806482"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Shah, Nihar; Pierce, Tracey; Kowdley, Kris V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic disease.  In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV.  Several DAAs currently in late-stage clin. trials, including NS3/NS4A serine PIs, NS5A inhibitors, NS5B polymerase inhibitors (both nucleoside and non-nucleoside) and cyclophilin inhibitors, both with and without peg-IFN and RBV, are promising for the treatment of HCV.  DAA regimens offer several advantages including that they specifically target HCV viral replication and thus appear to be less dependent on host characteristics, very high SVR rates accompanied by fewer side effects (SE) and lower pill burdens.  A review on the treatment of HCV is important and timely as the development on DAAs is progressing rapidly and the health-care providers need to be aware about this as these regimens are anticipated to become clin. available soon.  Areas covered: The literature was searched and reviewed using PubMed as well as data gathered from those presented at the international liver meetings, AASLD and EASL as well as CROI.  Expert opinion: With the potential of eliminating IFN and RBV, several DAAs under clin. development appear to be promising using novel approaches with good antiviral effects, shorter duration and lower SE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZExgJKmkr7Vg90H21EOLACvtfcHk0lg-VNZB7i4cog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO&md5=f761cff6a6710f4de9473db6509d20a9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.806482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.806482%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DPierce%26aufirst%3DT.%26aulast%3DKowdley%26aufirst%3DK.%26atitle%3DReview%2520of%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1107%26epage%3D1121%26doi%3D10.1517%2F13543784.2013.806482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adalja, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglesby, T.</span></span> <span> </span><span class="NLM_article-title">Broad-spectrum antiviral agents: a crucial pandemic tool</span>. <i>Expert Rev. Anti-Infect. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1080/14787210.2019.1635009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14787210.2019.1635009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31216912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1ersLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=467-470&author=A.+Adaljaauthor=T.+Inglesby&title=Broad-spectrum+antiviral+agents%3A+a+crucial+pandemic+tool&doi=10.1080%2F14787210.2019.1635009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool</span></div><div class="casAuthors">Adalja, Amesh; Inglesby, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anti-Infective Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">467-470</span>CODEN:
                <span class="NLM_cas:coden">ERATCK</span>;
        ISSN:<span class="NLM_cas:issn">1478-7210</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1XfpombjYCbVg90H21EOLACvtfcHk0lg-VNZB7i4cog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1ersLbK&md5=28134086c84d06611beed2c76bdf1153</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1080%2F14787210.2019.1635009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14787210.2019.1635009%26sid%3Dliteratum%253Aachs%26aulast%3DAdalja%26aufirst%3DA.%26aulast%3DInglesby%26aufirst%3DT.%26atitle%3DBroad-spectrum%2520antiviral%2520agents%253A%2520a%2520crucial%2520pandemic%2520tool%26jtitle%3DExpert%2520Rev.%2520Anti-Infect.%2520Ther.%26date%3D2019%26volume%3D17%26spage%3D467%26epage%3D470%26doi%3D10.1080%2F14787210.2019.1635009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Keating, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striker, R.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation events during viral infections provide potential therapeutic targets</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">166</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1002/rmv.722</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Frmv.722" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22113983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=166-181&author=J.+A.+Keatingauthor=R.+Striker&title=Phosphorylation+events+during+viral+infections+provide+potential+therapeutic+targets&doi=10.1002%2Frmv.722"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation events during viral infections provide potential therapeutic targets</span></div><div class="casAuthors">Keating, Julie A.; Striker, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">166-181</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : For many medically relevant viruses, there is now considerable evidence that both viral and cellular kinases play important roles in viral infection.  Ultimately, these kinases, and the cellular signaling pathways that they exploit, may serve as therapeutic targets for treating patients.  Currently, small mol. inhibitors of kinases are under investigation as therapy for herpes viral infections.  Addnl., a no. of cellular or host-directed tyrosine kinase inhibitors that have been previously FDA approved for cancer treatment are under study in animal models and clin. trials, as they have shown promise for the treatment of various viral infections as well.  This review will highlight the wide range of viral proteins phosphorylated by viral and cellular kinases, and the potential for variability of kinase recognition sites within viral substrates to impact phosphorylation and kinase prediction.  Research studying kinase-targeting prophylactic and therapeutic treatments for a no. of viral infections will also be discussed.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAakENW1lBobVg90H21EOLACvtfcHk0lg-VNZB7i4cog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVGksb4%253D&md5=101ce4dec72322383e78230028d79569</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Frmv.722&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.722%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DJ.%2BA.%26aulast%3DStriker%26aufirst%3DR.%26atitle%3DPhosphorylation%2520events%2520during%2520viral%2520infections%2520provide%2520potential%2520therapeutic%2520targets%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2012%26volume%3D22%26spage%3D166%26epage%3D181%26doi%3D10.1002%2Frmv.722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brass, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elledge, S.</span></span> <span> </span><span class="NLM_article-title">A genome-wide genetic screen for host factors required for hepatitis C virus propagation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">16410</span>– <span class="NLM_lpage">16415</span>, <span class="refDoi"> DOI: 10.1073/pnas.0907439106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.0907439106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19717417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1OjsbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=16410-16415&author=Q.+Liauthor=A.+Brassauthor=A.+Ngauthor=Z.+Huauthor=R.+Xavierauthor=T.+J.+Liangauthor=S.+Elledge&title=A+genome-wide+genetic+screen+for+host+factors+required+for+hepatitis+C+virus+propagation&doi=10.1073%2Fpnas.0907439106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A genome-wide genetic-screen for host factors required for hepatitis C virus propagation</span></div><div class="casAuthors">Li, Qisheng; Brass, Abraham L.; Ng, Aylwin; Hu, Zongyi; Xavier, Ramnik J.; Liang, T. Jake; Elledge, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">16410-16415, S16410/1-S16410/65</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease and a leading indication for liver transplantation.  Current therapy fails in many instances and is assocd. with significant side effects.  HCV encodes only a few proteins and depends heavily on host factors for propagation.  Each of these host dependencies is a potential therapeutic target.  To find host factors required by HCV, we completed a genome-wide small interfering RNA (siRNA) screen using an infectious HCV cell culture system.  We applied a two-part screening protocol to allow identification of host factors involved in the complete viral life cycle.  The candidate genes found included known or previously identified factors, and also implicate many addnl. host cell proteins in HCV infection.  To create a more comprehensive view of HCV and host cell interactions, we performed a bioinformatic meta-anal. that integrates our data with those of previous functional and proteomic studies.  The identification of host factors participating in the complete HCV life cycle will both advance our understanding of HCV pathogenesis and illuminate therapeutic targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRs-NQOwhbJrVg90H21EOLACvtfcHk0lg-VNZB7i4cog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1OjsbbK&md5=f984eed64ef7e89dbbf7439bbbf17baf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0907439106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0907439106%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DBrass%26aufirst%3DA.%26aulast%3DNg%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DXavier%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DT.%2BJ.%26aulast%3DElledge%26aufirst%3DS.%26atitle%3DA%2520genome-wide%2520genetic%2520screen%2520for%2520host%2520factors%2520required%2520for%2520hepatitis%2520C%2520virus%2520propagation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D16410%26epage%3D16415%26doi%3D10.1073%2Fpnas.0907439106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-Z.</span></span> <span> </span><span class="NLM_article-title">A high throughput RNAi screen reveals determinants of HIV-1 activity in host kinases</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2229</span>– <span class="NLM_lpage">2237</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24966931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1ejsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=2229-2237&author=W.-M.+Jiangauthor=X.-Y.+Zhangauthor=Y.-Z.+Zhangauthor=L.+Liuauthor=H.-Z.+Lu&title=A+high+throughput+RNAi+screen+reveals+determinants+of+HIV-1+activity+in+host+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A high throughput RNAi screen reveals determinants of HIV-1 activity in host kinases</span></div><div class="casAuthors">Jiang, Wei-Min; Zhang, Xin-Yun; Zhang, Yun-Zhi; Liu, Li; Lu, Hong-Zhou</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2229-2237, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Drug resistance remains a great challenge in HIV/AIDS treatment despite the recent advances in novel therapeutics.  It may be a good strategy to develop drugs targeting the essential host factors to decrease the risk of drug resistance.  Previous studies suggested that so many host kinases play roles in HIV life cycles.  More importantly, many kinase genes are drugable targets, therefore, it is vital to figure out host kinases responsible for HIV-1 infection and replication to provide novel therapeutic regimens and to deepen the authors' understanding to HIV-host interaction.  In present work, a high throughput RNAi screen with a shRNA library aginst 474 kinases was applied to HEK293T cells stably expressed a HIV-1 LTR (long terminal repeat)-driven reporter plasmid.  Four genes, AK1, EphB2, PRKACB and CDK5R2, were found to specifically suppress the HIV-1 LTR activity following effective knockdown.  Furthermore, overexpression of AK1 and PRKACB upregulated the HIV-1 LTR activity.  Therefore, AK1 and PRKACB are in pos. control of HIV-1 activity.  DNA microarray anal. demonstrated that overlapped genes between AK1-silenced and PRKACB-silenced cells were mainly enriched in several amino acid biosynthesis pathways, TGF-β signaling and p53 signaling pathways.  These alterations may repress the viral infection by the downregulation of ERK1/2, p38MAPK and NFκB signaling pathways.  Collectively, the authors' work uncovers several host kinases involving the HIV-1 infection and may provide potential therapeutic targets for AIDS treatment in future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPu7jevQHCqrVg90H21EOLACvtfcHk0lg-p6g8qNs1xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1ejsbbF&md5=bfcaf63a5a12bb3a686ae9f55c0999c6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DW.-M.%26aulast%3DZhang%26aufirst%3DX.-Y.%26aulast%3DZhang%26aufirst%3DY.-Z.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLu%26aufirst%3DH.-Z.%26atitle%3DA%2520high%2520throughput%2520RNAi%2520screen%2520reveals%2520determinants%2520of%2520HIV-1%2520activity%2520in%2520host%2520kinases%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2014%26volume%3D7%26spage%3D2229%26epage%3D2237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mondal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potts, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberger, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehle, A.</span></span> <span> </span><span class="NLM_article-title">Influenza virus recruits host protein kinase C to control assembly and activity of its replication machinery</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e26910</span> <span class="refDoi"> DOI: 10.7554/eLife.26910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.7554%2FeLife.26910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28758638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlelsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&author=A.+Mondalauthor=A.+R.+Dawsonauthor=G.+K.+Pottsauthor=E.+C.+Freibergerauthor=S.+F.+Bakerauthor=L.+A.+Moserauthor=K.+A.+Bernardauthor=J.+J.+Coonauthor=A.+Mehle&title=Influenza+virus+recruits+host+protein+kinase+C+to+control+assembly+and+activity+of+its+replication+machinery&doi=10.7554%2FeLife.26910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus recruits host protein kinase C to control assembly and activity of its replication machinery</span></div><div class="casAuthors">Mondal, Arindam; Dawson, Anthony R.; Potts, Gregory K.; Freiberger, Elyse C.; Baker, Steven F.; Moser, Lindsey A.; Bernard, Kristen A.; Coon, Joshua J.; Mehle, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e26910/1-e26910/23</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">Influenza virus expresses transcripts early in infection and transitions towards genome replication at later time points.  This process requires de novo assembly of the viral replication machinery, large ribonucleoprotein complexes (RNPs) composed of the viral polymerase, genomic RNA and oligomeric nucleoprotein (NP).  Despite the central role of RNPs during infection, the factors dictating where and when they assemble are poorly understood.  Here we demonstrate that human protein kinase C (PKC) family members regulate RNP assembly.  Activated PKCδ interacts with the polymerase subunit PB2 and phospho-regulates NP oligomerization and RNP assembly during infection.  Consistent with its role in regulating RNP assembly, knockout of PKCδ impairs virus infection by selectively disrupting genome replication.  However, primary transcription from pre-formed RNPs deposited by infecting particles is unaffected.  Thus, influenza virus exploits host PKCs to regulate RNP assembly, a step required for the transition from primary transcription to genome replication during the infectious cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQs9uzGI3iMLVg90H21EOLACvtfcHk0lg-p6g8qNs1xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlelsb7I&md5=319ca579e33707e57b1756f49e6f1e42</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.7554%2FeLife.26910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.26910%26sid%3Dliteratum%253Aachs%26aulast%3DMondal%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DA.%2BR.%26aulast%3DPotts%26aufirst%3DG.%2BK.%26aulast%3DFreiberger%26aufirst%3DE.%2BC.%26aulast%3DBaker%26aufirst%3DS.%2BF.%26aulast%3DMoser%26aufirst%3DL.%2BA.%26aulast%3DBernard%26aufirst%3DK.%2BA.%26aulast%3DCoon%26aufirst%3DJ.%2BJ.%26aulast%3DMehle%26aufirst%3DA.%26atitle%3DInfluenza%2520virus%2520recruits%2520host%2520protein%2520kinase%2520C%2520to%2520control%2520assembly%2520and%2520activity%2520of%2520its%2520replication%2520machinery%26jtitle%3DeLife%26date%3D2017%26volume%3D6%26doi%3D10.7554%2FeLife.26910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalindjian, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Philpott, K. L.</span></span> <span> </span><span class="NLM_article-title">Principles of early drug discovery</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2010.01127.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fj.1476-5381.2010.01127.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21091654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2011&pages=1239-1249&author=J.+P.+Hughesauthor=S.+Reesauthor=S.+B.+Kalindjianauthor=K.+L.+Philpott&title=Principles+of+early+drug+discovery&doi=10.1111%2Fj.1476-5381.2010.01127.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Principles of early drug discovery</span></div><div class="casAuthors">Hughes, J. P.; Rees, S.; Kalindjian, S. B.; Philpott, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1239-1249</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12-15 years and cost in excess of $1 billion.  The idea for a target can come from a variety of sources including academic and clin. research and from the com. sector.  It may take many years to build up a body of supporting evidence before selecting a target for a costly drug discovery program.  Once a target was chosen, the pharmaceutical industry and more recently some academic centers have streamlined a no. of early processes to identify mols. which possess suitable characteristics to make acceptable drugs.  This review will look at key preclin. stages of the drug discovery process, from initial target identification and validation, through assay development, high throughput screening, hit identification, lead optimization and finally the selection of a candidate mol. for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooCc74_F_90rVg90H21EOLACvtfcHk0ljWEVD4rfGZCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivF2lt7o%253D&md5=05a0016f45b155f9fb5822f5c7bcc35d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2010.01127.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2010.01127.x%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BP.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DKalindjian%26aufirst%3DS.%2BB.%26aulast%3DPhilpott%26aufirst%3DK.%2BL.%26atitle%3DPrinciples%2520of%2520early%2520drug%2520discovery%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D162%26spage%3D1239%26epage%3D1249%26doi%3D10.1111%2Fj.1476-5381.2010.01127.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perwitasari, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Donnell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing kinase inhibitors as antiviral agents to control Influenza A virus replication</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1089/adt.2015.0003.drrr</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1089%2Fadt.2015.0003.drrr" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26192013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=638-649&author=O.+Perwitasariauthor=X.+Yanauthor=J.+O%E2%80%99Donnellauthor=S.+Johnsonauthor=R.+A.+Tripp&title=Repurposing+kinase+inhibitors+as+antiviral+agents+to+control+Influenza+A+virus+replication&doi=10.1089%2Fadt.2015.0003.drrr"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication</span></div><div class="casAuthors">Perwitasari, Olivia; Yan, Xiuzhen; O'Donnell, Jason; Johnson, Scott; Tripp, Ralph A.</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">638-649</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Influenza A virus (IAV) infection causes seasonal epidemics of contagious respiratory illness that causes substantial morbidity and some mortality.  Regular vaccination is the principal strategy for controlling influenza virus, although vaccine efficacy is variable.  IAV antiviral drugs are available; however, substantial drug resistance has developed to two of the four currently FDA-approved antiviral drugs.  Thus, new therapeutic approaches are being sought to reduce the burden of influenza-related disease.  A high-throughput screen using a human kinase inhibitor library was performed targeting an emerging IAV strain (H7N9) in A549 cells.  The inhibitor library contained 273 structurally diverse, active cell permeable kinase inhibitors with known bioactivity and safety profiles, many of which are at advanced stages of clin. development.  The current study shows that treatment of human A549 cells with kinase inhibitors dinaciclib, flavopiridol, or PIK-75 exhibits potent antiviral activity against H7N9 IAV as well as other IAV strains.  Thus, targeting host kinases can provide a broad-spectrum therapeutic approach against IAV.  These findings provide a path forward for repurposing existing kinase inhibitors safely as potential antivirals, particularly those that can be tested in vivo and ultimately for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI0vSkwPosrrVg90H21EOLACvtfcHk0ljWEVD4rfGZCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVGiu7rF&md5=cf1f193bc2e8b0278caa3e43158180d7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1089%2Fadt.2015.0003.drrr&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2015.0003.drrr%26sid%3Dliteratum%253Aachs%26aulast%3DPerwitasari%26aufirst%3DO.%26aulast%3DYan%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520kinase%2520inhibitors%2520as%2520antiviral%2520agents%2520to%2520control%2520Influenza%2520A%2520virus%2520replication%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2015%26volume%3D13%26spage%3D638%26epage%3D649%26doi%3D10.1089%2Fadt.2015.0003.drrr" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors as broad-spectrum antiviral drugs</span>. <i>DNA Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1089/dna.2017.4033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1089%2Fdna.2017.4033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29148875" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=63-69&author=S.+Schorauthor=S.+Einav&title=Repurposing+of+kinase+inhibitors+as+broad-spectrum+antiviral+drugs&doi=10.1089%2Fdna.2017.4033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors as Broad-Spectrum Antiviral Drugs</span></div><div class="casAuthors">Schor, Stanford; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">DNA and Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">63-69</span>CODEN:
                <span class="NLM_cas:coden">DCEBE8</span>;
        ISSN:<span class="NLM_cas:issn">1044-5498</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">The high cost of drug development and the narrow spectrum of coverage typically provided by direct-acting antivirals limit the scalability of this antiviral approach.  This review summarizes progress and challenges in the repurposing of approved kinase inhibitors as host-targeted broad-spectrum antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNoqjCQHksU7Vg90H21EOLACvtfcHk0ljWEVD4rfGZCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ylsLg%253D&md5=4c6cad02eaecd11bf25b3d3de88f3cfe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1089%2Fdna.2017.4033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fdna.2017.4033%26sid%3Dliteratum%253Aachs%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520as%2520broad-spectrum%2520antiviral%2520drugs%26jtitle%3DDNA%2520Cell%2520Biol.%26date%3D2018%26volume%3D37%26spage%3D63%26epage%3D69%26doi%3D10.1089%2Fdna.2017.4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomperts, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svendsen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damoiseaux, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arumugaswami, V.</span></span> <span> </span><span class="NLM_article-title">Antiviral drug screen of kinase inhibitors identifies cellular signaling pathways critical for SARS-CoV-2 replication</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">108940</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2021.108940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2021.108940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33784499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnsVSmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2021&pages=108940&author=G.+Garciaauthor=A.+Sharmaauthor=A.+Ramaiahauthor=C.+Senauthor=D.+Kohnauthor=B.+Gompertsauthor=C.+N.+Svendsenauthor=R.+D.+Damoiseauxauthor=V.+Arumugaswami&title=Antiviral+drug+screen+of+kinase+inhibitors+identifies+cellular+signaling+pathways+critical+for+SARS-CoV-2+replication&doi=10.1016%2Fj.celrep.2021.108940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication</span></div><div class="casAuthors">Garcia, Gustavo; Sharma, Arun; Ramaiah, Arunachalam; Sen, Chandani; Purkayastha, Arunima; Kohn, Donald B.; Parcells, Mark S.; Beck, Sebastian; Kim, Heeyoung; Bakowski, Malina A.; Kirkpatrick, Melanie G.; Riva, Laura; Wolff, Karen C.; Han, Brandon; Yuen, Constance; Ulmert, David; Purbey, Prabhat K.; Scumpia, Phillip; Beutler, Nathan; Rogers, Thomas F.; Chatterjee, Arnab K.; Gabriel, Gulsah; Bartenschlager, Ralf; Gomperts, Brigitte; Svendsen, Clive N.; Betz, Ulrich A. K.; Damoiseaux, Robert D.; Arumugaswami, Vaithilingaraja</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108940</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">SARS-CoV-2 has currently pptd. the COVID-19 global health crisis.  We developed a medium-throughput drug-screening system and identified a small-mol. library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells.  These drug inhibitors are in various stages of clin. trials.  We detected key proteins involved in cellular signaling pathways mTOR-PI3K-AKT, ABL-BCR/MAPK, and DNA-damage response that are crit. for SARS-CoV-2 infection.  A drug-protein interaction-based secondary screen confirmed compds., such as the ATR kinase inhibitor berzosertib and torin2 with anti-SARS-CoV-2 activity.  Berzosertib exhibited potent antiviral activity against SARS-CoV-2 in multiple cell types and blocked replication at the post-entry step.  Berzosertib inhibited replication of SARS-CoV-1 and the Middle East respiratory syndrome coronavirus (MERS-CoV) as well.  Our study highlights key promising kinase inhibitors to constrain coronavirus replication as a host-directed therapy in the treatment of COVID-19 and beyond as well as provides an important mechanism of host-pathogen interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKjvqUTDcBubVg90H21EOLACvtfcHk0ljKjc_dX3HguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXnsVSmu78%253D&md5=94d62725aa7d42373572305576df4793</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2021.108940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2021.108940%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia%26aufirst%3DG.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DRamaiah%26aufirst%3DA.%26aulast%3DSen%26aufirst%3DC.%26aulast%3DKohn%26aufirst%3DD.%26aulast%3DGomperts%26aufirst%3DB.%26aulast%3DSvendsen%26aufirst%3DC.%2BN.%26aulast%3DDamoiseaux%26aufirst%3DR.%2BD.%26aulast%3DArumugaswami%26aufirst%3DV.%26atitle%3DAntiviral%2520drug%2520screen%2520of%2520kinase%2520inhibitors%2520identifies%2520cellular%2520signaling%2520pathways%2520critical%2520for%2520SARS-CoV-2%2520replication%26jtitle%3DCell%2520Rep.%26date%3D2021%26volume%3D35%26spage%3D108940%26doi%3D10.1016%2Fj.celrep.2021.108940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashraf, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, S.</span></span> <span> </span><span class="NLM_article-title">Quantitative phosphoproteomic analysis identifies the critical role of JNK1 in neuroinflammation induced by Japanese encephalitis virus</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">ra98</span> <span class="refDoi"> DOI: 10.1126/scisignal.aaf5132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscisignal.aaf5132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27703031" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&author=J.+Yeauthor=H.+Zhangauthor=W.+Heauthor=B.+Zhuauthor=D.+Zhouauthor=Z.+Chenauthor=U.+Ashrafauthor=Y.+Weiauthor=Z.+Liuauthor=Z.+F.+Fuauthor=H.+Chenauthor=S.+Cao&title=Quantitative+phosphoproteomic+analysis+identifies+the+critical+role+of+JNK1+in+neuroinflammation+induced+by+Japanese+encephalitis+virus&doi=10.1126%2Fscisignal.aaf5132"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.aaf5132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.aaf5132%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DAshraf%26aufirst%3DU.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DS.%26atitle%3DQuantitative%2520phosphoproteomic%2520analysis%2520identifies%2520the%2520critical%2520role%2520of%2520JNK1%2520in%2520neuroinflammation%2520induced%2520by%2520Japanese%2520encephalitis%2520virus%26jtitle%3DSci.%2520Signaling%26date%3D2016%26volume%3D9%26doi%3D10.1126%2Fscisignal.aaf5132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yángüez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunziker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobay, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yildiz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schading, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elshina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karakus, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehrig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dijkman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmolke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stertz, S.</span></span> <span> </span><span class="NLM_article-title">Phosphoproteomic-based kinase profiling early in influenza virus infection identifies GRK2 as antiviral drug target</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">3679</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-06119-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41467-018-06119-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30206219" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3679&author=E.+Y%C3%A1ng%C3%BCezauthor=A.+Hunzikerauthor=M.+P.+Dobayauthor=S.+Yildizauthor=S.+Schadingauthor=E.+Elshinaauthor=U.+Karakusauthor=P.+Gehrigauthor=J.+Grossmannauthor=R.+Dijkmanauthor=M.+Schmolkeauthor=S.+Stertz&title=Phosphoproteomic-based+kinase+profiling+early+in+influenza+virus+infection+identifies+GRK2+as+antiviral+drug+target&doi=10.1038%2Fs41467-018-06119-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-06119-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-06119-y%26sid%3Dliteratum%253Aachs%26aulast%3DY%25C3%25A1ng%25C3%25BCez%26aufirst%3DE.%26aulast%3DHunziker%26aufirst%3DA.%26aulast%3DDobay%26aufirst%3DM.%2BP.%26aulast%3DYildiz%26aufirst%3DS.%26aulast%3DSchading%26aufirst%3DS.%26aulast%3DElshina%26aufirst%3DE.%26aulast%3DKarakus%26aufirst%3DU.%26aulast%3DGehrig%26aufirst%3DP.%26aulast%3DGrossmann%26aufirst%3DJ.%26aulast%3DDijkman%26aufirst%3DR.%26aulast%3DSchmolke%26aufirst%3DM.%26aulast%3DStertz%26aufirst%3DS.%26atitle%3DPhosphoproteomic-based%2520kinase%2520profiling%2520early%2520in%2520influenza%2520virus%2520infection%2520identifies%2520GRK2%2520as%2520antiviral%2520drug%2520target%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D3679%26doi%3D10.1038%2Fs41467-018-06119-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0ljKjc_dX3HguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Sunitinib</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2255</span>– <span class="NLM_lpage">2266</span>, <span class="refDoi"> DOI: 10.2165/00003495-200666170-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.2165%2F00003495-200666170-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17137406" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCmu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=2255-2266&author=E.+D.+Deeksauthor=G.+M.+Keating&title=Sunitinib&doi=10.2165%2F00003495-200666170-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib</span></div><div class="casAuthors">Deeks, Emma D.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2255-2266</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Sunitinib and its active metabolite (SU012662) are selective inhibitors of multiple receptor tyrosine kinases assocd. with tumor growth and angiogenesis.  The clin. efficacy of oral sunitinib has been demonstrated in patients with advanced gastrointestinal stromal tumors (GIST).  In a phase III, randomised, double-blind, placebo-controlled, multicenter trial in patients with metastatic and/or unresectable GIST following unsuccessful imatinib therapy, the median time to tumor progression and median progression-free survival time were ≥4-fold longer in patients receiving sunitinib 50 mg/day than in those receiving placebo, in 6-wk cycles consisting of 4 wk of treatment followed by a 2-wk rest period.  Sunitinib also exhibited antitumor activity in patients with advanced renal cell carcinoma (RCC) following unsuccessful cytokine therapy.  In two multicentre, single-arm, phase II clin. trials in patients with cytokine-refractory metastatic RCC, partial responses were reported in 40% and 43% of patients receiving sunitinib 50 mg/day for 4 wk followed by 2 wk without treatment in 6-wk cycles; 27% and 22% of patients achieved stable disease for ≥3 mo.  Sunitinib was more effective than interferon-α as a first-line therapy in patients with metastatic RCC.  In a large, well designed, phase III trial in previously untreated patients, progression-free survival was significantly longer in patients receiving sunitinib 50 mg/day in 6-wk cycles (4 wk of treatment followed by a 2-wk rest period) compared with those receiving interferon-α 9MU three times weekly (47.3 vs 24.9 wk).  In general, sunitinib was well tolerated in patients with GIST and RCC, with adverse events usually being of mild or moderate severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj2acnnCHjT7Vg90H21EOLACvtfcHk0lgh2ol16Wbk9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCmu78%253D&md5=2ef4be4892ac6aab32355e0892501ddb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2165%2F00003495-200666170-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200666170-00007%26sid%3Dliteratum%253Aachs%26aulast%3DDeeks%26aufirst%3DE.%2BD.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DSunitinib%26jtitle%3DDrugs%26date%3D2006%26volume%3D66%26spage%3D2255%26epage%3D2266%26doi%3D10.2165%2F00003495-200666170-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelgalil, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kahtani, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Jenoobi, F. I.</span></span> <span> </span><span class="NLM_article-title">Erlotinib</span>. <i>Profiles Drug Subst., Excipients, Relat. Methodol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">117</span>, <span class="refDoi"> DOI: 10.1016/bs.podrm.2019.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fbs.podrm.2019.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32164971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB383islaqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2020&pages=93-117&author=A.+A.+Abdelgalilauthor=H.+M.+Al-Kahtaniauthor=F.+I.+Al-Jenoobi&title=Erlotinib&doi=10.1016%2Fbs.podrm.2019.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib</span></div><div class="casAuthors">Abdelgalil Ahmed A; Al-Kahtani Hamad M; Al-Jenoobi Fahad I</div><div class="citationInfo"><span class="NLM_cas:title">Profiles of drug substances, excipients, and related methodology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-117</span>
        ISSN:<span class="NLM_cas:issn">1871-5125</span>.
    </div><div class="casAbstract">Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer.  Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells.  This study presents a comprehensive profile of erlotinib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis).  Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry.  Chromatographic methods of analyses include thin layer chromatography, and high-performance liquid chromatography.  Pharmacology of erlotinib including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented.  An appropriate table and figures were attached to each of the above mentioned sections along with total of 48 references.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcScjIwfRcn866cY7HFp97qMfW6udTcc2eb31KwSCoaSw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383islaqtQ%253D%253D&md5=612f3c7b1ece857634ade4904b2f062c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fbs.podrm.2019.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.podrm.2019.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelgalil%26aufirst%3DA.%2BA.%26aulast%3DAl-Kahtani%26aufirst%3DH.%2BM.%26aulast%3DAl-Jenoobi%26aufirst%3DF.%2BI.%26atitle%3DErlotinib%26jtitle%3DProfiles%2520Drug%2520Subst.%252C%2520Excipients%252C%2520Relat.%2520Methodol.%26date%3D2020%26volume%3D45%26spage%3D93%26epage%3D117%26doi%3D10.1016%2Fbs.podrm.2019.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Markham, A.</span></span> <span> </span><span class="NLM_article-title">Baricitinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">704</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0723-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs40265-017-0723-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28290136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=697-704&author=A.+Markham&title=Baricitinib%3A+first+global+approval&doi=10.1007%2Fs40265-017-0723-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib: First Global Approval</span></div><div class="casAuthors">Markham, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">697-704</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Baricitinib (Olumiant) is an orally-administered, small-mol., janus-assocd. kinase (JAK) inhibitor developed by Eli Lilly and Incyte Corporation for the treatment of rheumatoid arthritis (RA), atopic dermatitis and systemic lupus erythematosus.  JAKs transduce intracellular signals from cell surface receptors for various cytokines and growth factors involved in inflammation and immune function, suggesting JAK inhibitors may be of therapeutic benefit in inflammatory conditions.  In Feb. 2017, baricitinib was approved in the EU, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs).  Regulatory approval to market baricitinib as a treatment for RA has also been sought in the USA and Japan.  This article summarizes the milestones in the development of baricitinib leading to this first global approval for the treatment for moderate to severe active RA in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-U2lbkEPpbVg90H21EOLACvtfcHk0lgh2ol16Wbk9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXksVOlur8%253D&md5=54dbb2c53eb3cfd5831284df95beb184</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0723-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0723-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarkham%26aufirst%3DA.%26atitle%3DBaricitinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D697%26epage%3D704%26doi%3D10.1007%2Fs40265-017-0723-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smythe, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayscough, K. R.</span></span> <span> </span><span class="NLM_article-title">The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin skeleton</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.embor776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fsj.embor.embor776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=12634840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFyntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=246-251&author=E.+Smytheauthor=K.+R.+Ayscough&title=The+Ark1%2FPrk1+family+of+protein+kinases.+Regulators+of+endocytosis+and+the+actin+skeleton&doi=10.1038%2Fsj.embor.embor776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Ark1/Prk1 family of protein kinases. Regulators of endocytosis and the actin cytoskeleton</span></div><div class="casAuthors">Smythe, Elizabeth; Ayscough, Kathryn R.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-251</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The Ark/Prk serine/threonine kinases initiate phosphorylation cycles that control the endocytic machinery in mammalian cells and yeast, and the actin cytoskeleton in yeast.  The members of this protein family are unified by homologies in their kinase domain, but are generally diverse in their other domains.  The evolution of Ark/Prk family members in different organisms may have allowed the conserved role of the kinase domain, which is required for the phosphorylation of both endocytic and cytoskeletal components, to be coupled to other functional domains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XGXyl51NTrVg90H21EOLACvtfcHk0lgh2ol16Wbk9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFyntr8%253D&md5=1faa1e2d9498cd426a5570b446b19fe8</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.embor776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.embor776%26sid%3Dliteratum%253Aachs%26aulast%3DSmythe%26aufirst%3DE.%26aulast%3DAyscough%26aufirst%3DK.%2BR.%26atitle%3DThe%2520Ark1%252FPrk1%2520family%2520of%2520protein%2520kinases.%2520Regulators%2520of%2520endocytosis%2520and%2520the%2520actin%2520skeleton%26jtitle%3DEMBO%2520Rep.%26date%3D2003%26volume%3D4%26spage%3D246%26epage%3D251%26doi%3D10.1038%2Fsj.embor.embor776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, G. R.</span></span> <span> </span><span class="NLM_article-title">Fusion of enveloped viruses in endosomes</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">614</span>, <span class="refDoi"> DOI: 10.1111/tra.12389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Ftra.12389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26935856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslWls70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=593-614&author=J.+M.+Whiteauthor=G.+R.+Whittaker&title=Fusion+of+enveloped+viruses+in+endosomes&doi=10.1111%2Ftra.12389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Fusion of enveloped viruses in endosomes</span></div><div class="casAuthors">White, Judith M.; Whittaker, Gary R.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">593-614</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Ari Helenius launched the field of enveloped virus fusion in endosomes with a seminal paper in the Journal of Cell Biol. in 1980.  In the intervening years, a great deal has been learned about the structures and mechanisms of viral membrane fusion proteins as well as about the endosomes in which different enveloped viruses fuse and the endosomal cues that trigger fusion.  We now recognize three classes of viral membrane fusion proteins based on structural criteria and four mechanisms of fusion triggering.  After reviewing general features of viral membrane fusion proteins and viral fusion in endosomes, we delve into three characterized mechanisms for viral fusion triggering in endosomes: by low pH, by receptor binding plus low pH and by receptor binding plus the action of a protease.  The authors end with a discussion of viruses that may employ novel endosomal fusion-triggering mechanisms.  A key take-home message is that enveloped viruses that enter cells by fusing in endosomes traverse the endocytic pathway until they reach an endosome that has all of the environmental conditions (pH, proteases, ions, intracellular receptors and lipid compn.) to (if needed) prime and (in all cases) trigger the fusion protein and to support membrane fusion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIH6MfR6awv7Vg90H21EOLACvtfcHk0ljLOPHIZGTWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslWls70%253D&md5=915c967ab0f18e75e824f6cfc3de5cdf</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Ftra.12389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftra.12389%26sid%3Dliteratum%253Aachs%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DWhittaker%26aufirst%3DG.%2BR.%26atitle%3DFusion%2520of%2520enveloped%2520viruses%2520in%2520endosomes%26jtitle%3DTraffic%26date%3D2016%26volume%3D17%26spage%3D593%26epage%3D614%26doi%3D10.1111%2Ftra.12389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Viral journeys on the intracellular highways</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">3693</span>– <span class="NLM_lpage">3714</span>, <span class="refDoi"> DOI: 10.1007/s00018-018-2882-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs00018-018-2882-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30043139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyrt7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2018&pages=3693-3714&author=M.+Robinsonauthor=S.+Schorauthor=R.+Barouch-Bentovauthor=S.+Einav&title=Viral+journeys+on+the+intracellular+highways&doi=10.1007%2Fs00018-018-2882-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Viral journeys on the intracellular highways</span></div><div class="casAuthors">Robinson, Makeda; Schor, Stanford; Barouch-Bentov, Rina; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3693-3714</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Viruses are obligate intracellular pathogens that are dependent on cellular machineries for their replication.  Recent technol. breakthroughs have facilitated reliable identification of host factors required for viral infections and better characterization of the virus-host interplay.  While these studies have revealed cellular machineries that are uniquely required by individual viruses, accumulating data also indicate the presence of broadly required mechanisms.  Among these overlapping cellular functions are components of intracellular membrane trafficking pathways.  Here, we review recent discoveries focused on how viruses exploit intracellular membrane trafficking pathways to promote various stages of their life cycle, with an emphasis on cellular factors that are usurped by a broad range of viruses.  We describe broadly required components of the endocytic and secretory pathways, the Endosomal Sorting Complexes Required for Transport pathway, and the autophagy pathway.  Identification of such overlapping host functions offers new opportunities to develop broad-spectrum host-targeted antiviral strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7AbAAm0W8PLVg90H21EOLACvtfcHk0ljLOPHIZGTWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyrt7fI&md5=5a964c5d61495441e6476013dded83d6</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2Fs00018-018-2882-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-018-2882-0%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DViral%2520journeys%2520on%2520the%2520intracellular%2520highways%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2018%26volume%3D75%26spage%3D3693%26epage%3D3714%26doi%3D10.1007%2Fs00018-018-2882-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulholland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">4387</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1128/JVI.02705-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.02705-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25653444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2015&pages=4387-4404&author=G.+Neveuauthor=A.+Ziv-Avauthor=R.+Barouch-Bentovauthor=E.+Berkermanauthor=J.+Mulhollandauthor=S.+Einav&title=AP-2-associated+protein+kinase+1+and+cyclin+G-associated+kinase+regulate+hepatitis+C+virus+entry+and+are+potential+drug+targets&doi=10.1128%2FJVI.02705-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets</span></div><div class="casAuthors">Neveu, Gregory; Ziv-Av, Amotz; Barouch-Bentov, Rina; Berkerman, Elena; Mulholland, Jon; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4387-4404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">1098-5514</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters its target cell via clathrin-mediated endocytosis.  AP-2-assocd. protein kinase 1 (AAK1) and cyclin G-assocd. kinase (GAK) are host kinases that regulate clathrin adaptor protein (AP)-mediated trafficking in the endocytic and secretory pathways.  We previously reported that AAK1 and GAK regulate HCV assembly by stimulating binding of the μ subunit of AP-2, AP2M1, to HCV core protein.  We also discovered that AAK1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HCV assembly.  Here, we hypothesized that AAK1 and GAK regulate HCV entry independently of their effect on HCV assembly.  Indeed, silencing AAK1 and GAK expression inhibited entry of pseudoparticles and cell culture grown-HCV and internalization of Dil-labeled HCV particles with no effect on HCV attachment or RNA replication.  AAK1 or GAK depletion impaired epidermal growth factor (EGF)-mediated enhanced HCV entry and endocytosis of EGF receptor (EGFR), an HCV entry cofactor and erlotinib's cancer target.  Moreover, either RNA interference-mediated depletion of AP2M1 or NUMB, each a substrate of AAK1 and/or GAK, or overexpression of either an AP2M1 or NUMB phosphorylation site mutant inhibited HCV entry.  Last, in addn. to affecting assembly, sunitinib and erlotinib inhibited HCV entry at a postbinding step, their combination was synergistic, and their antiviral effect was reversed by either AAK1 or GAK overexpression.  Together, these results validate AAK1 and GAK as crit. regulators of HCV entry that function in part by activating EGFR, AP2M1, and NUMB and as the mol. targets underlying the antiviral effect of sunitinib and erlotinib (in addn. to EGFR), resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1x5sJzyhrLVg90H21EOLACvtfcHk0ljLOPHIZGTWwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWlurg%253D&md5=cbdd3e12d29f383c73dc53c0e9954300</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1128%2FJVI.02705-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02705-14%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBerkerman%26aufirst%3DE.%26aulast%3DMulholland%26aufirst%3DJ.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAP-2-associated%2520protein%2520kinase%25201%2520and%2520cyclin%2520G-associated%2520kinase%2520regulate%2520hepatitis%2520C%2520virus%2520entry%2520and%2520are%2520potential%2520drug%2520targets%26jtitle%3DJ.%2520Virol.%26date%3D2015%26volume%3D89%26spage%3D4387%26epage%3D4404%26doi%3D10.1128%2FJVI.02705-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, L. E.</span></span> <span> </span><span class="NLM_article-title">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">4311</span>– <span class="NLM_lpage">4321</span>, <span class="refDoi"> DOI: 10.1242/jcs.02548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.02548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16155256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2005&pages=4311-4321&author=D.+W.+Leeauthor=X.+Zhaoauthor=F.+Zhangauthor=E.+Eisenbergauthor=L.+E.+Greene&title=Depletion+of+GAK%2Fauxilin+2+inhibits+receptor-mediated+endocytosis+and+recruitment+of+both+clathrin+and+clathrin+adaptors&doi=10.1242%2Fjcs.02548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors</span></div><div class="casAuthors">Lee, Dong-won; Zhao, Xiaohong; Zhang, Fang; Eisenberg, Evan; Greene, Lois E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4311-4321</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK/auxilin 2), the ubiquitous form of the neuronal-specific protein auxilin 1, is an essential cofactor for the Hsc70-dependent uncoating of clathrin-coated vesicles.  We have now investigated the effect of knocking down GAK in HeLa cells by vector-based small hairpin RNA.  Functionally, depletion of GAK caused a marked decrease in internalization of both transferrin and epidermal growth factor and altered mannose 6-phosphate receptor trafficking, but had little effect on the recycling of transferrin receptor back to the plasma membrane.  Structurally, depletion of GAK caused a marked redn. in perinuclear clathrin assocd. with the trans-Golgi network and in the no. of clathrin-coated pits on the plasma membrane, and reduced clathrin exchange on the few clathrin-coated pits that remained.  Surprisingly, while clathrin depletion does not prevent adaptors from assembling on the membrane, depletion of GAK caused a dramatic redn. in AP2 and epsin on the plasma membrane and AP1 and GGA at the trans-Golgi network.  A similar effect was caused by expression of a dominant neg. Hsp70 mutant.  These results suggest that GAK, in conjunction with Hsc70, not only uncoats clathrin-coated vesicles and induces clathrin exchange on clathrin-coated pits, but also mediates binding of clathrin and adaptors to the plasma membrane and the trans-Golgi network.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8IvRfVSaZT7Vg90H21EOLACvtfcHk0liOSWhwB78Xmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCgt7fK&md5=0172190491cf9b908e705e434b763d60</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1242%2Fjcs.02548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.02548%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BW.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DEisenberg%26aufirst%3DE.%26aulast%3DGreene%26aufirst%3DL.%2BE.%26atitle%3DDepletion%2520of%2520GAK%252Fauxilin%25202%2520inhibits%2520receptor-mediated%2520endocytosis%2520and%2520recruitment%2520of%2520both%2520clathrin%2520and%2520clathrin%2520adaptors%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2005%26volume%3D118%26spage%3D4311%26epage%3D4321%26doi%3D10.1242%2Fjcs.02548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0liOSWhwB78Xmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shulla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakken, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagamine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1338</span>– <span class="NLM_lpage">1352</span>, <span class="refDoi"> DOI: 10.1172/JCI89857</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1172%2FJCI89857" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28240606" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1338-1352&author=E.+Bekermanauthor=G.+Neveuauthor=A.+Shullaauthor=J.+Brannanauthor=S.+Y.+Puauthor=S.+Wangauthor=F.+Xiaoauthor=R.+Barouch-Bentovauthor=R.+R.+Bakkenauthor=R.+Mateoauthor=J.+Goveroauthor=C.+M.+Nagamineauthor=M.+S.+Diamondauthor=S.+De+Jongheauthor=P.+Herdewijnauthor=J.+M.+Dyeauthor=G.+Randallauthor=S.+Einav&title=Anticancer+kinase+inhibitors+impair+intracellular+viral+trafficking+and+exert+broad-spectrum+antiviral+effects&doi=10.1172%2FJCI89857"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects</span></div><div class="casAuthors">Bekerman Elena; Neveu Gregory; Shulla Ana; Brannan Jennifer; Pu Szu-Yuan; Wang Stanley; Xiao Fei; Barouch-Bentov Rina; Bakken Russell R; Mateo Roberto; Govero Jennifer; Nagamine Claude M; Diamond Michael S; De Jonghe Steven; Herdewijn Piet; Dye John M; Randall Glenn; Einav Shirit</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1338-1352</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Global health is threatened by emerging viral infections, which largely lack effective vaccines or therapies.  Targeting host pathways that are exploited by multiple viruses could offer broad-spectrum solutions.  We previously reported that AAK1 and GAK, kinase regulators of the host adaptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying mechanism and relevance to other viruses or in vivo infections remained unknown.  Here, we have discovered that AP1 and AP2 cotraffic with HCV particles in live cells.  Moreover, we found that multiple viruses, including dengue and Ebola, exploit AAK1 and GAK during entry and infectious virus production.  In cultured cells, treatment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or with more selective compounds inhibited intracellular trafficking of HCV and multiple unrelated RNA viruses with a high barrier to resistance.  In murine models of dengue and Ebola infection, sunitinib/erlotinib combination protected against morbidity and mortality.  We validated sunitinib- and erlotinib-mediated inhibition of AAK1 and GAK activity as an important mechanism of antiviral action.  Additionally, we revealed potential roles for additional kinase targets.  These findings advance our understanding of virus-host interactions and establish a proof of principle for a repurposed, host-targeted approach to combat emerging viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeR1dYk1i_czQLBVDQn4bCfW6udTcc2eZ18dFioKpGO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czgvFajtg%253D%253D&md5=2de0a5d7668651f92be3c2e79823ced4</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1172%2FJCI89857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI89857%26sid%3Dliteratum%253Aachs%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DShulla%26aufirst%3DA.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DBakken%26aufirst%3DR.%2BR.%26aulast%3DMateo%26aufirst%3DR.%26aulast%3DGovero%26aufirst%3DJ.%26aulast%3DNagamine%26aufirst%3DC.%2BM.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DRandall%26aufirst%3DG.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DAnticancer%2520kinase%2520inhibitors%2520impair%2520intracellular%2520viral%2520trafficking%2520and%2520exert%2520broad-spectrum%2520antiviral%2520effects%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1338%26epage%3D1352%26doi%3D10.1172%2FJCI89857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0libAOZ1uk4fpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oechsle, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phelan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savory, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span> <span> </span><span class="NLM_article-title">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">e30</span>– <span class="NLM_lpage">e31</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30304-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0140-6736%2820%2930304-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32032529" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=e30-e31&author=P.+Richardsonauthor=I.+Griffinauthor=C.+Tuckerauthor=D.+Smithauthor=O.+Oechsleauthor=A.+Phelanauthor=M.+Rawlingauthor=E.+Savoryauthor=J.+Stebbing&title=Baricitinib+as+potential+treatment+for+2019-nCoV+acute+respiratory+disease&doi=10.1016%2FS0140-6736%2820%2930304-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</span></div><div class="casAuthors">Richardson, Peter; Griffin, Ivan; Tucker, Catherine; Smith, Dan; Oechsle, Olly; Phelan, Anne; Stebbing, Justin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10223</span>),
    <span class="NLM_cas:pages">e30-e31</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Given the scale and rapid spread of the 2019 novel coronavirus (2019-nCoV) acute respiratory disease, there is an immediate need for medicines that can help before a vaccine can be produced.  Results of rapid sequencing of 2019-nCoV, coupled with mol. modeling based on the genomes of related virus proteins, have suggested a few compds. that are likely to be effective, including the anti-HIV lopinavir plus ritonavir combination.  Most viruses enter cells through receptor-mediated endocytosis.  One of the known regulators of endocytosis is the AP2-assocd. protein kinase 1 (AAK1).  Disruption of AAK1 might, in turn, interrupt the passage of the virus into cells and also the intracellular assembly of virus particles.  One of six high affinity AAK1-binding drugs was the janus kinase inhibitor baricitinib, which also binds the cyclin G-assocd. kinase, another regulator of endocytosis.  Because the plasma concn. of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient to inhibit AAK1, we suggest it could be trialled, using an appropriate patient population with 2019-nCoV acute respiratory disease, to reduce both the viral entry and inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT8bDm3HM7aLVg90H21EOLACvtfcHk0libAOZ1uk4fpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Chtr4%253D&md5=9e884d046780c8aa5f3a0934bf4a59ed</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930304-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930304-4%26sid%3Dliteratum%253Aachs%26aulast%3DRichardson%26aufirst%3DP.%26aulast%3DGriffin%26aufirst%3DI.%26aulast%3DTucker%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DOechsle%26aufirst%3DO.%26aulast%3DPhelan%26aufirst%3DA.%26aulast%3DRawling%26aufirst%3DM.%26aulast%3DSavory%26aufirst%3DE.%26aulast%3DStebbing%26aufirst%3DJ.%26atitle%3DBaricitinib%2520as%2520potential%2520treatment%2520for%25202019-nCoV%2520acute%2520respiratory%2520disease%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3De30%26epage%3De31%26doi%3D10.1016%2FS0140-6736%2820%2930304-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matarrese, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicastri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stobbione, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goletti, D.</span></span> <span> </span><span class="NLM_article-title">Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact</span>. <i>J. Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">356</span>, <span class="refDoi"> DOI: 10.1016/j.jinf.2020.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jinf.2020.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32333918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=2020&pages=318-356&author=F.+Cantiniauthor=L.+Niccoliauthor=D.+Matarreseauthor=E.+Nicastriauthor=P.+Stobbioneauthor=D.+Goletti&title=Baricitinib+therapy+in+COVID-19%3A+a+pilot+study+on+safety+and+clinical+impact&doi=10.1016%2Fj.jinf.2020.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</span></div><div class="casAuthors">Cantini, Fabrizio; Niccoli, Laura; Matarrese, Daniela; Nicastri, Emanuele; Stobbione, Paolo; Goletti, Delia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Infection</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">318-356</span>CODEN:
                <span class="NLM_cas:coden">JINFD2</span>;
        ISSN:<span class="NLM_cas:issn">1532-2742</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Preliminary results on 12 patients with moderate COVID-19 pneumonia confirmed the safety of baricitinib therapy in a clin. context.  In the baricitinib-treated group, all clin. characteristics and respiratory function parameters improved both at wk 1 and 2 compared to baseline.  C-reactive protein values significantly decreased in the same timeframes.  No infections, cardiovascular, and hematol. adverse events occurred after a 2 wk treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc0f8W8UmI8rVg90H21EOLACvtfcHk0lg7yAeqFwaXjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVKkt7zO&md5=d47bb194919c10f50d24312f137ec88d</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jinf.2020.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jinf.2020.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DCantini%26aufirst%3DF.%26aulast%3DNiccoli%26aufirst%3DL.%26aulast%3DMatarrese%26aufirst%3DD.%26aulast%3DNicastri%26aufirst%3DE.%26aulast%3DStobbione%26aufirst%3DP.%26aulast%3DGoletti%26aufirst%3DD.%26atitle%3DBaricitinib%2520therapy%2520in%2520COVID-19%253A%2520a%2520pilot%2520study%2520on%2520safety%2520and%2520clinical%2520impact%26jtitle%3DJ.%2520Infect.%26date%3D2020%26volume%3D81%26spage%3D318%26epage%3D356%26doi%3D10.1016%2Fj.jinf.2020.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puvvada, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">M, V. A.</span></span> <span> </span><span class="NLM_article-title">Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19</span>. <i>Int. J. Antimicrob. Agents</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">105967</span>, <span class="refDoi"> DOI: 10.1016/j.ijantimicag.2020.105967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ijantimicag.2020.105967" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32259575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsV2rtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2020&pages=105967&author=D.+Praveenauthor=R.+C.+Puvvadaauthor=V.+A.+M&title=Janus+kinase+inhibitor+baricitinib+is+not+an+ideal+option+for+management+of+COVID-19&doi=10.1016%2Fj.ijantimicag.2020.105967"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19</span></div><div class="casAuthors">Praveen, D.; Puvvada, Ranadheer Chowdary; M, Vijey Aanandhi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">105967</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Wuhan outbreak of novel Corona virus infection has been the global focus since Dec. 2019.  This infection has become a global pandemic.  It is highly important to understand the virol. of the pathogen and to explore the therapeutic options for management of this pandemic.  Drug repurposing strategies are being considered for management of COVID 19.  Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin assocd. endocytosis.  We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl3tkQaMBwdbVg90H21EOLACvtfcHk0lg7yAeqFwaXjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsV2rtb0%253D&md5=53ee40e8ae424cf392fbf9c7987707c3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ijantimicag.2020.105967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijantimicag.2020.105967%26sid%3Dliteratum%253Aachs%26aulast%3DPraveen%26aufirst%3DD.%26aulast%3DPuvvada%26aufirst%3DR.%2BC.%26aulast%3DM%26aufirst%3DV.%2BA.%26atitle%3DJanus%2520kinase%2520inhibitor%2520baricitinib%2520is%2520not%2520an%2520ideal%2520option%2520for%2520management%2520of%2520COVID-19%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2020%26volume%3D55%26spage%3D105967%26doi%3D10.1016%2Fj.ijantimicag.2020.105967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Favalli, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggioggero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maioli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caporali, R.</span></span> <span> </span><span class="NLM_article-title">Baricitinib for COVID-19: a suitable treatment?</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1012</span>– <span class="NLM_lpage">1013</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(20)30262-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS1473-3099%2820%2930262-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32251638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsVCitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=1012-1013&author=E.+G.+Favalliauthor=M.+Biggioggeroauthor=G.+Maioliauthor=R.+Caporali&title=Baricitinib+for+COVID-19%3A+a+suitable+treatment%3F&doi=10.1016%2FS1473-3099%2820%2930262-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Baricitinib for COVID-19: a suitable treatment?</span></div><div class="casAuthors">Favalli, Ennio G.; Biggioggero, Martina; Maioli, Gabriella; Caporali, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1012-1013</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  A correspondence to the use of baricitinib for COVID-19 and its complication is given.  In conclusion, we believe that, beyond the intriguing opportunity to directly block the penetration of SARS-CoV-2 into the cell, the use of baricitinib in susceptible patients with ongoing pneumonia assocd. with COVID-19 should be considered with extreme caution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqQU1fZWMa6LVg90H21EOLACvtfcHk0lg7yAeqFwaXjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsVCitLY%253D&md5=5fed9d0b4df4f489cf6d7d7768dff536</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930262-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930262-0%26sid%3Dliteratum%253Aachs%26aulast%3DFavalli%26aufirst%3DE.%2BG.%26aulast%3DBiggioggero%26aufirst%3DM.%26aulast%3DMaioli%26aufirst%3DG.%26aulast%3DCaporali%26aufirst%3DR.%26atitle%3DBaricitinib%2520for%2520COVID-19%253A%2520a%2520suitable%2520treatment%253F%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D1012%26epage%3D1013%26doi%3D10.1016%2FS1473-3099%2820%2930262-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovackova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekerman, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaikuad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heroven, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span> <span> </span><span class="NLM_article-title">Selective inhibitors of cyclin G associated kinase (GAK) as anti-hepatitis C agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3393</span>– <span class="NLM_lpage">3410</span>, <span class="refDoi"> DOI: 10.1021/jm501759m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501759m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3393-3410&author=S.+Kovackovaauthor=L.+Changauthor=E.+Bekermanauthor=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Chaikuadauthor=C.+Herovenauthor=M.+Salaauthor=S.+De+Jongheauthor=S.+Knappauthor=S.+Einavauthor=P.+Herdewijn&title=Selective+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+as+anti-hepatitis+C+agents&doi=10.1021%2Fjm501759m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibitors of Cyclin G Associated Kinase (GAK) as Anti-Hepatitis C Agents</span></div><div class="casAuthors">Kovackova, Sona; Chang, Lei; Bekerman, Elena; Neveu, Gregory; Barouch-Bentov, Rina; Chaikuad, Apirat; Heroven, Christina; Sala, Michal; De Jonghe, Steven; Knapp, Stefan; Einav, Shirit; Herdewijn, Piet</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3393-3410</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin G assocd. kinase (GAK) emerged as a promising drug target for the treatment of viral infections.  However, no potent and selective GAK inhibitors have been reported in the literature to date.  This paper describes the discovery of isothiazolo[5,4-b]pyridines as selective GAK inhibitors, with the most potent congeners displaying low nanomolar binding affinity for GAK.  Cocrystn. expts. revealed that these compds. behaved as classic type I ATP-competitive kinase inhibitors.  In addn., the authors have demonstrated that these compds. exhibit a potent activity against hepatitis C virus (HCV) by inhibiting two temporally distinct steps in the HCV life cycle (i.e., viral entry and assembly).  Hence, these GAK inhibitors represent chem. probes to study GAK function in different disease areas where GAK has been implicated (including viral infection, cancer, and Parkinson's disease).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmjwEtUi0av7Vg90H21EOLACvtfcHk0liljvoV-L4mBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlsFGntLY%253D&md5=ed7f93eb3d49f6c7265dd2c0da880b43</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm501759m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501759m%26sid%3Dliteratum%253Aachs%26aulast%3DKovackova%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DBekerman%26aufirst%3DE.%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DHeroven%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DM.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26atitle%3DSelective%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520as%2520anti-hepatitis%2520C%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3393%26epage%3D3410%26doi%3D10.1021%2Fjm501759m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozenski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Optimization of isothiazolo[4,3- b]pyridine-based inhibitors of cyclin G associated kinase (GAK) with broad-spectrum antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6178</span>– <span class="NLM_lpage">6192</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6178-6192&author=S.+Y.+Puauthor=R.+Woutersauthor=S.+Schorauthor=J.+Rozenskiauthor=R.+Barouch-Bentovauthor=L.+I.+Prugarauthor=C.+M.+O%E2%80%99Brienauthor=J.+M.+Brannanauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+De+Jongheauthor=S.+Einav&title=Optimization+of+isothiazolo%5B4%2C3-+b%5Dpyridine-based+inhibitors+of+cyclin+G+associated+kinase+%28GAK%29+with+broad-spectrum+antiviral+activity&doi=10.1021%2Facs.jmedchem.8b00613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Isothiazolo[4,3-b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity</span></div><div class="casAuthors">Pu, Szu-Yuan; Wouters, Randy; Schor, Stanford; Rozenski, Jef; Barouch-Bentov, Rina; Prugar, Laura I.; O'Brien, Cecilia M.; Brannan, Jennifer M.; Dye, John M.; Herdewijn, Piet; De Jonghe, Steven; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6178-6192</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is an urgent need for strategies to combat dengue and other emerging viral infections.  We reported that cyclin G-assocd. kinase (GAK), a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, regulates intracellular trafficking of multiple unrelated RNA viruses during early and late stages of the viral lifecycle.  We also reported the discovery of potent, selective GAK inhibitors based on an isothiazolo[4,3-b]pyridine scaffold, albeit with moderate antiviral activity.  Here, we describe our efforts leading to the discovery of novel isothiazolo[4,3-b]pyridines that maintain high GAK affinity and selectivity.  These compds. demonstrate improved in vitro activity against dengue virus, including in human primary dendritic cells, and efficacy against the unrelated Ebola and chikungunya viruses.  Moreover, inhibition of GAK activity was validated as an important mechanism of antiviral action of these compds.  These findings demonstrate the potential utility of a GAK-targeted broad-spectrum approach for combating currently untreatable emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDe8aVxkBtKLVg90H21EOLACvtfcHk0liljvoV-L4mBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altLfP&md5=fe33e256835ea01c5e1932c3ccea7eac</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00613%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DRozenski%26aufirst%3DJ.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DC.%2BM.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DOptimization%2520of%2520isothiazolo%255B4%252C3-%2520b%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%2520with%2520broad-spectrum%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6178%26epage%3D6192%26doi%3D10.1021%2Facs.jmedchem.8b00613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescrinier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">265</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.11.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ejmech.2018.11.065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30529544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVemsb%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=256-265&author=R.+Woutersauthor=S.+Y.+Puauthor=M.+Froeyenauthor=E.+Lescrinierauthor=S.+Einavauthor=P.+Herdewijnauthor=S.+De+Jonghe&title=Cyclin+G-associated+kinase+%28GAK%29+affinity+and+antiviral+activity+studies+of+a+series+of+3-C-substituted+isothiazolo%5B4%2C3-b%5Dpyridines&doi=10.1016%2Fj.ejmech.2018.11.065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin G-associated kinase (GAK) affinity and antiviral activity studies of a series of 3-C-substituted isothiazolo[4,3-b]pyridines</span></div><div class="casAuthors">Wouters, Randy; Pu, Szu-Yuan; Froeyen, Mathy; Lescrinier, Eveline; Einav, Shirit; Herdewijn, Piet; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">256-265</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cyclin G-assocd. kinase (GAK) is a cellular regulator of the clathrin-assocd. host adaptor proteins AP-1 and AP-2, which regulates intracellular trafficking of dengue virus during early and late stages of the viral lifecycle.  Previously, the discovery of isothiazolo[4,3-b]pyridines as potent and selective GAK inhibitors with promising antiviral activity was reported.  In this manuscript, the synthesis of isothiazolo[4,3-b]pyridines with a carbon-linked substituent at position 3 is described by the application of regioselective Suzuki and Sonogashira coupling reactions.  A deriv. I with a 3,4-dimethoxyphenyl residue at position 3 demonstrates low nanomolar binding affinity for GAK and antiviral activity against dengue virus.  These findings reveal that appropriate substitution of a Ph moiety at position 3 of the scaffold can improve GAK binding affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoUueVjB8L_7Vg90H21EOLACvtfcHk0liljvoV-L4mBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVemsb%252FE&md5=b12e5c6fddd96549f70cd6a06980f20d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.11.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.11.065%26sid%3Dliteratum%253Aachs%26aulast%3DWouters%26aufirst%3DR.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DLescrinier%26aufirst%3DE.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DCyclin%2520G-associated%2520kinase%2520%2528GAK%2529%2520affinity%2520and%2520antiviral%2520activity%2520studies%2520of%2520a%2520series%2520of%25203-C-substituted%2520isothiazolo%255B4%252C3-b%255Dpyridines%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D163%26spage%3D256%26epage%3D265%26doi%3D10.1016%2Fj.ejmech.2018.11.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115188</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bmc.2019.115188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31757682" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115188&author=B.+Martinez-Gualdaauthor=S.+Y.+Puauthor=M.+Froeyenauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Structure-activity+relationship+study+of+the+pyridine+moiety+of+isothiazolo%5B4%2C3-b%5Dpyridines+as+antiviral+agents+targeting+cyclin+G-associated+kinase&doi=10.1016%2Fj.bmc.2019.115188"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Pu, Szu-Yuan; Froeyen, Mathy; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">115188</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previously, the discovery of 3,6-disubstituted isothiazolo[4,3-b]pyridines as potent and selective cyclin G-assocd. kinase (GAK) inhibitors with promising antiviral activity was reported.  In this manuscript, the structure-activity relationship study was expanded to synthesis of isothiazolo[4,3-b]pyridines with modifications of the pyridine moiety.  This effort led to the discovery of an isothiazolo[4,3-b]pyridine deriv. with a 3,4-dimethoxyphenyl residue at position 5 that displayed low nanomolar GAK binding affinity and antiviral activity against dengue virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqu1a3iqS1i7Vg90H21EOLACvtfcHk0lihIykFCGfERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1SmsLfM&md5=cf709736ad37cfcda6e2310a243c55d4</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115188%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520the%2520pyridine%2520moiety%2520of%2520isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520antiviral%2520agents%2520targeting%2520cyclin%2520G-associated%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115188%26doi%3D10.1016%2Fj.bmc.2019.115188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schols, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">113158</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.ejmech.2021.113158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33497888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXit1artr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=2021&pages=113158&author=B.+Martinez-Gualdaauthor=S.+Saulauthor=M.+Froeyenauthor=D.+Scholsauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Discovery+of+3-phenyl-+and+3-N-piperidinyl-isothiazolo%5B4%2C3-b%5Dpyridines+as+highly+potent+inhibitors+of+cyclin+G-associated+kinase&doi=10.1016%2Fj.ejmech.2021.113158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase</span></div><div class="casAuthors">Martinez-Gualda, Belen; Saul, Sirle; Froeyen, Mathy; Schols, Dominique; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">213</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113158</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Structural modifications at position 3 of the isothiazolo[4,3-b]pyridine scaffold afforded a new series of cyclin G-assocd. kinase (GAK) inhibitors.  It was shown that the insertion of a carboxamide residue at position 3 of a Ph or piperidinyl moiety generated potent GAK inhibitors with IC50 values in a low nanomolar range.  This potent GAK binding affinity was rationalized by mol. modeling demonstrating that the carboxamide moiety engages in an extra hydrogen bond with GAK.  Moreover, this new series of compds. was also endowed with antiviral activity against dengue virus, highlighting the potential utility of GAK as a target for the development of antiviral drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVK3lpIDifX7Vg90H21EOLACvtfcHk0lihIykFCGfERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXit1artr8%253D&md5=8befd946b1eb30e7eb04a329dcce3933</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113158%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DSchols%26aufirst%3DD.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25203-phenyl-%2520and%25203-N-piperidinyl-isothiazolo%255B4%252C3-b%255Dpyridines%2520as%2520highly%2520potent%2520inhibitors%2520of%2520cyclin%2520G-associated%2520kinase%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D213%26spage%3D113158%26doi%3D10.1016%2Fj.ejmech.2021.113158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tizzard, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dornsife, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">Identification and optimization of 4-anilinoquinolines as inhibitors of cyclin G associated Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">48</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fcmdc.201700663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29072804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVKhurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=48-66&author=C.+R.+M.+Asquithauthor=T.+Laitinenauthor=J.+M.+Bennettauthor=P.+H.+Godoiauthor=M.+P.+Eastauthor=G.+J.+Tizzardauthor=L.+M.+Gravesauthor=G.+L.+Johnsonauthor=R.+E.+Dornsifeauthor=C.+I.+Wellsauthor=J.+M.+Elkinsauthor=T.+M.+Willsonauthor=W.+J.+Zuercher&title=Identification+and+optimization+of+4-anilinoquinolines+as+inhibitors+of+cyclin+G+associated+Kinase&doi=10.1002%2Fcmdc.201700663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase</span></div><div class="casAuthors">Asquith, Christopher R. M.; Laitinen, Tuomo; Bennett, James M.; Godoi, Paulo H.; East, Michael P.; Tizzard, Graham J.; Graves, Lee M.; Johnson, Gary L.; Dornsife, Ronna E.; Wells, Carrow I.; Elkins, Jonathan M.; Willson, Timothy M.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-66</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">4-Anilinoquinolines were identified as potent and narrow-spectrum inhibitors of the cyclin G assocd. kinase (GAK), an important regulator of viral and bacterial entry into host cells.  Optimization of the 4-anilino group and the 6,7-quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000-fold selectivity relative to other members of the numb-assocd. kinase (NAK) subfamily, and a compd. (6,7-dimethoxy-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine; I) with a narrow-spectrum kinome profile.  These compds. may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVCmCJJ-T_rrVg90H21EOLACvtfcHk0lihIykFCGfERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVKhurfJ&md5=4ea89909e674ef29c37e78fbe7622a68</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700663%26sid%3Dliteratum%253Aachs%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DTizzard%26aufirst%3DG.%2BJ.%26aulast%3DGraves%26aufirst%3DL.%2BM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DDornsife%26aufirst%3DR.%2BE.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DIdentification%2520and%2520optimization%2520of%25204-anilinoquinolines%2520as%2520inhibitors%2520of%2520cyclin%2520G%2520associated%2520Kinase%26jtitle%3DChemMedChem%26date%3D2018%26volume%3D13%26spage%3D48%26epage%3D66%26doi%3D10.1002%2Fcmdc.201700663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span> <span> </span><span class="NLM_article-title">Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127284</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bmcl.2020.127284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32631507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeksLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127284&author=S.+Saulauthor=S.+Y.+Puauthor=W.+J.+Zuercherauthor=S.+Einavauthor=C.+R.+M.+Asquith&title=Potent+antiviral+activity+of+novel+multi-substituted+4-anilinoquin%28az%29olines&doi=10.1016%2Fj.bmcl.2020.127284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines</span></div><div class="casAuthors">Saul, Sirle; Pu, Szu-Yuan; Zuercher, William J.; Einav, Shirit; Asquith, Christopher R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">127284</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Screening a series of 4-anilinoquinolines and 4-anilinoquinazolines enabled identification of potent novel inhibitors of dengue virus (DENV).  Prepn. of focused 4-anilinoquinoline/quinazoline scaffold arrays led to the identification of a series of high potency 6-substituted bromine and iodine derivs.  The most potent compd. 6-iodo-4-((3,4,5-trimethoxyphenyl)amino)quinoline-3-carbonitrile inhibited DENV infection with an EC50 = 79 nM.  Crucially, these compds. showed very limited toxicity with CC50 values >10μM in almost all cases.  This new promising series provides an anchor point for further development to optimize compd. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsDse-6-n89LVg90H21EOLACvtfcHk0liARSw9rrh24g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeksLfL&md5=af8311c1236ae5eca2d305d7f261c47d</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127284%26sid%3Dliteratum%253Aachs%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26atitle%3DPotent%2520antiviral%2520activity%2520of%2520novel%2520multi-substituted%25204-anilinoquin%2528az%2529olines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127284%26doi%3D10.1016%2Fj.bmcl.2020.127284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokania, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vattikundala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenarsipur, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouraldeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaffield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikramadithyan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.235333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1124%2Fjpet.116.235333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27411717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=371-386&author=W.+Kostichauthor=B.+D.+Hammanauthor=Y.+W.+Liauthor=S.+Naiduauthor=K.+Dandapaniauthor=J.+Fengauthor=A.+Eastonauthor=C.+Bourinauthor=K.+Bakerauthor=J.+Allenauthor=K.+Savelievaauthor=J.+V.+Louisauthor=M.+Dokaniaauthor=S.+Elavazhaganauthor=P.+Vattikundalaauthor=V.+Sharmaauthor=M.+L.+Dasauthor=G.+Shankarauthor=A.+Kumarauthor=V.+K.+Holenarsipurauthor=M.+Gulianelloauthor=T.+Molskiauthor=J.+M.+Brownauthor=M.+Lewisauthor=Y.+Huangauthor=Y.+Luauthor=R.+Pieschlauthor=K.+O%E2%80%99Malleyauthor=J.+Lippyauthor=A.+Nouraldeenauthor=T.+H.+Lanthornauthor=G.+Yeauthor=A.+Wilsonauthor=A.+Balakrishnanauthor=R.+Dentonauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=K.+S.+Santoneauthor=Y.+Biauthor=A.+Mainauthor=J.+Swaffieldauthor=K.+Carsonauthor=S.+Mandlekarauthor=R.+K.+Vikramadithyanauthor=S.+J.+Naraauthor=C.+Dzierbaauthor=J.+Bronsonauthor=J.+E.+Macorauthor=R.+Zaczekauthor=R.+Westphalauthor=L.+Kissauthor=L.+Bristowauthor=C.+M.+Conwayauthor=B.+Zambrowiczauthor=C.+F.+Albright&title=Inhibition+of+AAK1+kinase+as+a+novel+therapeutic+approach+to+treat+neuropathic+pain&doi=10.1124%2Fjpet.116.235333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span></div><div class="casAuthors">Kostich, Walter; Hamman, Brian D.; Li, Yu-Wen; Naidu, Sreenivasulu; Dandapani, Kumaran; Feng, Jianlin; Easton, Amy; Bourin, Clotilde; Baker, Kevin; Allen, Jason; Savelieva, Katerina; Louis, Justin V.; Dokania, Manoj; Elavazhagan, Saravanan; Vattikundala, Pradeep; Sharma, Vivek; Das, Manish Lal; Shankar, Ganesh; Kumar, Anoop; Holenarsipur, Vinay K.; Gulianello, Michael; Molski, Ted; Brown, Jeffrey M.; Lewis, Martin; Huang, Yanling; Lu, Yifeng; Pieschl, Rick; O'Malley, Kevin; Lippy, Jonathan; Nouraldeen, Amr; Lanthorn, Thomas H.; Ye, Guilan; Wilson, Alan; Balakrishnan, Anand; Denton, Rex; Grace, James E.; Lentz, Kimberley A.; Santone, Kenneth S.; Bi, Yingzhi; Main, Alan; Swaffield, Jon; Carson, Ken; Mandlekar, Sandhya; Vikramadithyan, Reeba K.; Nara, Susheel J.; Dzierba, Carolyn; Bronson, Joanne; Macor, John E.; Zaczek, Robert; Westphal, Ryan; Kiss, Laszlo; Bristow, Linda; Conway, Charles M.; Zambrowicz, Brian; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays.  One of the lines from this screen, which contained a null allele of the adapter protein-2 assocd. kinase 1 (AAK1) gene, had a normal response in acute pain assays (hot plate, phase I formalin), but a markedly reduced response to persistent pain in phase II formalin.  AAK1 knockout mice also failed to develop tactile allodynia following the Chung procedure of spinal nerve ligation (SNL).  Based on these findings, potent, small-mol. inhibitors of AAK1 were identified.  Studies in mice showed that one such inhibitor, LP-935509, caused a reduced pain response in phase II formalin and reversed fully established pain behavior following the SNL procedure.  Further studies showed that the inhibitor also reduced evoked pain responses in the rat chronic constriction injury (CCI) model and the rat streptozotocin model of diabetic peripheral neuropathy.  Using a nonbrain-penetrant AAK1 inhibitor and local administration of an AAK1 inhibitor, the relevant pool of AAK1 for antineuropathic action was found to be in the spinal cord.  Consistent with these results, AAK1 inhibitors dose-dependently reduced the increased spontaneous neural activity in the spinal cord caused by CCI and blocked the development of windup induced by repeated elec. stimulation of the paw.  The mechanism of AAK1 antinociception was further investigated with inhibitors of α2 adrenergic and opioid receptors.  These studies showed that α2 adrenergic receptor inhibitors, but not opioid receptor inhibitors, not only prevented AAK1 inhibitor antineuropathic action in behavioral assays, but also blocked the AAK1 inhibitor-induced redn. in spinal neural activity in the rat CCI model.  Hence, AAK1 inhibitors are a novel therapeutic approach to neuropathic pain with activity in animal models that is mechanistically linked (behaviorally and electrophysiol.) to α2 adrenergic signaling, a pathway known to be antinociceptive in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cJpGeOPjm7Vg90H21EOLACvtfcHk0liARSw9rrh24g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI&md5=d4cec6b3681b63ba7d9119424e53ab61</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.235333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.235333%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DW.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DY.%2BW.%26aulast%3DNaidu%26aufirst%3DS.%26aulast%3DDandapani%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DBourin%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DSavelieva%26aufirst%3DK.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDokania%26aufirst%3DM.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DVattikundala%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DM.%2BL.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHolenarsipur%26aufirst%3DV.%2BK.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DNouraldeen%26aufirst%3DA.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMain%26aufirst%3DA.%26aulast%3DSwaffield%26aufirst%3DJ.%26aulast%3DCarson%26aufirst%3DK.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DVikramadithyan%26aufirst%3DR.%2BK.%26aulast%3DNara%26aufirst%3DS.%2BJ.%26aulast%3DDzierba%26aufirst%3DC.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DInhibition%2520of%2520AAK1%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520approach%2520to%2520treat%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D371%26epage%3D386%26doi%3D10.1124%2Fjpet.116.235333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bamborough, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, K.</span></span> <span> </span><span class="NLM_article-title">Assessment of chemical coverage of kinome space and its implications for kinase drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7898</span>– <span class="NLM_lpage">7914</span>, <span class="refDoi"> DOI: 10.1021/jm8011036</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8011036" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7898-7914&author=P.+Bamboroughauthor=D.+Drewryauthor=G.+Harperauthor=G.+K.+Smithauthor=K.+Schneider&title=Assessment+of+chemical+coverage+of+kinome+space+and+its+implications+for+kinase+drug+discovery&doi=10.1021%2Fjm8011036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of Chemical Coverage of Kinome Space and Its Implications for Kinase Drug Discovery</span></div><div class="casAuthors">Bamborough, Paul; Drewry, David; Harper, Gavin; Smith, Gary K.; Schneider, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7898-7914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">More than 500 compds. chosen to represent kinase inhibitor space have been screened against a panel of over 200 protein kinases.  Significant results include the identification of hits against new kinases including PIM1 and MPSK1, and the expansion of the inhibition profiles of several literature compds.  A detailed anal. of the data through the use of affinity fingerprints has produced findings with implications for biol. target selection, the choice of tool compds. for target validation, and lead discovery and optimization.  In a detailed examn. of the tyrosine kinases, interesting relationships have been found between targets and compds.  Taken together, these results show how broad cross-profiling can provide important insights to assist kinase drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBRI-arQk3t7Vg90H21EOLACvtfcHk0liboUM9B4_clg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVequ7zI&md5=8d98c80fb157b987a19e32a1efb53103</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1021%2Fjm8011036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011036%26sid%3Dliteratum%253Aachs%26aulast%3DBamborough%26aufirst%3DP.%26aulast%3DDrewry%26aufirst%3DD.%26aulast%3DHarper%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DG.%2BK.%26aulast%3DSchneider%26aufirst%3DK.%26atitle%3DAssessment%2520of%2520chemical%2520coverage%2520of%2520kinome%2520space%2520and%2520its%2520implications%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7898%26epage%3D7914%26doi%3D10.1021%2Fjm8011036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 3,5-disubstituted-pyrrolo[2,3- b]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.+Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.+J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure-activity+relationships+of+3%2C5-disubstituted-pyrrolo%5B2%2C3-+b%5Dpyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0liboUM9B4_clg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.%2BY.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.%2BJ.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25203%252C5-disubstituted-pyrrolo%255B2%252C3-%2520b%255Dpyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">104966</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2020.104966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33137362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlOqs7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2020&pages=104966&author=S.+Puauthor=S.+Schorauthor=M.+Karimauthor=S.+Saulauthor=M.+Robinsonauthor=S.+Kumarauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+Brannanauthor=J.+M.+Dyeauthor=S.+Einav&title=BIKE+regulates+dengue+virus+infection+and+is+a+cellular+target+for+broad-spectrum+antivirals&doi=10.1016%2Fj.antiviral.2020.104966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">BIKE regulates dengue virus infection and is a cellular target for broad-spectrum antivirals</span></div><div class="casAuthors">Pu, Szuyuan; Schor, Stanford; Karim, Marwah; Saul, Sirle; Robinson, Makeda; Kumar, Sathish; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer; Dye, John M.; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104966</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Global health is threatened by emerging viruses, many of which lack approved therapies and effective vaccines, including dengue, Ebola, and Venezuelan equine encephalitis.  We previously reported that AAK1 and GAK, two of the four members of the understudied Numb-assocd. kinases (NAK) family, control intracellular trafficking of RNA viruses.  Nevertheless, the role of BIKE and STK16 in viral infection remained unknown.  Here, we reveal a requirement for BIKE, but not STK-16, in dengue virus (DENV) infection.  BIKE mediates both early (postinternalization) and late (assembly/egress) stages in the DENV life cycle, and this effect is mediated in part by phosphorylation of a threonine 156 (T156) residue in theμ subunit of the adaptor protein (AP) 2 complex.  Pharmacol. compds. with potent anti-BIKE activity, including the investigational anticancer drug 5Z-7-oxozeaenol and more selective inhibitors, suppress DENV infection both in vitro and ex vivo.  BIKE overexpression reverses the antiviral activity, validating that the mechanism of antiviral action is, at least in part, mediated by BIKE.  Lastly, 5Z-7-oxozeaenol exhibits antiviral activity against viruses from three unrelated RNA viral families with a high genetic barrier to resistance.  These findings reveal regulation of poorly understood stages of the DENV life cycle via BIKE signaling and establish a proof-of-principle that pharmacol. inhibition of BIKE can be potentially used as a broad-spectrum strategy against acute emerging viral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2OM0FhHoGxbVg90H21EOLACvtfcHk0liboUM9B4_clg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlOqs7vK&md5=4c32d80ba91b13ebecaa8387ad619867</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104966%26sid%3Dliteratum%253Aachs%26aulast%3DPu%26aufirst%3DS.%26aulast%3DSchor%26aufirst%3DS.%26aulast%3DKarim%26aufirst%3DM.%26aulast%3DSaul%26aufirst%3DS.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DBIKE%2520regulates%2520dengue%2520virus%2520infection%2520and%2520is%2520a%2520cellular%2520target%2520for%2520broad-spectrum%2520antivirals%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D184%26spage%3D104966%26doi%3D10.1016%2Fj.antiviral.2020.104966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asquith, C. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capuzzi, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crona, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">East, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrice, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Earp, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span> <span> </span><span class="NLM_article-title">SGC-GAK-1: a chemical probe for cyclin G associated kinase (GAK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">2830</span>– <span class="NLM_lpage">2836</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFCrtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=2830-2836&author=C.+R.+M.+Asquithauthor=B.+T.+Bergerauthor=J.+Wanauthor=J.+M.+Bennettauthor=S.+J.+Capuzziauthor=D.+J.+Cronaauthor=D.+H.+Drewryauthor=M.+P.+Eastauthor=J.+M.+Elkinsauthor=O.+Fedorovauthor=P.+H.+Godoiauthor=D.+M.+Hunterauthor=S.+Knappauthor=S.+Mullerauthor=C.+D.+Torriceauthor=C.+I.+Wellsauthor=H.+S.+Earpauthor=T.+M.+Willsonauthor=W.+J.+Zuercher&title=SGC-GAK-1%3A+a+chemical+probe+for+cyclin+G+associated+kinase+%28GAK%29&doi=10.1021%2Facs.jmedchem.8b01213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK)</span></div><div class="casAuthors">Asquith, Christopher R. M.; Berger, Benedict-Tilman; Wan, Jing; Bennett, James M.; Capuzzi, Stephen J.; Crona, Daniel J.; Drewry, David H.; East, Michael P.; Elkins, Jonathan M.; Fedorov, Oleg; Godoi, Paulo H.; Hunter, Debra M.; Knapp, Stefan; Muller, Susanne; Torrice, Chad D.; Wells, Carrow I.; Earp, H. Shelton; Willson, Timothy M.; Zuercher, William J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2830-2836</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe SGC-GAK-1 (11), a potent, selective, and cell-active inhibitor of cyclin G-assocd. kinase (GAK), together with a structurally related neg. control SGC-GAK-1N (14).  11 Was highly selective in an in vitro kinome-wide screen, but cellular engagement assays defined RIPK2 as a collateral target.  We identified 18 as a potent RIPK2 inhibitor lacking GAK activity.  Together, this chem. probe set can be used to interrogate GAK cellular biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo59Ri_VO0xCLVg90H21EOLACvtfcHk0ljoIzJsVdZ06w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFCrtr4%253D&md5=95b6a31e3df7d87fb129d0814dc81bad</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01213%26sid%3Dliteratum%253Aachs%26aulast%3DAsquith%26aufirst%3DC.%2BR.%2BM.%26aulast%3DBerger%26aufirst%3DB.%2BT.%26aulast%3DWan%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DCapuzzi%26aufirst%3DS.%2BJ.%26aulast%3DCrona%26aufirst%3DD.%2BJ.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DEast%26aufirst%3DM.%2BP.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DHunter%26aufirst%3DD.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DTorrice%26aufirst%3DC.%2BD.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26atitle%3DSGC-GAK-1%253A%2520a%2520chemical%2520probe%2520for%2520cyclin%2520G%2520associated%2520kinase%2520%2528GAK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D2830%26epage%3D2836%26doi%3D10.1021%2Facs.jmedchem.8b01213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agajanian, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-De-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serafin, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamir, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamichi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gammons, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Counago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godoi, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santiago, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Major, M. B.</span></span> <span> </span><span class="NLM_article-title">WNT activates the AAK1 kinase to promote clathrin-mediated endocytosis of LRP6 and establish a negative feedback loop</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2018.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2018.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30605688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVegug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=79-93&author=M.+J.+Agajanianauthor=M.+P.+Walkerauthor=A.+D.+Axtmanauthor=R.+R.+Ruela-De-Sousaauthor=D.+S.+Serafinauthor=A.+D.+Rabinowitzauthor=D.+M.+Grahamauthor=M.+B.+Ryanauthor=T.+Tamirauthor=Y.+Nakamichiauthor=M.+V.+Gammonsauthor=J.+M.+Bennettauthor=R.+M.+Counagoauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=C.+Gileadiauthor=O.+Gileadiauthor=P.+H.+Godoiauthor=N.+Kapadiaauthor=S.+Mullerauthor=A.+S.+Santiagoauthor=F.+J.+Sorrellauthor=C.+I.+Wellsauthor=O.+Fedorovauthor=T.+M.+Willsonauthor=W.+J.+Zuercherauthor=M.+B.+Major&title=WNT+activates+the+AAK1+kinase+to+promote+clathrin-mediated+endocytosis+of+LRP6+and+establish+a+negative+feedback+loop&doi=10.1016%2Fj.celrep.2018.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop</span></div><div class="casAuthors">Agajanian, Megan J.; Walker, Matthew P.; Axtman, Alison D.; Ruela-de-Sousa, Roberta R.; Serafin, D. Stephen; Rabinowitz, Alex D.; Graham, David M.; Ryan, Meagan B.; Tamir, Tigist; Nakamichi, Yuko; Gammons, Melissa V.; Bennett, James M.; Counago, Rafael M.; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Carina; Gileadi, Opher; Godoi, Paulo H.; Kapadia, Nirav; Muller, Susanne; Santiago, Andre S.; Sorrell, Fiona J.; Wells, Carrow I.; Fedorov, Oleg; Willson, Timothy M.; Zuercher, William J.; Major, Michael B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-93.e8</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">β-Catenin-dependent WNT signal transduction governs development, tissue homeostasis, and a vast array of human diseases.  Signal propagation through a WNT-Frizzled/LRP receptor complex requires proteins necessary for clathrin-mediated endocytosis (CME).  Paradoxically, CME also neg. regulates WNT signaling through internalization and degrdn. of the receptor complex.  Here, using a gain-of-function screen of the human kinome, we report that the AP2 assocd. kinase 1 (AAK1), a known CME enhancer, inhibits WNT signaling.  Reciprocally, AAK1 genetic silencing or its pharmacol. inhibition using a potent and selective inhibitor activates WNT signaling.  Mechanistically, we show that AAK1 promotes clearance of LRP6 from the plasma membrane to suppress the WNT pathway.  Time-course expts. support a transcription-uncoupled, WNT-driven neg. feedback loop; prolonged WNT treatment drives AAK1-dependent phosphorylation of AP2M1, clathrin-coated pit maturation, and endocytosis of LRP6.  We propose that, following WNT receptor activation, increased AAK1 function and CME limits WNT signaling longevity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1SJx0zBLnLLVg90H21EOLACvtfcHk0ljoIzJsVdZ06w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVegug%253D%253D&md5=c1b67d54b0bb92caa1b290b67803da92</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2018.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2018.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DAgajanian%26aufirst%3DM.%2BJ.%26aulast%3DWalker%26aufirst%3DM.%2BP.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26aulast%3DRuela-De-Sousa%26aufirst%3DR.%2BR.%26aulast%3DSerafin%26aufirst%3DD.%2BS.%26aulast%3DRabinowitz%26aufirst%3DA.%2BD.%26aulast%3DGraham%26aufirst%3DD.%2BM.%26aulast%3DRyan%26aufirst%3DM.%2BB.%26aulast%3DTamir%26aufirst%3DT.%26aulast%3DNakamichi%26aufirst%3DY.%26aulast%3DGammons%26aufirst%3DM.%2BV.%26aulast%3DBennett%26aufirst%3DJ.%2BM.%26aulast%3DCounago%26aufirst%3DR.%2BM.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DC.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DGodoi%26aufirst%3DP.%2BH.%26aulast%3DKapadia%26aufirst%3DN.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DSantiago%26aufirst%3DA.%2BS.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DWells%26aufirst%3DC.%2BI.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DMajor%26aufirst%3DM.%2BB.%26atitle%3DWNT%2520activates%2520the%2520AAK1%2520kinase%2520to%2520promote%2520clathrin-mediated%2520endocytosis%2520of%2520LRP6%2520and%2520establish%2520a%2520negative%2520feedback%2520loop%26jtitle%3DCell%2520Rep.%26date%3D2019%26volume%3D26%26spage%3D79%26epage%3D93%26doi%3D10.1016%2Fj.celrep.2018.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couñago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente-Macias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-De-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zutshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span> <span> </span><span class="NLM_article-title">SGC-AAK1–1: a chemical probe targeting AAK1 and BMP2K</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00399</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00399" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=340-345&author=C.+Wellsauthor=R.+M.+Cou%C3%B1agoauthor=J.+C.+Limasauthor=T.+L.+Almeidaauthor=J.+G.+Cookauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=O.+Gileadiauthor=N.+R.+Kapadiaauthor=A.+Lorente-Maciasauthor=J.+E.+Pickettauthor=A.+Riemenauthor=R.+R.+Ruela-De-Sousaauthor=T.+M.+Willsonauthor=C.+Zhangauthor=W.+J.+Zuercherauthor=R.+Zutshiauthor=A.+D.+Axtman&title=SGC-AAK1%E2%80%931%3A+a+chemical+probe+targeting+AAK1+and+BMP2K&doi=10.1021%2Facsmedchemlett.9b00399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span></div><div class="casAuthors">Wells, Carrow; Counago, Rafael M.; Limas, Juanita C.; Almeida, Tuanny L.; Cook, Jeanette Gowen; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Opher; Kapadia, Nirav R.; Lorente-Macias, Alvaro; Pickett, Julie E.; Riemen, Alexander; Ruela-de-Sousa, Roberta R.; Willson, Timothy M.; Zhang, Cunyu; Zuercher, William J.; Zutshi, Reena; Axtman, Alison D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors based on a 3-acylaminoindazole scaffold were synthesized to yield potent dual AAK1/BMP2K inhibitors.  Optimization furnished a small mol. chem. probe (SGC-AAK1-1, 25 (I)) that is potent and selective for AAK1/BMP2K over other NAK family members, demonstrates narrow activity in a kinome-wide screen, and is functionally active in cells.  This inhibitor represents one of the best available small mol. tools to study the functions of AAK1 and BMP2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSOYD5xWr1LVg90H21EOLACvtfcHk0ljr-Mx5rnJbbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K&md5=d525d20f1ba1282697684e6ac1d09693</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00399%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%26aulast%3DCou%25C3%25B1ago%26aufirst%3DR.%2BM.%26aulast%3DLimas%26aufirst%3DJ.%2BC.%26aulast%3DAlmeida%26aufirst%3DT.%2BL.%26aulast%3DCook%26aufirst%3DJ.%2BG.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DKapadia%26aufirst%3DN.%2BR.%26aulast%3DLorente-Macias%26aufirst%3DA.%26aulast%3DPickett%26aufirst%3DJ.%2BE.%26aulast%3DRiemen%26aufirst%3DA.%26aulast%3DRuela-De-Sousa%26aufirst%3DR.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DZutshi%26aufirst%3DR.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26atitle%3DSGC-AAK1%25E2%2580%25931%253A%2520a%2520chemical%2520probe%2520targeting%2520AAK1%2520and%2520BMP2K%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Facsmedchemlett.9b00399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1016/S0092-8674(00)00114-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0092-8674%2800%2900114-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11057895" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2000&pages=211-225&author=J.+Schlessinger&title=Cell+signaling+by+receptor+tyrosine+kinases&doi=10.1016%2FS0092-8674%2800%2900114-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-225</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review, with 109 refs.  The purpose of this review is to describe general concepts underlying the mechanism of action of RTKs and the signaling pathways that they regulate, while attempting to shed light on the question of how specificity is defined by the action of RTKs, and how a specific biol. response can be generated by the diverse array of signaling pathways activated by all RTKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0AvjN2PpaVbVg90H21EOLACvtfcHk0ljr-Mx5rnJbbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXns1Cltrs%253D&md5=7b4cacd2513290f3b3e6120b58647654</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2900114-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252900114-8%26sid%3Dliteratum%253Aachs%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCell%26date%3D2000%26volume%3D103%26spage%3D211%26epage%3D225%26doi%3D10.1016%2FS0092-8674%2800%2900114-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span> <span> </span><span class="NLM_article-title">Cell signaling by receptor-tyrosine kinases</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1134</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2010.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2010.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20602996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2010&pages=1117-1134&author=M.+A.+Lemmonauthor=J.+Schlessinger&title=Cell+signaling+by+receptor-tyrosine+kinases&doi=10.1016%2Fj.cell.2010.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Cell signaling by receptor tyrosine kinases</span></div><div class="casAuthors">Lemmon, Mark A.; Schlessinger, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1117-1134</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Recent structural studies of receptor tyrosine kinases (RTKs) have revealed unexpected diversity in the mechanisms of their activation by growth factor ligands.  Strategies for inducing dimerization by ligand binding are surprisingly diverse, as are mechanisms that couple this event to activation of the intracellular tyrosine kinase domains.  As the understanding of these details becomes increasingly sophisticated, it provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.  Much remains to be learned, however, about the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd5NvoN0Q9-7Vg90H21EOLACvtfcHk0ljr-Mx5rnJbbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFartb0%253D&md5=b88b55fe7a3eebc6ff7e883425676e45</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2010.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2010.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DCell%2520signaling%2520by%2520receptor-tyrosine%2520kinases%26jtitle%3DCell%26date%3D2010%26volume%3D141%26spage%3D1117%26epage%3D1134%26doi%3D10.1016%2Fj.cell.2010.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ségaliny, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellez-Gabriel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymann, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymann, D.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span>. <i>J. Bone Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/j.jbo.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.jbo.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26579483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-12&author=A.+I.+S%C3%A9galinyauthor=M.+Tellez-Gabrielauthor=M.-F.+Heymannauthor=D.+Heymann&title=Receptor+tyrosine+kinases%3A+Characterisation%2C+mechanism+of+action+and+therapeutic+interests+for+bone+cancers&doi=10.1016%2Fj.jbo.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span></div><div class="casAuthors">Segaliny Aude I; Tellez-Gabriel Marta; Heymann Marie-Francoise; Heymann Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn">2212-1366</span>.
    </div><div class="casAbstract">Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment.  In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche.  As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed.  These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours.  The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl42y4bB4mnvYfW6udTcc2eY9Ft2WKegL4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D&md5=57563bfe33ca5752242d56cc24546c1c</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.jbo.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbo.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A9galiny%26aufirst%3DA.%2BI.%26aulast%3DTellez-Gabriel%26aufirst%3DM.%26aulast%3DHeymann%26aufirst%3DM.-F.%26aulast%3DHeymann%26aufirst%3DD.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520Characterisation%252C%2520mechanism%2520of%2520action%2520and%2520therapeutic%2520interests%2520for%2520bone%2520cancers%26jtitle%3DJ.%2520Bone%2520Oncol.%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.jbo.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, W.</span></span> <span> </span><span class="NLM_article-title">Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">45</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0796-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fs12943-018-0796-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29455668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=45&author=Y.+Zhangauthor=M.+Xiaauthor=K.+Jinauthor=S.+Wangauthor=H.+Weiauthor=C.+Fanauthor=Y.+Wuauthor=X.+Liauthor=X.+Liauthor=G.+Liauthor=Z.+Zengauthor=W.+Xiong&title=Function+of+the+c-Met+receptor+tyrosine+kinase+in+carcinogenesis+and+associated+therapeutic+opportunities&doi=10.1186%2Fs12943-018-0796-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities</span></div><div class="casAuthors">Zhang, Yazhuo; Xia, Mengfang; Jin, Ke; Wang, Shufei; Wei, Hang; Fan, Chunmei; Wu, Yingfen; Li, Xiaoling; Li, Xiayu; Li, Guiyuan; Zeng, Zhaoyang; Xiong, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">45/1-45/14</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">C-Met is a receptor tyrosine kinase belonging to the MET (MNNG HOS transforming gene) family, and is expressed on the surfaces of various cells.  Hepatocyte growth factor (HGF) is the ligand for this receptor.  The binding of HGF to c-Met initiates a series of intracellular signals that mediate embryogenesis and wound healing in normal cells.  However, in cancer cells, aberrant HGF/c-Met axis activation, which is closely related to c-Met gene mutations, overexpression, and amplification, promotes tumor development and progression by stimulating the PI3K/AKT, Ras/MAPK, JAK/STAT, SRC, Wnt/β-catenin, and other signaling pathways.  Thus, c-Met and its assocd. signaling pathways are clin. important therapeutic targets.  In this review, we elaborate on the mol. structure of c-Met and HGF and the mechanism through which their interaction activates the PI3K/AKT, Ras/MAPK, and Wnt signaling pathways.  We also summarize the connection between c-Met and RON and EGFR, which are also receptor tyrosine kinases.  Finally, we introduce the current therapeutic drugs that target c-Met in primary tumors, and their use in clin. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxr1VpZ-qwwbVg90H21EOLACvtfcHk0lgl2jFH93hBTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitF2nt7nE&md5=23db43661c4a23160dbed1ee1c26f8db</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0796-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0796-y%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DXiong%26aufirst%3DW.%26atitle%3DFunction%2520of%2520the%2520c-Met%2520receptor%2520tyrosine%2520kinase%2520in%2520carcinogenesis%2520and%2520associated%2520therapeutic%2520opportunities%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D45%26doi%3D10.1186%2Fs12943-018-0796-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor cell proliferation signaling pathways</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">52</span>, <span class="refDoi"> DOI: 10.3390/cancers9050052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fcancers9050052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=52&author=P.+Weeauthor=Z.+Wang&title=Epidermal+growth+factor+receptor+cell+proliferation+signaling+pathways&doi=10.3390%2Fcancers9050052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor cell proliferation signaling pathways</span></div><div class="casAuthors">Wee, Ping; Wang, Zhixiang</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">52/1-52/45</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.  Various mechanisms mediate the upregulation of EGFR activity, including common mutations and truncations to its extracellular domain, such as in the EGFRvIII truncations, as well as to its kinase domain, such as the L858R and T790M mutations, or the exon 19 truncation.  These EGFR aberrations over-activate downstream pro-oncogenic signaling pathways, including the RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR pathways.  These pathways then activate many biol. outputs that are beneficial to cancer cell proliferation, including their chronic initiation and progression through the cell cycle.  Here, we review the mol. mechanisms that regulate EGFR signal transduction, including the EGFR structure and its mutations, ligand binding and EGFR dimerization, as well as the signaling pathways that lead to G1 cell cycle progression.  We focus on the induction of CYCLIN D expression, CDK4/6 activation, and the repression of cyclin-dependent kinase inhibitor proteins (CDKi) by EGFR signaling pathways.  We also discuss the successes and challenges of EGFR-targeted therapies, and the potential for their use in combination with CDK4/6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpti1TbuQ7GPrVg90H21EOLACvtfcHk0lgl2jFH93hBTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVemtL%252FK&md5=5d5a81e10b147d1a74957dfa293e75c3</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3390%2Fcancers9050052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers9050052%26sid%3Dliteratum%253Aachs%26aulast%3DWee%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520cell%2520proliferation%2520signaling%2520pathways%26jtitle%3DCancers%26date%3D2017%26volume%3D9%26spage%3D52%26doi%3D10.3390%2Fcancers9050052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pantua, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komuves, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, S. B.</span></span> <span> </span><span class="NLM_article-title">Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">10935</span>– <span class="NLM_lpage">10949</span>, <span class="refDoi"> DOI: 10.1128/JVI.00750-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.00750-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22855500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyru7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=10935-10949&author=J.+Diaoauthor=H.+Pantuaauthor=H.+Nguauthor=L.+Komuvesauthor=L.+Diehlauthor=G.+Schaeferauthor=S.+B.+Kapadia&title=Hepatitis+C+virus+induces+epidermal+growth+factor+receptor+activation+via+CD81+binding+for+viral+internalization+and+entry&doi=10.1128%2FJVI.00750-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry</span></div><div class="casAuthors">Diao, Jingyu; Pantua, Homer; Ngu, Hai; Komuves, Laszlo; Diehl, Lauri; Schaefer, Gabriele; Kapadia, Sharookh B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">10935-10949</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">While epidermal growth factor receptor (EGFR) has been shown to be important in the entry process for multiple viruses, including hepatitis C virus (HCV), the mol. mechanisms by which EGFR facilitates HCV entry are not well understood.  Using the infectious cell culture HCV model (HCVcc), we demonstrate that the binding of HCVcc particles to human hepatocyte cells induces EGFR activation that is dependent on interactions between HCV and CD81 but not claudin 1.  EGFR activation can also be induced by antibody mediated crosslinking of CD81.  In addn., EGFR ligands that enhance the kinetics of HCV entry induce EGFR internalization and colocalization with CD81.  While EGFR kinase inhibitors inhibit HCV infection primarily by preventing EGFR endocytosis, antibodies that block EGFR ligand binding or inhibitors of EGFR downstream signaling have no effect on HCV entry.  These data demonstrate that EGFR internalization is crit. for HCV entry and identify a hitherto-unknown assocn. between CD81 and EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpO8haZF28serVg90H21EOLACvtfcHk0lgl2jFH93hBTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyru7bK&md5=514c49e7f64fca75b2fe4d3643615bd5</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1128%2FJVI.00750-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00750-12%26sid%3Dliteratum%253Aachs%26aulast%3DDiao%26aufirst%3DJ.%26aulast%3DPantua%26aufirst%3DH.%26aulast%3DNgu%26aufirst%3DH.%26aulast%3DKomuves%26aufirst%3DL.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DKapadia%26aufirst%3DS.%2BB.%26atitle%3DHepatitis%2520C%2520virus%2520induces%2520epidermal%2520growth%2520factor%2520receptor%2520activation%2520via%2520CD81%2520binding%2520for%2520viral%2520internalization%2520and%2520entry%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D10935%26epage%3D10949%26doi%3D10.1128%2FJVI.00750-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baktash, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coller, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, G.</span></span> <span> </span><span class="NLM_article-title">Single particle imaging of polarized hepatoma organoids upon hepatitis C virus infection reveals an ordered and sequential entry process</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2018.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chom.2018.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29544098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslSmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2018&pages=382-394&author=Y.+Baktashauthor=A.+Madhavauthor=K.+E.+Collerauthor=G.+Randall&title=Single+particle+imaging+of+polarized+hepatoma+organoids+upon+hepatitis+C+virus+infection+reveals+an+ordered+and+sequential+entry+process&doi=10.1016%2Fj.chom.2018.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process</span></div><div class="casAuthors">Baktash, Yasmine; Madhav, Anisha; Coller, Kelly E.; Randall, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-394.e5</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) enters hepatocytes via various entry factors, including scavenger receptor BI (SR-B1), cluster of differentiation 81 (CD81), epidermal growth factor receptor (EGFR), claudin-1 (CLDN1), and occludin (OCLN).  As CLDN1 and OCLN are not readily accessible due to their tight junctional localization, HCV likely accesses them by either disrupting cellular polarity or migrating to the tight junction.  In this study, we image HCV entry into a three-dimensional polarized hepatoma system and reveal that the virus sequentially engages these entry factors through actin-dependent mechanisms.  HCV initially localizes with the early entry factors SR-B1, CD81, and EGFR at the basolateral membrane and then accumulates at the tight junction in an actin-dependent manner.  HCV assocs. with CLDN1 and then OCLN at the tight junction and is internalized via clathrin-mediated endocytosis by an active process requiring EGFR.  Thus, HCV uses a dynamic and multi-step process to engage and enter host cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3WXKlaIjjTLVg90H21EOLACvtfcHk0lim1lub3SpVww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslSmsLk%253D&md5=0678419260c3f14266ab3e8fd40610ce</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2018.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2018.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DBaktash%26aufirst%3DY.%26aulast%3DMadhav%26aufirst%3DA.%26aulast%3DColler%26aufirst%3DK.%2BE.%26aulast%3DRandall%26aufirst%3DG.%26atitle%3DSingle%2520particle%2520imaging%2520of%2520polarized%2520hepatoma%2520organoids%2520upon%2520hepatitis%2520C%2520virus%2520infection%2520reveals%2520an%2520ordered%2520and%2520sequential%2520entry%2520process%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2018%26volume%3D23%26spage%3D382%26epage%3D394%26doi%3D10.1016%2Fj.chom.2018.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eierhoff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrincius, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rescher, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1001099</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1001099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1001099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20844577" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=T.+Eierhoffauthor=E.+R.+Hrinciusauthor=U.+Rescherauthor=S.+Ludwigauthor=C.+Ehrhardt&title=The+epidermal+growth+factor+receptor+%28EGFR%29+promotes+uptake+of+influenza+A+viruses+%28IAV%29+into+host+cells&doi=10.1371%2Fjournal.ppat.1001099"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1001099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1001099%26sid%3Dliteratum%253Aachs%26aulast%3DEierhoff%26aufirst%3DT.%26aulast%3DHrincius%26aufirst%3DE.%2BR.%26aulast%3DRescher%26aufirst%3DU.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DEhrhardt%26aufirst%3DC.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520promotes%2520uptake%2520of%2520influenza%2520A%2520viruses%2520%2528IAV%2529%2520into%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1001099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueki, I. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min-Oo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalinowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballon-Landa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanier, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadel, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koff, J. L.</span></span> <span> </span><span class="NLM_article-title">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">1929</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1084/jem.20121401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1084%2Fjem.20121401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23999497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2013&pages=1929-1936&author=I.+F.+Uekiauthor=G.+Min-Ooauthor=A.+Kalinowskiauthor=E.+Ballon-Landaauthor=L.+L.+Lanierauthor=J.+A.+Nadelauthor=J.+L.+Koff&title=Respiratory+virus-induced+EGFR+activation+suppresses+IRF1-dependent+interferon+%CE%BB+and+antiviral+defense+in+airway+epithelium&doi=10.1084%2Fjem.20121401"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Respiratory virus-induced EGFR activation suppresses IRF1-dependent interferon λ and antiviral defense in airway epithelium</span></div><div class="casAuthors">Ueki, Iris F.; Min-Oo, Gundula; Kalinowski, April; Ballon-Landa, Eric; Lanier, Lewis L.; Nadel, Jay A.; Koff, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1929-1936</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Viruses suppress host responses to increase infection, and understanding these mechanisms has provided insights into cellular signaling and led to novel therapies.  Many viruses (e.g., influenza virus, Rhinovirus [RV], Cytomegalovirus, Epstein-Barr virus, and Hepatitis C virus) activate epithelial epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, but the role of EGFR in viral pathogenesis is not clear.  Interferon (IFN) signaling is a crit. innate antiviral host response and recent expts. have implicated IFN-λ, a type III IFN, as the most significant IFN for mucosal antiviral immune responses.  Despite the importance of IFN-λ in epithelial antiviral responses, the role and mechanisms of epithelial IFN-λ signaling have not been fully elucidated.  We report that respiratory virus-induced EGFR activation suppresses endogenous airway epithelial antiviral signaling.  We found that Influenza virus- and RV-induced EGFR activation suppressed IFN regulatory factor (IRF) 1-induced IFN-λ prodn. and increased viral infection.  In addn., inhibition of EGFR during viral infection augmented IRF1 and IFN-λ, which resulted in decreased viral titers in vitro and in vivo.  These findings describe a novel mechanism that viruses use to suppress endogenous antiviral defenses, and provide potential targets for future therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2xVzMrOcUv7Vg90H21EOLACvtfcHk0lim1lub3SpVww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFelsLvM&md5=121a4a1514a53f104045e6516447e860</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1084%2Fjem.20121401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20121401%26sid%3Dliteratum%253Aachs%26aulast%3DUeki%26aufirst%3DI.%2BF.%26aulast%3DMin-Oo%26aufirst%3DG.%26aulast%3DKalinowski%26aufirst%3DA.%26aulast%3DBallon-Landa%26aufirst%3DE.%26aulast%3DLanier%26aufirst%3DL.%2BL.%26aulast%3DNadel%26aufirst%3DJ.%2BA.%26aulast%3DKoff%26aufirst%3DJ.%2BL.%26atitle%3DRespiratory%2520virus-induced%2520EGFR%2520activation%2520suppresses%2520IRF1-dependent%2520interferon%2520%25CE%25BB%2520and%2520antiviral%2520defense%2520in%2520airway%2520epithelium%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2013%26volume%3D210%26spage%3D1929%26epage%3D1936%26doi%3D10.1084%2Fjem.20121401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weisberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parent, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sattler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Repurposing of kinase inhibitors for treatment of COVID-19</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">167</span>, <span class="refDoi"> DOI: 10.1007/s11095-020-02851-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2Fs11095-020-02851-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32778962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=167&author=E.+Weisbergauthor=A.+Parentauthor=P.+L.+Yangauthor=M.+Sattlerauthor=Q.+Liuauthor=Q.+Liuauthor=J.+Wangauthor=C.+Mengauthor=S.+J.+Buhrlageauthor=N.+Grayauthor=J.+D.+Griffin&title=Repurposing+of+kinase+inhibitors+for+treatment+of+COVID-19&doi=10.1007%2Fs11095-020-02851-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of Kinase Inhibitors for Treatment of COVID-19</span></div><div class="casAuthors">Weisberg, Ellen; Parent, Alexander; Yang, Priscilla L.; Sattler, Martin; Liu, Qingsong; Liu, Qingwang; Wang, Jinhua; Meng, Chengcheng; Buhrlage, Sara J.; Gray, Nathanael; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">167</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community.  In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be life-threatening.  There are numerous protein kinases assocd. with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clin. trials.  Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metab., or reprodn.  We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity.  Certain agents are projected to be dual-purpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotAd3_eFezr7Vg90H21EOLACvtfcHk0lhz0CGQmeZH3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFKksrfN&md5=5edc7624fa51b69ec9d487262584a051</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs11095-020-02851-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-020-02851-7%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DParent%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DP.%2BL.%26aulast%3DSattler%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DC.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DRepurposing%2520of%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520COVID-19%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D167%26doi%3D10.1007%2Fs11095-020-02851-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlin, C. V.</span></span> <span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">327</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0lhz0CGQmeZH3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejarnac, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinigaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet-Madin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Charpentier, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafirassou, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamborlini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao-Lormeau, V.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulpier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouvenet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabibiazar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressens, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">Axl mediates ZIKA virus entry in human glial cells and modulates innate immune responses</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">324</span>– <span class="NLM_lpage">333</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.12.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.celrep.2016.12.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28076778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=324-333&author=L.+Meertensauthor=A.+Labeauauthor=O.+Dejarnacauthor=S.+Ciprianiauthor=L.+Sinigagliaauthor=L.+Bonnet-Madinauthor=T.+Le+Charpentierauthor=M.+L.+Hafirassouauthor=A.+Zamborliniauthor=V.-M.+Cao-Lormeauauthor=M.+Coulpierauthor=D.+Miss%C3%A9author=N.+Jouvenetauthor=R.+Tabibiazarauthor=P.+Gressensauthor=O.+Schwartzauthor=A.+Amara&title=Axl+mediates+ZIKA+virus+entry+in+human+glial+cells+and+modulates+innate+immune+responses&doi=10.1016%2Fj.celrep.2016.12.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses</span></div><div class="casAuthors">Meertens, Laurent; Labeau, Athena; Dejarnac, Ophelie; Cipriani, Sara; Sinigaglia, Laura; Bonnet-Madin, Lucie; Le Charpentier, Tifenn; Hafirassou, Mohamed Lamine; Zamborlini, Alessia; Cao-Lormeau, Van-Mai; Coulpier, Muriel; Misse, Dorothee; Jouvenet, Nolwenn; Tabibiazar, Ray; Gressens, Pierre; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">324-333</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">ZIKA virus (ZIKV) is an emerging pathogen responsible for neurol. disorders and congenital microcephaly.  However, the mol. basis for ZIKV neurotropism remains poorly understood.  Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells.  Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells.  Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection.  During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection.  ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428.  Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses.  Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDbk6ixuAbyLVg90H21EOLACvtfcHk0lhz0CGQmeZH3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCjuro%253D&md5=fbc8799266529e2fef7f03e6bee1b6c6</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.12.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.12.045%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DLabeau%26aufirst%3DA.%26aulast%3DDejarnac%26aufirst%3DO.%26aulast%3DCipriani%26aufirst%3DS.%26aulast%3DSinigaglia%26aufirst%3DL.%26aulast%3DBonnet-Madin%26aufirst%3DL.%26aulast%3DLe%2BCharpentier%26aufirst%3DT.%26aulast%3DHafirassou%26aufirst%3DM.%2BL.%26aulast%3DZamborlini%26aufirst%3DA.%26aulast%3DCao-Lormeau%26aufirst%3DV.-M.%26aulast%3DCoulpier%26aufirst%3DM.%26aulast%3DMiss%25C3%25A9%26aufirst%3DD.%26aulast%3DJouvenet%26aufirst%3DN.%26aulast%3DTabibiazar%26aufirst%3DR.%26aulast%3DGressens%26aufirst%3DP.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DAxl%2520mediates%2520ZIKA%2520virus%2520entry%2520in%2520human%2520glial%2520cells%2520and%2520modulates%2520innate%2520immune%2520responses%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D18%26spage%3D324%26epage%3D333%26doi%3D10.1016%2Fj.celrep.2016.12.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meertens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnec, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoin, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramdasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guivel-Benhassine, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, A.</span></span> <span> </span><span class="NLM_article-title">The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">544</span>– <span class="NLM_lpage">557</span>, <span class="refDoi"> DOI: 10.1016/j.chom.2012.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chom.2012.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23084921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=544-557&author=L.+Meertensauthor=X.+Carnecauthor=M.+P.+Lecoinauthor=R.+Ramdasiauthor=F.+Guivel-Benhassineauthor=E.+Lewauthor=G.+Lemkeauthor=O.+Schwartzauthor=A.+Amara&title=The+TIM+and+TAM+families+of+phosphatidylserine+receptors+mediate+dengue+virus+entry&doi=10.1016%2Fj.chom.2012.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry</span></div><div class="casAuthors">Meertens, Laurent; Carnec, Xavier; Lecoin, Manuel Perera; Ramdasi, Rasika; Guivel-Benhassine, Florence; Lew, Erin; Lemke, Greg; Schwartz, Olivier; Amara, Ali</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">544-557</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases.  However, the mol. interactions mediating DV entry are poorly understood.  We detd. that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors.  Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors.  Conversely, DV infection of susceptible cells is inhibited by anti-TIM or anti-TAM antibodies or knockdown of TIM and TAM expression.  TIM receptors facilitate DV entry by directly interacting with virion-assocd. PtdSer.  TAM-mediated infection relies on indirect DV recognition, in which the TAM ligand Gas6 acts as a bridging mol. by binding to PtdSer within the virion.  This dual mode of virus recognition by TIM and TAM receptors reveals how DVs usurp the apoptotic cell clearance pathway for infectious entry.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYGMhUV8WdLVg90H21EOLACvtfcHk0ljYGQuvdH4tlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFClurzK&md5=7a00c7dc61dc042960aa302124140818</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DMeertens%26aufirst%3DL.%26aulast%3DCarnec%26aufirst%3DX.%26aulast%3DLecoin%26aufirst%3DM.%2BP.%26aulast%3DRamdasi%26aufirst%3DR.%26aulast%3DGuivel-Benhassine%26aufirst%3DF.%26aulast%3DLew%26aufirst%3DE.%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3DAmara%26aufirst%3DA.%26atitle%3DThe%2520TIM%2520and%2520TAM%2520families%2520of%2520phosphatidylserine%2520receptors%2520mediate%2520dengue%2520virus%2520entry%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D12%26spage%3D544%26epage%3D557%26doi%3D10.1016%2Fj.chom.2012.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">140</span>, <span class="refDoi"> DOI: 10.1038/s41422-020-00460-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41422-020-00460-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=33420426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2021&pages=126-140&author=S.+Wangauthor=Z.+Qiuauthor=Y.+Houauthor=X.+Dengauthor=W.+Xuauthor=T.+Zhengauthor=P.+Wuauthor=S.+Xieauthor=W.+Bianauthor=C.+Zhangauthor=Z.+Sunauthor=K.+Liuauthor=C.+Shanauthor=A.+Linauthor=S.+Jiangauthor=Y.+Xieauthor=Q.+Zhouauthor=L.+Luauthor=J.+Huangauthor=X.+Li&title=AXL+is+a+candidate+receptor+for+SARS-CoV-2+that+promotes+infection+of+pulmonary+and+bronchial+epithelial+cells&doi=10.1038%2Fs41422-020-00460-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells</span></div><div class="casAuthors">Wang, Shuai; Qiu, Zongyang; Hou, Yingnan; Deng, Xiya; Xu, Wei; Zheng, Tingting; Wu, Peihan; Xie, Shaofang; Bian, Weixiang; Zhang, Chong; Sun, Zewei; Liu, Kunpeng; Shan, Chao; Lin, Aifu; Jiang, Shibo; Xie, Youhua; Zhou, Qiang; Lu, Lu; Huang, Jing; Li, Xu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-140</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The current coronavirus disease 2019 (COVID-19) pandemic presents a global public health challenge.  The viral pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), binds to the host receptor ACE2 through its spike (S) glycoprotein, which mediates membrane fusion and viral entry.  Although the role of ACE2 as a receptor for SARS-CoV-2 is clear, studies have shown that ACE2 expression is extremely low in various human tissues, esp. in the respiratory tract.  Thus, other host receptors and/or co-receptors that promote the entry of SARS-CoV-2 into cells of the respiratory system may exist.  In this study, we found that the tyrosine-protein kinase receptor UFO (AXL) specifically interacts with the N-terminal domain of SARS-CoV-2 S.  Using both a SARS-CoV-2 virus pseudotype and authentic SARS-CoV-2, we found that overexpression of AXL in HEK293T cells promotes SARS-CoV-2 entry as efficiently as overexpression of ACE2, while knocking out AXL significantly reduces SARS-CoV-2 infection in H1299 pulmonary cells and in human primary lung epithelial cells.  Sol. human recombinant AXL blocks SARS-CoV-2 infection in cells expressing high levels of AXL.  The AXL expression level is well correlated with SARS-CoV-2 S level in bronchoalveolar lavage fluid cells from COVID-19 patients.  Taken together, our findings suggest that AXL is a novel candidate receptor for SARS-CoV-2 which may play an important role in promoting viral infection of the human respiratory system and indicate that it is a potential target for future clin. intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI1wmry9H6UrVg90H21EOLACvtfcHk0ljYGQuvdH4tlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhs1Sjs7s%253D&md5=d708204bc6dd130cdb30f0bf5fc2742b</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-00460-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-00460-y%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DP.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DShan%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DAXL%2520is%2520a%2520candidate%2520receptor%2520for%2520SARS-CoV-2%2520that%2520promotes%2520infection%2520of%2520pulmonary%2520and%2520bronchial%2520epithelial%2520cells%26jtitle%3DCell%2520Res.%26date%3D2021%26volume%3D31%26spage%3D126%26epage%3D140%26doi%3D10.1038%2Fs41422-020-00460-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stantchev, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telford, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clouse, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broder, C. C.</span></span> <span> </span><span class="NLM_article-title">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1016/j.virusres.2006.09.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.virusres.2006.09.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17030448" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2007&pages=178-189&author=T.+S.+Stantchevauthor=I.+Markovicauthor=W.+G.+Telfordauthor=K.+A.+Clouseauthor=C.+C.+Broder&title=The+tyrosine+kinase+inhibitor+genistein+blocks+HIV-1+infection+in+primary+human+macrophages&doi=10.1016%2Fj.virusres.2006.09.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages</span></div><div class="casAuthors">Stantchev, Tzanko S.; Markovic, Ingrid; Telford, William G.; Clouse, Kathleen A.; Broder, Christopher C.</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Binding of HIV-1 envelope glycoprotein (Env) to its cellular receptors elicits a variety of signaling events, including the activation of select tyrosine kinases.  To evaluate the potential role of such signaling, we examd. the effects of the tyrosine kinase inhibitor, genistein, on HIV-1 entry and infection of human macrophages using a variety of assays.  Without altering cell viability, cell surface expression of CD4 and CCR5 or their abilities to interact with Env, genistein inhibited infection of macrophages by reporter gene-encoding, β-lactamase contg., or wild type virions, as well as Env-mediated cell-fusion.  The observation that genistein blocked virus infection if applied before, during or immediately after the infection period, but not 24 h later; coupled with a more pronounced inhibition of infection in the reporter gene assays as compared to both β-lactamase and p24 particle entry assays, imply that genistein exerts its inhibitory effects on both entry and early post-entry steps.  These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as addnl. opportunities for the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPOAvO4kSxB7Vg90H21EOLACvtfcHk0ljYGQuvdH4tlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGkug%253D%253D&md5=310c85933553074029e094e7d3a1bdb8</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2006.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2006.09.004%26sid%3Dliteratum%253Aachs%26aulast%3DStantchev%26aufirst%3DT.%2BS.%26aulast%3DMarkovic%26aufirst%3DI.%26aulast%3DTelford%26aufirst%3DW.%2BG.%26aulast%3DClouse%26aufirst%3DK.%2BA.%26aulast%3DBroder%26aufirst%3DC.%2BC.%26atitle%3DThe%2520tyrosine%2520kinase%2520inhibitor%2520genistein%2520blocks%2520HIV-1%2520infection%2520in%2520primary%2520human%2520macrophages%26jtitle%3DVirus%2520Res.%26date%3D2007%26volume%3D123%26spage%3D178%26epage%3D189%26doi%3D10.1016%2Fj.virusres.2006.09.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowick, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzog, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, J. F.</span></span> <span> </span><span class="NLM_article-title">Genistein treatment of cells inhibits arenavirus infection</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2007.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2007.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17961732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2008&pages=153-156&author=E.+M.+Velaauthor=G.+C.+Bowickauthor=N.+K.+Herzogauthor=J.+F.+Aronson&title=Genistein+treatment+of+cells+inhibits+arenavirus+infection&doi=10.1016%2Fj.antiviral.2007.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Genistein treatment of cells inhibits arenavirus infection</span></div><div class="casAuthors">Vela, Eric M.; Bowick, Gavin C.; Herzog, Norbert K.; Aronson, Judith F.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">153-156</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Arenaviridae is a family of enveloped viruses some of which are capable of causing hemorrhagic fever syndromes in humans.  In this report, we demonstrate that treatment of host cells with the tyrosine kinase inhibitor genistein inhibits infection of cells with the New World arenavirus Pichinde (PICV).  The greatest degree of inhibition was obsd. in pre-treated target cells, but modest inhibition of infection was also seen when drug was added to cultures up to 48 h after infection.  We show that PICV-induced phosphorylation of the activating transcription factor-2 protein (ATF-2) and cAMP response element binding protein (CREB) is inhibited following genistein treatment.  Lastly, genistein treatment also inhibited transduction of cells with pseudotyped retrovirus particles expressing envelope proteins of the Old World arenavirus Lassa virus.  These results demonstrate that kinase activity is required for arenavirus infection and that therapeutics designed to inhibit kinase activity should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXxt-7U7F05bVg90H21EOLACvtfcHk0lg4ewAQBIyfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlOksg%253D%253D&md5=ed23a98d1235f071148053c4620f5594</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2007.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2007.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DE.%2BM.%26aulast%3DBowick%26aufirst%3DG.%2BC.%26aulast%3DHerzog%26aufirst%3DN.%2BK.%26aulast%3DAronson%26aufirst%3DJ.%2BF.%26atitle%3DGenistein%2520treatment%2520of%2520cells%2520inhibits%2520arenavirus%2520infection%26jtitle%3DAntiviral%2520Res.%26date%3D2008%26volume%3D77%26spage%3D153%26epage%3D156%26doi%3D10.1016%2Fj.antiviral.2007.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span>. <i>Arch. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1007/BF01309554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1007%2FBF01309554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8397505" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=1993&pages=451-461&author=Y.+Yuraauthor=H.+Yoshidaauthor=M.+Sato&title=Inhibition+of+herpes+simplex+virus+replication+by+genistein%2C+an+inhibitor+of+protein-tyrosine+kinase&doi=10.1007%2FBF01309554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase</span></div><div class="casAuthors">Yura, Y.; Yoshida, H.; Sato, M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">451-61</span>CODEN:
                <span class="NLM_cas:coden">ARVIDF</span>;
        ISSN:<span class="NLM_cas:issn">0304-8608</span>.
    </div><div class="casAbstract">Genistein, an inhibitor of protein-tyrosine kinase, inhibited the replication of herpes simplex virus type 1 (HSV-1) at genistein concns. of more than 25 μM, whereas the related compds., which do not inhibit protein-tyrosine kinases, did not affect the replication of HSV-1.  In the presence of genistein, the phosphorylation of tyrosine residues in specific viral polypeptides was markedly reduced.  These results indicate that the phosphorylation of tyrosine residues in viral polypeptides may be essential for the replication of HSV-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPTvlkqS9JUbVg90H21EOLACvtfcHk0lg4ewAQBIyfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhvVansbg%253D&md5=ddabba9625d89206daf303e7f4739274</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1007%2FBF01309554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF01309554%26sid%3Dliteratum%253Aachs%26aulast%3DYura%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520replication%2520by%2520genistein%252C%2520an%2520inhibitor%2520of%2520protein-tyrosine%2520kinase%26jtitle%3DArch.%2520Virol.%26date%3D1993%26volume%3D132%26spage%3D451%26epage%3D461%26doi%3D10.1007%2FBF01309554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parslow, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">2818</span>– <span class="NLM_lpage">2827</span>, <span class="refDoi"> DOI: 10.1128/JVI.01969-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01969-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21209112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=2818-2827&author=N.+Kumarauthor=Y.+Liangauthor=T.+G.+Parslowauthor=Y.+Liang&title=Receptor+tyrosine+kinase+inhibitors+block+multiple+steps+of+influenza+A+virus+replication&doi=10.1128%2FJVI.01969-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block multiple steps of influenza A virus replication</span></div><div class="casAuthors">Kumar, Naveen; Liang, Yuhong; Parslow, Tristram G.; Liang, Yuying</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2818-2827</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Host signaling pathways play important roles in the replication of influenza virus, but their functional effects remain to be characterized at the mol. level.  Here we identify two receptor tyrosine kinase inhibitors (RTKIs) of the tyrphostin class that exhibit robust antiviral activity against influenza A virus replication in cultured cells.  One of these (AG879) is a selective inhibitor of the nerve growth factor receptor and human epidermal growth factor receptor 2 (TrkA/HER2) signaling; the other, tyrphostin A9 (A9), inhibits the platelet-derived growth factor receptor (PDGFR) pathway.  We find that each inhibits at least three postentry steps of the influenza virus life cycle: AG879 and A9 both strongly inhibit the synthesis of all three influenza virus RNA species, block Crm1-dependent nuclear export, and also prevent the release of viral particles through a pathway that is modulated by the lipid biosynthesis enzyme farnesyl diphosphate synthase (FPPS).  Tests of short hairpin RNA (shRNA) knockdown and addnl. small-mol. inhibitors confirmed that interventions targeting TrkA can suppress influenza virus replication.  Our study suggests that host cell receptor tyrosine kinase signaling is required for maximal influenza virus RNA synthesis, viral ribonucleoprotein (vRNP) nuclear export, and virus release and that specific RTKIs hold promise as novel anti-influenza virus therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohDOKlH_iMWLVg90H21EOLACvtfcHk0lg4ewAQBIyfgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVWks7vM&md5=5b0e29955db6cd71e6d371db771138d0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1128%2FJVI.01969-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01969-10%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DN.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DParslow%26aufirst%3DT.%2BG.%26aulast%3DLiang%26aufirst%3DY.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520multiple%2520steps%2520of%2520influenza%2520A%2520virus%2520replication%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D2818%26epage%3D2827%26doi%3D10.1128%2FJVI.01969-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, G.</span></span> <span> </span><span class="NLM_article-title">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">104651</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2019.104651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2019.104651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31751591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2020&pages=104651&author=W.+Dongauthor=W.+Xieauthor=Y.+Liuauthor=B.+Suiauthor=H.+Zhangauthor=L.+Liuauthor=Y.+Tanauthor=X.+Tongauthor=Z.+F.+Fuauthor=P.+Yinauthor=L.+Fangauthor=G.+Peng&title=Receptor+tyrosine+kinase+inhibitors+block+proliferation+of+TGEV+mainly+through+p38+mitogen-activated+protein+kinase+pathways&doi=10.1016%2Fj.antiviral.2019.104651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase inhibitors block proliferation of TGEV mainly through p38 mitogen-activated protein kinase pathways</span></div><div class="casAuthors">Dong, Wanyu; Xie, Wenting; Liu, Yunbo; Sui, Baokun; Zhang, Hao; Liu, Liran; Tan, Yubei; Tong, Xiaohan; Fu, Zhen F.; Yin, Ping; Fang, Liurong; Peng, Guiqing</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104651</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) primarily cause severe gastroenteric or respiratory diseases in humans and animals, and no approved therapeutics are currently available.  Here, A9, a receptor tyrosine kinase inhibitor (RTKI) of the tyrphostin class, is identified as a robust inhibitor of transmissible gastroenteritis virus (TGEV) infection in cell-based assays.  Moreover, A9 exhibited potent antiviral activity against the replication of various CoVs, including murine hepatitis virus (MHV), porcine epidemic diarrhea virus (PEDV) and feline infectious peritonitis virus (FIPV).  We further performed a comparative phosphoproteomic anal. to investigate the mechanism of action of A9 against TGEV infection in vitro.  We specifically identified p38 and JNK1, which are the downstream mols. of receptor tyrosine kinases (RTKs) required for efficient TGEV replication, as A9 targets through plaque assays, qRT-PCR and Western blotting assays. p38 and JNK1 inhibitors and RNA interference further showed that the inhibitory activity of A9 against TGEV infection was mainly mediated by the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  All these findings indicated that the RTKI A9 directly inhibits TGEV replication and that its inhibitory activity against TGEV replication mainly occurs by targeting p38, which provides vital clues to the design of novel drugs against CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnYnZ9MxD37Vg90H21EOLACvtfcHk0lix6O-A0Giulg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Krsb%252FO&md5=d0b78e75caf0d2932528e2ff6706d961</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104651%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSui%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DFu%26aufirst%3DZ.%2BF.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DFang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DG.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520inhibitors%2520block%2520proliferation%2520of%2520TGEV%2520mainly%2520through%2520p38%2520mitogen-activated%2520protein%2520kinase%2520pathways%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D173%26spage%3D104651%26doi%3D10.1016%2Fj.antiviral.2019.104651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cargnello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roux, P. P.</span></span> <span> </span><span class="NLM_article-title">Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</span>. <i>Microbiol. Mol. Biol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1128/MMBR.00031-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FMMBR.00031-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21372320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2011&pages=50-83&author=M.+Cargnelloauthor=P.+P.+Roux&title=Activation+and+function+of+the+MAPKs+and+their+substrates%2C+the+MAPK-activated+protein+kinases&doi=10.1128%2FMMBR.00031-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases</span></div><div class="casAuthors">Cargnello, Marie; Roux, Philippe P.</div><div class="citationInfo"><span class="NLM_cas:title">Microbiology and Molecular Biology Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-83</span>CODEN:
                <span class="NLM_cas:coden">MMBRF7</span>;
        ISSN:<span class="NLM_cas:issn">1092-2172</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review. The mitogen-activated protein (MAP) kinases (MAPKs) regulate diverse cellular programs by relaying extracellular signals to intracellular responses.  In mammals, there are more than a dozen MAPKs that coordinately regulate cell proliferation, differentiation, motility, and survival.  The best known are the conventional MAPKs, which include the extracellular signal-regulated kinases 1 and 2 (ERK1/2), c-Jun N-terminal kinases 1-3 (JNK1 to JNK3), p38 (α, β, γ, and δ), and ERK5 families.  There are addnl., atypical MAPKs, including ERK3/4, ERK7/8, and Nemo-like kinase (NLK), which have distinct regulation and functions.  Together, the MAPKs regulate a large no. of substrates, including members of a family of protein Ser/Thr kinases termed MAPK-activated protein kinases (MAPKAPKs).  The MAPKAPKs are related enzymes that respond to extracellular stimulation through direct MAPK-dependent activation loop phosphorylation and kinase activation.  There are five MAPKAPK subfamilies: p90 ribosomal S6 kinase (RSK), mitogen- and stress-activated kinase (MSK), MAPK-interacting kinase (MNK), MAPK-activated protein kinase 2/3 (MK2/3), and MK5 (also known as p38-regulated/activated protein kinase).  These enzymes have diverse biol. functions, including regulation of nucleosome and gene expression, mRNA stability and translation, and cell proliferation and survival.  Here,the authors review the mechanisms of MAPKAPK activation by the different MAPKs and discuss their physiol. roles based on established substrates and recent discoveries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWcx7oIOM6lLVg90H21EOLACvtfcHk0lix6O-A0Giulg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsVequ78%253D&md5=e074f5af1f56957f0f10b2ecd837e69c</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1128%2FMMBR.00031-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMMBR.00031-10%26sid%3Dliteratum%253Aachs%26aulast%3DCargnello%26aufirst%3DM.%26aulast%3DRoux%26aufirst%3DP.%2BP.%26atitle%3DActivation%2520and%2520function%2520of%2520the%2520MAPKs%2520and%2520their%2520substrates%252C%2520the%2520MAPK-activated%2520protein%2520kinases%26jtitle%3DMicrobiol.%2520Mol.%2520Biol.%2520Rev.%26date%3D2011%26volume%3D75%26spage%3D50%26epage%3D83%26doi%3D10.1128%2FMMBR.00031-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braicu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buse, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busuioc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raduly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irimie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atanasov, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slaby, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ionescu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berindan-Neagoe, I.</span></span> <span> </span><span class="NLM_article-title">A comprehensive review on MAPK: a promising therapeutic target in cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1618</span>, <span class="refDoi"> DOI: 10.3390/cancers11101618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fcancers11101618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXns1GltLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1618&author=C.+Braicuauthor=M.+Buseauthor=C.+Busuiocauthor=R.+Drulaauthor=D.+Guleiauthor=L.+Radulyauthor=A.+Rusuauthor=A.+Irimieauthor=A.+G.+Atanasovauthor=O.+Slabyauthor=C.+Ionescuauthor=I.+Berindan-Neagoe&title=A+comprehensive+review+on+MAPK%3A+a+promising+therapeutic+target+in+cancer&doi=10.3390%2Fcancers11101618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive review on MAPK: a promising therapeutic target in cancer</span></div><div class="casAuthors">Braicu, Cornelia; Buse, Mihail; Busuioc, Constantin; Drula, Rares; Gulei, Diana; Raduly, Lajos; Rusu, Alexandru; Irimie, Alexandru; Atanasov, Atanas G.; Slaby, Ondrej; Ionescu, Calin; Berindan-Neagoe, Ioana</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1618</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch from extracellular signals to intracellular responses.  Alterations of signaling cascades are found in various diseases, including cancer, as a result of genetic and epigenetic changes.  Numerous studies focused on both the homeostatic and the pathol. conduct of MAPK signaling; however, there is still much to be deciphered in terms of regulation and action models in both preclin. and clin. research.  MAPK has implications in the response to cancer therapy, particularly the activation of the compensatory pathways in response to exptl. MAPK inhibition.  The present paper discusses new insights into MAPK as a complex cell signaling pathway with roles in the sustenance of cellular normal conduit, response to cancer therapy, and activation of compensatory pathways.  Unfortunately, most MAPK inhibitors trigger resistance due to the activation of compensatory feed-back loops in tumor cells and tumor microenvironment components.  Therefore, novel combinatorial therapies have to be implemented for cancer management in order to restrict the possibility of alternative pathway activation, as a perspective for developing novel therapies based on integration in translational studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIhFMNc9OogLVg90H21EOLACvtfcHk0lix6O-A0Giulg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXns1GltLw%253D&md5=55e2b6da7e8736cb486015b04a1c8938</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.3390%2Fcancers11101618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11101618%26sid%3Dliteratum%253Aachs%26aulast%3DBraicu%26aufirst%3DC.%26aulast%3DBuse%26aufirst%3DM.%26aulast%3DBusuioc%26aufirst%3DC.%26aulast%3DDrula%26aufirst%3DR.%26aulast%3DGulei%26aufirst%3DD.%26aulast%3DRaduly%26aufirst%3DL.%26aulast%3DRusu%26aufirst%3DA.%26aulast%3DIrimie%26aufirst%3DA.%26aulast%3DAtanasov%26aufirst%3DA.%2BG.%26aulast%3DSlaby%26aufirst%3DO.%26aulast%3DIonescu%26aufirst%3DC.%26aulast%3DBerindan-Neagoe%26aufirst%3DI.%26atitle%3DA%2520comprehensive%2520review%2520on%2520MAPK%253A%2520a%2520promising%2520therapeutic%2520target%2520in%2520cancer%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1618%26doi%3D10.3390%2Fcancers11101618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doria, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R. J.</span></span> <span> </span><span class="NLM_article-title">Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">4978</span>– <span class="NLM_lpage">4985</span>, <span class="refDoi"> DOI: 10.1128/JVI.70.8.4978-4985.1996</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.70.8.4978-4985.1996" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8764004" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK28Xktlejsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=1996&pages=4978-4985&author=J.+Bennauthor=F.+Suauthor=M.+Doriaauthor=R.+J.+Schneider&title=Hepatitis+B+virus+HBx+protein+induces+transcription+factor+AP-1+by+activation+of+extracellular+signal-regulated+and+c-Jun+N-terminal+mitogen-activated+protein+kinases&doi=10.1128%2FJVI.70.8.4978-4985.1996"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases</span></div><div class="casAuthors">Benn, Jacqueline; Su, Fei; Doria, Margherita; Schneider, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4978-4985</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The HBx protein of hepatitis B virus is a dual-specificity activator of transcription, stimulating signal transduction pathways in the cytoplasm and transcription factors in the nucleus, when expressed in cell lines in culture.  In the cytoplasm, HBx was shown to stimulate the Ras-Raf-mitogen-activated protein kinase (MAP kinase) cascade, which is essential for activation of transcription factor AP-1.  Here the authors show that HBx protein stimulates two independently regulated members of the MAP kinase family when expressed transiently in cells.  HBx protein stimulates the extracellular signal-regulated kinases (ERKs) and the c-Jun N-terminal kinases (JNKs).  HBx activation of ERKs and JNKs leads to induction and activation of AP-1 DNA binding activation involving transient de novo synthesis of c-Fos protein and prolonged synthesis of c-Jun, mediated by N-terminal phosphorylation of c-Jun carried out by HBx-activated JNK.  New c-Jun synthesis was blocked by coexpression with a dominant-neg. MAP kinase kinase (MEK kinase, MEKK-1), confirming that HBx stimulates the prolonged synthesis of c-Jun by activating JNK signaling pathways.  Activation of the c-fos gene was blocked by coexpression with a Raf-C4 catalytic mutant, confirming that HBx induces c-Fos by acting on Ras-Raf linked pathways.  HBx activation of ERK and JNK pathways resulted in prolonged accumulation of AP-1-cJun dimer complexes.  HBx activation of JNK and sustained activation of c-Jun, should they occur in the context of hepatitis B virus infection, might play a role in viral transformation and pathogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDzR7FTc2UQ7Vg90H21EOLACvtfcHk0lhZ-z4QKI-4Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktlejsbw%253D&md5=15866e858bcc3c4042a5a0dd85fb2c50</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FJVI.70.8.4978-4985.1996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.70.8.4978-4985.1996%26sid%3Dliteratum%253Aachs%26aulast%3DBenn%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DDoria%26aufirst%3DM.%26aulast%3DSchneider%26aufirst%3DR.%2BJ.%26atitle%3DHepatitis%2520B%2520virus%2520HBx%2520protein%2520induces%2520transcription%2520factor%2520AP-1%2520by%2520activation%2520of%2520extracellular%2520signal-regulated%2520and%2520c-Jun%2520N-terminal%2520mitogen-activated%2520protein%2520kinases%26jtitle%3DJ.%2520Virol.%26date%3D1996%26volume%3D70%26spage%3D4978%26epage%3D4985%26doi%3D10.1128%2FJVI.70.8.4978-4985.1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruder, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovesdi, I.</span></span> <span> </span><span class="NLM_article-title">Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1128/JVI.71.1.398-404.1997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.71.1.398-404.1997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=8985363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK28XnsF2gs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1997&pages=398-404&author=J.+T.+Bruderauthor=I.+Kovesdi&title=Adenovirus+infection+stimulates+the+Raf%2FMAPK+signaling+pathway+and+induces+interleukin-8+expression&doi=10.1128%2FJVI.71.1.398-404.1997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression</span></div><div class="casAuthors">Bruder, Joseph T.; Kovesdi, Imre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">398-404</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Previous studies have shown that airway administration of adenovirus or adenovirus vectors results in a dose-dependent inflammatory response which limits the duration of transgene expression.  The authors explored the possibility that adenovirus infection triggers signal transduction pathways that induce the synthesis of cytokines and thus contribute to the early inflammatory response.  Since stimulation of the Raf/mitogen-activated protein kinase (MAPK) pathway activates transcription factors that control the expression of inflammatory cytokines, the authors examd. the activation of this pathway following adenovirus infection.  Adenovirus infection induced the rapid activation of Raf-1 and a transient increase in the tyrosine phosphorylation and activation of p42mapk at early times post-infection.  Activation of the Raf/MAPK pathway by adenovirus is likely triggered by the infection process, since it occurred rapidly and with various mutant adenoviruses and adenovirus vectors.  Moreover, interleukin-8 (IL-8) mRNA accumulation was evident at 20 min post-infection and was induced even in the presence of cycloheximide.  Both MAPK activation and IL-8 prodn. were inhibited by forskolin, a potent inhibitor of Raf-1.  These results suggest that adenovirus-induced Raf/MAPK activation contributes to IL-8 prodn.  Adenovirus-induced activation of the Raf/MAPK signaling pathway and IL-8 prodn. may play crit. roles in the inflammation obsd. following in vivo administration of adenovirus vectors for gene therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2gUVkFOYlZLVg90H21EOLACvtfcHk0lhZ-z4QKI-4Cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XnsF2gs7o%253D&md5=0ad5443be939c580ecab85d492a262bd</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1128%2FJVI.71.1.398-404.1997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.71.1.398-404.1997%26sid%3Dliteratum%253Aachs%26aulast%3DBruder%26aufirst%3DJ.%2BT.%26aulast%3DKovesdi%26aufirst%3DI.%26atitle%3DAdenovirus%2520infection%2520stimulates%2520the%2520Raf%252FMAPK%2520signaling%2520pathway%2520and%2520induces%2520interleukin-8%2520expression%26jtitle%3DJ.%2520Virol.%26date%3D1997%26volume%3D71%26spage%3D398%26epage%3D404%26doi%3D10.1128%2FJVI.71.1.398-404.1997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobom, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapp, U. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span> <span> </span><span class="NLM_article-title">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">301</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1038/35060098</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2F35060098" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11231581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=301-305&author=S.+Pleschkaauthor=T.+Wolffauthor=C.+Ehrhardtauthor=G.+Hobomauthor=O.+Planzauthor=U.+R.+Rappauthor=S.+Ludwig&title=Influenza+virus+propagation+is+impaired+by+inhibition+of+the+Raf%2FMEK%2FERK+signalling+cascade&doi=10.1038%2F35060098"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade</span></div><div class="casAuthors">Pleschka, Stephan; Wolff, Thorsten; Ehrhard, Christina; Hobom, Gerd; Planz, Oliver; Rapp, Ulf R.; Ludwig, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-305</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Influenza A viruses are important worldwide pathogens in humans and different animal species.  The functions of most of the ten different viral proteins of this neg.-strand RNA virus have been well elucidated.  However, little is known about the virus-induced intracellular signalling events that support viral replication.  The Raf/MEK/ERK cascade is the prototype of mitogen-activated protein (MAP) kinase cascades and has an important role in cell growth, differentiation and survival.  Investigation of the function of this pathway has been facilitated by the identification of specific inhibitors, such as U0126, which blocks the cascade at the level of MAPK/ERK kinase (MEK).  Here, the authors show that infection of cells with influenza A virus leads to biphasic activation of the Raf/MEK/ERK cascade.  Inhibition of Raf signalling results in nuclear retention of viral ribonucleoprotein complexes (RNPs), impaired function of the nuclear-export protein (NEP/NS2) and concomitant inhibition of virus prodn.  Thus, signalling through the mitogenic cascade seems to be essential for virus prodn. and RNP export from the nucleus during the viral life cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx1KgfMDKJPLVg90H21EOLACvtfcHk0limlR7TjKWNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFemsLw%253D&md5=b5283932b9d29e474583d8dfa0ec5658</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2F35060098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35060098%26sid%3Dliteratum%253Aachs%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DHobom%26aufirst%3DG.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DRapp%26aufirst%3DU.%2BR.%26aulast%3DLudwig%26aufirst%3DS.%26atitle%3DInfluenza%2520virus%2520propagation%2520is%2520impaired%2520by%2520inhibition%2520of%2520the%2520Raf%252FMEK%252FERK%2520signalling%2520cascade%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D301%26epage%3D305%26doi%3D10.1038%2F35060098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wurzer, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span> <span> </span><span class="NLM_article-title">MEK inhibition impairs in£uenza B virus propagation without emergence of resistant variants</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>561</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(04)00108-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FS0014-5793%2804%2900108-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15013748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=561&publication_year=2004&pages=37-43&author=S.+Ludwigauthor=T.+Wolffauthor=C.+Ehrhardtauthor=W.+J.+Wurzerauthor=J.+Reinhardtauthor=O.+Planzauthor=S.+Pleschka&title=MEK+inhibition+impairs+in%C2%A3uenza+B+virus+propagation+without+emergence+of+resistant+variants&doi=10.1016%2FS0014-5793%2804%2900108-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">MEK inhibition impairs influenza B virus propagation without emergence of resistant variants</span></div><div class="casAuthors">Ludwig, Stephan; Wolff, Thorsten; Ehrhardt, Christina; Wurzer, Walter Jurgen; Reinhardt, Jens; Planz, Oliver; Pleschka, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">561</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">37-43</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">Influenza A and B viruses are still a major worldwide threat.  We demonstrate that influenza B virus infection induces signaling via the Raf/MEK/ERK cascade, a process required for efficient virus prodn.  Expression of dominant-neg. Raf and ERK mutants or treatment with a MEK inhibitor (U0126) strongly impaired viral propagation, while selective activation of the pathway resulted in increased virus titers.  MEK inhibition appears to interfere with a distinct viral nuclear export process.  Most importantly, no resistant virus variants emerged in the presence of U0126 demonstrating that influenza viruses cannot easily adapt to the missing cellular function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH2SOtrmGyrbVg90H21EOLACvtfcHk0limlR7TjKWNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFagu7w%253D&md5=30a70331cb39e18f1db14f415063ba91</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2804%2900108-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252804%252900108-5%26sid%3Dliteratum%253Aachs%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DWolff%26aufirst%3DT.%26aulast%3DEhrhardt%26aufirst%3DC.%26aulast%3DWurzer%26aufirst%3DW.%2BJ.%26aulast%3DReinhardt%26aufirst%3DJ.%26aulast%3DPlanz%26aufirst%3DO.%26aulast%3DPleschka%26aufirst%3DS.%26atitle%3DMEK%2520inhibition%2520impairs%2520in%25C2%25A3uenza%2520B%2520virus%2520propagation%2520without%2520emergence%2520of%2520resistant%2520variants%26jtitle%3DFEBS%2520Lett.%26date%3D2004%26volume%3D561%26spage%3D37%26epage%3D43%26doi%3D10.1016%2FS0014-5793%2804%2900108-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Droebner, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2011.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2011.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21854809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2011&pages=195-203&author=K.+Droebnerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+activity+of+the+MEK-inhibitor+U0126+against+pandemic+H1N1v+and+highly+pathogenic+avian+influenza+virus+in+vitro+and+in+vivo&doi=10.1016%2Fj.antiviral.2011.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo</span></div><div class="casAuthors">Droebner, Karoline; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The emergence of the 2009 H1N1 pandemic swine influenza A virus is a good example of how this viral infection can impact health systems around the world in a very short time.  The continuous zoonotic circulation and reassortment potential of influenza A viruses (IAV) in nature represents an enormous public health threat to humans.  Beside vaccination antivirals are needed to efficiently control spreading of the disease.  In the present work we investigated whether the MEK inhibitor U0126, targeting the intracellular Raf/MEK/ERK signaling pathway, is able to suppress propagation of the 2009 pandemic IV H1N1v (v = variant) as well as highly pathogenic avian influenza viruses (HPAIV) in cell culture and also in vivo in the mouse lung.  U0126 showed antiviral activity in cell culture against all tested IAV strains including oseltamivir resistant variants.  Furthermore, we were able to demonstrate that treatment of mice with U0126 via the aerosol route led to (i) inhibition of MEK activation in the lung (ii) redn. of progeny IAV titers compared to untreated controls (iii) protection of IAV infected mice against a 100× lethal viral challenge.  Moreover, no adverse effects of U0126 were found in cell culture or in the mouse.  Thus, we conclude that U0126, by inhibiting the cellular target MEK, has an antiviral potential not only in vitro in cell culture, but also in vivo in the mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6szZdpUCJ_bVg90H21EOLACvtfcHk0limlR7TjKWNFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlKkurfI&md5=2818e18e307a3cda653b302d30857638</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2011.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2011.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DDroebner%26aufirst%3DK.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520activity%2520of%2520the%2520MEK-inhibitor%2520U0126%2520against%2520pandemic%2520H1N1v%2520and%2520highly%2520pathogenic%2520avian%2520influenza%2520virus%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DAntiviral%2520Res.%26date%3D2011%26volume%3D92%26spage%3D195%26epage%3D203%26doi%3D10.1016%2Fj.antiviral.2011.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Cherry, S.</span></span> <span> </span><span class="NLM_article-title">Suppression of astrovirus replication by an ERK1/2 inhibitor</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">7475</span>– <span class="NLM_lpage">7482</span>, <span class="refDoi"> DOI: 10.1128/JVI.02193-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.02193-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18508903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVSltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=7475-7482&author=L.+A.+Moserauthor=S.+Schultz-Cherry&title=Suppression+of+astrovirus+replication+by+an+ERK1%2F2+inhibitor&doi=10.1128%2FJVI.02193-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of astrovirus replication by an ERK1/2 inhibitor</span></div><div class="casAuthors">Moser, Lindsey A.; Schultz-Cherry, Stacey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7475-7482</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human astroviruses are nonenveloped, pos.-sense single-strand RNA viruses assocd. with self-limiting diarrhea.  Although they are recognized as a leading cause of disease in young children, the cellular factors involved in astrovirus replication are not well defined.  The extracellular signal-regulated kinase (ERK) pathway has been shown to regulate many viral infections, but its role during astrovirus infection is unknown.  In this report, we show that astrovirus activates ERK1/2 early in infection independently of replication.  Inhibition of ERK activation with U0126, a specific ERK inhibitor, significantly reduced viral prodn.  Investigations into the mechanism of ERK1/2 regulation revealed that all steps of the viral life cycle, including early and late protein expression as well as subgenomic and genomic RNA transcription, were diminished during U0126 treatment of monolayers.  These data support a role for ERK1/2 in a postattachment step, although the precise mechanism remains under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj4Baf6rmSALVg90H21EOLACvtfcHk0lhGHxk3J-W71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVSltL4%253D&md5=916f786530b570845cc846eebe7fb328</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1128%2FJVI.02193-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02193-07%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DL.%2BA.%26aulast%3DSchultz-Cherry%26aufirst%3DS.%26atitle%3DSuppression%2520of%2520astrovirus%2520replication%2520by%2520an%2520ERK1%252F2%2520inhibitor%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D7475%26epage%3D7482%26doi%3D10.1128%2FJVI.02193-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ork, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traynor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span> <span> </span><span class="NLM_article-title">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1088</span>– <span class="NLM_lpage">1099</span>, <span class="refDoi"> DOI: 10.1128/AAC.03659-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.03659-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25487801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1088-1099&author=J.+Kindrachukauthor=B.+Orkauthor=B.+J.+Hartauthor=S.+Mazurauthor=M.+R.+Holbrookauthor=M.+B.+Friemanauthor=D.+Traynorauthor=R.+F.+Johnsonauthor=J.+Dyallauthor=J.+H.+Kuhnauthor=G.+G.+Olingerauthor=L.+E.+Hensleyauthor=P.+B.+Jahrling&title=Antiviral+potential+of+ERK%2FMAPK+and+PI3K%2FAKT%2FmTOR+signaling+modulation+for+middle+east+respiratory+syndrome+coronavirus+infection+as+identified+by+temporal+kinome+analysis&doi=10.1128%2FAAC.03659-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for middle east respiratory syndrome coronavirus infection as identified by temporal kinome analysis</span></div><div class="casAuthors">Kindrachuk, Jason; Ork, Britini; Hart, Brit J.; Mazur, Steven; Holbrook, Michael R.; Frieman, Matthew B.; Traynor, Dawn; Johnson, Reed F.; Dyall, Julie; Kuhn, Jens H.; Olinger, Gene G.; Hensley, Lisa E.; Jahrling, Peter B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1088-1099/1-1088-1099/12, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is a lineage C betacoronavirus, and infections with this virus can result in acute respiratory syndrome with renal failure.  Globally, MERS-CoV has been responsible for 877 lab.-confirmed infections, including 317 deaths, since Sept. 2012.  As there is a paucity of information regarding the mol. pathogenesis assocd. with this virus or the identities of novel antiviral drug targets, we performed temporal kinome anal. on human hepatocytes infected with the Erasmus isolate of MERS-CoV with peptide kinome arrays. bioinformatics anal. of our kinome data, including pathway overrepresentation anal. (ORA) and functional network anal., suggested that extracellular signalregulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphoinositol 3-kinase (PI3K)/serine-threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling responses were specifically modulated in response to MERS-CoV infection in vitro throughout the course of infection.  The overrepresentation of specific intermediates within these pathways detd. by pathway and functional network anal. of our kinome data correlated with similar patterns of phosphorylation detd. through Western blot array anal.  In addn., anal. of the effects of specific kinase inhibitors on MERS-CoV infection in tissue culture models confirmed these cellular response observations.  Further, we have demonstrated that a subset of licensed kinase inhibitors targeting the ERK/MAPK and PI3K/AKT/mTOR pathways significantly inhibited MERS-CoV replication in vitro whether they were added before or after viral infection.  Taken together, our data suggest that ERK/MAPK and PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent novel drug targets for therapeutic intervention strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwo9H9W_zXg7Vg90H21EOLACvtfcHk0lhGHxk3J-W71A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVagsbw%253D&md5=1fef3dd7bccc643cec0762fdfbee27bb</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1128%2FAAC.03659-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03659-14%26sid%3Dliteratum%253Aachs%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DOrk%26aufirst%3DB.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DMazur%26aufirst%3DS.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26aulast%3DTraynor%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DKuhn%26aufirst%3DJ.%2BH.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26atitle%3DAntiviral%2520potential%2520of%2520ERK%252FMAPK%2520and%2520PI3K%252FAKT%252FmTOR%2520signaling%2520modulation%2520for%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%2520as%2520identified%2520by%2520temporal%2520kinome%2520analysis%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1088%26epage%3D1099%26doi%3D10.1128%2FAAC.03659-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peppelenbosch, M. P.</span></span> <span> </span><span class="NLM_article-title">Kinome profiling</span>. <i>Scientifica</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2012</i></span>,  <span class="NLM_fpage">306798</span>, <span class="refDoi"> DOI: 10.6064/2012/306798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.6064%2F2012%2F306798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24278683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2c3ntFWqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2012&publication_year=2012&pages=306798&author=M.+P.+Peppelenbosch&title=Kinome+profiling&doi=10.6064%2F2012%2F306798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Kinome profiling</span></div><div class="casAuthors">Peppelenbosch Maikel P</div><div class="citationInfo"><span class="NLM_cas:title">Scientifica</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2012</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">306798</span>
        ISSN:<span class="NLM_cas:issn">2090-908X</span>.
    </div><div class="casAbstract">The use of arrays in genomics has led to a fast and reliable way to screen the transcriptome of an organism.  It can be automated and analysis tools have become available and hence the technique has become widely used within the past few years.  Signal-transduction routes rely mainly on the phosphorylation status of already available proteins; therefore kinases are central players in signal-transduction routes.  The array technology can now also be used for the analysis of the kinome.  To enable array analysis, consensus peptides for kinases are spot on a solid support.  After incubation with cell lysates and in the presence of radioactive ATP, radioactive peptides can be visualized and the kinases that are active in the cells can be determined.  The present paper reviews comprehensively the different kinome array platforms available and results obtained hitherto using such platforms.  It will appear that this technology does not disappoint its high expectations and is especially powerful because of its species independence.  Nevertheless, improvements are still possible and I shall also sketch future possible directions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRhIuTuUFCHQHRxY89Cm6SyfW6udTcc2eYTE0iDGyOw0Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3ntFWqtg%253D%253D&md5=83202cc92e99e3e1364e7c286a8e27cf</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.6064%2F2012%2F306798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.6064%252F2012%252F306798%26sid%3Dliteratum%253Aachs%26aulast%3DPeppelenbosch%26aufirst%3DM.%2BP.%26atitle%3DKinome%2520profiling%26jtitle%3DScientifica%26date%3D2012%26volume%3D2012%26spage%3D306798%26doi%3D10.6064%2F2012%2F306798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aggarwal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leser, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, R. A.</span></span> <span> </span><span class="NLM_article-title">Repurposing papaverine as an antiviral agent against influenza viruses and paramyxoviruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>94</i></span>, <span class="NLM_elocation-id">e01888-19</span> <span class="refDoi"> DOI: 10.1128/JVI.01888-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01888-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31896588" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2020&author=M.+Aggarwalauthor=G.+P.+Leserauthor=R.+A.+Lamb&title=Repurposing+papaverine+as+an+antiviral+agent+against+influenza+viruses+and+paramyxoviruses&doi=10.1128%2FJVI.01888-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1128%2FJVI.01888-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01888-19%26sid%3Dliteratum%253Aachs%26aulast%3DAggarwal%26aufirst%3DM.%26aulast%3DLeser%26aufirst%3DG.%2BP.%26aulast%3DLamb%26aufirst%3DR.%2BA.%26atitle%3DRepurposing%2520papaverine%2520as%2520an%2520antiviral%2520agent%2520against%2520influenza%2520viruses%2520and%2520paramyxoviruses%26jtitle%3DJ.%2520Virol.%26date%3D2020%26volume%3D94%26doi%3D10.1128%2FJVI.01888-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorusso, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varterasian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeLuca, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruzek, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asbury, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Becelaere, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebolt-Leopold, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. B.</span></span> <span> </span><span class="NLM_article-title">Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5281</span>– <span class="NLM_lpage">5293</span>, <span class="refDoi"> DOI: 10.1200/JCO.2005.14.415</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1200%2FJCO.2005.14.415" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16009947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpslOrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5281-5293&author=P.+M.+Lorussoauthor=A.+A.+Adjeiauthor=M.+Varterasianauthor=S.+Gadgeelauthor=J.+Reidauthor=D.+Y.+Mitchellauthor=L.+Hansonauthor=P.+DeLucaauthor=L.+Bruzekauthor=J.+Piensauthor=P.+Asburyauthor=K.+Van+Becelaereauthor=R.+Herreraauthor=J.+Sebolt-Leopoldauthor=M.+B.+Meyer&title=Phase+I+and+pharmacodynamic+study+of+the+oral+MEK+inhibitor+CI-1040+in+patients+with+advanced+malignancies&doi=10.1200%2FJCO.2005.14.415"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies</span></div><div class="casAuthors">LoRusso, Patricia M.; Adjei, Alex A.; Varterasian, Mary; Gadgeel, Shirish; Reid, Joel; Mitchell, David Y.; Hanson, Lorelei; DeLuca, Pamela; Bruzek, Laura; Piens, Jill; Asbury, Peggy; Van Becelaere, Keri; Herrera, Roman; Sebolt-Leopold, Judith; Meyer, Mark B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5281-5293</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, max. tolerated dose (MTD), and clin. activity of CI-1040, a small-mol. inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2, in patients with advanced malignancy.  Patients and Methods: CI-1040 was tested in multiple daily dosing frequencies administered for 21 days repeated every 28 days leading ultimately to continuous administration, and effect of food on absorption was tested.  Single dose and steady-state pharmacokinetics were assessed during cycle 1 and phosphorylated extracellular receptor kinase (pERK) levels were assessed in WBCs and also in tumor tissue from selected patients.  Results: Seventy-seven patients received CI-1040 at dose levels ranging from 100 mg QD to 800 mg tid.  Grade 3 asthenia was dose limiting at the highest dose level tested, 800 mg tid administered with food.  Ninety-eight percent of all drug-related adverse events were grade 1 or 2 in severity; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting.  Plasma concns. of CI-1040 and its active metabolite, PD 0184264, increased in a less than dose proportional manner from 100 to 800 mg QD.  Administration with a high-fat meal resulted in an increase in drug exposure.  The MTD and recommended phase II dose was 800 mg BID administered with food.  Sixty-six patients were assessable for response.  One partial response was achieved in a patient with pancreatic cancer and 19 patients (28%) achieved stable disease lasting a median of 5.5 mo (range, 4 to 17 mo).  Inhibition of tumor pERK (median, 73%; range, 46% to 100%) was demonstrated in 10 patients.  Conclusion: CI-1040 was well tolerated at 800 mg BID administered with food.  Both target suppression and antitumor activity were demonstrated in this phase I study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn9_7twRmM4LVg90H21EOLACvtfcHk0ljPKXzKr6yO0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpslOrtL8%253D&md5=6af34b8a2037ede667d91e6a3e884d87</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.14.415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.14.415%26sid%3Dliteratum%253Aachs%26aulast%3DLorusso%26aufirst%3DP.%2BM.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DVarterasian%26aufirst%3DM.%26aulast%3DGadgeel%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%26aulast%3DMitchell%26aufirst%3DD.%2BY.%26aulast%3DHanson%26aufirst%3DL.%26aulast%3DDeLuca%26aufirst%3DP.%26aulast%3DBruzek%26aufirst%3DL.%26aulast%3DPiens%26aufirst%3DJ.%26aulast%3DAsbury%26aufirst%3DP.%26aulast%3DVan%2BBecelaere%26aufirst%3DK.%26aulast%3DHerrera%26aufirst%3DR.%26aulast%3DSebolt-Leopold%26aufirst%3DJ.%26aulast%3DMeyer%26aufirst%3DM.%2BB.%26atitle%3DPhase%2520I%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520MEK%2520inhibitor%2520CI-1040%2520in%2520patients%2520with%2520advanced%2520malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5281%26epage%3D5293%26doi%3D10.1200%2FJCO.2005.14.415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamza, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch-Heier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quernheim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pleschka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planz, O.</span></span> <span> </span><span class="NLM_article-title">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104806</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2020.104806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2020.104806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32304723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104806&author=M.+Laureauthor=H.+Hamzaauthor=J.+Koch-Heierauthor=M.+Quernheimauthor=C.+M%C3%BCllerauthor=A.+Schreiberauthor=G.+M%C3%BCllerauthor=S.+Pleschkaauthor=S.+Ludwigauthor=O.+Planz&title=Antiviral+efficacy+against+influenza+virus+and+pharmacokinetic+analysis+of+a+novel+MEK-inhibitor%2C+ATR-002%2C+in+cell+culture+and+in+the+mouse+model&doi=10.1016%2Fj.antiviral.2020.104806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model</span></div><div class="casAuthors">Laure, Martin; Hamza, Hazem; Koch-Heier, Julia; Quernheim, Martin; Mueller, Christin; Schreiber, Andre; Mueller, Gerhard; Pleschka, Stephan; Ludwig, Stephan; Planz, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104806</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Antiviral therapies against influenza are required, esp. for high-risk patients, severe influenza and in case of highly pathogenic influenza virus (IV) strains.  This may be overcome by targeting host cell factors that are required for IV propagation.  IV induces a variety of host cell signaling cascades, such as the Raf/MEK/ERK kinase pathway.  MEK-inhibitors block the activation of the pathway on the bottleneck of the signaling cascade leading to impaired virus propagation.  In the present study, we aimed to compare the antiviral potency and bioavailability of the MEK-inhibitor CI-1040 vs. its major active metabolite ATR-002, in vitro as well as in the mouse model.  In cell culture assays, an approx. 10-fold higher concn. of ATR-002 is required to generate the same antiviral activity as for CI-1040.  Interestingly, we obsd. that considerably lower concns. of ATR-002 were required to achieve a redn. of the viral load in vivo.  Pharmacokinetic studies with ATR-002 and CI-1040 in mice have found the Cmax and AUC to be far higher for ATR-002 than for CI-1040.  Our results thereby demonstrate the in vivo superiority of the active metabolite ATR-002 over CI-1040 as an antiviral agent despite its weaker cell membrane permeability.  Therefore, ATR-002 is an attractive candidate for development as an efficient antiviral agent, esp. given the fact that a treatment based on cellular pathway inhibition would be far less likely to lead to viral drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCdKB75g1RNbVg90H21EOLACvtfcHk0lh_FVNXzWjRYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFaks7Y%253D&md5=9d7774956ebbe323b85b719653716ef4</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104806%26sid%3Dliteratum%253Aachs%26aulast%3DLaure%26aufirst%3DM.%26aulast%3DHamza%26aufirst%3DH.%26aulast%3DKoch-Heier%26aufirst%3DJ.%26aulast%3DQuernheim%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DSchreiber%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26aulast%3DPleschka%26aufirst%3DS.%26aulast%3DLudwig%26aufirst%3DS.%26aulast%3DPlanz%26aufirst%3DO.%26atitle%3DAntiviral%2520efficacy%2520against%2520influenza%2520virus%2520and%2520pharmacokinetic%2520analysis%2520of%2520a%2520novel%2520MEK-inhibitor%252C%2520ATR-002%252C%2520in%2520cell%2520culture%2520and%2520in%2520the%2520mouse%2520model%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104806%26doi%3D10.1016%2Fj.antiviral.2020.104806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><a href="http://www.clinicaltrials.gov/" class="extLink">http://www.clinicaltrials.gov/</a> (accessed February <span class="NLM_year">2021</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=http%3A%2F%2Fwww.clinicaltrials.gov%2F+%28accessed+February+2021%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.phrs.2015.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25662515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2015&pages=9-25&author=R.+Roskoski&title=Src+protein-tyrosine+kinase+structure%2C+mechanism%2C+and+small+molecule+inhibitors&doi=10.1016%2Fj.phrs.2015.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">9-25</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The physiol. Src proto-oncogene is a protein tyrosine kinase that plays key roles in cell growth, division, migration, and survival signaling pathways.  From the N- to C-terminus, Src contains a unique domain, an SH3 domain, an SH2 domain, a protein tyrosine kinase domain, and a regulatory tail.  The chief phosphorylation sites of human Src include an activating pTyr419 that results from phosphorylation in the kinase domain by an adjacent Src mol. and an inhibitory pTyr530 in the regulatory tail that results from phosphorylation by C-terminal Src kinase (Csk) or Chk (Csk homologous kinase).  The oncogenic Rous sarcoma viral protein lacks the equiv. of Tyr530 and is constitutively activated.  Inactive Src is stabilized by SH2 and SH3 domains on the rear of the kinase domain where they form an immobilizing and inhibitory clamp.  Protein kinases including Src contain hydrophobic regulatory and catalytic spines and collateral shell residues that are required to assemble the active enzyme.  In the inactive enzyme, the regulatory spine contains a kink or a discontinuity with a structure that is incompatible with catalysis.  The conversion of inactive to active Src is accompanied by electrostatic exchanges involving the breaking and making of distinct sets of kinase domain salt bridges and hydrogen bonds.  Src-catalyzed protein phosphorylation requires the participation of two Mg2+ ions.  Although nearly all protein kinases possess a common K/E/D/D signature, each enzyme exhibits its unique variations of the protein-kinase reaction template.  Bosutinib, dasatinib, and ponatinib are Src/multikinase inhibitors that are approved by the FDA for the treatment of chronic myelogenous leukemia and vandetanib is approved for the treatment of medullary thyroid cancer.  The Src and BCR-Abl inhibitors saracatinib and AZD0424, along with the previous four drugs, are in clin. trials for a variety of solid tumors including breast and lung cancers.  Both ATP and targeted therapeutic Src protein kinase inhibitors such as dasatinib and ponatinib make hydrophobic contacts with catalytic spine residues and form hydrogen bonds with hinge residues connecting the small and large kinase lobes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWw-wmm7q2cbVg90H21EOLACvtfcHk0lh_FVNXzWjRYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1SjtLg%253D&md5=a40c394ab772b445fe0944c58e1f3deb</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DSrc%2520protein-tyrosine%2520kinase%2520structure%252C%2520mechanism%252C%2520and%2520small%2520molecule%2520inhibitors%26jtitle%3DPharmacol.%2520Res.%26date%3D2015%26volume%3D94%26spage%3D9%26epage%3D25%26doi%3D10.1016%2Fj.phrs.2015.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rivera-Torres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San José, E.</span></span> <span> </span><span class="NLM_article-title">Src tyrosine kinase inhibitors: new perspectives on their immune, antiviral, and senotherapeutic potential</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1011</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2019.01011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31619990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1011&author=J.+Rivera-Torresauthor=E.+San+Jos%C3%A9&title=Src+tyrosine+kinase+inhibitors%3A+new+perspectives+on+their+immune%2C+antiviral%2C+and+senotherapeutic+potential&doi=10.3389%2Ffphar.2019.01011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential</span></div><div class="casAuthors">Rivera-Torres Jose; San Jose Esther</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1011</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Deregulated activity of the Src tyrosine kinases leads to malignant transformation.  Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has increased notably due to their beneficial effects.  Dasatinib, a second-generation STKI inhibitor widely studied, proved high efficiency in CML patients resistant to imatinib.  In the last decade STKIs have also been implicated and showed therapeutic potential for the treatment of diverse pathologies other than cancer.  In this regard, we review the properties of STKIs, dasatinib in particular, including its immunomodulatory role.  Similarly, the potential benefits, adverse effects, and safety concerns of these inhibitors regarding viral infections are considered.  Moreover, since life expectancy has increased in the last decades accompanied by age-related morbidity, the reduction of undesirable effects associated to aging has become a powerful therapeutic target.  Here, we comment on the ability of STKIs to alleviate age-associated physical dysfunction and their potential impact in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRFuB58-0Ghq7mQt-ICR3qNfW6udTcc2eZpMIi8Yk3xt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3Mnos1Srsw%253D%253D&md5=abb7070b94a2328a1c01559aecbeb7d5</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01011%26sid%3Dliteratum%253Aachs%26aulast%3DRivera-Torres%26aufirst%3DJ.%26aulast%3DSan%2BJos%25C3%25A9%26aufirst%3DE.%26atitle%3DSrc%2520tyrosine%2520kinase%2520inhibitors%253A%2520new%2520perspectives%2520on%2520their%2520immune%252C%2520antiviral%252C%2520and%2520senotherapeutic%2520potential%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1011%26doi%3D10.3389%2Ffphar.2019.01011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Go, Y. Y.</span></span> <span> </span><span class="NLM_article-title">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">283</span>, <span class="refDoi"> DOI: 10.3390/v10060283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fv10060283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=283&author=J.+S.+Shinauthor=E.+Jungauthor=M.+Kimauthor=R.+S.+Baricauthor=Y.+Y.+Go&title=Saracatinib+inhibits+middle+east+respiratory+syndrome-coronavirus+replication+in+vitro&doi=10.3390%2Fv10060283"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro</span></div><div class="casAuthors">Shin, Jin Soo; Jung, Eunhye; Kim, Meehyein; Baric, Ralph S.; Go, Yun Young</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">283/1-283/19</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The Middle East respiratory syndrome-coronavirus (MERS-CoV), first identified in Saudi Arabia, is an emerging zoonotic pathogen that causes severe acute respiratory illness in humans with a high fatality rate.  Since its emergence, MERS-CoV continues to spread to countries outside of the Arabian Peninsula and gives rise to sporadic human infections following the entry of infected individuals to other countries, which can ppt. outbreaks similar to the one that occurred in South Korea in 2015.  Current therapeutics against MERS-CoV infection have primarily been adapted from previous drugs used for the treatment of severe acute respiratory syndrome.  In search of new potential drug candidates, we screened a library composed of 2334 clin. approved drugs and pharmacol. active compds.  The drug saracatinib, a potent inhibitor of Src-family of tyrosine kinases (SFK), was identified as an inhibitor of MERS-CoV replication in vitro.  Our results suggest that saracatinib potently inhibits MERS-CoV at the early stages of the viral life cycle in Huh-7 cells, possibly through the suppression of SFK signaling pathways.  Furthermore, saracatinib exhibited a synergistic effect with gemcitabine, an anticancer drug with antiviral activity against several RNA viruses.  These data indicate that saracatinib alone or in combination with gemcitabine can provide a new therapeutic option for the treatment of MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ_gxf2E7R7Vg90H21EOLACvtfcHk0ljP2hRAVJyo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVanurzF&md5=46083e949f27772ec4ed534ea8933f27</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.3390%2Fv10060283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10060283%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DJ.%2BS.%26aulast%3DJung%26aufirst%3DE.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DGo%26aufirst%3DY.%2BY.%26atitle%3DSaracatinib%2520inhibits%2520middle%2520east%2520respiratory%2520syndrome-coronavirus%2520replication%2520in%2520vitro%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D283%26doi%3D10.3390%2Fv10060283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">c-Src protein kinase inhibitors block assembly and maturation of dengue virus</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">3520</span>– <span class="NLM_lpage">3525</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611681104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.0611681104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17360676" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=3520-3525&author=J.+J.+H.+Chuauthor=P.+L.+Yang&title=c-Src+protein+kinase+inhibitors+block+assembly+and+maturation+of+dengue+virus&doi=10.1073%2Fpnas.0611681104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">c-Src protein kinase inhibitor block assembly and maturation of dengue virus</span></div><div class="casAuthors">Chu, J. J. H.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3520-3525</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Dengue virus is a mosquito-borne flavivirus that represents an important emerging infectious disease and is an international health concern.  Currently, there is no vaccine or effective antiviral therapy to prevent or to treat dengue virus infection.  The slow progress in developing antiviral agents might be alleviated by the availability of efficient high-throughput anti-dengue virus screening assays.  In this study, we report an immunofluorescence image-based assay suitable for identification of small mol. inhibitors of dengue virus infection and replication.  Using this assay, we have discovered that inhibitors of the c-Src protein kinase exhibit a potent inhibitory effect on dengue virus (serotypes 1-4) and murine flavivirus Modoc.  Mechanism of action studies demonstrated that the c-Src protein kinase inhibitor dasatinib prevents the assembly of dengue virions within the virus-induced membranous replication complex.  These results demonstrate that this cell-based screen may provide a powerful means to identify new potential targets for anti-dengue drug development while simultaneously providing pharmacol. probes to investigate dengue virus-host cell interactions at the biochem. level.  Given the simplicity and excellent reproducibility of the assay, it should be useful in high-throughput screens of both small mol. and RNAi libraries when implemented on a robotic image-based high- throughput screen (HTS) platform.  Given the reasonable clin. safety of inhibitors such as dasatinib and AZD0530, inhibitors of c-Src protein kinase may have the potential to become a new class of anti-dengue viral therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT5wnglMCrULVg90H21EOLACvtfcHk0ljP2hRAVJyo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjtVWltbc%253D&md5=7b8dd352cb73b762b349ee386a39f649</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611681104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611681104%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3Dc-Src%2520protein%2520kinase%2520inhibitors%2520block%2520assembly%2520and%2520maturation%2520of%2520dengue%2520virus%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D3520%26epage%3D3525%26doi%3D10.1073%2Fpnas.0611681104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Wispelaere, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaCroix, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">7367</span>– <span class="NLM_lpage">7381</span>, <span class="refDoi"> DOI: 10.1128/JVI.00632-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.00632-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23616652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=7367-7381&author=M.+De+Wispelaereauthor=A.+J.+LaCroixauthor=P.+L.+Yang&title=The+small+molecules+AZD0530+and+dasatinib+inhibit+dengue+virus+RNA+replication+via+Fyn+kinase&doi=10.1128%2FJVI.00632-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase</span></div><div class="casAuthors">de Wispelaere, Melissanne; LaCroix, Amy J.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">7367-7381</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">In this study, we characterized the antiviral mechanism of action of AZD0530 and dasatinib, two pharmacol. inhibitors of host kinases, that also inhibit dengue virus (DV) infection.  Using Northern blot and reporter replicon assays, we demonstrated that both small mols. inhibit the DV2 infectious cycle at the step of steady-state RNA replication.  In order to identify the cellular target of AZD0530 and dasatinib mediating this anti-DV2 activity, we examd. the effects of RNA interference (RNAi)-mediated depletion of the major kinases known to be inhibited by these small mols.  We detd. that Fyn kinase, a target of both AZD0530 and dasatinib, is involved in DV2 RNA replication and is probably a major mediator of the anti-DV activity of these compds.  Furthermore, serial passaging of DV2 in the presence of dasatinib led to the identification of a mutation in the transmembrane domain 3 of the NS4B protein that overcomes the inhibition of RNA replication by AZD0530, dasatinib, and Fyn RNAi.  Although we obsd. that dasatinib also inhibits DV2 particle assembly and/or secretion, this activity does not appear to be mediated by Src-family kinases.  Together, our results suggest that AZD0530 and dasatinib inhibit DV at the step of viral RNA replication and demonstrate a crit. role for Fyn kinase in this viral process.  The antiviral activity of these compds. in vitro makes them useful pharmacol. tools to validate Fyn or other host kinases as anti-DV targets in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDobBEv8oAxrVg90H21EOLACvtfcHk0ljP2hRAVJyo9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFCqsbs%253D&md5=3030a3de1e36bdf7563f97d6e97b5f29</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1128%2FJVI.00632-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00632-13%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BWispelaere%26aufirst%3DM.%26aulast%3DLaCroix%26aufirst%3DA.%2BJ.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DThe%2520small%2520molecules%2520AZD0530%2520and%2520dasatinib%2520inhibit%2520dengue%2520virus%2520RNA%2520replication%2520via%2520Fyn%2520kinase%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D7367%26epage%3D7381%26doi%3D10.1128%2FJVI.00632-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cervantes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">547</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1080/14740338.2017.1313224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F14740338.2017.1313224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28387147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=547-559&author=M.+Coirasauthor=J.+Ambrosioniauthor=F.+Cervantesauthor=J.+M.+Mir%C3%B3author=J.+Alcam%C3%AD&title=Tyrosine+kinase+inhibitors%3A+potential+use+and+safety+considerations+in+HIV-1+infection&doi=10.1080%2F14740338.2017.1313224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors: potential use and safety considerations in HIV-1 infection</span></div><div class="casAuthors">Coiras, Mayte; Ambrosioni, Juan; Cervantes, Francisco; Miro, Jose M.; Alcami, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">547-559</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Infection caused by HIV-1 is nowadays a chronic disease due to a highly efficient antiretroviral treatment that is nevertheless, unable to eliminate the virus from the organism.  New strategies are necessary in order to impede the formation of the viral reservoirs, responsible for the failure of the antiretroviral treatment to cure the infection.: The purpose of this review is to discuss the possibility of using tyrosine kinase inhibitors (TKIs) for the treatment of HIV-1 infection.  These inhibitors are successfully used in patients with distinct cancers such as chronic myeloid leukemia.  The most relevant papers have been selected and commented.: The family of TKIs are directed against the activation of tyrosine kinases from the Src family.  Some of these kinases are essential for the activation of CD4 + T cells, the major target of HIV-1.  During acute or primary infection the CD4 + T cells are massively activated, which is mostly responsible for the generation of the reservoirs, the spread of the infection and the destruction of activated CD4 + T cells, infected or not.  Consequently, we discuss the possibility of using TKIs as adjuvant of the antiretroviral treatment against HIV-1 infection mostly, but not exclusively, during the acute/recent phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBdl_4AHijwrVg90H21EOLACvtfcHk0lhXV8fUmjQKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleitrs%253D&md5=5976725b6d26c627218be0207febd954</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1080%2F14740338.2017.1313224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14740338.2017.1313224%26sid%3Dliteratum%253Aachs%26aulast%3DCoiras%26aufirst%3DM.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DCervantes%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%2520potential%2520use%2520and%2520safety%2520considerations%2520in%2520HIV-1%2520infection%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2017%26volume%3D16%26spage%3D547%26epage%3D559%26doi%3D10.1080%2F14740338.2017.1313224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayrhofer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span> <span> </span><span class="NLM_article-title">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">330</span>– <span class="NLM_lpage">339</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.clim.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18395492" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2008&pages=330-339&author=S.+Blakeauthor=T.+P.+Hughesauthor=G.+Mayrhoferauthor=A.+B.+Lyons&title=The+Src%2FABL+kinase+inhibitor+dasatinib+%28BMS-354825%29+inhibits+function+of+normal+human+T-lymphocytes+in+vitro&doi=10.1016%2Fj.clim.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro</span></div><div class="casAuthors">Blake, Stephen; Hughes, Timothy P.; Mayrhofer, Graham; Lyons, A. Bruce</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (San Diego, CA, United States)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">330-339</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Dasatinib (BMS-354825) is a Src/ABL tyrosine kinase inhibitor currently approved for the treatment of chronic myeloid leukemia.  Dasatinib has increased potency against ABL compared to the current therapy imatinib, and is effective in many cases where disease is resistant to imatinib.  Dasatinib also inhibits many Src-family tyrosine kinases.  We have demonstrated in this study that dasatinib is able to block the function of normal human T-lymphocytes in vitro at clin. relevant concns.  T-cell functions including proliferation, activation and cytokine prodn. were all uniformly inhibited in the presence of dasatinib.  We also demonstrated inhibition of TCR signaling through Src-family kinase LCK, and predicted that inhibition of LCK and other kinases involved in T-cell signaling by dasatinib is responsible for the suppression of T-cell function.  These findings raise the concern about potential T-cell inhibition in patients taking dasatinib, and suggest a possible application for the treatment of T-cell mediated immune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon59yxL66SFLVg90H21EOLACvtfcHk0lhXV8fUmjQKfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12ru7c%253D&md5=59574b5a4a2bf4e774a152e74d57850e</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBlake%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DT.%2BP.%26aulast%3DMayrhofer%26aufirst%3DG.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26atitle%3DThe%2520Src%252FABL%2520kinase%2520inhibitor%2520dasatinib%2520%2528BMS-354825%2529%2520inhibits%2520function%2520of%2520normal%2520human%2520T-lymphocytes%2520in%2520vitro%26jtitle%3DClin.%2520Immunol.%26date%3D2008%26volume%3D127%26spage%3D330%26epage%3D339%26doi%3D10.1016%2Fj.clim.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratner, L.</span></span> <span> </span><span class="NLM_article-title">Role of Abl kinase and the wave2 signaling complex in HIV-1 entry at a post-hemifusion</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e1000956</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1000956" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20585556" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2010&author=B.+Harmonauthor=N.+Campbellauthor=L.+Ratner&title=Role+of+Abl+kinase+and+the+wave2+signaling+complex+in+HIV-1+entry+at+a+post-hemifusion&doi=10.1371%2Fjournal.ppat.1000956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000956%26sid%3Dliteratum%253Aachs%26aulast%3DHarmon%26aufirst%3DB.%26aulast%3DCampbell%26aufirst%3DN.%26aulast%3DRatner%26aufirst%3DL.%26atitle%3DRole%2520of%2520Abl%2520kinase%2520and%2520the%2520wave2%2520signaling%2520complex%2520in%2520HIV-1%2520entry%2520at%2520a%2520post-hemifusion%26jtitle%3DPLoS%2520Pathog.%26date%3D2010%26volume%3D6%26doi%3D10.1371%2Fjournal.ppat.1000956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bermejo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López-Huertas, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Pérez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Climent, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Descours, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrosioni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Mora, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rus-Bercial, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benkirane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcamí, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coiras, M.</span></span> <span> </span><span class="NLM_article-title">Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2016.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.bcp.2016.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26851491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2016&pages=30-45&author=M.+Bermejoauthor=M.+R.+L%C3%B3pez-Huertasauthor=J.+Garc%C3%ADa-P%C3%A9rezauthor=N.+Climentauthor=B.+Descoursauthor=J.+Ambrosioniauthor=E.+Mateosauthor=S.+Rodr%C3%ADguez-Moraauthor=L.+Rus-Bercialauthor=M.+Benkiraneauthor=J.+M.+Mir%C3%B3author=M.+Planaauthor=J.+Alcam%C3%ADauthor=M.+Coiras&title=Dasatinib+inhibits+HIV-1+replication+through+the+interference+of+SAMHD1+phosphorylation+in+CD4%2B+T+cells&doi=10.1016%2Fj.bcp.2016.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells</span></div><div class="casAuthors">Bermejo, Mercedes; Lopez-Huertas, Maria Rosa; Garcia-Perez, Javier; Climent, Nuria; Descours, Benjamin; Ambrosioni, Juan; Mateos, Elena; Rodriguez-Mora, Sara; Rus-Bercial, Lucia; Benkirane, Monsef; Miro, Jose M.; Plana, Montserrat; Alcami, Jose; Coiras, Mayte</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-45</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Massive activation of infected CD4+ T cells during acute HIV-1 infection leads to reservoir seeding and T-cell destruction.  During T-cell activation, the antiviral effect of the innate factor SAMHD1 is neutralized through phosphorylation at T592, allowing HIV-1 infection.  Dasatinib, a tyrosine kinase inhibitor currently used for treating chronic myeloid leukemia, has been described to control HIV-1 replication through its neg. effect on T-cell proliferation and viral entry.  The authors demonstrate that Dasatinib can actually interfere with SAMHD1 phosphorylation in human peripheral blood lymphocytes, preserving its antiviral activity against HIV-1.  Dasatinib prevented SAMHD1 phosphorylation in vitro and ex vivo, impairing HIV-1 reverse transcription and proviral integration.  This was the major mechanism of action because the presence of Vpx, which degrades SAMHD1, in HIV-1 virions impeded the inhibitory effect of Dasatinib on HIV-1 replication.  In fact, infection with VSV-pseudotyped HIV-1 virions and fusion of BlaM-Vpr-contg. HIV-1 viruses with activated PBMCs in the presence of Dasatinib suggested that Dasatinib was not acting at fusion level.  Finally, PBMCs from patients on chronic treatment with Dasatinib showed a lower level of SAMHD1 phosphorylation in response to activating stimuli and low susceptibility to HIV-1 infection ex vivo.  Consequently, Dasatinib is a compd. currently used in clinic that preserves the antiviral function of SAMHD1.  Using Dasatinib as adjuvant of antiretroviral therapy during early primary HIV-1 infection would contribute to reduce viral replication and spread, prevent reservoir seeding, and preserve CD4 counts and CTL responses.  These events would create a more favorable virol. and immunol. environment for future interventional studies aiming at HIV-1 eradication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIRkqB8GdNRbVg90H21EOLACvtfcHk0lhUCECmwd5i3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2lt7s%253D&md5=af4ec2aea6fa9ece9bda63f9980b3240</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2016.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2016.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DBermejo%26aufirst%3DM.%26aulast%3DL%25C3%25B3pez-Huertas%26aufirst%3DM.%2BR.%26aulast%3DGarc%25C3%25ADa-P%25C3%25A9rez%26aufirst%3DJ.%26aulast%3DCliment%26aufirst%3DN.%26aulast%3DDescours%26aufirst%3DB.%26aulast%3DAmbrosioni%26aufirst%3DJ.%26aulast%3DMateos%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Mora%26aufirst%3DS.%26aulast%3DRus-Bercial%26aufirst%3DL.%26aulast%3DBenkirane%26aufirst%3DM.%26aulast%3DMir%25C3%25B3%26aufirst%3DJ.%2BM.%26aulast%3DPlana%26aufirst%3DM.%26aulast%3DAlcam%25C3%25AD%26aufirst%3DJ.%26aulast%3DCoiras%26aufirst%3DM.%26atitle%3DDasatinib%2520inhibits%2520HIV-1%2520replication%2520through%2520the%2520interference%2520of%2520SAMHD1%2520phosphorylation%2520in%2520CD4%252B%2520T%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2016%26volume%3D106%26spage%3D30%26epage%3D45%26doi%3D10.1016%2Fj.bcp.2016.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fofana, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thumann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mailly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alles, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaeffer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habersetzer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doffoël, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeisel, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumert, T. F.</span></span> <span> </span><span class="NLM_article-title">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">483</span>– <span class="NLM_lpage">494</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2013-306155</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1136%2Fgutjnl-2013-306155" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24848265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2015&pages=483-494&author=F.+Xiaoauthor=I.+Fofanaauthor=C.+Thumannauthor=L.+Maillyauthor=R.+Allesauthor=E.+Robinetauthor=N.+Meyerauthor=M.+Schaefferauthor=F.+Habersetzerauthor=M.+Doffo%C3%ABlauthor=P.+Leyssenauthor=J.+Neytsauthor=M.+B.+Zeiselauthor=T.+F.+Baumert&title=Synergy+of+entry+inhibitors+with+direct-acting+antivirals+uncovers+novel+combinations+for+prevention+and+treatment+of+hepatitis+C&doi=10.1136%2Fgutjnl-2013-306155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C</span></div><div class="casAuthors">Xiao, Fei; Fofana, Isabel; Thumann, Christine; Mailly, Laurent; Alies, Roxane; Robinet, Eric; Meyer, Nicolas; Schaeffer, Mickael; Habersetzer, Francois; Doffoel, Michel; Leyssen, Pieter; Neyts, Johan; Zeisel, Mirjam B.; Baumert, Thomas F.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">483-494</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Objective Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection.  Viral entry is a promising target for antiviral therapy.  Design Aiming to explore the role of entry inhibitors for future clin. development, we investigated the antiviral efficacy and toxicity of entry inhibitors in combination with DAAs or other host-targeting agents (HTAs).  Screening a large series of combinations of entry inhibitors with DAAs or other HTAs, we uncovered novel combinations of antivirals for prevention and treatment of HCV infection.  Results Combinations of DAAs or HTAs and entry inhibitors including CD81-, scavenger receptor class B type I (SR-BI)- or claudin-1 (CLDN1)-specific antibodies or small-mol. inhibitors erlotinib and dasatinib were characterised by a marked and synergistic inhibition of HCV infection over a broad range of concns. with undetectable toxicity in exptl. designs for prevention and treatment both in cell culture models and in human liver-chimeric uPA/SCID mice.  Conclusions Our results provide a rationale for the development of antiviral strategies combining entry inhibitors with DAAs or HTAs by taking advantage of synergy.  The uncovered combinations provide perspectives for efficient strategies to prevent liver graft infection and novel interferon-free regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFEKArTUoU-LVg90H21EOLACvtfcHk0lhUCECmwd5i3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXntFemtb8%253D&md5=553f99c08b810f3a9058ed71124ee7c9</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2013-306155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2013-306155%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DF.%26aulast%3DFofana%26aufirst%3DI.%26aulast%3DThumann%26aufirst%3DC.%26aulast%3DMailly%26aufirst%3DL.%26aulast%3DAlles%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DE.%26aulast%3DMeyer%26aufirst%3DN.%26aulast%3DSchaeffer%26aufirst%3DM.%26aulast%3DHabersetzer%26aufirst%3DF.%26aulast%3DDoffo%25C3%25ABl%26aufirst%3DM.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DZeisel%26aufirst%3DM.%2BB.%26aulast%3DBaumert%26aufirst%3DT.%2BF.%26atitle%3DSynergy%2520of%2520entry%2520inhibitors%2520with%2520direct-acting%2520antivirals%2520uncovers%2520novel%2520combinations%2520for%2520prevention%2520and%2520treatment%2520of%2520hepatitis%2520C%26jtitle%3DGut%26date%3D2015%26volume%3D64%26spage%3D483%26epage%3D494%26doi%3D10.1136%2Fgutjnl-2013-306155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-dependent kinases</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">122</span>, <span class="refDoi"> DOI: 10.1186/gb4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fgb4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25180339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=122&author=M.+Malumbres&title=Cyclin-dependent+kinases&doi=10.1186%2Fgb4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinases</span></div><div class="casAuthors">Malumbres Marcos</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">122</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are protein kinases characterized by needing a separate subunit - a cyclin - that provides domains essential for enzymatic activity.  CDKs play important roles in the control of cell division and modulate transcription in response to several extra- and intracellular cues.  The evolutionary expansion of the CDK family in mammals led to the division of CDKs into three cell-cycle-related subfamilies (Cdk1, Cdk4 and Cdk5) and five transcriptional subfamilies (Cdk7, Cdk8, Cdk9, Cdk11 and Cdk20).  Unlike the prototypical Cdc28 kinase of budding yeast, most of these CDKs bind one or a few cyclins, consistent with functional specialization during evolution.  This review summarizes how, although CDKs are traditionally separated into cell-cycle or transcriptional CDKs, these activities are frequently combined in many family members.  Not surprisingly, deregulation of this family of proteins is a hallmark of several diseases, including cancer, and drug-targeted inhibition of specific members has generated very encouraging results in clinical trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQodaug4zJdjgHqQV89nF-2fW6udTcc2eY-QtTrGkahBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FnsVehsg%253D%253D&md5=9fd79ec8f495f712bada681b0a0b5afe</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1186%2Fgb4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb4184%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinases%26jtitle%3DGenome%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D122%26doi%3D10.1186%2Fgb4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M.</span></span> <span> </span><span class="NLM_article-title">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span>. <i>Curr. Drug Targets: Infect. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">37</span>, <span class="refDoi"> DOI: 10.2174/1568005053174609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.2174%2F1568005053174609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15777196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=29-37&author=L.+M.+Schang&title=Advances+on+cyclin-dependent+kinases+%28CDKs%29+as+novel+targets+for+antiviral+drugs&doi=10.2174%2F1568005053174609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs</span></div><div class="casAuthors">Schang, L. M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: Infectious Disorders</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-37</span>CODEN:
                <span class="NLM_cas:coden">CDTIAS</span>;
        ISSN:<span class="NLM_cas:issn">1568-0053</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although targeting viral proteins has lead to many successful antiviral drugs, these antivirals have certain limitations.  They rapidly select for resistance, tend to be active against only a few related viruses and the proteins of a pathogen must be characterized before such drugs can be developed.  Consequently, a long period is required from the identification of a new pathogen to the development of relevant antivirals, a major concern for emerging diseases.  Cellular proteins are now considered as potential targets for antivirals.  Drugs that target cellular proteins required for several viral functions might not easily select for drug-resistance.  They may also be active against a variety of unrelated viruses, which commonly require the same cellular proteins, and against viral strains resistant to conventional antiviral drugs.  These antivirals could be promptly tested against emerging viruses because even distantly related viruses commonly require the same cellular proteins.  Cellular cyclin-dependent kinases (CDKs) are required for replication of many viruses and specific pharmacol. CDK inhibitors (PCIs) are proving to have surprisingly few neg. side effects in clin. trials (against cancer).  PCIs inhibit replication of wild-type and multi-drug resistant strains of HIV, HSV-1, HSV-2, HCMV, EBV and VZV.  Two PCIs, roscovitine and flavopiridol, were recently proven active in a mouse model of HIV-induced nephropathy.  Because the antiviral mechanisms of PCIs require no viral proteins, mutations in viral genes may not easily overcome inhibition by these drugs.  In fact, no PCI-resistant viral mutant has been reported.  PCIs are scheduled to enter clin. trials as antivirals in 2005.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhr4tc-sGqnrVg90H21EOLACvtfcHk0lgMW8DLl6v5RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVGhs7g%253D&md5=9a1ded4e83f36e236f4d5e2bc83e3f6e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.2174%2F1568005053174609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568005053174609%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM.%26atitle%3DAdvances%2520on%2520cyclin-dependent%2520kinases%2520%2528CDKs%2529%2520as%2520novel%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520Infect.%2520Disord.%26date%3D2005%26volume%3D5%26spage%3D29%26epage%3D37%26doi%3D10.2174%2F1568005053174609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galán, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerezo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">493</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2004.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2004.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15315761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2004&pages=493-504&author=M.+Malumbresauthor=R.+Sotilloauthor=D.+Santamar%C3%ADaauthor=J.+Gal%C3%A1nauthor=A.+Cerezoauthor=S.+Ortegaauthor=P.+Dubusauthor=M.+Barbacid&title=Mammalian+cells+cycle+without+the+D-type+cyclin-dependent+kinases+Cdk4+and+Cdk6&doi=10.1016%2Fj.cell.2004.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6</span></div><div class="casAuthors">Malumbres, Marcos; Sotillo, Rocio; Santamaria, David; Galan, Javier; Cerezo, Ana; Ortega, Sagrario; Dubus, Pierre; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">493-504</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cdk4 and Cdk6 are thought to be essential for initiation of the cell cycle in response to mitogenic stimuli.  Previous studies have shown that Cdk4 is dispensable for proliferation in most cell types, an observation attributed to a putative compensatory role by Cdk6.  Cdk6-null mice are viable and develop normally although hematopoiesis is slightly impaired.  Embryos defective for Cdk4 and Cdk6 die during the late stages of embryonic development due to severe anemia.  However, these embryos display normal organogenesis and most cell types proliferate normally.  In vitro, embryonic fibroblasts lacking Cdk4 and Cdk6 proliferate and become immortal upon serial passage.  Moreover, quiescent Cdk4/Cdk6-null cells respond to serum stimulation and enter S phase with normal kinetics although with lower efficiency.  These results indicate that D-type cyclin-dependent kinases are not essential for cell cycle entry and suggest the existence of alternative mechanisms to initiate cell proliferation upon mitogenic stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoonn2gu_HOALVg90H21EOLACvtfcHk0lgMW8DLl6v5RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlCmu7c%253D&md5=b6b54b2b4d7c69bd66e79e2bbcc5e3e1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DSotillo%26aufirst%3DR.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DGal%25C3%25A1n%26aufirst%3DJ.%26aulast%3DCerezo%26aufirst%3DA.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMammalian%2520cells%2520cycle%2520without%2520the%2520D-type%2520cyclin-dependent%2520kinases%2520Cdk4%2520and%2520Cdk6%26jtitle%3DCell%26date%3D2004%26volume%3D118%26spage%3D493%26epage%3D504%26doi%3D10.1016%2Fj.cell.2004.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Malumbres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">153</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0lgMW8DLl6v5RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, P.</span>; <span class="NLM_string-name">Narayanan, S.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span>, <span> </span><span class="NLM_article-title">CDK inhibitors as sensitizing agents for cancer chemotherapy</span>. In  <i>Protein Kinase Inhibitors as Sensitizing Agents for Cancer Chemotherapy</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.-S.</span>; <span class="NLM_string-name">Yang, D.-H.</span></span>, Eds.; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">United States</span>, <span class="NLM_year">2019</span>, Vol.  <span class="NLM_volume">4</span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">149</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2FB978-0-12-816435-8.00009-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&pages=125-149&author=P.+Gupta&author=S.+Narayanan&author=D.-H.+Yangauthor=Z.-S.+Chen&author=D.-H.+Yang&title=Protein+Kinase+Inhibitors+as+Sensitizing+Agents+for+Cancer+Chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-816435-8.00009-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-12-816435-8.00009-2%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DP.%26atitle%3DCDK%2520inhibitors%2520as%2520sensitizing%2520agents%2520for%2520cancer%2520chemotherapy%26btitle%3DProtein%2520Kinase%2520Inhibitors%2520as%2520Sensitizing%2520Agents%2520for%2520Cancer%2520Chemotherapy%26aulast%3DChen%26aufirst%3DZ.-S.%26pub%3DAcademic%2520Press%26date%3D2019%26volume%3D4%26spage%3D125%26epage%3D149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angulo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pujantell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martí, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1093/jac/dkv363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fjac%2Fdkv363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=26542306" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2016&pages=387-394&author=R.+Badiaauthor=G.+Anguloauthor=E.+Riveira-Mu%C3%B1ozauthor=M.+Pujantellauthor=T.+Puigauthor=C.+Ramirezauthor=J.+Torres-Torronterasauthor=R.+Mart%C3%ADauthor=E.+Paulsauthor=B.+Clotetauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Inhibition+of+herpes+simplex+virus+type+1+by+the+CDK6+inhibitor+PD-0332991+%28palbociclib%29+through+the+control+of+SAMHD1&doi=10.1093%2Fjac%2Fdkv363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of herpes simplex virus type 1 by the CDK6 inhibitor PD-0332991 (palbociclib) through the control of SAMHD1</span></div><div class="casAuthors">Badia, Roger; Angulo, Guillem; Riveira-Munoz, Eva; Pujantell, Maria; Puig, Teresa; Ramirez, Cristina; Torres-Torronteras, Javier; Marti, Ramon; Pauls, Eduardo; Clotet, Bonaventura; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">387-394</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives Sterile α motif and histidine-aspartate domain-contg. protein 1 (SAMHD1) has been shown to restrict retroviruses and DNA viruses by decreasing the pool of intracellular deoxynucleotides.  In turn, SAMHD1 is controlled by cyclin-dependent kinases (CDK) that regulate the cell cycle and cell proliferation.  Here, we explore the effect of CDK6 inhibitors on the replication of herpes simplex virus type 1 (HSV-1) in primary monocyte-derived macrophages (MDM).  Methods MDM were treated with palbociclib, a selective CDK4/6 inhibitor, and then infected with a GFP-expressing HSV-1.  Intracellular deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results CDK6 inhibitor palbociclib blocked SAMHD1 phosphorylation, intracellular dNTP levels and HSV-1 replication in MDM at subtoxic concns.  Treatment of MDM with palbociclib reduced CDK2 activation, measured as the phosphorylation of the T-loop at Thr160.  The antiviral activity of palbociclib was lost when SAMHD1 was degraded by viral protein X.  Similarly, palbociclib did not block HSV-1 replication in SAMHD1-neg. Vero cells at subtoxic concns., providing further evidence for a role of SAMHD1 in mediating the antiviral effect.  Conclusions SAMHD1-mediated HSV-1 restriction is controlled by CDK and points to a preferential role for CDK6 and CDK2 as mediators of SAMHD1 activation.  Similarly, the restricting activity of SAMHD1 against DNA viruses suggests that control of dNTP availability is the major determinant of its antiviral activity.  This is the first study describing the anti-HSV-1 activity of palbociclib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-y_UxXw_iDbVg90H21EOLACvtfcHk0lgPmQkYjmp2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslWjtr4%253D&md5=b527d13ba9403fd4da637f39dd20ad5b</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdkv363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdkv363%26sid%3Dliteratum%253Aachs%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DAngulo%26aufirst%3DG.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DPujantell%26aufirst%3DM.%26aulast%3DPuig%26aufirst%3DT.%26aulast%3DRamirez%26aufirst%3DC.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DMart%25C3%25AD%26aufirst%3DR.%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DInhibition%2520of%2520herpes%2520simplex%2520virus%2520type%25201%2520by%2520the%2520CDK6%2520inhibitor%2520PD-0332991%2520%2528palbociclib%2529%2520through%2520the%2520control%2520of%2520SAMHD1%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2016%26volume%3D71%26spage%3D387%26epage%3D394%26doi%3D10.1093%2Fjac%2Fdkv363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ko, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byun, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shum, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span> <span> </span><span class="NLM_article-title">Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>64</i></span>, <span class="NLM_elocation-id">e00819-20</span> <span class="refDoi"> DOI: 10.1128/AAC.00819-20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.00819-20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32366720" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2020&author=S.+Jeonauthor=M.+Koauthor=J.+Leeauthor=I.+Choiauthor=S.+Y.+Byunauthor=S.+Parkauthor=D.+Shumauthor=S.+Kim&title=Identification+of+antiviral+drug+candidates+against+SARS-CoV-2+from+FDA-approved+drugs&doi=10.1128%2FAAC.00819-20"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1128%2FAAC.00819-20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00819-20%26sid%3Dliteratum%253Aachs%26aulast%3DJeon%26aufirst%3DS.%26aulast%3DKo%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DByun%26aufirst%3DS.%2BY.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DShum%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520antiviral%2520drug%2520candidates%2520against%2520SARS-CoV-2%2520from%2520FDA-approved%2520drugs%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2020%26volume%3D64%26doi%3D10.1128%2FAAC.00819-20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bresnahan, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldogh, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>231</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1006/viro.1997.8489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1006%2Fviro.1997.8489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=9168886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=1997&pages=239-247&author=W.+A.+Bresnahanauthor=I.+Boldoghauthor=P.+Chiauthor=E.+A.+Thompsonauthor=T.+Albrecht&title=Inhibition+of+cellular+Cdk2+activity+blocks+human+cytomegalovirus+replication&doi=10.1006%2Fviro.1997.8489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication</span></div><div class="casAuthors">Bresnahan, Wade A.; Boldough, Istvan; Chi, Ping; Thompson, E. Aubrey; Albrecht, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">231</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">239-247</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Human cytomegalovirus is a herpesvirus that induces numerous cellular processes upon infection.  Among these are activation of cyclin-dependent kinase 2, which regulates cell cycle progression in G1 and S phase.  We report here that inhibition of cellular Cdk2 activity blocks HCMV replication.  Inhibition of Cdk2 activity by roscovitine inhibits HCMV DNA synthesis, prodn. of infectious progeny, and late antigen expression in infected cells in a dose-dependent manner.  HCMV replication is also inhibited by the expression of a Cdk2 dominant neg. mutant, whereas expression of wild-type Cdk2 has no effect on viral replication.  These data indicate that activation of cellular Cdk2 is necessary for HCMV replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx3AKL3CzS17Vg90H21EOLACvtfcHk0lgPmQkYjmp2FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjt1Omu7c%253D&md5=ae27d67b0473636f85e5a292eb5db347</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1006%2Fviro.1997.8489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fviro.1997.8489%26sid%3Dliteratum%253Aachs%26aulast%3DBresnahan%26aufirst%3DW.%2BA.%26aulast%3DBoldogh%26aufirst%3DI.%26aulast%3DChi%26aufirst%3DP.%26aulast%3DThompson%26aufirst%3DE.%2BA.%26aulast%3DAlbrecht%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520cellular%2520Cdk2%2520activity%2520blocks%2520human%2520cytomegalovirus%2520replication%26jtitle%3DVirology%26date%3D1997%26volume%3D231%26spage%3D239%26epage%3D247%26doi%3D10.1006%2Fviro.1997.8489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schang, L. M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Vincent, M. R</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacasse, J. J</span></span> <span> </span><span class="NLM_article-title">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span>. <i>Antivir. Chem. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">320</span>, <span class="refDoi"> DOI: 10.1177/095632020601700601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1177%2F095632020601700601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17249245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2006&pages=293-320&author=L.+M+Schangauthor=M.+R+St.+Vincentauthor=J.+J+Lacasse&title=Five+years+of+progress+on+cyclin-dependent+kinases+and+other+cellular+proteins+as+potential+targets+for+antiviral+drugs&doi=10.1177%2F095632020601700601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs</span></div><div class="casAuthors">Schang, Luis M.; St. Vincent, Mireille R.; Lacasse, Jonathan J.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Chemistry & Chemotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">293-320</span>CODEN:
                <span class="NLM_cas:coden">ACCHEH</span>;
        ISSN:<span class="NLM_cas:issn">0956-3202</span>.
    
            (<span class="NLM_cas:orgname">International Medical Press, Ltd.</span>)
        </div><div class="casAbstract">A review.  In 1997-1998, the pharmacol. cyclin-dependent kinase (CDK) inhibitors (PCIs) were independently discovered to inhibit replication of human cytomegalovirus, herpes simplex virus type 1 and HIV-1.  The results from small clin. trials against cancer were then suggesting that PCIs could be safe enough to be used clin.  It was thus hypothesized that PCIs could have the potential to be developed as novel antivirals targeting cellular proteins.  Consequently, Antiviral Chem. & Chemotherapy published in 2001 the first review on the potential of CDKs, and cellular proteins in general, as potential targets for antivirals.  The viral functions inhibited by PCIs, or their cellular targets, were then just starting to be characterized.  The antiviral spectrum of PCIs and their effects on viral disease were still mostly untested.  Even their actual specificity was not yet completely characterized.  In addn., cellular proteins were not accepted as valid targets for antivirals.  Significant progress has been made in the last 5 years in understanding the antiviral activities of PCIs and the potential roles of cellular proteins in general as targets for antivirals.  The first clin. trials of the antiviral activities of PCIs and other inhibitors of cellular protein kinases have now been scheduled.  Herein, we review the progress made since the publication of the first review on PCIs as potential antiviral drugs and on CDKs, and cellular proteins in general, as potential targets for antiviral drugs.  We also highlight the major issues that still need to be addressed before PCIs or other drugs targeting cellular proteins can be developed as clin. antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrVdUG1WNgiLVg90H21EOLACvtfcHk0liBeN7_kqcseQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1CktA%253D%253D&md5=df2f56161599faf496637f3259c7f605</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1177%2F095632020601700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F095632020601700601%26sid%3Dliteratum%253Aachs%26aulast%3DSchang%26aufirst%3DL.%2BM%26aulast%3DSt.%2BVincent%26aufirst%3DM.%2BR%26aulast%3DLacasse%26aufirst%3DJ.%2BJ%26atitle%3DFive%2520years%2520of%2520progress%2520on%2520cyclin-dependent%2520kinases%2520and%2520other%2520cellular%2520proteins%2520as%2520potential%2520targets%2520for%2520antiviral%2520drugs%26jtitle%3DAntivir.%2520Chem.%2520Chemother.%26date%3D2006%26volume%3D17%26spage%3D293%26epage%3D320%26doi%3D10.1177%2F095632020601700601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujinaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marion, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senderowicz, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterlin, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">28345</span>– <span class="NLM_lpage">28348</span>, <span class="refDoi"> DOI: 10.1074/jbc.C000446200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.C000446200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10906320" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=28345-28348&author=S.-H.+Chaoauthor=K.+Fujinagaauthor=J.+E.+Marionauthor=R.+Taubeauthor=E.+A.+Sausvilleauthor=A.+M.+Senderowiczauthor=B.+M.+Peterlinauthor=D.+H.+Price&title=Flavopiridol+inhibits+P-TEFb+and+blocks+HIV-1+replication&doi=10.1074%2Fjbc.C000446200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol inhibits P-TEFb and blocks HIV-1 replication</span></div><div class="casAuthors">Chao, Sheng-Hao; Fujinaga, Koh; Marion, Jon E.; Taube, Ran; Sausville, Edward A.; Senderowicz, Adrian M.; Peterlin, B. Matija; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">28345-28348</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor that is in clin. trials as a cancer treatment because of its antiproliferative properties.  We found that the flavonoid potently inhibited transcription by RNA polymerase II in vitro by blocking the transition into productive elongation, a step controlled by P-TEFb.  The ability of P-TEFb to phosphorylate the carboxyl-terminal domain of the large subunit of RNA polymerase II was inhibited by flavopiridol with a Ki of 3 nM.  Interestingly, the drug was not competitive with ATP.  P-TEFb composed of Cdk9 and cyclin T1 is a required cellular cofactor for the human immunodeficiency virus (HIV-1) transactivator, Tat.  Consistent with its ability to inhibit P-TEFb, flavopiridol blocked Tat transactivation of the viral promoter in vitro.  Furthermore, flavopiridol blocked HIV-1 replication in both single-round and viral spread assays with an IC50 of less than 10 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmLtfeSo62BrVg90H21EOLACvtfcHk0liBeN7_kqcseQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1Crtbs%253D&md5=3458cf5e661acf6e5de7dd99bc8e8502</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C000446200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C000446200%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DS.-H.%26aulast%3DFujinaga%26aufirst%3DK.%26aulast%3DMarion%26aufirst%3DJ.%2BE.%26aulast%3DTaube%26aufirst%3DR.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DSenderowicz%26aufirst%3DA.%2BM.%26aulast%3DPeterlin%26aufirst%3DB.%2BM.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DFlavopiridol%2520inhibits%2520P-TEFb%2520and%2520blocks%2520HIV-1%2520replication%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D28345%26epage%3D28348%26doi%3D10.1074%2Fjbc.C000446200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guendel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agbottah, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kehn-Hall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashanchi, F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span>. <i>AIDS Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7</span>, <span class="refDoi"> DOI: 10.1186/1742-6405-7-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2F1742-6405-7-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20334651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=7&author=I.+Guendelauthor=E.+T.+Agbottahauthor=K.+Kehn-Hallauthor=F.+Kashanchi&title=Inhibition+of+human+immunodeficiency+virus+type-1+by+cdk+inhibitors&doi=10.1186%2F1742-6405-7-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of human immunodeficiency virus type-1 by cdk inhibitors</span></div><div class="casAuthors">Guendel Irene; Kashanchi Fatah; Guendel Irene; Kehn-Hall Kylene; Kashanchi Fatah; Agbottah Emmanuel T; Kashanchi Fatah</div><div class="citationInfo"><span class="NLM_cas:title">AIDS research and therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current therapy for human immunodeficiency virus (HIV-1) infection relies primarily on the administration of anti-retroviral nucleoside analogues, either alone or in combination with HIV-protease inhibitors.  Although these drugs have a clinical benefit, continuous therapy with the drugs leads to drug-resistant strains of the virus.  Recently, significant progress has been made towards the development of natural and synthetic agents that can directly inhibit HIV-1 replication or its essential enzymes.  We previously reported on the pharmacological cyclin-dependent kinase inhibitor (PCI) r-roscovitine as a potential inhibitor of HIV-1 replication.  PCIs are among the most promising novel antiviral agents to emerge over the past few years.  Potent activity on viral replication combined with proliferation inhibition without the emergence of resistant viruses, which are normally observed in HAART patients; make PCIs ideal candidates for HIV-1 inhibition.  To this end we evaluated twenty four cdk inhibitors for their effect on HIV-1 replication in vitro.  Screening of these compounds identified alsterpaullone as the most potent inhibitor of HIV-1 with activity at 150 nM.  We found that alsterpaullone effectively inhibits cdk2 activity in HIV-1 infected cells with a low IC50 compared to control uninfected cells.  The effects of alsterpaullone were associated with suppression of cdk2 and cyclin expression.  Combining both alsterpaullone and r-roscovitine (cyc202) in treatment exhibited even stronger inhibitory activities in HIV-1 infected PBMCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSgNOPCu4WBGeb6AVA-44PTfW6udTcc2eYogw80sI0hxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ltFyntg%253D%253D&md5=1abe0f1c81cf604ffd3ac7354e5b7d95</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1186%2F1742-6405-7-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-6405-7-7%26sid%3Dliteratum%253Aachs%26aulast%3DGuendel%26aufirst%3DI.%26aulast%3DAgbottah%26aufirst%3DE.%2BT.%26aulast%3DKehn-Hall%26aufirst%3DK.%26aulast%3DKashanchi%26aufirst%3DF.%26atitle%3DInhibition%2520of%2520human%2520immunodeficiency%2520virus%2520type-1%2520by%2520cdk%2520inhibitors%26jtitle%3DAIDS%2520Res.%2520Ther.%26date%3D2010%26volume%3D7%26spage%3D7%26doi%3D10.1186%2F1742-6405-7-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Torronteras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Permanyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riveira-Muñoz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clotet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballana, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esté, J. A.</span></span> <span> </span><span class="NLM_article-title">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile a motif and HD domain-containing protein-1 (SAMHD1) activity</span>. <i>AIDS</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2213</span>– <span class="NLM_lpage">2222</span>, <span class="refDoi"> DOI: 10.1097/QAD.0000000000000399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1097%2FQAD.0000000000000399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25036183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=2213-2222&author=E.+Paulsauthor=R.+Badiaauthor=J.+Torres-Torronterasauthor=A.+Ruizauthor=M.+Permanyerauthor=E.+Riveira-Mu%C3%B1ozauthor=B.+Clotetauthor=R.+Martiauthor=E.+Ballanaauthor=J.+A.+Est%C3%A9&title=Palbociclib%2C+a+selective+inhibitor+of+cyclin-dependent+kinase4%2F6%2C+blocks+HIV-1+reverse+transcription+through+the+control+of+sterile+a+motif+and+HD+domain-containing+protein-1+%28SAMHD1%29+activity&doi=10.1097%2FQAD.0000000000000399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity</span></div><div class="casAuthors">Pauls, Eduardo; Badia, Roger; Torres-Torronteras, Javier; Ruiz, Alba; Permanyer, Marc; Riveira-Munoz, Eva; Clotet, Bonaventura; Marti, Ramon; Ballana, Ester; Este, Jose A.</div><div class="citationInfo"><span class="NLM_cas:title">AIDS (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2213-2222</span>CODEN:
                <span class="NLM_cas:coden">AIDSET</span>;
        ISSN:<span class="NLM_cas:issn">0269-9370</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Background: Sterile α motif and HD domain-contg. protein-1 (SAMHD1) inhibits HIV-1 reverse transcription by decreasing the pool of intracellular deoxynucleotides.  SAMHD1 is controlled by cyclin-dependent kinase (CDK)-mediated phosphorylation.  However, the exact mechanism of SAMHD1 regulation in primary cells is unclear.  We explore the effect of palbociclib, a CDK6 inhibitor, in HIV-1 replication.  Methods: Human primary monocytes were differentiated into macrophages with monocyte-colony stimulating factor and CD4 T lymphocytes stimulated with phytohaemagglutinin (PHA)/interleukin-2.  Cells were treated with palbociclib and then infected with a Green fluorescent protein-expressing HIV-1 or R5 HIV-1 BaL.  Viral DNA was measured by quant. PCR and infection assessed by flow cytometry.  Deoxynucleotide triphosphate (dNTP) content was detd. using a polymerase-based method.  Results: Pan-CDK inhibitors AT7519, roscovitine and purvalanol A reduced SAMHD1 phosphorylation.  HIV-1 replication was blocked by AT7519 (66.4±3.8%; n=4), roscovitine (47.3±3.9%; n=4) and purvalanol A (55.7±15.7%; n=4) at subtoxic concns.  Palbociclib, a potent and selective CDK6 inhibitor, blocked SAMHD1 phosphorylation, intracellular dNTP levels, HIV-1 reverse transcription and HIV-1 replication in primary macrophages and CD4 T lymphocytes.  Notably, treatment of macrophages with palbociclib led to reduced CDK2 activation, measured as the phosphorylation of the T-loop at the Thr160.  The antiviral effect was lost when SAMHD1 was degraded by Vpx, providing further evidence for a role of SAMHD1 in mediating the antiretroviral effect.  Conclusions: Our results indicate that SAMHD1-mediated HIV-1 restriction is controlled by CDK as previously suggested but point to a preferential role for CDK2 and CDK6 as mediators of SAMHD1 activation.  Our study provides a new signaling pathway susceptible for the development of new therapeutic approaches against HIV-1 infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrnbJDONasm7Vg90H21EOLACvtfcHk0lijcTJlsF_0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWitLbM&md5=68935096ca65c2f15a2b24423c006302</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1097%2FQAD.0000000000000399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FQAD.0000000000000399%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DE.%26aulast%3DBadia%26aufirst%3DR.%26aulast%3DTorres-Torronteras%26aufirst%3DJ.%26aulast%3DRuiz%26aufirst%3DA.%26aulast%3DPermanyer%26aufirst%3DM.%26aulast%3DRiveira-Mu%25C3%25B1oz%26aufirst%3DE.%26aulast%3DClotet%26aufirst%3DB.%26aulast%3DMarti%26aufirst%3DR.%26aulast%3DBallana%26aufirst%3DE.%26aulast%3DEst%25C3%25A9%26aufirst%3DJ.%2BA.%26atitle%3DPalbociclib%252C%2520a%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase4%252F6%252C%2520blocks%2520HIV-1%2520reverse%2520transcription%2520through%2520the%2520control%2520of%2520sterile%2520a%2520motif%2520and%2520HD%2520domain-containing%2520protein-1%2520%2528SAMHD1%2529%2520activity%26jtitle%3DAIDS%26date%3D2014%26volume%3D28%26spage%3D2213%26epage%3D2222%26doi%3D10.1097%2FQAD.0000000000000399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onogi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsubota, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span> <span> </span><span class="NLM_article-title">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1172/JCI73805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1172%2FJCI73805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25003190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2014&pages=3479-3488&author=M.+Yamamotoauthor=H.+Onogiauthor=I.+Kiiauthor=S.+Yoshidaauthor=K.+Iidaauthor=H.+Sakaiauthor=M.+Abeauthor=T.+Tsubotaauthor=N.+Itoauthor=T.+Hosoyaauthor=M.+Hagiwara&title=CDK9+inhibitor+FIT-039+prevents+replication+of+multiple+DNA+viruses&doi=10.1172%2FJCI73805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 inhibitor FIT-039 prevents replication of multiple DNA viruses</span></div><div class="casAuthors">Yamamoto, Makoto; Onogi, Hiroshi; Kii, Isao; Yoshida, Suguru; Iida, Kei; Sakai, Hiroyuki; Abe, Minako; Tsubota, Toshiaki; Ito, Nobutoshi; Hosoya, Takamitsu; Hagiwara, Masatoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3479-3488</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A wide range of antiviral drugs is currently available; however, drug-resistant viruses have begun to emerge and represent a potential public health risk.  Here, we explored the use of compds. that inhibit or interfere with the action of essential host factors to prevent virus replication.  In particular, we focused on the cyclin-dependent kinase 9 (CDK9) inhibitor, FIT-039, which suppressed replication of a broad spectrum of DNA viruses through inhibition of mRNA transcription.  Specifically, FIT-039 inhibited replication of herpes simplex virus 1 (HSV-1), HSV-2, human adenovirus, and human cytomegalovirus in cultured cells, and topical application of FIT-039 ointment suppressed skin legion formation in a murine HSV-1 infection model.  FIT-039 did not affect cell cycle progression or cellular proliferation in host cells.  Compared with the general CDK inhibitor flavopiridol, transcriptome analyses of FIT-039-treated cells revealed that FIT-039 specifically inhibited CDK9.  Given at concns. above the inhibitory concn., FIT-039 did not have a cytotoxic effect on mammalian cells.  Importantly, administration of FIT-039 ameliorated the severity of skin lesion formation in mice infected with an acydovir-resistant HSV-1, without noticeable adverse effects.  Together, these data indicate that FIT-039 has potential as an antiviral agent for clin. therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_l0ZnQV7lWLVg90H21EOLACvtfcHk0lijcTJlsF_0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlGkt73I&md5=f5e7516ba1e29c56f33530b2cd2f6811</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1172%2FJCI73805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI73805%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DOnogi%26aufirst%3DH.%26aulast%3DKii%26aufirst%3DI.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIida%26aufirst%3DK.%26aulast%3DSakai%26aufirst%3DH.%26aulast%3DAbe%26aufirst%3DM.%26aulast%3DTsubota%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DN.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DHagiwara%26aufirst%3DM.%26atitle%3DCDK9%2520inhibitor%2520FIT-039%2520prevents%2520replication%2520of%2520multiple%2520DNA%2520viruses%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2014%26volume%3D124%26spage%3D3479%26epage%3D3488%26doi%3D10.1172%2FJCI73805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okuyama-Dobashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosoya, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagiwara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriishi, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">156</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1016/j.antiviral.2016.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.antiviral.2016.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27515132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2016&pages=156-164&author=T.+Tanakaauthor=K.+Okuyama-Dobashiauthor=S.+Murakamiauthor=W.+Chenauthor=T.+Okamotoauthor=K.+Uedaauthor=T.+Hosoyaauthor=Y.+Matsuuraauthor=A.+Ryoauthor=Y.+Tanakaauthor=M.+Hagiwaraauthor=K.+Moriishi&title=Inhibitory+effect+of+CDK9+inhibitor+FIT-039+on+hepatitis+B+virus+propagation&doi=10.1016%2Fj.antiviral.2016.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation</span></div><div class="casAuthors">Tanaka, Tomohisa; Okuyama-Dobashi, Kaori; Murakami, Shuko; Chen, Wenjia; Okamoto, Toru; Ueda, Keiji; Hosoya, Takamitsu; Matsuura, Yoshiharu; Ryo, Akihide; Tanaka, Yasuhito; Hagiwara, Masatoshi; Moriishi, Kohji</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">156-164</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Current therapies for hepatitis B virus (HBV) cannot completely eliminate the HBV genome because of the stable population of covalently closed circular DNA (cccDNA) and so on.  FIT-039, which is a cyclin-dependent kinase (CDK) 9 inhibitor, is known to suppress the replication of several DNA viruses including HSV, HPV and human adenovirus.  In this study, we investigated the antiviral effect of FIT-039 on HBV infection.  HepG2 cells expressing human sodium taurocholate cotransporting polypeptide (HepG2/NTCP cells) were infected with HBV in the presence of FIT-039.  FIT-039 dose-dependently reduced intracellular viral RNA, nucleocapsid-assocd. viral DNA, and supernatant viral antigens without cytotoxicity in the infected cells (IC50 = 0.33 μM, CC50 > 50 μM).  The antiviral activity of FIT-039 was prominent at an early phase of viral infection, although the compd. did not inhibit preS1-binding to HepG2/NTCP cells.  FIT-039 reduced cccDNA in HBV-replicating or HBV-infected cells.  Furthermore, the antiviral activity of entecavir was significantly enhanced by the combination with FIT-039 in the chimeric mice having human hepatocytes infected with HBV.  None of the mice had significant drug-related body wt. or serum human-albumin concn. changes.  These data suggest that CDK9 inhibitor FIT-039 is a promising antiviral candidate for HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWi-qx6kiD2rVg90H21EOLACvtfcHk0lijcTJlsF_0uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlKqsLzL&md5=1ab41f68b2a0645ce4d1031798e281d0</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2016.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2016.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DOkuyama-Dobashi%26aufirst%3DK.%26aulast%3DMurakami%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DOkamoto%26aufirst%3DT.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DT.%26aulast%3DMatsuura%26aufirst%3DY.%26aulast%3DRyo%26aufirst%3DA.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DM.%26aulast%3DMoriishi%26aufirst%3DK.%26atitle%3DInhibitory%2520effect%2520of%2520CDK9%2520inhibitor%2520FIT-039%2520on%2520hepatitis%2520B%2520virus%2520propagation%26jtitle%3DAntiviral%2520Res.%26date%3D2016%26volume%3D133%26spage%3D156%26epage%3D164%26doi%3D10.1016%2Fj.antiviral.2016.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa Marrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulferts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojc, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson-Payant, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knerr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugourd, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdeolivas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muralidharan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manners, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felix, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez-Rodriguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">tenOever, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullins, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kochs, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">The global phosphorylation landscape of SARS-CoV-2 infection</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.06.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2020.06.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32645325" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=685-712&author=M.+Bouhaddouauthor=D.+Memonauthor=B.+Meyerauthor=K.+M.+Whiteauthor=V.+V.+Rezeljauthor=M.+Correa+Marreroauthor=B.+J.+Polaccoauthor=J.+E.+Melnykauthor=S.+Ulfertsauthor=R.+M.+Kaakeauthor=J.+Batraauthor=A.+L.+Richardsauthor=E.+Stevensonauthor=D.+E.+Gordonauthor=A.+Rojcauthor=K.+Obernierauthor=J.+M.+Fabiusauthor=M.+Soucherayauthor=L.+Miorinauthor=E.+Morenoauthor=C.+Kohauthor=Q.+D.+Tranauthor=A.+Hardyauthor=R.+Robinotauthor=T.+Valletauthor=B.+E.+Nilsson-Payantauthor=C.+Hernandez-Armentaauthor=A.+Dunhamauthor=S.+Weigangauthor=J.+Knerrauthor=M.+Modakauthor=D.+Quinteroauthor=Y.+Zhouauthor=A.+Dugourdauthor=A.+Valdeolivasauthor=T.+Patilauthor=Q.+Liauthor=R.+Huttenhainauthor=M.+Cakirauthor=M.+Muralidharanauthor=M.+Kimauthor=G.+Jangauthor=B.+Tutuncuogluauthor=J.+Hiattauthor=J.+Z.+Guoauthor=J.+Xuauthor=S.+Bouhaddouauthor=C.+J.+P.+Mathyauthor=A.+Gaultonauthor=E.+J.+Mannersauthor=E.+Felixauthor=Y.+Shiauthor=M.+Goffauthor=J.+K.+Limauthor=T.+McBrideauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=E.+De+Witauthor=A.+R.+Leachauthor=T.+Kortemmeauthor=B.+Shoichetauthor=M.+Ottauthor=J.+Saez-Rodriguezauthor=B.+R.+tenOeverauthor=R.+D.+Mullinsauthor=E.+R.+Fischerauthor=G.+Kochsauthor=R.+Grosseauthor=A.+Garcia-Sastreauthor=M.+Vignuzziauthor=J.+R.+Johnsonauthor=K.+M.+Shokatauthor=D.+L.+Swaneyauthor=P.+Beltraoauthor=N.+J.+Krogan&title=The+global+phosphorylation+landscape+of+SARS-CoV-2+infection&doi=10.1016%2Fj.cell.2020.06.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">The Global Phosphorylation Landscape of SARS-CoV-2 Infection</span></div><div class="casAuthors">Bouhaddou, Mehdi; Memon, Danish; Meyer, Bjoern; White, Kris M.; Rezelj, Veronica V.; Correa Marrero, Miguel; Polacco, Benjamin J.; Melnyk, James E.; Ulferts, Svenja; Kaake, Robyn M.; Batra, Jyoti; Richards, Alicia L.; Stevenson, Erica; Gordon, David E.; Rojc, Ajda; Obernier, Kirsten; Fabius, Jacqueline M.; Soucheray, Margaret; Miorin, Lisa; Moreno, Elena; Koh, Cassandra; Tran, Quang Dinh; Hardy, Alexandra; Robinot, Remy; Vallet, Thomas; Nilsson-Payant, Benjamin E.; Hernandez-Armenta, Claudia; Dunham, Alistair; Weigang, Sebastian; Knerr, Julian; Modak, Maya; Quintero, Diego; Zhou, Yuan; Dugourd, Aurelien; Valdeolivas, Alberto; Patil, Trupti; Li, Qiongyu; Huttenhain, Ruth; Cakir, Merve; Muralidharan, Monita; Kim, Minkyu; Jang, Gwendolyn; Tutuncuoglu, Beril; Hiatt, Joseph; Guo, Jeffrey Z.; Xu, Jiewei; Bouhaddou, Sophia; Mathy, Christopher J. P.; Gaulton, Anna; Manners, Emma J.; Felix, Eloy; Shi, Ying; Goff, Marisa; Lim, Jean K.; McBride, Timothy; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; De wit, Emmie; Leach, Andrew R.; Kortemme, Tanja; Shoichet, Brian; Ott, Melanie; Saez-Rodriguez, Julio; tenOever, Benjamin R.; Mullins, R. Dyche; Fischer, Elizabeth R.; Kochs, Georg; Grosse, Robert; Garcia-Sastre, Adolfo; Vignuzzi, Marco; Johnson, Jeffery R.; Shokat, Kevan M.; Swaney, Danielle L.; Beltrao, Pedro; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">685-712.e19</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies.  Here, we present a quant. mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells, revealing dramatic rewiring of phosphorylation on host and viral proteins.  SARS-CoV-2 infection promoted casein kinase II (CK2) and p38 MAPK activation, prodn. of diverse cytokines, and shutdown of mitotic kinases, resulting in cell cycle arrest.  Infection also stimulated a marked induction of CK2-contg. filopodial protrusions possessing budding viral particles.  Eighty-seven drugs and compds. were identified by mapping global phosphorylation profiles to dysregulated kinases and pathways.  We found pharmacol. inhibition of the p38, CK2, CDK, AXL, and PIKFYVE kinases to possess antiviral efficacy, representing potential COVID-19 therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaeZZGqGpEn7Vg90H21EOLACvtfcHk0lhKKMEO7SBEzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKkt7zF&md5=cb6e1da08aaaf061b76004416ce27355</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.06.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.06.034%26sid%3Dliteratum%253Aachs%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DCorrea%2BMarrero%26aufirst%3DM.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DUlferts%26aufirst%3DS.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DStevenson%26aufirst%3DE.%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DRojc%26aufirst%3DA.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DHardy%26aufirst%3DA.%26aulast%3DRobinot%26aufirst%3DR.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DNilsson-Payant%26aufirst%3DB.%2BE.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DDunham%26aufirst%3DA.%26aulast%3DWeigang%26aufirst%3DS.%26aulast%3DKnerr%26aufirst%3DJ.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DQuintero%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDugourd%26aufirst%3DA.%26aulast%3DValdeolivas%26aufirst%3DA.%26aulast%3DPatil%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DHuttenhain%26aufirst%3DR.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMuralidharan%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DJang%26aufirst%3DG.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DBouhaddou%26aufirst%3DS.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DManners%26aufirst%3DE.%2BJ.%26aulast%3DFelix%26aufirst%3DE.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DGoff%26aufirst%3DM.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DMcBride%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DE.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DShoichet%26aufirst%3DB.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DSaez-Rodriguez%26aufirst%3DJ.%26aulast%3DtenOever%26aufirst%3DB.%2BR.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26aulast%3DFischer%26aufirst%3DE.%2BR.%26aulast%3DKochs%26aufirst%3DG.%26aulast%3DGrosse%26aufirst%3DR.%26aulast%3DGarcia-Sastre%26aufirst%3DA.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DThe%2520global%2520phosphorylation%2520landscape%2520of%2520SARS-CoV-2%2520infection%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D685%26epage%3D712%26doi%3D10.1016%2Fj.cell.2020.06.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tcw, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kouznetsova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogden, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammack, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itkin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michael, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christian, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennand, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, G.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1107</span>, <span class="refDoi"> DOI: 10.1038/nm.4184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnm.4184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27571349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=1101-1107&author=M.+Xuauthor=E.+M.+Leeauthor=Z.+Wenauthor=Y.+Chengauthor=W.-K.+Huangauthor=X.+Qianauthor=J.+Tcwauthor=J.+Kouznetsovaauthor=S.+C.+Ogdenauthor=C.+Hammackauthor=F.+Jacobauthor=H.+N.+Nguyenauthor=M.+Itkinauthor=C.+Hannaauthor=P.+Shinnauthor=C.+Allenauthor=S.+G.+Michaelauthor=A.+Simeonovauthor=W.+Huangauthor=K.+M.+Christianauthor=A.+Goateauthor=K.+J.+Brennandauthor=R.+Huangauthor=M.+Xiaauthor=G.-I.+Mingauthor=W.+Zhengauthor=H.+Songauthor=H.+Tang&title=Identification+of+small-molecule+inhibitors+of+Zika+virus+infection+and+induced+neural+cell+death+via+a+drug+repurposing+screen&doi=10.1038%2Fnm.4184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen</span></div><div class="casAuthors">Xu, Miao; Lee, Emily M.; Wen, Zhexing; Cheng, Yichen; Huang, Wei-Kai; Qian, Xuyu; Tcw, Julia; Kouznetsova, Jennifer; Ogden, Sarah C.; Hammack, Christy; Jacob, Fadi; Nguyen, Ha Nam; Itkin, Misha; Hanna, Catherine; Shinn, Paul; Allen, Chase; Michael, Samuel G.; Simeonov, Anton; Huang, Wenwei; Christian, Kimberly M.; Goate, Alison; Brennand, Kristen J.; Huang, Ruili; Xia, Menghang; Ming, Guo-li; Zheng, Wei; Song, Hongjun; Tang, Hengli</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1101-1107</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In response to the current global health emergency posed by the Zika virus (ZIKV) outbreak and its link to microcephaly and other neurol. conditions, we performed a drug repurposing screen of ∼6,000 compds. that included approved drugs, clin. trial drug candidates and pharmacol. active compds.; we identified compds. that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells.  A pan-caspase inhibitor, emricasan, inhibited ZIKV-induced increases in caspase-3 activity and protected human cortical neural progenitors in both monolayer and three-dimensional organoid cultures.  Ten structurally unrelated inhibitors of cyclin-dependent kinases inhibited ZIKV replication.  Niclosamide, a category B anthelmintic drug approved by the US Food and Drug Administration, also inhibited ZIKV replication.  Finally, combination treatments using one compd. from each category (neuroprotective and antiviral) further increased protection of human neural progenitors and astrocytes from ZIKV-induced cell death.  Our results demonstrate the efficacy of this screening strategy and identify lead compds. for anti-ZIKV drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm3-p_dTqQnbVg90H21EOLACvtfcHk0lifjQJdpHO3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWks7%252FF&md5=dd03539176ee2712f45391eca46d996f</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fnm.4184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4184%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DE.%2BM.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.-K.%26aulast%3DQian%26aufirst%3DX.%26aulast%3DTcw%26aufirst%3DJ.%26aulast%3DKouznetsova%26aufirst%3DJ.%26aulast%3DOgden%26aufirst%3DS.%2BC.%26aulast%3DHammack%26aufirst%3DC.%26aulast%3DJacob%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DH.%2BN.%26aulast%3DItkin%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DC.%26aulast%3DShinn%26aufirst%3DP.%26aulast%3DAllen%26aufirst%3DC.%26aulast%3DMichael%26aufirst%3DS.%2BG.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DChristian%26aufirst%3DK.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DBrennand%26aufirst%3DK.%2BJ.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DMing%26aufirst%3DG.-I.%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DTang%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520small-molecule%2520inhibitors%2520of%2520Zika%2520virus%2520infection%2520and%2520induced%2520neural%2520cell%2520death%2520via%2520a%2520drug%2520repurposing%2520screen%26jtitle%3DNat.%2520Med.%26date%3D2016%26volume%3D22%26spage%3D1101%26epage%3D1107%26doi%3D10.1038%2Fnm.4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Lartigue, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tooze, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clague, M. J.</span></span> <span> </span><span class="NLM_article-title">PIKfyve regulation of endosome-linked pathways</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">893</span>, <span class="refDoi"> DOI: 10.1111/j.1600-0854.2009.00915.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1111%2Fj.1600-0854.2009.00915.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19582903" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXotFGrsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=883-893&author=J.+de+Lartigueauthor=H.+Polsonauthor=M.+Feldmanauthor=K.+Shokatauthor=S.+A.+Toozeauthor=S.+Urbeauthor=M.+J.+Clague&title=PIKfyve+regulation+of+endosome-linked+pathways&doi=10.1111%2Fj.1600-0854.2009.00915.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve regulation of endosome-linked pathways</span></div><div class="casAuthors">de Lartigue, Jane; Polson, Hannah; Feldman, Morri; Shokat, Kevan; Tooze, Sharon A.; Urbe, Sylvie; Clague, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-893</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The phosphoinositide 5-kinase (PIKfyve) is a crit. enzyme for the synthesis of PtdIns(3,5)P2, that was implicated in various trafficking events assocd. with the endocytic pathway.  We have now directly compared the effects of siRNA-mediated knockdown of PIKfyve in HeLa cells with a specific pharmacol. inhibitor of enzyme activity.  Both approaches induce changes in the distribution of cation-independent mannose 6-phosphate receptor (CI-M6PR) and trans-Golgi network (TGN)-46 proteins, which cycles between endosomes and TGN, leading to their accumulation in dispersed punctae, while the TGN marker golgin-245 retains a perinuclear disposition.  Trafficking of CD8-CI-M6PR (retromer-dependent) and CD8-Furin (retromer-independent) chimeras from the cell surface to the TGN is delayed following drug administration, as is the transport of the Shiga toxin B-subunit.  SiRNA knockdown of PIKfyve produced no defect in epidermal growth factor receptor (EGFR) degrdn., unless combined with knockdown of its activator mol. Vac14, suggesting that a low threshold of PtdIns(3,5)P2 is necessary and sufficient for this pathway.  Accordingly pharmacol. inhibition of PIKfyve results in a profound block to the lysosomal degrdn. of activated epidermal growth factor (EGF) and Met receptors.  Immunofluorescence revealed EGF receptors to be trapped in the interior of a swollen endosomal compartment.  In cells starved of amino acids, PIKfyve inhibition leads to the accumulation of the lipidated form of GFP-LC3, a marker of autophagosomal structures, which can be visualized as fluorescent punctae.  We suggest that PIKfyve inhibition may render the late endosome/lysosome compartment refractory to fusion with both autophagosomes and with EGFR-contg. multivesicular bodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjAHcsNBejkbVg90H21EOLACvtfcHk0lifjQJdpHO3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXotFGrsb8%253D&md5=5522c9dfb2e576da77e2a6b166f08b51</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0854.2009.00915.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0854.2009.00915.x%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BLartigue%26aufirst%3DJ.%26aulast%3DPolson%26aufirst%3DH.%26aulast%3DFeldman%26aufirst%3DM.%26aulast%3DShokat%26aufirst%3DK.%26aulast%3DTooze%26aufirst%3DS.%2BA.%26aulast%3DUrbe%26aufirst%3DS.%26aulast%3DClague%26aufirst%3DM.%2BJ.%26atitle%3DPIKfyve%2520regulation%2520of%2520endosome-linked%2520pathways%26jtitle%3DTraffic%26date%3D2009%26volume%3D10%26spage%3D883%26epage%3D893%26doi%3D10.1111%2Fj.1600-0854.2009.00915.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ijuin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Core protein machinery for mammalian phosphatidylinositol 3,5-bisphosphate synthesis and turnover that regulates the progression of endosomal transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve complex</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">23878</span>– <span class="NLM_lpage">23891</span>, <span class="refDoi"> DOI: 10.1074/jbc.M611678200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.M611678200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=17556371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXoslOntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=23878-23891&author=D.+Sbrissaauthor=O.+C.+Ikonomovauthor=Z.+Fuauthor=T.+Ijuinauthor=J.+Gruenbergauthor=T.+Takenawaauthor=A.+Shisheva&title=Core+protein+machinery+for+mammalian+phosphatidylinositol+3%2C5-bisphosphate+synthesis+and+turnover+that+regulates+the+progression+of+endosomal+transport.+Novel+Sac+phosphatase+joins+the+ArPIKfyve-PIKfyve+complex&doi=10.1074%2Fjbc.M611678200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Core Protein Machinery for Mammalian Phosphatidylinositol 3,5-Bisphosphate Synthesis and Turnover That Regulates the Progression of Endosomal Transport: Novel Sac Phosphatase Joins the ArPIKfyve-PIKfyve Complex</span></div><div class="casAuthors">Sbrissa, Diego; Ikonomov, Ognian C.; Fu, Zhiyao; Ijuin, Takeshi; Gruenberg, Jean; Takenawa, Tadaomi; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">23878-23891</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Perturbations in phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2)-synthesizing enzymes result in enlarged endocytic organelles from yeast to humans, indicating evolutionarily conserved function of PtdIns(3,5)P2 in endosome-related events.  This is reinforced by the structural and functional homol. of yeast Vac14 and human Vac14 (ArPIKfyve), which activate yeast and mammalian PtdIns(3,5)P2-producing enzymes, Fab1 and PIKfyve, resp.  In yeast, PtdIns(3,5)P2-specific phosphatase, Fig4, in assocn. with Vac14, turns over PtdIns(3,5)P2, but whether such a mechanism operates in mammalian cells and what the identity of mammalian Fig4 may be are unknown.  Here we have identified and characterized Sac3, a Sac domain phosphatase, as the Fig4 mammalian counterpart.  Endogenous Sac3, a widespread 97-kDa protein, formed a stable ternary complex with ArPIKfyve and PIKfyve.  Concordantly, Sac3 cofractionated and colocalized with ArPIKfyve and PIKfyve.  The intrinsic Sac3WT phosphatase activity preferably hydrolyzed PtdIns(3,5)P2 in vitro, although the other D5-phosphorylated polyphosphoinositides were also substrates.  Ablation of endogenous Sac3 by short interfering RNAs elevated PtdIns(3,5)P2 in 32P-labeled HEK293 cells.  Ectopically expressed Sac3WT in COS cells colocalized with and dilated EEA1-pos. endosomes, consistent with the PtdIns(3,5)P2 requirement in early endosome dynamics.  In vitro reconstitution of carrier vesicle formation from donor early endosomes revealed a gain of function upon Sac3 loss, whereas PIKfyve or ArPIKfyve protein depletion produced a loss of function.  These data demonstrate a coupling between the machinery for PtdIns(3,5)P2 synthesis and turnover achieved through a phys. assembly of PIKfyve, ArPIKfyve, and Sac3.  We suggest that the tight regulation in PtdIns(3,5)P2 homeostasis is mechanistically linked to early endosome dynamics in the course of cargo transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsZiUzSilWWbVg90H21EOLACvtfcHk0lifjQJdpHO3HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXoslOntrc%253D&md5=f45f6265aae85924bbff3a1edb3925a4</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M611678200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M611678200%26sid%3Dliteratum%253Aachs%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DIjuin%26aufirst%3DT.%26aulast%3DGruenberg%26aufirst%3DJ.%26aulast%3DTakenawa%26aufirst%3DT.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DCore%2520protein%2520machinery%2520for%2520mammalian%2520phosphatidylinositol%25203%252C5-bisphosphate%2520synthesis%2520and%2520turnover%2520that%2520regulates%2520the%2520progression%2520of%2520endosomal%2520transport.%2520Novel%2520Sac%2520phosphatase%2520joins%2520the%2520ArPIKfyve-PIKfyve%2520complex%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D23878%26epage%3D23891%26doi%3D10.1074%2Fjbc.M611678200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Localized PtdIns 3,5-P2 synthesis to regulate early endosome dynamics and fusion</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>291</i></span>,  <span class="NLM_fpage">C393</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.00019.2006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1152%2Fajpcell.00019.2006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16510848" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2006&pages=C393-404&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Localized+PtdIns+3%2C5-P2+synthesis+to+regulate+early+endosome+dynamics+and+fusion&doi=10.1152%2Fajpcell.00019.2006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.00019.2006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.00019.2006%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DLocalized%2520PtdIns%25203%252C5-P2%2520synthesis%2520to%2520regulate%2520early%2520endosome%2520dynamics%2520and%2520fusion%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2006%26volume%3D291%26spage%3DC393%26epage%3D404%26doi%3D10.1152%2Fajpcell.00019.2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schink, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raiborg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, H.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-phosphate, a lipid that regulates membrane dynamics, protein sorting and cell signalling</span>. <i>BioEssays</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">900</span>– <span class="NLM_lpage">912</span>, <span class="refDoi"> DOI: 10.1002/bies.201300064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fbies.201300064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23881848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFGgu7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=900-912&author=K.+O.+Schinkauthor=C.+Raiborgauthor=H.+Stenmark&title=Phosphatidylinositol+3-phosphate%2C+a+lipid+that+regulates+membrane+dynamics%2C+protein+sorting+and+cell+signalling&doi=10.1002%2Fbies.201300064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-phosphate, a lipid that regulates membrane dynamics, protein sorting and cell signalling</span></div><div class="casAuthors">Schink, Kay O.; Raiborg, Camilla; Stenmark, Harald</div><div class="citationInfo"><span class="NLM_cas:title">BioEssays</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">900-912</span>CODEN:
                <span class="NLM_cas:coden">BIOEEJ</span>;
        ISSN:<span class="NLM_cas:issn">0265-9247</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-phosphate (PtdIns3P) is generated on the cytosolic leaflet of cellular membranes, primarily by phosphorylation of phosphatidylinositol by class II and class III phosphatidylinositol 3-kinases.  The bulk of this lipid is found on the limiting and intraluminal membranes of endosomes, but it can also be detected in domains of phagosomes, autophagosome precursors, cytokinetic bridges, the plasma membrane and the nucleus.  PtdIns3P controls cellular functions through recruitment of specific protein effectors, many of which contain FYVE or PX domains.  Cellular processes known to be controlled by PtdIns3P and its effectors include endosomal fusion, sorting and motility, autophagy, cytokinesis, regulated exocytosis and signal transduction.  Here we discuss how Ptdins3P is generated on specific cellular membranes, how its localizations and functions can be studied, and how its effectors serve to control cellular functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXUrll_PcBbVg90H21EOLACvtfcHk0lgNKLm-TS_VcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFGgu7fJ&md5=93fa2b0d09c538b9528eecdddac4a89b</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1002%2Fbies.201300064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.201300064%26sid%3Dliteratum%253Aachs%26aulast%3DSchink%26aufirst%3DK.%2BO.%26aulast%3DRaiborg%26aufirst%3DC.%26aulast%3DStenmark%26aufirst%3DH.%26atitle%3DPhosphatidylinositol%25203-phosphate%252C%2520a%2520lipid%2520that%2520regulates%2520membrane%2520dynamics%252C%2520protein%2520sorting%2520and%2520cell%2520signalling%26jtitle%3DBioEssays%26date%3D2013%26volume%3D35%26spage%3D900%26epage%3D912%26doi%3D10.1002%2Fbies.201300064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardia, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassilev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saric, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griner, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marugan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DePamphilis, M. L.</span></span> <span> </span><span class="NLM_article-title">A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1080/15548627.2019.1586257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F15548627.2019.1586257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30806145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFKmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=1694-1718&author=G.+Sharmaauthor=C.+M.+Guardiaauthor=A.+Royauthor=A.+Vassilevauthor=A.+Saricauthor=L.+N.+Grinerauthor=J.+Maruganauthor=M.+Ferrerauthor=J.+S.+Bonifacinoauthor=M.+L.+DePamphilis&title=A+family+of+PIKFYVE+inhibitors+with+therapeutic+potential+against+autophagy-dependent+cancer+cells+disrupt+multiple+events+in+lysosome+homeostasis&doi=10.1080%2F15548627.2019.1586257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis</span></div><div class="casAuthors">Sharma, Gaurav; Guardia, Carlos M.; Roy, Ajit; Vassilev, Alex; Saric, Amra; Griner, Lori N.; Marugan, Juan; Ferrer, Marc; Bonifacino, Juan S.; DePamphilis, Melvin L.</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1694-1718</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8635</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">High-throughput screening identified 5 chem. analogs (termed the WX8-family) that disrupted 3 events in lysosome homeostasis: (1) lysosome fission via tubulation without preventing homotypic lysosome fusion; (2) trafficking of mols. into lysosomes without altering lysosomal acidity, and (3) heterotypic fusion between lysosomes and autophagosomes.  Remarkably, these compds. did not prevent homotypic fusion between lysosomes, despite the fact that homotypic fusion required some of the same machinery essential for heterotypic fusion.  These effects varied 400-fold among WX8-family members, were time and concn. dependent, reversible, and resulted primarily from their ability to bind specifically to the PIKFYVE phosphoinositide kinase.  The ability of the WX8-family to prevent lysosomes from participating in macroautophagy/autophagy suggested they have therapeutic potential in treating autophagy-dependent diseases.  In fact, the most potent family member (WX8) was 100-times more lethal to 'autophagy-addicted' melanoma A375 cells than the lysosomal inhibitors hydroxychloroquine and chloroquine.  In contrast, cells that were insensitive to hydroxychloroquine and chloroquine were also insensitive to WX8.  Therefore, the WX8-family of PIKFYVE inhibitors provides a basis for developing drugs that could selectively kill autophagy-dependent cancer cells, as well as increasing the effectiveness of established anti-cancer therapies through combinatorial treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlajGQ8jh2DLVg90H21EOLACvtfcHk0lgNKLm-TS_VcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFKmtLw%253D&md5=77481df9d3e911f58e6b9645f89714b4</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1080%2F15548627.2019.1586257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15548627.2019.1586257%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DG.%26aulast%3DGuardia%26aufirst%3DC.%2BM.%26aulast%3DRoy%26aufirst%3DA.%26aulast%3DVassilev%26aufirst%3DA.%26aulast%3DSaric%26aufirst%3DA.%26aulast%3DGriner%26aufirst%3DL.%2BN.%26aulast%3DMarugan%26aufirst%3DJ.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26aulast%3DDePamphilis%26aufirst%3DM.%2BL.%26atitle%3DA%2520family%2520of%2520PIKFYVE%2520inhibitors%2520with%2520therapeutic%2520potential%2520against%2520autophagy-dependent%2520cancer%2520cells%2520disrupt%2520multiple%2520events%2520in%2520lysosome%2520homeostasis%26jtitle%3DAutophagy%26date%3D2019%26volume%3D15%26spage%3D1694%26epage%3D1718%26doi%3D10.1080%2F15548627.2019.1586257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mlak, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeb, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fligger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finley, R. L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Active PIKfyve associates with and promotes the membrane attachment of the late endosome-to-trans-Golgi network transport factor Rab9 effector p40</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">50863</span>– <span class="NLM_lpage">50871</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307260200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1074%2Fjbc.M307260200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=14530284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpslOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=50863-50871&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=K.+Mlakauthor=R.+Deebauthor=J.+Fliggerauthor=A.+Soansauthor=R.+L.+Finleyauthor=A.+Shisheva&title=Active+PIKfyve+associates+with+and+promotes+the+membrane+attachment+of+the+late+endosome-to-trans-Golgi+network+transport+factor+Rab9+effector+p40&doi=10.1074%2Fjbc.M307260200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Active PIKfyve Associates with and Promotes the Membrane Attachment of the Late Endosome-to-trans-Golgi Network Transport Factor Rab9 Effector p40</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Mlak, Krzysztof; Deeb, Robert; Fligger, Jason; Soans, Aleric; Finley, Russell L., Jr.; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">50863-50871</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">PIKfyve, a kinase that displays specificity for phosphatidylinositol (PtdIns), PtdIns 3-phosphate (3-P), and proteins, is important in multivesicular body/late endocytic function.  Enzymically inactive PIKfyve mutants elicit enormous dilation of late endocytic structures, suggesting a role for PIKfyve in endosome-to-trans-Golgi network (TGN) membrane retrieval.  Here we report that p40, a Rab9 effector reported previously to bind Rab9-GTP and stimulate endosome-to-TGN transport, interacts with PIKfyve as detd. by yeast two-hybrid assays, glutathione S-transferase (GST) pull-down assays, and co-immunopptn. in doubly transfected HEK293 cells.  The interaction engages the PIKfyve chaperonin domain and four out of the six C-terminally positioned kelch repeats in p40.  Differential centrifugation in a HEK293 cell line, stably expressing PIKfyveWT, showed the membrane-assocd. immunoreactive p40 co-sedimenting with PIKfyve in the high speed pellet (HSP) fraction.  Remarkably, similar anal. in a HEK293 cell line stably expressing dominant-neg. kinase-deficient PIKfyveK1831E demonstrated a marked depletion of p40 from the HSP fraction.  GST-p40 failed to specifically assoc. with the PIKfyve lipid products PtdIns 5-P and PtdIns 3,5-P2 in a liposome binding assay but was found to be an in vitro substrate of the PIKfyve serine kinase activity.  A band with the p40 electrophoretic mobility was found to react with a phosphoserine-specific antibody mainly in the PIKfyveWT-contg. fractions obtained by d. gradient sedimentation of total membranes from PIKfyveWT-expressing HEK293 cells.  Together these results identify the Rab9 effector p40 as a PIKfyve partner and suggest that p40-PIKfyve interaction and the subsequent PIKfyve-catalyzed p40 phosphorylation anchor p40 to discrete membranes facilitating late endosome-to-TGN transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjGs3YUluHk7Vg90H21EOLACvtfcHk0lgNKLm-TS_VcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpslOiu7s%253D&md5=e5bc482a93c1ae22aeb619715d4bfac1</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307260200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307260200%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DMlak%26aufirst%3DK.%26aulast%3DDeeb%26aufirst%3DR.%26aulast%3DFligger%26aufirst%3DJ.%26aulast%3DSoans%26aufirst%3DA.%26aulast%3DFinley%26aufirst%3DR.%2BL.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DActive%2520PIKfyve%2520associates%2520with%2520and%2520promotes%2520the%2520membrane%2520attachment%2520of%2520the%2520late%2520endosome-to-trans-Golgi%2520network%2520transport%2520factor%2520Rab9%2520effector%2520p40%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D50863%26epage%3D50871%26doi%3D10.1074%2Fjbc.M307260200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutherford, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassmer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bujny, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlton, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenmark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. J.</span></span> <span> </span><span class="NLM_article-title">The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">3944</span>– <span class="NLM_lpage">3957</span>, <span class="refDoi"> DOI: 10.1242/jcs.03153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.03153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16954148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1CgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=3944-3957&author=A.+C.+Rutherfordauthor=C.+Traerauthor=T.+Wassmerauthor=K.+Pattniauthor=M.+V.+Bujnyauthor=J.+G.+Carltonauthor=H.+Stenmarkauthor=P.+J.+Cullen&title=The+mammalian+phosphatidylinositol+3-phosphate+5-kinase+%28PIKfyve%29+regulates+endosome-to-TGN+retrograde+transport&doi=10.1242%2Fjcs.03153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport</span></div><div class="casAuthors">Rutherford, Anna C.; Traer, Colin; Wassmer, Thomas; Pattni, Krupa; Bujny, Miriam V.; Carlton, Jeremy G.; Stenmark, Harald; Cullen, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3944-3957</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The yeast gene fab1 and its mammalian orthologue Pip5k3 encode the phosphatidylinositol 3-phosphate [PtdIns(3)P] 5-kinases Fab1p and PIKfyve, resp., enzymes that generates phosphatidylinositol 3,5-bisphosphate [PtdIns(3,5)P2].  A shared feature of fab1Δ yeast cells and mammalian cells overexpressing a kinase-dead PIKfyve mutant is the formation of a swollen vacuolar phenotype: a phenotype that is suggestive of a conserved function for these enzymes and their product, PtdIns(3,5)P2, in the regulation of endomembrane homeostasis.  In the current study, fixed and live cell imaging has established that, when overexpressed at low levels in HeLa cells, PIKfyve is predominantly assocd. with dynamic tubular and vesicular elements of the early endosomal compartment.  Moreover, through the use of small interfering RNA, it has been shown that suppression of PIKfyve induces the formation of swollen endosomal structures that maintain their early and late endosomal identity.  Although internalization, recycling and degradative sorting of receptors for epidermal growth factor and transferrin was unperturbed in PIKfyve suppressed cells, a clear defect in endosome to trans-Golgi-network (TGN) retrograde traffic was obsd.  These data argue that PIKfyve is predominantly assocd. with the early endosome, from where it regulates retrograde membrane trafficking to the TGN.  It follows that the swollen endosomal phenotype obsd. in PIKfyve-suppressed cells results primarily from a redn. in retrograde membrane fission rather than a defect in multivesicular body biogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAqgs0VHr1Z7Vg90H21EOLACvtfcHk0liaFR4qTXq0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1CgtA%253D%253D&md5=1e4111d4d82c8636424d7b60a79d06d8</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1242%2Fjcs.03153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.03153%26sid%3Dliteratum%253Aachs%26aulast%3DRutherford%26aufirst%3DA.%2BC.%26aulast%3DTraer%26aufirst%3DC.%26aulast%3DWassmer%26aufirst%3DT.%26aulast%3DPattni%26aufirst%3DK.%26aulast%3DBujny%26aufirst%3DM.%2BV.%26aulast%3DCarlton%26aufirst%3DJ.%2BG.%26aulast%3DStenmark%26aufirst%3DH.%26aulast%3DCullen%26aufirst%3DP.%2BJ.%26atitle%3DThe%2520mammalian%2520phosphatidylinositol%25203-phosphate%25205-kinase%2520%2528PIKfyve%2529%2520regulates%2520endosome-to-TGN%2520retrograde%2520transport%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2006%26volume%3D119%26spage%3D3944%26epage%3D3957%26doi%3D10.1242%2Fjcs.03153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikonomov, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbrissa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shisheva, A.</span></span> <span> </span><span class="NLM_article-title">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">114771</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2019.114771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.taap.2019.114771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31628917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2019&pages=114771&author=O.+C.+Ikonomovauthor=D.+Sbrissaauthor=A.+Shisheva&title=Small+molecule+PIKfyve+inhibitors+as+cancer+therapeutics%3A+Translational+promises+and+limitations&doi=10.1016%2Fj.taap.2019.114771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule PIKfyve inhibitors as cancer therapeutics: Translational promises and limitations</span></div><div class="casAuthors">Ikonomov, Ognian C.; Sbrissa, Diego; Shisheva, Assia</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114771</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Through synthesis of two rare phosphoinositides, PtdIns(3,5)P2 and PtdIns5P, the ubiquitously expressed phosphoinositide kinase PIKfyve is implicated in pleiotropic cellular functions.  Small mols. specifically inhibiting PIKfyve activity cause cytoplasmic vacuolation in all dividing cells in culture yet trigger non-apoptotic death through excessive vacuolation only in cancer cells.  Intriguingly, cancer cell toxicity appears to be inhibitor-specific suggesting that addnl. targets beyond PIKfyve are affected.  One PIKfyve inhibitor - apilimod - is already in clin. trials for treatment of B-cell malignancies.  However, apilimod is inactivated in cultured cells and exhibits unexpectedly low plasma levels in patients treated with max. oral dosage.  Thus, the potential widespread use of PIKfyve inhibitors as cancer therapeutics requires progress on multiple fronts: (i) advances in methods for isolating relevant cancer cells from individual patients; (ii) delineation of the mol. mechanisms potentiating the vacuolation induced by PIKfyve inhibitors in sensitive cancer cells; (iii) design of PIKfyve inhibitors with favorable pharmacokinetics; and (iv) development of effective drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVCqd6_1ZLsrVg90H21EOLACvtfcHk0liaFR4qTXq0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKgt7rJ&md5=992d773408d82e75fe81132678d6c0df</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.114771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.114771%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomov%26aufirst%3DO.%2BC.%26aulast%3DSbrissa%26aufirst%3DD.%26aulast%3DShisheva%26aufirst%3DA.%26atitle%3DSmall%2520molecule%2520PIKfyve%2520inhibitors%2520as%2520cancer%2520therapeutics%253A%2520Translational%2520promises%2520and%2520limitations%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D383%26spage%3D114771%26doi%3D10.1016%2Fj.taap.2019.114771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcazar-Roman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazal, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouwmeester, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finan, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ploegh, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Camilli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tallarico, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span> <span> </span><span class="NLM_article-title">PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">912</span>– <span class="NLM_lpage">921</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2013.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23890009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=912-921&author=X.+Caiauthor=Y.+Xuauthor=A.+K.+Cheungauthor=R.+C.+Tomlinsonauthor=A.+Alcazar-Romanauthor=L.+Murphyauthor=A.+Billichauthor=B.+Zhangauthor=Y.+Fengauthor=M.+Klumppauthor=J.+M.+Rondeauauthor=A.+N.+Fazalauthor=C.+J.+Wilsonauthor=V.+Myerauthor=G.+Jobertyauthor=T.+Bouwmeesterauthor=M.+A.+Labowauthor=P.+M.+Finanauthor=J.+A.+Porterauthor=H.+L.+Ploeghauthor=D.+Bairdauthor=P.+De+Camilliauthor=J.+A.+Tallaricoauthor=Q.+Huang&title=PIKfyve%2C+a+class+III+PI+kinase%2C+is+the+target+of+the+small+molecular+IL-12%2FIL-23+inhibitor+apilimod+and+a+player+in+Toll-like+receptor+signaling&doi=10.1016%2Fj.chembiol.2013.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling</span></div><div class="casAuthors">Cai, Xinming; Xu, Yongyao; Cheung, Atwood K.; Tomlinson, Ronald C.; Alcazar-Roman, Abel; Murphy, Leon; Billich, Andreas; Zhang, Bailin; Feng, Yan; Klumpp, Martin; Rondeau, Jean-Michel; Fazal, Aleem N.; Wilson, Christopher J.; Myer, Vic; Joberty, Gerard; Bouwmeester, Tewis; Labow, Mark A.; Finan, Peter M.; Porter, Jeffrey A.; Ploegh, Hidde L.; Baird, Daniel; De Camilli, Pietro; Tallarico, John A.; Huang, Qian</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">912-921</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Toll-like receptor (TLR) signaling is a key component of innate immunity.  Aberrant TLR activation leads to immune disorders via dysregulation of cytokine prodn., such as IL-12/IL-23.  Herein, we identify and characterize PIKfyve, a lipid kinase, as a crit. player in TLR signaling using apilimod as an affinity tool.  Apilimod is a potent small mol. inhibitor of IL-12/IL-23 with an unknown target and has been evaluated in clin. trials for patients with Crohn's disease or rheumatoid arthritis.  Using a chem. genetic approach, we show that it binds to PIKfyve and blocks its phosphotransferase activity, leading to selective inhibition of IL-12/IL-23p40.  Pharmacol. or genetic inactivation of PIKfyve is necessary and sufficient for suppression of IL-12/IL-23p40 expression.  Thus, we have uncovered a phosphoinositide-mediated regulatory mechanism that controls TLR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpALdejwmIR_rVg90H21EOLACvtfcHk0liaFR4qTXq0qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOktbbE&md5=9b296c00beb17b95ec9a17c1750a1862</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCheung%26aufirst%3DA.%2BK.%26aulast%3DTomlinson%26aufirst%3DR.%2BC.%26aulast%3DAlcazar-Roman%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DL.%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DKlumpp%26aufirst%3DM.%26aulast%3DRondeau%26aufirst%3DJ.%2BM.%26aulast%3DFazal%26aufirst%3DA.%2BN.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DMyer%26aufirst%3DV.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBouwmeester%26aufirst%3DT.%26aulast%3DLabow%26aufirst%3DM.%2BA.%26aulast%3DFinan%26aufirst%3DP.%2BM.%26aulast%3DPorter%26aufirst%3DJ.%2BA.%26aulast%3DPloegh%26aufirst%3DH.%2BL.%26aulast%3DBaird%26aufirst%3DD.%26aulast%3DDe%2BCamilli%26aufirst%3DP.%26aulast%3DTallarico%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26atitle%3DPIKfyve%252C%2520a%2520class%2520III%2520PI%2520kinase%252C%2520is%2520the%2520target%2520of%2520the%2520small%2520molecular%2520IL-12%252FIL-23%2520inhibitor%2520apilimod%2520and%2520a%2520player%2520in%2520Toll-like%2520receptor%2520signaling%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D912%26epage%3D921%26doi%3D10.1016%2Fj.chembiol.2013.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gayle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landrette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeharry, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conrad, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckett, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandelkern, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichenstein, H.</span></span> <span> </span><span class="NLM_article-title">Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">1768</span>– <span class="NLM_lpage">1778</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-09-736892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1182%2Fblood-2016-09-736892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28104689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=1768-1778&author=S.+Gayleauthor=S.+Landretteauthor=N.+Beeharryauthor=C.+Conradauthor=M.+Hernandezauthor=P.+Beckettauthor=S.+M.+Fergusonauthor=T.+Mandelkernauthor=M.+Zhengauthor=T.+Xuauthor=J.+Rothbergauthor=H.+Lichenstein&title=Identification+of+apilimod+as+a+first-in-class+PIKfyve+kinase+inhibitor+for+treatment+of+B-cell+non-Hodgkin+lymphoma&doi=10.1182%2Fblood-2016-09-736892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma</span></div><div class="casAuthors">Gayle, Sophia; Landrette, Sean; Beeharry, Neil; Conrad, Chris; Hernandez, Marylens; Beckett, Paul; Ferguson, Shawn M.; Mandelkern, Talya; Zheng, Meiling; Xu, Tian; Rothberg, Jonathan; Lichenstein, Henri</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1768-1778</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">We identified apilimod as an antiproliferative compd. by high-throughput screening of clin.-stage drugs.  Apilimod exhibits exquisite specificity for phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) lipid kinase and has selective cytotoxic activity in B-cell non-Hodgkin lymphoma (B-NHL) compared with normal cells.  Apilimod displays nanomolar activity in vitro, and in vivo studies demonstrate single-agent efficacy as well as synergy with approved B-NHL drugs.  Using biochem. and knockdown approaches, and discovery of a kinase domain mutation conferring resistance, we demonstrate that apilimod-mediated cytotoxicity is driven by PIKfyve inhibition.  Furthermore, a crit. role for lysosome dysfunction as a major factor contributing to apilimod's cytotoxicity is supported by a genome-wide CRISPR screen.  In the screen, TFEB (master transcriptional regulator of lysosomal biogenesis) and endosomal/lysosomal genes CLCN7, OSTM1, and SNX10 were identified as important determinants of apilimod sensitivity.  These findings thus suggest that disruption of lysosomal homeostasis with apilimod represents a novel approach to treat B-NHL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqTjIKokPhHrVg90H21EOLACvtfcHk0ljYbvH9d4heRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVOlu7fM&md5=224b5d68b7c4e202010f4d192398491e</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-09-736892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-09-736892%26sid%3Dliteratum%253Aachs%26aulast%3DGayle%26aufirst%3DS.%26aulast%3DLandrette%26aufirst%3DS.%26aulast%3DBeeharry%26aufirst%3DN.%26aulast%3DConrad%26aufirst%3DC.%26aulast%3DHernandez%26aufirst%3DM.%26aulast%3DBeckett%26aufirst%3DP.%26aulast%3DFerguson%26aufirst%3DS.%2BM.%26aulast%3DMandelkern%26aufirst%3DT.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DRothberg%26aufirst%3DJ.%26aulast%3DLichenstein%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520apilimod%2520as%2520a%2520first-in-class%2520PIKfyve%2520kinase%2520inhibitor%2520for%2520treatment%2520of%2520B-cell%2520non-Hodgkin%2520lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D1768%26epage%3D1778%26doi%3D10.1182%2Fblood-2016-09-736892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandoorne, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steyaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staats, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span> <span> </span><span class="NLM_article-title">The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1651</span>– <span class="NLM_lpage">1673</span>, <span class="refDoi"> DOI: 10.1093/brain/awaa022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1093%2Fbrain%2Fawaa022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32206784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB383mvV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2020&pages=1651-1673&author=W.+Guoauthor=T.+Vandoorneauthor=J.+Steyaertauthor=K.+A.+Staatsauthor=L.+Van+Den%0ABosch&title=The+multifaceted+role+of+kinases+in+amyotrophic+lateral+sclerosis%3A+genetic%2C+pathological+and+therapeutic+implications&doi=10.1093%2Fbrain%2Fawaa022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">The multifaceted role of kinases in amyotrophic lateral sclerosis: genetic, pathological and therapeutic implications</span></div><div class="casAuthors">Guo Wenting; Vandoorne Tijs; Steyaert Jolien; Van Den Bosch Ludo; Guo Wenting; Vandoorne Tijs; Steyaert Jolien; Van Den Bosch Ludo; Guo Wenting; Staats Kim A</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1651-1673</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Amyotrophic lateral sclerosis is the most common degenerative disorder of motor neurons in adults.  As there is no cure, thousands of individuals who are alive at present will succumb to the disease.  In recent years, numerous causative genes and risk factors for amyotrophic lateral sclerosis have been identified.  Several of the recently identified genes encode kinases.  In addition, the hypothesis that (de)phosphorylation processes drive the disease process resulting in selective motor neuron degeneration in different disease variants has been postulated.  We re-evaluate the evidence for this hypothesis based on recent findings and discuss the multiple roles of kinases in amyotrophic lateral sclerosis pathogenesis.  We propose that kinases could represent promising therapeutic targets.  Mainly due to the comprehensive regulation of kinases, however, a better understanding of the disturbances in the kinome network in amyotrophic lateral sclerosis is needed to properly target specific kinases in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuvu_j6jnHPQqdek-gHSrIfW6udTcc2eaIoqthkUgsD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383mvV2lug%253D%253D&md5=578afee922c410314ba84a284f56b8ab</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawaa022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawaa022%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DVandoorne%26aufirst%3DT.%26aulast%3DSteyaert%26aufirst%3DJ.%26aulast%3DStaats%26aufirst%3DK.%2BA.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DThe%2520multifaceted%2520role%2520of%2520kinases%2520in%2520amyotrophic%2520lateral%2520sclerosis%253A%2520genetic%252C%2520pathological%2520and%2520therapeutic%2520implications%26jtitle%3DBrain%26date%3D2020%26volume%3D143%26spage%3D1651%26epage%3D1673%26doi%3D10.1093%2Fbrain%2Fawaa022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staats, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendricks, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linares, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menendez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugawara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolwine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koutsodendris, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangoor, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilkumar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennes, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seah, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">August, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson-Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belgard, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunseich, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berg, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasterkamp, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zlokovic, B. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichida, J. K.</span></span> <span> </span><span class="NLM_article-title">Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nm.4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnm.4490" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29400714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=313-325&author=Y.+Shiauthor=S.+Linauthor=K.+A.+Staatsauthor=Y.+Liauthor=W.+H.+Changauthor=S.+T.+Hungauthor=E.+Hendricksauthor=G.+R.+Linaresauthor=Y.+Wangauthor=E.+Y.+Sonauthor=X.+Wenauthor=K.+Kislerauthor=B.+Wilkinsonauthor=L.+Menendezauthor=T.+Sugawaraauthor=P.+Woolwineauthor=M.+Huangauthor=M.+J.+Cowanauthor=B.+Geauthor=N.+Koutsodendrisauthor=K.+P.+Sandorauthor=J.+Kombergauthor=V.+R.+Vangoorauthor=K.+Senthilkumarauthor=V.+Hennesauthor=C.+Seahauthor=A.+R.+Nelsonauthor=T.+Y.+Chengauthor=S.+J.+Leeauthor=P.+R.+Augustauthor=J.+A.+Chenauthor=N.+Wisniewskiauthor=V.+Hanson-Smithauthor=T.+G.+Belgardauthor=A.+Zhangauthor=M.+Cobaauthor=C.+Grunseichauthor=M.+E.+Wardauthor=L.+H.+van+den+Bergauthor=R.+J.+Pasterkampauthor=D.+Trottiauthor=B.+V.+Zlokovicauthor=J.+K.+Ichida&title=Haploinsufficiency+leads+to+neurodegeneration+in+C9ORF72+ALS%2FFTD+human+induced+motor+neurons&doi=10.1038%2Fnm.4490"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons</span></div><div class="casAuthors">Shi, Yingxiao; Lin, Shaoyu; Staats, Kim A.; Li, Yichen; Chang, Wen-Hsuan; Hung, Shu-Ting; Hendricks, Eric; Linares, Gabriel R.; Wang, Yaoming; Son, Esther Y.; Wen, Xinmei; Kisler, Kassandra; Wilkinson, Brent; Menendez, Louise; Sugawara, Tohru; Woolwine, Phillip; Huang, Mickey; Cowan, Michael J.; Ge, Brandon; Koutsodendris, Nicole; Sandor, Kaitlin P.; Komberg, Jacob; Vangoor, Vamshidhar R.; Senthilkumar, Ketharini; Hennes, Valerie; Seah, Carina; Nelson, Amy R.; Cheng, Tze-Yuan; Lee, Shih-Jong J.; August, Paul R.; Chen, Jason A.; Wisniewski, Nicholas; Hanson-Smith, Victor; Belgard, T. Grant; Zhang, Alice; Coba, Marcelo; Grunseich, Chris; Ward, Michael E.; van den Berg, Leonard H.; Pasterkamp, R. Jeroen; Trotti, Davide; Zlokovic, Berislav V.; Ichida, Justin K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">313-325</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">An intronic GGGGCC repeat expansion in C9ORF72 is the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but the pathogenic mechanism of this repeat remains unclear.  Using human induced motor neurons (iMNs), we found that repeat-expanded C9ORF72 was haploinsufficient in ALS.  We found that C9ORF72 interacted with endosomes and was required for normal vesicle trafficking and lysosomal biogenesis in motor neurons.  Repeat expansion reduced C9ORF72 expression, triggering neurodegeneration through two mechanisms: accumulation of glutamate receptors, leading to excitotoxicity, and impaired clearance of neurotoxic dipeptide repeat proteins derived from the repeat expansion.  Thus, cooperativity between gain- and loss-of-function mechanisms led to neurodegeneration.  Restoring C9ORF72 levels or augmenting its function with constitutively active RAB5 or chem. modulators of RAB5 effectors rescued patient neuron survival and ameliorated neurodegenerative processes in both gain- and loss-of-function C9ORF72 mouse models.  Thus, modulating vesicle trafficking was able to rescue neurodegeneration caused by the C9ORF72 repeat expansion.  Coupled with rare mutations in ALS2, FIG4, CHMP2B, OPTN and SQSTM1, our results reveal mechanistic convergence on vesicle trafficking in ALS and FTD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZRo0XUC17WrVg90H21EOLACvtfcHk0ljs-a-T3kecgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCiu7Y%253D&md5=0d79b78361920b00ef1c4e8d397fd4ce</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1038%2Fnm.4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.4490%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DStaats%26aufirst%3DK.%2BA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DW.%2BH.%26aulast%3DHung%26aufirst%3DS.%2BT.%26aulast%3DHendricks%26aufirst%3DE.%26aulast%3DLinares%26aufirst%3DG.%2BR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSon%26aufirst%3DE.%2BY.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DKisler%26aufirst%3DK.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DMenendez%26aufirst%3DL.%26aulast%3DSugawara%26aufirst%3DT.%26aulast%3DWoolwine%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DCowan%26aufirst%3DM.%2BJ.%26aulast%3DGe%26aufirst%3DB.%26aulast%3DKoutsodendris%26aufirst%3DN.%26aulast%3DSandor%26aufirst%3DK.%2BP.%26aulast%3DKomberg%26aufirst%3DJ.%26aulast%3DVangoor%26aufirst%3DV.%2BR.%26aulast%3DSenthilkumar%26aufirst%3DK.%26aulast%3DHennes%26aufirst%3DV.%26aulast%3DSeah%26aufirst%3DC.%26aulast%3DNelson%26aufirst%3DA.%2BR.%26aulast%3DCheng%26aufirst%3DT.%2BY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DAugust%26aufirst%3DP.%2BR.%26aulast%3DChen%26aufirst%3DJ.%2BA.%26aulast%3DWisniewski%26aufirst%3DN.%26aulast%3DHanson-Smith%26aufirst%3DV.%26aulast%3DBelgard%26aufirst%3DT.%2BG.%26aulast%3DZhang%26aufirst%3DA.%26aulast%3DCoba%26aufirst%3DM.%26aulast%3DGrunseich%26aufirst%3DC.%26aulast%3DWard%26aufirst%3DM.%2BE.%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DL.%2BH.%26aulast%3DPasterkamp%26aufirst%3DR.%2BJ.%26aulast%3DTrotti%26aufirst%3DD.%26aulast%3DZlokovic%26aufirst%3DB.%2BV.%26aulast%3DIchida%26aufirst%3DJ.%2BK.%26atitle%3DHaploinsufficiency%2520leads%2520to%2520neurodegeneration%2520in%2520C9ORF72%2520ALS%252FFTD%2520human%2520induced%2520motor%2520neurons%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D313%26epage%3D325%26doi%3D10.1038%2Fnm.4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span> <span> </span><span class="NLM_article-title">From hitchhiker to hijacker: pathogen exploitation of endosomal phosphoinositides (1)</span>. <i>Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1139/bcb-2017-0317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1139%2Fbcb-2017-0317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29746785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2019&pages=1-9&author=S.+Qiuauthor=M.+Cote&title=From+hitchhiker+to+hijacker%3A+pathogen+exploitation+of+endosomal+phosphoinositides+%281%29&doi=10.1139%2Fbcb-2017-0317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">From hitchhiker to hijacker: pathogen exploitation of endosomal phosphoinositides1</span></div><div class="casAuthors">Qiu, Shirley; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and Cell Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">BCBIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0829-8211</span>.
    
            (<span class="NLM_cas:orgname">Canadian Science Publishing</span>)
        </div><div class="casAbstract">Signalling through phosphoinositide lipids is essential for regulating many cellular processes, including endosomal trafficking.  A no. of intracellular pathogens have found ways to subvert host trafficking pathways via exploitation of endosomal phosphoinositides.  This review will discuss how pathogens such as bacteria, viruses, and eukaryotic parasites depend on endosomal phosphoinositides for infection as well as the mechanisms through which some are able to actively manipulate these signalling lipids to facilitate invasion, survival, replication, and immune evasion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHame4AaAjTrVg90H21EOLACvtfcHk0ljs-a-T3kecgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1ClsL7F&md5=54653a8857f5729eeb38051eeebf8d7f</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1139%2Fbcb-2017-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1139%252Fbcb-2017-0317%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DM.%26atitle%3DFrom%2520hitchhiker%2520to%2520hijacker%253A%2520pathogen%2520exploitation%2520of%2520endosomal%2520phosphoinositides%2520%25281%2529%26jtitle%3DBiochem.%2520Cell%2520Biol.%26date%3D2019%26volume%3D97%26spage%3D1%26epage%3D9%26doi%3D10.1139%2Fbcb-2017-0317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lozach, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huotari, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helenius, A.</span></span> <span> </span><span class="NLM_article-title">Late-penetrating viruses</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2011.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.coviro.2011.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22440565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=35-43&author=P.+Y.+Lozachauthor=J.+Huotariauthor=A.+Helenius&title=Late-penetrating+viruses&doi=10.1016%2Fj.coviro.2011.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Late-penetrating viruses</span></div><div class="casAuthors">Lozach, Pierre-Yves; Huotari, Jatta; Helenius, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-43</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Many enveloped and non-enveloped animal viruses delay the penetration into the cytosol of host cells until they have arrived to endocytic vacuoles deep in the cytoplasm.  The late timing is generally detd. by a low pH-threshold for the acid-activated penetration process (pH 6.2-4.9), but there can be a combination of other reasons for a delay.  Since late-penetrating viruses (L-PVs) must be sorted into the degradative pathway, they are particularly sensitive to perturbations that interfere with mol. sorting and proper maturation of endosomes, including switching of Rabs, formation of intraluminal vesicles, and microtubule-mediated transport.  In this short review, we focus on L-PVs from several virus families, and their interactions with the endocytic machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrt3_5Yz_K9K7Vg90H21EOLACvtfcHk0ljs-a-T3kecgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFKgtL3I&md5=7bbfd1cf3008b8a75ea1b4670b6dc44c</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2011.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2011.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DLozach%26aufirst%3DP.%2BY.%26aulast%3DHuotari%26aufirst%3DJ.%26aulast%3DHelenius%26aufirst%3DA.%26atitle%3DLate-penetrating%2520viruses%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2011%26volume%3D1%26spage%3D35%26epage%3D43%26doi%3D10.1016%2Fj.coviro.2011.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta-Geijo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galindo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernaez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quetglas, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalmau-Mena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, C.</span></span> <span> </span><span class="NLM_article-title">Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine fever virus entry</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e48853</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0048853</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0048853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23133661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslWjsbzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=M.+A.+Cuesta-Geijoauthor=I.+Galindoauthor=B.+Hernaezauthor=J.+I.+Quetglasauthor=I.+Dalmau-Menaauthor=C.+Alonso&title=Endosomal+maturation%2C+Rab7+GTPase+and+phosphoinositides+in+African+swine+fever+virus+entry&doi=10.1371%2Fjournal.pone.0048853"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Endosomal maturation, Rab7 GTPase and phosphoinositides in African swine fever virus entry</span></div><div class="casAuthors">Cuesta-Geijo, Miguel A.; Galindo, Inmaculada; Hernaez, Bruno; Quetglas, Jose Ignacio; Dalmau-Mena, Inmaculada; Alonso, Covadonga</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e48853</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The authors analyzed the dependence of African swine fever virus (ASFV) infection on the integrity of the endosomal pathway.  Using confocal immunofluorescence with antibodies against viral capsid proteins, we found colocalization of incoming viral particles with early endosomes (EE) during the first minutes of infection.  Conversely, viral capsid protein was not detected in acidic late endosomal compartments, multivesicular bodies (MVBs), late endosomes (LEs) or lysosomes (LY).  Using an antibody against a viral inner core protein, we found colocalization of viral cores with late compartments from 30 to 60 min postinfection.  The absence of capsid protein staining in LEs and LYs suggested that virus desencapsidation would take place at the acid pH of these organelles.  In fact, inhibitors of intraluminal acidification of endosomes caused retention of viral capsid staining virions in Rab7 expressing endosomes and more importantly, severely impaired subsequent viral protein prodn.  Endosomal acidification in the first hour after virus entry was essential for successful infection but not thereafter.  In addn., altering the balance of phosphoinositides (PIs) which are responsible of the maintenance of the endocytic pathway impaired ASFV infection.  Early infection steps were dependent on the prodn. of phosphatidylinositol 3-phosphate (PtdIns3P) which is involved in EE maturation and multivesicular body (MVB) biogenesis and on the interconversion of PtdIns3P to phosphatidylinositol 3,5-biphosphate (PtdIns(3,5)P2).  Likewise, GTPase Rab7 activity should remain intact, as well as processes related to LE compartment physiol., which are crucial during early infection.  The data demonstrate that the EE and LE compartments and the integrity of the endosomal maturation pathway orchestrated by Rab proteins and PIs play a central role during early stages of ASFV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQBz20LmA_rVg90H21EOLACvtfcHk0lhZ-F7YkPjzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslWjsbzN&md5=256c351c18985dab5f4002e90b263d75</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0048853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0048853%26sid%3Dliteratum%253Aachs%26aulast%3DCuesta-Geijo%26aufirst%3DM.%2BA.%26aulast%3DGalindo%26aufirst%3DI.%26aulast%3DHernaez%26aufirst%3DB.%26aulast%3DQuetglas%26aufirst%3DJ.%2BI.%26aulast%3DDalmau-Mena%26aufirst%3DI.%26aulast%3DAlonso%26aufirst%3DC.%26atitle%3DEndosomal%2520maturation%252C%2520Rab7%2520GTPase%2520and%2520phosphoinositides%2520in%2520African%2520swine%2520fever%2520virus%2520entry%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0048853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoenen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelotti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewey, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeWald, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp-Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKnight, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span> <span> </span><span class="NLM_article-title">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e0005540</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0005540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pntd.0005540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28403145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&author=E.+A.+Nelsonauthor=J.+Dyallauthor=T.+Hoenenauthor=A.+B.+Barnesauthor=H.+Zhouauthor=J.+Y.+Liangauthor=J.+Michelottiauthor=W.+H.+Deweyauthor=L.+E.+DeWaldauthor=R.+S.+Bennettauthor=P.+J.+Morrisauthor=R.+Guhaauthor=C.+Klumpp-Thomasauthor=C.+McKnightauthor=Y.+C.+Chenauthor=X.+Xuauthor=A.+Wangauthor=E.+Hughesauthor=S.+Martinauthor=C.+Thomasauthor=P.+B.+Jahrlingauthor=L.+E.+Hensleyauthor=G.+G.+Olingerauthor=J.+M.+White&title=The+phosphatidylinositol-3-phosphate+5-kinase+inhibitor+apilimod+blocks+filoviral+entry+and+infection&doi=10.1371%2Fjournal.pntd.0005540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection</span></div><div class="casAuthors">Nelson, Elizabeth A.; Dyall, Julie; Hoenen, Thomas; Barnes, Alyson B.; Zhou, Huanying; Liang, Janie Y.; Michelotti, Julia; Dewey, William H.; DeWald, Lisa Evans; Bennett, Richard S.; Morris, Patrick J.; Guha, Rajarshi; Klumpp-Thomas, Carleen; McKnight, Crystal; Chen, Yu-Chi; Xu, Xin; Wang, Amy; Hughes, Emma; Martin, Scott; Thomas, Craig; Jahrling, Peter B.; Hensley, Lisa E.; Olinger, Gene G. Jr.; White, Judith M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e0005540/1-e0005540/22</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is a lipid kinase involved in endosome maturation that emerged from a haploid genetic screen as being required for Ebola virus (EBOV) infection.  Here we analyzed the effects of apilimod, a PIKfyve inhibitor that was reported to be well tolerated in humans in phase 2 clin. trials, for its effects on entry and infection of EBOV and Marburg virus (MARV).  We first found that apilimod blocks infections by EBOV and MARV in Huh 7, Vero E6 and primary human macrophage cells, with notable potency in the macrophages (IC50, 10 nM).  We next obsd. that similar doses of apilimod block EBOV-glycoprotein-virus like particle (VLP) entry and transcription-replication competent VLP infection, suggesting that the primary mode of action of apilimod is as an entry inhibitor, preventing release of the viral genome into the cytoplasm to initiate replication.  After providing evidence that the anti-EBOV action of apilimod is via PIKfyve, we showed that it blocks trafficking of EBOV VLPs to endolysosomes contg. Niemann-Pick C1 (NPC1), the intracellular receptor for EBOV.  Concurrently apilimod caused VLPs to accumulate in early endosome antigen 1-pos. endosomes.  We did not detect any effects of apilimod on bulk endosome acidification, on the activity of cathepsins B and L, or on cholesterol export from endolysosomes.  Hence by antagonizing PIKfyve, apilimod appears to block EBOV trafficking to its site of fusion and entry into the cytoplasm.  Given the drug's obsd. anti-filoviral activity, relatively unexplored mechanism of entry inhibition, and reported tolerability in humans, we propose that apilimod be further explored as part of a therapeutic regimen to treat filoviral infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlUaAMvLkQT7Vg90H21EOLACvtfcHk0lhZ-F7YkPjzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWrsb3O&md5=c2f72fa69b941bcc8c97dcacf0e210bd</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0005540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0005540%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DE.%2BA.%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DHoenen%26aufirst%3DT.%26aulast%3DBarnes%26aufirst%3DA.%2BB.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BY.%26aulast%3DMichelotti%26aufirst%3DJ.%26aulast%3DDewey%26aufirst%3DW.%2BH.%26aulast%3DDeWald%26aufirst%3DL.%2BE.%26aulast%3DBennett%26aufirst%3DR.%2BS.%26aulast%3DMorris%26aufirst%3DP.%2BJ.%26aulast%3DGuha%26aufirst%3DR.%26aulast%3DKlumpp-Thomas%26aufirst%3DC.%26aulast%3DMcKnight%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DY.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DC.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520phosphatidylinositol-3-phosphate%25205-kinase%2520inhibitor%2520apilimod%2520blocks%2520filoviral%2520entry%2520and%2520infection%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2017%26volume%3D11%26doi%3D10.1371%2Fjournal.pntd.0005540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothlauf, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soh, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cureton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamond, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, S. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">20803</span>– <span class="NLM_lpage">20813</span>, <span class="refDoi"> DOI: 10.1073/pnas.2007837117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1073%2Fpnas.2007837117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32764148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2020&pages=20803-20813&author=Y.+L.+Kangauthor=Y.+Y.+Chouauthor=P.+W.+Rothlaufauthor=Z.+Liuauthor=T.+K.+Sohauthor=D.+Curetonauthor=J.+B.+Caseauthor=R.+E.+Chenauthor=M.+S.+Diamondauthor=S.+P.+J.+Whelanauthor=T.+Kirchhausen&title=Inhibition+of+PIKfyve+kinase+prevents+infection+by+Zaire+ebolavirus+and+SARS-CoV-2&doi=10.1073%2Fpnas.2007837117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2</span></div><div class="casAuthors">Kang, Yuan-Lin; Chou, Yi-ying; Rothlauf, Paul W.; Liu, Zhuoming; Soh, Timothy K.; Cureton, David; Case, James Brett; Chen, Rita E.; Diamond, Michael S.; Whelan, Sean P. J.; Kirchhausen, Tom</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">20803-20813</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Virus entry is a multistep process.  It initiates when the virus attaches to the host cell and ends when the viral contents reach the cytosol.  Genetically unrelated viruses can subvert analogous subcellular mechanisms and use similar trafficking pathways for successful entry.  Antiviral strategies targeting early steps of infection are therefore appealing, particularly when the probability for successful interference through a common step is highest.  We describe here potent inhibitory effects on content release and infection by chimeric vesicular stomatitis virus (VSV) contg. the envelope proteins of Zaire ebolavirus (VSV-ZEBOV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (VSV-SARS-CoV-2) elicited by Apilimod and Vacuolin-1, small-mol. inhibitors of the main endosomal phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, PIKfyve.  We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.  These results define tools for studying the intracellular trafficking of pathogens elicited by inhibition of PIKfyve kinase and suggest the potential for targeting this kinase in developing small-mol. antivirals against SARS-CoV-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYcbVh--KCN7Vg90H21EOLACvtfcHk0lhZ-F7YkPjzzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1KhtbnP&md5=a7e1b43b16edffb6dabc91258b88ab7c</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1073%2Fpnas.2007837117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.2007837117%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DY.%2BL.%26aulast%3DChou%26aufirst%3DY.%2BY.%26aulast%3DRothlauf%26aufirst%3DP.%2BW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DSoh%26aufirst%3DT.%2BK.%26aulast%3DCureton%26aufirst%3DD.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DChen%26aufirst%3DR.%2BE.%26aulast%3DDiamond%26aufirst%3DM.%2BS.%26aulast%3DWhelan%26aufirst%3DS.%2BP.%2BJ.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DInhibition%2520of%2520PIKfyve%2520kinase%2520prevents%2520infection%2520by%2520Zaire%2520ebolavirus%2520and%2520SARS-CoV-2%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2020%26volume%3D117%26spage%3D20803%26epage%3D20813%26doi%3D10.1073%2Fpnas.2007837117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruchez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filone, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ory, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, J.</span></span> <span> </span><span class="NLM_article-title">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>477</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1038/nature10380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnature10380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21866101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=477&publication_year=2011&pages=344-348&author=M.+Coteauthor=J.+Misasiauthor=T.+Renauthor=A.+Bruchezauthor=K.+Leeauthor=C.+M.+Filoneauthor=L.+Hensleyauthor=Q.+Liauthor=D.+Oryauthor=K.+Chandranauthor=J.+Cunningham&title=Small+molecule+inhibitors+reveal+Niemann-Pick+C1+is+essential+for+Ebola+virus+infection&doi=10.1038%2Fnature10380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection</span></div><div class="casAuthors">Cote, Marceline; Misasi, John; Ren, Tao; Bruchez, Anna; Lee, Kyung-Ae; Filone, Claire Marie; Hensley, Lisa; Li, Qi; Ory, Daniel; Chandran, Kartik; Cunningham, James</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">477</span>
        (<span class="NLM_cas:issue">7364</span>),
    <span class="NLM_cas:pages">344-348</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Ebola virus (EboV) is a highly pathogenic enveloped virus that causes outbreaks of zoonotic infection in Africa.  The clin. symptoms are manifestations of the massive prodn. of pro-inflammatory cytokines in response to infection and in many outbreaks, mortality exceeds 75%.  The unpredictable onset, ease of transmission, rapid progression of disease, high mortality and lack of effective vaccine or therapy have created a high level of public concern about EboV.  Here, the authors report the identification of a novel benzylpiperazine adamantane diamide-derived compd. that inhibits EboV infection.  Using mutant cell lines and informative derivs. of the lead compd., they show that the target of the inhibitor is the endosomal membrane protein Niemann-Pick C1 (NPC1).  They find that NPC1 is essential for infection, that it binds to the virus glycoprotein (GP), and that antiviral compds. interfere with GP binding to NPC1.  Combined with the results of previous studies on GP structure and function, these findings support a model of EboV infection in which cleavage of the GP1 subunit by endosomal cathepsin proteases removes heavily glycosylated domains to expose the amino-terminal domain, which is a ligand for NPC1 and regulates membrane fusion by the GP2 subunit.  Thus, NPC1 is essential for EboV entry and a target for antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH09MFk31Ol7Vg90H21EOLACvtfcHk0liGGnfOhr_vYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFers7%252FI&md5=99e7763b2b95af9d046992a9d36fd3a2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1038%2Fnature10380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10380%26sid%3Dliteratum%253Aachs%26aulast%3DCote%26aufirst%3DM.%26aulast%3DMisasi%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DBruchez%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DFilone%26aufirst%3DC.%2BM.%26aulast%3DHensley%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DOry%26aufirst%3DD.%26aulast%3DChandran%26aufirst%3DK.%26aulast%3DCunningham%26aufirst%3DJ.%26atitle%3DSmall%2520molecule%2520inhibitors%2520reveal%2520Niemann-Pick%2520C1%2520is%2520essential%2520for%2520Ebola%2520virus%2520infection%26jtitle%3DNature%26date%3D2011%26volume%3D477%26spage%3D344%26epage%3D348%26doi%3D10.1038%2Fnature10380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozak, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warkentin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salambanga, F. D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobinger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobasa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, M.</span></span> <span> </span><span class="NLM_article-title">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1016/j.virol.2017.09.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.virol.2017.09.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=29031163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2018&pages=17&author=S.+Qiuauthor=A.+Leungauthor=Y.+Boauthor=R.+A.+Kozakauthor=S.+P.+Anandauthor=C.+Warkentinauthor=F.+D.+R.+Salambangaauthor=J.+Cuiauthor=G.+Kobingerauthor=D.+Kobasaauthor=M.+Cote&title=Ebola+virus+requires+phosphatidylinositol+%283%2C5%29+bisphosphate+production+for+efficient+viral+entry&doi=10.1016%2Fj.virol.2017.09.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry</span></div><div class="casAuthors">Qiu, Shirley; Leung, Anders; Bo, Yuxia; Kozak, Robert A.; Anand, Sai Priya; Warkentin, Corina; Salambanga, Fabiola D. R.; Cui, Jennifer; Kobinger, Gary; Kobasa, Darwyn; Cote, Marceline</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-28</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">For entry, Ebola virus (EBOV) requires the interaction of its viral glycoprotein with the cellular protein Niemann-Pick C1 (NPC1) which resides in late endosomes and lysosomes.  How EBOV is trafficked and delivered to NPC1 and whether this is pos. regulated during entry remain unclear.  Here, we show that the PIKfyve-ArPIKfyve-Sac3 cellular complex, which is involved in the metab. of phosphatidylinositol (3,5) bisphosphate (PtdIns(3,5)P2), is crit. for EBOV infection.  Although the expression of all subunits of the complex was required for efficient entry, PIKfyve kinase activity was specifically crit. for entry by all pathogenic filoviruses.  Inhibition of PIKfyve prevented colocalization of EBOV with NPC1 and led to virus accumulation in intracellular vesicles with characteristics of early endosomes.  Importantly, genetically-encoded phosphoinositide probes revealed an increase in PtdIns(3,5)P2-pos. vesicles in cells during EBOV entry.  Taken together, our studies suggest that EBOV requires PtdIns(3,5)P2 prodn. in cells to promote efficient delivery to NPC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBj4bGDkDZELVg90H21EOLACvtfcHk0liGGnfOhr_vYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1GlsrbI&md5=1a0bed541a6186ca937abcc2cabc4bb6</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2017.09.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2017.09.028%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DS.%26aulast%3DLeung%26aufirst%3DA.%26aulast%3DBo%26aufirst%3DY.%26aulast%3DKozak%26aufirst%3DR.%2BA.%26aulast%3DAnand%26aufirst%3DS.%2BP.%26aulast%3DWarkentin%26aufirst%3DC.%26aulast%3DSalambanga%26aufirst%3DF.%2BD.%2BR.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DKobinger%26aufirst%3DG.%26aulast%3DKobasa%26aufirst%3DD.%26aulast%3DCote%26aufirst%3DM.%26atitle%3DEbola%2520virus%2520requires%2520phosphatidylinositol%2520%25283%252C5%2529%2520bisphosphate%2520production%2520for%2520efficient%2520viral%2520entry%26jtitle%3DVirology%26date%3D2018%26volume%3D513%26spage%3D17%26doi%3D10.1016%2Fj.virol.2017.09.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine-Weber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiergens, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlmann, S.</span></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">280</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.cell.2020.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32142651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=271-280&author=M.+Hoffmannauthor=H.+Kleine-Weberauthor=S.+Schroederauthor=N.+Krugerauthor=T.+Herrlerauthor=S.+Erichsenauthor=T.+S.+Schiergensauthor=G.+Herrlerauthor=N.+H.+Wuauthor=A.+Nitscheauthor=M.+A.+Mullerauthor=C.+Drostenauthor=S.+Pohlmann&title=SARS-CoV-2+cell+entry+depends+on+ACE2+and+TMPRSS2+and+is+blocked+by+a+clinically+proven+protease+inhibitor&doi=10.1016%2Fj.cell.2020.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span></div><div class="casAuthors">Hoffmann, Markus; Kleine-Weber, Hannah; Schroeder, Simon; Krueger, Nadine; Herrler, Tanja; Erichsen, Sandra; Schiergens, Tobias S.; Herrler, Georg; Wu, Nai-Huei; Nitsche, Andreas; Mueller, Marcel A.; Drosten, Christian; Poehlmann, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280.e8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency.  Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases.  Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets.  Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.  A TMPRSS2 inhibitor approved for clin. use blocked entry and might constitute a treatment option.  Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry.  Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq92X1lVQaLirVg90H21EOLACvtfcHk0liDDq3m_rZONQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D&md5=60aea5c939a2d4df034a91d6198fb3ef</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DKleine-Weber%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DKruger%26aufirst%3DN.%26aulast%3DHerrler%26aufirst%3DT.%26aulast%3DErichsen%26aufirst%3DS.%26aulast%3DSchiergens%26aufirst%3DT.%2BS.%26aulast%3DHerrler%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DN.%2BH.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%2BA.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DPohlmann%26aufirst%3DS.%26atitle%3DSARS-CoV-2%2520cell%2520entry%2520depends%2520on%2520ACE2%2520and%2520TMPRSS2%2520and%2520is%2520blocked%2520by%2520a%2520clinically%2520proven%2520protease%2520inhibitor%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D271%26epage%3D280%26doi%3D10.1016%2Fj.cell.2020.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasilieva, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berne, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somasundaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzuriaga, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenough, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farzan, M.</span></span> <span> </span><span class="NLM_article-title">Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">454</span>, <span class="refDoi"> DOI: 10.1038/nature02145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnature02145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=14647384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1GlsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=450-454&author=W.+Liauthor=M.+J.+Mooreauthor=N.+Vasilievaauthor=J.+Suiauthor=S.+K.+Wongauthor=M.+A.+Berneauthor=M.+Somasundaranauthor=J.+L.+Sullivanauthor=K.+Luzuriagaauthor=T.+C.+Greenoughauthor=H.+Choeauthor=M.+Farzan&title=Angiotensin-converting+enzyme+2+is+a+functional+receptor+for+the+SARS+coronavirus&doi=10.1038%2Fnature02145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</span></div><div class="casAuthors">Li, Wenhui; Moore, Michael J.; Vasilieva, Natalya; Sui, Jianhua; Wong, Swee Kee; Berne, Michael A.; Somasundaran, Mohan; Sullivan, John L.; Luzuriaga, Katherine; Greenough, Thomas C.; Choe, Hyeryun; Farzan, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6965</span>),
    <span class="NLM_cas:pages">450-454</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), assoc. with cellular receptors to mediate infection of their target cells.  Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SARS coronavirus (SARS-CoV)-permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein.  We found that a sol. form of ACE2, but not of the related enzyme ACE1, blocked assocn. of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein.  Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells.  Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells.  Together our data indicate that ACE2 is a functional receptor for SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqK17Cf3rQS7Vg90H21EOLACvtfcHk0liDDq3m_rZONQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1GlsLs%253D&md5=884851c53d0f77cbdd6520aaa79efbed</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1038%2Fnature02145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02145%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMoore%26aufirst%3DM.%2BJ.%26aulast%3DVasilieva%26aufirst%3DN.%26aulast%3DSui%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%2BK.%26aulast%3DBerne%26aufirst%3DM.%2BA.%26aulast%3DSomasundaran%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DJ.%2BL.%26aulast%3DLuzuriaga%26aufirst%3DK.%26aulast%3DGreenough%26aufirst%3DT.%2BC.%26aulast%3DChoe%26aufirst%3DH.%26aulast%3DFarzan%26aufirst%3DM.%26atitle%3DAngiotensin-converting%2520enzyme%25202%2520is%2520a%2520functional%2520receptor%2520for%2520the%2520SARS%2520coronavirus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D450%26epage%3D454%26doi%3D10.1038%2Fnature02145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgonovo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumperman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meldolesi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeil, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">The small chemical vacuolin-1 inhibits Ca(2+)-dependent lysosomal exocytosis but not cell resealing</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">888</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7400243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fsj.embor.7400243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15332114" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2cXot1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=883-888&author=J.+Cernyauthor=Y.+Fengauthor=A.+Yuauthor=K.+Miyakeauthor=B.+Borgonovoauthor=J.+Klumpermanauthor=J.+Meldolesiauthor=P.+L.+McNeilauthor=T.+Kirchhausen&title=The+small+chemical+vacuolin-1+inhibits+Ca%282%2B%29-dependent+lysosomal+exocytosis+but+not+cell+resealing&doi=10.1038%2Fsj.embor.7400243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">The small chemical vacuolin-1 inhibits Ca2+-dependent lysosomal exocytosis but not cell resealing</span></div><div class="casAuthors">Cerny, Jan; Feng, Yan; Yu, Anan; Miyake, Katsuya; Borgonovo, Barbara; Klumperman, Judith; Meldolesi, Jacopo; McNeil, Paul L.; Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">883-888</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Resealing after wounding, the process of repair following plasma membrane damage, requires exocytosis.  Vacuolins are mols. that induce rapid formation of large, swollen structures derived from endosomes and lysosomes by homotypic fusion combined with uncontrolled fusion of the inner and limiting membranes of these organelles.  Vacuolin-1, the most potent compd., blocks the Ca2+-dependent exocytosis of lysosomes induced by ionomycin or plasma membrane wounding, without affecting the process of resealing.  In contrast, other cell structures and membrane trafficking functions including exocytosis of enlargeosomes are unaffected.  Because cells heal normally in the presence of vacuolin-1, we suggest that lysosomes are dispensable for resealing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx4hEOqmL3SbVg90H21EOLACvtfcHk0liiawuT5darRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXot1Kgtro%253D&md5=bf07123ddc68d80d585e8066914f6a0c</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7400243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7400243%26sid%3Dliteratum%253Aachs%26aulast%3DCerny%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DA.%26aulast%3DMiyake%26aufirst%3DK.%26aulast%3DBorgonovo%26aufirst%3DB.%26aulast%3DKlumperman%26aufirst%3DJ.%26aulast%3DMeldolesi%26aufirst%3DJ.%26aulast%3DMcNeil%26aufirst%3DP.%2BL.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DThe%2520small%2520chemical%2520vacuolin-1%2520inhibits%2520Ca%25282%252B%2529-dependent%2520lysosomal%2520exocytosis%2520but%2520not%2520cell%2520resealing%26jtitle%3DEMBO%2520Rep.%26date%3D2004%26volume%3D5%26spage%3D883%26epage%3D888%26doi%3D10.1038%2Fsj.embor.7400243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Blanc, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luyet, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pons, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petiot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayran, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demaurex, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faure, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadoul, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parton, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruenberg, J.</span></span> <span> </span><span class="NLM_article-title">Endosome-to-cytosol transport of viral nucleocapsids</span>. <i>Nat. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">664</span>, <span class="refDoi"> DOI: 10.1038/ncb1269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fncb1269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=15951806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlslWhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=653-664&author=I.+Le+Blancauthor=P.+P.+Luyetauthor=V.+Ponsauthor=C.+Fergusonauthor=N.+Emansauthor=A.+Petiotauthor=N.+Mayranauthor=N.+Demaurexauthor=J.+Faureauthor=R.+Sadoulauthor=R.+G.+Partonauthor=J.+Gruenberg&title=Endosome-to-cytosol+transport+of+viral+nucleocapsids&doi=10.1038%2Fncb1269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Endosome-to-cytosol transport of viral nucleocapsids</span></div><div class="casAuthors">Le Blanc, Isabelle; Luyet, Pierre-Philippe; Pons, Veronique; Ferguson, Charles; Emans, Neil; Petiot, Anne; Mayran, Nathalie; Demaurex, Nicolas; Faure, Julien; Sadoul, Remy; Parton, Robert G.; Gruenberg, J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">653-664</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">During viral infection, fusion of the viral envelope with endosomal membranes and nucleocapsid release were thought to be concomitant events.  We show here that for the vesicular stomatitis virus they occur sequentially, at two successive steps of the endocytic pathway.  Fusion already occurs in transport intermediates between early and late endosomes, presumably releasing the nucleocapsid within the lumen of intra-endosomal vesicles, where it remains hidden.  Transport to late endosomes is then required for the nucleocapsid to be delivered to the cytoplasm.  This last step, which initiates infection, depends on the late endosomal lipid lysobisphosphatidic acid (LBPA) and its putative effector Alix/AIP1, and is regulated by phosphatidylinositol-3-phosphate (PtdIns(3)P) signaling via the PtdIns(3)P-binding protein Snx16.  We conclude that the nucleocapsid is exported into the cytoplasm after the back-fusion of internal vesicles with the limiting membrane of late endosomes, and that this process is controlled by the phospholipids LBPA and PtdIns(3)P and their effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy7VMWqmq1Y7Vg90H21EOLACvtfcHk0liiawuT5darRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlslWhtLw%253D&md5=f6e1e7a16b55f62007b6767844fba82e</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1038%2Fncb1269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1269%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBlanc%26aufirst%3DI.%26aulast%3DLuyet%26aufirst%3DP.%2BP.%26aulast%3DPons%26aufirst%3DV.%26aulast%3DFerguson%26aufirst%3DC.%26aulast%3DEmans%26aufirst%3DN.%26aulast%3DPetiot%26aufirst%3DA.%26aulast%3DMayran%26aufirst%3DN.%26aulast%3DDemaurex%26aufirst%3DN.%26aulast%3DFaure%26aufirst%3DJ.%26aulast%3DSadoul%26aufirst%3DR.%26aulast%3DParton%26aufirst%3DR.%2BG.%26aulast%3DGruenberg%26aufirst%3DJ.%26atitle%3DEndosome-to-cytosol%2520transport%2520of%2520viral%2520nucleocapsids%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D653%26epage%3D664%26doi%3D10.1038%2Fncb1269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sands, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylwestrowicz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dryden, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenbloom, S.</span></span> <span> </span><span class="NLM_article-title">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn’s disease</span>. <i>Inflamm. Bowel Dis.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1209</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1002/ibd.21159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Fibd.21159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19918967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1209-1218&author=B.+E.+Sandsauthor=E.+W.+Jacobsonauthor=T.+Sylwestrowiczauthor=Z.+Younesauthor=G.+Drydenauthor=R.+Fedorakauthor=S.+Greenbloom&title=Randomized%2C+double-blind%2C+placebo-controlled+trial+of+the+oral+interleukin-12%2F23+inhibitor+apilimod+mesylate+for+treatment+of+active+Crohn%E2%80%99s+disease&doi=10.1002%2Fibd.21159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease</span></div><div class="casAuthors">Sands Bruce E; Jacobson Eric W; Sylwestrowicz Thomas; Younes Ziad; Dryden Gerald; Fedorak Richard; Greenbloom Susan</div><div class="citationInfo"><span class="NLM_cas:title">Inflammatory bowel diseases</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1209-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Interleukin-12 (IL-12) and interleukin-23 (IL-23) are inflammatory cytokines linked to the Th-1 and Th-17 phenotypes associated with Crohn's disease (CD).  We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD.  METHODS:  We performed a multicenter, Phase 2, randomized, double-blinded, placebo-controlled study to evaluate the efficacy of apilimod mesylate in treating 220 adult patients with moderate-to-severe CD (Crohn's Disease Activity Index [CDAI] score 220-450).  Patients were stratified according to C-reactive protein (CRP) levels and corticosteroid use and were randomly assigned to receive placebo or apilimod mesylate 50 mg daily or 100 mg daily.  The study was divided into an induction phase (43 days) and a maintenance phase (125 days).  The primary analysis involved a comparison of the proportion of patients experiencing clinical response, defined as at least a 100-point decrease in CDAI score from baseline at day 29.  Data on adverse events were also collected.  RESULTS:  In all, 220 of the planned 282 patients were enrolled when the Data Monitoring Committee determined that the drug was not efficacious as a treatment and closed enrollment.  A clinical response was experienced by 18 patients (24.7%) in the 50-mg daily (QD) group (n = 73) and 19 patients (25.7%) in the 100 mg QD group (n = 74), as compared with 21 patients (28.8%) in the placebo group (n = 73) on day 29 (P = 0.71 for each comparison).  No significant adverse safety signal was observed.  CONCLUSIONS:  Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKP1Ngip31hrrIbt-tGZmxfW6udTcc2eZtzuFrmSGsu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3crhsFSqsg%253D%253D&md5=4e87fe88e4b06cb7a47d7554a6597a4a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fibd.21159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fibd.21159%26sid%3Dliteratum%253Aachs%26aulast%3DSands%26aufirst%3DB.%2BE.%26aulast%3DJacobson%26aufirst%3DE.%2BW.%26aulast%3DSylwestrowicz%26aufirst%3DT.%26aulast%3DYounes%26aufirst%3DZ.%26aulast%3DDryden%26aufirst%3DG.%26aulast%3DFedorak%26aufirst%3DR.%26aulast%3DGreenbloom%26aufirst%3DS.%26atitle%3DRandomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%2520of%2520the%2520oral%2520interleukin-12%252F23%2520inhibitor%2520apilimod%2520mesylate%2520for%2520treatment%2520of%2520active%2520Crohn%25E2%2580%2599s%2520disease%26jtitle%3DInflamm.%2520Bowel%2520Dis.%26date%3D2010%26volume%3D16%26spage%3D1209%26epage%3D1218%26doi%3D10.1002%2Fibd.21159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardinale, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khatcherian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatsuta, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsoum, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, J. G.</span></span> <span> </span><span class="NLM_article-title">Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e35069</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0035069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.pone.0035069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22493730" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvVyqu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=Y.+Wadaauthor=I.+Cardinaleauthor=A.+Khatcherianauthor=J.+Chuauthor=A.+B.+Kantorauthor=A.+B.+Gottliebauthor=N.+Tatsutaauthor=E.+Jacobsonauthor=J.+Barsoumauthor=J.+G.+Krueger&title=Apilimod+inhibits+the+production+of+IL-12+and+IL-23+and+reduces+dendritic+cell+infiltration+in+psoriasis&doi=10.1371%2Fjournal.pone.0035069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis</span></div><div class="casAuthors">Wada, Yumiko; Cardinale, Irma; Khatcherian, Artemis; Chu, John; Kantor, Aaron B.; Gottlieb, Alice B.; Tatsuta, Noriaki; Jacobson, Eric; Barsoum, James; Krueger, James G.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e35069</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Psoriasis is characterized by hyperplasia of the epidermis and infiltration of leukocytes into both the dermis and epidermis.  IL-23, a key cytokine that induces TH17 cells, has been found to play a crit. role in the pathogenesis of psoriasis.  Apilimod is a small-mol. compd. that selectively suppresses synthesis of IL-12 and IL-23.  An open-label clin. study of oral administration of apilimod was conducted in patients with psoriasis.  Substantial improvements in histol. and clin. measurements were obsd. in patients receiving 70mg QD.  The expression of IL-23p19 and IL-12/IL-23p40 in skin lesions was significantly reduced in this dose group, with a simultaneous increase in IL-10 obsd.  A decrease in the levels of TH1 and TH17 cytokines/chemokines in skin lesions followed these p19 and p40 changes.  In parallel, a redn. in skin-infiltrating CD11c+ dendritic cells and CD3+ T cells was seen, with a greater decrease in the CD11c+ population.  This was accompanied by increases in T and B cells, and decreases in neutrophils and eosinophils in the periphery.  This study demonstrates the immunomodulatory activity of apilimod and provides clin. evidence supporting the inhibition of IL-12/IL-23 synthesis for the treatment of TH1- and TH17-mediated inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxAQtGmEdUGbVg90H21EOLACvtfcHk0lhHZ0OYoeCj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvVyqu7c%253D&md5=18f569c46e0e86ee9167ceb96cce2b49</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0035069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0035069%26sid%3Dliteratum%253Aachs%26aulast%3DWada%26aufirst%3DY.%26aulast%3DCardinale%26aufirst%3DI.%26aulast%3DKhatcherian%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DKantor%26aufirst%3DA.%2BB.%26aulast%3DGottlieb%26aufirst%3DA.%2BB.%26aulast%3DTatsuta%26aufirst%3DN.%26aulast%3DJacobson%26aufirst%3DE.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DKrueger%26aufirst%3DJ.%2BG.%26atitle%3DApilimod%2520inhibits%2520the%2520production%2520of%2520IL-12%2520and%2520IL-23%2520and%2520reduces%2520dendritic%2520cell%2520infiltration%2520in%2520psoriasis%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0035069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sano, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazetani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span> <span> </span><span class="NLM_article-title">Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>590</i></span>,  <span class="NLM_fpage">1576</span>– <span class="NLM_lpage">1585</span>, <span class="refDoi"> DOI: 10.1002/1873-3468.12195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2F1873-3468.12195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27135648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KrurfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=590&publication_year=2016&pages=1576-1585&author=O.+Sanoauthor=K.+Kazetaniauthor=M.+Funataauthor=Y.+Fukudaauthor=J.+Matsuiauthor=H.+Iwata&title=Vacuolin-1+inhibits+autophagy+by+impairing+lysosomal+maturation+via+PIKfyve+inhibition&doi=10.1002%2F1873-3468.12195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Vacuolin-1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition</span></div><div class="casAuthors">Sano, Osamu; Kazetani, Kenichi; Funata, Masaaki; Fukuda, Yasunori; Matsui, Junji; Iwata, Hidehisa</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">590</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1576-1585</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Lysosomal protein degrdn. via autophagy strictly regulates cellular protein homoeostasis.  Here, the authors performed high-content screening to identify compds. that inhibit autophagy pathways.  The authors obtained 11 hit compds. and performed cluster anal. using cellular morphol. information.  Vacuolin-1, which induces the formation of giant vacuoles and is a target unknown compd., clustered with known phosphatidylinositol inositol kinase PIKfyve inhibitor YM 201636.  The authors further confirmed that vacuolin-1 is a potent PIKfyve inhibitor, and finally concluded that PIKfyve inhibitors are novel chem. tools for regulating autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK_2ltJVHVo7Vg90H21EOLACvtfcHk0lhHZ0OYoeCj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KrurfO&md5=6be36200b98fce892f0be438731ddf9d</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1002%2F1873-3468.12195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1873-3468.12195%26sid%3Dliteratum%253Aachs%26aulast%3DSano%26aufirst%3DO.%26aulast%3DKazetani%26aufirst%3DK.%26aulast%3DFunata%26aufirst%3DM.%26aulast%3DFukuda%26aufirst%3DY.%26aulast%3DMatsui%26aufirst%3DJ.%26aulast%3DIwata%26aufirst%3DH.%26atitle%3DVacuolin-1%2520inhibits%2520autophagy%2520by%2520impairing%2520lysosomal%2520maturation%2520via%2520PIKfyve%2520inhibition%26jtitle%3DFEBS%2520Lett.%26date%3D2016%26volume%3D590%26spage%3D1576%26epage%3D1585%26doi%3D10.1002%2F1873-3468.12195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurevich, E. V.</span></span> <span> </span><span class="NLM_article-title">GPCR signaling regulation: the role of GRKs and arrestins</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">125</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00125</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2019.00125" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30837883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaktLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=125&author=V.+V.+Gurevichauthor=E.+V.+Gurevich&title=GPCR+signaling+regulation%3A+the+role+of+GRKs+and+arrestins&doi=10.3389%2Ffphar.2019.00125"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR signaling regulation: the role of GRKs and arrestins</span></div><div class="casAuthors">Gurevich, Vsevolod V.; Gurevich, Eugenia V.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">125</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Every animal species expresses hundreds of different G protein-coupled receptors (GPCRs) that respond to a wide variety of external stimuli.  GPCRs-driven signaling pathways are involved in pretty much every physiol. function and in many pathologies.  Therefore, GPCRs are targeted by about a third of clin. used drugs.  The signaling of most GPCRs via G proteins is terminated by the phosphorylation of active receptor by specific kinases (GPCR kinases, or GRKs) and subsequent binding of arrestin proteins, that selectively recognize active phosphorylated receptors.  In addn., GRKs and arrestins play a role in multiple signaling pathways in the cell, both GPCR-initiated and receptor-independent.  Here we focus on the mechanisms of GRK- and arrestin-mediated regulation of GPCR signaling, which includes homologous desensitization and redirection of signaling to addnl. pathways by bound arrestins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq199I_nwuu6LVg90H21EOLACvtfcHk0lhHZ0OYoeCj2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaktLzJ&md5=bd1f9e684e6cad5d0c4fdd59bd955e72</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00125%26sid%3Dliteratum%253Aachs%26aulast%3DGurevich%26aufirst%3DV.%2BV.%26aulast%3DGurevich%26aufirst%3DE.%2BV.%26atitle%3DGPCR%2520signaling%2520regulation%253A%2520the%2520role%2520of%2520GRKs%2520and%2520arrestins%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D125%26doi%3D10.3389%2Ffphar.2019.00125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colicelli, J.</span></span> <span> </span><span class="NLM_article-title">ABL tyrosine kinases: evolution of function, regulation, and specificity</span>. <i>Sci. Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">re6</span> <span class="refDoi"> DOI: 10.1126/scisignal.3139re6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1126%2Fscisignal.3139re6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20841568" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&author=J.+Colicelli&title=ABL+tyrosine+kinases%3A+evolution+of+function%2C+regulation%2C+and+specificity&doi=10.1126%2Fscisignal.3139re6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.3139re6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.3139re6%26sid%3Dliteratum%253Aachs%26aulast%3DColicelli%26aufirst%3DJ.%26atitle%3DABL%2520tyrosine%2520kinases%253A%2520evolution%2520of%2520function%252C%2520regulation%252C%2520and%2520specificity%26jtitle%3DSci.%2520Signaling%26date%3D2010%26volume%3D3%26doi%3D10.1126%2Fscisignal.3139re6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyall, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kindrachuk, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olinger, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jahrling, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laidlaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lear-Rooney, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hensley, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieman, M. B.</span></span> <span> </span><span class="NLM_article-title">Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4885</span>– <span class="NLM_lpage">4893</span>, <span class="refDoi"> DOI: 10.1128/AAC.03036-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FAAC.03036-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24841273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=4885-4893&author=J.+Dyallauthor=C.+M.+Colemanauthor=B.+J.+Hartauthor=T.+Venkataramanauthor=M.+R.+Holbrookauthor=J.+Kindrachukauthor=R.+F.+Johnsonauthor=G.+G.+Olingerauthor=P.+B.+Jahrlingauthor=M.+Laidlawauthor=L.+M.+Johansenauthor=C.+M.+Lear-Rooneyauthor=P.+J.+Glassauthor=L.+E.+Hensleyauthor=M.+B.+Frieman&title=Repurposing+of+clinically+developed+drugs+for+treatment+of+middle+east+respiratory+syndrome+coronavirus+infection&doi=10.1128%2FAAC.03036-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</span></div><div class="casAuthors">Dyall, Julie; Coleman, Christopher M.; Hart, Brit J.; Venkataraman, Thiagarajan; Holbrook, Michael R.; Kindrachuk, Jason; Johnson, Reed F.; Olinger, Gene G.; Jahrling, Peter B.; Laidlaw, Monique; Johansen, Lisa M.; Lear-Rooney, Calli M.; Glass, Pamela J.; Hensley, Lisa E.; Frieman, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4885-4893, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacol. treatments in the clinic with little time available for drug testing and development.  Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options.  Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers and funding agencies.  Given the development times and manufg. requirements for new products, repurposing of existing drugs is likely the only soln. for outbreaks due to emerging viruses.  In the studies described here, a library of 290 compds. was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV).  Selection of compds. for inclusion in the library was dependent on current or previous FDA approval or advanced clin. development.  Some drugs that had a well-defined cellular pathway as target were included.  In total, 27 compds. with activity against both MERS-CoV and SARS-CoV were identified.  The compds. belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics.  The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpE_PH7j54pPrVg90H21EOLACvtfcHk0lhjeFCSKJ7MvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1art73L&md5=4cd7f71c09de4c1965b7c6f42f3ae2ce</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1128%2FAAC.03036-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.03036-14%26sid%3Dliteratum%253Aachs%26aulast%3DDyall%26aufirst%3DJ.%26aulast%3DColeman%26aufirst%3DC.%2BM.%26aulast%3DHart%26aufirst%3DB.%2BJ.%26aulast%3DVenkataraman%26aufirst%3DT.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DKindrachuk%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DR.%2BF.%26aulast%3DOlinger%26aufirst%3DG.%2BG.%26aulast%3DJahrling%26aufirst%3DP.%2BB.%26aulast%3DLaidlaw%26aufirst%3DM.%26aulast%3DJohansen%26aufirst%3DL.%2BM.%26aulast%3DLear-Rooney%26aufirst%3DC.%2BM.%26aulast%3DGlass%26aufirst%3DP.%2BJ.%26aulast%3DHensley%26aufirst%3DL.%2BE.%26aulast%3DFrieman%26aufirst%3DM.%2BB.%26atitle%3DRepurposing%2520of%2520clinically%2520developed%2520drugs%2520for%2520treatment%2520of%2520middle%2520east%2520respiratory%2520syndrome%2520coronavirus%2520infection%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D4885%26epage%3D4893%26doi%3D10.1128%2FAAC.03036-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Assaad, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Assaad-Khalil, S.</span></span> <span> </span><span class="NLM_article-title">Imatinib a tyrosine kinase inhibitor: a potential treatment for SARS- COV-2 induced pneumonia</span>. <i>Alex. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1080/20905068.2020.1778417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1080%2F20905068.2020.1778417" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2020&pages=68-72&author=H.+S.+Assaadauthor=S.+Assaad-Khalil&title=Imatinib+a+tyrosine+kinase+inhibitor%3A+a+potential+treatment+for+SARS-+COV-2+induced+pneumonia&doi=10.1080%2F20905068.2020.1778417"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1080%2F20905068.2020.1778417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F20905068.2020.1778417%26sid%3Dliteratum%253Aachs%26aulast%3DAssaad%26aufirst%3DH.%2BS.%26aulast%3DAssaad-Khalil%26aufirst%3DS.%26atitle%3DImatinib%2520a%2520tyrosine%2520kinase%2520inhibitor%253A%2520a%2520potential%2520treatment%2520for%2520SARS-%2520COV-2%2520induced%2520pneumonia%26jtitle%3DAlex.%2520J.%2520Med.%26date%3D2020%26volume%3D56%26spage%3D68%26epage%3D72%26doi%3D10.1080%2F20905068.2020.1778417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deininger, M. W.</span></span> <span> </span><span class="NLM_article-title">Imatinib is not a potent anti-SARS-CoV-2 drug</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3085</span>– <span class="NLM_lpage">3087</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-01045-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41375-020-01045-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32999432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2020&pages=3085-3087&author=H.+Zhaoauthor=M.+Mendenhallauthor=M.+W.+Deininger&title=Imatinib+is+not+a+potent+anti-SARS-CoV-2+drug&doi=10.1038%2Fs41375-020-01045-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib is not a potent anti-SARS-CoV-2 drug</span></div><div class="casAuthors">Zhao, Helong; Mendenhall, Michelle; Deininger, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3085-3087</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Imatinib is not a potent anti-SARS-CoV-2 drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC_1Nzxr3RxrVg90H21EOLACvtfcHk0lhjeFCSKJ7MvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSqurvJ&md5=44846fa32deeaf672ba1b8bf2d066b7b</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-01045-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-01045-9%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMendenhall%26aufirst%3DM.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DImatinib%2520is%2520not%2520a%2520potent%2520anti-SARS-CoV-2%2520drug%26jtitle%3DLeukemia%26date%3D2020%26volume%3D34%26spage%3D3085%26epage%3D3087%26doi%3D10.1038%2Fs41375-020-01045-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Touret, F.</span>; <span class="NLM_string-name">Driouich, J.-S.</span>; <span class="NLM_string-name">Cochin, M.</span>; <span class="NLM_string-name">Petit, P. R.</span>; <span class="NLM_string-name">Gilles, M.</span>; <span class="NLM_string-name">Barthélémy, K.</span>; <span class="NLM_string-name">Moureau, G.</span>; <span class="NLM_string-name">Malvy, D.</span>; <span class="NLM_string-name">Solas, C.</span>; <span class="NLM_string-name">De Lamballerie, X.</span>; <span class="NLM_string-name">Nougairède, A.</span></span>, <span> </span><span class="NLM_article-title">Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2</span>.  <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.11.17.386904</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1101%2F2020.11.17.386904" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=32511380" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=F.+Touret&author=J.-S.+Driouich&author=M.+Cochin&author=P.+R.+Petit&author=M.+Gilles&author=K.+Barth%C3%A9l%C3%A9my&author=G.+Moureau&author=D.+Malvy&author=C.+Solas&author=X.+De+Lamballerie&author=A.+Nougair%C3%A8de&title=Preclinical+evaluation+of+Imatinib+does+not+support+its+use+as+an+antiviral+drug+against+SARS-CoV-2&doi=10.1101%2F2020.11.17.386904"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1101%2F2020.11.17.386904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.11.17.386904%26sid%3Dliteratum%253Aachs%26aulast%3DTouret%26aufirst%3DF.%26atitle%3DPreclinical%2520evaluation%2520of%2520Imatinib%2520does%2520not%2520support%2520its%2520use%2520as%2520an%2520antiviral%2520drug%2520against%2520SARS-CoV-2%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.11.17.386904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miduturu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potisopon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojciechowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P. L.</span></span> <span> </span><span class="NLM_article-title">GNF-2 inhibits dengue virus by targeting Abl kinases and the viral E protein</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2016.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.chembiol.2016.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=27105280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=443-452&author=M.+J.+Clarkauthor=C.+Miduturuauthor=A.+G.+Schmidtauthor=X.+Zhuauthor=J.+D.+Pittsauthor=J.+Wangauthor=S.+Potisoponauthor=J.+Zhangauthor=A.+Wojciechowskiauthor=J.+J.+H.+Chuauthor=N.+S.+Grayauthor=P.+L.+Yang&title=GNF-2+inhibits+dengue+virus+by+targeting+Abl+kinases+and+the+viral+E+protein&doi=10.1016%2Fj.chembiol.2016.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein</span></div><div class="casAuthors">Clark, Margaret J.; Miduturu, Chandra; Schmidt, Aaron G.; Zhu, Xuling; Pitts, Jared D.; Wang, Jinhua; Potisopon, Supanee; Zhang, Jianming; Wojciechowski, Amy; Chu, Justin Jang Hann; Gray, Nathanael S.; Yang, Priscilla L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">443-452</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dengue virus infects more than 300 million people annually, yet there is no widely protective vaccine or drugs against the virus.  Efforts to develop antivirals against classical targets such as the viral protease and polymerase have not yielded drugs that have advanced to the clinic.  Here, we show that the allosteric Abl kinase inhibitor GNF-2 interferes with dengue virus replication via activity mediated by cellular Abl kinases but addnl. blocks viral entry via an Abl-independent mechanism.  To characterize this newly discovered antiviral activity, we developed disubstituted pyrimidines that block dengue virus entry with structure-activity relationships distinct from those driving kinase inhibition.  We demonstrate that biotin- and fluorophore-conjugated derivs. of GNF-2 interact with the dengue glycoprotein, E, in the pre-fusion conformation that exists on the virion surface, and that this interaction inhibits viral entry.  This study establishes GNF-2 as an antiviral compd. with polypharmacol. activity and provides "lead" compds. for further optimization efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-_Dumc6V_A7Vg90H21EOLACvtfcHk0lhlFSKEhkstMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntlSqtbs%253D&md5=d5bd0ad159a7df03b992ecb96a7d231f</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2016.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2016.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DM.%2BJ.%26aulast%3DMiduturu%26aufirst%3DC.%26aulast%3DSchmidt%26aufirst%3DA.%2BG.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DPitts%26aufirst%3DJ.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DPotisopon%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DChu%26aufirst%3DJ.%2BJ.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYang%26aufirst%3DP.%2BL.%26atitle%3DGNF-2%2520inhibits%2520dengue%2520virus%2520by%2520targeting%2520Abl%2520kinases%2520and%2520the%2520viral%2520E%2520protein%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2016%26volume%3D23%26spage%3D443%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2016.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bayer, K. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, H.</span></span> <span> </span><span class="NLM_article-title">CaM kinase: still inspiring at 40</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">394</span>, <span class="refDoi"> DOI: 10.1016/j.neuron.2019.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1016%2Fj.neuron.2019.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=31394063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFKjtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2019&pages=380-394&author=K.+U.+Bayerauthor=H.+Schulman&title=CaM+kinase%3A+still+inspiring+at+40&doi=10.1016%2Fj.neuron.2019.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">CaM Kinase: Still Inspiring at 40</span></div><div class="casAuthors">Bayer, K. Ulrich; Schulman, Howard</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-394</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) was touted as a memory mol., even before its involvement in long-term potentiation (LTP) was shown.  The enzyme has not disappointed, with subsequent demonstrations of remarkable structural and regulatory properties.  Its neuronal functions now extend to long-term depression (LTD), and last year saw the first direct evidence for memory storage by CaMKII.  Although CaMKII may have taken the spotlight, it is a member of a large family of diverse and interesting CaM kinases.  Our aim is to place CaMKII in context of the other CaM kinases and then review certain aspects of this kinase that are of current interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4GLt04enxbVg90H21EOLACvtfcHk0lhlFSKEhkstMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFKjtLzK&md5=c576935107864506b1d940e9fcae32a6</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2019.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2019.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DBayer%26aufirst%3DK.%2BU.%26aulast%3DSchulman%26aufirst%3DH.%26atitle%3DCaM%2520kinase%253A%2520still%2520inspiring%2520at%252040%26jtitle%3DNeuron%26date%3D2019%26volume%3D103%26spage%3D380%26epage%3D394%26doi%3D10.1016%2Fj.neuron.2019.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellicena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulman, H.</span></span> <span> </span><span class="NLM_article-title">CaMKII inhibitors: from research tools to therapeutic agents</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3389%2Ffphar.2014.00021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24600394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2cfls1ynsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=21&author=P.+Pellicenaauthor=H.+Schulman&title=CaMKII+inhibitors%3A+from+research+tools+to+therapeutic+agents&doi=10.3389%2Ffphar.2014.00021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">CaMKII inhibitors: from research tools to therapeutic agents</span></div><div class="casAuthors">Pellicena Patricia; Schulman Howard</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The cardiac field has benefited from the availability of several CaMKII inhibitors serving as research tools to test putative CaMKII pathways associated with cardiovascular physiology and pathophysiology.  Successful demonstrations of its critical pathophysiological roles have elevated CaMKII as a key target in heart failure, arrhythmia, and other forms of heart disease.  This has caught the attention of the pharmaceutical industry, which is now racing to develop CaMKII inhibitors as safe and effective therapeutic agents.  While the first generation of CaMKII inhibitor development is focused on blocking its activity based on ATP binding to its catalytic site, future inhibitors can also target sites affecting its regulation by Ca(2+)/CaM or translocation to some of its protein substrates.  The recent availability of crystal structures of the kinase in the autoinhibited and activated state, and of the dodecameric holoenzyme, provides insights into the mechanism of action of existing inhibitors.  It is also accelerating the design and development of better pharmacological inhibitors.  This review examines the structure of the kinase and suggests possible sites for its inhibition.  It also analyzes the uses and limitations of current research tools.  Development of new inhibitors will enable preclinical proof of concept tests and clinical development of successful lead compounds, as well as improved research tools to more accurately examine and extend knowledge of the role of CaMKII in cardiac health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRHND5-dNwnhC-bLEOO4dYpfW6udTcc2eZXPForUnZO2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfls1ynsA%253D%253D&md5=90410be031e0b96ca2810e239a60bffd</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00021%26sid%3Dliteratum%253Aachs%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DSchulman%26aufirst%3DH.%26atitle%3DCaMKII%2520inhibitors%253A%2520from%2520research%2520tools%2520to%2520therapeutic%2520agents%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D21%26doi%3D10.3389%2Ffphar.2014.00021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simanjuntak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ping, Y.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.-S.</span></span> <span> </span><span class="NLM_article-title">Benzenesulfonamide derivatives as calcium/calmodulin-dependent protein kinase inhibitors and antiviral agents against dengue and zika virus infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1313</span>– <span class="NLM_lpage">1327</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01779</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01779" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1313-1327&author=W.-C.+Chenauthor=Y.+Simanjuntakauthor=L.-W.+Chuauthor=Y.-H.+Pingauthor=Y.-L.+Leeauthor=Y.-L.+Linauthor=W.-S.+Li&title=Benzenesulfonamide+derivatives+as+calcium%2Fcalmodulin-dependent+protein+kinase+inhibitors+and+antiviral+agents+against+dengue+and+zika+virus+infections&doi=10.1021%2Facs.jmedchem.9b01779"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Benzenesulfonamide Derivatives as Calcium/Calmodulin-Dependent Protein Kinase Inhibitors and Antiviral Agents against Dengue and Zika Virus Infections</span></div><div class="casAuthors">Chen, Wei-Chia; Simanjuntak, Yogy; Chu, Li-Wei; Ping, Yueh-Hsin; Lee, Yi-Ling; Lin, Yi-Ling; Li, Wen-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1313-1327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Emerging and resurging mosquito-borne flaviviruses are an important public health challenge.  The increased prevalence of dengue virus (DENV) infection has had a significant socioeconomic impact on epidemic countries.  The recent outbreak of Zika virus (ZIKV) has created an international public health emergency because ZIKV infection has been linked to congenital defects and Guillain-Barr´e syndrome.  To develop potentially prophylactic antiviral drugs for combating these acute infectious diseases, we have targeted the host calcium/calmodulin-dependent kinase II (CaMKII) for inhibition.  By using CaMKII structure-guided inhibitor design, we generated four families of benzenesulfonamide (BSA) derivs. for SAR anal.  Among these substances, N-(4-cycloheptyl-4-oxobutyl)-4-methoxy-N-phenylbenzenesulfonamide (9) showed superior properties as a lead CaMKII inhibitor and antiviral agent.  BSA 9 inhibited CaMKII activity with an IC50 value of 0.79 μM and displayed EC50 values of 1.52 μM and 1.91 μM against DENV and ZIKV infections of human neuronal BE(2)C cells, resp.  Notably, 9 significantly reduced the viremia level and increased animal survival time in mouse-challenge models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPIVcnOOQM9LVg90H21EOLACvtfcHk0ljSHNhoQjLoZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1elsbg%253D&md5=4222b9a25616a59243c22bfd57b223e7</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01779&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01779%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DW.-C.%26aulast%3DSimanjuntak%26aufirst%3DY.%26aulast%3DChu%26aufirst%3DL.-W.%26aulast%3DPing%26aufirst%3DY.-H.%26aulast%3DLee%26aufirst%3DY.-L.%26aulast%3DLin%26aufirst%3DY.-L.%26aulast%3DLi%26aufirst%3DW.-S.%26atitle%3DBenzenesulfonamide%2520derivatives%2520as%2520calcium%252Fcalmodulin-dependent%2520protein%2520kinase%2520inhibitors%2520and%2520antiviral%2520agents%2520against%2520dengue%2520and%2520zika%2520virus%2520infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1313%26epage%3D1327%26doi%3D10.1021%2Facs.jmedchem.9b01779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saldivar, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cimprich, K. A.</span></span> <span> </span><span class="NLM_article-title">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.67</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrm.2017.67" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28811666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=622-636&author=J.+C.+Saldivarauthor=D.+Cortezauthor=K.+A.+Cimprich&title=The+essential+kinase+ATR%3A+ensuring+faithful+duplication+of+a+challenging+genome&doi=10.1038%2Fnrm.2017.67"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">The essential kinase ATR: ensuring faithful duplication of a challenging genome</span></div><div class="casAuthors">Saldivar, Joshua C.; Cortez, David; Cimprich, Karlene A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">622-636</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  One way to preserve a rare book is to lock it away from all potential sources of damage.  Of course, an inaccessible book is also of little use, and the paper and ink will continue to degrade with age in any case.  Like a book, the information stored in our DNA needs to be read, but it is also subject to continuous assault and therefore needs to be protected.  In this Review, we examine how the replication stress response that is controlled by the kinase ataxia telangiectasia and Rad3-related (ATR) senses and resolves threats to DNA integrity so that the DNA remains available to read in all of our cells.  We discuss the multiple data that have revealed an elegant yet increasingly complex mechanism of ATR activation.  This involves a core set of components that recruit ATR to stressed replication forks, stimulate kinase activity and amplify ATR signalling.  We focus on the activities of ATR in the control of cell cycle checkpoints, origin firing and replication fork stability, and on how proper regulation of these processes is crucial to ensure faithful duplication of a challenging genome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi-97TQtMh0bVg90H21EOLACvtfcHk0ljSHNhoQjLoZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlemu7jF&md5=b65c70da63f009deae253c8f3f215234</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.67&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.67%26sid%3Dliteratum%253Aachs%26aulast%3DSaldivar%26aufirst%3DJ.%2BC.%26aulast%3DCortez%26aufirst%3DD.%26aulast%3DCimprich%26aufirst%3DK.%2BA.%26atitle%3DThe%2520essential%2520kinase%2520ATR%253A%2520ensuring%2520faithful%2520duplication%2520of%2520a%2520challenging%2520genome%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2017%26volume%3D18%26spage%3D622%26epage%3D636%26doi%3D10.1038%2Fnrm.2017.67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newsome, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eustace, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hare, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takemoto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charrier, J.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golec, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reaper, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollard, J. R.</span></span> <span> </span><span class="NLM_article-title">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5674</span>– <span class="NLM_lpage">5685</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.18632%2Foncotarget.2158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=25010037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5674-5685&author=A.+B.+Hallauthor=D.+Newsomeauthor=Y.+Wangauthor=D.+M.+Boucherauthor=B.+Eustaceauthor=Y.+Guauthor=B.+Hareauthor=M.+A.+Johnsonauthor=H.+Liauthor=S.+Miltonauthor=C.+E.+Murphyauthor=D.+Takemotoauthor=C.+Tolmanauthor=M.+Woodauthor=P.+Charltonauthor=J.-D.+Charrierauthor=B.+Fureyauthor=J.+Golecauthor=P.+M.+Reaperauthor=J.+R.+Pollard&title=Potentiation+of+tumor+responses+to+DNA+damaging+therapy+by+the+selective+ATR+inhibitor+VX-970&doi=10.18632%2Foncotarget.2158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970</span></div><div class="casAuthors">Hall Amy B; Newsome Dave; Wang Yuxin; Boucher Diane M; Eustace Brenda; Gu Yong; Hare Brian; Johnson Mac A; Milton Sean; Murphy Cheryl E; Takemoto Darin; Tolman Crystal; Wood Mark; Furey Brinley; Charlton Peter; Charrier Jean-Damien; Golec Julian; Reaper Philip M; Pollard John R</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5674-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor.  This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR).  ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents.  However, there are limited in vivo proof-of-concept data for ATR inhibition.  To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1.  VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed.  In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts.  The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model.  These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8Vj8UJVglDeLt9HypzAgQfW6udTcc2eZfYuiW7nOqlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbhtVOjsw%253D%253D&md5=8901708b1d60ad622d534a14da665414</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2158%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%2BB.%26aulast%3DNewsome%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBoucher%26aufirst%3DD.%2BM.%26aulast%3DEustace%26aufirst%3DB.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHare%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMilton%26aufirst%3DS.%26aulast%3DMurphy%26aufirst%3DC.%2BE.%26aulast%3DTakemoto%26aufirst%3DD.%26aulast%3DTolman%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DCharlton%26aufirst%3DP.%26aulast%3DCharrier%26aufirst%3DJ.-D.%26aulast%3DFurey%26aufirst%3DB.%26aulast%3DGolec%26aufirst%3DJ.%26aulast%3DReaper%26aufirst%3DP.%2BM.%26aulast%3DPollard%26aufirst%3DJ.%2BR.%26atitle%3DPotentiation%2520of%2520tumor%2520responses%2520to%2520DNA%2520damaging%2520therapy%2520by%2520the%2520selective%2520ATR%2520inhibitor%2520VX-970%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5674%26epage%3D5685%26doi%3D10.18632%2Foncotarget.2158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herzig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, R. J.</span></span> <span> </span><span class="NLM_article-title">AMPK: guardian of metabolism and mitochondrial homeostasis</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1038/nrm.2017.95</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrm.2017.95" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28974774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsF2rtb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=121-135&author=S.+Herzigauthor=R.+J.+Shaw&title=AMPK%3A+guardian+of+metabolism+and+mitochondrial+homeostasis&doi=10.1038%2Fnrm.2017.95"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">AMPK: guardian of metabolism and mitochondrial homeostasis</span></div><div class="casAuthors">Herzig, Sebastien; Shaw, Reuben J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-135</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cells constantly adapt their metab. to meet their energy needs and respond to nutrient availability.  Eukaryotes have evolved a very sophisticated system to sense low cellular ATP levels via the serine/threonine kinase AMP-activated protein kinase (AMPK) complex.  Under conditions of low energy, AMPK phosphorylates specific enzymes and growth control nodes to increase ATP generation and decrease ATP consumption.  In the past decade, the discovery of numerous new AMPK substrates has led to a more complete understanding of the minimal no. of steps required to reprogramme cellular metab. from anabolism to catabolism.  This energy switch controls cell growth and several other cellular processes, including lipid and glucose metab. and autophagy.  Recent studies have revealed that one ancestral function of AMPK is to promote mitochondrial health, and multiple newly discovered targets of AMPK are involved in various aspects of mitochondrial homeostasis, including mitophagy.  This Review discusses how AMPK functions as a central mediator of the cellular response to energetic stress and mitochondrial insults and coordinates multiple features of autophagy and mitochondrial biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWI3PnQxZd7Vg90H21EOLACvtfcHk0lij3_if6fRUgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsF2rtb7L&md5=d3bf6ff181c0d620e9179faecbc0b4fc</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1038%2Fnrm.2017.95&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm.2017.95%26sid%3Dliteratum%253Aachs%26aulast%3DHerzig%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DR.%2BJ.%26atitle%3DAMPK%253A%2520guardian%2520of%2520metabolism%2520and%2520mitochondrial%2520homeostasis%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2018%26volume%3D19%26spage%3D121%26epage%3D135%26doi%3D10.1038%2Fnrm.2017.95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mankouri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, M.</span></span> <span> </span><span class="NLM_article-title">Viruses and the fuel sensor: the emerging link between AMPK and virus replication</span>. <i>Rev. Med. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1002/rmv.687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1002%2Frmv.687" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=21538667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVensbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=205-212&author=J.+Mankouriauthor=M.+Harris&title=Viruses+and+the+fuel+sensor%3A+the+emerging+link+between+AMPK+and+virus+replication&doi=10.1002%2Frmv.687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Viruses and the fuel sensor: the emerging link between AMPK and virus replication</span></div><div class="casAuthors">Mankouri, Jamel; Harris, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Reviews in Medical Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">205-212</span>CODEN:
                <span class="NLM_cas:coden">RMVIEW</span>;
        ISSN:<span class="NLM_cas:issn">1052-9276</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Adenosine 5' monophosphate-activated protein kinase (AMPK) is conserved in all eukaryotic cells and functions as the key regulator of cellular metab. by responding to the energy status of the cell.  It is activated by an increase in the AMP : ATP ratio and then attempts to redress the balance by upregulating catabolic processes, while concomitantly inhibiting anabolic processes.  Despite its crit. importance in the functioning of eukaryotic cells, there has been a paucity of studies investigating the potential for dysregulation of AMPK by viruses.  Recently, however, there have been a no. of reports that have begun to address this gap in our knowledge.  In this article, we will review this emerging field, outlining how a variety of viruses have been shown to either stimulate or inhibit AMPK activity.  We will also document the effects of these perturbations on the biol. of virus infection, in particular with regard to the ability of viruses to persist or cause cytopathogenesis.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRtuWl3zqqtrVg90H21EOLACvtfcHk0lij3_if6fRUgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVensbY%253D&md5=d8460c465146485e41732ca01ce13565</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1002%2Frmv.687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frmv.687%26sid%3Dliteratum%253Aachs%26aulast%3DMankouri%26aufirst%3DJ.%26aulast%3DHarris%26aufirst%3DM.%26atitle%3DViruses%2520and%2520the%2520fuel%2520sensor%253A%2520the%2520emerging%2520link%2520between%2520AMPK%2520and%2520virus%2520replication%26jtitle%3DRev.%2520Med.%2520Virol.%26date%3D2011%26volume%3D21%26spage%3D205%26epage%3D212%26doi%3D10.1002%2Frmv.687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kondratowicz, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cherry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maury, W. J.</span></span> <span> </span><span class="NLM_article-title">AMP-activated protein kinase is required for the macropinocytic internalization of ebolavirus</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">746</span>– <span class="NLM_lpage">755</span>, <span class="refDoi"> DOI: 10.1128/JVI.01634-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1128%2FJVI.01634-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=23115293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2jtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=746-755&author=A.+S.+Kondratowiczauthor=C.+L.+Huntauthor=R.+A.+Daveyauthor=S.+Cherryauthor=W.+J.+Maury&title=AMP-activated+protein+kinase+is+required+for+the+macropinocytic+internalization+of+ebolavirus&doi=10.1128%2FJVI.01634-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">AMP-activated protein kinase is required for the macropinocytic internalization of Ebolavirus</span></div><div class="casAuthors">Kondratowicz, Andrew S.; Hunt, Catherine L.; Davey, Robert A.; Cherry, Sara; Maury, Wendy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">746-755</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Identification of host factors that are needed for Zaire Ebolavirus (EBOV) entry provides insights into the mechanism(s) of filovirus uptake, and these factors may serve as potential antiviral targets.  In order to identify novel host genes and pathways involved in EBOV entry, gene array findings in the National Cancer Institute's NCI-60 panel of human tumor cell lines were correlated with permissivity for EBOV glycoprotein (GP)-mediated entry.  The gene encoding the γ2 subunit of AMP-activated protein kinase (AMPK) strongly correlated with EBOV transduction in the tumor panel.  The AMPK inhibitor compd. C inhibited infectious EBOV replication in Vero cells and diminished EBOV GP-dependent, but not Lassa fever virus GPC-dependent, entry into a variety of cell lines in a dose-dependent manner.  Compd. C also prevented EBOV GP-mediated infection of primary human macrophages, a major target of filoviral replication in vivo.  Consistent with a role for AMPK in filovirus entry, time-of-addn. studies demonstrated that compd. C abrogated infection when it was added at early time points but became progressively less effective when added later.  Compd. C prevented EBOV pseudovirion internalization at 37° as cell-bound particles remained susceptible to trypsin digestion in the presence of the inhibitor but not in its absence.  Mouse embryonic fibroblasts lacking the AMPKa1 and AMPKα2 catalytic subunits were significantly less permissive to EBOV GP-mediated infection than their wild-type counterparts, likely due to decreased macropinocytic uptake.  In total, these findings implicate AMPK in macropinocytic events needed for EBOV GP-dependent entry and identify a novel cellular target for new filoviral antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0gJca2kyg7Vg90H21EOLACvtfcHk0lij3_if6fRUgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2jtL0%253D&md5=33cdce39496e6ae3070af5ea112cb2a3</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1128%2FJVI.01634-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01634-12%26sid%3Dliteratum%253Aachs%26aulast%3DKondratowicz%26aufirst%3DA.%2BS.%26aulast%3DHunt%26aufirst%3DC.%2BL.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26aulast%3DCherry%26aufirst%3DS.%26aulast%3DMaury%26aufirst%3DW.%2BJ.%26atitle%3DAMP-activated%2520protein%2520kinase%2520is%2520required%2520for%2520the%2520macropinocytic%2520internalization%2520of%2520ebolavirus%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D746%26epage%3D755%26doi%3D10.1128%2FJVI.01634-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantrell, D. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase signalling pathways</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1439</span>– <span class="NLM_lpage">1445</span>, <span class="refDoi"> DOI: 10.1242/jcs.114.8.1439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1242%2Fjcs.114.8.1439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=11282020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjsVyiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=1439-1445&author=D.+A.+Cantrell&title=Phosphoinositide+3-kinase+signalling+pathways&doi=10.1242%2Fjcs.114.8.1439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase signalling pathways</span></div><div class="casAuthors">Cantrell, Doreen Ann</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1439-1445</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review, with 83 refs.  Phosphoinositide 3-kinases (PI3Ks) phosphorylate the 3'-OH position of the inositol ring of inositol phospholipids, producing three lipid products: PtdIns(3)P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3.  These lipids bind to the pleckstrin homol. (PH) domains of proteins and control the activity and subcellular localization of a diverse array of signal transduction mols.  Three major classes of signaling mol. are regulated by binding of D-3 phosphoinositides to PH domains: guanine-nucleotide-exchange proteins for Rho family GTPases, the TEC family tyrosine kinases such as BTK and ITK in B and T lymphocytes, resp., and the AGC superfamily of serine/threonine protein kinases.  These mols. are activated by a variety of extracellular stimuli and have been implicated in a wide range of cellular processes, including cell cycle progression, cell growth, cell motility, cell adhesion and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR4dxjthM76bVg90H21EOLACvtfcHk0ljpoO_Wx17jlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjsVyiu74%253D&md5=cb1910b42b49b62561279a315450c76b</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1242%2Fjcs.114.8.1439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.114.8.1439%26sid%3Dliteratum%253Aachs%26aulast%3DCantrell%26aufirst%3DD.%2BA.%26atitle%3DPhosphoinositide%25203-kinase%2520signalling%2520pathways%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D1439%26epage%3D1445%26doi%3D10.1242%2Fjcs.114.8.1439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span>. <i>Nat. Rev. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1038/nrg1879</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrg1879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=16847462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=606-619&author=J.+A.+Engelmanauthor=J.+Luoauthor=L.+C.+Cantley&title=The+evolution+of+phosphatidylinositol+3-kinases+as+regulators+of+growth+and+metabolism&doi=10.1038%2Fnrg1879"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</span></div><div class="casAuthors">Engelman, Jeffrey A.; Luo, Ji; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Genetics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-619</span>CODEN:
                <span class="NLM_cas:coden">NRGAAM</span>;
        ISSN:<span class="NLM_cas:issn">1471-0056</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metab. and growth in multicellular organisms.  In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms.  In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphucxYJIwcQLVg90H21EOLACvtfcHk0ljpoO_Wx17jlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFCnu7Y%253D&md5=cd9eb85158710db6b33336af4e0a8cfe</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1038%2Fnrg1879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrg1879%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DThe%2520evolution%2520of%2520phosphatidylinositol%25203-kinases%2520as%2520regulators%2520of%2520growth%2520and%2520metabolism%26jtitle%3DNat.%2520Rev.%2520Genet.%26date%3D2006%26volume%3D7%26spage%3D606%26epage%3D619%26doi%3D10.1038%2Fnrg1879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the phosphoinositide 3-kinase pathway in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1038/nrd2926</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fnrd2926" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=19644473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=627-644&author=P.+Liuauthor=H.+Chengauthor=T.+M.+Robertsauthor=J.+J.+Zhao&title=Targeting+the+phosphoinositide+3-kinase+pathway+in+cancer&doi=10.1038%2Fnrd2926"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the phosphoinositide 3-kinase pathway in cancer</span></div><div class="casAuthors">Liu, Pixu; Cheng, Hailing; Roberts, Thomas M.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">627-644</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The phosphoinositide 3-kinase (PI3K) pathway is a key signal transduction system that links oncogenes and multiple receptor classes to many essential cellular functions, and is perhaps the most commonly activated signalling pathway in human cancer.  This pathway therefore presents both an opportunity and a challenge for cancer therapy.  Even as inhibitors that target PI3K isoforms and other major nodes in the pathway, including AKT and mammalian target of rapamycin (mTOR), reach clin. trials, major issues remain.  Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUk9T-ZoNDtLVg90H21EOLACvtfcHk0ljpoO_Wx17jlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Wgtb4%253D&md5=fdc94abd15178a9dbe7c56dafbfb7787</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1038%2Fnrd2926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2926%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520the%2520phosphoinositide%25203-kinase%2520pathway%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D627%26epage%3D644%26doi%3D10.1038%2Fnrd2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+cancer%3A+mechanisms+and+advances+in+clinical+trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eY2ZT6eKpIIabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520cancer%253A%2520mechanisms%2520and%2520advances%2520in%2520clinical%2520trials%26jtitle%3DMol.%2520Cancer%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaal, H.</span></span> <span> </span><span class="NLM_article-title">Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">3192</span>– <span class="NLM_lpage">3212</span>, <span class="refDoi"> DOI: 10.3390/v5123192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fv5123192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=24351799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVyitLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=3192-3212&author=N.+Diehlauthor=H.+Schaal&title=Make+yourself+at+home%3A+viral+hijacking+of+the+PI3K%2FAkt+signaling+pathway&doi=10.3390%2Fv5123192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Make yourself at home: viral hijacking of the PI3K/Akt signaling pathway</span></div><div class="casAuthors">Diehl, Nora; Schaal, Heiner</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3192-3212, 21 pp.</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  As viruses do not possess genes encoding for proteins required for translation, energy metab. or membrane biosynthesis, they are classified as obligatory intracellular parasites that depend on a host cell to replicate.  This genome limitation forces them to gain control over cellular processes to ensure their successful propagation.  A diverse spectrum of virally encoded proteins tackling a broad spectrum of cellular pathways during most steps of the viral life cycle ranging from the host cell entry to viral protein translation has evolved.  Since the host cell PI3K/Akt signaling pathway plays a crit. regulatory role in many cellular processes including RNA processing, translation, autophagy and apoptosis, many viruses, in widely varying ways, target it.  This review focuses on a no. of remarkable examples of viral strategies, which exploit the PI3K/Akt signaling pathway for effective viral replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZQHZafpgAH7Vg90H21EOLACvtfcHk0liHwgDDSrnAkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVyitLc%253D&md5=a113117ad659018ed1f18e52fba605a9</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fv5123192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv5123192%26sid%3Dliteratum%253Aachs%26aulast%3DDiehl%26aufirst%3DN.%26aulast%3DSchaal%26aufirst%3DH.%26atitle%3DMake%2520yourself%2520at%2520home%253A%2520viral%2520hijacking%2520of%2520the%2520PI3K%252FAkt%2520signaling%2520pathway%26jtitle%3DViruses%26date%3D2013%26volume%3D5%26spage%3D3192%26epage%3D3212%26doi%3D10.3390%2Fv5123192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolokoltsov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freiberg, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. A.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e1000141</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1000141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1000141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=18769720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&author=M.+F.+Saeedauthor=A.+A.+Kolokoltsovauthor=A.+N.+Freibergauthor=M.+R.+Holbrookauthor=R.+A.+Davey&title=Phosphoinositide-3+kinase-Akt+pathway+controls+cellular+entry+of+Ebola+virus&doi=10.1371%2Fjournal.ppat.1000141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide-3 kinase-Akt pathway controls cellular entry of Ebola virus</span></div><div class="casAuthors">Saeed Mohammad F; Kolokoltsov Andrey A; Freiberg Alexander N; Holbrook Michael R; Davey Robert A</div><div class="citationInfo"><span class="NLM_cas:title">PLoS pathogens</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1000141</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide-3 kinase (PI3K) pathway regulates diverse cellular activities related to cell growth, migration, survival, and vesicular trafficking.  It is known that Ebola virus requires endocytosis to establish an infection.  However, the cellular signals that mediate this uptake were unknown for Ebola virus as well as many other viruses.  Here, the involvement of PI3K in Ebola virus entry was studied.  A novel and critical role of the PI3K signaling pathway was demonstrated in cell entry of Zaire Ebola virus (ZEBOV).  Inhibitors of PI3K and Akt significantly reduced infection by ZEBOV at an early step during the replication cycle.  Furthermore, phosphorylation of Akt-1 was induced shortly after exposure of cells to radiation-inactivated ZEBOV, indicating that the virus actively induces the PI3K pathway and that replication was not required for this induction.  Subsequent use of pseudotyped Ebola virus and/or Ebola virus-like particles, in a novel virus entry assay, provided evidence that activity of PI3K/Akt is required at the virus entry step.  Class 1A PI3Ks appear to play a predominant role in regulating ZEBOV entry, and Rac1 is a key downstream effector in this regulatory cascade.  Confocal imaging of fluorescently labeled ZEBOV indicated that inhibition of PI3K, Akt, or Rac1 disrupted normal uptake of virus particles into cells and resulted in aberrant accumulation of virus into a cytosolic compartment that was non-permissive for membrane fusion.  We conclude that PI3K-mediated signaling plays an important role in regulating vesicular trafficking of ZEBOV necessary for cell entry.  Disruption of this signaling leads to inappropriate trafficking within the cell and a block in steps leading to membrane fusion.  These findings extend our current understanding of Ebola virus entry mechanism and may help in devising useful new strategies for treatment of Ebola virus infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSVYOnEFnn8xZVVjGoY74BafW6udTcc2ea3Z7r070oU2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1crotV2jsg%253D%253D&md5=337fa485785e2a091d392f6ff1dcc1a4</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1000141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1000141%26sid%3Dliteratum%253Aachs%26aulast%3DSaeed%26aufirst%3DM.%2BF.%26aulast%3DKolokoltsov%26aufirst%3DA.%2BA.%26aulast%3DFreiberg%26aufirst%3DA.%2BN.%26aulast%3DHolbrook%26aufirst%3DM.%2BR.%26aulast%3DDavey%26aufirst%3DR.%2BA.%26atitle%3DPhosphoinositide-3%2520kinase-Akt%2520pathway%2520controls%2520cellular%2520entry%2520of%2520Ebola%2520virus%26jtitle%3DPLoS%2520Pathog.%26date%3D2008%26volume%3D4%26doi%3D10.1371%2Fjournal.ppat.1000141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tiwari, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, D.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry</span>. <i>J. Gen. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">3002</span>– <span class="NLM_lpage">3009</span>, <span class="refDoi"> DOI: 10.1099/vir.0.024166-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1099%2Fvir.0.024166-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20810749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2010&pages=3002-3009&author=V.+Tiwariauthor=D.+Shukla&title=Phosphoinositide+3+kinase+signalling+may+affect+multiple+steps+during+herpes+simplex+virus+type-1+entry&doi=10.1099%2Fvir.0.024166-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3 kinase signalling may affect multiple steps during herpes simplex virus type-1 entry</span></div><div class="casAuthors">Tiwari, Vaibhav; Shukla, Deepak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3002-3009</span>CODEN:
                <span class="NLM_cas:coden">JGVIAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-1317</span>.
    
            (<span class="NLM_cas:orgname">Society for General Microbiology</span>)
        </div><div class="casAbstract">Early interactions of herpes simplex virus type-1 (HSV-1) with cells lead to cytoskeletal changes facilitating filopodia formation and membrane fusion.  Here, we demonstrate that phosphoinositide 3 kinase (PI3K) signaling may affect multiple steps during HSV-1 entry.  An inhibitor of PI3K (LY294002) blocked HSV-1 entry and the blockage was cell-type- and gD receptor-independent.  Entry inhibition was also obsd. with primary cultures of the human corneal fibroblasts and unrelated β- and γ-herpesviruses.  Immunofluorescence anal. demonstrated that LY294002 neg. affected HSV-1-induced filopodia formation.  Similar effects of the inhibitor were seen on HSV-1 glycoprotein-induced cell-to-cell fusion.  Cells expressing HSV-1 glycoproteins (gB, gD, gH and gL) showed significantly less fusion with target cells in the presence of the inhibitor.  Expression of a dominant-neg. PI3K mutant neg. affected both entry and fusion.  We also show that inhibition of PI3K signaling also affected RhoA activation required for HSV-1 entry into certain cell types.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZM1xcsTUErVg90H21EOLACvtfcHk0liHwgDDSrnAkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jsLfI&md5=32c707fe3d6630cbc7dd9252911f2194</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1099%2Fvir.0.024166-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1099%252Fvir.0.024166-0%26sid%3Dliteratum%253Aachs%26aulast%3DTiwari%26aufirst%3DV.%26aulast%3DShukla%26aufirst%3DD.%26atitle%3DPhosphoinositide%25203%2520kinase%2520signalling%2520may%2520affect%2520multiple%2520steps%2520during%2520herpes%2520simplex%2520virus%2520type-1%2520entry%26jtitle%3DJ.%2520Gen.%2520Virol.%26date%3D2010%26volume%3D91%26spage%3D3002%26epage%3D3009%26doi%3D10.1099%2Fvir.0.024166-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Nunez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barroso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrascosa, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revilla, Y.</span></span> <span> </span><span class="NLM_article-title">African swine fever virus uses macropinocytosis to enter host cells</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002754</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1371%2Fjournal.ppat.1002754" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=22719252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1WrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=E.+G.+Sanchezauthor=A.+Quintasauthor=D.+Perez-Nunezauthor=M.+Nogalauthor=S.+Barrosoauthor=A.+L.+Carrascosaauthor=Y.+Revilla&title=African+swine+fever+virus+uses+macropinocytosis+to+enter+host+cells&doi=10.1371%2Fjournal.ppat.1002754"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">African swine fever virus uses macropinocytosis to enter host cells</span></div><div class="casAuthors">Sanchez, Elena G.; Quintas, Ana; Perez-Nunez, Daniel; Nogal, Marisa; Barroso, Susana; Carrascosa, Angel L.; Revilla, Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1002754</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">African swine fever (ASF) is caused by a large and highly pathogenic DNA virus, African swine fever virus (ASFV), which provokes severe economic losses and expansion threats.  Presently, no specific protection or vaccine against ASF is available, despite the high hazard that the continued occurrence of the disease in sub-Saharan Africa, the recent outbreak in the Caucasus in 2007, and the potential dissemination to neighboring countries, represents.  Although virus entry is a remarkable target for the development of protection tools, knowledge of the ASFV entry mechanism is still very limited.  Whereas early studies have proposed that the virus enters cells through receptor-mediated endocytosis, the specific mechanism used by ASFV remains uncertain.  Here we used the ASFV virulent isolate Ba71, adapted to grow in Vero cells (Ba71V), and the virulent strain E70 to demonstrate that entry and internalization of ASFV includes most of the features of macropinocytosis.  By a combination of optical and electron microscopy, we show that the virus causes cytoplasm membrane perturbation, blebbing and ruffles.  We have also found that internalization of the virions depends on actin reorganization, activity of Na+/H+ exchangers, and signaling events typical of the macropinocytic mechanism of endocytosis.  The entry of virus into cells appears to directly stimulate dextran uptake, actin polarization and EGFR, PI3K-Akt, Pak1 and Rac1 activation.  Inhibition of these key regulators of macropinocytosis, as well as treatment with the drug EIPA, results in a considerable decrease in ASFV entry and infection.  In conclusion, this study identifies for the first time the whole pathway for ASFV entry, including the key cellular factors required for the uptake of the virus and the cell signaling involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWmiT3epDeT7Vg90H21EOLACvtfcHk0liHwgDDSrnAkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1WrtbY%253D&md5=1cc17081dd757815ca20add6cb30a8b1</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002754%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DE.%2BG.%26aulast%3DQuintas%26aufirst%3DA.%26aulast%3DPerez-Nunez%26aufirst%3DD.%26aulast%3DNogal%26aufirst%3DM.%26aulast%3DBarroso%26aufirst%3DS.%26aulast%3DCarrascosa%26aufirst%3DA.%2BL.%26aulast%3DRevilla%26aufirst%3DY.%26atitle%3DAfrican%2520swine%2520fever%2520virus%2520uses%2520macropinocytosis%2520to%2520enter%2520host%2520cells%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fikrig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, P.</span></span> <span> </span><span class="NLM_article-title">An essential role of PI3K in the control of West Nile virus infection</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3724</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03912-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1038%2Fs41598-017-03912-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=28623344" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptFGjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3724&author=L.+Wangauthor=L.+Yangauthor=E.+Fikrigauthor=P.+Wang&title=An+essential+role+of+PI3K+in+the+control+of+West+Nile+virus+infection&doi=10.1038%2Fs41598-017-03912-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">An essential role of PI3K in the control of West Nile virus infection</span></div><div class="casAuthors">Wang Leilei; Yang Long; Wang Penghua; Wang Leilei; Fikrig Erol; Fikrig Erol</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphatidyl-inositol-3 kinases (PI3K) pathway regulates a variety of cellular processes, including cell proliferation, RNA processing, protein translation, autophagy, apoptosis and antiviral immunity.  Many viruses depend on PI3K signaling for replication.  However, its role in flaviviral infection has not been clearly defined.  Here we report that PI3K signaling is critical for the control of West Nile virus (WNV) infection by regulating type I IFN (IFN-I) response.  Inhibition of PI3K activity by 3-methyl adenine (3-MA), Wortmannin (WM) and LY294002 (LY) increased viral titers by 3-16 folds in primary mouse macrophages, embryonic fibroblasts and human cell lines.  Both 3-MA and LY repressed IFN-I mRNA and protein expression significantly.  Surprisingly, WM enhanced the mRNA expression of IFN-I and TNF-α, and TNF-α protein production modestly, while dramatically decreased the secreted IFN-I.  Further studies showed that the catalytic subunit p110δ of class I PI3K played a role in induction of antiviral immune responses.  Lastly translocation of interferon regulatory factor 7(IRF7) from the cytosol to the nuclei was effectively blocked in the presence of PI3K inhibitors.  Our results clearly define an antiviral role of PI3K by modulating immune responses and demonstrate differential mode of action of three PI3K inhibitors on IFN-I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJFccvOyb6-f9pSBfyDvp7fW6udTcc2eanfkKTJuxgsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptFGjsA%253D%253D&md5=2358dee5af4d0bd714017a84632eaaba</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03912-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03912-5%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DFikrig%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DP.%26atitle%3DAn%2520essential%2520role%2520of%2520PI3K%2520in%2520the%2520control%2520of%2520West%2520Nile%2520virus%2520infection%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3724%26doi%3D10.1038%2Fs41598-017-03912-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGowan, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddadi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassif, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span> <span> </span><span class="NLM_article-title">Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">7189</span>, <span class="refDoi"> DOI: 10.3390/ijms21197189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.3390%2Fijms21197189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWit7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=7189&author=E.+M.+McGowanauthor=N.+Haddadiauthor=N.+T.+Nassifauthor=Y.+Lin&title=Targeting+the+SphK-S1P-SIPR+pathway+as+a+potential+therapeutic+approach+for+COVID-19&doi=10.3390%2Fijms21197189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the SphK-S1P-SIPR pathway as a potential therapeutic approach for COVID-19</span></div><div class="casAuthors">McGowan, Eileen M.; Haddadi, Nahal; Nassif, Najah T.; Lin, Yiguang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7189</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The world is currently experiencing the worst health pandemic since the Spanish flu in 1918-the COVID-19 pandemic-caused by the coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  This pandemic is the world's third wake-up call this century.  In 2003 and 2012, the world experienced two major coronavirus outbreaks, SARS-CoV-1 and Middle East Respiratory syndrome coronavirus (MERS-CoV), causing major respiratory tract infections.  At present, there is neither a vaccine nor a cure for COVID-19.  The severe COVID-19 symptoms of hyperinflammation, catastrophic damage to the vascular endothelium, thrombotic complications, septic shock, brain damage, acute disseminated encephalomyelitis (ADEM), and acute neurol. and psychiatric complications are unprecedented.  Many COVID-19 deaths result from the aftermath of hyperinflammatory complications, also referred to as the "cytokine storm syndrome", endotheliitus and blood clotting, all with the potential to cause multiorgan dysfunction.  The sphingolipid rheostat plays integral roles in viral replication, activation/modulation of the immune response, and importantly in maintaining vasculature integrity, with sphingosine 1 phosphate (S1P) and its cognate receptors (SIPRs: G-protein-coupled receptors) being key factors in vascular protection against endotheliitus.  Hence, modulation of sphingosine kinase (SphK), S1P, and the S1P receptor pathway may provide significant beneficial effects towards counteracting the life-threatening, acute, and chronic complications assocd. with SARS-CoV-2 infection.  This review provides a comprehensive overview of SARS-CoV-2 infection and disease, prospective vaccines, and current treatments.  We then discuss the evidence supporting the targeting of SphK/S1P and S1P receptors in the repertoire of COVID-19 therapies to control viral replication and alleviate the known and emerging acute and chronic symptoms of COVID-19.  Three clin. trials using FDA-approved sphingolipid-based drugs being repurposed and evaluated to help in alleviating COVID-19 symptoms are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof8DR8YuR9t7Vg90H21EOLACvtfcHk0ljO6uTx1aVxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWit7zM&md5=cbbdcef7e1509a760411e882728628bd</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.3390%2Fijms21197189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21197189%26sid%3Dliteratum%253Aachs%26aulast%3DMcGowan%26aufirst%3DE.%2BM.%26aulast%3DHaddadi%26aufirst%3DN.%26aulast%3DNassif%26aufirst%3DN.%2BT.%26aulast%3DLin%26aufirst%3DY.%26atitle%3DTargeting%2520the%2520SphK-S1P-SIPR%2520pathway%2520as%2520a%2520potential%2520therapeutic%2520approach%2520for%2520COVID-19%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D7189%26doi%3D10.3390%2Fijms21197189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maines, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beljanski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upson, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. D.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>333</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">139</span>, <span class="refDoi"> DOI: 10.1124/jpet.109.163444</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1124%2Fjpet.109.163444" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=20061445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFGktro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=333&publication_year=2010&pages=129-139&author=K.+J.+Frenchauthor=Y.+Zhuangauthor=L.+W.+Mainesauthor=P.+Gaoauthor=W.+Wangauthor=V.+Beljanskiauthor=J.+J.+Upsonauthor=C.+L.+Greenauthor=S.+N.+Kellerauthor=C.+D.+Smith&title=Pharmacology+and+antitumor+activity+of+ABC294640%2C+a+selective+inhibitor+of+sphingosine+kinase-2&doi=10.1124%2Fjpet.109.163444"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2</span></div><div class="casAuthors">French, Kevin J.; Zhuang, Yan; Maines, Lynn W.; Gao, Peng; Wang, Wenxue; Beljanski, Vladimir; Upson, John J.; Green, Cecelia L.; Keller, Staci N.; Smith, Charles D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">333</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-139</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sphingolipid-metabolizing enzymes control the dynamic balance of the cellular levels of important bioactive lipids, including the apoptotic compd. ceramide and the proliferative compd. sphingosine 1-phosphate (S1P).  Many growth factors and inflammatory cytokines promote the cleavage of sphingomyelin and ceramide leading to rapid elevation of S1P levels through the action of sphingosine kinases (SK1 and SK2).  SK1 and SK2 are overexpressed in a variety of human cancers, making these enzymes potential mol. targets for cancer therapy.  We have identified an aryladamantane compd., termed ABC294640 [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], that selectively inhibits SK2 activity in vitro, acting as a competitive inhibitor with respect to sphingosine with a Ki of 9.8 μM, and attenuates S1P formation in intact cells.  In tissue culture, ABC294640 suppresses the proliferation of a broad panel of tumor cell lines, and inhibits tumor cell migration concomitant with loss of microfilaments.  In vivo, ABC294640 has excellent oral bioavailability, and demonstrates a plasma clearance half-time of 4.5 h in mice.  Acute and chronic toxicol. studies indicate that ABC294640 induces a transient minor decrease in the hematocrit of rats and mice; however, this normalizes by 28 days of treatment.  No other changes in hematol. parameters, or gross or microscopic tissue pathol., result from treatment with ABC294640.  Oral administration of ABC294640 to mice bearing mammary adenocarcinoma xenografts results in dose-dependent antitumor activity assocd. with depletion of S1P levels in the tumors and progressive tumor cell apoptosis.  Therefore, this newly developed SK2 inhibitor provides an orally available drug candidate for the treatment of cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsJFYxYhWjhbVg90H21EOLACvtfcHk0ljO6uTx1aVxtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFGktro%253D&md5=63e0792b887d9ad70c76f209e577a693</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1124%2Fjpet.109.163444&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.109.163444%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DK.%2BJ.%26aulast%3DZhuang%26aufirst%3DY.%26aulast%3DMaines%26aufirst%3DL.%2BW.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DBeljanski%26aufirst%3DV.%26aulast%3DUpson%26aufirst%3DJ.%2BJ.%26aulast%3DGreen%26aufirst%3DC.%2BL.%26aulast%3DKeller%26aufirst%3DS.%2BN.%26aulast%3DSmith%26aufirst%3DC.%2BD.%26atitle%3DPharmacology%2520and%2520antitumor%2520activity%2520of%2520ABC294640%252C%2520a%2520selective%2520inhibitor%2520of%2520sphingosine%2520kinase-2%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2010%26volume%3D333%26spage%3D129%26epage%3D139%26doi%3D10.1124%2Fjpet.109.163444" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corman, A.</span>; <span class="NLM_string-name">Kanellis, D. C.</span>; <span class="NLM_string-name">Häggblad, M.</span>; <span class="NLM_string-name">Lafarga, V.</span>; <span class="NLM_string-name">Bartek, J.</span>; <span class="NLM_string-name">Carreras-Puigvert, J.</span>; <span class="NLM_string-name">Fernandez-Capetillo, O.</span></span>, <span> </span><span class="NLM_article-title">A chemical screen identifies a link between lipid metabolism and mRNA translation</span>.  <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1101/2020.05.11.088005</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=10.1101%2F2020.05.11.088005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=A.+Corman&author=D.+C.+Kanellis&author=M.+H%C3%A4ggblad&author=V.+Lafarga&author=J.+Bartek&author=J.+Carreras-Puigvert&author=O.+Fernandez-Capetillo&title=A+chemical+screen+identifies+a+link+between+lipid+metabolism+and+mRNA+translation&doi=10.1101%2F2020.05.11.088005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1101%2F2020.05.11.088005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.11.088005%26sid%3Dliteratum%253Aachs%26aulast%3DCorman%26aufirst%3DA.%26atitle%3DA%2520chemical%2520screen%2520identifies%2520a%2520link%2520between%2520lipid%2520metabolism%2520and%2520mRNA%2520translation%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.11.088005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span> <span> </span><span class="NLM_article-title">Small-molecule kinase inhibitors for the treatment of nononcologic diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1283</span>– <span class="NLM_lpage">1345</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01511</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01511" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhslOjsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2021&pages=1283-1345&author=Z.+Xieauthor=X.+Yangauthor=Y.+Duanauthor=J.+Hanauthor=C.+Liao&title=Small-molecule+kinase+inhibitors+for+the+treatment+of+nononcologic+diseases&doi=10.1021%2Facs.jmedchem.0c01511"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases</span></div><div class="casAuthors">Xie, Zhouling; Yang, Xiaoxiao; Duan, Yajun; Han, Jihong; Liao, Chenzhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1283-1345</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Great successes have been achieved in developing small-mol. kinase inhibitors as anticancer therapeutic agents.  However, kinase deregulation plays essential roles not only in cancer but also in almost all major disease areas.  Accumulating evidence has revealed that kinases are promising drug targets for different diseases, including cancer, autoimmune diseases, inflammatory diseases, cardiovascular diseases, central nervous system disorders, viral infections, and malaria.  Indeed, the first small-mol. kinase inhibitor for treatment of a nononcol. disease was approved in 2011 by the U.S.  To date, 10 such inhibitors have been approved, and more are in clin. trials for applications other than cancer.  This Perspective discusses a no. of kinases and their small-mol. inhibitors for the treatment of diseases in nononcol. therapeutic fields.  The opportunities and challenges in developing such inhibitors are also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj9Nmho6XaDbVg90H21EOLACvtfcHk0lghNuv8MEQS8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhslOjsLc%253D&md5=ad9d3e32276fef906c1832e9bb91d7a1</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DC.%26atitle%3DSmall-molecule%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520nononcologic%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2021%26volume%3D64%26spage%3D1283%26epage%3D1345%26doi%3D10.1021%2Facs.jmedchem.0c01511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00302&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00302%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00302" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ab59eaf303d7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
